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SUMMARY
Xeroderma pigmentosum ()|P) and Cockayne syndrome (CS) are syndromes 
characterised by defects iqf nucleotide excision repair (NER), they can be 
distinguished by contrasting clinical manifestations. Although the genes 
responsible for XP and CShave been identified, the precise molecular roles of 
the normal proteins remaiis poorly understood. In the present study, primary 
dermal fibroblasts derived from patients assigned to XP complementation group 
C (XP-C; XP8CA) and CS type A (CS-A; CS3BE) were characterised. Patient 
XP8CA was homozygous for a 2 bp TG deletion in the XPC  gene at codon 547 
resulting in a premature termination at position 572, while patient CS3BE was a 
compound heterozygote for a 37G>T (E13X) and a novel 479C>T (A 160V) 
mutation in CKN1, the jene that encodes the CSA protein. Permanent XP-C and 
CS-A cell lines were ©tablished by transducing primary XP8CA and CS3BE 
fibroblasts with a retroviral vector, expressing the catalytic subunit o f telomerase, 
hTERT. The reconstitution of telomerase activity resulted in: (1) the preservation 
of the primary NER capabilities; (2) an extension of proliferative lifespan; (3) 
maintenance o f  the p53/p21WAF,/CIPI and pR b/p l6INK4A tumour suppressor 
pathways. Using midoarrays, the UV-induced global transcriptional response of 
telomerised XP-C ajd CS-A fibroblasts was characterised. The data indicate that 
UV-irradiation resulted in the differential regulation of a diverse range of cellular 
responses such as transcription, cell cycle arrest, DNA repair and apoptosis. 
Additionally, celUype-specific signatures were observed in telomerised XP-C 
and CS-A fibroblasts. The utility of RNAi was also demonstrated by transiently 
ablating XPC or CSA function in telomerised repair competent (MRC-5) 
fibroblasts, and a stable, permanent mutant was constructed by retrovirally 
transducing the telomerised CS-A cell line with an X P C -specific shRNA 
construct. Thus, permanent and stable telomerase-immortalised XP-C and CS-A 
cell lines have been established and partially characterised at both the genetic and 
molecular level, so providing in vitro models for investigating NER.
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Chapter 1 
General Introduction
1.1 DNA damage
The human genome is composed o f three billion base pairs and comprises 
approximately 20-30,000 genes (Lander et al., 2001; Venter et al., 2001). The 
preservation o f cellular deoxyribonucleic acid (DNA) is fundamental for the 
accurate transmission of genetic information from parental to daughter cells. 
However, the chemical structure and integrity o f DNA is under perpetual attack 
from spontaneous modifications induced by replication errors, and a plethora of 
exogenous and endogenous sources o f DNA damage. It has been estimated that 
the various sources o f spontaneous base damage elicit modifications in 
approximately 25,000 bases per human genome per cell per day, out o f the 
estimated 3x l09 bases present within the genome (Friedberg, 2001). The 
continued presence o f DNA damage in the human genome has potential 
deleterious implications. At the cellular level, genome damage impedes 
fundamental DNA metabolic processes, such as transcription, replication and 
recombination, resulting in cell cycle arrest, senescence, apoptosis and genome 
instability. Moreover, at the organismal level, DNA damage has been implicated 
in a multiplicity o f genetically inherited disorders, carcinogenesis and ageing (de 
Boer et al., 2000).
The most prevalent sources o f DNA damage are derived from exogenous 
physical and chemical agents, such as ultraviolet (UV) light, ionising radiation 
(IR) and toxiuos chemicals, including those found in cigarette smoke. Moreover, 
normal cellular metabolism can damage DNA because the generation of 
adenosine triphosphate (ATP) by the mitochondria, via the electron transport 
chain, results in the production of various reactive oxygen species (ROS), such as 
superoxide anion, singlet oxygen and hydrogen peroxide. Further sources of ROS 
include enzymes and processes required for normal cellular functionality, such as
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nicotinamide adenine dinucleotide (NADPH)- oxidases, cyclooxygenases and 
lipid peroxidation. It is noteworthy that even in the absence of environmental 
genotoxins (such as UV light and cigarette smoke) human cells are subjected to 
>10,000 base modifications per day, resulting from endogenous sources of 
genotoxins (Lindahl, 1993; Setlow, 2001). Modifications in DNA structure and 
integrity can also occur spontaneously through the instability of chemical bonds, 
resulting in deamination and depurination (reviewed by Lindahl, 1993).
1.1.1 Consequences o f UV-induced damage
UV light is a major source o f DNA damage, and provides the principle 
etiological agent causing cutaneous neoplasia. Both epidemiological and 
molecular investigations have implicated that non-melanoma skin malignancies 
(such as basal cell carcinoma (BCC) and squamous cell carcinoma (SCC)) are 
associated with extreme exposure to the UV constituent of sunlight (reviewed by 
Ananthaswamy & Pierceall, 1990). The UV spectrum is categorised into three 
distinct wavelength ranges: UVA (320-400 nm), UVB (290-320 nm) and UVC 
(<290 nm). Although UVC possesses the highest energy, and is the most 
biologically damaging constituent of the UV spectrum, UVC is filtered by the 
stratospheric ozone layer and absorbed by atmospheric oxygen.
UVA has been implicated as the principal source of UV exposure, constituting 
90% of the terrestrial UV (Afaq et al., 2005). It is thought that UVA accounts for 
approximately 10-20% of the carcinogenic dose o f the sun (de Laat et al., 1997). 
Conversely, only 1-10% of UV radiation that penetrates the Earth’s atmosphere 
is UVB (de Gruijl, 1999; Woodhead et al., 1999).
UV can inflict damage on DNA both directly (type I), and indirectly (type II) 
through the excitation of a photosensitizer molecule with oxygen, resulting in the 
generation of ROS. Although both UVA and UVB cause oxidative damage, 
UVA is thought to cause its detrimental effects predominantly via this indirect 
mechanism, whilst UVB causes damage directly (Danpure & Tyrrell, 1976). At 
the organismal level, UVA radiation contributes to the carcinogenicity o f the sun
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(reviewed by Pfeifer et al., 2005), photoaging of the skin (Krutmann, 2000) and 
the development o f cataracts in the eye lens (Balasubramanian, 2000). 
Additionally, UVA has deleterious consequences at the cellular and molecular 
level, causing growth inhibition, cytotoxicity, cell membrane and cytoskeletal 
abnormalities and the abolition o f enzymatic activity (Matsui & DeLeo, 1991; 
Krutmann, 2000; de Gruijl, 2000). Moreover, detrimental effects on the immune 
system have been correlated with UV-A exposure (Ullrich et al., 1989).
In addition, cells possess photosensitive biomolecules known as chromophores, 
such as porphyrins, heme, ferritin, flavins and melanin precursors/polymers, 
which accept photons from UV radiation (Tyrrell & Keyse, 1990; Vile et al., 
1994; Kvam et al., 2000). This results in the subsequent transfer o f electrons to a 
higher energy state. The displacement o f excited energy from one chromophore 
to another can initiate a chain reaction, which is dependent upon the structural 
nature o f the chromophore, wavelength o f radiation and the intricacy and 
quantity o f different biomolecules present. The principal endogenous 
chromophores for UV radiation include DNA and reactive oxygen-generating 
species. DNA constitutes the principal cellular chromophore for UVC; the 
aromatic ring structure o f the constituent bases in DNA facilitates the efficient 
absorption o f short wavelength UV (<300 nm). Unlike UVB, UVA is not 
significantly absorbed by DNA per se. UVA induces modifications to DNA 
structure and chemistry indirectly, through the photoexcitation o f these 
endogenous photosensitising biomolecules. These chromophores transfer their 
energy to molecular oxygen, resulting in the generation o f ROS, such as 
superoxide and hydrogen peroxide, which promotes oxidative DNA damage and 
initiates mutagenesis.
The epidermis contains antioxidant defence mechanisms, including enzymes 
such a superoxide dismutase, glutathione peroxidase and catalase, which 
removes ROS from the skin (Moysan et al., 1995). Further defence mechanisms 
include free radical scavengers, such as vitamin C and E, which reduce the 
detrimental effects o f ROS. However, the continued production o f ROS, 
subsequent to further UV exposure, depletes these innate antioxidant defence 
mechanisms and physiological levels o f free radical scavengers (Podda et al.,
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1998). The continued generation o f these endogenously synthesised ROS 
molecules elicit a plethora o f biological effects including: (1) poly(ADP-ribose) 
polymerase (PARP) activation, resulting in energy depletion in the skin; (2) 
oxidative DNA damage; (3) lipid peroxidation and nitric oxide synthase 
activation leading to inflammation and further generation of ROS and nitrogen 
species from inflammatory cells; (4) immunosuppression (reviewed by Halliday, 
2005). Moreover, the continued generation of ROS also causes a multiplicity o f 
DNA base modifications, including DNA strand breaks, DNA-protein cross­
links, and oxidised bases (8-hydroxy-deoxyguanosine). The mutagenic effect of 
UVA is typified by the chromosomal aberrations and point mutations observed in 
cultured human and mouse cells, following exposure to UVA (reviewed in 
Friedberg et al., 2006). In addition to DNA damage, UVA irradiation impedes 
fundamental processes, which preserve cellular homeostasis. For example, the 
peroxidation o f lipid constituents o f cellular membranes causes structural 
modifications, resulting in disturbances to cellular transport mechanisms. 
Furthermore, lipid peroxidation causes the synthesis of prostaglandins (PG), such 
as PGE2, which causes inflammation of the skin (Hruza & Pentland, 1993).
Although UVB represents only 1-10% of the solar spectrum that penetrates the 
Earth’s atmosphere (de Gruijl, 1999; Woodhead et al., 1999), UVB is considered 
the most mutagenic wavelength, compared to UVA (Courdavault et al., 2005), 
which is thought to be 1000-fold less damaging than UVB. DNA is the principle 
chromophore for UVB radiation (Rosenstein & Mitchell, 1987). Moreover, UVB 
radiation acts on DNA via the direct excitation of the nucleobases in an oxygen- 
independent manner. This results in the generation o f dimeric photo lesions at 
bipyrimidine sites (discussed further in Sections 1.1.3 & 1.1.4). Conversely, the 
damaging effect o f UVA on cellular DNA occurs via a photosensitisation 
reaction, as nucleobases weakly absorb wavelengths above 320 nm (reviewed by 
Cadet et al., 2005). However, UVA and UVB radiation generate free radicals, 
such as OH radical, one-electron oxidation, oxidants and peroxynitrite that can 
damage DNA via the production o f 8-hydroxyguanine, bass loss, single-strand 
breaks and protein-DNA cross linking (reviewed in Hildesheim & Fomace, 
2004).
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1.1.2 DNA lesions induced by UV irradiation
Following exposure to UV radiation, two principal mutagenic DNA lesions are 
generated: cyclobutane pyrimidine dimers (CPDs) and pyrimidine (6-4) 
pyrimidone (6-4PP) adducts (and their Dewar valence isomers), which account 
for a high proportion of the UV-induced lesions (-95%). Previous studies have 
demonstrated the involvement of these photoproducts in photocarcinogenesis, by 
the multitude o f mutations identified at bipyrimidine sites in human cutaneous 
tumours (Agar et al., 2004; Dumaz et al., 1993; Ziegler et al., 1993). In addition 
to 6~4PPs and CPDs, UV induces a multitude o f DNA lesions, including cytosine 
photohydrates, oxidation o f guanine into 8-oxo 7,8-dihydroguanine purine 
photoproducts and single stranded breaks (reviewed by Ravanat et al., 2001). 
However, UV lesions involving purines equate to <1% o f UV-induced 
photolesions (Friedberg, 2006). The ratio o f induction o f 6-4PP.CPD is 1:3 in 
human and hamster cells (Mitchell, 1988; Van HofFen et al., 1995; Balajee et al.,
1999).
1.1.3 Cyclobutane pyrimidine dimers (CPDs)
CPDs possess a high mutagenic potential. This is attributed to the high level of 
induction, reduced repair capacity and increased bypass tolerance (Pfeifer et al., 
1997; Johnson et al., 1999; Smith et al., 1998). Although DNA polymerase r\ 
(POLH) correctly bypasses 5’-TT sequences, within a CPD, a high frequency of 
C to T transition mutations at dipyrimidine sites have been observed (Pfeifer et 
al., 2005). Two models involving bypass tolerance have been implicated, which 
drive UV-induced mutagenesis. Firstly, it has been speculated that a lesion is 
bypassed by an alternative error-prone polymerase, which incorporates an 
adenine opposite a cytosine or 5-methylcytosine within the CPD. However, the 
precise polymerase involved in this mechanism remains elusive. Alternatively, 
the second model involves the initial deamination o f a cytosine or 5- 
methylcytosine within a CPD. This is followed by the correct bypass during 
DNA replication. In concordance, recent studies have shown that the 
deamination model contributes significantly to UVB-induced mutagenesis (Lee
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et al.y 2003; Tu et al., 1998). More recently, You et al. (2001) showed that CPDs 
induced by UVB irradiation, are responsible for 80% o f mutations in a mouse 
cell line harbouring the transgenic mutation reporter genes, L acI and C/7. 
Whether this frequency occurs at different loci in human cells remains to be seen.
CPDs are generated by the covalent interaction between two adjacent pyrimidine 
bases. The saturation o f the C5-C6 double bonds results in the formation o f a 
four-membered cyclobutyl ring (Fig. 1.1 A). CPDs can form between adjacent 
T o T , C o T ,  T<>C, or C<>C residues with a ratio o f 68:13:16:3 in plasmid 
DNA. A similar trend has been observed in irradiated human cells (Mitchell et 
al., 1992; Tomaletti et al., 1993). However, the distribution of CPDs between 
pyrimidines depends on UV wavelength, dose o f irradiation and adjacent 
sequence (Gillet & Scharer, 2006). Most frequently, however, the formation of 
CPDs occurs between adjacent thymine residues (T<>T) in DNA. By contrast, 
the lowest yield o f CPDs is generated between two adjacent cytosine (C<>C) 
residues. Theoretically, the formation of CPDs can occur in twelve structural 
configurations. However, only four isomeric forms with the configurations cis- 
syn, cis-anti, trans-syn or trans-anti are found in significant yields (Fig. 1.1B; 
Friedberg et al., 2006). Interestingly, it was initially thought that CPDs are 
distributed randomly throughout the genome, and that the formation o f CPDs 
between two adjacent thymine residues occurs with equal probability. However, 
the generation of CPDs is dependent upon sequence content (discussed further in 
Section 1.1.6).
1.1.4 Pyrimidine (6-4) pyrimidone (6-4PPs) photoproducts
Following UV radiation, 6-4PPs are primarily found between thymine and 
cytosine bases. Prior to the formation of 6-4PPs, however, cycloaddition occurs 
between the C5-C6 bond of a 5’ prymidine residue and the C4 carbonyl group of 
an adjacent 3 ’ thymine (or the 4-imino group of the 3 ’ cytosine), resulting in the 
creation of an oxetane intermediate (Fig. 1.1C). The subsequent formation of 6- 
4PPs, occurs via spontaneous rearrangement o f the oxetane intermediate, 
resulting in the linkage between C6 position of the 5’ pyrimidine and C4 position
6
of the adjacent 3 ’ pyrimidine (Fig. 1.1D). Further exposure to UVB can induce 
further structural modifications, resulting in the generation of Dewar isomers 
(Ravanat et a l., 2001; Fig. 1.1E). These isomers are derivatives o f 6-4PPs, 
generated by the photoisom erisation o f 6-4PPs, following exposure to 
wavelengths longer than 290 nm, which corresponds to the maximum absorption 
peak of 6-4PPs. However, the precise biological relevance of Dewar isomer 
formation in relation to mutagenesis and carcinogenesis in human cells remains 
poorly understood.
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1.1.5 UV-induced damage and DNA structure
Both CPDs and 6-4PPs distort the structural configuration of DNA, inducing a 
bend of 7-9° and 44°, respectively (Friedberg et al., 2006; Kim et al., 1995). The 
formation of CPDs has a negligible effect on Watson-Crick base pairing. By 
contrast, the extensive distortion to the DNA backbone by 6-4PPs results in 
significant disruption to base pairing. So, although CPDs are the most prevalent 
and cytotoxic UV-induced lesion, 6-4PPs are potentially more mutagenic, as a 
result o f increased helical distortion. In concordance, Nakajima et al. (2004) 
speculated that a single 6-4PP is several fold more toxic than a single CPD. In 
disagreement with these studies, it has been suggested that the deleterious 
consequences induced by the UV constituent of solar light, such as mutagenesis, 
photocarcinogenesis and immunosuppression, are a consequence of unrepaired 
CPDs (Jans et al., 2005). While damage recognition is dependent upon the 
degree of helical distortion, lesions which elicit only negligible distortions are 
weakly recognised by the global genome repair (GGR) recognition complex, 
XPC-hHR23B, and are inefficiently repaired. This causes the incessant 
accumulation o f unrepaired CPDs in the genome. Furthermore, 6-4PPs are 
removed 15 times more efficiently compared to CPDs (Grossman, 1997). In 
concordance, using liquid chromatography in combination with mass 
spectrometry, Courdavault et al. (2005), showed that CPDs are the most 
abundant and less efficiently repaired bipyrimidine photoproducts, irrespective of 
UV wavelength.
1.1.6 UV-induced damage and chromatin structure
The yield and distribution o f CPDs and 6-4PPs is highly heterogeneous, and 
dependent upon DNA sequence, local DNA structure and the association 
between DNA and chromosomal proteins. Notably, the distribution of CPDs 
predominantly occurs at poly (dA.dT) tracts. Indeed, studies have implicated 
chromatin arrangement as having the most significant affect on photolesion 
formation in nucleosomes (Gale et al., 1987; Pehrson, 1995). Interestingly, the 
interval between CPD distribution has been a periodicity of approximately 10.3
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bps (Gale et al., 1987). This suggests that CPD formation reflects the structural 
organisation of a nucleosomal unit. Furthermore, the formation of CPDs appears 
to preferentially occur at sites where the minor groove is positioned away from 
the core histone surface (Gale et al., 1987; Pehrson, 1995). In contrast, 6-4PPs 
are dispersed randomly within nucleosome cores and preferentially in linker 
DNA nucleosome free regions o f chromatin (Gale & Smerdon, 1990; Mitchell et 
a/., 1990).
1.1.7 A molecular model: the role o f CPDs and 6-4PPs in 
UV-induced mutagenesis and photocarcinogenesis
The transition from a normal cell to a cancerous cell is a highly intricate and 
sequential process involving a m ultiplicity o f genetic and epigenetic 
modifications, resulting in the emergence of clones with a selective growth 
advantage. Under normal physiological conditions, following UV exposure, 
epidermal keratinocytes containing unrepaired UV-induced lesions are removed 
by apoptosis. However, continued exposure to UV results in the accumulation of 
DNA damage and the initiation of photocarcinogenesis (reviewed by Melnikova 
& Ananthaswamy, 2005). This is attributed to the failure o f DNA repair 
mechanisms to eliminate cells containing DNA damage. UV-induced lesions that 
are not repaired before DNA replication can generate mutations in cancer- 
associated genes, such as tumour suppressors and oncogenes. Although 
mutations in the tumour protein 53 (TP 53) gene is a well-characterised 
prerequisite for the progression o f cutaneous tumours, the precise molecular and 
cellular events remains poorly delineated. However, recent studies have 
implicated the activation o f proto-oncogens such as ras and the inactivation of 
additional tumour suppressor genes, such as PTC H  and IN K 4a-ARF , in the 
photocarcinogenic process (reviewed by Melnikova & Ananthaswamy, 2005).
A hallmark of UVC- and UVB-induced mutagenesis is a high frequency of 
transition m utations at dipyrim idine sequences containing cytosine. 
Approximately 35% of mutations identified in cutaneous malignancies occur as a 
result of transition mutations at dipyrimidines within the sequence 5’-TCG and
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5*-CCG in the TP53 gene (Pfeifer et a\,9 2005). Interestingly, Tomaletti & Pfeifer 
(1994) also showed an association between TP53 mutation hotspots and the slow 
removal o f UV-induced CPDs in cutaneous malignancy. Indeed, based on the 
mutations observed in human premalignant actinic keratosis (AK) lesions and 
data from UV-induced carcinogenesis studies in mice, mutations in the TP53 
gene in epidermal keratinocytes is thought to promote the initiating event in skin 
tumorigenesis (Ziegler et al., 1994; Brash et al., 1996; Leffell & Brash, 1996). In 
concordance, Jiang et al. (1999) showed the rapid progression of UV-induced 
cutaneous tumours in p53~‘' and p53+l' mice compared to wild-type mice.
Continued exposure to UV promotes dysregulation of the apoptotic pathway, 
causing aberrant proliferation and clonal expansion of premalignant apoptotic- 
resistant clones, possessing DNA damage, accumulated TP53 gene mutations 
and the abolition o f Fas-Fas ligand interaction. Repeated UV exposure facilitates 
further expansion o f clones possessing additional UV-induced mutations in 
further genes, resulting in the inactivation of tumour suppressor genes or the 
activation o f oncogenes. This ultimately results in the transition from a 
preneoplastic lesion, AK, to a carcinoma, such as SCC (Fig. 1.2).
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Figure 1.2. A model for UV-induced initiation and progression for SCC. Generation of DNA 
photoproducts by UVB and defects in DNA repair and re replication leads to the accumulation 
of mutations in the TP53 tumour suppressor gene in keratinocytes, loss o f Fas ligand expression 
and apoptosis resistance. After repeated exposure to UV, rz^i-m utant cells undergo clonal 
expansion and accumulate mutations in other key genes such as p l6 INK4A. Clones form 
preneoplastic lesions (actinic keratosis), and some of them progress into SCC (adapted from 
Melnikova & Ananthaswamy, 2005).
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Although the relationship between UVB and non-melanoma cutaneous 
malignancies has been well documented (Kraemer, 1997; de Gruijl, 1999), the 
association between UV and the molecular targets in malignant melanoma 
remains poorly understood (Houghton & Polsky, 2002). Kamb et al. (1994) 
speculated that the CDKN2 (p l6 rNK4A) tumour suppressor gene carries germ line 
mutations in melonoma kindreds, and it has been shown that sporadic melanomas 
carry somatic missense mutations in the CDKN2 gene (Pollock et al., 1996). 
Notably, Pollock et al. (1996) reported a frequent UV-induced signature C to T 
transition mutation in the CD KN2  gene o f melanomas, thus suggesting a 
potential m olecular candidate for photocarcinogenesis in melanom a 
tumorigenesis. In concordance, mouse models have also implicated an 
association between UV and melanoma (Jhappan et al., 2003). Additionally, 
Kannan et al. (2003) showed that the inactivation o f the retinoblastoma 
pRb/plb1***4* pathway was instrumental in UV mutagenesis in a melanoma 
mouse model, driven by H-RAS activation.
A multiplicity o f epidemiological studies has implicated UVB as the principal 
initiator o f non-melanoma skin cancers. Conversely, UVA is thought to play an 
instrumental role in melanomas (Moan et al., 1999; Wang et al., 2001), but this 
remains controversial. A further identified hotspot for UVB-mediated 
mutagenesis is 5-methycytosine, which is found at CpG dinucleotides in 
mammalian genomes. For example, in skin cancer, C to T transition mutations 
are frequently observed at the trinucleotide sequence 5’-PyCG in the TP53 gene 
following UV (Tommasi et al., 1997). These mutations are frequently observed 
in the skin tumours o f individuals with the UV sensitive syndrome, xeroderma 
pigmentosum (XP; Giglia-Mari & Sarasin, 2003).
1.2 UV exposure: The cellular response
Normal human skin provides a protective biological barrier against a multiplicity 
of exogenous stresses, including UV. Following exposure to UV, a series of 
primary cellular responses are elicited by the skin, such as induction of melanin 
pigmentation, immunomodulation and endocrine modulation, which is coupled
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with vitamin D and neuropeptide synthesis (reviewed by Slominski & Pawelek, 
1998; Slominski & Wortsman, 2000). The skin is regarded as a peripheral 
neuroendocrine organ, which elicits a multiplicity o f defence mechanisms via a 
network o f intracellular pathways; these are orchestrated by the local 
neuroendocrine-immune system (reviewed by Slominski & Wortsman, 2000). 
These intricate cellular responses require the co-ordinated regulation of 
hormones, neurotransmitters, neuropeptides, cytokines and their receptors. 
Consequently, it is essential that the expression of the respective network of 
genes regulating these pathways is hierarchical, coordinated and highly organised 
(Pisarchik et al., 2004).
Despite these protective cellular responses, it has been estimated that acute 
exposure to the UV component o f sunlight at a biologically relevant dose can 
induce approximately 100,000 CPDs per epidermal keratinocyte (Ichihashi et al., 
2003) and 40,000 damaged sites in exposed cells in the human epidermis in 1 
hour, resulting from the absorption of UV (200-300 nm) radiation by DNA (Ura 
& Hayes, 2002). This can cause erythema, tanning and localised or systemic 
immuno-suppression. Continued exposure to UV, however, will have greater 
deleterious consequences, including premature aging and carcinogenesis, 
resulting from the accumulation o f genetic modifications (as previously 
discussed). These molecular alterations facilitate selective growth and clonal 
expansion o f cells with a mutator phenotype, which will ultimately promote 
tumorigenesis, resulting in the aggressive progression of UV-induced cutaneous 
malignancies, which are the most prevalent cancers in Caucasians (Kraemer et 
al., 1997). In the UK, over 65,400 cases o f non-melanoma skin cancers are 
diagnosed each year making it the most prevalent type of cancer. BCC is the 
most common type o f skin cancer accounting for approximately 75% of all 
reported non-melanoma skin cancers, whereas SCC account for 20% of all non­
melanoma skin cancers in the UK. Approximately 8,000 new cases of malignant 
melanoma are reported every year, which accounts for 3% of all reported cancers 
(http://www.cancerresearchuk.org).
14
1.3 DNA repair mechanisms
Mammalian cells possess an intricate network of DNA repair mechanisms, which 
function to reduce the detrimental effects o f DNA damage, thereby preserving 
genome stability and reducing tumorigenesis. Approximately 130 human DNA 
repair genes have been cloned and sequenced (Ronen & Glickman, 2001; Wood 
et al., 2001). These genes orchestrate cell signalling and the mechanistic 
functioning of distinct DNA repair mechanisms, including: nucleotide excision 
repair (NER), base excision repair (BER), mismatch repair (MMR) homologous 
recombination (HR) and non-homologous end joining (NHEJ; reviewed by 
Christmann et al., 2003). However, the commencement o f DNA repair also 
activates a series o f DNA damage checkpoints to delay or arrest cell cycle 
progression.
1.3.1 Nucleotide excision repair (NER): genetic and 
structural characterisation o f core repair factors in 
humans
Both prokaryotic and eukaryotic organisms adopt analogous NER repair factors 
and mechanistic strategies to eliminate and repair DNA lesions. NER repair 
genes in a multitude o f organisms, such as bacteria, yeast, human and mouse 
have been identified. Furthermore, the advent o f modem recombinant DNA 
techniques and in vitro reconstitution assays has resulted in the biochemical and 
functional characterisation o f the corresponding NER proteins.
Over the past forty years, numerous experimental strategies have been exploited 
in the cloning of DNA repair genes. These methodologies have been based on: 
(1) the complementation o f mutant rodent cells with human genomic DNA; (2) 
the transfection of cDNA libraries into human or rodent cells; (3) the transfection 
of microbial mutants with human cDNA; (4) antibody screening o f bacterial 
expression libraries (5) degenerate primers based on peptide sequence; (6) library 
screening using homology-based probes; (7) homology comparison combined
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with database analysis; (8) positional mapping strategies; (9) the yeast two- 
hybrid system; (10) protein interactions in mammalian cells.
The isolation of genes inactivated in human cells and subsequent assignment to 
the different XP groups was in part achieved on the basis o f functional 
complementation, using mutant Chinese hamster ovary (CHO) cells that possess 
gene defects analogous to XP cells (Thompson, 1998; Bootsma, 2001). Like 
human XP cells, CHO cells were assigned to excision repair cross­
complementation (ERCC) groups (Busch et al., 1989) and, utilising recombinant 
DNA methodologies, were screened with libraries o f human DNA fragments. 
This resulted in the identification of human DNA sequences, which causes UV 
survival in CHO cells previously exhibiting severe UV sensitivity. This 
technology facilitated the identification and cloning of the first ERCC  human 
genes: ERCC1 (Westerveld & Hoeijmakers, 1984), ERCC2 (Weber et al., 1888), 
ERCC3 (Weeda et al., 1990a), ERCC4 (Thompson et al., 1994) and ERCC6 
(Troelstra et al., 1990). These were found to correct the corresponding UV- 
sensitive CHO cells complementation groups. Further analysis revealed that 
ERCC2, ERCC3, ERCC4 and ERCC6 complemented the human cells assigned to 
XP-D, XP-B, XP-F and CS-B complementation groups respectively. However, 
the first cloned DNA repair gene, ERCC1, failed to correct the UV sensitivity in 
any known XP complementation group, and for this reason retained its rodent 
name.
Alternative methods have been used to identify DNA repair genes. For example, 
the direct complementation o f human cells is illustrated by the identification of 
the XPA  gene, which was identified following large-scale screening o f XP-A 
cells transfected with mouse genomic libraries (Tanaka, et al., 1989; Tanaka et 
al., 1990). Conversely, both X P C  and CSA genes were identified by direct 
cloning from human cells, using episomally replicating plasmids containing viral 
replication systems and human cDNA libraries (Legerski & Peterson, 1992; 
Henning et al., 1995). Genes such as XPG  (Maclnnes et al., 1993; Scherly et al.,
1993), XPF  (Sijbers et al., 1996; Brookman et a l,  1996), hHR23B (Masutani et 
al., 1994), and the more recently identified TTDA (Giglia-Mari et al., 2004) were 
identified serendipitously or through sequence homology with repair genes
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cloned in other organisms. The cloning of XPG  was cloned by chance and was 
found to be equivalent to E R C C 5 (O ’Donovan & Wood, 1993). Some 
investigators have adopted a reverse approach, whereby purification of the 
protein was achieved first. Subsequent microsequencing facilitated the 
generation of DNA primers, which resulted in the cloning of the corresponding 
gene by PCR amplification. This method was used for the identification of the 
DDB protein, which was initially elucidated as a DNA damage binding (DDB) 
factor absent in XP-E cells (Chu & Chang, 1988; Dualan et al., 1995; Takao et 
al., 1993). This technique was also adopted for the XPC protein, which was 
isolated by fractionation of cell extracts used to complement the activity XP-C 
cell extracts (Masutani et al., 1994).
1.3.1.1 XPA
The human XPA gene was cloned through the complementation of UV sensitive 
XP-A cells; following transfection with total mouse genomic DNA (Tanaka et 
al., 1989; Tanaka et al., 1990). Cells lacking XPA protein exhibit no residual 
NER activity (Tanaka et al., 1990). The XPA gene encodes a 273 amino acid 31 
kDa protein. However, the separation o f XPA on polyacrylamide gels most 
frequently results in the detection of multiple bands between 40-45 kDa. These 
additional bands do not correspond to posttranslational modifications, but occurs 
due to the formation of different denatured conformations. The initial indication 
that exogenous proteins can translocate into the nucleus of XP cells and correct 
their phenotype was first shown in XP-A and XP-C with cytoblasts from 
different repair-proficient cells (Giannelli et al., 1982; Keijzer et al., 1982).
XPA possesses a zinc finger motif, a nuclear localisation signal and four further 
domains, which facilitate the formation of protein-protein interactions with 
proteins o f the NER machinery, such as transcription factor II H (TFIIH), 
ERCC1 and replication protein A (RPA; discussed in Section 1.6.4).
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1.3.1.2 XPB (ERCC3)
The human XPB  gene was cloned by complementation of the UV radiation 
sensitivity o f cells derived from RGCG3 (Weeda et al., 1990a). Mutational 
analysis o f XP-B cells showed that E R C C 3 and XPB  are synonymous 
(Vermeulen et al., 1994; Weeda et al., 1990b). XPB  cDNA possesses an open 
reading frame (ORF) o f 782 codons that encodes a protein of 89.2 kDa. Like 
XPD, the amino acid sequence shows that the XPB protein is a DNA helicase. 
XPB is a constituent o f TFIIH (Schaeffer et al., 1993) that has ATP-dependent 
DNA helicase activity with a 3 ’-* 5 ’ polarity (Drapkin et al., 1994; Ma et al.,
1994).
1.3.1.3 XPC-hHR23B
Legerski & Peterson (1992) characterised the molecular defect in human XP-C 
defective cells and isolated a partial APC-complementing cDNA sequence. The 
subsequent cloning of the XPC  cDNA was undertaken by the purification of the a 
93 kDa XPC-complementing protein, derivation of partial amino acid sequence 
and the construction of DNA probes based on the amino acid sequence (Masutani 
et al, 1994). The XPC  gene is located on chromosome 3p25, and the complete 
X PC  ORF encodes a hydrophilic 940 amino acid polypeptide with an 
electrophoretic mobility o f ca. 125 kDa (Masutani et al., 1994).
Purification o f the XPC protein resulted in the copurification o f a further 
polypeptide o f ca. 58 kDa, known as hHR23B (Masutani et al., 1994). This 
polypeptide is a highly conserved ortholog o f the yeast RAD23B protein. 
Humans contain a second ortholog, RAD23A (HR23A). Both the hHR23A and 
hHR23B proteins contain ubiquitin-like (UbL) and ubiqutin-associated (UbA) 
domains. Furthermore, one or more conserved regions in hHR23A and hHR23B 
are required for interactions with the C-terminal region of XP-C (Li et al., 1997; 
Masutani et al., 1997). In a reconstituted reaction, recombinant XPC protein 
displays weak NER efficiency without either hHR23 polypeptide. However, 
inclusion o f the hHR23B protein stimulates NER (Sugasawa et al., 1996).
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Furthermore, although recombinant hHR23A or hHR23B can bind to XPC, the 
hHR23B protein is most often associated with XPC (Sugasawa et al., 1997).
1.3.1.4XPD (ERCC2)
The XPD  gene was cloned from a cosmid that only corrects the cellular 
phenotype of CHO mutants derived from RGCG2 (Weber et al., 1990). The XPD  
gene encodes a protein of 760 amino acids with a size of 87 kDa. Like XPB , the 
XPD  gene product contains a DNA-dependent ATPase with DNA helicase 
activity (Sung et al., 1993). XPD is an essential constituent o f the TFIIH 
complex (Schaeffer et al., 1994). This is exemplified in mice, as deletion of XPD 
results in embryonic lethality (de Boer et al., 1998).
1.3.1.5 DNA damage-binding protein (DDB) complex 
(XPE)
DDB also referred to as UV-DDB was identified using electrophoretic mobility 
shift or filter-binding assays. The purification of DDB resulted in the detection of 
a heterodimer consisting o f a 127 kDa subunit known as DDB1 and a 48 kDa 
subunit called DDB2 (Keeney et al., 1993). Microinjection of purified DDB 
complex into XP-E cells results in the restoration of NER activity (Keeney et al., 
1994; Rapic-Otrin et al., 1998). The DDB  genes encoding both the DDB1 and 
DDB2 subunits were identified by Dualan et al. (1995) as previously discussed.
1.3.1.6 XPF (ERCC4)
The XPF  gene was cloned by functional correction of a rodent cell line derived 
from RGCG4 (Brookman et al., 1996). The XPF  ORF encodes a 916 amino acid 
polypeptide with a molecular mass of 104 kDa.
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1.3.1.7 ERCC1
The human ERCC1 cDNA encodes a polypeptide of 297 amino acids with a 
molecular mass o f 32.5 kDa (van Duin et al., 1986), and complements the 
sensitivity o f RGCG1 cells. The human ERCC1 gene does not complement the 
UV sensitivity of cell lines derived from patients with the XP syndrome that are 
defective in NER (van Duin et al., 1989). Early investigations showed that 
ERCC1 and XP-F mutant cell extracts did not complement one another for DNA 
repair when mixed in vitro (Biggerstaff et al., 1993; van Vuuren et al., 1993). 
The ERCC1 and XPF NER factors were shown to be part o f a heterodimeric 
complex in human cells (Brookman et al., 1996; Sijbers et al., 1996). XPF- 
ERCC1 exhibits structure-specific nuclease activity, as it can cut DNA at 
junctions between a duplex and a single strand in a 5’ to 3 ’ direction (de Laat et 
al., 1998a; Sijbers e ta l., 1996).
1.3.1.8 XPG (ERCC5)
Somatic cell analysis showed that human chromosome 13q contained a gene 
capable o f correcting the UV radiation sensitivity in cells derived from RGCG5 
(Thompson et al., 1987). Previous to these findings, Maclnnes et al. (1984) 
showed that transfection o f human genomic DNA corrected this phenotype in a 
group of 5 known mutants. However, the correcting activity was initially isolated 
as two overlapping cosmids that generated a functional 32 kb ERCC5 gene only 
by intercosmid recombination (Mudgett & Maclnnes, 1990). The human XPG  
cDNA was found to correct the UV radiation sensitivity of cells from individuals 
with XP-G (Scherly et al., 1993). Furthermore, complementation of NER activity 
was absent when extracts o f human XP-G and RGCG5 cells were combined 
(O’Donovan & Wood, 1993; Reardon et al., 1993b). The isolation of the ERCC5 
cDNA (Maclnnes et al., 1993; Shiomi et al., 1994), and in situ mapping of XPG  
cDNA to chromosome 13q33 (Samec et al., 1994) to the same site that the 
ERCC5 gene was mapped (Takahashi et al., 1992) provided further evidence that 
ERCC5 and XPG  are identical.
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XPG has an ORF o f 1,186 codons, which encodes a polypeptide of 133 kDa. The 
amino acid sequence contains several possible nuclear localisation signals. 
Furthermore, XPG protein possesses endonuclease activity that cleaves several 
DNA structures containing junctions between unpaired and duplex DNA, cutting 
the strand in a 3*-*5’ polarity away from the junction (Cloud et al., 1995; Evans 
et al., 1997a; O ’Donavan et al., 1994).
1.3.1.9 CSA (ERCC8)
The human CSA (Cockayne syndrome type A) gene was originally cloned by 
functional complementation o f the UV sensitivity o f a CSA mutant cell line 
(Henning et al., 1995). The CSA gene also corrects the UV sensitivity in the 
rodent cell line, US31. Furthermore, the defect is not corrected following fusion 
with CS-A ceils after UV (Itoh et al., 1996). CSA is located on chromosome 5 
and encodes a 396 amino acid repeat protein that has a molecular weight o f 44 
kDa (Henning et al., 1995). Investigations using the two-hybrid protein-protein 
interaction method found that the human CSA and CSB proteins form 
interactions and that CSA further binds with p44, a subunit of the TFIIH complex 
(Henning et al., 1995). In contrast, cell fractionation studies found that CSA and 
CSB are present in separate multiprotein complexes (van Gool et al., 1997). 
These conflicting findings have been attributed to the fact that CSA protein 
resides in the cytoplasm, but translocates to the nucleus following UV irradiation 
(Kamiuchi et al., 2002).
1.3.1.10 CSB (ERCC6)
The ERCC6 gene was originally identified by virtue of its ability to correct the 
UV sensitivity phenotype in rodent cells from the genetic complementation 
group 6. It was subsequently shown that ERCC6 corrects the UV sensitivity 
observed in CS-B cells (Troelstra et al., 1992), thus ERCC6 was reassigned as 
CSB. The CSB gene also corrects the phenotype of defective transcription- 
coupled repair (TCR) in the CHO cell line, UV61 (Orren et al., 1996). The CSB 
gene encodes a polypeptide o f 168 kDa (Orren et al., 1996). A noticeable
21
characteristic o f the predicted amino acid sequence is the presence of an ATPase- 
helicase motif that is common to the SWI2/SNF2 ATPase superfamily (Orren et 
al., 1996), which is frequently associated with chromatin remodelling. Although 
the CSB protein possesses consensus domains that are common to many DNA 
helicases, this activity has not been observed in the CSB protein (Citterio et al., 
1998; Licht et al., 2003; Selby & Sancar, 1997b). However, Licht et al. (2003) 
reported the disruption o f the RNA polymerase II (RNA Pol II) transcription 
complex by CSB. Significant homology has been observed between CSB and the 
Escherichia coli (E.coli) transcription-repair coupling factor (Selby & Sancar, 
1993). The ATPase activity o f CSB is stimulated by DNA (Selby & Sancar, 
1997b; Tantin et al., 1997). Moreover, the ATPase activity is more active when 
stimulated by double-stranded than single-stranded DNA. Interestingly, site- 
directed mutagenesis o f highly conserved amino acid residues in the ATP- 
binding domain of the CSB protein results in the inactivation of the ATPase 
activity (Citterio et al., 1998), which has also been shown to abolish the ability of 
CSB protein to correct the mutant phenotype displayed by CSB cells (Licht et 
al., 2003). It is thought that the ATPase activity of CSB plays a role in chromatin 
remodelling during transcription and/or TCR. Citterio et al. (2000) showed that 
CSB alters the conformation of nucleosomes reconstituted on plasmid DNA in an 
ATP-dependent manner. They also found that CSB interacts with core histones.
1.3.1.11 XPA binding protein (XAB2)
The XAB2 gene was first identified in a yeast two-hybrid screen for proteins that 
interact with XPA (Nakatsu et a l, 2000). The XAB2 gene encodes an 855 amino 
acid protein, which is characterised by 15 tetratricopeptide repeat motifs 
(Nakatsu et al., 2000). Furthermore, the XAB2 protein has been found to interact 
with CSA, CSB and RNA Pol II. Attempts to generate a mouse model defective 
in Xab2 has resulted in embryonic lethality, suggesting that the gene is 
indispensable (Nakatsu et al., 2000).
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1.4 Mechanistic action of NER in humans
NER is a ubiquitous and highly versatile mechanism, which has remained 
conserved between species, such as bacteria, yeast and mammalian cells. 
However, the repertoire of enzyme and protein constituents utilised during NER 
structurally and functionally differs between prokaryotic and eukaryotic 
organisms and exhibit minimal homology (Eisen & Hanawalt, 1999; Petit & 
Sancar, 1999; Zou & van Houten, 1999). NER orchestrates the elimination and 
repair o f an array o f structurally unrelated bulky DNA lesions, which induce 
helical distortions and modify DNA chemistry. These lesions are induced by a 
multiplicity o f exogenous and endogenous sources of DNA damage, such as UV- 
induced photoproducts, electrophilic chemicals, adducts induced by polycyclic 
carcinogens (such as cisplatin and psoralens), crosslinks and oxidised bases. 
Additionally, previous in vitro studies have shown that NER can mediate the 
removal o f lesions, which cause significantly less helical distortion, including AP 
sites and thymine glycols (Sancar, 1996; Reardon et al., 1997).
Principally, NER orchestrates the removal o f UV-induced photolesions, such as 
CPDs, 6-4PPs and Dewar valence isoforms. The initial discovery of NER in 
E.coli (Setlow & Carrier, 1964; Boyce & Howard-Flanders, 1964) provided a 
paradigm for the subsequent identification of NER in eukaryotes (Cleaver, 1968; 
Cleaver, 1969; Setlow et al., 1969). This resulted in the serendipitous association 
between defective NER and the human hereditary, cancer prone, photosensitive 
syndrome, XP (Cleaver, 1968; Cleaver, 1969).
When operating on damage in naked DNA, approximately 30 polypeptides are 
required to orchestrate the six sequential mechanistic steps in NER (Aboussekhra 
et al., 1995): (i) damage recognition; (ii) unwinding and formation of the 
preincision complex; (iii) stabilisation o f the pre incision complex; (iv) bimodal 
incision and excision o f an oligonucleotide fragment; (v) polymerisation by 
repair synthesis, using the complementary undamaged strand as a template; (vi) 
ligation o f the remaining single-stranded nick. The intricate recruitment,
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assembly and disassembly o f the NER machinery is completed within ~4 
minutes in human cells (Hoogstraten et al., 2002).
The efficiency of NER varies throughout the entire genome, depending upon 
both the structural nature and precise location of the lesion. In particular, it has 
been previously shown that the repair rate o f a-DNA is significantly impaired 
compared to the entire genome. This has been attributed to the complex 
chromatin structure in the repetitive centromeric DNA sequences and the 
presence o f a multitude o f DNA binding proteins (Zolan et al., 1982; Cline & 
Hanawalt, 2003).
The most intricate rate-limiting mechanistic step in the NER pathway is the 
initial recognition o f UV-induced photolesions. This is attributed to the 
differences in the complexity of chromatin structure in the transcribed and non­
transcribed regions o f the genome, and the requirement for different specific 
proteins.
Previous analysis o f the repair o f CPDs in transcriptionally active regions, 
compared to transcriptionally silent regions o f the genome, and between the 
transcribed and non-transcribed strand of constitutively expressed genes, through 
the utilisation o f strand-specific DNA repair assays (Bohr et al., 1985; Mellon et 
al., 1987; Mellon & Hanawalt, 1989; van Hoffen et al., 1993), resulted in the 
discovery o f two partially distinct mechanistic NER pathways. NER is 
subdivided into two overlapping recognition subpathways: global genome repair 
(GGR) and TCR. GGR is initiated by the recognition of UV-induced helical 
distorting lesions on the nontranscribed strand of transcriptionally active genes 
and transcriptionally silent regions of the genome. In contrast, TCR exclusively 
operates on the transcribed strand of transcriptionally active genes, probably 
following the recognition of an arrested RNA Pol II at a stalled transcription 
complex (Mellon & Hanawalt, 1989). Most importantly, following initial 
recognition of DNA damage per se, or the recognition of an arrested RNA Pol II, 
both GGR and TCR converge at a common node.
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Differences in the dynamics o f NER are observed between GGR and TCR. The 
temporal differences in lesion removal throughout the genome were explained by 
the preferential removal o f lesions from the transcribed strand of transcriptionally 
active genes, by TCR, compared to the slower removal and repair of lesions by 
GGR in the remaining regions of the genome, including the nontranscribed 
strand o f transcriptionally active genes (Hanawalt, 2002). Furthermore, the 
dynamics o f lesion demarcation and repair by GGR is dependent upon the nature 
of the lesion. For instance, 6-4 PPs, which induce major structural distortions in 
the double helix compared to CPDs (Kim et al.y 1995), are eliminated five- to 
ten-fold faster than CPDs (Tomaletti & Hanawalt, 1999), while the latter are 
more prevalent in the genome, following UV irradiation (Mitchell et al., 1989). It 
has been estimated that the NER apparatus removes CPDs at a rate o f only 10- 
20% that of the removal o f 6-4PPs (Ford & Hanawalt, 1997; Reardon & Sancar, 
2003). However, it should be noted that repair rates o f CPDs can vary 
enormously depending on sequence and chromatin.
1.5 Chromatin remodelling and NER in humans
The human genome is systematically organised in chromatin structures, which 
are further condensed and packaged into chromosomes. The spatial organisation 
o f the genome operates at several levels o f complexity. The genome is 
principally organised into linear chromosomes, which are packaged within the 
nucleus. In addition, the structural integrity of chromosomes is maintained by a 
series o f structural constituents, such as centromeres, telomeres and repetitive 
DNA sequence. The second level o f chromatin organisation necessitates the 
association between DNA and histone proteins. The structural composition of 
chromatin includes a nucleosomal core, which consists of approximately 147 bp 
of DNA wrapped around a histone octamer composed of H2A, H2B, H3 and H4 
histone proteins. In addition, linker DNA binds two nucleosomes together via 
histones HI & H5, which stabilises nucleosomal structures, thus further 
condensing the chromatin and reducing the accessibility to regulatory factors 
involved in DNA metabolism. Therefore, the in vivo initiation of processes of 
DNA metabolism, such as replication, recombination, transcription or repair,
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necessitates decondensation o f chromatin and chromatin re-modelling to permit 
chromatin relaxation, thereby increasing the accessibility to factors essential to 
these DNA metabolising processes. The final level of genome organisation is the 
three dimensional topology within the nucleus (reviewed by Reed, 2005).
A preliminary investigation by Smerdon & Lieberman (1978), showed an 
increase in the accessibility o f nucleases to damaged DNA, during UV-induced 
repair synthesis. This indicated that highly condensed chromatin underwent 
significant nucleosomal rearrangement, in response to UV, thus permitting 
access o f the entire repair apparatus to damaged sites. This led to the postulation 
of the ‘access, repair, restore* (ARR) model for NER repair (Smerdon, 1991). In 
concordance, a battery o f in vitro NER assays, using purified proteins and cell 
extracts, has shown that the repair rates o f DNA damage is significantly 
compromised in nucleosomal structures compared to naked DNA, thus 
reiterating the importance of chromatin remodelling in NER (Araki et al., 2000; 
Hara et al., 2000; Sugasawa et al.9 1993; Ura et al., 2001; Wang & Taylor, 
1991).
Chromatin re-modelling occurs via two essential processes: (1) posttranslational 
modification o f histone tails and (2) ATP-dependent chromatin re-modelling. 
Histone tails can undergo a multiplicity o f modifications, such as methylation, 
acetylation, phosphorylation and ubiquitylation. In particular, histone acetylation 
has been detected subsequent to UV irradiation (Ramanathan & Smerdon, 1986). 
Furthermore, hyperacetylation of histones by inhibiting histone deacetylases 
(HDACs) augments the repair o f UV-induced lesions (Dresler, 1985; 
Ramanathan & Smerdon, 1989; Smerdon et al., 1982). A battery of histone 
acetyltransferases (HAT) have been implicated as accessibility factors during 
NER: STAGA (SPT3, TAFn31-GCN51 acetylase), TFTC (TBP-free TAF„ 
complex) and p300 (reviewed in Gillet & Scharer, 2006). ATP-dependent 
chromatin remodelling has also been implicated in NER. A recent in vitro study 
has shown that the ATP-utilising chromatin assembly and re-modelling factor 
(ACF) enhances the removal of 6-4PPs from the linker DNA between two 
nuclosomes (Ura et al., 2001). This suggests that ACF is a potential requisite for
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histone octamer sliding, thereby increasing the accessibility to the lesion situated 
within the linker regions (Ura et al., 2001).
Significant controversy, however, surrounds the precise mechanistic steps 
involved in chromatin remodelling prior to the initiation of NER, as both histone 
modifying enzymes and ATP-dependent chromatin remodelling factors do not 
possess a specific binding affinity for lesions located in nucleosomal DNA. It has 
been speculated, however, that NER factors play an instrumental role in 
chromatin accessibility. In particular, DDB1 has been isolated in several 
complexes involved in histone acetylation (as previously described): p300, 
STAGA or TFTC (reviewed by Gillet & Scharer, 2006). It was recently 
speculated that p53 acts as a global relaxer of chromatin through the activation of 
p300, which mediates the hyperacetylation of histones. This hyperacetylation of 
histones was proposed to elicit the initiation of GGR, but this maybe a 
considerable over interpretation (Rubbi et al., 2003). Although the body of 
evidence implicates the DDB complex as the linking between NER and 
chromatin remodelling, in vivo evidence for this remains unreported. 
Furthermore, a paradox between damage recognition and chromatin remodelling 
becomes apparent, as the remodelling of chromatin is essential for the 
recognition o f damage, while DNA damage recognition is a prerequisite for 
chromatin remodelling (reviewed by Gillet & Scharer, 2006).
Following the completion of NER, further chromatin remodelling is essential for 
the repositioning o f nucleosomal structures, thus facilitating the restoration of 
chromatin structure to its original state (Gontijo et al., 2003). The repositioning 
o f core histones protects the repaired DNA patches from nuclease digestion 
within 20 minutes o f the completion o f NER. However, this immediate 
protection is followed by an extended period (1-24 hours) of nuclease sensitivity, 
which corresponds with the slow nucleosomal repositioning at exposed sites, 
containing newly synthesised DNA (Smerdon & Conconi, 1999). Numerous 
studies have implicated that the mechanistic function of chromatin assembly 
factor 1 (CAF-1) is essential in the reassembly o f chromatin following NER 
(Gaillard et al., 1996; Gaillard et al., 1997; Moggs et al., 1999).
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1.6 Sequential assembly of the NER apparatus
In human cells, the sequential formation of the NER machinery necessitates a 
minimal set o f protein constituents: XPA, XPC-hHR23B, XPG, RPA, ERCC1- 
XPF, TFIIH, proliferating cell nuclear antigen (PCNA), replication factor C 
(RCF), DNA polymerases 6 or e, and DNA ligase III (Fig. 1.3; Araujo et al.,
2000). These components are further divided into two mechanistic groups; the 
six core components required for the recognition and dual incision (hHR23B- 
XPC, RPA, XPA, XPG, ERCC1-XPF and TFIIH) and those required for repair 
synthesis and ligation (PCNA, RCF, DNA polymerase 6 or e, and DNA ligase 
III).
Following the initial in vitro reconstitution o f the NER apparatus (Aboussekhra 
et al., 1995), controversy surrounded the precise assembly o f the NER 
machinery. Numerous models have been postulated for the recruitment o f the 
NER apparatus and subsequent formation o f a repair complex at the site o f 
damage. Principally, two contrasting models have been proposed: (1) the 
existence o f a pre-assembled repairosome complex; (2) the sequential assembly 
o f repair factors at the lesion site. Initial yeast studies suggested that a pre­
assembled repairosome complex was a prerequisite for proficient NER 
(Svejstrup et al., 1995). However, Thoma & Vasquez (2003) has approximated 
that the assembled mammalian NER machinery has a mass o f ~3 MDa. 
Therefore, the preassembled repairosome model presents numerous caveats, such 
as its large size and reduced mobility, thus making nuclear translocation 
problematic. Alternatively, from subsequent mammalian cell studies, Maldonado 
et al. (1996) speculated that the NER apparatus was a constituent of the RNA Pol 
II holoenzyme. Following further yeast studies, however, it has been widely 
accepted that the individual protein constituents of the NER apparatus undergo 
nuclear translocation and are sequestered to the site of damage, whereby they 
sequentially assemble to form a pre-incision complex (Guzder et al., 1995). In 
concordance with these findings, Volker et al. (2001) showed no evidence for the 
existence of a pre-assembled repairosome complex, and favoured the sequential 
assembly of the NER machinery.
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1.6.1 Global genome repair (GGR): damage recognition by 
XPC-hHR23B and the DDB complex
The recognition mechanisms involved in NER are highly intricate, necessitating 
systematic and complex interactions between a multitude of repair factors. To 
date, numerous models have been suggested for the initial recognition of UV- 
induced lesions in GGR, which involve the initial recruitment o f several potential 
NER proteins: DDB, XPC-hHR23B, XPA and/or RPA. Alternatively, a further 
model termed the concerted or cooperative recognition model, suggests that the 
XPA, RPA and XPC-hHR23B proteins form a recognition complex that permits 
increasing selectivity for damaged DNA by amalgamating the specific selectivity 
of each constituent o f the complex.
Initial experimentation involved the measurement of binding affinities between 
the various repair candidates and DNA. However, none of the candidates, such as 
DDB (Keeney et al., 1993; Reardon et al., 1993a; Fujiwara et al., 1999), XPC- 
hHR23B (Batty et al., 2000; Hey et al., 2002; Sugasawa et al., 1998; Sugasawa 
et al., 2001), XPA (Li et al., 1995a; Jones & Wood 1993; Buschta-Hedayat et al., 
1999) or RPA (He et al., 1995; Bums et al., 1996; Schweizer et al., 1999) 
displayed preferential binding for damaged DNA, compared to undamaged 
DNA. Competition assays were subsequently utilised to elucidate the precise 
sequence of recruitment and interaction events of NER proteins at a lesion site. 
Sugasawa et al. (1998) showed that damaged plasmids, incubated with the 
heterodimeric XPC-hHR23B complex, preferentially binds to damaged DNA and 
facilitates the rapid removal and repair o f DNA damage. By contrast, slower 
repair rates were observed in damaged plasmids incubated with the XPA-RPA 
heterodimeric complex alone. This supported a previous study by Evans et al. 
(1997b), who suggested that the XPA-RPA complex was instrumental for the 
stabilisation o f the TFIIH apparatus, rather than the initiator o f GGR. Further 
studies have supported these findings (Batty et al., 2000; Reardon et al., 1996), 
suggesting that the XPC-hHR23B complex is instrumental in initiating GGR and 
is a prerequisite for the recruitment o f the NER apparatus. In particular, the
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utilisation o f reconstitution methodologies indicated that the presence of ATP 
was not necessary for the recruitment o f XPC (Aboussekhra et al., 1995; Mu et 
al., 1995), while XPA (and the core NER apparatus) is sequestered to the site of 
damage only in the presence of ATP. This suggested that the ATP-dependent 
unwinding of DNA, by the TFIIH apparatus is a prerequisite for the subsequent 
recruitment o f XPA (Riedl et al., 2003). However, in contrast, Wakasugi & 
Sancar (1999) showed that preincubation o f damaged DNA with XPA-RPA 
facilitates the rapid induction o f repair, in comparison to preincubation of XPC- 
hHR23B with the damaged DNA substrate. The incongruity between these 
findings results from the inherent caveats associated with the in vitro 
biochemical assays adopted. In particular, in vitro assays do not reflect the 
complexity o f chromatin structure. Moreover, the alteration in protein 
conformation and localisation in vivo may differ to an in vitro situation.
Alternative approaches were also adopted to determine the systematic assembly 
of the NER apparatus. For example, Volker et al. (2001) analysed the nuclear 
trafficking o f each NER protein in living cells. This was accomplished by UV 
irradiating cells through isopore polycarbonate filters (with pores o f 3 and 8 pm 
diameter), which facilitated the localisation of DNA damage at defined positions. 
This facilitated the detection o f both DNA damage foci formation, using CPD- 
and 6-4PP-specific antibodies. Furthermore, the localisation o f NER repair 
factors was determined, using corresponding antibodies targeting the NER 
factors. The migration o f XPC-hHR23B and XPA from unirradiated regions of 
the nuclei to damaged foci was investigated by staining the damage (such as 
CPDs and 6-4PPs) and NER factors with fluorescently labelled antibodies. In 
agreement with previous studies, the XPC-hHR23B complex was found to 
accumulate at damaged foci. Interestingly, the recruitment o f XPA was not 
observed in the absence o f the XPC-hHR23B complex (Volker et al., 2001). 
Adopting a similar experimental approach, using cells derived from other XP 
complementation groups, Rademakers et al. (2003) showed that both XPG and 
RPA are sequestered to the NER complex before and independently of XPA. 
More recently, biochemical analysis has shown that XPC orchestrates an 
instrumental role in opening the DNA surrounding the damaged site (Riedl et al.,
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2003), and is therefore a prerequisite for the recruitment o f the core NER 
apparatus (Tapias et al., 2004).
Significant debate still surrounds the precise molecular mechanistic trigger for 
the initiation of GGR. Until recently, the body of evidence suggested that GGR 
was initiated following the recruitment, localisation and preferential binding of 
the XPC-hHR23B heterodimeric complex to the site of damage (Sugasawa et al.,
1998). More recently however, it has been suggested that DDB binding is a 
prerequisite to the binding of XPC-hHR23B (Fitch et al., 2003b; Wakasugi et a l,  
2002). Furthermore, it has been speculated that DDB is a prerequisite for histone 
acetylation, which is thought to augment NER, through its association with 
histone acetylase p300 (Datta et al., 2001). The importance of DDB is also 
exemplified in rodents, where the p48 subunit is not upregulated in response to 
UV (Tan & Chu, 2002). This has been attributed to the absence o f a p53- 
responsive element in the p48 promoter (Tan & Chu, 2002), as the upregulation 
of p48 occurs in a p53-dependent manner (Ford & Hanawalt, 1997; Hwang et al.,
1999). This causes the complete cessation of CPD repair on the nontranscribed 
strand (and silent regions o f the genome) by GGR in rodents (Bohr et al., 1985; 
Vreeswijk et al., 1994). The binding o f DDB, however, is not essential for the 
recognition o f 6-4PPs by XPC-hHR23B (Hwang et al., 1998), due to the 
significant helical distortion generated by 6-4PPs (Gunz et a l, 1996).
Interestingly, it has been shown that XPC-hHR23B selectively binds to helical 
distortions, regardless o f whether they possess a UV-induced lesion (Hess et a l,  
1997; Sugasawa et a l ,  2001). For example, XPC-hHR23B binds to helical 
distortions generated by a 3-5 bp mispaired nucleotide bubble, despite the 
absence o f a lesion (Sugasawa et al., 2001). This suggests the possible 
requirement for a verification mechanism to ascertain whether the helical 
distortion detected by XPC-hHR23B is a permissible NER substrate (Hess et al., 
1997). It has been shown that the XPC-hHR23B complex preferentially binds 6- 
4PPs with high affinity (Hey et al., 2002). Additionally, it has also been 
demonstrated that the XPC-hHR23B complex does not recognise CPDs 
(Kusumoto et al., 2001), thus suggesting the requirement o f additional 
recognition factor(s) to mediate the recognition of CPDs. However, conflicting
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data has shown that XPC selectively repairs CPDs compared to 6-4PPs (Emmert 
et a l, 2000).
In addition to its DNA-damage binding properties, the XPC-hHR23B complex 
can be described as a multifaceted complex, orchestrating a multitude of 
functions, including the subsequent recruitment of the repair protein apparatus, 
thus facilitating the sequential assembly of the NER machinery. The hHR23A 
and hHR23B, human homologs of the yeast repair factor RAD23; appear to have 
a redundant role in NER (Ng et al., 2003; Sugasawa et al., 1997). Moreover, the 
stability o f XPC is completely dependent on hHR23B, which is thought to 
protect it from proteolytic degradation (Ng et al., 2003). Accordingly, XPC is 
found bound to the hHR23B protein (van der Spek et al., 1996). Furthermore, a 
recent study has speculated that hHR23B enhances XPA/RPA-mediated 
displacement o f XPC from damaged DNA (You et al., 2003), thus suggesting 
that hHR23B is instrumental in regulating downstream NER events. More 
recently, the centrosomal protein, centrin 2 (caltractin 1), has been isolated bound 
to the XPC-hHR23B complex, and is thought to facilitate stabilisation of XPC by 
hHR23B. This may suggest a possible regulatory association between NER and 
cell division (Araki et al., 2001). Both centrin 2 and hHR23B bind to the 
carboxy-terminal o f XPC (Uchida et al., 2002; Nishi et al., 2005).
The damaged DNA binding protein (DDB), is a heterodimeric complex 
composed o f two protein constituents, DDB1 (pi 27; Fu et al., 2003) and DDB2 
(p48), which belong to the XPE complementation group (as previously 
discussed). Hwang et al. (1999) previously reported that the mechanistic function 
of DDB is instrumental in the recognition of, and subsequent excision of CPDs 
in vitro with high efficacy. It is thought that DDB binds to CPDs, which induces 
further helical distortions, thus facilitating recognition by the GGR-specific 
heterodimeric complex, XPC-hHR23B (Fitch et al., 2003b; Fujiwara et al.,
1999), thereby providing an accessory function to the XPC-hHR23B complex. 
Kusumoto et al. (2001) showed that the XPC-hHR23B complex possesses a 
reduced affinity for CPDs. Interestingly, like XPC, DDB2 exhibits an increased 
affinity for 6-4PP compared to CPDs (Keeney et al., 1993; Fujiwara et al., 1999; 
Batty et al., 2000). More recently, however, Moser et al. (2005) showed that UV-
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DDB accelerates the repair o f 6-4PPs, while an increase in CPD repair was 
observed at later time points. They also showed that the proportion of 6-4PPs that 
is bound by UV-DDB is restricted by the presence of low physiological levels 
and rapid UV-dependent degradation. Even in the absence of UV-DDB, it was 
further shown that a slow XPC-hHR23B dependent pathway was capable o f 
removing 6-4PPs and to some extent CPDs (Moser et al., 2005).
The precise relationship between the two complexes (XPC-hHR23B and DDB1- 
DDB2) remains to be fully delineated. In addition, the elucidation o f the 
mechanistic function o f UV-DDB remains poorly understood. As the 
reconstitution o f the repair reaction can be accomplished in the absence of UV- 
DDB (Aboussekra et al., 1995). However, it has been shown that the inclusion of 
UV-DDB can stimulate repair up to 17-fold and ~2-fold for CPDs and 6-4PPs 
respectively (Wakasugi et al., 2001; Wakasugi et al., 2002). However, it has 
been suggested that the localisation of XPC is dependent upon the basal levels of 
DDB2, as the recruitment o f XPC to damaged sites is hindered with reduced 
basal DDB2 levels. Conversely, XPC is rapidly sequestered when DDB2 is over­
expressed (Fitch et al., 2003b). Furthermore, cells deficient in DDB exhibit a 
deficiency in the GGR of CPDs, but maintain proficiency in TCR, thus resulting 
in the XP-E phenotype. Hwang et al. (1999) also showed that DDB has a 5xl06 
fold preference for binding to damaged DNA compared to undamaged DNA. 
Therefore, it has been suggested that the initial binding of DDB facilitates the 
subsequent recruitment and binding of XPC-hHR23B to the lesion in the non­
transcribed strand. To date, no interaction between the DDB and XPC-hHR23B 
heterodimeric complexes has been demonstrated (Batty et al., 2000). However, 
the importance o f both XPC and DDB2 in coordinating GGR has been 
exemplified in XP-C and XP-E cells, which are deficient in GGR, but proficient 
in TCR (Venema et al., 1991; Hwang et al., 1999).
Investigators have started to elucidate the precise mechanistic complexity of 
DDB. For example, DDB was found to interact with a multitude o f proteins 
required for chromatin remodelling and ubiquitin ligation (Shiyanov et al., 1999; 
Nag et al., 2001). In addition, Groisman et al. (2003) isolated DDB as part of a
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complex, containing Cullin4A (CUL4A), R o d  and COP9 signalosome (CSN), 
which are constituents of ubiquitin ligase (discussed further in Section 1.8). More 
recently, Kulaksiz et al. (2005) showed that DDB2 exists in at least four forms 
within the cell: monomeric DDB2, DDB1-DDB2 heterodimer (UV-DDB) and as 
a protein associated with both the CUL4A complex and the CSN.
Following the recognition o f lesions on the nontranscribed stand of 
transcriptionally active genes or transcriptionally silent regions of the genome by 
the GGR subpathway (Fig. 1.3), the XPC-hHR23B heterodimeric complex 
mediates the recruitment o f the TFIIH complex, through protein-protein 
interactions with the XPB and p62 subunits of TFIIH (Yokoi et al., 2000). 
Recently, it was shown that the carboxy-terminal domain of the XPC protein is 
required for the subsequent binding o f TFIIH, as truncations in this region 
significantly impair the binding of TFIIH (Uchida et al., 2002). The recruitment 
and binding of the TFIIH complex facilitates lesion demarcation and verification 
(discussed in Section 1.6.3).
1.6.2 Transcription-coupled repair (TCR): Recognition of  
stalled RNA Pol II
The recommencement o f transcription following damage is essential for normal 
cellular functionality. Although bacterial TCR has been well characterised 
(reviewed by Saxowsky & Doetsch, 2006), the precise mechanistic action of 
TCR in mammalian cells remains poorly delineated. As previously discussed, the 
GGR subpathway has been extensively characterised due to the establishment of 
an in vitro reaction (Sibghat-Ullah et al., 1989; Wood et al., 1988) and 
reconstitution exploiting recombinant NER factors (Aboussekhra et al., 1995). In 
contrast, the establishment o f an in vitro TCR assay has remained unsuccessful, 
due to the mechanistic complexity o f TCR.
TCR, first described by Mellon et al. (1987), specifically targets DNA lesions in 
the transcribed strand of transcriptionally active genes. Proficient TCR is not 
only paramount for the repair of cytotoxic lesions on the transcribed strand of
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transcriptionally active genes, but also facilitates the rapid recovery and 
restoration of basal and/or inducible transcription. Furthermore, an arrested RNA 
Pol II at a stalled transcription fork elicits a cytotoxic stress signal, which 
initiates apoptosis in a p53-dependent and independent manner (Ljungman & 
Zhang, 1996). The importance of TCR as a prerequisite for the removal o f UV- 
induced lesions on the transcribed strand and resumption of transcription is 
exemplified in cells derived from patients with CS, where the inhibition of 
transcription in certain genes, such as DHFR  or glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), is abolished following UV irradiation (Proietti-De- 
Santis et al., 2006). It was assumed this defect occurs for all RNA Pol II 
transcribed genes, but this may not be the case (see below). The defect has been 
attributed to a failure to assemble the transcription initiation complex at the 
promoter due to the abolition of TATA-binding protein (TBP), the failure to 
recruit TFIIB and aberrant histone H4 acetylation. Therefore, the mechanistic 
action of the TCR apparatus is paramount for the recognition of an arrested RNA 
Pol II at a stalled transcription fork, efficient recruitment o f the NER apparatus 
and the subsequent recruitment o f the transcription apparatus, thus permitting the 
resumption of transcription. This was further illustrated by van Oosterwijk et al. 
(1996), who suggest that CS gene products mediate the transition of the TFIIH 
apparatus from a repair mechanism to a transcription mechanism, thus protecting 
the cell from apoptosis, induced by transcription blocking lesions (Proietti-De- 
Santis et al., 2002). More recently, McKay et al. (2004) suggested that 
transcription may regulate cellular homeostasis, by acting as a DNA-damage 
dosimeter.
The initiation o f TCR is dependent upon the recognition of an arrested RNA Pol 
II at a stalled transcription fork, by an XPC-, XPE-independent mechanism 
(Kamiuchi et al., 2002). It was previously shown that human cells, defective in 
XPC, retain the capacity to undertake TCR, thus suggesting that the XPC protein 
is superfluous for the preferential repair o f lesions on the transcribed strand of 
transcriptionally active genes (Venema et al., 1991; van Hoffen et al., 1995; Mu 
& Sancar, 1997). In human cells, a multitude of proteins have been implicated in 
the mechanistic functioning of TCR, including: CSA, CSB, XPB, XPD, XPG, 
hMSH2 (Mellon et al., 1996), hMLHl (Mellon et al., 1996) and XAB2 (Nakatsu
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et al., 2000). However, the precise mechanistic function and relationship between 
these proteins remains unclear.
A stress signal initiated by an arrested RNA Pol II at a stalled transcription fork 
is thought to elicit the recruitment o f the TCR-specific proteins, CSA and CSB 
(Fig. 1.3; Henning et al., 1995; Troelstra et al., 1992), which facilitates the 
subsequent assembly of the core NER apparatus. CSA is a 44 kDa protein, 
possessing seven WD-40 repeats, instrumental for protein-protein interactions, 
which provide a molecular scaffold for the stabilisation of further repair and/or 
transcription factors (Henning et al., 1995). WD-repeat proteins have been 
implicated in a multiplicity o f cellular processes, such as signal transduction, 
vesicular trafficking, cytoskeletal assembly, cell cycle regulation, RNA 
processing, transcriptional regulation and DNA repair. This suggests that CSA 
provides a regulatory function, as no WD-repeat proteins have been identified 
possessing catalytic activity. Previously, it has been shown that CSA interacts 
with XAB2, CSB and the p44 subunit of TFIIH (Nakatsu et al., 2000; Henning et 
al., 1995). More recently, it was shown that CSA associates with CUL4A 
containing the ubiquitin ligase (E3) complex, consisting of DDB 1, CUL4A and 
ROCl/rbxl proteins (Section 1.8; Groisman et al., 2003).
The interaction between CSA and CSB has been shown by employing in vitro 
translated proteins in combination with the yeast two-hybrid system (Henning et 
al., 1995). CSA and CSB have also been co-purified with large molecular weight 
complexes devoid o f the other (van Gool et al., 1997; Groisman et al., 2003). 
Kamiuchi et al. (2002), however, has proposed that following UV, the CSA 
protein is translocated from the nucleoplasm to the nuclear matrix, by a CSB- 
dependent mechanism, whereby CSA colocalises with the hyperphosphorylated 
form of RNA Pol II, engaged in transcription elongation (Kamiuchi et al., 2002). 
Originally, there was no evidence to suggest that CSA directly binds to RNA Pol 
II (Tantin, 1998), or displaces the arrested RNA Pol II from the elongation 
apparatus (Selby & Sancar, 1997b). However, Groisman et al. (2003) & 
Kamiuchi et al. (2002) showed that CSA physically associates with RNA Pol II 
in a UV-dependent manner.
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The CSB gene encodes a 168 kDa protein that possesses a helicase domain 
(Troelstra et al., 1992), and is a member o f the SWI2/SNF2 family o f DNA- 
dependent ATPases (Eisen et al., 1995; Selby & Sancar, 1997b). It is found 
complexed with both RNA Pol I and II, and is thought to stimulate the enzymatic 
activity of both RNA polymerases (Bradsher et a l , 2002; van Gool et al., 1997). 
The SWI2/SNF2 family have been implicated in a multitude o f cellular 
processes, such as transcriptional regulation, chromosome stability and DNA 
repair (Eisen et al., 1995). The DNA-dependent ATPase activity o f CSB has 
been implicated in chromatin remodelling in vitro, and it has been suggested that 
it is required for the subsequent recruitment o f the NER apparatus following 
TCR-specific recognition (Citterio et al., 1998; Selzer et al., 2002). It has been 
shown that CSB interacts with components of the NER apparatus, such as XPA 
(Selby & Sancar, 1997), XPG (Bradsher et al., 2002; Iyer et al., 1996) and 
TFIIH, which contains the XPB and XPD helicases (Selby & Sancar, 1997b; 
Bradsher et al., 2002; Tantin, 1998). The precise role o f CSB in transcription 
remains poorly delineated. Several studies have suggested that CSB promotes 
elongation by RNA Pol I (Bradsher et al., 2002), II (Selby & Sancar 1997a; 
Tantin et al., 1997) and III (Yu et al., 2000a). Selby & Sancar (1997a) has also 
suggested that CSB counteracts the rescue o f backtracked and arrested 
transcription complexes by the elongation factor TFIIS. Interestingly, a recent 
study undertaken by Proietti-De-Santis et al. (2006) has shown that CSB is 
dispensable for the transcription o f p53-responsive genes, following DNA 
damage, both in wild-type and CSB cells, but is required for the resumption of 
transcription in p53-independent housekeeping genes.
Immediately after UV, transcription is globally downregulated to permit the 
recruitment o f the NER machinery. The recovery of RNA synthesis occurs 
immediately following the completion of DNA repair. However, this recovery is 
not observed in CS cells (Rockx et al., 2000). The abolition of transcription is 
thought to occur due to the reduction of hypophosphorylated RNA Pol II, which 
is required for entry into the pre-initiation complex situated at the promoter. 
Moreover, UV damage on the transcribed strand promotes hyperphosphorylation 
of the C-terminal domain (CTD) of unbound RNA Pol II, which inhibits its 
recruitment into new pre-initiation complexes. Under normal physiological
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conditions hyperphosphorylated RNA Pol II is required for the transition of 
initiation to elongation. Interestingly, however, the level o f inactive 
hyperphosphorylated RNA Pol II remains high in CS cells. In contrast, wild-type 
cells rapidly replenish their levels o f the active hypophosphorylated form of 
RNA Pol II. This suggests that the cessation of RNA synthesis following UV 
irradiation, is not simply caused by blocked elongation at sites o f lesions, but is 
also caused by the abolition of transcription initiation. In addition, it has been 
speculated that the TBP has a selective affinity for DNA containing UV-induced 
lesions, compared to undamaged DNA. This reduces the availability o f TBP for 
transcription at the promoter site o f undamaged DNA (Vichi et al., 1997).
The displacement o f an arrested RNA Pol II elongation complex from the 
transcribed strand, following UV damage, is a prerequisite for the initiation of 
TCR, sequential recruitment o f core NER factors and repair. Single nucleotide 
resolution analysis has shown that initial rapid repair occurs near the promoter. 
This is followed by the initiation of CSA- and CSB-dependent TCR at the coding 
region of the JU N  gene (Tu et al., 1996; Tu et al., 1997; Tu et al., 1998). A 
recent study has shown that TFIIH dissociates from RNA Pol II as the 
polymerase passes the promoter 30-60 bases downstream of the transcription 
initiation site (Dvir et al., 2001). From these findings, it has been speculated that 
this dissociation o f TFIIH at the promoter explains the superfluous requirement 
of CSB for rapid TCR, adjacent to the point of transcription initiation (Svejstrup,
2002). However, the subsequent recruitment o f CSB is necessitated further 
downstream in the coding region for the recruitment o f TFIIH at the site of an 
arrested RNA Pol II (Tantin et al., 1997; Tantin, 1998).
Although the mechanistic function of CSA and the functional relationship 
between CSA and CSB in TCR has remained enigmatic, several recent studies 
have established a link between the two TCR-specific factors. For example, 
Groisman et al. (2006) have shown that the degradation o f CSB occurs in a 
proteasome- and CSA-dependent manner. Groisman et al. (2006) has speculated 
that this ubiquitin-dependent degradation of CSB is essential for the resumption 
of transcription following TCR. A further investigation undertaken by Fousteri et 
al. (2006), used an in vivo crosslinking approach coupled with chromatin
38
coimmunoprecipitation (ChIP) to shown that CSA and CSB differentially 
regulate the recruitment o f chromatin remodelling and repair factors to stalled 
RNA Pol II in vivo. Fousteri et al. (2006), showed that CSB provides an essential 
role as a coupling factor, by attracting HAT p300 and core NER factors 
(excluding XPC-hHR23B) to the stalled RNA Pol Ho, whereas the CSA-DDB1 
E3/CSN complex is required for the recruitment of the nucleosomal binding 
protein HMGN1, XAB2 and TFIIS. Interestingly, Fousteri et al. (2006) showed 
that lesion-stalled RNA Pol Ho does not dissociate from its template during the 
assembly of the TCR complex.
Several lines o f evidence have resulted in the postulation of six models for TCR 
initiation, which necessitate the displacement or remodelling o f RNA Pol II 
(reviewed by Svejstrup, 2002). Most o f which require the SWI/SNF-mediated 
activity o f CSB: (1) dissociation o f RNA Pol II from damaged strand; (2) 
temporary displacement of RNA Pol II by retrograde motion; (3) remodelling of 
the RNA Pol II at a transcription-blocking DNA lesion, through the addition of a 
single nucleotide; (4) Accessory-factor-mediated lesion bypass; (5) Binding of 
repair factors to damaged site prior to the arrival of RNA Pol II; (6) Immediate 
degradation of a stalled RNA Pol II.
Following the initial recognition of UV-induced lesions on the transcribed strand 
of transcriptionally active genes by TCR-specific mechanisms, the subsequent 
processing o f the lesion requires a series of sequential mechanistic steps identical 
to those necessitated for GGR (Fig. 1.3; discussed in Sections 1.6.3-1.6.6).
1.6.3 Lesion demarcation and verification: TFIIH
Following lesion recognition by the GGR- or TCR-specific pathway, the 
formation o f an open complex through local unwinding of the DNA helix and 
demarcation of the lesion is essential for the recruitment of the core NER 
apparatus (TFIIH, XPA, RPA and XPG) and subsequent formation of the pre­
incision complex (Fig. 1.3). The basal transcription factor, TFIIH, a multiprotein, 
multifunctional complex composed of ten subunits, is able to switch between
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transcription and NER (Hoogstraten et al., 2002). The structural composition of 
TFIIH is further divided into two complexes; the core complex (containing p8, 
p34, p44, p52, p62 and XPB) and the cdk-activating kinase (CAK) complex 
(containing cyclin-dependent kinase 7 (CDK7), cyclin H and MAT1). Both 
complexes are bound together through their association with XPD (Schultz et a l , 
2000). In transcription, TFIIH facilitates the unwinding of DNA, which mediates 
the transition of RNA Pol II from initiation near the promoter to the elongation 
phase. In GGR, the TFIIH complex is sequestered to the damaged site by XPC- 
hHR23B in an ATP-independent manner. In both GGR and TCR, the XPB and 
XPD subunits, which possess DNA-dependent helicase activity, mediate the 
local unwinding o f the DNA helix around the lesion, in a 3 ’-> 5’ and 5’-*3 ’ 
polarity, respectively, in an ATP-dependent manner. It has been speculated that 
the XPB and XPD helicases transclocate with opposite polarities in the same 
direction on each strand of the antiparallel DNA helix (Dillingham et al., 2003). 
The presence o f a UV-induced lesion is thought to cause a strand-specific 
unilateral block o f either the XPB or XPD helicase, whilst the other helicase 
continues to translocate along the undamaged strand. This is thought to generate 
distortion and bending in the DNA helix, which is essential for damage 
verification and the subsequent recruitment o f the core NER apparatus (reviewed 
by Dip et al., 2004).
In transcription, the helicase activity of TFIIH permits the unwinding o f 
approximately 10-20 bp near the promoter region, thus facilitating the initiation 
of the nascent mRNA synthesis on the DNA template strand (Holstege et al.,
1996). In NER, the XPB and XPD helicases generates a demarcation around the 
lesion of similar size, 20-25 nucleotides (Evans et al., 1997b), thus facilitating 
the recruitment of the endonucleases, XPG and XPF-ERCC1. Whilst the 3’-* 5 ’ 
helicase activity of XPB is essential for transcription, XPD helicase activity is 
superfluous for in vitro basal transcription (Tirode et al., 1999). The essential 
role o f XPB in transcription is thought to explain the infrequency o f XP-B 
phenotypes, compared to XP-D, where a battery of pathological phenotypes 
associated with XPD  gene defects have been identified such as XP, TTD, XP-CS, 
and COFS syndrome (Section 1.9).
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The precise mechanistic function of the core TFIIH constituents, such as p8, p34, 
p44, p52 and p62, are not well understood. However, recently, Ranish et al. 
(2004) and Giglia-Mari et al. (2004) identified a novel component o f the TFIIH 
complex, TFB5 (p8), which is encoded by the GTF2H5 gene. TFB5 is thought to 
stabilise the TFIIH complex and defects in the GTF2H5 gene causes a global 
reduction in the levels o f TFIIH, resulting in a TTD-A phenotype (discussed in 
Section 1.9.4). The p34 and p44 constituents are thought to possess Zn2+ motifs 
and putative DNA-binding capabilities (Humbert et al., 1994). In addition, the N- 
terminal domain o f p44 positively regulates the helicase activity of XPD. 
Conversely, the C-terminal end orchestrates a role in promoter escape (Tremeau- 
Bravard et al., 2001). It has also been shown that p52 plays a role in facilitating 
the interaction between XPB and TFIIH. Unlike the core complex, the 
mechanistic functions o f the CAK complex have been well characterised, and it 
promotes the phosphorylation of CDKs, which mediate the regulation of the cell 
cycle. The CAK complex is also required for the phosphorylation o f the C- 
terminus end o f RNA Pol II. Interestingly, the transient association o f the CAK 
complex with TFIIH and its superfluous nature in NER provides further evidence 
for the existence of different modes of TFIIH specific for either transcription or 
repair (Svejstrup et a l, 1995).
1.6.4 Assembly o f the preincision complex: RPA, XPA and 
XPG
Following the preliminary denaturation and unwinding of the DNA duplex by 
TFIIH, three further NER factors are sequestered to the site of damage, including 
RPA, XPA and XPG (Fig. 1.3). The recruitment of these factors is essential for 
the assembly o f the preincision complex. The precise order of recruitment and 
assembly o f these factors remains unclear, but it has been suggested that they 
assemble independently o f each other. RPA is a trimeric complex composed of 
three subunits: 70, 32 and 14 kDa. The 70 kDa component possesses three DNA 
binding domains, which covers approximately 30 nucleotides o f DNA during 
DNA repair. RPA is sequestered to the site of DNA damage devoid of XPA or 
XPG (Rademakers et al., 2003). Furthermore, the colocalisation of XPA and
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RPA can occur without recruiting XPG (Rademakers et al., 2003), and the 
recruitment o f XPG can take place without XPA (Volker et al., 2001).
RPA is indispensable for DNA replication, recombination and repair. In NER, 
RPA is essential for both dual incision (Coverley et al., 1992; Guzder et al., 
1995; Mu et al., 1995) and the repair synthesis steps (Coverley et al., 1991; 
Shivji et al., 1995). In accordance, RPA exhibits two binding configurations, 
which occupy either 8-10 or -30  nucleotides of single stranded (ss) DNA. RPA 
binds to the undamaged strand o f the unwound DNA helix (Bochkarev et al.,
1997), thus facilitating the accurate positioning of the XPG and XPF-ERCC1 
endonucleases. Similarly, Lee et al. (2003) showed that RPA preferentially 
interacts with the undamaged DNA strand. In addition, it has been speculated 
that RPA mechanistically functions as a recognition factor, through the detection 
of unwound ssDNA regions rather than lesion recognition per se. In agreement, 
Hermanson-Miller & Turchi (2002) demonstrated the strand-specific photo­
cross-linking of RPA to damaged oligonucleotides. The mechanistic functioning 
of RPA is enhanced by the inclusion of XPA, suggesting that XPA and RPA 
function synergistically to ensure the correct positioning o f RPA on the 
nondamaged strand of the DNA (Hermanson-Miller & Turchi, 2002).
XPA is a 31 kDa zinc metalloprotein, which forms associations with a multitude 
of NER factors, and exhibits a preference for damaged DNA. XPA is thought to 
undertake a structural role in the preincision complex by binding both to other 
NER factors (such as RPA, XPF-ERCC1, TFIIH and XPC-hHR23B) and to 
damaged DNA. XPA has a preferential affinity for binding distorted DNA in the 
absence of DNA lesions (Missura et al., 2001). From these findings, it was 
speculated that XPA provides an essential role in the recognition of DNA kinks 
that are generated following lesion recognition by TCR or GGR, thus providing 
the common node between the GGR and TCR subpathways and facilitating the 
recruitment o f the core NER apparatus. Moreover, it has been suggested that the 
XPA-RPA complex ensures the correct three-dimensional assembly of the NER 
apparatus, before endonucleolytic incision by XPG and XPF-ERCC1.
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The N-terminal region of XPA binds to RPA32 and ERCC1 (Li et al., 1994; Li et 
a l, 1995a; Park et al., 1994), whereas the C-terminal domain targets TFIIH (Park 
et al., 1995). The central zinc finger domain is required for the binding of RPA70 
(Li et al., 1995b). The formation of the heterodimeric XPA-RPA complex is 
essential for positioning the XPG and XPF-ERCC1 endonucleases for correct 
incision of damaged DNA (de Latt et al., 1998a). The binding of XPA to RPA 
also contributes to the stabilisation o f the incision complex by preventing the 
strand separation activity o f RPA (Missura et al., 2001).
Interestingly, XPA interacts with two recently identified proteins, XAB1 and 
XAB2, whose mechanistic function(s) in NER remain to be fully discovered 
(Nitta et al., 2000; Nakatsu et al., 2000). XAB1 is a GTPase protein found within 
the cytoplasm and is thought to provide an accessory role in the nuclear 
localisation of XPA (Nitta et al., 2000). Conversely, XAB2 binds to CSA, CSB 
and RNA Pol II (Nakatsu et al., 2000). The importance o f XAB2 in both TCR 
and transcription was demonstrated by microinjecting XAB2-specific antibodies 
into fibroblasts. This caused the complete abolition of both processes (Nakatsu et 
al., 2000). Intriguingly, a recent study has also identified functional association 
between NER, via XPA, and the DNA damage-induced ATR-dependent 
checkpoint pathway. Wu et al. (2006) showed that ATR modulates the cellular 
activity of NER through the phosphorylation of XPA at serl96, following UV- 
irradiation, thus providing evidence for a direct link between DNA damage 
signalling and NER.
Subsequent to damage verification, XPG is sequestered to the preincision 
complex via its interaction with TFIIH (Araujo et al., 2001). A recent body of 
evidence has suggested that XPG interacts with TFIIH, prior to the recruitment 
of both XPA and XPF-ERCC1 (Araujo et al., 2001; Volker et al., 2001). 
Conflicting reports, however, suggest that XPA, RPA and XPG reciprocally 
stabilise their association with the NER complex (Reardon & Sancar, 2003; Riedl 
et al., 2003). This suggests that these three NER proteins interact with DNA in a 
synergistic manner. It has also been shown that the removal of XPC-hHR23B 
from the preincision complex is essential for the binding of XPG (Riedl et al., 
2003; Wakasugi & Sancar, 1998). XPG is a member of the flap endonuclease 1
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(FEN-1) family o f structure-specific endonucleases, which incise flap or bubble 
DNA structures.
1.6.5 Dual incision and excision o f the oligonucleotide 
fragment: XPG and XPF-ERCC1
Although both XPG and XPF-ERCC1 orchestrate the bimodal incision of the 
damaged DNA, the recruitment o f both endonucleases occurs asynchronously. 
The recruitment o f the XPF-ERCC1 heterodimeric complex completes the 
formation o f the incision complex, prior to dual incision (Fig. 1.3). The XPF- 
ERCC1 heterodimeric complex is formed by the interaction between the 103 kDa 
XPF and the 33 kDa ERCC1 proteins, respectively (de Laat et al., 1998b; 
Westerveld et al., 1984). XPF-ERCC1 is sequestered to the NER incision 
complex, through the direct interaction between XPA and ERCC1. As previously 
discussed, the XPA protein is not required for the recruitment of XPG. However, 
the binding o f XPG alone is insufficient to activate its endonuclease activity, 
which was previously shown in XP-A cells. Therefore, it has been speculated 
that the XPA-RPA complex is required to activate the endonuclease activity (de 
Laat et al., 1998b). By contrast, the recruitment o f XPF-ERCC1 requires the 
XPA protein (Volker et al., 2001). Recently, Winkler et al. (2001) showed that 
TFIIH inhibits the endonuclease activity of XPG and XPF-ERCC1 in the absence 
o f ATP. This regulation o f endonuclease activity is thought to prevent 
inadvertent incision prior to the completion of lesion demarcation.
The dual incisions mediated by XPG and XPF-ERCC1 are made asymmetrically 
to the UV-induced lesion (Mu et al., 1996). XPG cleaves 2-8 nucleotides 3’ to 
the lesion, whereas XPF-ERCC1 cleaves 20-24 nucleotides 5’ to the lesion. 
Following bimodal incision, a 15-24 bp oligonucleotide fragment is excised, 
containing the UV-induced lesion (Evans et al., 1997b). Although XPG is 
sequestered to the NER complex prior to XPF-ERCC1, it has been speculated 
that the 5* incision made by XPF-ERCC1 occurs first (Gillet & Scharer, 2006). 
This results in the production of a free 3 ’ hydroxyl group on the damaged DNA 
strand, which provides a primer site for the initiation of repair synthesis.
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1.6.6 Polymerisation and ligation by repair synthesis: RPA,  
RFC\ PCNA Pol S/e and DNA ligase III
Following dual incision by the XPG and XPF-ERCC1 endonucleases, the 
recruitment o f additional factors, such as replication factor C (RFC), PCNA and 
DNA polymerases 6 and e, are essential for repair synthesis (Shivji et al., 1995). 
As previously discussed, RPA is a central component of the DNA re-synthesis 
apparatus. RPA remains bound to the undamaged strand following dual incision, 
whilst the entire core NER machinery dissociate (Fig. 1.3). It is thought that RPA 
is required for the subsequent recruitment of RFC and PCNA (Yuzhakov et al., 
1999; Gomes & Burgers, 2001). Both RFC and PCNA provide accessory 
functions, which facilitate the assembly of the polymerases.
RFC is sequestered to the OH group at the 3’-termini, generated during dual 
incision by XPF-ERCC1, which provides a primer site for DNA polymerases 6 
and e . The binding o f RFC permits the subsequent loading of PCNA onto the 
DNA at the 3’ termini, in an ATP-dependent manner. PCNA is a homotrimeric 
protein that possesses a ring-shaped clamp, which facilitates the sliding of PCNA 
along DNA whilst bound to DNA polymerase (Gulbis et al., 1996). More 
recently, it has been shown that the recruitment of CAF-1, which is essential for 
chromatin restoration following NER, requires PCNA (Green & Almouzni,
2003). This further reiterates the association between repair synthesis and the 
reconstitution of chromatin following NER. Finally, ligation of the 5’-end o f the 
newly synthesised DNA to the original sequence is completed by DNA ligase III 
(Tomkinson & Levin et al., 1997). Interestingly, Barnes et al. (1992) reported an 
individual with mutations in the DNA ligase III  gene, displaying sensitivity to 
UV.
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Figure 1.3. Schematic representation of the GGR- and TCR-NER mechanism. (A) UV lesions 
induce DNA helical distortion; (B) Arrested RNA Pol II on the transcribed strand of an active 
gene results in the recruitment of the CSA and CSB TCR-specific proteins, facilitating the 
displacement of the stalled RNA Pol II from the damaged site; (C) Recognition of a lesion on the 
non-transcribed strand of an active gene (and the transcriptionally silent regions of the genome) 
is undertaken by the recruitment of the XPC-hHR23B and XPE (DDB2) GGR-specific NER 
factors; (D) Lesion demarcation and verification is performed by the sequestration of the core 
NER apparatus including the bi-directional XPB/XPD helicase subunits of TFIIH, XPA 
(common node for GGR and TCR) and RPA; (E) Denaturation and unwinding of the DNA 
duplex (-20  bp) by XPB and XPD results in the recruitment of the XPG endonuclease. The 
recruitment of RPA, XPA and XPG mediate the formation of the preincision complex; (F) The 
XPF-ERCC1 heterodimeric complex joins the preincision complex and bimodal incision and 
excision (5’ by ERCC1-XPF and 3’ by XPG) occurs; (G) A 15-24 bp oligonucleotide fragment is 
excised, containing the UV lesion and RPA remains bound to the ssDNA, thus facilitating the 
transition to repair synthesis; (H) The subsequent recruitment of the Pol 6 (or e) supported by 
RFC and PCNA (not shown) orchestrate synthesis. Ligase III seals the remaining nick (adapted 
from http://ccr.coriell.org/nigms/pathways/ner.html).
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1.7 Multifunctionality of NER factors
In addition to their roles in NER, many of the proteins that regulate and 
orchestrate the NER process have been described as multifaceted, as additional 
functions outside NER have been elucidated. For example, the multi-protein 
TFIIH complex was initially described as a basal transcription factor required for 
promoter demarcation and phosphorylation of RNA Pol II (Egly, 2001). TFIIH 
also acts as a protein kinase for transcription activators (Keriel et al., 2002) in 
activated RNA Pol II transcription and in basal transcription initiation of rRNA 
genes by RNA Pol I (Hoogstraten et al., 2002; Iben et al., 2002). Furthermore, 
the discovery o f the CAK. complex suggests the involvement o f TFIIH in cell 
cycle regulation (Egly, 2001). The ERCC1-XPF complex is a further example, 
which has been described as multifaceted. It has been proposed that ERCC1-XPF 
plays roles in the removal o f inter-strand cross-links via HR and in double strand 
break repair (Niedem hofer et al., 2001). Controversially, XPG has been 
implicated in the repair o f lesions in BER (Dianov et al., 2000).
1.8 Regulation of NER
Although the biochemical and mechanistic function of the NER machinery on 
naked DNA has been comprehensively elucidated, the mechanisms that govern 
NER remain poorly delineated. Indeed, the recognition o f UV-induced 
photoproducts, subsequent recruitment and sequential assembly o f the NER 
apparatus is an intricate process, requiring meticulous regulation. Our 
understanding of NER regulation has been made particularly problematic due to 
the intricate association between genomic DNA and histone complexes, which 
further fold to form nucleosomes. These highly ordered structures require 
mechanisms that orchestrate the remodelling of chromatin, thus permitting the 
NER apparatus to obtain access to the damaged bases. The accessibility o f NER 
factors varies significantly within different regions of the genome (reviewed by 
Moggs & Almouzni, 1999). It has been suggested that the presence o f the 
transcription machinery on the transcribed strand increases accessibility to the 
NER apparatus due to a more ‘open’ chromatin conformation (Friedberg, 1996).
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Furthermore, the presence o f TFIIH, which plays an indispensable role in both 
transcription and DNA repair, may further increase accessibility to the NER 
apparatus (Hoeijmakers et al., 1996). Therefore, the remodelling of chromatin is 
a particularly fundamental prerequisite in transcriptionally silent regions of the 
genome.
A recent body of evidence, however, has identified the ubiquitin-proteasome 
pathway as an essential regulator in the co-ordinated assembly and disassembly 
of the NER apparatus (Sweder & Madura, 2002). The ubiquitin-proteasome 
pathway is instrumental in orchestrating a multiplicity of processes fundamental 
to normal cellular functionality, such as cell cycle progression, stress responses 
and cellular differentiation. Although ubiquitylation is most frequently associated 
with the targeted degradation o f cellular proteins, via the proteasome, several 
non-degradative functions have been identified in NER (reviewed by Huang & 
D’Andrea, 2006; Sugasawa, 2006). Following the first association between DNA 
repair and ubiquitylation in yeast (Jentsch et al., 1987), further associations have 
been characterised. Recent studies in yeast and humans have suggested both 
proteolytic and non-proteolytic functions o f ubiquitin in modulating the NER 
pathway (Gillette et al., 2006; Sweder & Madura, 2002).
Indeed, it has been previously demonstrated that proteins required for the 
recognition steps o f both GGR and TCR undergo ubiquitylation. This suggests a 
regulatory role not only in NER per se, but that ubiquitylation is instrumental in 
modulating the GGR and TCR subpathways (Sweder & Madura, 2002; 
Svejstrup, 2003; Lommel et a l, 2002; Wang et a l ,  2005b). In particular, recent 
evidence suggests that the XPC and DDB2 proteins provide the principal targets 
for ubiquitin-mediated regulation of the NER machinery, thus facilitating the 
assembly and degradation o f the recognition apparatus. For example, the yeast 
homologue of XPC, Rad4, is ubiquitylated, following UV-irradiation, and elicits 
the targeted degradation of Rad4 by the 26S proteasome (Lommel et a l ,  2002; 
Ramsey et a l ,  2004). Conversely, the UV-induced ubiquitylation of XPC in 
human cells is reversible, and is not targeted by the ubiquitin-proteasome 
pathway (Sugasawa et a l ,  2005; Wang et a l ,  2005c). Additionally, the 26S
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proteasome also operates as a molecular chaperone, which facilitates the 
disassembly of the NER apparatus (Sweder & Madura, 2002).
Recently, Groisman et al. (2003) showed that both the DDB2 and CSA proteins 
are incorporated in separate, but otherwise identical complexes, via the direct 
interaction with DDB1. Additionally, Groisman et a l  (2003) found that both 
complexes possess CUL4A and R o d , which are constituents of the E3 complex. 
Furthermore, both complexes were found to contain CSN, a negative regulator of 
cullin-based ubiquitin ligases. However, CSN differentially regulates the 
ubiquitin ligase activity o f the DDB2 and the CSA complexes, following UV 
irradiation. Although the constituent proteins within both the DDB2 and CSA 
complex exhibit significant homology, they differ biochemically, which reflects 
the differential function o f DDB2 and CSA in GGR and TCR, respectively. So, 
although both the DDB2 and CSA complexes contain CSN, UV-irradiation 
differentially modulates the interaction of CSN with both complexes. It has been 
shown that the CSN complex is displaced from the DDB2 complex following 
UV irradiation, which facilitates the modification of CUL4A by neuronal- 
precursor-cell-expressed developmentally downregulated protein-8 (NEDD8) 
through neddylation (Groisman et al., 2003). This suggests that the E3 activity of 
the DDB2 complex is stimulated by UV irradiation. In contrast, UV irradiation 
initiates the rapid interaction between the CSA and CSN complex, which 
facilitates the suppression of the E3 activity. It has been further speculated by 
Groisman et al. (2003), that the CSA complex is incorporated into the 
transcription preinitiation complex, via its interaction with RNA Pol II. However, 
the mechanistic function of suppressed E3 activity in modulating TCR, following 
the detection o f the stalled transcription apparatus, remains poorly understood. 
Although the DDB2 and CSA E3 complexes mediate different mechanistic 
functions in GGR and TCR, the similarity in the complexes provides a link 
between the two NER subpathways and the ubiquitin/proteasome pathway.
It has also been shown that the polyubiquitylation of DDB2, results in its rapid 
degradation by the ubiquitin-proteasome pathway (Fig. 1.4), which occurs 
following UV-irradiation (Rapic-Otrin et al., 2002). In agreement, Fitch et al. 
(2003b) have shown that the degradation of DDB2 is inhibited following the
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inclusion of proteasome inhibitors, thus further supporting the requirement of the 
ubiquitin-proteasome pathway in the regulation o f GGR. Therefore, the 
ubiquitylation of DDB2 is orchestrated following the direct association between 
DDB1 and CUL4A, which possess E3 activity (Shiyanov et al., 1999; Groisman 
et al., 2003; Matsuda et al., 2005). Furthermore, the importance of functional 
DDB has been shown by Shiyanov et al. (1999), who reported the abolition of 
co-immunoprecipitation between CUL4A and DDB in naturally occurring DDB 
mutants.
More recently, Kapetanaki et al. (2006) have shown that the DDB1-CUL4Ade>B2 
ubiquitin ligase complex is deficient in XP-E cells. Moreover, Kapetanaki et al. 
(2006) have implicated a novel function of the DDB1-CUL4ADDB2 ligase in 
histone modification facilitating subsequent chromatin remodelling from a 
condensed to a relaxed configuration, thus increasing the accessibility for the 
NER apparatus. It was also demonstrated that DDB1-CUL4Ade>B2 E3 colocalises 
with CPDs and co-immunoprecipitates with monoubiquitylated H2A following 
UV-irradiation, which is also dependent upon functional DDB2. This suggests 
that DDB1-CUL4Ade>B2 E3 targets histone H2A for ubiquitylation at UV- 
induced lesions, and that DDB2 mechanistically functions as a possible substrate 
receptor (Kapetanaki et al., 2006).
The systematic modulation of GGR is further regulated by the post-translational 
modification o f the XPC NER factor. The XPC protein displays significant 
modifications immediately following UV-irradiation, which is consistent with 
polyubiquitylation or sumoylation (Sugasawa et al., 2005; Wang et al., 2005c). 
These modifications to XPC do not cause protein degradation, but are reversed 
within two hours (Fig 1.4). Furthermore, these modifications are thought to 
stabilise the XPC protein, thus augmenting the recognition of CPDs. Recently, 
Sugasawa et al. (2005) showed that the DDB2 E3 complex is essential in 
orchestrating the subsequent polyubiquitylation of the XPC protein. Interestingly, 
however, unlike the targeted degradation of DDB2 by the proteasome, following 
DDB2-induced polyubiquitylation, the XPC protein potentiates the DNA-binding 
activity of XPC by displacing DDB (Sugasawa et al., 2005). Furthermore, it has 
been speculated that the polyubiquitylation of the DDB ligase complex, CUL4A,
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facilitates the dissociation of the complex from the lesion. This causes the 
subsequent cessation o f the ubiquitin-proteasom e pathway through 
deubiquitylating enzymes (DUBs), as opposed to targeted degradation through 
the proteasomal pathway. These modifications are reversed within two hours, 
following UV exposure.
Recent evidence presented by Wang et al. (2005c), suggests that XPC is 
covalently modified following UV, through both the small ubiquitin-related 
modifier-1 (SUMO-1) and ubiquitin. Furthermore, it was shown that in addition 
to the ubiquitin-proteasome system, both functional DDB2 and XPA are required 
for these XPC modifications, following UV-irradiation. From these data Wang et 
al. (2005c) further speculated that the UV-induced sumoylation o f XPC is 
essential for the stabilisation of the XPC protein, thus preventing its degradation. 
Wang et al. (2005c) have also postulated that the sumoylation o f XPC may 
abolish the affinity o f the XPC protein to damaged sites, thus facilitating the 
dissociation o f XPC from the NER apparatus, permitting the subsequent 
recruitment o f further NER proteins. XPC-hHR23B is essential in the initial 
assembly of the preincision complex; however, XPC-hHR23B is superfluous 
during the formation of the dual incision complex (Wakasugi & Sancar, 1998).
Interestingly, it has been speculated that polyubiquitylated XPC is protected from 
proteasome-mediated degradation through its interaction with the ubiquitin- 
associated (UBA) domains o f the hHR23A and hHR23B proteins, which protect 
XPC from degradation (Ng et al., 2003; Okuda et al., 2004). In agreement with 
these findings, further investigations in yeast have shown that the homologous 
protein, Rad23, regulates NER through its interaction with members o f the 
proteasome (Russell et al., 1999; Ortolan et al., 2004; Heessen et al., 2005; 
Gillette et al., 2006).
Although basal levels o f both DDB2 and p53 are required for the modifications 
exhibited by the XPC protein, it has been speculated that the ubiquitylation and 
subsequent degradation of DDB2 is also essential for the successful modification 
of the XPC protein (Ford et al., 2005). In addition, however, it has been 
speculated that these modifications require both the ubiquitylation and
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degradation of DDB2; the first to assist DDB-CUL4A mediated ubiquitylation of 
XPC, and the second to facilitate the displacement of DDB2 from a damaged 
site, thus permitting the subsequent recruitment of XPC. Additionally, the 
degradation of DDB2 is thought to facilitate the recruitment of NER proteins and 
increases the accessibility for the sequential assembly of the NER apparatus (Fig. 
1.4).
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Figure 1.4. Regulation of GGR by the polyubiquitylation of XPC. In undamaged cells, the DDB E3-ligase complex 
(including DDB1-DDB2, CUL4A and ROC1) is in an inactive state, due to its interaction with the negative regulator, CSN. 
Furthermore, XPC is not ubiquitylated irrespective of its association with the DDB ligase complex (step 1). Following UV 
exposure, the DDB ligase complex translocates onto the DNA lesion, causing neddylation (N) of the CUL4A subunit and the 
disassociation of CSN. This results in the activation of the DDB ligase complex and the recruitment of XPC-hHR23B to the 
damaged DNA (step 2). XPC, DDB2 and CUL4A are polyubiquitylated by the DDB ligase complex (step 3). The 
polyubiquitylation of XPC potentates the DNA-binding and mechanistic action of XPC. Conversely, polyubiquitylation of 
DDB2 targets it for proteasomal-mediated degradation. The ubiquitylated DDB ligase complex mediates the displacement of 
the complex from the damaged site (step 4). The final abolition of this pathway may involve DUBs (adapted from Huang & 
D’Andrea, 2006).
As previously discussed, TCR preferentially repairs lesions on the transcribed 
strand o f transcriptionally active genes, and is regulated through the 
polyubiquitylation of RNA Pol II. It has been previously shown that both CS-A 
and CS-B cells are defective in UV-induced ubiquitylation of RNA Pol II 
(Bregman et al., 1996), which suggests that the functional activity of both CSA 
and CSB is essential in orchestrating the polyubiquitylation of RNA Pol II. 
Polyubiquitylated RNA Pol II is thought to undergo degradation or bypass the 
transcriptional block, thus facilitating the continuation of mRNA synthesis 
(Huang & D ’Andrea, 2006). From the currently available data, it has been 
suggested that the CSA and CSB proteins co-purify with the CSN complex 
(Huang & D ’Andrea, 2006), and possesses E3 activity (Groisman et al., 2003). 
Recently, Groisman et al. (2006) has for the first time shown a functional 
relationship between the CSA and CSB proteins in the regulation of TCR, via the 
ubiquitin-dependent degradation pathway. They showed that CSB is 
ubiquitylated by CSA ligase and degraded by the proteasome in a UV-dependent 
manner during the final stages o f TCR. Furthermore, they showed that CSB 
degradation influences the recovery of RNA synthesis after TCR. Fousteri et al. 
(2006) has also shown that CSA and CSB display differential roles in TCR 
regulation through the recruitment of chromatin remodelling or repair factors to 
stalled RNA Pol II in vivo. They showed that CSB regulates the recruitment of 
the chromatin remodelling factor HAT p300, TFIIH, XPG, RPA, CSA/DDB1 
E3-ub ligase with the CSN complex, and the other core NER components 
(excluding XPC). Conversely, while CSA is dispensable for the recruitment of 
the NER factors, CSA is required for the recruitment of the nucleosomal binding 
protein HMGN1, XAB2 and TFIIS. Interestingly, Fousteri et al. (2006) also 
showed that the assembly of this multiprotein complex occurs without disruption 
to the stalled RNA Pol II.
The precise molecular function of ubiquitylated RNA Pol II has remains elusive. 
However, a recent study has suggested that the E3 complex facilitates the 
degradation of stalled RNA Pol II (Kleiman et al., 2005). In support o f these 
findings, previous yeast studies have shown that the yeast orthologue of CSB, 
Rad 26, interacts with Defl, which is essential in the ubiquitylation of RNA Pol 
II, following DNA damage. This interaction between Rad26 and Defl is not
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required for TCR (Woudstra et al., 2002). By contrast, Rad26 is indispensable 
for TCR, but is not required for the degradation of RNA Pol II. Therefore, it has 
been speculated by Svejstrup et al. (2003), that the abolition of Rad26-dependent 
TCR o f UV-induced damage, activates the targeted ubiquitylation and 
degradation of RNA Pol II through D efl. The targeted degradation of RNA Pol 
II is thought to initiate the removal o f lesions from the transcribed strand by 
GGR.
1.9 Syndromes associated with defective NER
The importance o f functional DNA metabolism and stress signalling/repair 
pathways, in maintaining genome stability and cellular homeostasis, has been 
exemplified by a series o f human genetic disorders associated with defects in 
DNA repair and cellular signalling. Defects in approximately 35 distinct genes 
have been shown to cause 16 human genetic disorders, phenotypically presenting 
segmental progeria, a predisposition to tumorigenesis, or a complexity o f both 
(Lehmann, 2003). In particular, defects in 11 distinct genes, which orchestrate 
the functioning o f the NER pathway and/or basal transcription (and translesion 
synthesis), have been associated with autosomal recessive photosensitive 
syndromes: XP, XP with neurological deficiency and CS (Fig. 1.5). Additionally, 
less frequent photosensitive syndromes (<50 characterised individuals 
worldwide), include: trichothiodystrophy (TTD), combined xeroderma 
pigmentosum with Cockayne syndrome (XP-CS), combined xeroderma 
pigmentosum with trichothiodystrophy (XP-TTD), XP with DeSanctis- 
Cacchione syndrome (XP-DSC), cerebro-oculo-facio-skeletal syndrome (COFS) 
and UV-sensitive (UVsS) syndrome (Fig. 1.5). Although XP, CS and TTD are 
genetic disorders o f defective NER, the spectrum of clinical manifestations 
exhibited by these three syndromes differs significantly. Moreover, the more 
recent emergence of genotypes that exhibit the combined phenotypes (such as 
XP-CS, XP-TTD and XP-DSC) has further increased the clinical and molecular 
complexity o f these syndromes (Fig. 1.5).
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1.9.1 ‘Classical’xeroderma pigmentosum (XP)
XP, initially described in the late 19th century by Hebra & Kaposi, is a rare 
(approximately 1 in 250, 000 newborns) autosomal recessive hereditary human 
skin disease. XP is further classified into two distinct entities, known as 
“classical” and variant. Systematic analysis o f classical XP, utilising cell fusion 
methodologies (de Weerd-Kastelein et al., 1972), resulted in the elucidation of 
seven complementation groups designated XP-A to XP-G (Fig. 1.5; as described 
in section 1.1.4). Each corresponding to defects in the XPA to XPG  genes, which 
perform vital functions during NER and transcription. Accordingly, abolition of 
GGR (with or without defects in TCR) causes XP. GGR has a greater influence 
on carcinogenesis compared to defective TCR. Evidence in support o f this comes 
from human tumours where 90% of the G to T transversion mutations identified 
in the TP 5 3 tumour suppressor gene correspond to damage on the non­
transcribed DNA strand (Denissenko et al., 1998).
The heterogeneous nature o f XP is typified by the multitude o f clinical 
manifestations documented in ~1000 XP cases (Andressoo & Hoeijmakers, 
2005). The hallmark clinical manifestations exhibited by XP patients include a 
severe photosensitivity to the UV constituent o f sunlight and a marked 
predisposition to skin neoplasia, with a >2000-fold incidence of skin tumours 
(Stary & Sarasin, 2002). Initially, XP patients present extensive dermatitis Solaris 
and freckling, subsequent to minimal exposure to sunlight. Dermatitis Solaris 
may continue for weeks resulting in erythema. This is followed by the 
appearance o f atypical UV-induced cutaneous hyperpigmentation with dry 
parchment-like skin. XP patients exhibit further atypical cutaneous alterations, 
including increased melanin production in the basal cell layer, loss o f skin 
elasticity, actinic keratosis, poikiloderma and premature skin aging. Further 
pathophysiological disturbances to the skin include atrophy, scabbing and 
extensive scarring. This is followed by the progressive formation of cutaneous 
lesions, resulting in a multiplicity of cutaneous tumours. This is observed in XP 
patients as young as 3-5 years old, who present cutaneous tumours, including: 
BCC and SCC, resulting in extensive facial disfigurement. Conversely, the
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occurrence of BCCs and SCCs in NER-proficient individuals is observed at a 
mean age o f 50-60 years (Fig. 1.2; Daya-Grosjean & Sarasin, 2005). In XP 
patients under the age of 20 years, the incidence of pigmentary tumours, such as 
malignant melanoma, is >2000-fold higher than in age-matched NER-proficient 
individuals. BCCs and SCCs account for approximately 96% of sporadic skin 
cancers and malignant melanoma account for 4% in the general population. By 
contrast, approximately 22% of skin cancers in XP patients are malignant 
melanoma (Takebe et al., 1989; Kraemer et al., 1994). Further malignancies 
including keratoakanthomas and sarcoma have been reported (De Silva et al.,
1999). Additionally, the incidence of neoplasia in the oral mucosa and internal 
organs is significantly higher in XP compared to the general population. XP 
patients most frequently die prior to adulthood, as a result o f metastatic 
dissemination (English & Swerdlow, 1987).
XP patients exhibit several other pathophysiological features associated with 
neurological degeneration (Fig. 1.5), resulting from the progressive accumulation 
of DNA base damage. Symptoms of motor impairment, such as reduced reflexes, 
ataxia and spasticity have been widely documented. In addition, mental 
retardation coupled with impaired speech development has been reported. The 
presentation o f severe neurological abnormalities has been further termed as 
DeSanctis-Caccione syndrome (discussed in Section 1.9.6). These patients are 
characterised by severe growth retardation, spasticity and intellectual 
impairment. Further pathophysiological manifestations exhibited in DeSanctis- 
Caccione syndrome included segmental demyelination, microcephaly, deafness 
and epilepsy. Tumours o f the central nervous system (CNS), including 
astocytomas, medulloblastomas, glioblastomas and malignant schwannoma, have 
been reported (Nakamura et al., 1991).
Ophthalmological manifestations are a key pathophysiological feature, and have 
been documented in approximately 40% o f XP patients. Conjunctival 
inflammation, blepharitis, ectropion, symblepharon, vascular pterygia, 
fibrovascular pannus formation and comeal ulcerations have been described 
(Goyal et al., 1994). Benign lid papillomas, comeal dysplasias and ocular 
neoplasis have been observed.
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1.9.2 Xeroderma Pigmentosum variant (XP-V)
Initially described as ‘pigmented xerodermoid (Jung et al., 1970), XP-V patients 
exhibit a phenotype frequently observed in classical XP, such as photosensitivity 
and a marked predisposition to cutaneous malignancy. However, the 
symptomatic presentation in XP-V patients is significantly milder than ‘classical’ 
XP and documented much later in life (~30 years o f age). Furthermore, 
approximately only 20% of individuals with XP are assigned to the XP-V 
complementation group (reviewed by Gratchev et al., 2003). Intriguingly, at the 
cellular and biochemical level, XP-V cells display proficient NER, but possess a 
defect in post replication repair following UV irradiation (Lehmann et al., 1977). 
Therefore, XP-V cells are deficient in the ability to synthesise intact 
complementary daughter DNA on the UV damaged parental template strand. 
Furthermore, cultured fibroblasts, obtained from XP-V individuals, exhibit a 
mild sensitivity to the killing effects of UV, compared to ‘classical’ XP 
individuals, which display a severe hypersensitivity. Burk et al. (1971) reported 
that a patient exhibiting severe pathophysiological features o f XP displayed 
normal NER in his fibroblasts, lymphocytes and neoplastic cells. Subsequent 
cases of pigmented xerodermoid and XP-V were reported as discrete entities; 
until Cleaver et al. (1980) substantiated that the biochemical and molecular 
defects in pigmented xerodermoid and XP-V were analogous (Fischer et al., 
1980).
Following extensive biochemical studies, Masutani et al. (1999) showed that a 
protein isolated from HeLa cells restored the capability of XP-V cells to replicate 
DNA containing CPDs, by bypassing a TT-dimer in a error-free manner, while 
incorporating two adenines opposite the TT-dimer. Sequencing o f the isolated 
protein resulted in the subsequent cloning of a translesion DNA polymerase, 
referred to as polymerase eta (pofri). Polri is a member of the Y-family 
polymerases, which facilitate error-free bypass of replication-blocking lesions, 
via a process called translesion synthesis (TLS). Additionally, the highly 
specialised properties o f Y-family DNA polymerases (including high flexibility 
and low processivity) permits polq to bypass DNA lesions and rapidly dissociate,
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thus facilitating the rapid resumption o f the replication machinery and the 
continuation o f the replicative polymerase (Ling et al., 2001). Further studies 
have suggested that polq activity is perturbed by the presence of a 6-4PP. 
Following the misincorporation of a G opposite the 3 ’ (only) T of the 6-4PP, 
polri is displaced from the DNA (Zhang et al., 2000), thus suggesting an 
incapacity to bypass 6-4PPs. Additionally, this further suggests that polri is a 
highly specialised bypass DNA polymerase, which facilitates the repair of UV- 
induced CPDs in an error-free manner. Therefore, aberrant TLS explains the 
molecular characteristics o f XP-V cells and the phenotypic features displayed by 
XP-V patients. As the accurate bypass activity o f polri is abolished and TLS is 
undertaken by an alternative error-prone bypass polymerase(s), thus resulting in 
an increase in the number o f mutagenic events in the genome. Additionally, the 
cessation of polr) activity causes the attenuation of S phase progression and the 
formation o f double strand breaks and sister chromatid exchange (Cordeiro- 
Stone et al., 2002; Limoli et al., 2000; Limoli et al., 2002), which significantly 
contributes to the increased incidence of cutaneous malignancy.
1.9.3 Cockayne syndrome (CS)
CS, first described by Edward Alfred Cockayne (1936), is a rare autosomal 
recessive disease typically characterised by a severe photophobia to sunlight. At 
the molecular level, CS is characterised by the abolition o f recovery of RNA 
synthesis, after UV exposure, despite the normal repair capacity displayed by the 
genome overall (Mayne & Lehmann, 1982; Proietti-De-Santis et al., 2006). Like 
XP, the photosensitivity in CS is manifested as a severe rash, however, the 
hallmark characteristic o f XP, a marked predisposition to skin neoplasia, is 
absent in CS. This is exemplified by the —180 characterised CS patients, which 
have displayed no predisposition to cutaneous or internal neoplasia (Spivak & 
Hanawalt, 2006). An extensive review of the clinical manifestations exhibited by 
140 CS cases suggests that growth failure is the most frequently observed 
feature, which is exhibited within the first year of life (Nance & Berry, 1992). 
Premature aging is a further cardinal pathophysiological feature exhibited in CS. 
The observation that CS cells exhibit a severe deficiency in the recommencement
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of RNA synthesis following damage has resulted in CS being described as a 
‘transcription syndrome’ in addition to a ‘repair syndrome’ (Bootsma & 
Hoeijmakers, 1993). It has been shown that cell extracts, derived from UV- 
irradiated CS cells, were unable to transcribe even though the DNA template was 
free of lesions (Rockx et al., 2000). Additionally, both RNA Pol II and the 
associated basal transcription apparatus are not sequestered to the promoter sites 
of ‘housekeeping’ genes. It has also been suggested that the acetylation of H4 is 
severely compromised at transcription initiation sites. The deficiency in 
transcription suggests a reason for the complete absence o f tumour 
predisposition, as a result o f the elimination o f damaged cells by UV-induced 
apoptosis (Ljungman & Zhang, 1996). Conversely, it has been shown that the 
presence of wild-type CSB is dispensable for the transcription of p53-responsive 
genes, following DNA damage (Proietti-De-Santis et al., 2006).
Characteristically, normal in utero development is followed by a state o f 
cachectic dwarfism, which progresses during the first year of life. Subsequently, 
CS patients present an atypical progeroid phenotype coupled with large ears and 
nose, sunken eyes, thinning of the skin and hair, and a curved standing posture. 
CS patients also demonstrate a thin appearance, resulting from the progressive 
loss of subcutaneous fat tissue (Nance & Berry, 1992). Further symptomology 
displayed in CS, includes an array of skeletal abnormalities such as a bird-like 
face, dental caries, kyphosis o f the spinal cord and osteoporosis. In addition, 
progressive neurological degeneration is observed, coupled with delayed 
psychomotor development and mental retardation. Microcephaly is observed in 
CS patients over 2 years o f age, and nerve biopsies frequently demonstrate 
myelination abnormalities. The postnatal neurological manifestations displayed 
by CS patients are thought to occur due to aberrant neuronal proliferation, 
migration and deployment (Rapin et al., 2000). Moreover, the progressive 
accumulation in oxidative DNA damage may further explain the postnatal onset 
o f CS. The early onset o f cataracts coupled with marked neurological 
abnormalities and microcephaly, is frequently indicative of poor prognosis and 
survival. Further clinical features exhibited in CS include sensorineural hearing 
loss, progressive pigmentary retinopathy. CS patients also present impaired 
sexual development along with their postnatal growth failure. The failure to
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thrive coupled with neurological degeneration is followed by pneumonia and 
respiratory infections, resulting in death at a mean age of 12.5 years. Historically, 
CS patients have been assigned to one of two classic complementation groups 
(Fig. 1.5), CS-A or CS-B (Troelstra et al., 1992; Henning et al., 1995). However, 
patients with mutations in three XP genes, X P B , XPD  and XPG  also exhibit 
clinical manifestations exhibited by CS patients, in addition to displaying 
features common to XP. Further classification of CS has resulted in the 
characterisation o f a spectrum of distinct but associated syndromes differing in 
the underlying genetic defect and pathophysiological severity. These include CS 
type 1 (CS-A), CS type 2 (CS-B), COFS (discussed in section 1.9.7), Pena- 
Shokeir type 2, CS type 3, and XP-CS (discussed in Section 1.9.5).
1.9.4 Trichothiodystrophy (TTD)
TTD, first described by Price et al. (1980), is a rare autosomal recessive 
syndrome. Three genetic complementation groups have been identified, which 
correspond to mutations in the XPB, XPD  and TTD A (TFB5) genes (Fig. 1.5), 
and all o f which are constituents of the 11-subunit transcription/repair factor 
TFIIH apparatus. Therefore, the phenotypic characteristics exhibited by TTD 
patients are attributed to an impairment of the basal transcription machinery, in 
addition to the DNA repair defect. Therefore, like CS, TTD has been referred to 
as a ‘transcriptional syndrome’ (de Boer & Hoeijmakers, 2000; Bergmann & 
Egly, 2001). Like XP and CS, TTD is frequently characterised by a severe 
photophobia to sunlight. Unlike XP however, TTD patients do not display an 
atypical predisposition to skin neoplasia or pigmentary abnormalities. Indeed, 
many TTD patients exhibit varying degrees o f photosensitivity and aberrant NER 
(Stefanini et al., 1986). Furthermore, it has been previously shown that TTD 
patients exhibit a concordant relationship between photosensitivity and 
heterogeneous repair of UV-induced lesions (Broughton et al., 1990; Stefanini et 
al., 1992). However, some TTD patients do not display sensitivity to sunlight 
(Lehmann, 2001).
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The cardinal manifestations of TTD include an atypical predisposition to 
sulphur-deficient brittle hair caused by a diminution of cysteine-rich matrix 
proteins within the hair shaft, resulting in trichoschisis. This is further typified by 
“tiger tail” patterns observed in the brittle hair fibres (Liang et al., 2004). Further 
clinical features presented by TTD patients, include ichthyosis, mental and 
physical retardation. Due to the heterogeneous nature of TTD, a multiplicity of 
syndromes have been erroneously described as discrete entities (including Pollitt 
syndrome, Tay’s syndrome, Amish brittle hair syndrome, Sabinas syndrome and 
Marinesco-Sjogren syndrome), which have subsequently been reassigned as 
TTD. Although infrequently documented, TTD patients display a pattern of 
mental development that is comparable to that o f CS patients. Further 
symptomatic features include: low IQ, hyperreflexia, tremor and ataxia. In 
addition, microcephaly and neurodysmyelination of the cerebral white matter has 
been observed. Aberrant development o f the reproductive system, such as 
hypogonadism and cryptorchidism has been reported, resulting in reduced 
fertility. As observed in CS, cachectic dwarfism is a feature frequently exhibited 
in TTD. However, the extent o f cachexia varies considerably in TTD. 
Additionally, like CS, skeletal abnormalities are a further feature o f TTD, 
including: a bird-like face, abating chin, delayed skeletal development, axial 
osteosclerosis and peripheral osteoporosis.
1.9.5 Combined XP-CS
A combined XP-CS phenotype has been documented in an infrequent number of 
photosensitive individuals (Lindenbaum et al., 2001). These patients display the 
cutaneous disturbances (such as freckling, BCCs, SCCs and malignant 
melanomas) associated with XP, coupled with the progressive neurological 
abnormalities observed in CS. Pigmentary disturbances have been observed as 
early as 2 weeks of age, with cutaneous neoplasia displayed at 2.5 years of age. 
Among the 9 reported cases, the additional clinical manifestations displayed by 
combined XP-CS patients are extensively heterogeneous, as XP-CS patients 
exhibit a complexity of additional pathophysiological features, such as cachexia, 
dwarfism and pigmentary retinal degeneration. However, the clinical features
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typically associated with CS are more prevalent in combined XP-CS patients. For 
example, in XP, the neurological abnormalities are attributed to primary 
neurological degeneration. By contrast, the neurological pathology observed in 
CS results from demyelinating neuropathy. At autopsy, like CS, combined XP- 
CS patient’s present marked dysmyelination (Lindenbaum et al., 2001). At the 
cellular level, however, XP-CS cells are analogous to XP cells, displaying 
attenuation in UDS and the complete abolition of photoproduct repair. This has 
been further associated with the generation of nicks in DNA subsequent to UV 
radiation. Intriguingly, Bemeburg et al. (2000) established that the formation of 
nicks occurred at sites other than that induced by DNA damage. It has been 
speculated that the induction o f nicks is caused by a defect in the TFIIH 
complex. This causes the NER apparatus to erroneously recognise a transcription 
initiation site as a damaged region, thus resulting in generation of DNA nick at a 
transcription initiation site.
To date, three complementation groups (XP-B, XP-D and XP-G) have been 
elucidated, which display a combined XP-CS phenotype (Fig. 1.5). Three 
patients have been identified with a point mutation in the XPB  gene, and display 
a relatively mild CS phenotype. Two patients have been assigned to the XP-D 
complementation groups, whilst the remaining four patients possess mutations in 
the XPG  gene (Lindenbaum et a l , 2001). The XPD-XPCS and XPG-XPCS 
patients presented severe phenotypes and all died before the age of seven.
1.9.6 Xeroderma pigmentosum with DeSanctis-Cacchione 
(XP-DSC) syndrome
XP-DSC was first identified by DeSanctis & Cacchione (1939), who reported the 
association between severe neurological abnormalities coupled with the 
dermatological manifestations o f XP. Approximately 20% of XP patients display 
neurological abnormalities (Fig. 1.5). Whilst the formation and progression of 
cutaneous neoplasia in XP-DSC are comparable to that observed in XP, the 
average presentation of photosensitivity for XP-DSC is 6 months. Conversely, 
patients assigned to “classical” XP complementation groups display sensitivity to
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sunlight at 2 years (Kraemer et al., 1987). Although 80% of XP-DSC patients 
present severe mental retardation, less than 25% of patients exhibit concurrent 
microcephaly, growth retardation and gait disturbances, such as spasticity, and 
ataxia (Kraemer et al., 1987; Itoh et al., 1999; Brooks, 2002).
Interestingly, XP-DSC patients do not present demyelination of CNS and the 
peripheral nervous system (PNS), or retinal degeneration and calcification of the 
basal ganglia, typically associated with CS. However, XP-DSC patients display 
diminution o f specific neuronal populations. In particular, extensive cell death 
occurs within the cortex and substantia nigra of the CNS, resulting in severe 
intellectual impairment and dementia (Brooks, 2002; Itoh et al., 1999).
1.9.7 Cerebro-oculo-facial-skeletal (COFS) syndrome
Although COFS was first identified in 1971 (Lowry et al., 1971), the multiplicity 
of clinical manifestations was not unequivocally documented until 1974 (Pena & 
Shokeir, 1974). COFS is an autosomal recessive hereditary syndrome with only 
approximately 50% o f patients presenting a hypersensitivity to the UV 
constituent o f sunlight. Until recently, COFS was considered a severe variant 
form of CS type II, as the phenotypic characterisation of cell lines ascertained 
from genotypically characterised COFS patients are indistinguishable from those 
cell lines derived from typical CS patients. However, the comprehensive analysis 
of a recently identified COFS patient resulted in the elucidation of a previously 
uncharacterised mutation in the XPD  gene. This suggests that, the underlying 
molecular defect is not limited to a single gene mutation. The cardinal diagnostic 
features indicative of COFS includes skeletal defects at birth resulting from fetal 
immobility and cataracts. However, these two clinical features in isolation may 
not permit a definitive diagnosis (Bohr et al., 2005). The differentiation between 
COFS and CS can be determined by the dissimilar ocular defects exhibited by 
the two syndromes. COFS patients present microcomea with optic atrophy. By 
contrast, CS patients exhibit less severe ocular defects and are most frequently 
associated with pigmentary retinopathy (Andressoo & Hoeijmakers, 2005). 
Further clinical manifestations o f COFS include: reduced birth weight, loss of
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subcutaneous fat, hypogonadism, microcephaly, cerebral atrophy, severe mental 
retardation, hypoplasia o f the corpus callosum, progressive joint contractures and 
hypotonia (Pena & Shokeir, 1974).
Until recently, the underlying molecular defect in COFS has remained 
uncharacterised. However, recent reports have suggested that COFS is 
heterogeneous for mutations in the X P D ,X P G  and CSB genes (Fig. 1.5). For 
example, Graham et al. (2001) identified a point mutation in the XPD  gene. 
Furthermore, Meira et al. (2000) documented a mutation in the CSB  gene, 
resulting in a mild C-terminal truncation of the CSB protein.
1.9.8 UV-sensitive syndrome (UV^S)
Unlike XP, CS and TTD, the identification of patients with UVsS remains 
extensively problematic, due to a relatively asymptomatic presentation and the 
complete absence of any distinguishing pathophysiological features. The first 
realisation that UVsS was a discrete entity was made by Cleaver & Thomas 
(1993), who took a large cohort of UV sensitive individuals and concluded that a 
subset were distinct from XP and CS. Initially, patients with UVsS present an 
atypical response to UV exposure similar to that exhibited by mild XP, resulting 
in acute sunburn, coupled with cutaneous photosensitivity (erythema) and mild 
pigmentary disturbances (skin dryness and extensive freckling), while the 
multiplicity o f clinical manifestations observed in XP, CS and TTD are 
completely absent.
To date, UVsS has remained idiopathic, due to an insufficient number of patients 
and the erroneous assignment of previously documented cases to the CS-B and 
XP-E complementation groups (Miyauchi-Hashimoto et al., 1998; Itoh et al.,
2000). However, more recent investigations have revealed that UVsS is 
attributed to a defect in the TCR of UV-induced cytotoxic lesions in the 
transcribed strand of transcriptionally active genes (Spivak et al., 2002), whilst 
the GGR of UV-induced CPDs and 6-4PPs remains normal. Additionally, at the
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cellular and biochemical level, the responses elicited by UV S and CS cells in
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response to UV light are indistinguishable (Spivak et al., 2002), which may 
explain the absence o f cutaneous or internal tumours. Furthermore, UVsS cells 
exhibit a similar pattern o f p53 accumulation to CS cells (Ohta et al., 1999). 
UVsS cells, like CS cells, are defective in the recovery of RNA and DNA 
synthesis following UV damage. Interestingly, the cardinal hallmark 
characteristics o f CS, including neurological and developmental abnormalities, 
are not observed. It has been speculated that the absence of neurological and 
developmental abnormalities in UVsS patients is attributed to the preservation of 
the proficient removal and repair of oxidative lesions, or in transcriptional bypass 
of these lesions (Spivak, 2004). In agreement with this, Spivak & Hanawalt 
(2006) have demonstrated that UVsS, but not CS-B cells, are proficient in host 
cell reactivation of plasmids possessing oxidative DNA lesions.
To date, six patients with UVsS have been identified (Spivak, 2005), and 
assigned to one of two complementation groups and allocated the nomenclatures: 
UVsS/CS-B and UVsS/A. In concordance, cell fusion studies o f cells obtained 
from UVsS patients, resulted in the complementation of cell lines derived from 
previously characterised XP and CS patients (Itoh et al., 1995). Further 
experimentation has resulted in the identification o f a CSB  gene mutation 
specific for two UVsS patients and their reclassification to the UVsS/CS-B
• c t t
complementation group. However, the gene defect in four UV S patients remains 
uncharacterised (UVsS/A).
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1.10 p53: The guardian of the genome
The p53 tumour suppressor, identified in 1979 (Lane & Crawford, 1979; Linzer 
& Levine, 1979), was first isolated in transformed human cells, bound to the 
simian virus 40 (SV40) large T antigen (LTAg). The elucidation of p53 structure 
and function has revolutionised research into tumour biology. Indeed, a landmark 
study undertaken by Finlay et al. (1989), significantly contributed to the 
realisation that p53 was an essential inhibitor of cellular transformation. In 
addition to its antiproliferative role, p53 function has been extended to the 
regulation o f an array o f cellular processes, which are essential for the 
preservation of cellular homeostasis and maintaining genome stability.
The TP53 tumour suppressor gene encodes a sequence-specific transcription 
factor that regulates the activation of general stress signalling cascades in 
response to a plethora of exogenous and endogenous DNA damage such as UV, 
hypoxia, oxidative stress, nucleotide insufficiency, spindle damage, telomere 
dysfunction and hyperproliferative oncogenic signals. In addition, p53 maintains 
genome stability and preserves cellular homeostasis by modulating cellular 
growth and differentiation through the activation and regulation of a diverse 
range o f cellular responses: transcriptional activation, cell cycle arrest, DNA 
repair, apoptosis, senescence and angiogenesis (reviewed by Latonen & Laiho, 
2005). The dysregulation o f these cellular processes results in genomic 
instability, cellular transformation and tumorigenesis. Following genotoxic 
stress, p53 is activated and stabilised via a multiplicity o f posttranslational 
modifications including: phosphorylation, dephosphorylation, acetylation, 
sumoylation and glycosylation. This generates a sequence-specific DNA binding 
domain, which binds to consensus p53 response elements situated within the 
promoter or intronic constituents o f target genes. In particular, N-terminal 
residues of p53 such as Seri 5, Ser20, Ser33, Ser37, and Ser392 at the C-terminal 
end are phosphorylated within minutes, following genotoxic damage such as UV 
(reviewed by Melnikova et al., 2005).
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Essentially, the p53 tumour suppressor mechanistically functions as a 
transcription factor, which orchestrates the differential regulation o f a 
multiplicity o f downstream gene targets. Previously, Tokino et al. (1994) 
identified 57 tagged sequences from a human genomic library, which 
corresponded to p53 binding sites. Furthermore, Zhao et al. (2000) used 
oligonucleotide arrays to characterise p53 regulated gene expression and 
identified over one hundred downstream targets.
The importance o f  p53 in orchestrating cellular homeostasis and the 
antiproliferative machinery has been exemplified in human cancers. TP 5 3 
mutations, resulting in aberrant functioning or complete abolition of p53 activity, 
are found in approximately 50% of all human cancers (Harris & Hollstein, 1993). 
Furthermore, 5% of TP53 gene mutations have been identified in the regulatory 
domain, with 95% of the mutations occurring in the central DNA binding domain 
(Hoogervorst et al., 2005). Furthermore, mutations in the TP53 gene can result in 
the addition of oncogenic functions through a dominant-negative phenotype. The 
wild-type p53 protein, produced by the normal allele, is inactivated by 
hetrodimerization with the mutated p53 protein (Milner and Medcalf, 1991).
1.10.1 p53 structure
The TP53 gene has remained relatively conserved throughout evolution (Soussi 
et al., 1987; Soussi et al., 1990). In human cells, p53 is found situated on the 
short arm of chromosome 17 (17pl3). The human TP53 gene encodes a nuclear 
phosphoprotein of 393 amino acids and possesses a molecular weight o f 43.6 
kDa. Like many transcription factors, p53 contains a series of functional 
domains, which tightly regulate the functional activity of its transcription factor 
activity and a multitude of downstream events. p53 contains five structurally and 
functional discrete domains: (1) amino-terminal (N-terminal domain); (2) 
proline-rich domain; (3) sequence-specific DNA binding domain; (4) 
oligmerisation domain; (5) carboxy-terminal (C-terminal) domain (Fig. 1.6). The 
N-terminus, also referred to as the transactivation domain (TAD), possesses an 
acidic domain (amino acids 1-42), which is essential for the interaction with
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constituents o f the transcriptional apparatus, such as TBP and TAFs, thus 
facilitating the transcriptional activation and repression of downstream target 
genes (Seto et a l , 1992; Xiao et a l , 1994; Lu & Lavine, 1995; Thut et a l , 1995; 
Chao et a l , 2000). Contiguous to the N-terminal domain is a proline-rich domain 
(amino acids 63-97), which contains five proline repeats. This region is 
instrumental in the regulation of the apoptotic pathway (Walker & Lavine, 1996; 
Sakamuro et a l, 1997; Venot et a l, 1998). Furthermore, the proline-rich domain 
has been implicated as a negative regulator of p53. The sequence-specific DNA 
binding domain (102-292) is composed of a DNA consensus sequence 5 ’- 
PuPuPuC(A/T)-(T/A)GPyPyPy-3’ (Pu, purine; py, pyrimidine) that is located in 
the central region of the p53 protein (el-Deiry et a l,  1992). The oligomerisation 
domain (amino acids 323-356) is required for the formation of p53 tetramers, 
which permits the sequence-specific binding o f p53 with DNA (Wang et a l ,  
1993; Friedman et a l ,  1993). Finally, the C-terminal domain, which resides 
between amino acids 363-393, maintains p53 in an inactive state until 
posttranslational modifications (such as phosphorylation and acetylation) 
allosterically activate the protein (Fig. 1.6).
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Figure 1.6. Schematic of human p53 protein structure. The p53 protein is composed of 393 
amino acids. A multiplicity of factors interact with p53 and those that are of particular 
interest are highlighted. Normal p53 functionality is dependent upon a series of 
posttranscriptional modifications, such as phosphorylation, acetylation and sumoylation. 
The most significant and well-characterised residues that undergo posttranslational 
modification have been highlighted. Abbreviations: Lys, lysine; NES, nuclear export 
signal; NLS, nuclear localisation signal; Ser, serine; SH3, SRC homology 3-like.
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1.10.2 Regulation o f p53
Under normal physiological conditions, wild-type p53 is expressed at low basal 
levels in cells. The transient nature of p53 is attributed to a relatively short half- 
life of approximately 10-20 minutes, resulting from the rapid turnover of p53, 
mediated by the ubiquitin-proteasomal pathway (Giaccia and Kastan, 1998). 
However, exposure to a plethora o f exogenous and endogenous agents, such as 
UV, IR, hypoxia, nucleotide imbalance, spindle damage or hyperproliferative 
signals (Levine, 1997), elicit the transient induction of nuclear p53 protein levels 
(Kastan & Kuerbitz, 1993), in a dose-dependent manner with negligible effect on 
p53 mRNA levels. The increased stability of the p53 protein occurs within 
minutes following DNA damage, due to a series o f posttranslational 
modifications at the N-terminus (including S eri5, Ser20 and Ser33), which 
inhibits the interaction of proteins that regulate its degradation (Fig. 1.7), such as 
the transformed 3T3 cell double minute 2, p53 binding protein (Mdm2; Shieh et 
al., 1997; Shieh et al., 1999).
The ubiquitin-proteasome pathway mediates the degradation of p53 through the 
targeted action o f the 26S proteasome complex (Rodriguez et al., 2000). The 
ubiquitylation of p53 is initiated by the mechanistic action of the proto-oncogene, 
Mdm2, which possesses E3 activity (Yang et al., 2004; Vargas et al., 2003). 
Interestingly, Mdm2 is a transcriptional downstream target of p53 and a repressor 
of p53 function, thus resulting in the establishment of a negative autoregulatory 
feedback loop (Momand et al., 1992; Wu et al., 1993). Mdm2 binds the N- 
terminus of p53, thus preventing the subsequent interaction between p53 and the 
transcriptional apparatus. This results in the mono-ubiquitylation of p53, which 
mediates the nuclear export o f Mdm2-bound p53 for subsequent degradation by 
the ubiquitin-mediated proteolytic pathway (Honda et al., 1997; Freedman & 
Lavine, 1998). Furthermore, Mdm2 interacts with the p53 TAD, resulting in the 
abolition o f p53-mediated transcriptional activation (Chen et al., 1993). In 
addition to Mdm2, HAT p300 is required for p53 degradation (Grossman et al., 
1998; Zhu et al., 2001), as Mdm2 can only monoubiquitinate p53 (Lai et al.,
2001). Following nuclear export, HAT mediates the polyubiquitylation of p53
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(Grossman et al., 2003), which results in the subsequent ubiquitylation of both 
p53 and Mdm2 (Honda et al., 1997; Haupt et al., 1997). However, the N- 
terminal phosphorylation of p53 abolishes its interaction with Mdm2, thus 
resulting in stabilisation of p53.
Subsequent to cellular stress (such as UV-irradiation), the dissociation of the 
p53-Mdm2 complex occurs, resulting in the accumulation of the p53 protein. The 
disruption o f the p53-Mdm2 complex is mediated by the recruitment of 
interacting proteins, which preferentially binds to Mdm2. Alternatively, 
posttranslational modifications to the p53 and/or Mdm2 proteins, promotes the 
liberation of p53. For example, ARP (alternative reading frame; p l4ARF) interacts 
with the C-terminus of the Mdm2 protein, resulting in the relocation of Mdm2 to 
the nucleoli, thus inhibiting Mdm2-mediated ubiquitylation of p53 (reviewed by 
Sherr &Weber, 2000).
The functional activation of p53 occurs through posttranscriptional covalent 
modifications, at both the amino-terminal and the carboxyl-terminal domains via 
phosphorylation, acetylation and sumolation (Fig. 1.6). These modifications 
facilitate the subsequent regulation o f p53 by promoting DNA binding, 
degradation, cellular localisation, oligomerisation and affiliation with cellular 
molecules.
1.10.3 p53 and cell cycle arrest
Following genotoxic damage, activation and accumulation of the p53 tumour 
suppressor signals the Gi cell cycle checkpoint to inhibit the transition from Gi to 
S phase. This increases the opportunity for the repair of DNA damage prior to 
the commencement o f replication in S phase. This prevents the propagation of 
potentially mutagenic defects from parental to daughter cell populations. Cell- 
cycle arrest is mediated in part by the p53-dependent induction of p2 iWAF1/CIP1 
(Fig. 1.7), an inhibitor of CDKs, which abolishes the interaction between cyclin 
D/cdk4, cyclin D/cdk6 and cyclin E/cdk2 complexes (Harper et al., 1993; El- 
Deiry et al., 1993; Dulic et al., 1994). The coupling of cyclin D to cdk4/6 causes
73
the phosphorylation o f serine and threonine residues on the Rb tumour 
suppressor, this tethers Rb from the E-box factor 2 (E2F) transcription factor, 
thus permitting E2F-mediated activation of a multiplicity of downstream 
transcriptional gene targets required for S phase progression. However, the 
overexpression of p 2 iWAF1/CIP1 causes the accumulation of hypophosphorylated 
Rb (pRb) and the sequestration of E2F, resulting cell-cycle arrest.
1.10.4 The role o f pS3 in UV-induced NER
The p53 tumour suppressor protein mediates a series of cellular responses that 
inhibit photocarcinogenesis following UV, such as enhancing NER and inducing 
apoptosis (Hall et al., 1993; Brash et al., 1996). In addition to a high nuclear 
accumulation o f p53 (Hall et al., 1993), exposure to UV also causes the 
phosphorylation of p53 at Ser46 (Fig. 1.7), which regulates the activation of p53- 
dependent apoptotic genes (Oda et al., 2000). Phosphorylation of p53 also occurs 
at Seri 5 and Ser20 (Fig. 1.7), which regulate the transcriptional activation of Gi 
checkpoint arrest genes, such as p21WAF1/CIP1, and genes involved in DNA repair 
(reviewed by Adimoolam & Ford, 2003; Ford, 2005; Hanawalt, 2002; McKay et 
al., 1999; Seo & Jung, 2004).
The systematic investigation into the mechanistic action and regulation of the 
NER machinery has resulted in the identification of key effector molecules, such 
as the p53 tumour suppressor, which coordinates the spatial and temporal 
regulation of the NER pathway. A recent body of evidence has shown that NER 
factors are upregulated in response to UV in a p53-dependent manner at both the 
transcriptome and proteome level (Adimoolam & Ford, 2002; Amundson et al., 
2002; Amundson et al., 2003; Ng et al., 2003).
Since the initial observation that p53 stabilisation occurs in nontransformed 
mouse cells subsequent to UV-irradiation (Maltzman et al., 1984), it has been 
shown that the core domain of p53 contains 3’-5’ exonuclease activity (Janus et 
al., 1999). However, this remains poorly delineated. Numerous studies have also 
demonstrated that the C-terminal domain directly interacts with DNA lesions or
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single-stranded DNA (Bakalkin et al., 1995; Jayaraman & Prives, 1995; Lee et 
al., 1997). Conversely, Jackson et al. (1994) has shown that p53 does not localise 
at sites of NER. Following further extensive investigation, however, p53 is now 
thought to regulate stress signalling pathways and modulate the NER machinery 
through the transcriptional activation of downstream gene targets. Alternatively, 
p53 modulates the NER machinery through direct interaction with proteins that 
coordinate the DNA damage response and the NER pathway, which are 
independent of transcriptional modifications.
The initial discovery that p53 orchestrates an essential function in NER 
regulation, was first identified in Li-Fraumeni syndrome (LFS) skin fibroblasts 
(Ford & Hanawalt, 1995). Cells derived from LFS patients possess germline 
mutations in the TP53 gene, which phenotypically causes a marked 
predisposition to cancer. From studies utilising LFS cells, Ford & Hanawalt
(1995) found that LFS cells possessing homozygous mutations for TPS3, resulted 
in the attenuation o f GGR. In contrast, LFS cells, heterozygous for TP5 3 
mutations, displayed levels o f GGR comparable to normal cells. Additionally, 
using strand-specific DNA repair assays, based on Southern blot methodologies 
first described by Bohr et al. (1985), Ford & Hanawalt (1997) further reported 
that the abolition o f p53 activity in LFS cells had no effect on the removal of 
CPDs by TCR. Furthermore, it has been shown that the abolition of p53 activity 
by viral proteins, such as the E6 constituent of the human papillomavirus (HPV)- 
16 virus, abrogates GGR (Ford et al., 1998; El-Mahdy et a l., 2000). In 
concordance, other groups have shown that TP53 mutations or disruption to p53 
function cause a significant reduction in the removal of CPDs by GGR (Smith et 
al., 1995; Zhu et al., 2000). These findings were further substantiated by repair 
analysis at single nucleotide resolution, where Wani et al. (1999) showed that the 
removal o f CPDs from the nontranscribed strand by GGR was attenuated in 
TP53 mutant and null cell lines, compared to wild-type cells. In contrast, the 
removal of CPDs in the transcribed strand was similar in the TP53 mutant, null 
and wild-type cells. Indeed, a multiplicity of studies has indicated that basal p53 
levels are indispensable for the proficient repair of CPDs by GGR. However, it 
has been speculated that the regulation of GGR could occur via p53-independent 
mechanisms in a cell-type specific manner. For example, Oh & Yhe (2005) have
75
reported the proficient removal of CPDs in differentiated kerationcytes in the 
absence of detectable basal levels of p53.
Conflicting studies, however, have demonstrated that p53 modulates TCR (Wang 
et al., 1995; Mirzayans et al., 1996; Therrien et al., 1999). In concordance with 
these reports, McKay & Ljungman (1999) have shown that the p53-deficient LFS 
cells utilised in previous studies (Ford & Hanawalt, 1995; Ford et a l , 1998) 
display a defect in the recovery o f RNA synthesis, following UV-irradiation. 
This suggests that TCR is impaired in LFS cells. Whereas, Leveillard et al.
(1996) reported that the inclusion of recombinant p53 protein in vitro did not 
enhance NER per se. These conflicting and controversial observations have been 
attributed to technical differences between studies, such as in vitro versus in vivo 
assays, cell-type used and the UV wavelength utilised. For example, it was 
shown that the requirement for functional p53 in TCR, but not in GGR, is 
dependent upon UV wavelength (Mathonnet et al., 2003).
Recent studies have shown that functional p53 is a requisite for the NER of a 
multiplicity o f DNA adducts (Lloyd & Hanawalt, 2000; Wani et al., 2002a; 
Lloyd & Hanawalt, 2002), while other investigations have shown that the 
abolition of p53 activity inhibits the repair of certain UV-induced lesions. For 
example, Ford & Hanawalt (1997) adopted an immunoassay, utilising CPD- and 
6-4PP-specific monoclonal antibodies, to measure the rate of CPD and 6-4PP 
removal by GGR. They found that TP53 mutations had a negligible effect on the 
removal of 6-4PPs, compared to a complete cessation in CPD repair. Therefore, 
it has been suggested that functional p53 is indispensable for the proficient GGR 
of CPDs, but modulates the efficiency of GGR in the repair of both CPDs and 6- 
4PPs. From the multiplicity of studies, Ford & Hanawalt (1997) postulated that 
functional p53 regulates NER through the transcriptional activation of NER 
genes required for the GGR subpathway, but not TCR. However, Wang et al. 
(1995) has shown that p53 interacts directly with the XPB and XPD constituents 
of the TFIIH transcription apparatus, which are instrumental in the NER 
pathway.
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Whilst it has been demonstrated that p53 is superfluous for proficient NER in 
vitro (Leveillard et al, 1996), it has been shown that p53 is required in vivo 
(Hwang et al., 1999). Furthermore, recent evidence suggests that p53 
orchestrates NER by modulating transcription and through direct interaction with 
constituents of the NER machinery (Hanawalt et al., 2002). Recently, Chen et al. 
(2002) utilised a p53 null cell line, possessing regulated wild-type p53 
expression, to characterise the transcriptional portrait o f 23,000 genes in response 
to UV-irradiation. Interestingly, both the XPC  and DDB2 transcripts clustered 
with previously characterised p53 transcriptional targets. This confirmed a 
previous study, which identified a promoter region in DDB2 that facilitates the 
preferential binding o f p53 and subsequent transcriptional activation of DDB2 
(Tan et al., 2002). These findings agree with Hwang et al. (1999), who 
demonstrated that DDB2 was transcriptionally regulated in a p53-dependent 
manner. More recently, Fitch et al. (2003a) has shown that the overexpression of 
DDB2 augments the removal of CPDs by GGR in the absence of p53.
The accumulation o f p53 has been observed in NER-defective cells, in response 
to low doses o f UV, compared to normal cells, which mirrors the progressive 
accumulation o f unrepaired CPDs (Dumaz et al., 1997). Although the precise 
function of p53 in orchestrating the mechanistic action of NER remains elusive, 
it has been speculated that the principal p53 transcriptional target o f the NER 
machinery is the p48 constituent of the UV-DDB complex. However, it has also 
been reported that the rapid binding of both XPC and p48 to UV-induced lesions 
can occur in the absence o f p53. The p53 tumour suppressor also 
transcriptionally activates the XPC  gene, modulating both basal and inducible 
levels of mRNA and protein in a p53- and UV-dependent manner (Amundson et 
al., 2002; Adimoolam & Ford, 2002).
The p53-dependent induction o f DDB2 and XPC, following UV irradiation, 
facilitates the rapid accumulation of depleted levels, resulting from proteasomal 
degradation, following the recognition o f UV-induced photolesions. 
Additionally, it has been speculated that the p5 3-dependent induction of XPC 
and DDB2 facilitates the recognition of CPDs that remain present within the 
genome following repair (Fitch et al., 2003a). It has also been shown that the
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basal levels o f DDB2 and XPC are significantly reduced in p53 deficient cells, 
compared to cells exhibiting normal p53 activity (Hwang et al., 1999; Fitch et 
al., 2003a; Adimoolam & Ford, 2002). Interestingly, although p53 regulates the 
basal and inducible expression of the p48  and XPC  genes, it has been recently 
speculated that DDB2 may regulate p53 expression (Itoh et al., 2003).
The first documented target of p53, growth arrest- and DNA damage-inducible 
45 alpha (GADD45a), is upregulated in response to UV radiation. Furthermore, 
it has been shown that GADD45a is instrumental in modulating GGR, but is 
superfluous in TCR (Smith et al., 2000), which further suggests that p53 is 
required for GGR. Additionally, it has been suggested that GADD45a binds to 
UV-damaged DNA, increasing the accessibility to the NER apparatus (Carrier et 
al., 1999; Smith et al., 2000). In addition to its functional role in the G2/M arrest 
(Jin et al., 2002), GADD45a is thought to facilitate NER through its interaction 
with PCNA, core histones and p 2 iWAF1/CIP1 (Smith et al., 1994).
p53 regulates several o f its regulatory effects indirectly through a p53-dependent 
manner, via the transcriptional activation of downstream effector molecules, such 
as the CDK inhibitor, p 2 iWAF1/CIP1 (El-Deiry et a l ,  1993; Xiong et al., 1993). 
Principally, p 2 iWAF1/CIP1 binds to CDKs, resulting in the attenuation of their 
activity (as previously discussed). This results in cell cycle arrest at Gi and the 
inhibition of DNA replication, thus facilitating DNA repair before entry into S 
phase (Nakanishi et al., 1995; Gu et al., 1993). The transcriptional activation of 
p21WAF1/CIP1, however, is not required for p53 to activate GGR, which suggests 
that the initiation of cell cycle arrest is superfluous for repair (Adimoolam et a l, 
2001; Smith et al., 2000). Furthermore, Adimoolam et al. (2001) has shown that 
the transactivation of p 2 iWAF1/CIP1 is not required for TCR. Interestingly, Loignon 
et al. (1997) previously showed that exposure to 254 nm UV resulted in the 
concurrent activation of the p 2 iWAF1/CIP1 protein and Gi arrest in p53-deficient 
fibroblasts originating from LFS patients, thus suggesting that the induction of 
p21WAF1/CIP1 can occur through a p53-independent mechanism.
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Although extensive investigations have been undertaken, adopting numerous 
methodologies, the precise mechanistic functionality o f p 2 iWAF1/CIP1 in 
modulating NER remains to be completely delineated, as conflicting reports have 
suggested a multiplicity o f functions of p53-dependent activation of p 2 iWAF1/CIP1 
in response to UV. It has been suggested that p53-dependent transactivation of 
p21 WAF1/CIP1 modulates the activity o f NER through direct interaction with 
PCNA. Essentially, PCNA is a replication factor (Waga et al., 1994), which is 
also thought to play a role in the modulation of NER. p21 WAF1/CIP1 inhibits 
PCNA activity, resulting in the inhibition of DNA replication (Sherr & Roberts, 
1995). In addition to its mechanistic role in DNA replication, PCNA is also 
required for repair synthesis in NER. Exposure to UV promotes the translocation 
of soluble PCNA to an insoluble form, which is found coupled to chromatin 
(Otrin et al., 1997), which further facilitates its interaction with DNA polymerase 
r\ (Haracska et al., 2001). However, optimal DNA repair necessitates the 
ubiquitin-dependent degradation of p21WAF1/CIP1, following exposure to low 
doses of UV (Bendjennat et al., 2003). Furthermore, the interaction between 
PCNA and chromatin is sustained in cells possessing TP53 gene mutations and 
in p2 iWAF1/CIP1 null cells (Riva et al., 2001; Stivala et al., 2001). In concordance, 
Therrien et a l  (2001) reported the enhancement of NER in p5 3-deficient cells 
with abolished p 2 iWAF1/CIP1 expression. From these studies it has been speculated 
that p 2 iWAF1/CIP1 has an inhibitory effect on the initial mechanistic steps of NER, 
but the subsequent induction of p2 iWAF1/CIP1 is a prerequisite for the translocation 
of PCNA following post-incision repair synthesis (Latonen et al., 2005). 
Conflicting reports, however, have suggested that p 2 iWAF1/CIP1 has either no 
effect on the modulation of NER (Li et al., 1996; Shivji et al., 1994; Wani et al., 
2002b), or has an inhibitory effect on NER functionality (Pan et al., 1995). 
Conversely, it has been reported that p 2 iWAF1/CIP1 may regulate the NER 
apparatus in the repair of UV damage (Sheikh et al., 1997).
Several studies have reported the direct protein-protein interaction between p53 
and an array of DNA repair proteins required for NER, such as XPB, XPD and 
RPA (de Laat et al., 1999). Additionally, studies have shown the direct 
interaction between p53 and the TCR specific protein, CSB (Wang et al., 1995;
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Yu et al., 2000a). In addition, p53 interacts with other transcription factors, 
including TFIID and p300/CBP (Chen et al., 1993; Wang et al., 1995; Lill et al., 
1997). More recently, it was proposed that p53 assists GGR through sequestering 
HAT complexes to the site o f DNA damage, thus permitting chromatin 
relaxation, required for maximal accessibility to DNA lesions, by the NER 
machinery (Rubbi & Milner, 2003).
Despite extensive investigation, the precise mechanistic function(s) of p53 in the 
regulation of GGR and/or TCR remains largely controversial. Investigators have 
argued against the role of UV-induced transactivation of p53 responsive genes in 
the regulation of NER, as UV-induced DNA damage blocks elongation of RNA 
Pol II. Therefore, the presence of photolesions will inhibit expression of p53- 
responsive genes. Moreover, reduced p 2 iWAF1/CIP1 mRNA and protein levels have 
been documented following UV irradiation in human cells (Gorospe et al., 1998; 
McKay et al., 1998). It has also been shown that the time required for the 
recovery o f and induction of 21WAF1/CIP1 protein levels inversely correlates with 
the TCR capacity o f cells (McKay et al., 1998). It has therefore been argued that 
for UV-induced p53-dependent genes to contribute to DNA repair, the removal, 
modification or bypass of transcription blocking lesions would be required to 
allow the expression of these genes (Ljungman, 1999; McKay et al., 1998). This 
would suggest that cells derived from a CS patient would be defective in GGR, 
as these cells are devoid of TCR and mRNA recovery. However, CS cells exhibit 
no defect in GGR, which implies that the recovery of transcription does not 
significantly contribute to GGR. These findings contradict the observations of a 
transactivation-dependent role of p53 in the induction of GGR and/or TCR after 
UV irradiation (McKay et al., 1999). However, it has been further speculated that 
p53 may regulate the steady-state levels of proteins that are essential for the 
repair of UV-induced damage and/or the recovery of transcription (McKay et al., 
1999). For example, it has been shown that the basal level o f p53-regulated 
proteins in cells under normal physiological conditions is affected by the basal 
levels of p53 (Tang et al., 1998). Furthermore, Crowley & Hanawalt (1998) 
showed that the expression of the p48  gene is regulated by wild-type p53 in the 
absence of damage. So, although the UV-induced expression of gene products 
that are required for NER and the recovery of transcription is not fast enough to
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contribute to these processes immediately following UV-irradiation (McKay et 
al., 1998), it has been argued that p53 regulates NER and the recovery of 
transcription by regulating the basal levels o f DNA-damage response and/or 
repair proteins (McKay et al., 1999).
1.10.5 p53 and Apoptosis
The accumulation o f UV-induced DNA damage results in the induction of 
apoptosis in a p53-dependent manner (Ziegler et al., 1994; Smith & Fomace, 
1997). The role o f p53 in apoptosis is both transcription-dependent and 
-independent (Fig. 1.7; Jimenez et al., 2000; Chao et al., 2000). For example, 
p53 directly induces the expression of proapoptotic genes, which mediate 
cytochrome c release from the mitochondria. This results in the interaction 
between cytochrome c and the apoptotic protease activating factor (Apaf-1), 
which initiates the recruitment of procaspase 9, activation of the apoptosomal 
complex, the processing o f caspase 9 and the initiation of apoptosis. p53 is also 
essential for the transcriptional activation of a multiplicity o f proapoptotic 
factors, such as the B-cell CLL/lymphoma 2 (Bcl-2) members: Bcl2-associated X 
protein (Bax), p53-upregulated modulator of apoptosis (PUMA), phorbol-12- 
myristate-induced protein 1 (PMAIP1/NOXA), p53-upregulated apoptosis- 
inducing protein 1 (p53A IPl) and PIGa (galectin-7). These proteins 
mechanistically function by interacting with the Bcl2 protein. This causes the 
abolition of its antiapoptotic function, resulting in the sequestration of Bcl2 to the 
mitochondria, where it induces the release o f cytochrome c and apoptosis 
(reviewed by Melnikova & Ananthaswamy, 2005).
In addition, p53 can mediate the immediate disruption of the mitochondria via 
the upregulation of the death receptor TNF receptor superfamily member 6 
(Fas/APOl), TNF receptor superfamily member 10a (KILLER/DR5) and 
leucine-rich repeats and death domain (PIDD). This promotes the cleavage of 
procaspase 8 and release o f cytochrome c from the mitochondria, resulting in the 
subsequent activation of the Apafl -caspase 9-caspase 3 pathway (reviewed by 
Melnikova & Ananthaswamy, 2005).
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p53 can further elicit apoptosis by activating genes which repress survival 
signalling such as insulin-like growth factor-binding protein 3 (IGF-BP3), or by 
repressing the expression of survival-promoting or antiapoptotic genes including 
IGF-receptor 1, Bcl-2 and survivin (reviewed by Latonen & Laiho, 2005).
p53-mediated apoptosis is further enhanced by inhibitor o f growth family 
member l(p33IN G lb), a splice variant o f the tumour suppressor ING1. 
p33INGlb enhances apoptosis through its direct interaction with p53, which 
results in both the accumulation and activity o f p53, by preventing Mdm2 
binding. p33IN G lb can further mediate the acetylation o f p53 and 
transcriptionally activate the p53 homologues, p63a and p73a (reviewed by 
Latonen & Laiho, 2005).
Interestingly, p53 can promote apoptosis via the negative regulation of NER. The 
cessation of XPB and XPD helicase activity is mediated via the direct interaction 
of the p53 C-terminus (reviewed by Latonen & Laiho, 2005).
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Figure 1.7. Functions of p53 tumour suppressor protein. In response to various stresses (such as UV), 
p53 is activated by the upstream mediators. The transcriptional modification o f p53 may elicit cell cycle 
arrest at Gj/S or G2/M checkpoints, initiate DNA repair, induce apoptosis and inhibit apoptosis 
(adapted from Melnikova & Anathaswamy, 2005).
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1.11 Retinoblastoma (pRb) mediated tumour 
suppression
In addition to the tumour suppressing functions of p53, the Rb tumour suppressor 
protein is an essential mediator of the DNA damage response and an inhibitor of 
tumorigenesis. Rb has been implicated in several cellular processes that maintain 
cellular homeostasis, including transcriptional repression (Weintraub et al., 
1995), DNA-damage-induced checkpoints (Harrington et al., 1998; Brugarolas et 
al., 1999), regulation of the cell cycle (DeCaprio et al., 1988; DeCaprio et al., 
1989; Whyte et al., 1988), DNA repair (Bosco & Knudsen, 2005), DNA 
replication (Bosco et al., 2001; Kennedy et al., 2000), apoptosis (Shan & Lee, 
1994; Qin et al., 1994; Wu & Levine, 1994), proliferation and cellular 
differentiation (reviewed by Adams, 2001; Classon & Harlow, 2002; Park & Lee, 
2003). Rb  is a member of the gene family that encodes structurally and 
mechanistically analogous proteins, such as p i07 and p i30. These three proteins 
(including Rb, p i 07 and p i 30) are collectively described as ‘pocket proteins’, 
due to the location of a common sequence, which resides in a domain termed the 
‘pocket domain’(Weinberg, 1995). The pocket domain preferentially interacts 
with the oncogenic constituents o f DNA tumour viruses, including the 
adenovirus E l A, SV40 LTAg and the E7 protein o f the HPV, causing 
dysregulation to the cell cycle (Whyte et al., 1988; DeCaprio et al., 1988). 
Similarly to Rb, p i07 and p i 30 are also regulated during the cell cycle by CDK 
phosphorylation. The Rb tumour suppressor coordinates a fundamental role in 
cell cycle entry and progression from Gi to S phase. During early Gi phase of the 
cell cycle, hypophosphorylated Rb is functionally active, which promotes the 
preferential binding to the E2F family of transcription factors and HDACs, thus 
negatively regulating both E2F and CDK function. The binding of Rb to E2F 
results in the formation of an Rb-E2F complex on the promoters of a multiplicity 
of E2F target genes. This represses the transcriptional activation of these E2F 
downstream gene targets that orchestrates cell cycle progression (such as cyclin 
A, cyclin E, cdc2, cdk2, p i 07, b-myb and DHFR), through the inactivation of 
promoter sites. In addition, Rb orchestrates the transcriptional repression of 
genes, which mediate DNA replication, including: PCNA, mini-chromosome
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maintenance-7 (MCM-7), topoisomerase I la  and thymidine kinase. The 
indispensable nature o f these Rb transcriptional targets, results in the inhibition 
of S-phase progression. In the presence of DNA damage, low serum or high cell 
confluency during culture, pRb is activated via its dephosphorylation 
(Buchkvoich et al., 1989; DeCaprio et al., 1989). Under normal physiological 
conditions, however, as cells progress through late Gi, the transcriptional 
activation and subsequent formation of cdk4/cyclin D1 and cdk2/cyclin E 
complexes orchestrate the phosphorylation and inactivation o f Rb and 
dissociation o f the Rb-E2F complex (Sherr, 1996; Weinberg, 1995). The 
cessation of repression of E2F regulated genes facilitates cell cycle progression 
through a Gi exit and subsequent entry into S-phase.
The importance of Rb function is exemplified in the majority of human cancers 
where the functional inactivation of Rb has been reported. Furthermore, the 
cloning of the pR bl tumour suppressor gene was undertaken by virtue of its 
association with the familial cancer, retinoblastoma, a tumour o f the retina 
caused by germline mutations in the pR bl gene (Lee et al., 1987). Rb has also 
been implicated in further human malignancies, such as small-cell lung 
carcinoma and osteosarcoma. The abrogation of Rb results in the dysregulation 
of the Gi CDK pathway and the subsequent initiation of tumorigenesis. This has 
been demonstrated in studies where the overexpression of Rb causes cells to 
undergo arrest in the Gi phase of the cell cycle. Conversely, the abolition of Rb 
function promotes accelerated Gi transition, which further supports the 
mechanistic function of Rb as an inhibitor o f proliferation (Whyte et al., 1988; 
DeCaprio et al., 1988).
p i6 ^ ^ ,  a CyCJjn D-CDK4/6 dependent kinase inhibitor, is an important 
regulator of the pRb pathway, and is upregulated in response to cellular stress, 
such as prolonged tissue culture and DNA damage, resulting in a Gi cell cycle 
arrest (reviewed by Sherr & Roberts, 1999).
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1.11.1 Role o f Rb in response to UV
Following the exposure to exogenous and endogenous sources of DNA damage, 
such as UV, cells elicit signal transduction cascades, which promote a series of 
effector responses, thus maintaining genome stability. A multitude of checkpoint 
proteins play an instrumental role in mounting an appropriate DNA damage 
response. Subsequent to DNA damage, Rb is functionally activated through 
dephosphorylation, resulting in the abolition of cell cycle progression (Herrera et 
a l ., 1996; H arrington et a l., 1998; Knudsen et al., 1998). The 
hypophosphorylated state of Rb facilitates the formation of Rb-E2F complexes, 
which antagonises the binding of E2F transcription factor family members to 
their downstream transcriptional targets. In previous studies, accumulating 
evidence has implicated Rb as a mediator o f DNA repair following UV or IR 
exposure, as several recently elucidated Rb/E2F transcriptional downstream gene 
targets have been implicated in the repair o f UV- and IR-induced damage. 
Consequently, it has been suggested that the abolition of Rb function causes 
dysregulation of DNA repair, resulting in genome instability. More recently 
however, Bosco & Knudsen (2005) demonstrated that although temporally 
ablated Rb gene function compromised rapid cell cycle arrest following UV, Rb- 
deficient murine adult fibroblasts displayed an accelerated repair of 6-4 PPs. 
Furthermore, a body of evidence has shown that pRb regulates the expression of 
several NER repair factors such as FEN1, XPC, RPA2-3, RCF4 and PCNA (Cam 
et al., 2004; Ishida et al., 2001; Polager et al., 2002; Markey et al., 2002; Classon 
et al., 2002). In accordance with these findings, Therrien et al. (1999) previously 
showed that HPV E7-expressing lung fibroblasts, which were compromised for 
pRb function, were defective in GGR (Section 4.1).
1.12 Replicative senescence
Human diploid fibroblasts possess a finite replicative capacity in vitro, following 
extensive subcultivation (Hayflick & Moorhead, 1961; Hayflick, 1965). This has 
been attributed to a state o f permanent and irreversible growth arrest, a 
phenomenon known as replicative senescence, the Hayflick limit (Shay &
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Wright, 2000), or mortality stage 1 (M l) (Fig. 1.8; Wright et al., 1989). In 
addition, to human diploid fibroblasts, replicative senescence has also been 
reported in a number o f cell types in vitro, including glial cells, keratinocytes 
(Rheinwald, 1975), vascular smooth muscle cells (Bierman, 1978), lens cells 
(Tassin et al., 1979), endothelial cells (Mueller et al., 1980) and lymphocytes 
(Tice et al., 1979).
Indeed, the progressive attenuation of proliferative capacity has also been 
observed in vivo, thus signifying similarities in replicative capacity between in 
vitro culture models and in vivo. However, only a limited number of reports have 
observed reductions in telomere length in proliferating and non-proliferating 
tissues in vivo (Allsopp et al., 1992; Frenck et al., 1998; Kveiborg et al., 1999; 
Aikata et al., 2000). In contrast, Kang et al. (2003) showed a correlation between 
telomere length attrition and increasing donor age in oral keratinocytes, but not 
in oral fibroblasts in situ. By contrast, many reports have failed to demonstrate a 
relationship between donor age and proliferative capacity in vitro (Goldstein et 
al., 1978; Cristofalo et al., 1998a,b; Smith et al., 2002). Thus, the extrapolation 
of in vitro culture models to in vivo aging has been extensively problematic and 
controversial. This is thought to be attributed to selection pressures placed upon 
slower proliferating cells present within the culture.
It was postulated that senescence is initiated by the progressive erosion of 
telomeric ends (Olovnikov, 1973; Harley et al., 1990), thus suggesting that 
telomere shortening functions as a mitotic “clock” (Harely, 1991). During the 
replicative lifespan of normal diploid somatic cells, telomere attrition is thought 
to occur at approximately 50-200 base pairs (bp) per cell division (Harley et al., 
1990). The progressive attrition of hexameric telomeric sequence (5’-TTAGGG- 
3’) has been attributed to the incapability o f DNA polymerase to replicate the 
ends of chromosomal DNA during lagging strand synthesis (Olovnikov, 1973; 
Harley, 1991). This phenomenon, first postulated by Olovnikov (1971), known 
as the end replication problem, occurs when somatic diploid fibroblasts undergo 
each cell division. Olovnikov (1971, 1973) showed that the presence of an RNA 
primer at the 5’ end is a prerequisite for the initiation of lagging strand synthesis 
by DNA polymerase. The subsequent displacement of the RNA primer,
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following the completion of DNA replication, elicits the progressive loss of 
telomeric ends. Cells obtained from older individuals displayed a restricted 
replicative capacity and attenuation in telomeric length, compared to cells 
derived from younger donors (Harley et al., 1990; Hastie et al., 1990).
Whilst previous evidence suggests that progressive telomeric erosion remains the 
speculated “replicometer” mechanism o f replicative senescence (Wright & 
Hayflick, 1975; Muggleton-Harris & Hayflick, 1976; Wright & Shay, 1992; 
Bodnar et al., 1998), the precise molecular trigger(s) that initiate replicative (M l) 
senescence, following critical telomeric shortening, remain(s) elusive. Current 
models o f (M l) replicative senescence initiation, associated with aberrant 
telomeres include; telomere positioning effects (Baur et al., 2001; Koering et al., 
2002; Shay et al., 2000), DNA damage signalling induced by telomere attrition 
(d’Adda et al., 2003; Zou et al., 2004; Sedelnikova et al., 2004; Gire et al., 2004; 
Herbig et al., 2004) and loss of the 3* G-rich telomeric overhang (Stewart et al., 
2003).
The limited replicative capacity o f normal diploid cells provides an innate 
mechanism, which prevents malignant transformation and indefinite proliferation 
(immortalisation), thus inhibiting tumorigenesis (Reddel, 2000; Campisi, 2000; 
Campisi, 2001). Conversely, Krtolica et al. (2001) has argued that senescent 
dermal fibroblasts incite premalignant and malignant epithelial cells to 
proliferate in vitro and promote tumorigenesis in mice.
Whilst the hallmark of replicative senescence is the cessation of responsiveness 
to mitogens (Seshadri & Campisi, 1990), the senescent phenotype is typically 
characterised by marked alterations in growth kinetics, morphological 
appearance and dysregulation of biological processes. Senescent cells maintained 
under routine culture conditions are morphologically characterised by an increase 
in cell size, with a marked flattened and vacuolated appearance coupled with an 
associated increase in nucleus and nucleoli size (Cristofalo & Kritchevsky, 1969; 
Greenberg et al., 1977; Mitsui & Schneider, 1976). A marked increase in the 
number of lysosomes and golgi (Cristofalo & Kabakjian, 1975; Maciera-Coelho 
et al., 1971) and a pronounced increase in the number o f cytoplasmic
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microfilaments are also features indicative of replicative senescence (Brandes et 
al., 1972; Comings & Okada, 1970; Lipetz & Cristofalo, 1972). In addition to the 
morphological alterations, senescent cell populations exhibit a pronounced 
increase in the number of multinucleated cells (Galloway & Buckton, 1978; 
Matsumura, 1980; Matsumura et al., 1979; Yanishevsky & Carrano, 1975) and 
heterochromatic foci are observed (Narita et al., 2003). Although in a 
nonproliferative state, senescent cells remain metabolically active. Furthermore, 
the progressive accumulation of senescent cells causes attenuation in tissue 
function (Dimri et al., 1995; Fenton et al., 2001; Minamino et al., 2002). For 
example, investigators have shown that the NER repair of UV-induced lesions is 
severely compromised in senescent cells compared to their young isogenic 
counterparts (Boyle et al., 2005; discussed further in Chapter 4).
The complete cessation o f proliferation in senescent fibroblasts in associated 
with alterations in gene expression patterns and posttranslational modifications in 
a cell-type specific manner, resulting in an altered phenotype compared to their 
young isogenic counterparts (Cristofalo et al., 1998; Park et al., 2001; Shelton et 
al., 1999). For example, altered patterns of gene expression are seen in the 
transduction and secretory pathways. In particular, the differential regulation of 
proteases and constituents of the extracellular matrix, such as extracellular matrix 
(ECM)-degrading secreted proteases, collagenase (Millis et al., 1992a,b; West et 
al., 1989), tissue plasminogen activator (West et al., 1996; Zeng & Millis, 1994) 
ECM-modifying proteins (matrix metalloproteinases (MMPs), tissue inhibitor of 
metalloproteinase family), growth factors and inflammatory cytokines have been 
reported (Campisi, 1998; Faragher & Kipling, 1998; Shay & Wright, 2005). 
Additionally, senescent fibroblasts express reduced levels of MMP inhibitors, 
tissue inhibitor o f metalloproteinase (TIMP1) and Ras-related C3 botulinum 
toxin substrate 1 (MIG5; Wick et al., 1994), a reduction in ECM components, 
including elastin, laminin (Linskens et al., 1995) and constituents of collagen 
(Furth, 1991). These modifications in cellular homeostasis have been shown to 
facilitate the acceleration of tumorigenesis by promoting the survival, metastasis 
and proliferation of pre-malignant cells.
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Historically, cellular senescence in vitro is determined experimentally by the 
staining of senescence associated-P-galactosidase (SA-pG). P-galactosidase (pG) 
functions as a hydrolase, which is found localised in the lysosome. PG 
enzymatically cleaves p-D-galactose residues in P-D-galactosides. Dimri et al. 
(1995) first reported that senescent cells express SA-PG, which optimally 
functions at pH 6. Apart from the exit of the cell cycle, the SA-PG assay has 
become the most frequently utilised marker to characterise cellular senescence in 
culture. For example, SA-PG staining has been implemented to investigate the 
accelerative ageing effects of homocysteine (Xu et al., 2000), ceramide (Mouton 
& Venable, 2000), oxidative stress (Dumont et al.9 2000) and cardiolipin 
(Arivazhagan et al., 2004). However, despite the extensive application of the SA- 
PG assay as an indicator o f senescence, the validity and reliability of the assay 
has been challenged, due to the lack of specificity. An increase in SA-PG 
staining has been reported in immortalised cells subsequent to serum starvation 
(Yegorov et al., 1998), oxidative treatment with H2O2 and in confluent primary 
fibroblast cultures grown in vitro (Severio et al., 2000). Most recently, Yang & 
Hu (2005) also found that in addition to cellular ageing and cell confluency, 
serum starvation and H2O2 also increased SA-pG activity.
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Figure 1.8. The ectopic expression o f the catalytic subunit o f telomerase, hTERT, results in the 
immortalisation o f human cells. The ectopic expression of telomerase can facilitate the bypass of 
senescence (M l) and crisis (M2), as hTERT expression either before Ml or after M l results in cellular 
immortalisation (adapted from Shay & Wright, 2005).
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1.12.1 Replicative senescence: activation through the DNA 
damage response pathways
Although the precise mechanism(s) that recognise critically short telomere 
lengths remain poorly delineated, short telomeres are thought to serve as a DNA- 
damage like signal. Two pathways have been implicated in the activation of 
cellular senescence; including the p53/p21WAF1/CIP1 and pRb/plb™1^  tumour 
suppressor pathways. As previously discussed, p53 is an important downstream 
target o f the DNA damage response pathway, which is activated via ATM 
through several mechanisms (reviewed by Kastan & Bartek, 2004). ATM 
activates downstream kinases Chkl and Chk2, which mediates the 
phosphorylation of p53 at Ser20. This disrupts the Mdm2-p53 interaction, which 
facilitates the stabilisation o f p53. p53 regulates cellular proliferation and 
replicative senescence, which is thought to provide a protective mechanism that 
suppresses tumorigenesis (Campisi, 2005). In late passage cultured cells, the 
activation o f p53 maintains a permanent state of growth arrest, via the 
transcriptional activation of p 2 iWAF1/CIP1s which induces both cell cycle arrest 
and senescence. Moreover, the level of p2 iWAF1/CIP1 gradually increases as cells 
progress into a state of senescence (Alcorta et al., 1996). In support o f these 
findings, Brown et al. (1997) showed that the targeted deletion of p 2 iWAF1/CIP1 in 
fibroblasts resulted in the bypass of cellular senescence. Collectively, these 
findings suggest that the p53/p21WAF1/CIP1 and pRb/p 16INK4A pathways orchestrate 
cellular senescence in response to telomere shortening.
1.12.2 Replicative senescence and DNA repair
Although initial observations suggest that replicative senescence occurs as a 
result o f telomere shortening (Harley et al., 1990) during semi-conservative 
replication (Olovnikov, 1973, Watson 1972), recent finding suggest that cellular 
senescence can be triggered by DNA damage (reviewed by Lou & Chen, 2006). 
Indeed, as previously mentioned, both telomere dysfunction- and DNA-damage- 
induced replicative senescence elicit the same mechanism, the DNA damage 
response pathway (d’Adda di Fagagna et al., 2003; von Zglinicki et al., 2005).
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Mutations in many constituents of DNA repair pathways have been associated 
with cellular senescence (reviewed by Lou Sc Chen, 2006). For example, mouse 
embryonic fibroblasts (MEFs) defective in Ku70, Ku80, XRCC4 and DNA ligase 
IV fail to repair double-strand breaks (DSBs) by NHEJ, and enter a state of 
accelerated premature senescence (Lombard et al., 2005). A further link between 
HR mutation and cellular senescence and aging has been identified in BRCA1. In 
BRCA1AU/An MEFs, a deficiency in BRCA1 causes impaired HR-mediated 
DSB repair and premature senescence, as indicated by P-galactosidase activity 
(Cao et al., 2003). As previously discussed, defects in XPD  causes TTD, while 
mutations in CSA and CSB result in CS (Mitchell et al., 2003). Although both 
TTD and CS patients exhibit premature aging phenotypes, the role o f XPD  and 
CSA mutations in accelerated cellular senescence (if any) remains unknown.
In addition to factors directly involved in DNA repair, further factors are 
involved in other aspects o f the DNA damage response, including signal 
transduction and checkpoint activation. ATM elicits the entire damage response 
pathway and activates a multitude of downstream substrates. Defects in ATM 
cause atax ia-telang iectasia  (AT), resulting in neurodegeneration, 
immunodeficiency and premature aging. Fibroblasts derived from AT patients 
enter a state of premature senescence. H2AX and MDC1 function downstream to 
ATM. H2AX, a histone variant, rapidly phosphorylates at regions flanking DSBs 
(Rogakou et al., 1999). Phospho-H2AX (yH2AX) provides a molecular docking 
site for sequestered DNA repair factors. MDC1 binds yH2AX resulting in further 
H2AX phosphorylation (Stucki et al., 2005). Therefore, H2AX and MDC1 
provide a positive feedback loop to amplify the ATM-mediated DNA damage 
response (Lou et al., 2006). It has been shown that H2AX'7 and MDCl 7' MEFs 
grow slowly in vitro and enter a state of premature senescence (reviewed by Lou 
Sc Chen, 2006). Collectively, these data suggest that, similar to telomere 
dysfunction, genome instability induced by defects in the DNA damage response 
pathway further contribute to cellular senescence and premature aging.
Like DNA damage, telomere dysfunction results in the exposure of DNA ends, 
thus resulting in the elicitation of the DNA damage response. Numerous studies
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have provided evidence for the involvement of the DNA damage response in 
both telomere dysfunction- and DNA-damage-induced cellular senescence. For 
example, Takai et al. (2003) showed that overexpression of mutant telomeric 
repeat binding factor 2 (TRF2) resulted in t-loop uncapping, telomere shortening 
and replicative senescence. Furthermore, overexpression of mutant TRF2 induces 
yH2AX foci formation (Takai et al., 2003), which is indicative o f DSB 
formation. It has been shown that, DNA damage factors such as tumour protein 
p53 binding protein 1 (53BP1), mediator of DNA damage checkpoint 1 (MDC1), 
phospho-ATM, Nibrin (NBS1) and Rad 17, have been found to accumulate at 
mutant TRF2-induced foci (d’Adda di Fagagna et a l , 2003). From these 
findings, it can be speculated that telomere shortening, like DNA damaging 
agents, elicit DNA damage responses.
1.12.3 Telomere-independent senescence
In addition to telomere-dependent replicative senescence, further mechanisms 
that elicit a permanent state o f growth arrest, which recapitulates the 
morphological and biological characteristics exhibited by telomere-dependent 
senescence, have been described. The most frequently reported causes of 
telomere-independent senescence include; oxidative damage (Parrinello et al., 
2003), genotoxic damage (Schmitt et al., 2002) and oncogene dysregulation 
(Serrano et al., 1997). It is thought that ROS causes DNA damage and elicits the 
progressive acceleration of telomere attrition (von Zglinicki et al., 1995: Forsyth 
et al., 2003; Parrinello et al., 2003). For example, mortality stage 0 (M0) 
senescence is frequently observed in keratinocytes and mammary epithelial cells 
in vitro, due to the activity o f the p 16INK4A/pRb pathway (Brenner et al., 1998; 
Kiyono et al., 1998). However, it is thought that M0 may be an artifactual 
consequence of continued in vitro cultivation, resulting in a delayed response to 
insufficient culture conditions, rather than a physiological process. Most recently, 
Ramirez et al. (2001) found that culturing keratinocytes and mammary epithelial 
cells on feeder layers can circumvent M0 senescence. This reiterates the 
requirement for fully optimised culture conditions, in order to maintain a viable 
culture and the establishment of permanent cell lines. Post-mitotic, terminally
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differentiated cells also possess a senescence-associated phenotype, due to the 
complete cessation of proliferative capability following differentiation, such as 
neuronal cells. Furthermore, the inability to recapitulate an in vivo environment 
can be problematical in vitro, such as hepatocytes, thus resulting in premature 
senescence.
1.13 Telomeres, telomerase and immortalisation
1.13.1 Telomeres: An essential genomic element
Telomeres, the DNA-protein structures that cap the ends of eukaryotic liner 
chromosomes, protect chromosomal ends from normal cellular activity and 
genome instability promoting events (Muller, 1938; McClintock, 1941). 
Telomeres form a higher-order chromatin structure that physically hides the 3’- 
overhang. This is achieved by the 3’-overhang, which folds back and invades the 
double-stranded region of the telomere, resulting in the formation of the T-loop, 
which is displaced to form the D-loop. This structure performs a minimum of 
three essential roles in chromosome preservation. Firstly, capping allows the cell 
to differentiate chromosome ends from DSBs in the genome. Uncapped 
chromosome ends can have catastrophic consequences for the cell, as uncapped 
telomeres are susceptible to degradation, recombination or fusion of the DNA 
ends by NH and/or end-joining DNA repair mechanisms. Chromosome 
degradation causes loss o f genetic information, resulting in cell death. 
Recombination causes rearrangements or a reduction or increase in telomere 
length, which can cause the premature onset or delay on cellular senescence. 
Telomere fusion results in the formation of dicentric chromosomes, which break 
during mitosis, thus resulting in the formation of additional DSBs, further cycles 
of breakage and fusion, resulting in genome instability. Secondly, telomeres 
facilitate the attachment of chromosomes to the nuclear envelope during meiosis. 
Finally, the replication of chromosome ends (reviewed by Davis & Kipling, 
2005). Therefore, the loss o f telomeres ultimately results in the loss, 
rearrangement or destabilisation of genetic information (Shore, 1997; Blackburn, 
2000; Gasser, 2000). There are three rudimentary requisites essential for the
95
protective function of telomeres: (1) a minimum length of TTAGGG repeats 
(Moyzis et al., 1988); (ii) the telomere-binding proteins; (iii) the integrity of the 
G-strand overhang.
1.13.2 Immortalisation using telomerase
Telomerase, a cellular reverse transcriptase, provides the main regulator of 
telomere length and facilitates the replication of telomeric DNA via the addition 
of TTAGGG repeats onto pre-existing telomeres. Telomerase is composed of 
two essential constituents, the reverse transcriptase subunit, human telomerase 
reverse transcriptase (hTERT), and the RNA component, human telomerase 
RNA component (hTERC), which contains the template for the synthesis of new 
tandem telomeric repeats (reviewed by Blasco, 2003). As previously mentioned, 
most human normal somatic cells do not possess sufficient telomerase activity to 
retain telomere length, thus resulting in telomere attrition (Harley et al., 1990). 
Most normal primary human somatic cells either completely lack telomerase 
activity or possess residual levels that are insufficient for telomere maintenance 
(Kim et al., 1994).
The isolation and subsequent cloning of the hTERT gene (Nakamura et al., 1997; 
Meyerson et al., 1997; Harrington et al., 1997; Kilian et al., 1997), has 
revolutionised the development of in vitro culture models. As the exploitation of 
hTERT facilitates the establishment o f immortalised cell lines with a relatively 
impervious phenotype, which resemble their primary isogenic counterparts. 
Therefore, unlike conventional methods adopted to establish immortalised cell 
lines, such as the expansion of tumour biopsies or the utilisation of oncogenic 
viral proteins, the utilisation of hTERT permits an extension of proliferative 
lifespan, remain diploid, differentiated, contact-inhibited, nontumorigenic and 
anchorage dependent. More importantly, hTERT-immortalisation facilitates the 
maintenance of normal p53/p21WAF1/CIP1 and pRb/plb1*'1*4* functionally, thus 
sustaining genome preservation, without inducing cancer-associated alterations 
(discussed in Chapter 4).
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The ectopic expression of hTERT cDNA in normal fibroblasts and retinal 
pigment cells has been shown to facilitate senescence bypass (Bodnar et al., 
1998; Vaziri & Benchimol, 1998) and immortalisation, without inducing 
alterations that resemble a malignant phenotype (Jiang et al., 1999; Morales et 
a l ., 1999; Vaziri et al., 1999). In stark contrast, telomerase-mediated 
immortalisation alone does not extend the proliferative lifespan of a multiplicity 
o f epithelial cells maintained under certain culture conditions, unless the 
pRb/plb1**4* pathway is abrogated (Kiyono et al., 1998; Farwell et al., 2000; 
Kim et al., 2002; Toouli et al., 2002). Further strains of lung (MacKenzie et al., 
2000; Franco et al., 2001), mammary (O’Hare et al., 2001 and periodontal 
ligament (Tsutsui et al., 2002) fibroblasts require further loss of p i 6 ^ ^  
function in conjunction with hTERT expression for immortalisation.
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1.14 Aims
To date, the availability o f permanent human in vitro models of defective NER 
are limited to those derived from characterised human genetic diseases, such as 
XP, CS and TTD, which have been established by in vitro transformation using 
viral oncogenes. These cell lines are compromised by an undesirable legacy of 
immortalisation, namely disruption of the p53/p21WAF1/CIP1 and pRb/plb1*1^  
tumour suppressor pathways, which are instrumental in the elicitation of a DNA 
damage response and efficient NER. Therefore, in the cell lines currently 
available a critical response to DNA damage is missing. Telomerase-mediated 
immortalisation, however, provides an alternative for the establishment of 
permanent cell lines defective in NER, as their primary NER defect is preserved, 
while retaining both p53/p21WAF1/cn>1 and pRb/plb1^ 4* function. Currently, the 
availability o f telomerised cells, defective in NER, is limited to cell lines derived 
from XP-E, XP-V and CS-B individuals.
Cells derived from XP-C and CS-A individuals, which are defective in the XPC  
and CKN1 genes respectively, represent defects in the GGR and TCR 
subpathways of NER. For that reason, primary XP-C (GM02996, XP8CA) and 
CS-A (GM01856, CS3BE) dermal fibroblasts were selected for subsequent 
investigation.
In the present study, the first aim was to characterise the underlying molecular 
defect in XP-C and CS-A fibroblasts (Chapter 3) and establish permanent in vitro 
XP-C and CS-A culture models with an extended proliferative lifespan. This was 
achieved by transducing primary XP-C and CS-A fibroblasts with a retroviral 
vector expressing the catalytic subunit o f telomerase, hTERT  (Chapter 4). 
Additional requisites to the establishment o f permanent telomerised XP-C and 
CS-A cell lines included the preservation of the phenotypic characteristics 
observed in their primary isogenic counterparts and the maintenance of the 
p53/p21WAF1/CIP1 and pRb/plb1* * ^  pathways. Following the establishment of 
telomerised XP-C and CS-A cell lines, three representative clone of each cell line 
was maintained in continuous culture for -100  PDs, thereby allowing the
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conformation of immortality. Once immortality was confirmed, the removal of 
damage was assessed in the XP-C and CS-A cell lines, using DNA repair assays. 
Furthermore, the preservation of p53/p21WAF1/CIP1 and pRb/p 16INK4A pathways 
was addressed at the translational level. In particular, p53 activation and 
stabilisation is a well-documented response to DNA damage, but the nature of its 
activation in terms of post-translational modifications is poorly understood. 
Hence, a further aim was to characterise these responses.
To date, our current understanding o f the UV-induced global transcriptional 
response in NER-defective cell lines remains limited. Therefore, once 
telomerised XP-C and CS-A cell lines were established, a further aim was to 
utilise Affymetrix™ microarrays to dissect the global UV-induced transcriptional 
response of telomerised XP-C and CS-A cells (Chapter 5). The transcription 
expression responses of telomerised XP-C and CS-A cells were compared to the 
transcriptional profile o f normal telomerised MRC-5 fibroblasts previously 
generated in our laboratory. Transcription profiling in the different genetic 
backgrounds permitted the identification of genes differentially regulated in 
response to UV and what aspect of defective DNA repair blocks their expression. 
Furthermore, gene expression profiling facilitated the identification of cell-type- 
specific transcriptional ‘signatures’ in telomerised XP-C and CS-A cells. This 
will further assist in unravelling any underlying molecular defects, which 
contribute to the neoplastic and progeroid phenotypes observed in XP and CS 
patients, respectively. Following transcription profiling, a further aim was to 
validate the Affymetrix™ data, at the transcriptional level, by qRT-PCR. 
Additionally, validation was undertaken at the protein level by Western blotting 
and immunocytochemisty, to substantiate whether changes at the protein level 
reflect those changes observed at the mRNA level (Chapter 5).
As previously mentioned, the availability of permanent cell lines defective in 
NER are limited to rare human genetic diseases such as XP, CS and TTD, which 
are defective in a subset of DNA repair genes. Therefore, a further aim of this 
investigation was to demonstrate the applicability of RNAi in investigations of 
DNA repair by transiently ablating XPC  or CSA function in normal telomerised
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MRC-5 cells, by transfection with siRNAs specific to XPC  or CSA mRNA 
(Chapter 6). A further aim was to create a permanent X P C ^/C S A  double 
knockdown phenotype by transducing the telomerised CS-A cell line with a 
retroviral vector expressing an ATC-targeted shRNA construct (Chapter 6). 
Logic dictates that complete ablation of XPC  and CKN1 would result in the 
removal of the GGR and TCR subpathways that feed into the convergence point 
of NER where XPA co-ordinates excision of damage. One might expect that an 
X P d ^ /C S-A null cell would exhibit the UV-induced DNA damage response and 
repair kinetics of an XPA null cell. However, this is by no means a certainty as 
the rad 16 (GGR) and rad26 (TCR) S. cerervisiae double mutant is less sensitive 
than the rad 14 (XPA) mutant, which is completely defective in NER (Verhage et 
al., 1996). Additionally, attempts have been made to establish a double Csa'Xpc  
transgenic model (van der Horst et al., 2002). However, double mutants are 
severely runted and die within a month of birth. Once the establishment of the 
XPCkd/CS-A phenotype was confirmed at the protein level by Western blotting 
and immunocytochemistry (ICC), a further aim was to assess the biological 
effect of the X PC  shRNA construct. To address this, immuno-slot-blot assays 
were undertaken to determine whether knocking down XPC in a CSA null 
background had a biological effect on the global repair of UV-induced damage. 
The successful establishment o f NER defective cell lines, through the 
exploitation of RNAi technology, will provide an alternative to the establishment 
of cell lines derived from donors with defined genetic backgrounds such as XP, 
CS and TTD.
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Chapter 2 
Materials and Methods
All general chemicals were purchased from Fisher and all molecular biology 
grade chemicals and reagents were obtained from Sigma® (Chemical Co., 
Dorset, UK) unless otherwise stated. Water was prepared by reverse osmosis 
(Millipore). Further diethyl pyrocarbonate (DEPC) treatment o f water was 
performed were stated.
2.1 Cell strains and routine culture conditions
Normal human diploid MRC-5 fibroblasts, derived from lung tissue o f a 14- 
week-old male foetus (ECACC No. 84101801), were purchased from the 
European Collection of Cell Culture (ECACC). These were grown in monolayers 
at 37°C in a humidified incubator (95% air), 5% CO2 atmosphere in Eagle’s 
minimum essential medium with Earle’s salts (EMEM; Invitrogen™, Life 
Technologies) and supplemented with 10% foetal calf serum (FCS; Imperial 
Laboratories, London), IX MEM non-essential amino acids (NEAA) without L- 
glutamine (Sigma®), 2 mM MEM L-glutamine (Invitrogen™), 0.002% NaHCC>3 
(Invitrogen™), 10 mM Hepes (Sigma®). The pH was adjusted to 7.2 using 10 
N NaOH (-100 ptl/100 ml). All growth media were supplemented with 10,000 
U/ml penicillin (Sigma®) and 10 pg/ml streptomycin (Sigma®). Medium was 
made to the correct concentration with autoclaved milli Q H2O. Fibroblasts were 
subcultured at subconfluence (-80-90% confluent) and reseeded in T75 cm2 
flasks at a density of -1  X 105-4 X 105. Cells were refed with 10 ml of EMEM 
medium approximately every 3-4 days.
DNA repair-deficient primary and SV40-transformed human dermal fibroblast 
cell lines were purchased from the National Institute of General Medical 
Sciences (NIGMS) Human Genetic Mutant Cell Repository (Coriell Institute for
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Medical Research, Camden, NJ). The following cell lines were used: primary 
XP-A human fibroblasts (catalogue No.: GM05509, patient No.: XP12BE); 
primary XP-C human fibroblasts (GM02996, XP8CA); primary CS-A (CKN1) 
human fibroblasts (GM01856, CS3BE); isogenic SV40-transformed XP-A 
human fibroblasts (GM04429, XP12BE); isogenic SV40-transformed CS-A 
(CKN1) human fibroblasts (GM 16094, CS3BE.s3gl). The donor for the 
GM05509 (and GM04429) cells was a 17-year-old Caucasian female, cells of 
strain GM02996 were from a skin biopsy of 7-week-old Caucasian Egyptian 
male, and the cells of strain GM01856 (and GM 16094) were derived from a 13- 
year-old Caucasian male. All primary and SV40-transformed DNA repair- 
defective human fibroblasts were grown under identical condition in medium 
recommended by the NIGMS Human Genetic Mutant Cell Repository. Briefly, 
cultures were grown in growth medium previously described, supplemented with 
IX vitamins (Invitrogen™) and 10 mM Hepes was omitted from the medium.
Fibroblasts were trypsinised and subcultured close to confluence (-80-90% ). 
Briefly, the medium was aspirated from the flask and washed with 2 ml of IX 
trypsin/ethylenediamine tetracetate (EDTA; Invitrogen™) to remove any residual 
medium. The trypsin was discarded and a further 2 ml of fresh trypsin was 
added. The fibroblasts were incubated at 37°C for approximately 5-15 minutes, 
depending on cell-type. Once the cells had detached from the surface of the flask, 
they were resuspended in 8 ml of medium and transferred to a 15 ml Falcon tube 
(Becton Dickinson). Total cell counts were determined by counting the total 
number of cells distributed over the top-left and bottom-right primary squares of 
a Neubauer ruled haemocytometer (Hawksley). Approximately 10 pi of the cell 
suspension was pipetted onto a haemocytometer. Fibroblasts that were within, or 
that touched the right or bottom periphery of the primary squares were counted, 
whereas fibroblasts that touched, or were outside the upper, or left periphery was 
excluded from the cell count. The number of cells counted within two primary 
squares were added together and divided by two, to give the mean number of 
cells per ml of cell suspension. The total cell count was obtained by multiplying 
the number of cells per ml by ten (10 ml). The number of population doublings 
(PDs) for each passage (P) was calculated from the cell count by comparing the
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total cell count following trypsinisation with the initial number of cells seeded. 
For cumulative PDs, the number of PDs calculated following each subcultivation 
was added to the total number of PDs accumulated whilst in culture.
For routine passing of cells, fibroblasts were reseeded into a fresh T75 cm2 flask 
approximately every 7 days at a density of between 1 X 105 -  4 X 105, which 
equated to approximately l-2ml of cell suspension in 8-9 ml of fresh medium. 
All cell strains were grown in this manner. However, for specific 
experimentation, cells were grown in a range of different sized flasks or dishes, 
and cells were re-seeded and refed with the appropriate volume of medium and 
cell densities were modified accordingly.
Primary XP-C (XP8CA, GM02996) and CS-A (CS3BE, GM01856) dermal 
fibroblasts that were first seeded for subsequent retroviral infection with hTERT 
were assigned PD 0. During the exponential phase of growth, fibroblasts that 
were not re-seeded were frozen and stored as viable stocks. Briefly, once an 
appropriate volume of cell suspension had been reseeded, the remaining cells 
were centrifuged at 90 g for 5 minutes at room temperature in a Centaur 2 
centrifuge (Sanyo). The supernatant was discarded and the cell pellet was re­
suspended in 1 ml of IX Cell Freezing Medium-Glycerol (Sigma®), thus 
permitting the cryopreservation of cell cultures. The cell suspension was 
transferred to a freezing CryoTube™ (Nunc™, Denmark) and stored at -80°C in 
a storage box, containing isopropanol, for a minimum of 2 hours, before 
transferring the ampoule to liquid nitrogen. When recovering viable cell cultures 
from liquid nitrogen, the ampoule was rapidly thawed in a 37°C sterile water 
bath. Once thawed, the cell suspension was transferred to a 15 ml Falcon tube. 
Subsequently, 9 ml of warm medium was pipetted into the Falcon tube in a drop- 
wise manner. The cell suspension was gently mixed by pipetting up and down. 
To remove any residual Cell Freezing Medium-Glycerol, the cell suspension was 
centrifuged at 90 g for 5 minutes at room temperature. The supernatant was 
carefully aspirated and 10 ml of fresh EMEM medium was added. The cell 
suspension was transferred to a T75 cm flask.
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2.2 hTERT-immortalisation of primary XP-C and 
CS-A human dermal fibroblasts with \|>CRIP- 
pBABE-neo-hTERT
All manipulations during the retroviral infection procedure were undertaken with 
significant caution and in accordance with the Advisory committee on Genetic 
Modification (ACGM) guidelines. Briefly, all procedures involving the transfer 
and filtration of retroviral-containing supernatants were performed using a sterile 
plastic kwill and syringe. All pipette tips and stripettes were thoroughly rinsed 
with neat bleach. All retroviral-containing supernatants were aspirated from cell 
cultures into a retroviral trap, containing neat bleach. All disposable plastics 
including filters, kwills and syringes were re-sheathed to minimise potential 
generation of aerosols. All retroviral waste was placed in a specially designated 
metal container and all retroviral waste was autoclaved.
A retrovirus co-expressing the catalytic subunit of telomerase, hTERT, and the 
neomycin phosphotransferase selectable (G418) gene marker was previously 
constructed in the laboratory and made available as a general reagent. The 
pBABE-neo-hTERT construct was transduced into primary XP-C (GM02996, 
XP8CA) and CS-A (GM01856, CS3BE) human dermal fibroblasts, using this 
amphotropic retroviral vector. In addition, an empty pBABE-neo vector without 
the hTERT insert was used as a control. For retroviral infection, primary XP-C 
and CS-A dermal fibroblasts were plated out in three 60 mm dishes/cell type, 
containing 2 ml o f fresh non-selective EMEM medium (without G418), at a 
density of 2.8 X 105 and 2.7 X 105 cells/dish, respectively. One day later and 1 
hour prior to infection, the fibroblasts were refed with 4 ml of fresh non-selective 
medium, containing 40 pi of (10 pg/ml) polybrene (Aldrich Chemical Company, 
Inc.). Immediately prior to infection, amphotropic retroviral supernatants, 
previously harvested from near confluent ipCRIP producer cells, were rapidly 
thawed at 37°C. Using a sterile plastic 5 ml syringe (Tyco Healthcare Ltd., UK) 
and Avon kwill filling Tube (127 mm; Sims™ Portex, UK), the supernatants 
were drawn up, and the kwill was replaced with a sterile plastic 0.45 pm
104
Acrodisc syringe membrane filter (Pall Cor., MI, USA). The supernatant was 
filtered through the 0.45 pm membrane filter into a bijou. A 1/100 volume of 
100X polybrene was added to the filtered supernatant to give a final 
concentration of IX polybrene (8 pg/ml). The non-selective medium (containing 
10 pg/ml o f polybrene) was aspirated from the 60 mm dishes. The fibroblasts 
were exposed to either 2 ml of retrovirus-containing medium from near­
confluent producer cells expressing iJjCRIP-pBABE-neo-hTERT or 2ml of 
retrovirus-containing harvest medium expressing the empty pBABE-neo control 
vector, or mock treated with non-selective medium alone (containing polybrene). 
The dishes were incubated at 37°C for 4 hours. Following incubation, 3 ml of 
non-selective medium was added to the dishes. The fibroblasts were incubated 
overnight (16-18 hours) at 37°C in a humidified incubator. The next day, the 
retroviral-containing medium was aspirated and cells were refed with non- 
selective medium and incubated for a further 24 hours.
Fibroblasts infected with the xj)CRIP-pBABE-neo-hTERT were trypsinised, 
serially diluted in non-selective medium and seeded in 100 mm Petri dishes at 
densities appropriate for the production of polyclonal and monoclonal 
populations. The dilutions that were used included: 1/2, 1/10, 1/50, 1/100, 1/250 
and 1/500. Fibroblasts infected with an empty pBABE-neo retroviral control 
vector or mock infected without retroviral supernatant were trypsinised and 
transferred directly from the 60 mm dish to a T75 flask and maintained under 
routine culture conditions as a polyclonal population. Fibroblasts infected with 
the ipCRIP-pBABE-neo-hTERT vector, empty pBABE-neo vector, or mock 
infected were refed 24 hours post dilution with selective medium, containing 
G418 at a concentration of 400 p-g/ml. The 100 mm dishes were frequently 
analysed for colony formation and refed with selective medium every 3-4 days. 
Individual colonies were selected by trypsinisation, using autoclaved cloning 
rings. Selected clones were subsequently transferred to a 24 well plate. Once 
monoclonal populations were transferred to a 24 well plate the culture was 
denoted as passage 1 (PI) post retroviral infection. Confluent monoclonal 
populations were passaged into 35 mm dishes followed by T25 cm2 flasks. A cell 
count was obtained from confluent T25 flasks and cumulative PDs were
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calculated post infection. A fraction of the culture was passaged into a T75 flask 
(as described above). Both monoclonal and polyclonal populations were 
maintained under routine culture conditions and routinely subcultivated in T75 
flasks.
Monoclonal XP-C and CS-A populations, infected with the xpCRIP-pBABE-neo- 
hTERT retroviral supernatant, were isolated and maintained under routine 
culture conditions for approximately 25-30 PDs. Three monoclonal populations, 
derived from each cell-type (XP-C and CS-A), which exhibited the best growth 
characteristics, were maintained under routine culture conditions for a further 70 
PDs, as immortality was defined as ^100 PDs. A single hTERT-immortalised 
XP-C (clone 19) and CS-A (clone 3) monoclonal population was selected from 
the three clones for all subsequent experimentation. The XP-C and CS-A 
polyclonal populations were maintained under routine culture conditions for 
^100 PDs and stored in liquid nitrogen as viable cultures.
2.3 Transfection of XPC and CSA short interfering 
RNA (siRNA) duplexes
Three 21mer siRNA sequences, targeting different regions of the XPC  and CKN1 
mRNA gene transcript were designed using the Qiagen siRNA design tool 
(http://www.qiagen.com/Products/GeneSilencing/CustomSiRnaDesigner.aspx) 
and were synthesised and purified by Qiagen. The sequences of the siRNAs 
were: 5’-AAG TGG CCA AGG TGA CTG TTA-3’ (XPC#1), 5’-AAG CAT 
AGC TGG TAT AGA CCA-3’ (XPC#2), 5’-AAT TCA AAG ACG TGC TCC 
TGA-3’ (XPC#3), 5’-AAG CAG TGT GTT CCA TTG GCA-3’ (<CKN1# \ ), 5’- 
AAT CGA ATG AGG CTC TGG AAT-3’ (CKN1#2) and 5’-AAT CAC AAT 
TAA ATC CGG CCT-3’ (CKN1#3). All siRNA sequences were confirmed by 
submitting the sequences to a BLAST search (using the National Centre for 
Biotechnology Information (NCBI) database) against the human genome 
sequences, thereby ensuring that the target-specific siRNAs only targeted the 
XPC  or CSA gene.
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Exponentially growing human hTERT-immortalised MRC-5 lung fibroblasts 
(previously established in the laboratory) were cultured in EMEM medium 
supplemented with 10% FCS (as previously described). Cells were seeded in 60 
mm dishes, at a density of 2 X 105 cells/60 mm dish, 24 hours prior to 
transfection. Three 60 mm dishes were seeded/ATC (or CSA) siRNA duplex. 
Three further 60 mm dishes were seeded at a density of 2 X 105 cells for 
transfection of the scramble control. At the time of the initial transfection 
(treatment 1), the cell density was approximately 4 X 105 cells/60 mm dish. For 
each 60 mm dish, solution A was prepared as a master mix for the appropriate 
number of samples (XI) by combining 24 pi of 20 pM stock siRNA solution/60 
mm dish with 400 pi o f IX serum-free Opti-MEM (Invitrogen)/60 mm dish in a 
plastic Bijou. Solution B was also prepared as a master mix for the appropriate 
number of samples XI by combining 24 pi o f Oligofectamine™ Reagent 
(Invitrogen ™)/60 mm dish with 96 pi of serum-free Opti-MEM/60 mm dish in a 
plastic bijou. Solutions A and B were allowed to equilibrate at room temperature 
for 10 minutes. Solutions A and B were combined and incubated for a further 25 
minutes at room temperature. Following incubation, 256 pi of Opti-MEM/60 mm 
dish was added to the combined solution A and B master mix. During the 
preparation of the transfection mix, the 60 mm dishes were washed with EMEM 
medium omitting penicillin (10,000 U/ml) and streptomycin (10 pg/ml). 3 ml of 
fresh EMEM was added to each 60 mm dish followed by 800 pi of the resulting 
transfection mixture and incubated overnight at 37°C. Following overnight 
incubation, the medium containing the transfection mix was aspirated, and the 
cells were refed with 4 ml of EMEM, containing penicillin (10,000 U/ml) and 
streptomycin (10 pg/ml). The hTERT-immortalised MRC-5 lung fibroblasts 
were treated with three treatments of XPC- or CSA -specific siRNAs (or control 
scramble) during a nine day treatment cycle (Fig. 2.1). Whole cell extracts 
(WCEs) were prepared following each siRNA treatment and western blot 
analysis was performed (Sections 2.9.0-2.9.5).
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Day 0— ► Cells seeded in 60 mm dishes
Day 5
Three 60 mm dishes transfected with either XPC #1, #2 or #3 (or 
yT C SA  #1, #2 or #3) siRNA duplex
Day 1— ► Treatment 1-
Three 60 mm dishes transfected with scramble (transfection control)\
a.m. - Medium changed in all transfected dishes/
Day 2—
p.m. - Protein extracted from one of each treated 60 mm dishes (treatment 1) 
Day 3— ► Remaining 60 mm dishes maintained in incubator at 37°C for further 24 hours
Two remaining 60 mm dishes/siRNA, transfected with APC#1,
Day 4— ► Treatment 2 f  #2 or #3 (or CSA #1, #2 or #3) siRNA duplex\
Two remaining 60 mm dishes transfected with scramble (transfection 
control)
^  a.m. - Medium changed in all transfected dishes
p.m. - Protein extracted from one of each treated 60 mm dishes (treatment 2)
Day 6— ► 60 mm dishes maintained in incubator at 37°C for further 24 hours
^ 6 0  mm dish/siRNA, transfected with XPC #1, #2 or #3 (or CSA
S  #1, #2 or #3) siRNA duplex Day 7 ►Treatment 3
60 mm dish transfected with scramble (transfection control)
SDay 8---- ►
a.m. - Medium changed in all transfected dishes 
p.m. - Protein extracted from the treated 60 mm dishes (treatment 3)
Figure 2.1. Experimental methodology adopted for the transient knockdown of XPC or CSA in 
normal MRC-5 fibroblasts, using XPC- or CSA-targeted siRNA duplexes.
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2.4 Creation of permanent and stable double 
XPC?01 CS-A and XPAKD/CS-A cell lines using the 
CRUK pSUPER RNAi library
2.4.1 Background to the pSUPER RNAi ™ system
The human SUPER RNAi ™ library, utilised in the creation of a permanent and 
stable X P C ^ /C S-A double knockdown, was based on the pSUPER RNAi 
system (Fig. 2.2), first described by Brummelkamp et al. (2002) and the human 
SUPER RNAi™ library (NKi library) described by Bems et al. (2004). The 
complete CRUK SUPER RNAi ™ library was made available within eighty-three 
96 well plates.
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Figure 2.2. Schematic of pRETROSUPER vector derived from pMSCV. The 
59mer hairpin oligonucleotides were cloned downstream of the polymerase III 
Histone Hl-RNA promoter (H I; 1506-1721). The phosphoglycerate kinase 
promoter (PGK; 1721-2229) drives the expression of the puromycin resistance 
gene (puro; 2255-2854) in eukaryotic cells. The pRETROSUPER plasmid was 
propagated in E.coli under ampicillin (AMP; 5468-4611) selection.
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2.4.2 Isolation o f XPC shRNA constructs from DHSa 
bacteria using the QIAprep ™ Spin Miniprep Kit 
(QIAGEN)
The QIAprep miniprep (and Maxiprep) methodologies are based on three 
principle steps: (1) alkaline lysis of bacterial cells; (2) adsorption of DNA onto a 
silica-based QIAprep membrane in the presence of high salt; (3) washing and 
elution of plasmid DNA. All buffers and QIAprep Spin Columns used during the 
isolation and purification of the pRS vector harbouring the XPC  shRN A  
constructs were provided in the QIAprep™ Spin Miniprep Kit (QIAGEN).
A scraping was taken from the CRUK SUPER RNAi™ library frozen DH5a 
bacterial stock (stored in 96 well plates), containing the three XPC  shRNA 
constructs, using a sterile plastic pipette tip.
The scraping was streaked out on agar plates (15 g of DIFCO™ agar (Becton & 
Dickinson)/l of Luria Bertani (LB) broth (containing 1.0% tryptone, 0.5% yeast 
extract, 1.0% NaCl (pH 7.0)), containing ampicillin (100 mg/ml). Following 
overnight incubation at 37°C, 20 individual colonies were selected with a sterile 
plastic pipette tip and placed in 5 ml culture tubes, containing 3 ml of L-broth 
and ampicillin (100 mg/ml). The cultures were incubated in an Orbital incubator 
(Sanyo) at 37°C overnight with agitation at 250 rpm.
After overnight incubation, 1.5 ml of the DH5a bacterial cultures, harbouring the 
XPC  shRNA constructs, was added to a 1.5 ml Eppendorf tube, whilst the 
remaining 1.5 ml of the overnight cultures were stored at 4°C. The Eppendorf 
tubes were centrifuged at 13,400 g for 1 minute at room temperature in a Centra- 
M2 centrifuge (International Equipment Company, USA). The supernatant was 
decanted from the 1.5 ml Eppendorf tube, and the bacterial pellet was 
resuspended in 250 pi of buffer PI. Following complete resuspension, 250 pi of 
buffer P2 was added. The samples were mixed by gently inverting 4-6 times. 350 
pi of buffer N3 was added and the tubes were mixed by gently inverting 4-6
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times, or until the sample appeared cloudy. The tubes were centrifuged for 10 
minutes at 13,400 g in a Centra-M2 centrifuge. The supernatant was decanted 
into a QIAprep Spin Column. The QIAprep Spin Columns were centrifuged for 1 
minute at 13,400 g in a Centra-M2 centrifuge. Following centrifugation, the 
flow-through was discarded from the QIAprep Spin Column. The QIAprep Spin 
Columns were washed by adding 750 pi of buffer PE, and centrifuged for 1 
minute at 13,400 g in a Centra-M2 centrifuge. The flow-through was discarded, 
and the QIAprep Spin Column was centrifuged for a further minute at 13,400 g 
in a Centra-M2 centrifuge to remove any residual wash buffer. The QIAprep 
Spin Column was placed in a fresh 1.5 ml Eppendorf tube. The purified pRS 
retroviral vector, containing the XPC  expression cassette was eluted by adding 
50 pi of buffer EB to the centre of each QIAprep spin column, whilst avoiding 
direct contact between the pipette tip and the column surface. The column was 
left to stand for 1 minute and centrifuged for 1 minute at 13,400 g in a Centra- 
M2 centrifuge.
Following isolation and purification of the pRETROSUPER plasmid DNA, 
containing the XPC-specific shRNA cassette, a double EcoRI/XhoI digest was 
performed on the 20 isolated clones. The double EcoRI/XhoI digests were 
performed in a final reaction volume of 20 pi, containing 2 pi of plasmid DNA, 2 
pi of 10X buffer H (Promega), 1 pi of EcoRI (Promega), 1 pi of Xhol (Promega) 
and 14 pi of water. The double EcoRI/XhoI digests were incubated for 1 hour at 
37°C. Following digestion, 10 pi of each digest, containing 2 pi of bromophenol 
blue, was electrophoresied on a 0.7% agarose gel (containing 2.5 pi ethidium 
bromide /50 ml agarose) for approximately 2 hours at 120 volts (V) in TBE 
(Tris-base, boric acid, EDTA) buffer. The expected size of the shRNA hairpin 
insert was 301 bp.
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2.4.3 Identification o f XPC shRNA sequences
The sequencing reactions were undertaken in a final reaction volume of 10 jutl, 
containing 1 |xl of miniprep DNA, 1 pi of the pRS sequencing primer 5’-GCT 
GAC GTC ATC AAC CCG CT-3’ (3.3 pmol/pl), 4 pi of ABI PRISM® BigDye® 
Terminator v3.1 Cycle Sequencing Reaction Ready Kit (Applied Biosystems), 
and 4 pi of water. Sequencing reactions were prepared using a GRI MJ Tetrad 
Thermocycler. The sequencing conditions were 24 cycles o f 96° C for 30 
seconds, 50°C for 15 seconds and 60°C for 4 minutes. Following the completion 
of the sequencing reactions, a further 10 pi of water was added to each reaction 
to give a total volume of 20 pi.
2.4.4 Sequence reaction cleanup using the DyeEx ™ Spin 
Kit
The sequencing reactions were subsequently purified, using the DyeEx™ 2.0 
Spin Kit (Quiagen). The DyeEx™ 2.0 Spin Kit uses gel-filtration technology for 
the rapid removal o f unincorporated dye terminators directly from sequencing. 
Spin columns provided with the DyeEx™ Spin Kit, were vortexed to resuspend 
the resin. The cap of the column was loosened and the bottom closure of the spin 
column was removed. The spin column was placed in a 2 ml collection tube and 
centrifuged for 3 minutes at 101 g using a Micro Centaur bench-top centrifuge 
(Sanyo). The collection tube was discarded and the spin column was transferred 
to a fresh collection tube. The sequencing reaction (20 pi) was applied to the gel 
bed with a pipette, whilst avoiding direct contact with the resin. The sequencing 
reaction product was collected by further centrifugation for 3 minutes at 101 g in 
a Micro Centaur bench-top centrifuge. Sequencing reactions were sent to the in- 
house Central Biotechnology Service (CBS; www.cardiff.ac.uk/cbs), where 
sequence analysis was undertaken using an automated ABI PRISM 3100 Genetic 
Analyser. Data was received as text files and electropherograms.
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After sequencing and conformation of the successful isolation of the pRS vector 
harbouring the X PC  shRNA constructs, 1 ml of the overnight 3 ml culture, 
previously stored at 4°C, was pipetted into 500 ml of L-broth, containing 
ampicillin (100 mg/ml). The cultures were incubated in a 2 1 conical flask at 
37°C overnight (16-18 hours) with agitation at 250 rpm in an Orbital incubator.
2.4. S Maxiprep o f XPC shRNA overnight 500 ml culture 
using the QIAGEN plasmid Maxi Kit
Following incubation, the 500 ml overnight cultures were divided into two 250 
ml fractions and transferred to two 500 ml bacterial containers. An SLA-3000 
rotor was chilled to 4°C and the two fractions were pelleted by centrifugation at
6,000 g for 15 minutes at 4°C using a Sorvall® Evolution RC refrigerated 
centrifuge. After centrifugation, the supernatant was aspirated.
One of the pelleted bacterial fractions was resuspended in 10 ml of buffer PI. 
The sample was transferred to the second container, containing the second 
fraction. The two fractions of the same sample were resuspended and 10 ml of 
buffer P2 was added. The samples were mixed gently by inverting 4-6 times, and 
incubated at room temperature for 5 minutes. Buffer P3 was chilled to 4°C, and 
10 ml was added to each sample. The samples were mixed immediately by 
inverting 4-6 times and incubated on ice for 20 minutes. The samples were 
centrifuged at 6000 g for 30 minutes at 4°C. The supernatant, containing the 
plasmid DNA, was transferred to a 30 ml Sorvall tube. A SS-34 rotor was chilled 
and the Sorvall tubes were centrifuged at 9,000 g for 15 minutes at 4°C, using a 
Sorvall® Evolution RC centrifuge. A Qiagen-tip 500, provided in the Qiagen kit, 
was equilibrated by applying 10 ml of buffer QBT and the column was allowed 
to empty by gravity flow. The supernatant, containing the plasmid DNA, was 
applied to the Qiagen-tip and allowed to enter the resin by gravity flow. The 
Qiagen-tip was washed twice with 30 ml of buffer QC. The plasmid DNA was 
eluted from the Qiagen-tip with 15 ml of buffer QF into a fresh Sorvall tube. The 
plasmid DNA was precipitated by adding 10.5 ml (0.7 volumes) of isopropanol 
to the eluted DNA. The plasmid DNA was mixed and centrifuged immediately at
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9,000 g for 30 minutes at 4°C. The supernatant was carefully decanted from the 
30 ml Sorvall tube. The isolated plasmid DNA was washed with 5 ml of 70% 
ethanol and centrifuged at 9,000 g for 10 minutes at 4°C. The supernatant was 
decanted from the Sorvall tube. The pellet was air-dried for 10 minutes and 
resuspended in 400 pi of TE (10 mM Tris-Cl, 1 mM EDTA) buffer.
10 pi of each plasmid DNA, harbouring the XPC  shRNA construct, was diluted 
in 990 pi of water. The diluted plasmid DNA samples were quantified, using an 
UltraSpec 31000 PRO spectrophotometer (Amersham Biosciences). To ensure 
that the isolated plasmid DNA harboured the XPC  shRNA construct, a double 
EcoRI/Xohl digest was performed as previously described. Following digestion, 
10 pi of each digest, containing 2 pi of bromophenol blue, was electrophoresied 
on a 0.7% agarose gel (as previously described). To ensure that the sequence of 
the maxipreped plasmid DNA corresponded to the minipreped DNA, 1 pi of 
each plasmid DNA sample, prepared by the Maxiprep kit, was used to prepare 
sequencing reactions. The sequencing reactions were purified using the DyeEx™ 
Spin Kit (as previously described in Sections 2.4.5-2.4.6) and sequencing was 
performed (as before) by the CBS on an ABI PRISM 3100 Genetic Analyser.
2.4.6 Calcium phosphate transfection of XPC, XPA shRNA 
or an empty pBABE-puro plasmid DNA into FLY A l 3 cells
The XPA shRNA (isolated from the CRUK human SUPER RNAi ™ library) and 
the pBABE-puro plasmid DNA, used as transfection controls, were previously 
prepared in the laboratory and made available as a general reagent.
Subconfluent FLY A 13 human epithelial cells (retroviral packaging cell line), 
derived from fibrosarcoma tissue (Cosset et al., 1995), were trypsinised from a 
T75 flask and seeded in 60 mm dishes at a density of 1 X 105 cells/dish. The 
cells were allowed to equilibrate overnight (16-18 hours) at 37°C in a humidified 
incubator (with 95% air, 5% CO2 atmosphere). The next day and four hours prior 
to infection, the cells were re-fed with 3.6 ml of fresh non-selective Dulbecco’s
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modified Eagle’s medium (DMEM; without puromycin) supplemented with 10% 
FCS, L-glutamine, 10,000 U/ml penicillin and 10 pg/ml streptomycin. Thq XPC  
and XPA shRNA plasmid DNA, previously prepared by the Quiagen maxi prep 
kit, was transferred from the 30 ml Sorvell tubes to 1.5 ml Eppendorf tubes. The 
tubes were centrifuged at 13,400 g for 10 minutes at room temperature in a 
Micro Centaur bench-top centrifuge, to remove residual proteins and cell debris. 
The supernatants were transferred to fresh 1.5 ml Eppendorf tubes. For each 60 
mm dish transfected, 20 pg of plasmid DNA (containing either XPC/XPA 
shRNA or the pBABE-puro construct) was mixed with 200 pi of 0.25 M CaCI2 
(solution A). Solution B was prepared for each 60 mm dish to be transfected, by 
adding 200 pi of (2X) Hepes-buffered saline (HBS) solution (pH 7.05-7.12) to a 
sterile universal container. Solution A was taken up in a 200 pi plugged sterile 
pipette tip and pipetted drop by drop into solution B, whilst simultaneously 
blowing air through a 1 ml plastic stripette into solution B. The combined 
solution was incubated at room temperature for 25 minutes to allow the 
formation of a precipitate. The precipitate was gently resuspended and added 
drop-wise to the 60 mm dishes, containing the FLY A13 epithelial cells, using a 
1 ml plugged sterile pipette tip and Gilson. The 60 mm dishes were transferred to 
an incubator and maintained under routine culture conditions overnight (16-18 
hours). Following overnight incubation, the medium was aspirated from the 60 
mm dishes and discarded. The 60 mm dishes were refed with fresh non-selective 
DMEM medium and incubated for 24 hours under routine culture conditions. 
Following incubation, the retroviral supernatant containing the retroviral virions 
was collected using a sterile plastic kwill and 5 ml syringe. The harvested 
supernatants were snap frozen in liquid nitrogen for 5 minutes and transferred to 
a -80°C freezer. The cells were refed with non-selective DMEM medium and 
incubated for a further 24 hours under routine culture conditions. Supernatants 
were harvested as previously described 48 hours post feeding.
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2.4.7 Retroviral infection o f hTERT-immortalised CS-A 
human dermal fibroblasts with XPC/XPA shRNA 
constructs or an empty pBABE-puro vector
The transfection (pBABE-puro) control supernatant was generated (during the 
calcium phosphate transfection of the shRNA constructs) from previously 
prepared plasmid DNA. In addition, pBABE-puro supernatant, previously 
generated in the laboratory was also obtained and used in the retroviral infection, 
thus providing an infection control.
For retroviral infection, hTERT-immortalised CS-A dermal fibroblasts were 
plated out in six 60 mm dishes, containing 2 ml of fresh non-selective medium 
(without puromycin), at a density of lx l0 5 cells/dish. Retroviral infection of 
hTERT-immortalised CS-A dermal fibroblasts with the XPC/XPA  shRNA 
constructs, the empty pBABE-puro control plasmid vector, or mock-infected 
(nontransduced) was performed as previously described (Section 2.2). 
Fibroblasts infected with the shRNA constructs or empty pBABE-puro vector 
were serially diluted in non-selective medium and seeded in 100 mm dishes at 
densities appropriate for the production of monoclonal populations (as previously 
described). The 60 mm dish infected with either the pBABE-puro supernatant 
(previously generated in the lab) or mock-infected (nontransduced) were 
transferred directly to a T75 flask and maintained in culture as polyclonal 
populations. Fibroblasts infected with the XPC  or XPA  shRNA vectors, empty 
pBABE-puro vector, or mock-infected were refed 24 hours post dilution with 
selective medium, containing puromycin at a concentration of 1 pg/m l. 
Monoclonal populations of hTERT-immortalised CS-A dermal fibroblasts, 
infected with either the XPC  (or XPA) shRNA constructs, or the empty pBABE- 
puro vector were selected (as previously described in Section 2.2).
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2.5 Plating efficiency
Prior to cell survival determination by colony forming ability, plating efficiencies 
were undertaken. Fibroblasts were seeded at densities of 1 X 102, 5 X 102, 1 X 
103 and 5 X 103 in triplicate 100 mm Petri dishes, and were maintained under 
routine culture conditions for 10-16 days (depending upon cell-type). Following 
incubation, cells were washed twice in phosphate-buffered saline (PBS) and 
fixed for 15 minutes with methanol: acetic acid (3:1) and left to dry for 30 
minutes at room temperature. The plates were subsequently stained in Giemsa’s 
solution: Sorenson’s buffer (pH 6.8; BDH, Poole, Dorset). Purple colonies with a 
minimum of 50 cells were scored. Plating efficiency was calculated as a 
percentage of the number of colonies formed compared to the initial number of 
cells seeded.
2.6 Cell survival determination by colony forming 
ability
Sub-confluent, exponentially growing human fibroblasts were trypsinized from 
T75 flasks and 5 X 102 to 2 X 103 cells were seeded in 100 mm Petri dishes, and 
allowed to attach overnight (16-18 hours), prior to UV-C irradiation (254 nm). 
For UV treatment, a UVP germicidal lamp (UVP, Ltd., Cambridge), emitting 
UV-C light, was calibrated using a UVX digital radiometer (UVP, Ltd., 
Cambridge) to emit an incident fluence rate of 1 J/m2/s. Cells were washed twice 
with prewarmed (37°C) Hank’s balanced salt solution (Sigma®) and irradiated 
with 0-10 J/m2 in increments o f 2 J/m2. Fibroblasts were refed with fresh 
medium and maintained in culture for 7-14 days at 37°C in a humidified 
atmosphere containing 5% CO2 . Mock-irradiated (0 J/m2) cells were treated as 
previously described, however, irradiation was omitted. At the end of the 
experiment, dishes were stained and scored (as above) to determine the 
clonogenic survival of cells. Survival values were calculated as a percentage of 
the number of colonies from irradiated cells compared to non-irradiated cells. 
Three data points (UV-irradiations) were obtained per experiment, which was
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performed in triplicate. Therefore, each data point is representative of nine 
replicates.
2.7 Immuno-slot-blot assay
The immuno-slot-blot assay facilitated the detection of DNA damage following 
exposure to UV radiation, through the detection of both CPDs and 6-4PPs in 
genomic DNA, using specific mouse monoclonal antibodies, raised against either 
CPDs or 6-4PPs, respectively.
Exponentially growing hTERT-immortalised MRC-5, XP-C (GM02996, 
XP8CA), CS-A (GM01856, CS3BE) and double X P C ^ICS-A knockdown 
fibroblasts were seeded in 4-8 100 mm culture dishes/time point at a density of 
lx l0 6 cells/100 mm dish. Cells were irradiated with 10 J/m2 (as previously 
described) and incubated under routine culture conditions for an indicated period 
of time following UV-irradiation. Genomic DNA was isolated (as described 
below) and stored at -20°C.
The Bio-Dot SF Microfiltration apparatus (BioRad) was assembled and a 
Vacugene pump (Pharmacia Biotech, UK) was attached to the outlet valve. Two 
layers o f Whatman paper (Whatman International Ltd., UK) were placed on the 
blot machine as a base. This was followed by a piece of GeneScreenPlus nylon 
membrane (NEN Life Sciences Products, Inc., USA), soaked in a 0.4N NaOH 
solution. The lid was positioned and secured tightly. The vacuum pump was 
started and allowed a pressure of 40-50 mbar. Once the desired pressure was 
reached, 1 pg of DNA from each sample (in TE buffer) was loaded into each 
well and left for 5 minutes under pressure. Once the DNA had absorbed into the 
membrane, a final rinse of the individual wells was performed, by applying 200 
pi o f 0.4N NaOH. The membrane was removed from the Bio-Dot SF 
Microfiltration apparatus and washed once with IX TBST (containing 100 mM 
Tris-base (pH 8), 500 mM NaCl, Tween 20 made up in water) solution for 5 
minutes at room temperature. The membrane was blocked overnight (16-18 
hours) at 4°C, in IX TBST/3% non-fat milk (Marvel). The membrane was placed
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in a plastic bag and was incubated with either 2 pg of CPD- (TDM-2) or a 6- 
4PP- (64M-2) specific monoclonal mouse antibody (both purchased from MBL® 
International Corporation; Mori et al., 1991) in 10 ml of IX TBST/3% non-fat 
milk solution. The membrane was incubated with agitation on a Gyro-Rocker® 
STR9 (Stuart) for 1 hour at room temperature. This was followed by three 15 
minute washes in fresh IX TBST solution. The membrane was incubated in 0.5 
pi of the alkaline phosphatase-linked anti-mouse secondary antibody provided in 
the ECF ™ (enhanced chemifluorescence) Western Blotting Analysis system Kit 
(Amersham Pharmacia Biotech), diluted in 10 ml of IX TBST/3% non-fat milk 
solution, for 1 hour with agitation at room temperature. Residual secondary 
antibody was removed by extensive washing with IX TBST solution as 
previously described. The ECF detection solution, provided with the ECF™ 
Western Blotting Analysis system, was prepared by adding 36 mg o f ECF 
substrate to 60 ml o f ECF dilution buffer. The ECF detection solution was 
pipetted onto Clingfilm, and the membrane was placed on top of the solution, 
with the side harbouring the DNA samples facing the detection solution. The 
membrane was incubated for 2 minutes at room temperature. The fluorescent 
emission from the samples bound to the membrane was detected using a STORM 
860 phosphorimager (Molecular Dynamics, Inc.) and quantification was 
performed using ImageQuant software (Molecular Dynamics, Inc.). The 
percentage of lesions remaining at each time point was calculated in comparison 
to the lesions present immediately (0 hours) after UV-irradiation. Three 
biological replicates were performed for each indicated time point.
2.8 Detection of telomerase activity by the 
Telomeric repeat amplification protocol (TRAP) 
assay
The TRAP assay is a two-stage methodology used to detect telomerase activity 
in cell extracts of cultured cells or tumour samples. Stage 1 requires a 
nontelomeric TS oligonucleotide, which is extended by the synthesis of telomeric 
(TTAGGG) repeats, as a result of telomerase activity. The second step involves
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the PCR amplification of the extension products, using the downstream CX 
primer and the presence of the upstream TS primer. Amplification products are 
resolved on a polyacrylamide gel and detected by fluoro-imaging. The TRAP 
assay was performed in accordance to the methodology first described by Kim et 
al. (1994), and undertaken in an RNase-free environment. All tubes were DEPC 
treated and solutions were made using DEPC treated water. All glassware used to 
prepare stock solutions was baked with a metal lid at 200°C for 2 hours and 
sealed with parafilm when cooled. In addition, to avoid contamination, all 
manipulations were performed in a PCR hood, using RNase-free pipette tips.
2.8.1 Preparation of SI 00 cell extracts
Following the selection of monoclonal and polyclonal populations of fibroblasts 
infected with hTERT, exponentially growing fibroblast cell cultures were 
trypsinised and resuspended in 8 ml of medium and counted (as previously 
described in Section 2.1). The cells were centrifuged at 277 g for 5 minutes at 
room temperature and the medium was discarded. The cell pellets were 
resuspended and washed in 10 ml of IX sterile PBS. The cells were centrifuged 
at 202 g for a further 5 minutes at room temperature and the supernatant was 
aspirated. The pellets were resuspended in 1 ml of IX PBS and transferred to a
1.5 ml RNase-free Eppendorf tube. The samples were centrifuged at 15,000 g for 
2 minutes at 4°C in a OLE DICH Type 154.RF cooling centrifuge (Camlab Ltd., 
Cambrige, UK) and the supernatant was discarded. The pellets were stored at - 
80°C.
The cells were thawed on ice and resuspended in 1 ml of wash buffer (containing 
100 pi 0.1 M Hepes-KOH, 1.5 pi 1 M MgCL, 1 pi 1 M KC1, made up to 1 ml 
with DEPC treated water) with 1 pi of 1 M dithiothreitol (DTT) added 
immediately prior to use. The cell suspension was centrifuged at 15,000 g for 2 
minutes at 4°C and the supernatant aspirated. Fresh lysis buffer was prepared by 
adding 3 pi of 10% (3-mercaptoethanol (diluted 1/10 in DEPC treated water) and 
2 pi of 0.5 M phenylmethylsulphonyl fluoride (PMSF; diluted in methanol) to 
500 pi of lysis buffer (100 pi 0.1 M Tris-HCl (pH 8.3), 1.5 pi 1 M MgCh, 10 pi
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0.1 M ethyleneglycol tetraacetic acid (EGTA), 100 pi glycerol, 100 pi 5% 
chapso (CHAPS; Pierce) made up to 1 ml with DEPC water, immediately prior 
to use. The cell pellets were resuspended in 20 pi of lysis buffer and incubated 
on ice for 30 minutes. During incubation, a S150AT rotor was placed in a 
RCI50GX micro-ultracentrifuge (Sorvall) and cooled to 4°C under vacuum. The 
cell suspension was transferred to cooled DEPC-treated polycarbonate centrifuge 
tubes (Sorvall) during the 30 minutes incubation on ice. Lysates were centrifuged 
at 100,000 g for 30 minutes at 4°C in a RC M l50 GX ultracentrifuge. 
Supernatants were aliquoted into fresh DEPC-treated polycarbonate tubes. The 
supernatants were snap frozen on dry ice and stored at -80°C. All cell lysates, 
including positive cell extract 293 (derived from adenovirus transformed human 
embryonic kidney cells (HEK 293; Graham, 1977)), were thawed on ice, and 
further diluted in lysis buffer to give approximately 5000 cell equivalents/pl.
2.8.2 Pre-treatment of TRAP assay lysates
To prepare negative controls (and destroy telomerase activity), the diluted cell 
lysates (prepared in 2.8.1) were divided into two equal aliquots by transferring 
half the cell lysate to a fresh RNase free 0.5 ml microcentrifuge tube. One aliquot 
from each sample was incubated at 85 °C for 10 minutes to destroy telomerase 
activity, thus providing a negative control for the detection o f possible 
contamination within the assay. The other aliquot of each sample was placed on 
ice for 10 minutes.
2.8.3 TRAP assay -  Stage 1 (extension of TSprimer)
TRAP assay reactions were prepared by transferring 1 pi of each heat-treated and 
non-heat treated cell extract to a fresh 0.5 ml RNase-free microcentrifuge tube 
incubated on ice, containing 50 pi IX reaction buffer (20 mM Tris-HCl (pH 8.3),
1.5 mM MgCl2, 63 mM KC1, 0.005% Tween 20, 1 mM EGTA (pH 8), 50 pM 
dNTP’s (Promega), 0.1 mg/ml bovine serum albumin (BSA; acetylated: nuclease 
free: Promega). In addition, 1 pg of the single-stranded DNA (ssDNA) binding
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protein T4 Gene 32 protein (New England BioLabs, Inc.), 100 ng TS (5’- 
AATCCGTCGAGCAGAGTT-3’) primer (MWG Biotech) was added to each 
reaction immediately prior to extension. The samples were capped with mineral 
oil (Sigma®), transferred to a GRI MJ Tetrad Thermocycler, and incubated for 
30 minutes at 30°C. The temperature was increased to 92°C in preparation for 
stage 2.
2.8.4 TRAP assay -  Stage 2 (PCR amplification)
Extension products generated in stage 1 are undetectable by conventional 
methods. Therefore, products were amplified by PCR. Following the initial 
extension, 100 ng of CX (5’-CCCTTACCCTTACCCTTACCCTAA-3’) primer 
(MWG Biotech), 2.5 U of Taq polymerase (Promega) and 0.5 X 1 0 18 g (0.5 
pl/reaction) of the internal telomerase amplification standard (ITAS) PCR 
control was added to each reaction at 92°C. PCR amplification was performed in 
a GRI MJ Tetrad Thermocycler. The amplification conditions were 31 cycles of 
denaturation (92°C, 30 seconds), annealing (50°C, 30 seconds) and extension 
(72°C , 90 seconds). Following PCR amplification, the reaction mix 
(approximately 50 pi) was carefully transferred to a fresh microcentrifuge tube, 
without carrying over mineral oil. 10 pi of 6X xylene cyanol/bromophenol blue 
(0.25% xylene cyanol (Sigma®), 0.25% bromophenol blue (Sigma®), 15% 
Ficoll (Pharmacia) dissolved in water) was added to each sample. 20 pi of each 
sample was electrophoresed at 300 V on a 10% polyacrylamide 20 cm Protean II 
gel (containing 45 ml distilled water, 30 ml 5X TBE buffer (54 g Tris base, 27.5 
g boric acid and 20 ml 0.5 M EDTA made up to 1 litre with water), 25 ml 
acrylamide (19:1 bis: acrylamide; BIO-RAD Laboratories, Inc.), 500 pi 100 
mg/ml ammonium persulphate (APS) and 100 p i  N, N, N ,’ N ,’- 
tetramethylethylenediamine (TEMED)) in a tank containing 1.5X TBE buffer, 
for approximately 4 hours or until the bromophenol blue electrophoresed to ~ 3 
cm from the bottom of the gel. The gel was incubated in SybrGold (Cambridge 
Bioscience) diluted 1:10,000 in water for 10 minutes at room temperature with 
agitation. The gel was washed for 5 minutes in water at room temperature to 
remove excess SybrGold. After washing, the gel was scanned on STORM
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(Amersham Biosciences), employing the blue fluorescence mode. A DNA ladder 
of 6 bp increments typified a telomerase positive extract.
2.9.0 Western blotting
2.9.1 Sample preparation and protein extraction
Fibroblasts were seeded in 100 mm Petri dishes or 60 mm dishes at a density of 
-1 X 106 cells/dish or -2  X 105/dish, respectively, and maintained under routine 
culture conditions for 1-3 days (depending on cell-type and experimental 
procedure) prior to extraction. For UV-irradiated and mock-irradiated samples, 
fibroblasts were seeded in multiple 100 mm Petri dishes/time point and allowed 
to equilibrate overnight at 37°C under routine culture conditions. Dishes were 
UV treated as previously described (Section 2.6) and maintained in culture at 
37°C for the indicated period of time. Total protein was harvested at the 
indicated time point (hours) post UV-irradiation (as described below). Mock- 
irradiated samples were prepared in an identical manner, omitting UVC- 
irradiation.
Subconfluent (-80-90% confluence) dishes were washed twice with 5 ml ice- 
cold sterile IX PBS. The cells were incubated and policed off with 1 ml ice-cold 
sterile STE buffer (containing 10 mM Tris; pH 8, 150 mM NaCl, 1 mM EDTA 
(pH 8)) and transferred to a 15 ml Falcon tube. This was repeated for each dish 
with a further 1 ml of STE buffer. The cells were centrifuged at 123 g for 5 
minutes at 4°C in a refrigerated Falcon 6/300 (Sanyo). Following centrifugation, 
the supernatant was aspirated and discarded. The total cell volume was 
estimated, and WCEs were prepared by resuspending pellets in 2.5 packed cell 
volumes of 1 X lysis buffer (150 mM NaCl, 50 mM Tris, 5 mM EDTA and 1% 
nonident P40 (NP40)), containing protease inhibitors; 100 mM PMSF dissolved 
in propan-2-ol, 20 pg/ml Aprotinin and 10 pg/ml Leupeptin (all Sigma®) were 
both added to the lysis buffer. For the analysis of phosphorylated proteins, 
additional phosphatase inhibitors were added, including 200 pM sodium
124
orthovanadate and 50 mM sodium fluoride. WCEs were centrifuged at 20,000 g 
for 30 minutes at 4°C in an OLE DICH Type 154.RF cooling centrifuge. 
Following centrifugation, supernatants were transferred to a fresh 0.5 ml 
microcentrifuge tube and stored at -80°C.
2.9.2 Protein quantification
Total protein lysates were quantified by the Bradford colormetric method, using 
the Coomassie® Plus Protein Assay Reagent (Pierce). Lysis buffer, previously 
used to obtain the WCEs, was diluted 1/10 with sterile water, and used to dilute a 
stock solution of Comassie® Plus -  The Better Bradford Assay™ Kit BSA 
reagent (Pierce, Ltd., UK) at a concentration of 2 mg/ml (stored at 4°C). A series 
of BSA standards were prepared in triplicate with final concentrations in the 
range of 0-400 p-g/ml, in increments of 100 pg/ml. 5 pi of each WCE was diluted 
in 45 pi of water to give a 1/10 dilution. 40 pi of each WCE and BSA standard 
was transferred to a 1.6 ml plastic cuvette, before adding 1 ml of Coomassie Plus 
Protein Assay Reagent (Pierce). The Coomassies® Plus Protein Assay Reagent 
and WCEs or BSA standards were mixed thoroughly by vigorous pipetting. A 
1/10 dilution of the lysis buffer (diluted with sterile water) was also prepared as a 
reference for subsequent spectrophotometric analysis. The OD (at 595 nm) of 
WCEs and BSA standards was determined using an UltraSpec 31000 PRO 
(Amersham Biosciences). Each BSA standard was assayed in triplicate and a 
mean value was calculated. Linear regression analysis of the BSA standards was 
used to calculate the concentration of protein (pg/pl) present in each WCE.
2.9.3 SDS-PAGE electrophoresis and transfer
A Biorad mini-protean II electrophoresis cell system was used to separate and 
transfer protein lysates to a polyvinylidene difluoride (PVDF) Immobilon™-P 
membrane (Millipore). WCEs were run on 8-12 % polyacrylamide, sodium 
dodecyl sulphate (SDS) resolving gels (containing 40% acrylamide:bis (29:1) 1.5 
M tris (pH 8.8), 10% SDS, 10% APS and TEMED), depending upon the
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molecular weight of the protein of interest (Table 2.1). The resolving gel was 
pipetted directly between the glass plates of the mini gel apparatus, using a 
Pasteur pipette, to approximately 2 cm from the top of the glass plates. Sterile 
water was subsequently pipetted directly on top of the resolving gel to promote 
polymerisation. Following polymerisation (approximately 1 hour at room 
temperature) of the resolving gel, the water was decanted from the gel apparatus, 
and any residual moisture was removed with 3 MM paper (Whatman). The 
stacking gel (2.5 ml 0.5 M Tris (pH 6.8), 1.25 ml 40% acrylamide:bis 29:1 (BIO­
RAD Laboratories, Inc.), 100 pi 10% SDS, 50 pi 10% APS, 10 pi TEMED in 
6.25 ml water) was pipetted directly onto the resolving gel between the glass 
plates o f the minigel apparatus, using a Pasteur pipette. A plastic 10 lane (0.75 
mm) comb was inserted into the stacking gel. The SDS-PAGE gels were allowed 
to stand at room temperature for a further 30 minutes to permit polymerisation of 
the stacking gel. Aliquots, containing 20 pg of the soluble WCEs was made up to 
the maximum allowable volume of 18 pi with sterile water and 9 pi of 3X 
loading buffer (for 960 pi stock: 300 pi 0.5 M Tris (pH 6.8), 300 pi glycerol, 300 
pi 10% SDS, 60 pi 1% bromophenol blue and 30 pi P-mercaptoethanol) was 
added to give a total volume of 27 pi. 8 pi of 1 pg/pl High Molecular Weight 
Rainbow™ coloured marker (Amersham Pharmacia Biotech) was made up to 30 
pi with IX loading buffer. The WCEs and rainbow marker were denatured at 
100°C for 5 minutes in a boiling water bath, and centrifuged at 12,000 g for 1 
minute in a OLE DICH Type 154.RF cooling centrifuge, and loaded using “duck 
bill” tips. The High Molecular Weight Rainbow™ marker was also loaded in 
parallel to confirm the precise location of the protein of interest. 30 pi of IX 
loading buffer was loaded in empty lanes to prevent the uneven electrophoresis 
of the protein extracts. Protein extracts were electrophoresed and separated at 
100 V for 1 hour (or until the loading buffer migrated to the bottom of the SDS- 
PAGE gel) in IX SDS running buffer (containing 15 g of Tris base, 94 g of 
glycine and 5 g of SDS made up to 1 litre with water, -pH  8.3) using a vertical 
Biorad Mini-Protean II Electrophoresis Cell.
Following electrophoresis, the SDS-PAGE gel was removed from the Biorad 
Mini-Protean II electrophoresis cell, and the separated proteins were transferred
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from the SDS-PAGE gel to a (0.45 pm) PVDF Immobilon™-P membrane, using 
a Mini Trans-blot Electrophoresis Transfer Cell (BIO-RAD Laboratories, Inc.). 
Preceding transfer, the PVDF membrane was prepared by immersing in methanol 
for 3 seconds. The membrane was washed in sterile de-ionised water for 2 
minutes, thus removing any residual solvent from the membrane. The PVDF 
membrane was transferred and maintained in transfer buffer (containing 3.03 g 
Tris base, 14.4 g glycine, 200 ml methanol, made up to 1 litre with water, pH 
8.1-8.4) to prevent drying and facilitate equilibration between the transfer buffer 
and membrane, until the assembly of the Mini Trans-blot Electrophoresis 
Transfer Cell was completed. In addition to the PVDF membrane, the Mini 
Trans-blot electrophoresis transfer pads and 3 MM filter paper were equilibrated 
in transfer buffer prior to transfer. Following electrophoresis, the Biorad Mini- 
Protean II Electrophoresis Cell was disassembled and the SDS-PAGE gel was 
carefully removed from the gel plates. The gel was washed and allowed to 
equilibrate in transfer buffer. The Trans-blot electrophoresis apparatus was 
assembled by transferring the PVDF membrane to a piece of 3 MM filter paper 
prior to positioning the SDS-PAGE gel onto the PVDF membrane. A further 
piece of 3 MM filter paper was positioned on top of the SDS-PAGE gel. The gel 
and PVDF membrane was secured by the Mini Trans-blot electrophoresis clamps 
and transferred to a Mini Trans-blot electrophoresis tank. Transfer buffer was 
poured into the electrophoresis tank, and a stir bar was added. In addition, an ice 
block was inserted into the Mini Trans-blot electrophoresis tank to prevent the 
electrophoresis tank from overheating. The electrophoresis tank was placed on a 
stirrer and transfer of the separated proteins was performed at 100 V for 1 hour.
2.9.4 Immunoprobing
PVDF membranes were blocked by overnight incubation at 4°C in IX PBS, 
containing 5% non-fat milk and 0.2% Tween 20 (Sigma®). Following overnight 
incubation, the PVDF membrane was incubated with the primary antibody 
(Table 2.1) in a 30 ml Sorvall tube for 1 hour at room temperature (unless where 
otherwise stated) on a Roller Mixer SRT2 (Stuart Scientific, UK) in (a minimum 
volume of 2 ml) IX PBS containing 5% non-fat milk/1% BSA/0.2% Tween 20,
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or TBS. The PVDF membrane was washed with 1% Tween 20 in PBS, at room 
temperature on a Gyro-Rocker® STR9 (Stuart Scientific, UK) for 15 minutes. 
This was followed by three further 5 minute washes with fresh 1% Tween 20 in 
PBS. The PVDF membrane was transferred to a fresh 30 ml Sorvall tube before 
incubating with a rabbit anti-mouse (RAM) or goat anti-rabbit (GAR) 
horseradish peroxidase (HRP)-conjugated secondary antibody (Table 2.1) 
supplied with the ECL™ (enhanced chemiluminescence) Western Blotting 
Analysis system (Amersham Pharmacia Biotech), or with a peroxidase- 
conjugated rabbit anti-goat (RAG) immunoglobulin (Dako). The secondary 
HRP-coupled antibody was diluted as before in (a minimum volume of 2 ml) IX 
PBS, containing 5% non-fat milk/1% BSA/0.2% Tween 20 (Table 2.1). The 
PVDF membrane was incubated with the secondary HRP-coupled antibody for 1 
hour at room temperature on a Roller Mixer SRT2. The PVDF membrane was 
washed with 1% Tween 20 in IX PBS, as previously described. The protein- 
antibody complexes were detected using the ECL™ Western Blotting Analysis 
system (Amersham Pharmacia Biotech) and was used according to the 
manufacturers recommendations. Briefly, ECL Reagents A (luminol) & B 
(enhancer) were equilibrated at room temperature, and 1 ml of each reagent was 
pipetted into a Bijou and mixed. Residual wash buffer was removed from the 
PVDF membrane by blotting, and the combined solution of reagents A & B was 
pipetted onto the PVDF membrane at a recommended (by Amersham Pharmacia
9  9Biotech) volume of 1 ml of combined reagent per 8 cm (or 0.125 ml/cm ) of 
PVDF membrane. The PVDF membrane was incubated at room temperature for 
1 minute, and any residual reagent was blotted from the membrane. The 
membrane was tightly wrapped in Saran wrap. Protein bands, immobilised on 
PVDF membranes, were visualised by exposing the membrane to 
autoradiography hyperfilm (Amersham Pharmacia Biotech) for 5-120 minutes. 
After exposure, the autoradiography hyperfilm was developed and fixed using a 
XOGRAPH Compact X4 Automatic X-ray Film Processor (X-Ograph Imaging 
System, Ltd., Gloucestershire, UK).
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2.9.5 Verification of equal protein loading
To account for differences in cell size (and therefore differences in the total 
amount of certain cellular proteins), India ink staining was used to verify equal 
protein loading of the WCEs.
Following visualisation of the hyperfim, equal loading of the WCEs was verified 
by washing the PVDF membrane with 0.2% Tween 20 in IX PBS for 15 
minutes, at room temperature with agitation on a rotator. The membrane was 
stained with 100 pi of India ink (Windsor & Newton) diluted in 100 ml of 0.2% 
Tween 20 in IX PBS. To remove excess India ink residue, the PVDF membrane 
was washed with 0.2% Tween 20 in IX PBS as previously stated. The membrane 
was subsequently dried at room temperature.
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Table 2.1. Antibodies used during Western blot analysis and optimised immunoblot conditions (where the antibody concentration was not available the antibody dilution has 
been provided).
Antibody Resolving gel (%) 1° antibody Con. Diluent 2° antibody Con. Diluent
ATF-3
C-terminus
12 ATF-3 (C-19):sc-188 
(Santa Cruz 
Biotechnology, Inc)
1 p,g/ml PBS GAR 1/2000 PBS
CSA
C-terminus
12 CSA (W16): sc-10997 
(Santa Cruz 
Biotechnology, Inc)
2 pg/ml PBS RAG 1/1000 PBS
FDXR
Full-length
12 FDXR [6C2] (abl6810) 
(Abeam)
1 pg/ml PBS RAM 1/2000 PBS
GADD45a
N-terminus
12 GADD45 (AB3863) 
(Chemicon 
International)
4 pg/ml PBS GAR 1/1000 PBS
PMAIP1 (NOXA) 
pl6 (DCS50)
12 NOXA [114C307] 
(ab13654) 
(Abeam)
1.25 pg/ml PBS RAM 1/2000 PBS
C-terminus 12 Calbiochem® 2.5 |i.g/ml PBS RAM 1/1000 PBS
Table 2.1. Continued.
Antibody Resolving gel (%) 1° antibody Con/ Diluent 2° antibody Con. Diluent
p2I (sdil/6B6) 12 Pharmingen (Cat No. 554228) 2 ng/ml PBS RAM 1/2000 PBS
p38 12 Cell Signalling (Cat No. 9212) 1/250 TBS GAR 1/2000 PBS
p53 
(aa 21-25)
12 DO-1 (Ab6) 
(Calbiochem)
0.1 pg/ml PBS RAM 1/2000 PBS
Phospho-p53 
(Ser-15)
12 Phospho-p53 16G8 
(Cell Signalling)
1/1000 TBS RAM 1/2000 PBS
RB 
(aa 332-344)
7 RB (G3-245): 554136 
BD Pharmingen
2 pg/ml PBS RAM 1/10,000 PBS
XPA (12F5) 12 Abeam 
(Cat No. ab2352)
2 jig/ml PBS RAM 1/1000 PBS
XPC 8 Abeam 
XPC [3.261 (ab6264)
2 pg/ml PBS RAM 1/1000 PBS
Abbreviations'. ATF-3, activating transcription factor 3; Con., concentration; CSA, Cockayne syndrome A; FDXR, ferredoxin reductase; GADD45a, growth arrest and 
DNA-damage-inducible, alpha; GAR, goat anti-rabbit; PBS, phosphate-buffered saline; Phospho, phosphorylated; PMAIP1 (NOXA), phorbol-12-myristate-13- 
acetate-induced protein 1; RAG, rabbit anti-goat; RAM, rabbit ant-mouse; Rb, retinoblastoma; Ser, serine; XPA, xeroderma pigmentosum A; XPC, xeroderma 
pigmentosum group C; TBS, tris-buffered saline.
2.10 Immunocytochemistry (ICC)
The VECTRASTAIN® ABC system (Vector Laboratories, Peterborough, UK) 
utilises an immunoperoxidase system, which facilitates the immunocytochemical 
detection through: (1) binding of a primary antibody; (2) subsequent binding of a 
biotinylated secondary antibody; (3) formation of an Avidin and Biotinylated 
horseradish peroxidase macromolecular Complex (ABC). The horseradish 
peroxidase is visualised by the development of a peroxidase substrate that 
generates a brown reaction product.
Cells used for XPC labelling were plated onto Thermanox coverslips (which 
were previously attached to 35 mm culture dishes) at a density of 1 X 105 
cells/35 mm dish. The dishes were allowed to equilibrate and attach to the 
surface of the coverslips in a humidified incubator at 37°C for 48 hours, prior to 
4% paraformaldyhyde fixation and antibody labelling (as described below). For 
p21WAF1/CIP1 labelling, following UV-irradiation, cells were plated onto 
Thermanox coverslips at a density of 1 X 105/35 mm dish (as previously 
described) and allowed to equilibrate and attach to the surface of the coverslips 
for 48 hours before UV treatment. The 35 mm dishes were irradiated (or not) as 
previously described (Section 2.6). Cells were fixed with 4% paraformaldyhyde 
at the indicated time points, post UV-C irradiation or mock-irradiation and 
labelled with the appropriate antibodies (as described below).
Following irradiation (or not), growth medium was aspirated and the 35 mm 
dishes were washed twice with 2 ml IX PBS. The fibroblasts were fixed in 2 ml 
of 4% paraformaldehyde in IX PBS for 10 minutes at room temperature. The 
paraformaldyhyde was aspirated and the coverslips were washed twice with IX 
PBS. The dishes were stored in 2 ml IX PBS at 4°C for up to 48 hours prior to 
undertaking ICC. To quench, the IX PBS was decanted and the culture dishes 
were incubated with 2 ml of 50 mM glycine in IX PBS for 10 minutes at room 
temperature. The glycine was decanted, and the dishes were washed three further 
times in IX PBS. The dishes were incubated with 2 ml of 0.2% Triton X-100 in 
IX PBS for 10 minutes at room temperature, and washed three times in IX PBS.
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The dishes were incubated for 3 minutes with 0.3% hydrogen peroxide (H2O2) in 
water and washed three further times in IX PBS. To block, the dishes were 
incubated with 2% horse serum in IX PBS for 10 minutes at room temperature. 
Coverslips were incubated for 1 hour at room temperature in a humidified 
chamber with 50 pi o f either the anti-XPC (1/200) or anti-p21WAFl/CIP1 (1/500) 
mouse monoclonal primary antibody, which was diluted in 2% horse serum IX 
PBS. Coverslips were washed three times in IX PBS, and incubated for 10 
minutes at room temperature in a humidified chamber with 50 pi of the anti­
mouse biotinylated secondary antibody (1/200) provided in the Vectastain® 
Elite® ABC Kit diluted in 2% horse serum/IX PBS. Coverslips were placed in a 
clean 24 well culture dish and washed in IX PBS. The ABC reagents, supplied 
with the Vectastain® Elite® ABC Kit, was prepared by adding 2 pi of avidin 
solution DH (solution A)/100 pi 2% horse serum in IX PBS, followed by 2 pi of 
biotinylated enzyme (solution B)/100 pi 2% horse serum in IX PBS, containing 
solution A. Coverslips were incubated for 5 minutes at room temperature with 50 
pi of the solution A and B mix and transferred to a clean 24 well dish and 
washed in IX PBS. After washing, coverslips were incubated with 50 pi of 
diaminobenzidine (DAB) solution (containing 1 ml DAB/9 ml IX PBS and 3.4 
pi H2O2) for 5 minutes at room temperature, transferred to a clean 24 well plate 
and washed in distilled water. To enhance visualisation of the cells, coverslips 
were counter-stained with haematoxylin for 45 seconds and rinsed in tap water. 
Coverslips were dehydrated in 100% ethanol and xylene, mounted onto square 
coverslips using DPX (BDH), and left to dry overnight. Once dry, the coverslips 
were further mounted onto glass microscope slides, using DPX. Positive cells 
exhibited brown nuclei that were indicative of a peroxidase reaction product. By 
contrast, negative cells displayed blue nuclei, under a light microscope. For 
p21WAF1/CIP1 ICC, the percentage of positively labelled nuclei was ascertained 
from a count of 500 cells/coverslip.
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2.11 Characterisation of XPC  and CKN1 gene 
variants
2.11.1 Genomic DNA isolation & purification
The pellet was resuspended in 400 pi of digestion buffer (containing 100 mM 
NaCl, 10 mM Tris-Cl (pH 8), 25 mM EDTA and 0.5% SDS). 2.5 pi of 20 mg/ml 
RNase (Sigma®) was added, and the samples were incubated for 1 hour at 37°C 
in a water bath before adding 5 pi of 20 mg/ml proteinase K (Sigma®). The 
samples were incubated at 50°C in a water bath overnight (16-18 hours). 
Following overnight incubation, an equal volume of phenol (200 pi) and 
chloroform/isoamyl alcohol (200 pi) at a ratio of 25:24:1 was added, and the 
samples were mixed thoroughly by repeated inversion. The samples were 
emulsified by mixing gently on a ROTATOR DRIVE STR4 (Stuart Scientific, 
UK) at room temperature for 15 minutes. The centrifuge tubes were centrifuged 
at 13,400 g for 10 minutes in a bench-top Micro Centaur (Sanyo) centrifuge at 
room temperature. The upper aqueous layer, containing genomic DNA, was 
carefully transferred to a fresh 1.5 ml DNase-free Eppendorf tube, using a wide 
bore pipette tip. A 1/10 volume (40 pi) o f 3 M sodium acetate (pH 5.2) was 
added, and the samples were mixed gently before adding 2.5 volumes (1000 pi) 
of ice cold absolute (100%) ethanol. The samples were mixed gently and 
incubated for a minimum of 20 minutes at -20°C. The samples were centrifuged 
at 20,000 g for 10 minutes at 4°C in an OLE DICH Type 154.RF cooling 
centrifuge. The ethanol was carefully aspirated from the Eppendorf tube. The 
pellet was washed with 500 pi of 70% ethanol, and the samples were incubated 
on ice for 5 minutes. The samples were centrifuged at 20,000 g for 5 minutes at 
4°C in an OLE DICH Type 154.RF cooling centrifuge, and the supernatant was 
decanted. The pellet was air-dried for 5-10 minutes to remove any residual 
ethanol before resuspending the pellet in an appropriate volume of TE buffer to 
give a concentration of approximately 1-2 pg/pl. The genomic DNA was stored 
at 4°C overnight to redissolve. The DNA concentration was determined by 
measuring the absorbance at 260 nm (A260) in an UltraSpec 31000 PRO
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spectrophotometer (Amersham Biosciences), using a quartz cuvette. In addition, 
the purity was determined by the 260 nm and 280 nm ratio (A260/A280). 
Following quantification, genomic DNA was stored at -20°C.
2.11.2 PCR amplification of XPC & CKN1 gene fragments 
from isolated genomic DNA
To reduce the risk of contamination, PCR reaction mixes were prepared in a 
laboratory separate from PCR product analysis. All subsequent manipulations 
were performed in a sterile laboratory dedicated to genomic DNA amplification. 
In addition, all procedures were undertaken in a DNase-free environment, using 
DNase-free pipette tips and microcentrifuge tubes.
PCR primer sets, used to amplify the XPC  (Table 2.2) and CKN1 (Table 2.3) 
coding regions and sequences flanking the intron-exon boundaries, from isolated 
XP8CA and CS3BE genomic DNA, respectively, were devised using NCBI 
sequences, NT_0.22517.17 and NT_006713.14 (respectively). Genomic DNA, 
isolated from XP-C (XP8CA) and CS-A (CS3BE) dermal fibroblasts, was 
thawed on ice and diluted to give a final concentration of 5 ng/pl. PCR 
amplification was performed in a final reaction volume of 25 pi, containing 2.5 
pi of GeneAmp® 10X PCR Gold Buffer (containing 150 mM Tris-HCl (pH 8.0), 
500 mM KC1 and 25 mM MgCh), 0.5 pi of each forward and reverse primer (25 
pmol), 0.1 pi of (5 U/pl) AmpliTaq Gold® polymerase (Applied Biosystems), 0.5 
pi of dNTP mix (10 pmol for each dNTP) and 15.9 pi of water. The PCR 
reaction mix was prepared as a master mix for the appropriate number of samples 
(XI). The PCR reaction mix was gently mixed and pulsed in a bench-top 
centrifuge, and 20 pi of reaction mix was aliquoted into Thermo Hybaid 96 well 
plates for subsequent thermocycling on a GRI MJ Tetrad thermocycler. Finally, 5 
pi of XP8CA or CS3BE (5 ng/pl) genomic DNA was added to each individual 
well and 5 pi of dH20 was added to a well containing only PCR reaction mix, 
thus providing a negative control. The Thermo Hybaid 96 well plate was spun in 
a salad spinner. PCR amplification was performed on a GRI MJ Tetrad
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thermocycler. Amplification conditions were 95 °C for 12 minutes, followed by 
33-35 cycles of 30 seconds each at 94° C, the primer specific annealing 
temperature (Tables 2.2 & 2.3), and 72°C, ending with a final 10 minute 
extension step at 72°C. The PCR amplification of XPC  exon 1 required the 
inclusion of 4% dimethyl sulphoxide (DMSO).
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Table 2.2. Forward and reverse primer sets for XPC  amplification from genomic
DNA isolated from human XP-C (XP8CA) dermal fibroblasts.
Exon Sequence Direction Annealing tem p. ( ° C )  Product size  (bp)
1 5'-TGA CTA GGC CTC CAA CGA A G -3' F 60
1 5'-TAC GCA GGA GCT TGG ATC G -3 ' R 60 45 3
2 5'-ATA AGC TGC ACT GCC TCC AC-3 ' F 62
2 5'-GAT CCA ATC TTC CAT GGA C C -3 ' R 62 371
3 5'-G CT TGA ATG GAA CAC TAG G -3 ' F 62
3 5 '-TAG TGA TCT GAC TCC AAA CAG-3' R 62 257
4 5'-TGA TTC TGT TCA GTA CAG TAG C -3 ' F 62
4 5'-CAA AGT CCT CCT AAG CAG C -3 ' R 62 308
5 5 '-GAG GAG AAG GAA TTG CCT G -3 ' F 62
5 5 '-AGC ACA AGC TCT TTG CAC C -3 ' R 62 224
6 5'-CAT GTC TTG ACT TTG GCA G C -3 ' F 62
6 5'-CTG  TGG AAG TGA CCT GAA C C -3 ' R 62 325
7 5'-CTT GGC TGG AAA TGA AAA TTC C -3 ' F 62
7 5'-GCA CAT GGC TGC CAT TAT C -3 ' R 62 25 7
8 5'-TTC TTA GGA TAA CTA TGT TCT TC C -3' F 58
8 5 '-ACT CCG TGA ATA CCA GCT C -3 ' R 58 232
9 .1 5'-CTC TAG CTG GTG ACT TAA C C -3 ' F 6 2
9 .1 5'-C TT GAA GAG CTT GAG GAT G C -3 ' R 6 2 4 5 3
9 .2 5'-G CT CTG ATT TTG AGC TCT C C -3 ' F 6 2
9 .2 5'-C C T GAC TGT GTC TTG GAG C -3 ' R 6 2 588
10 5'-G TC TAA GGA TCA TCT CCC T C -3 ' F 6 2
10 5'-TG C  TGT CCA GTC AGA TGA G C -3 ' R 62 3 4 4
11 5'-ACG TTC AAG GCT GTT TGC C -3 ' F 62
11 5'-G C T CAT CAT CAC TTC TCT G C -3 ' R 6 2 344
1 2 /1 3 5'-TGA GGA ACT GGA TGC CTT T G -3 ' F 62
1 2 /1 3 5'-TGA AAA TTG GAG CCA CCA G G -3 ' R 62 558
14 5'-CAC TGT CTT CCA CAA ACT G G -3 ' F 62
14 5'-TG T ATT CAG TGC TCG CTC C -3 ' R 6 2 333
15 5'-ACTTGGTGTGAAGGAGAGGC-3' F 6 2
15 5'-C C T TTC TGA GCT GCA TCT C C -3 ' R 62 291
16 5'-GAA CTT GCT GCC TCT TCA T G G -3 ' F 62
16 5'-TG C CTT CTC AGC AGA GAA G C -3 ' R 62 4 1 6
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Table 2.3. Forward and reverse primer sets for CKN1 am plification from
genomic DNA isolated from human CS-A (CS3BE) dermal fibroblasts.
Exon Sequence Direction Annealing tem p. (°C) Product size  (bp)
1 5'-GAC TCT GCT GTT CCA GTC C -3 ' F 60
1 5'-CAA AGC TTA CAG TCA TTG GTC C -3 ' R 60 220
2 5'-TAC GTT AGG ATG TGT GGT A G -3 ' F 60
2 5'-ATG CCA GAT TCA AAA ATG CTA C -3 ' R 60 500
3 5'-TGA AGT CTG TGT TAT TGA G G -3 ' F 60
3 5'-CAG TCA AGT GAA TGG GTC A A-3' R 60 363
4 5'-ATG TGA TCT CGG TTT G G C -3' F 55
4 5'-GGA TTA AAT TCT CCT TTA TCC TAC-3' R 55 3 0 2
5 5 '-TG T TTA AGT TGA ATT GCT AAC AGT C -3 ' F 60
5 5'-TTG TGA TAT TCC TCT G G G -3' R 60 31 6
6 5'-TTC TGC ATG GAT ACA GTG AAA A TG -3' F 60
6 5'-TGA GTC TCA ACA ACC AGC A C-3' R 60 302
7 5 '-CAC TTT CTT CAG AAT CAG G C -3 ' F 60
7 5'-GGA AGA TTT CTT TTG GTG ACA-3' R 60 367
8 5'-TAA CGA GAC CTC TGT GTG CCA-3' F 60
8 5'-GAA AGT GAT ATA CGA TGA ATG C C -3 ' R 60 3 4 2
9 5'-GTA ACT CAA GTA GTT GTC C T -3 ' F 60
9 5'-ATC AAG TGT ATG TCA CAG ATC -3 'C R 60 2 9 5
10 5 '-AGT ATT TCT CCT AGG CTT TGT TGT G -3 ' F 60
10 5 '-ACA TAT AAC TGG TCT GGC AAG C -3 ' R 60 3 3 4
11 5 '-ATT GGC CTA GTT TCT TTA GGG A G -3' F 60
11 5'-TAA GCT TTA GAA GTC ACT GTA C C -3 ' R 60 299
12 5'-TTT TCT TCC AAA ATA ATG TAA TTG C T-3 ' F 60
12 5'-CTG TAT GGT CTA TTC CTG A C -3' R 60 235
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2.11.3 Exonuclease I, Shrimp Alkaline Phosphatase 
(EXOSAP) treatment: post PCR reaction purification 
protocol
Exonuclease I (New England Biolabs, Ipswich, MA, USA) and Shrimp alkaline 
phosphatase (Amersham Pharmacia Biotech, Sweden) were utilised following 
PCR amplification, to remove single stranded DNA, such as excess 
oligonucleotides, and unincorporated dNTPs in preparation for Sanger dideoxy 
sequencing. Exonuclease I and Shrimp Alkaline Phosphatase were thawed on 
ice. Following PCR, 0.5 p i of Exonucelase and 1 p i of Shrimp alkaline 
phosphatase was added to 5 pi of the amplification product. The samples were 
incubated at 37°C for 15 minutes and immediately incubated at 85°C for 15 
minutes in the GRI MJ Tetrad Thermocycler.
2.11.4 Screening XPC and CKN1 for genomic DNA 
variants by fluorescent, Sanger dideoxy sequencing
PCR amplification products were prepared for sequencing using the ABI 
PRISM® BigDye® Terminator v3.1 Cycle Sequencing Reaction Ready Kit 
(Applied Biosystems), and sequencing was performed in both forward and 
reverse directions, using the XPC- and CKN1 -specific primers (Tables 2.2 &
2.3). Briefly, sequencing was performed in a final reaction volume of 10 pi, 
containing 1.5 pi of 5X sequencing buffer, 0.75 pi of ABI PRISM® BigDye® 
Terminator Mix (Applied Biosystems) and 5.75 pi of water. 1 pi of the XPC  or 
CKN1 forward or reverse primer, and 1 pi of the PCR product was added to a 
fresh Thermo Hybaid 96 well plate. A master mix was prepared and 8 pi of the 
reaction mix was aliquoted into allocated wells in the Thermo Hybaid 96 well 
plate, containing both the primer and PCR product. The Thermo Hybaid 96 well 
plate was sealed and placed on the GRI MJ Tetrad Thermocycler. Sequencing 
conditions were 25 cycles of 10 seconds at 96°C, 5 seconds at 50°C and 4 
minutes at 60°C.
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2.11.5 Millipore Montage sequence reaction cleanup
The Mont&ge SEQ96 Sequencing Reaction Cleanup Kit (Millipore) facilitated the 
elimination of contaminating salts and excess unincorporated dye terminators 
(generated during the preparation of the DNA sequencing reactions) through a 
vacuum-based size exclusion separation platform. The Montage Seq96 Sequence 
Reaction was undertaken by adding 20 pi of injection solution to each 10 pi 
sequence reaction, using a multi-well pipette. The 30 pi of mix was transferred to 
the relevant wells of a Montage plate, avoiding direct contact between the pipette 
tip and the membrane. The plate was placed onto the Millipore vacuum manifold 
and the vacuum was adjusted to 17”Hg. The vacuum was allowed to run for 
approximately 3 minutes, or until all of the liquid had been drawn through the 
plate. Once the wells o f the plate had dried, the vacuum was disconnected and 
the plate was removed from the manifold. The plate was placed onto the 
manifold and 25 pi of injection solution was added to the relevant wells. The 
vacuum was reconnected for a further 3 minutes at 17”Hg. Once the relevant 
wells had dried, the vacuum was disconnected, and the plate was removed from 
the manifold. A further 25 pi of injection fluid was added to the relevant wells 
and the lid was placed on the plate. The plated was subsequently placed into the 
plate holder of the Vortex Genie and was vortexed on setting 3 for 10 minutes. 
The samples were prepared for analysis on the ABI PRISM 3100 Genetic 
Analyser by removing the plate from the shaker. Approximately 10 pi o f the 
solution from each sample was transferred to a fresh 96 well ABgene, semi­
skirted plate.
2.11.6 Sequence analysis
For each sequence reaction, a minimum of 10 pi o f the purified sequence 
product, present in the relevant wells of an ABgene, semi-skirted plate (AB- 
0999) from the Montage Sequence Reaction Clean up, was required for 
subsequent sequence analysis, using the automated ABI PRISM 3100 Genetic 
Analyser. The ABI PRISM 3100 Genetic Analyser parameters for RunModule 1 
RapidSeq36_Pop6DefaultModule used for sequence analysis were as followed:
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Temperature -  55.0°C 
Current -  100 uAmps 
Voltage -  1 Kvolt 
Injection time -  22 seconds 
Run time -  2400 seconds
Following data acquisition, X PC  and CKN1 gene variants were identified by 
direct comparison with consensus cDNA sequences obtained from NCBI, using 
Sequencher™ Version 4.5 software (Gene Codes Corp.).
2.12 Analysis o f CS3BE CKN1 mRNA
Total RNA was extracted using TRIzol reagent (Invitrogen™) and reverse 
transcribed with Superscript II (Invitrogen™) in accordance to the manufacturers 
recommendations (as described below). PCR amplification of CS3BE cDNA was 
performed in a final reaction volume of 50 pi, containing 5 pi of (10X) Taq 
DNA polymerase magnesium free reaction buffer (Promega; containing 100 mM 
Tris-HCl (pH 9), 500 mM KC1 and 1% Triton® X-100), 3 pi of 25 mM MgCl2, 1 
pi of each CKN1-specific forward 5’-GGT TTT TGT CCG CAC GCC AA-3’ 
and reverse 5’-GTG GAG ACC AGG AAA CTG CT-3’ primers (25 pmol; 
MWG), 0.5 pi of (5 U/pl) Taq DNA polymerase (Promega), 1 pi of dNTP mix 
(10 mM/dNTP) and 34.5 pi of water. The PCR reaction was prepared as a master 
mix for the appropriate number of samples (XI). The PCR reaction mix was 
gently mixed and pulsed in a bench top centrifuge, and 49 pi of reaction mix was 
aliquoted into thin-walled PCR tubes. Finally, 1 pi o f CS3BE or MRC-5 
(control) CKN1 cDNA was pipetted into the PCR tubes, containing the reaction 
mix. In addition, 1 pi o f H20  was added to a PCR tube containing only PCR 
reaction mix, thus providing a negative control. PCR amplification was 
performed on a GRI MJ Tetrad thermocycler. Amplification conditions were 
94°C for 3 minutes, followed by 29 cycles of 1 minute each at 94°C, 63°C and 
72°C, ending with a final 10 minute extension step at 72°C. Following PCR 
amplification, 10 pi of each reaction was electrophorised for approximately 2
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hours at 120 V in TBE buffer (as previously described). The expected size of the 
CKNJ cDNA amplification product was 567 bp.
2.12.1 TA cloning
Following PCR amplification of CS3BE and MRC-5 (control) CKN1 cDNA, 10 
pi ligation reactions were prepared on ice, containing 5 pi sterile water, 1 pi of 
10X ligation buffer (60 mM Tris-HCl (pH 7.5), 60 mM MgCE, 50 mM NaCl, 1 
mg/ml BSA, 70 mM |3-mercaptoethanol, 1 mM ATP, 20 mM DTT and 10 mM 
spermidine; Invitrogen™), 2 pi of 25ng/pl pCR®2.1 vector (Invitrogen™; Fig.
2.3), 1 pi of fresh PCR product (~10 ng) and 1 pi of T4 DNA ligase (4.0 Weiss 
units/pl; Invitrogen™). A self-ligation control reaction was further prepared, 
omitting the 1 pi of fresh PCR product. The ligation reaction was incubated 
overnight (16-18 hours) at 14°C in a PTC-200 Peltier MJ Tetrad Thermocycler 
(GRI). The overnight ligation reactions were briefly centrifuged and placed on 
ice. For One Shot® chemical transformation, a 50 pi vial of frozen IN V aF’ 
Escherichia coli One Shot® Competent cells/transformation was thawed on ice, 
and 2 pi of each ligation reaction was pipetted directly into the vial of competent 
cells. Gentle stirring with the pipette tip facilitated complete mixing of the 
ligation reaction and competent cells. The vials were incubated on ice for 30 
minutes, and heat shock was performed for 30 seconds at 42°C in a prewarmed 
water bath. The vials were immediately transferred to ice, and 250 pi of room 
temperature super optimal catabolite (SOC) medium (containing 2% tryptone, 
0.5% yeast extract, 10 mM NaCl, 2.5 mM KC1, 10 mM MgCb, 10 mM MgSC>4 
and 20 mM glucose) provided in the TA Cloning® Kit (Invitrogen™), was added 
to each vial. The vials were shaken horizontally at 37°C for 1 hour at 225 rpm in 
an Orbital shaking incubator. After transformation, 50 pi and 200 pi from each 
transformation vial (including the self-ligation control) was spread onto LB agar 
plates and incubated overnight at 37°C. The LB agar plates (containing 100 
pg/ml ampicillin) were previously prepared by spreading each plate with 40 pi of 
(40 mg/ml) 5-bromo-4-chloro-3-indolyl-|3-D-galactopyranoside (X-Gal) and 
allowed to equilibrate at 37°C for 30 minutes, prior to overnight incubation.
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After overnight incubation, the plates were stored at 4°C for 3 hours to facilitate 
complete colour development. For plasmid isolation, 60 white colonies 
theoretically harbouring the PCR amplified CKN1 cDNA were selected from 
CS3BE, using a sterile pipette tip, and transferred to a 5 ml culture tube, 
containing 3 ml of LB (containing 100 p-g/ml ampicillin). Additionally, ten white 
clones were selected from the wild-type MRC-5 control sample. The isolated 
colonies were expanded by incubating at 37°C overnight at 225 rpm in a shaking 
incubator.
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AGA TAT OCA TCA CAC TOG COG COG CTC GAO CAT OCA TCT AGA QGG COC AAT TOG 
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CCC TAT 
ATA
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AGT GAG TOG TAT TA C AAT TCA 
TCA g jg  AflC.AIA A AOT
CTG GCC GTC GTT TTA C AA CGT COT GAC TOG GAA AAC 
QAC OQQ CAG CAA AAT Q TT GCA GCA CTG ACC CTT TTG
pCR*2
Comments for pCR*2.1 
3829 nucleotides
LacZa gene: bases 1-545
M13 Reverse priming site: bases 205*221
T7 promoter bases 962-381
M13 (-20) Forward priming site: bases 389-404
fl origin: bases 546-983
Kanamydn resistance ORF: bases 1317-2111
Ampictlin resistance ORF: bases 2129-2969
pUC origin: bases 3134-3807
Figure 2.3. Schematic of the linearised TA cloning vector, pCR®2.1. The arrow 
indicates the start of transcription for the T7 RNA polymerase (taken from the TA 
Cloning® Kit Version V Manual, Invitrogen™).
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2.12.2 Plasmid isolation
The isolation and purification of the pCR®2.1 plasmid, harbouring the amplified 
CKN1 cDNA PCR product, was undertaken using the QIAprep Spin Miniprep 
Kit protocol (as previously described in Section 2.4.4). To confirm the ligation of 
the CKN1 cDNA product into pCR®2.1 and subsequent transformation into 
INVaF’ E.coli One Shot cells, an EcoRI digest was performed in a final reaction 
volume of 20 pi, containing 2 pi o f 10X buffer H, 1 pi of EcoRI, 2 pi of 
pCR®2.1 plasmid DNA (harbouring the amplified CKN1 cDNA) and 15 pi of 
water. The EcoRI digests were incubated for 1 hour at 37°C. Following 
digestion, 10 pi o f each digest was electrophoresed on a 0.7% agarose gel. The 
expected size of the CKN1 cDNA insert was 582 bp.
2.12.3 Sequencing
To further analyse isolated clones, harbouring the CKN1 cDNA amplified PCR 
product, 10 pi sequencing reactions were prepared, containing 1 pi of plasmid 
DNA, 1 pi of (3.3 pmol/pl) M13 forward (-20) (5’d[GTA AAA CGA CGG CCA 
G]-3’) or M13 reverse (5’d[-CAG GAA ACA GCT ATG AC]-3’) sequencing 
primers (both purchased from Invitrogen™), 4 pi of ABI PRISM BigDye® 
Terminator v3.1 Cycle Sequencing Reaction Ready Kit and 4 pi of sterile water. 
Thermocycling was performed on a GRI MJ Tetrad Thermocycler. Standard 
amplification conditions were used to sequence CKN1 cDNA: 24 cycles of 96°C 
for 30 seconds, 50°C for 15 seconds and 60°C for 4 minutes. Following 
amplification, 10 pi of sterile water was added to each reaction to give a final 
volume of 20 pi and the DyeEx™ Spin Kit was used to purify sequencing 
reactions (as previously described in Sections 2.4.5-6). Sequencing reactions 
were sent to the in-house CBS sequencing facility, where sequence analysis was 
performed, using the automated ABI PRISM 3100 Genetic Analyser. Data was 
received as text files and electropherograms.
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2.13.0 Transcription expression profiling using the 
Affymetrix™ GeneChip® array platform
2.13.1 Sample preparation for Affymetrix “  GeneChip® 
analysis
Exponentially growing hTERT-immortalised XP-C (GM02996, XP8CA) and 
CS-A (GM01856, CS3BE) dermal fibroblasts were seeded in three 60 mm 
culture dishes/time point (hours) at a density o f 5 X 105 cells/60 mm dish. The 
cells were allowed to equilibrate overnight (16-18 hours) at 37°C in a humidified 
incubator containing 5% CO2 . UV-C (254 nm) irradiation was performed on 80- 
90% confluent cultures. A UVP germicidal lamp, emitting UV-C light (254 nm), 
was calibrated using a UVX digital radiometer to emit an incident fluence rate of 
1 J/m2/s (as previously described in Section 2.6). For UV treatment, cells were 
washed twice with 2 ml o f warm (37°C) Hank’s balanced salt solution and 
irradiated with 10 J/m2. After irradiation, the cells were refed with fresh pre­
warmed (37°C) EMEM medium and maintained at 37°C in a humidified 
incubator containing 5% CO2 for the indicated period of time. Three independent 
biological replicates of UV-treated fibroblasts were performed at the indicated 
time points for the hTERT-immortalised XP-C (XP8CA) and CS-A (CS3BE) 
dermal fibroblasts. Samples were processed for subsequent Affymetrix™ 
GeneChip probe array analysis, utilising the Affymetrix™ platform (as described 
below in Section 2.13.2).
2.13.2 Total RNA isolation and purification
All procedures involved in total RNA extraction were undertaken in an RNase- 
free environment, using RNase-free, DNase-free pipette tips (Fisher) and 
microcentrifuge tubes. All solutions used for RNA isolation and purification was 
prepared using purchased sterile RNase-free water (Fresenius Kabi Inc., France), 
and all manipulations were performed in a laboratory dedicated for total RNA
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isolation and purification. All surfaces were treated with RNaseZap® 
(Ambion®) to reduce RNase contamination.
Total RNA was isolated from fibroblasts using the TRIzol® reagent 
(Invitrogen™) in accordance to the manufacturers recommendations. Following 
incubation at the indicated time points after UV treatment or mock-irradiation (as 
previously described in Section 2.13.1), 1.5 ml of ice-cold TRIzol® reagent was 
added to each 60 mm culture dish. After 15 minutes incubation at room 
temperature, the cells were scraped off the 60 mm culture dishes, using a Nunc 
Cell Scraper (Nalge Nunc, Intl.). The cell lysates were pipetted and aspirated 
several times to ensure complete homogenisation. The cell lysate was divided 
into two 750 pi fractions, and transferred to 1.5 ml RNase-free centrifuge tubes 
and 175 pi of chloroform (Sigma®) was added to each sample fraction. The 
chloroform and TRIzol® were mixed thoroughly by repeated inversion. The 
chloroform/TRIzol® mix was transferred to a Heavy Phase Lock Gel™ (PLG; 
Eppendorf), which had been previously centrifuged in a microcentrifuge at 
13,400 g for 25 seconds at room temperature in a bench top Sorvall® Pico 
centrifuge. The heavy PLG, containing the chloroform/TRIzol® mix, was 
subsequently centrifuged in a microcentrifuge at 13,400 g for 2 minutes at room 
temperature in a bench top Sorvall® Pico centrifuge. The upper colourless 
aqueous layer was transferred to a fresh 1.5 ml RNase-free Eppendorf tube. Total 
RNA was recovered from the aqueous phase by precipitating with 500 pi of 
isopropanol and 1 pi of 5 mg/ml glycogen (Ambion®), followed by incubation at 
room temperature for 10 minutes. Total RNA was precipitated by centrifugation 
at 12,000 g for 10 minutes at 4°C in a refrigerated ROTINA 35R centrifuge 
(Hettich Zentrifugen). The supernatant was aspirated and the pellet was washed 
with 500 pi o f 75% ethanol (EtOH). The tubes were centrifuged at 7,500 g for 5 
minutes at 4°C in a refrigerated ROTINA 35R centrifuge, and the supernatant 
was discarded. The RNA pellets were briefly air-dryed for 10 minutes and 
resuspended in 50 pi of RNase-free water. The RNA pellet was heated at 65°C 
for 10 minutes, using a Techne DRI-Block® DB-2D (JENCONS-PCS). 
Following resuspension, the RNA was rehydrated on ice for 1 hour. Fractions of 
the same sample were recombined to give a total volume of 100 pi. Total RNA
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(1 pi) was assessed for purity by A260/A280 (1.9-2) and quantified using the 
NanoDrop® ND-1000 spectrophotometer (NanoDrop Technologies, USA). For 
overnight EtOH precipitation, a 1/10* volume (lOpl) of 3M sodium acetate, 2.5 
volumes (250 pi) of 100% EtOH and 1 pi o f glycogen was added to the RNA. 
The tubes were mixed thoroughly by repeated inversion, and precipitated at - 
20°C overnight. Following overnight precipitation, the samples were centrifuged 
at 12,000 g for 20 minutes at 4°C in a ROTINA 35R centrifuge. The supernatant 
was aspirated and the pellet was washed twice with 500 pi o f 80% EtOH. The 
samples were centrifuged at 12,000 g for 10 minutes at 4°C between each 80% 
EtOH wash. The supernatant was removed and the pellet was air-dried for 10 
minutes at room temperature and resuspended in the required volume of RNase- 
free water to give a final RNA concentration of ~2 pg/pl. The RNA pellet was 
redissolved by placing the centrifuge tube on a Techne DRI-Block® DB-2D at 
65°C for 10 minutes. Rehydration of the RNA was undertaken by incubating the 
centrifuge tubes on ice for 30 minutes. Following incubation on ice, RNA 
isolated from the three 60 mm dishes/time point were pooled and 1 pi o f each 
total RNA sample was diluted in 1 pi of RNase-free water. To ascertain the final 
concentration of total RNA, following overnight precipitation, a 1 pi aliquot of 
the diluted sample was used for quantification using a NanoDrop® ND-1000 
spectrophotometer (as above). The final 1 pi fraction was used to assess the 
integrity o f the post EtOH total RNA by capillary electrophoresis, using the 
Agilent 2100 Bioanalyzer. Total RNA was subjected to subsequent labelling and 
hybridisation only if the 18S/28S ratio was approximately 2.
2.13.3 Reverse transcription (RT) by cDNA synthesis
An appropriate volume of total RNA, to give 10 pg RNA, was added to RNase- 
free water (if required) in a 0.5 ml RNase-free microcentrifuge tube, to make up 
to the maximum allowable volume of 9 pi for a cDNA synthesis reaction, 
containing 10 pg total RNA. First strand cDNA synthesis was undertaken by 
adding 2 pi of the (50 mM) chimeric T7-01igo(dT) promoter primer, 5’-GGC 
CAG TGA ATT GTA ATA CGA CTC ACT ATA GGG AGG CGG-(dT)24-3’
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(Affymetrix™, Inc.), to the 10 pg of total RNA, which was subsequently 
incubated at 70°C in an PTC-200 Peltier MJ Tetrad thermocycler (GRI) for 10 
minutes. Following hybridisation of the T7-OHgo(dT) promoter primer, the 
samples were incubated on ice for 2 minutes and pulsed down in a bench top 
Sorvall® Pico microcentrifuge. A master mix, containing 4 pi of 5X first strand 
synthesis buffer (250 mM Tris-HCl (pH8.3), 375 mM KC1, 15 mM MgCh; 
Invitrogen™), 2 pi o f 0.1 M DTT (Invitrogen™) and 1 p i of 10 mM 2’- 
deoxynucleoside 5’-triphosphate (dNTP) mix (Invitrogen™, Life Technologies) 
per reaction (XI) was prepared, and 7 pi of the master mix was added to each 
sample on ice. The samples were incubated at 42°C for 2 minutes, using an MJ 
Tetrad Thermocycler. Following the 2 minute incubation, the samples were 
retained in the MJ Tetrad thermocycler, and 2 pi of Superscript II reverse 
transcriptase (Invitrogen™) was added to each reaction. The samples were 
incubated in the GRI MJ Tetrad Thermocycler for 1 hour at 42°C. First strand 
synthesis reactions were placed on ice and pulsed down. For second strand 
synthesis, a master mix containing 91 p.1 RNase-free water, 30 pi 5X second 
strand synthesis buffer (100 mM Tris-HCl (pH 6.9), 23 mM MgC^, 450 mM 
KC1, 0.75 mM (3-NAD+, 50 mM (NH4)2S04; Invitrogen™), 3 pi 10 mM dNTP 
mix (Invitrogen™), 1 pi of 10 U/pl E.coli DNA ligase (Invitrogen™), 4 pi of 10 
U/pl E.coli DNA polymerase I (Invitrogen™) and 1 pi of 2 U/pl E.coli RNase H 
(Invitrogen™) per reaction was prepared, and 130 pi of the master mix was 
added to each reaction on ice. The samples were incubated for 2 hours at 16°C, 
using an MJ Tetrad thermocycler. Following the 2 hour incubation, 2 pi of 5 
U/pl E.coli T4 DNA polymerase (Invitrogen™) was added to the reactions and 
incubated in the MJ Tetrad thermocycler at 16°C for a further 5 minutes. The 
reaction was terminated by the addition of 10 pi of 0.5 M EDTA (Sigma®). The 
cDNA was purified by adding 162 pi phenol:chloroform:IAA (Invitrogen™) to 
the cDNA. The sample was mixed thoroughly by vortexing, using a Vortex 
Gene® 2 (Jencons-PLS) and was transferred to a fresh pre-spun light PLG 
(Eppendorf), which had been previously spun at 13,400 g for 25 seconds in a 
bench top Sorvall® Pico microcentrifuge. The light PLG, containing the cDNA 
and phenol: chloroform: I AA, was centrifuged at 13,400 g for 2 minutes at room
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temperature in a bench top Sorvall® Pico microcentrifuge. The upper resultant 
aqueous layer, containing the cDNA, was transferred to a fresh RNase-free 1.5 
ml centrifuge tube. To precipitate the cDNA, 0.5 volumes (80 pi) of 7.5 M NH4 
acetate (Sigma®), 2.5 volumes (400 pi) of 100% EtOH, and 1 pi of (5 mg/ml) 
glycogen was added. The samples were precipitated at -20° C overnight. 
Following precipitation, the samples were centrifuged at 12,000 g for 20 minutes 
at 4°C. The supernatant was aspirated, and the pellet was washed twice with 500 
pi of 80% EtOH. The sample was centrifuged at 12,000 g for 5 minutes at 4 °C 
between each wash. The supernatant was discarded and the pellet was air-dried 
for 10 minutes at room temperature. The cDNA pellet was resuspended in 10 pi 
of RNase-free water and heated to 65°C for 5 minutes, using a Techne DRI- 
Block® DB-2D. The cDNA was incubated on ice for 1 hour to rehydrate. The 
samples were stored at -20°C.
2.13.4 cRNA synthesis by in vitro transcription (IVT)
Biotin-labelled cRNA was prepared by in vitro transcription from a 
bacteriophage T7 RNA polymerase promoter by T7 RNA polymerase and biotin- 
labelled nucleotides, using the ENZO BioArray™ High Yield™ RNA Transcript 
Labelling Kit (Enzo Lifesciences, Farmingdale, NY, USA). Synthesised cDNA 
and the first three components of the ENZO BioArray™ High Yield™ RNA 
Transcript Labelling Kit were allowed to equilibrate to room temperature. These 
components included: 10X hybridisation buffer, 10X biotin-labelled 
ribonucleotides and 10X DTT. The 10X RNase inhibitor mix and 20X T7 RNA 
polymerase were left on ice. Once the cDNA and the reagents from the ENZO 
BioArray™ High Yield™ RNA Transcript Labelling Kit had equilibrated to 
room temperature, a master mix was prepared containing 12 pi RNase-free water 
(to give a final volume of 40 pi), 4 pi of 10X hybridisation buffer, 4 pi 10X 
biotin-labelled ribonucleotides, 4 pi of 10X DTT, 4 pi of 10X RNase inhibitor 
mix and 2 pi of T7 RNA polymerase per sample. 30 pi of the pre-prepared IVT 
master mix was added to 10 pi of cDNA, previously prepared by reverse 
transcription (Section 2.13.3). The samples were incubated at 37°C in a
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Thermomixer Comfort mixer (Eppendorf) for 6 hours. The mixer was 
programmed to agitate the samples every 30 minutes for 30 seconds. Following 
the 6 hour incubation, the IVT reactions were made up to 50 pi by adding 10 pi 
of RNase-free water, and left on ice. A BD Chroma Spin™ Column (BD 
Biosciences Clontech) was prepared per reaction, by inverting the column 
several times to ensure complete resuspension of the gel matrix. The end of the 
column was snapped off and the lid was removed. The column was placed in a 2 
ml collection tube (provided in the BD Chroma Spin™ Column kit) and 
centrifuged at 700 g for 5 minutes at 4°C in a refrigerated ROTINA 35R 
centrifuge. The 2 ml collection tube was discarded and the Chroma Spin column 
was placed in a fresh 2 ml collection tube. The IVT reaction (50 pi) was applied 
to the centre of the Chroma Spin column gel bed, while avoiding direct contact 
between the pipette tip and the gel bed. The Chroma Spin column was 
centrifuged at 700 g for 5 minutes at 4°C in a refrigerated ROTINA 35R 
centrifuge. Following centrifugation, 50 pi of RNase-free water was pipetted into 
the centre of the column gel bed. The Chroma Spin column was centrifuged at 
700 g for a further 5 minutes at 4°C in a refrigerated ROTINA 35R centrifuge. 
The cRNA (100 pi) was transferred from the 2 ml collection tube to a fresh 1.5 
ml RNase-free centrifuge tube. The cRNA was precipitated by adding 50 pi (0.5 
volumes) of RNase-free 7.5 M ammonium acetate (Sigma®), 250 pi (2.5 
volumes) of 100% EtOH and 1 pi of 5 mg/ml glycogen. The samples were mixed 
thoroughly by repeated inversion, and the samples were precipitated overnight at 
-20°C. Following overnight precipitation, the samples were centrifuged at 20,000 
g for 30 minutes at 4°C in a refrigerated ROTINA 35R centrifuge. The cRNA 
pellet was washed twice with 80% EtOH, and centrifuged at 12,000 g for 10 
minutes at 4°C in a refrigerated ROTINA 35R centrifuge, following each EtOH 
wash. The EtOH was aspirated and the pellet was air-dried at room temperature 
for 10 minutes, and resuspended in 34 pi of RNase-free water. The samples were 
incubated at 65°C for 5 minutes on a Techne DRI-Block® DB-2D, and left on 
ice for 1 hour to rehydrate. 1 pi of the resuspended cRNA was quantified, using 
the NanoDrop® ND-1000 spectrophotometer. The integrity of the cRNA was 
assessed by capillary electrophoresis, using the Agilent 2100 Bioanalyzer.
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2.13.5 Calculated adjusted cRNA yield and cRNA 
fragmentation
Prior to cRNA fragmentation, the adjusted cRNA yield was calculated by 
subtracting the quantity of cRNA measured subsequent to the IVT reaction (in 
pg) from the amount of total RNA used in the cDNA synthesis reaction, and 
multiplied by the fraction of the synthesised cDNA used in the IVT reaction. The 
adjusted cRNA yield was calculated to take into account the presence of residual 
total RNA. To reduce the frequency of secondary structure formation, the cRNA 
samples were fragmented, thus enabling the production of cRNA fragments 
between 50-200 bases in length. cRNA fragmentation was undertaken in a 0.5 ml 
RNase-free microcentrifuge tube, by adding the appropriate volume (in pi) of 
cRNA to give a total of 15 pg of cRNA and 8 pi of 5 X fragmentation buffer, 
containing 40 mM Tris-acetate (pH 8.1), 100 mM potassium-acetate and 30 mM 
magnesium-acetate. The reaction was made up to a final volume of 40 pi with 
RNase-free water. The samples were incubated at 94°C for 35 minutes and 
placed on ice. After cRNA fragmentation, a 1 pi aliquot of the cRNA sample was 
applied to the Agilent 2100 Bioanalyzer (Agilent). The fragmented cRNA was 
stored at -80°C.
Following sample preparation (Sections 2.13.1-2.13.6), all subsequent 
procedures performed using the Affymetrix™ GeneChip® platform was 
undertaken by our in-house CBS facility (Sections 2.13.6).
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2.13.6 Microarray hybridisation, staining, washing and 
scanning of HG-U133A probe arrays
All solutions and buffers used in the following procedures were prepared in a 
DNase- and RNase-free environment, using molecular biology grade water.
Hybridisation to and scanning of the Affymetrix™ HG-U133A oligonuclotide 
arrays was performed by our core in-house microarray facility provided by the 
CBS, and was undertaken in accordance to the manufacturers guidelines 
(http://www.affymetrix.com/support/technical/manual/expression_manual.affx).
The hybridisation cocktail was prepared for each reaction (in accordance to the 
recommendations for a 49 format array) by adding 15 pg (0.5 pg /p l) of 
fragmented cRNA to 5 pi of (3 nM) control oligonucleotide B2 (50 pM), 15 pi of 
20X eukaryotic hybridisation control BioB (1.5 pM, equating to three transcripts 
per cell), BioC, BioD and CreX (5, 25 and 100 pM, respectively; Affymetrix™ 
GeneChip® Eukaryotic Hybridisation Control Kit), 3 pi of (10 mg/ml) Herring 
sperm DNA (0.1 mg/ml; Promega, Cor.), 3 pi of (50 mg/ml) acetylated BSA (0.5 
mg/ml; Invitrogen™), 150 pi of 2X hybridisation buffer (at a final concentration 
of 100 mM MES (2[N-Morpholino] ethanesulfonic acid), 1 M [Na+], 20 mM 
EDTA and 0.01% Tween 20). The hybridisation cocktail was preheated to 99°C 
for 5 minutes in a heat block, then transferred to a 45 °C heat block for a further 5 
minutes. Meanwhile, the Affymetrix™ GeneChip® Human HG-U133A probe 
arrays (Affymetrix™) were equilibrated to room temperature and 200 pi o f IX 
hybridisation buffer was pipetted through the septa o f the array, using a 
micropipettor. The probe array was then incubated at 45°C for 10 minutes with 
rotation at 60 rpm. The hybridisation cocktail was centrifuged at 13,400 g for 5 
minutes in a Sorvall® Pico microcentrifuge to remove insoluble matter from the 
hybridisation mixture. The buffer solution was removed from the probe array 
cartridge and was filled with 200 pi of hybridisation cocktail. The probe arrays 
were transferred to a preheated Affymetrix™ GeneChip® hybridisation oven 640 
and hybridised at 45°C for 16 hours with rotation at 60 rpm. After hybridisation,
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HG-U133A arrays were prepared for scanning using the Affymetrix™ wash 
protocols on an Affymetrix™ Fluidics Station FS 450 under the control o f 
Affymetrix™ GeneChip Operation software. Briefly, an initial wash of 10 cycles 
of 2 mixes was performed with the non-stringent wash buffer A (containing 6X 
SSPE and 0.01% Tween 20) at 25°C. This was followed by 4 cycles of 15 mixes 
with the stringent wash buffer B (containing 100 mM MES, 0.1 M [Na+] and 
0.01% Tween 20) at 50°C. The probe array was incubated for 10 minutes with 
Streptavidin Phycoerythrin (SAPE) solution (containing IX MES stain buffer, 2 
mg/ml acetylated BSA and 10 pg/ml SAPE) at 25°C. A post stain wash of the 
arrays was undertaken for 10 cycles of 4 mixes with the non-stringent wash 
buffer A at 25°C. The probe array was incubated for 10 minutes in antibody 
solution (containing IX MES stain buffer, 2 mg/ml acetylated BSA, 0.1 mg/ml 
Normal Goat IgG and 3 pg/ml biotinylated antibody) at 25°C. A final incubation 
of the probe array was performed for 10 minutes in SAPE solution at 25°C (as 
above). This was followed by a final wash for 15 cycles of 4 mixes with wash 
buffer A at 30°C. The HG-U133A arrays were scanned using an Affymetrix™ 
GeneChip® Scanner 3000 System. Image scanning and data pre-processing to 
obtain transcript measurements were performed using Affymetrix™ MAS 5.0.
2.14 Validation of UVC inducible genes by real­
time quantitative reverse transcriptase polymerase 
chain reaction (qRT-PCR)
The TaqMan® real-time qRT-PCR system exploits fluorogenic-labelled probes 
that utilise the 5’ nuclease activity of Taq DNA polymerase to detect and 
quantify a specific PCR amplification product, as it accumulates throughout the 
PCR reaction. A gene-specific oligonucleotide probe is constructed, which 
possesses a reporter fluorescent dye on the 5’ end and a quencher dye on the 3’ 
end. The proximity of the quencher dye reduces the fluorescence emitted by the 
reporter dye by fluorescence resonance energy transfer (FRET). However, in the 
presence of the target sequence, the probe anneals downstream from one of the
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primer sites and is cleaved by the 5’ nuclease activity of Taq DNA polymerase as 
the primer extends. The cleavage of the probe separates the reporter dye from the 
quencher dye, which increases the reporter dye signal. Therefore, the increase in 
fluorescence intensity is proportional to the amount of amplicon generated 
during the PCR reaction.
Real-time qRT-PCR analysis was undertaken, using the TaqMan® 7000 
detection system, to independently validate differentially regulated gene 
candidates at the transcriptome level, identified following transcription 
expression profiling, using the Affymetrix™ GeneChip® system.
2.14.1 Sample preparation
Exponentially growing hTERT-immortalised XP-C (GM02996, XP8CA) and 
CS-A (GM01856, CS3BE) dermal fibroblasts were seeded in three 60 mm 
culture dishes/time point (hours) at a density of 5 X 105 cells/60 mm dish (as 
previously described in Section 2.13.1). In addition, exponentially growing 
hTERT-immortalised MRC-5 fibroblasts were also seeded (as described) for the 
subsequent construction of a standard curve for relative quantification. For real­
time qRT-PCR experiments, fibroblasts were subjected to the identical UV 
treatment (10 J/m2) and incubated for the indicated periods of time as in the 
Affymetrix™ microarray experiments (previously described in Sections 2.6 and
2.13.1). In addition, time-matched mock-irradiated controls were performed in 
parallel. The time matched non-irradiated controls were processed in an identical 
manner to the experimental cultures, and maintained under routine culture 
conditions for 0, 6, 12 or 24 hours. However, mock-irradiated cultures were not 
exposed to UVC radiation. Three independent biological replicates of UV-treated 
and time-matched, mock-irradiated fibroblasts were performed at the indicated 
time points for each cell line and processed for subsequent real-time qRT-PCR 
(Section 4.14.2), utilising the ABI Prism 7000 Detection System (PE Applied 
Biosystems).
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2.14.2 Total RNA isolation and first-strand cDNA synthesis 
for qRT-PCR
Total RNA was isolated at the indicated time points using TRIzol® reagent 
according to the manufacturers recommendations (and as previously described in 
Section 2.13.2). RNA isolated from three 60 mm dishes/time point was pooled 
and first-strand cDNA synthesis was performed using Superscript II 
(Invitrogen™). Briefly, 5 pg of total RNA, isolated from the irradiated or mock- 
irradiated samples, was reverse transcribed by adding 1 pi of (500 pg/pl) 
Oligo(dT) primer (Invitrogen™) and 1 pi of 10 mM dNTP mix to the 5 pg of 
RNA in a 0.5 ml nuclease-free microcentrifuge tube. The sample was made up to 
13 pi with sterile water. The reaction mixture was heated to 65°C for 5 minutes, 
using a GRI MJ Tetrad Thermocycler. The samples were placed on ice for 2 
minutes and the contents was collected by brief centrifugation. After 
centrifugation, 4 pi of 5X first-strand buffer and 2 pi of 0.1 M DTT was added. 
The contents was gently mixed and incubated at 42°C for 2 minutes in a GRI MJ 
Tetrad Thermocycler. 1 pi of (200 U) Superscript II was added to the reaction 
and mixed by pipetting gently up and down. The reactions were incubated at 
42 °C for 50 minutes in a GRI MJ Tetrad Thermocycler. The reaction was 
inactivated by heating at 70°C for 15 minutes in a GRI MJ Tetrad Thermocycler. 
The resulting XP-C and CS-A cDNA was diluted 1 in 25 by adding 480 pi of 
sterile water. cDNA generated from the irradiated and mock-irradiated hTERT- 
immortalised MRC-5 fibroblasts (at the indicated time points) was pooled, thus 
providing a stock of cDNA standard, which was used to construct a standard 
curve for relative quantification.
2.14.3 qRT-PCR assay using the ABI PRISM® 7000 
Sequence Detector
For real-time qRT-PCR, 5 pi of the diluted first-strand cDNA product, generated 
by reverse transcription, was used as the template. Each cDNA was amplified in 
triplicate using gene-specific primers (Table 2.4) and the TaqMan® Universal
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PCR Master Mix (2X) No AmpErase® UNG (PE Applied Biosystems), 
according to the manufacturer’s recommendations. Briefly, 5 pi o f the cDNA 
sample was pipetted into the appropriate well of a MicroAmp™ Optical 96-Well 
Reaction Plate (PE Applied Biosystems). Amplification was performed in a final 
reaction volume of 20 pi containing 10 pi of (2X) TaqMan® Universal PCR 
Reaction Mix, 1 pi of Assay on Demand (Table 2.4; PE Applied Biosystems), 
and 4 pi of sterile water. A master mix was prepared and 15 pi was pipetted 
down the wall of the appropriate well of the MicroAmp™ Optical 96-well 
reaction plate, containing the 5 pi of cDNA, using a Finnpipette® Novus-Single 
Channel Pipette (Thermo electron Cor.) A MicroAmp™ Optical Adhesive Film 
(PE Applied Biosystems) was firmly attached to the MicroAmp™ Optical 96- 
Well Reaction Plate, using a MicroAmp™ Adhesive Film Applicator (PE 
Applied Biosystems). A MicroAmp™ Optical Film compression Pad (PE 
Applied Biosystems) was subsequently placed over the MicroAmp™ Optical 
Adhesive Film, providing a thermal seal between the thermal cycler and the 
reaction plate. The MicroAmp™ Optical 96-Well Reaction Plate was loaded and 
run on an ABI PRISM® 7000 system. The amplification reaction was 
undertaken in an ABI PRISM® 7000 Sequence Detector (PE Applied 
Biosystems), using the following amplification conditions: an initial hot start 
incubation at 95 °C for 10 minutes (AmpliTaq Gold® enzyme activation cycle), 
followed by 40 cycles o f denaturation at 95°C for 15 seconds and 
annealing/extension at 60°C for 1 minute. GAPDH was used as an endogenous 
control and the level of expression of each gene was normalised against these 
GAPDH levels, employing the standard curve method. GAPDH  levels were 
determined for each irradiated and mock-irradiated sample at the indicated time 
points, by performing a GAPDH only RT-PCR assay in separate 96-well reaction 
plates for each cell line (XP8CA and CS3BE). In addition to preparing three 
independent biological replicates for UV-treated and time-matched mock- 
irradiated control samples, all RT-PCR reactions were performed in triplicate. 
Therefore, each expression value was representative of nine replicates. A PCR 
reaction, containing TaqMan® Universal PCR Master Mix and gene-specific 
probe in the absence of template cDNA, was performed in each assay, thus 
permitting the detection of contaminating products.
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Table 2.4. Gene-specific TaqMan® Gene Expression Assays used in real-time qRT-PCR.
Gene symbol Gene Name
TaqMan® Gene 
Expression Assay ID
ATF-3 Activating transcription factor 3 H s00231069
CDKN1A (p21) Cyclin dependent kinase inhibitor 1A H s00355782
Ccng2 Cyclin G2 H s0154 8 1 6 0
DDB2 D am age-specific  DNA binding protein 2 H s00172068
DTR Heparin-binding EGF-like Growth Factor H s00181813
FDXR Ferredoxin reductase H s01031621
GAPDH G lyceraldehyde-3-phosphate d eh yd rogen ase H S 99999905
GDF15 Growth differentiation factor 15 H s00171132
PMAIP1 (NOXA) Phorbol-12-m yristate-13-acetate-induced protein 1 H s00382168
PPM1D (wipl) Protein 1D m agnesium -dependent H s0018 6230
SAT Sperm idine/sperm ine N1 -acetyl transferase 1 H s0 0 9 7 1735
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2.14.4 Data acquisition, analysis and normalisation
The relative quantification of gene expression was undertaken using a standard 
curve methodology in accordance to the manufacturer’s recommendations (PE 
Applied Biosystems). During the run, the ABI PRISM® 7000 instrument was 
used to record the fluorescence emission. After the run, the ABI PRISM® 7000 
SDS software was used to process the raw fluorescence data to produce threshold 
cycle (Ct) values of the diluted standards. Relative quantities were obtained for 
the unknown experimental samples based on their C t values. For comparison of 
transcript levels between control (mock-irradiated) and UVC-irradiated samples 
at the indicated time points and between hTERT-immortalised XP-C and CS-A 
dermal fibroblasts, a standard curve of Cts for several serial dilutions of MRC-5 
cDNA was constructed for each RT-PCR assay (as previously discussed). The 
standard curve was used to calculate the relative abundance of mRNA for each 
gene studied. The expression values for each gene, generated from UVC- 
irradiated and mock-irradiated samples at the indicated time points, were 
normalised to the relative amounts of GAPDH mRNA. The expression level of 
each gene-specific mRNA was determined relative to the GAPDH mRNA levels 
of the same sample by dividing the Ct value obtained for the gene of interest by 
the Ct value obtained for GAPDH.
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Chapter 3
Characterisation of Novel Mutations in 
Cockayne Syndrome type A and 
Xeroderma Pigmentosum Group C
Subjects
[Published in J. Hum. Genet. (2005) 50: 151-154]
3.1 Introduction
XP is characterised by hyperphotosensitivity to the UV constituent of sunlight. 
The clinical hallmarks of XP include initial pigmentation disturbances followed 
by a marked predisposition to skin neoplasia, with a > 1000-fold incidence of 
UV-induced cutaneous neoplasia, such as SCC, BCC and malignant melanoma 
(Section 1.9.1). Seven ‘classical’ XP complementation groups have been 
characterised, each corresponding to mutations in one of seven genes, XPA-XPG, 
involved in NER (Section 1.9.1). The XP-C complementation group is the most 
prevalent form of the XP syndrome (Khan et al., 1998; Kraemer et al., 1987). 
Patients from this complementation group exhibit skin abnormalities with no 
associated neurological abnormalities (Section 1.9.1). To date, mental retardation 
has been described in patient XP1MI (Li et al., 1993). The differences in 
cutaneous manifestations between XP-C patients depend on age, climate and life­
style. At the cellular level, cultured fibroblasts from XP-C patients display partial 
UV-induced DNA repair synthesis, which range between 10-20% of normal, and 
are only defective in GGR. Indeed, XP-C cells are fully proficient in the removal
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of lesions from the transcribed strand of active genes (Kantor et al., 1990; 
Venema et al., 1991; van Hoffen et al., 1995), as TCR activity is retained. Initial 
complementation studies (Legerski & Peterson, 1992), by transfecting partial but 
fully active XPC  cDNA, resulted in phenotypic correction of XP-C cells. This led 
•to the subsequent purification and cloning of the XPC-hHR23B complex 
(Masutani et al., 1994). The full-length XPC  cDNA is 3558 nucleotides long and 
encodes a 940 amino acid polypeptide of 106 kDa (Fig 3.1). The XPC protein is 
composed of three principle binding regions, which facilitate binding to DNA, 
hHR23B and TFIIH (Fig. 3.1). XPC forms a heterodimeric complex with 
hHR23B (XPC-hHR23B). The XPC domain that facilitates the interaction with 
hHR23B has been mapped to the evolutionary conserved carboxy-terminal 
region. Interestingly, the carboxy-terminal 125 aa’s are superfluous for both 
DNA and hHR23B binding. However, interactions with TFIIH are disturbed by 
truncation of this domain (Uchida et al., 2002).
606 742
495 734642 816 940 aa
hHR23B
DNA TFIIH
Figure 3.1. Schematic of the domain structure of human XPC protein (adapted from Dip et al., 
2004).
Unlike XP, CS patients do not display a predisposition to UV-induced skin 
neoplasia, but exhibit a battery of other clinical manifestations (Section 1.9.3). 
Principally, segmental progeria is the hallmark clinical pathophysiological 
manifestation exhibited by CS patients (Nance & Berry, 1992). Further clinical 
features include; cachetic dwarfism, deafness, retinal degeneration, neurological 
dysfunction and skeletal-associated abnormalities, such as osteoporosis and a
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bird-like face (Section 1.9.3). Death occurs at a mean age of 12 years. Mutations 
in the CKN1 (CSA) and CSB genes are responsible for CS.
Whilst CS and XP cells have defective NER, the striking differences between the 
.syndromes are explained by the fact that the NER mechanism is divided into two 
distinct sub-pathways, GGR and TCR (Sections 1.6.1-1.6.2). GGR facilitates the 
removal of lesions from the non-transcribed strand and transcriptionally silent 
regions of the genome. Conversely, TCR preferentially removes lesions from the 
transcribed strand of active genes. In GGR, the recruitment of the 106 kDa XPC 
protein, complexed with the 43 kDa hHR23B protein, allows interaction with 
damaged DNA, facilitating the recognition of UV-induced lesions (Sugasawa et 
al., 1998). Conversely, the arrest of an elongating RNA polymerase II at a lesion 
on the transcribed strand of an active gene is considered to elicit the recruitment 
of TCR-specific proteins, including CSA. The 44 kDa CSA protein is encoded by 
the CKN1 gene and contains multiple WD-40 repeats (Henning et al., 1995). The 
two NER sub-pathways converge at the point where the presence of a lesion is 
confirmed. Excision, resynthesis and ligation follow using a common mechanism 
(Sections 1.6.3-1.6.6)
3.2 Aims
Both XPC  and CKN1 genes were previously cloned as a result o f screening 
cDNA libraries for genes that corrected the UV sensitivity of XP-C and CS-A 
cell lines (Legerski & Peterson, 1992; Henning et al., 1995). Interestingly, the 
mutations present in the original CS-A line (CS3BE) used for library screening 
have not previously been identified (Henning et al., 1995), although it was 
reported that the cell line appeared to produce no CSA protein (van Gool et al., 
1997). Furthermore, although the XP-C line, derived from donor XP8CA, has 
been extensively used in previous structural, biochemical and functional studies 
(Baxter & Smerdon, 1998; Azzam et al., 2002; Hashem et al., 1980), the 
underlying genetic defect remains uncharacterised. Therefore, genetic analysis 
was undertaken to identify the XPC  and CKN1 genomic DNA variants in patients
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XP8CA (GM02996) and CS3BE (GM01856), respectively, and to confirm that 
the cultures had the desired genetic defects required for subsequent analysis.
3.3 Materials and methods
Primary XP-C (GM02996, XP8CA) and CS-A (CKN1; GM01856, CS3BE) 
human dermal fibroblasts were purchased from the NIGMS Human Genetic 
Mutant Cell Repository (Coriell Institute for Medical Research, Camden, NJ). 
Genomic DNA was isolated and purified by proteinase K digestion, followed by 
a phenol/chloroform extraction (Section 2.11.1). PCR amplification of XPC  and 
CSA gene fragments from isolated XP8CA and CS3BE genomic DNA, 
respectively, was performed on a GRI MJ Tetrad Thermocycler. Sequence 
analysis was undertaken by the Wales Gene Park, using an automated ABI 
PRISM 3100 Genetic Analyser (Sections 2.11.2-2.11.6). XPC  and CSA genomic 
DNA variants were identified using Sequencher™ Version 4.5 software (Gene 
Codes Corp.).
Total RNA was extracted from CS-A human dermal fibroblasts, using the 
TRIzol® reagent according to the manufacturers recommendations (Section
2.13.2) and reverse transcribed using Superscript II (Section 2.13.3). 
Amplification of CKN1 cDNA was performed by PCR (Section 2.12) and 
amplification products were ligated into the TA cloning vector, pCR2.1, and 
transformed into IN V aF’ E.coli One Shot cells (Section 2.12.1). Individual 
colonies were isolated, expanded and sequenced in both directions, using M l3 
forward and reverse primers (Sections 2.12.2-3). Sequence analysis was 
performed by our in-house CBS facility, using an automated ABI PRISM 3100 
Genetic Analyser.
Immunoblotting was performed using a Biorad Mini-Protean II Electrophoresis 
Cell System. Briefly, WCEs were prepared as previously described (Sections 
2.9.1-2.9.2). Proteins were separated on SDS-PAGE gels (Section 2.9.3), 
transferred to PVDF membranes (Section 2.9.3) and exposed to either an anti- 
XPC mouse monoclonal antibody or an anti-CSA goat polyclonal antibody
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(Table 2.1, Section 2.9.4). Blots were visualised using an appropriate HRP- 
coupled secondary antibody and an ECL system using Hyperfilm (Table 2.1, 
Section 2.9.4). Equal protein loading was confirmed by staining the PVDF 
membrane with India ink (Section 2.9.5).
For the immunocytochemical detection of XPC, the VECTRASTAIN® ABC 
system (Vector Laboratories, Peterborough, UK) was used as previously 
described (Section 2.10).
3.4 Results
3.4.1 Identification of XPC and CKN1 genomic DNA gene 
variants
The causative mutations in the XPC  and CKN1 gene were identified by isolating 
genomic DNA from patients XP8CA and CS3BE, respectively, and the 16 exons 
of XPC  and 12 exons of CSA were amplified by PCR. The PCR products were 
sequenced and base changes identified by comparing to consensus cDNA 
sequences (NM_000082 [CKN1]\ NM_004628 [.XPC]) obtained from NCBI.
In patient XP8CA, a homozygous 2 bp TG deletion (del) was identified in codon 
547 at position 1639 (1639delTG) in exon 9 (Fig. 3.2.4). This creates a frame 
shift and a premature termination at codon 572, resulting in a predicted protein of
63.4 kDa. Two homozygous missense mutations were identified. The first, a 
2061A>G transition in exon 11 (R687R; Fig. 3.2B), resulted in no change to the 
amino acid sequence, as the single base change also encoded an Arg residue. In 
addition, patient XP8CA displayed a further missense mutation consisting of a 
2815A>C transversion in exon 16 (Fig. 3.2C), which caused an amino acid 
substitution at position 939 from Lys to Gin (K939Q). Notably, the location of 
both the homozygous missense variants (2061A>G and 2815A>C) lie 3’ to the 2 
bp TG deletion (1639delTG), therefore these variants would not appear in the
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final translated protein product. Accordingly, these missense variants should not 
contribute to the XP-C phenotype presented by patient XP8CA.
Patient CS3BE, assigned to CS complementation type A, was a compound 
heterozygote for mutations in CKN1, the gene encoding the CSA protein (MIM 
216400). The first heterozygous mutation found, was a previously described 
nonsense mutation consisting of a G to T transversion (37G>T) at position 37 
(Fig. 3.3,4). This nonsense mutation caused a change at aa 13 from Glu to a non­
coding codon (E13X). In addition, patient CS3BE displayed a novel missense 
mutation consisting of a C to T transition at position 479 (479C>T; Fig. 3.3B), 
resulting in a change in aa 160 from Ala to Val (A 160V).
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Figure 3.2. XPC genomic DNA variants in cells derived from patient XP8CA 
(GM02996). Genomic DNA was isolated from patient XP8CA and the 16 exons of 
XPC was PCR amplified and sequenced, using the non-radioactive Sanger di-deoxy 
protocol. Patient XP8CA was homozygous for a (A) 2 bp TG deletion at codon 547 . 
Two further homozygous missense variants were identified; (B) 2061A>G and (C) 
2815A>C.
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Figure 3.3. CKN1 genomic DNA variants in cells derived from patient CS3BE 
(GM01856). Genomic DNA was isolated from patient CS3BE and the 12 exons of 
CKN1 was PCR amplified and sequenced using the non-radiaoactive Sanger di- 
deoxy protocol. Pateint CS3BE was a compound heterozygote for CKNl mutations 
(A) 37G>T and (B) 479C>T.
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3.4.2 Analysis o f CS3BE mRNA
To confirm that the two heterozygous variants, nonsense 37G>T (E13X) and 
missense 479C>T (A 160V), were present on separate alleles, reverse 
transcription of CS3BE total RNA was performed. Amplification of CKN1 
cDNA was performed using the primers 5’GGT TTT TGT CCG CAC GCC AA- 
3’ (forward) and 5’-GTG GAG ACC AGG AAA CTG CT-3’ (reverse). PCR 
Products were ligated into the TA cloning vector pCR2.1, and transformed into 
INVaF’ E.coli one shot cells. Sixty individual clones were isolated, expanded 
and sequenced in both directions, using M13 forward and reverse primers. In 
clones where the nonsense 37G>T mutation was present, the 479C>T mutation 
was absent. Interestingly, no clones were recovered containing the 479C>T 
mutation, although cDNA containing the wild-type 37G appeared to have spliced 
out the exon containing 479C>T. Therefore, the instability of the mRNA from 
the second allele is likely to explain the lack of CSA protein in CS3BE cells. In 
concordance with these data, Bertola et al. (2006) has speculated aberrant mRNA 
splicing is central to the molecular etiology of CS.
3.4.3 XPC and CSA protein levels
To confirm the status of XPC and CSA protein basal levels in the XP-C 
(XP8CA) and CS-A (CS3BE) cells, respectively, immunoblotting and 
immunocytochemical analysis were undertaken, using a mouse monoclonal 
antibody that targeted the full-length XPC protein, and an affinity-purified goat 
polyclonal antibody that targeted the carboxy-terminal region of the CSA 
protein.
As expected, XPC protein was clearly visible in the WCE derived from wild- 
type, hTERT-immortalised MRC-5 fibroblasts (Fig. 3.4,4, lane 1). Moreover, 
immunoblotting confirmed the presence of XPC protein in WCEs derived from 
hTERT-immortalised, DNA repair-defective XP-A (XP12BE) and CS-A 
(CS3BE) dermal fibroblasts (Fig. 3.4,4, lanes 2 & 4). In subject XP8CA, the 
homozygous 2 bp TG deletion causes a frame shift and creates a premature
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termination codon that predicts the translation of a protein product of 63.4 kDa. 
However, immunoblotting, using the XPC-specific antibody confirmed the 
absence of full-length protein in the cell extract derived from patient XP8CA 
(Fig. 3.4A, lane 3). Interestingly, XPC protein levels were slightly reduced in the 
CS-A cell extract, with apparently equal protein loading. These data are in 
concordance with a recent study undertaken by Adimoolam & Ford (2002), who 
reported that XPC is an inducible protein regulated in a p53-dependent manner, 
and the lower expression in CS3BE cells may reflect the different steady state 
level compared to other cell lines. Alternatively, the reduced protein levels may 
have been attributed to a global reduction in transcription, which is frequency 
observed in CS cells. Furthermore, the presence of a further mutation at K939 in 
subject XP8CA is likely to have no effect because firstly, translation terminates 
prior to the mutation, and secondly, K939 is adjacent to the final amino acid of 
the normal protein.
XPC protein levels were further confirmed by immunocytochemical staining, 
using the same XPC-specific mouse monoclonal antibody. This resulted in the 
detection of a nuclear brown peroxidase reaction product in hTERT- 
immortalised normal MRC-5 fibroblasts (Fig. 3.5A) indicative o f XPC 
expression. However, XPC expression was not detected in hTERT-immortalised 
XP-C (XP8CA) fibroblasts (Fig. 3.5B). These data recapitulated data obtained 
from Western blotting for both hTERT-immortalised MRC-5 and XP-C 
fibroblasts (Fig. 3.4A).
Western blot analysis of MRC-5 and CS-A (CS3BE) WCEs, using an anti-CSA 
goat polyclonal antibody, resulted in the detection of a lower non-specific, cross­
reacting band in both cell extracts (Fig. 3AB, lanes 1 & 2, respectively). 
However, an upper band corresponding to the CSA protein was present in MRC- 
5 (Fig. 3.4B, lane 1) and absent in CS3BE (Fig. 3.4B, lane 2). This indicated that 
the CSA protein in patient CS3BE either was not present or lacked the COOH- 
terminal region that was used to raise the CSA antibody. These data 
complemented an earlier report that the CSA protein was not expressed in the 
CS3BE cell line (van Gool et al., 1997).
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Figure 3.3. Loss of expression of XPC and CSA proteins in mutant 
cell lines. (A) Protein extracts from a normal (MRC-5) and DNA 
repair-defective XP-A, XP-C and CS-A cell lines were seperated 
on SDS-PAGE gels, transferred and membranes probed with an 
anti-XPC antibody. A band of approximately 125 kDa 
corresponding to XPC protein was absent in XP8CA. (B) Protein 
extracts from MRC-5 and CS3BE (CS-A) were seperated as above 
and transferred protein probed with an anti-CSA antibody. CS3BE 
cell extracts showed no expression of a protein of approximately 44 
kDa (upper band) that was present in MRC-5 extracts.
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Figure 3.5. Detection of XPC protein expression. XPC expression levels analysed 
by immunocytochemistry in hTERT-immortalised (A) MRC-5 and (B) XP-C 
(XP8CA) fibroblasts. Positivity indicated by brown peroxidase reaction product. 
Nuclei are lightly counterstained to aid visualisation. Bar = 25 pm.
171
3.5 Discussion
As the mutations within the XP-C and CS-A repair-defective cell lines were 
previously uncharacterised, genetic analysis was undertaken to confirm that the 
cultures had the postulated genetic defects.
In this investigation we screened an XP-C (XP8CA, GM02996) and a CS-A 
(CS3BE, GM01856) cell line for XPC  and CKN1 genomic DNA variants, 
respectively, by amplifying XPC  and CKN1 coding regions and the intron-exon 
boundaries from XP8CA and CS3BE genomic DNA. The original assignments 
of subjects XP8CA to XP complementation group C and subject CS3BE to the 
Cockayne syndrome type A complementation groups were previously made on 
the basis o f cell fusion studies (Hashem et al., 1980; Tanaka et al., 1981). 
Subsequent cloning of the XPC  and CKN1 genes was achieved as a result of 
screening cDNA libraries for genes that corrected the UV sensitivity o f XP-C 
and CS-A cell lines (Legerski & Peterson, 1992; Henning et al., 1995).
While the XP-C complementation group remains the most prevalent XP group 
found in North America and Europe (Kahn et al., 1998; Kraemer et al., 1987), 
only a limited number of causative mutations, resulting in an XP-C phenotype, 
have been published in the literature (Chavanne et al., 2000; Cleaver et al., 1999; 
Gozukara et al., 2001; Khan et al., 1998; Khan et al., 2004; Li et al., 1993; Slor 
et al., 2000). From these studies, 17 inactivating mutations, which include 9 
frameshifts, 3 nonsense and 3 splice site mutations, have been described. 
Interestingly, only two inactivating missense mutations have been characterised: 
Pro 334 His in patient XP1MI (Li et al., 1993) and Trp 690 Ser in patient 
XP13PV (Chavanne et al., 2000). Until recently, the body of evidence suggested 
that mutations characterised in the XPC  gene are distributed throughout the gene, 
with no evidence of hotspots or founder effects (Chavanne et al., 2000). 
However, a more recent study undertaken by Khan et al. (2006), reported a 
battery of novel XPC  genomic variants, including 5 nonsense, 2 frameshifts and 
3 splice mutations, all resulting in a classical XP-C phenotype. Notably, Khan et 
al. (2006) identified a 1744-5delTG in exon 8 common to 4 kindreds (XP16VI,
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XP664VI, XP132BE and XP30BE), which was previously reported in patients 
XP4PA (Li et al., 1993) and XP26PV (Chavanne et al., 2000), thus suggesting a 
possible hotspot. From this body of evidence, Khan et al. (2006) speculated that 
this region was highly susceptible to polymerase slippage, as the deleted TG 
(1744-5) is situated in a run of 3 TGs. Conversely, Chavanne et al. (2000) has 
suggested that the presence of the 1643-44delTG at the 3’ end of exon 8 may 
interfere with normal splicing, thus resulting in the partial activation of a cryptic 
donor site at position 1627. This will result in the appearance of a transcript 
where the final 246 nucleotides of exon 8 are lost. Alternatively, Khan et al. 
(2006) speculated that the 1744-5delTG may have been attributed to a founder 
mutation, as two of the families in their study, and the previously described 
patient, XP4PA (Li et al., 1993), originated from North Africa.
The data presented here, suggest that the previously uncharacterised XP-C 
subject (XP8CA) was homozygous for mutations in the XPC  gene. XP8CA was 
homozygous for a 2 bp TG deletion at codon 547 (1639delTG). This nonsense 
mutation would result in a frame shift and cause a premature termination at 
codon 572. The homozygous missense variant, identified in patient XP8CA 
(Ridley et al., 2005), consisting of a 2815A>C transversion in exon 16, which 
caused a change in 939 aa from a Lys to a Gin (K939Q) was previously 
described by Li et al. (1993) as a second putative mutation in patient XP8BE. 
However, in disagreement with these findings (Li et al., 1993), more recent 
analysis undertaken by Chavanne et al. (2000) has revealed that the 2815A>C 
variant is actually a polymorphism.
It is apparent from the literature, that the 1639delTG in exon 9 reported in this 
study (Ridley et al., 2005), is identical to the 1744-5delTG in exon 8, previously 
identified in patients XP4PA (Li et al., 1993), XP26PV (Chavanne et al., 2000), 
and more recently in patients XP16VI, XP664VI, XP132BE and XP30BE (Khan 
et al., 2006). The incongruity in the TG position between the various mutation 
reports can be attributed to the difference in base and exon nomenclature within 
the literature. For example, Khan et al. (2002) identified a 1.6 kb intron within 
exon 5 between nucleotides 726 and 727. Accordingly, a recent paper published 
by Khan et al. (2006) describes exon 5 as exons 5.1 and 5.2. Conversely, the
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NCBI data bank and the data presented here (Ridley et al., 2005) describe exons 
1 to 16 and have assigned exons 5.1 and 5.2 as exons 5 and 6 respectively. 
Therefore, the 1639delTG in exon 9 described herein, corresponds to the 1744- 
5delTG in exon 8 reported elsewhere (Chavanne et al., 2000; Li et al., 1993; 
Khan et al., 2006).
As previously discussed, Khan et al. (2006) describes the TGdel as occurring at 
position 1744-1745. Conversely, the same TGdel reported herein, has been 
described as occurring at position 1639 (Ridley et al., 2005). Khan et al. (2006) 
describes the A residue from the methionine (AUG) initiation signal as being at 
base position 106, whereas in this study the same A residue is described as 
position 1 of exon 1, thus suggesting that Khan et al. (2002) have included part 
of the 5’-untranslated region (5’-UTR). This results in a 105 base discrepancy 
between the two reported nomenclatures, thus explaining the difference between 
the 1744-5delTG reported by Khan et al. (2006) and the 1639delTG described in 
this study (Ridley et al., 2005). Taking this into account, the 1639delTG reported 
herein, provides additional evidence for the existence of a hotspot, as speculated 
by Khan et al. (2006). Although Khan et al. (2006) has also speculated a founder 
effect as being a possible cause for the 1744-5delTG, as two of the affected 
families originate from South Africa, patient XP8CA reported herein originates 
from Egypt. Furthermore, the precise relationship between subjects XP8CA and 
XP4PA is unknown, although they were originally identified in different 
laboratories.
Recently, Khan et al. (2006) speculated that mutant X PC  mRNA transcripts, 
resulting from the creation of a premature termination codon (PTC) in the XPC  
gene, are degraded by the nonsense-mediated mRNA decay (NMD) pathway. It 
is thought that the degradation of XPC  transcripts, possessing pre-termination 
signals, is a protective biological process that inhibits the expression of low 
levels of mutant XPC  mRNA. Therefore, preventing the translation of truncated 
proteins, which may have a significantly more deleterious consequence on 
normal cellular functionality, compared to the complete lack of XPC protein 
(reviewed by Amrani et al., 2006).
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As expected, XPC protein was detected by Western blotting in normal hTERT- 
immortalised MRC-5 and DNA repair-defective XP-A (XP12BE) and CS-A 
(CS3BE) fibroblasts (Fig. 3.4A). Conversely, neither full-length nor truncated 
XPC protein was detected in WCEs derived from patient XP8CA (Fig. 3.4A), 
thus suggesting that the truncated XPC protein product is either expressed at low 
levels undetected by Western blotting or is unstable. This finding is consistent 
with a previous study by Chavanne et al. (2000), where no full-length or 
truncated XPC protein was detected in cells derived from twelve XP-C patients. 
All twelve XP-C patients where XPC protein was not detected possessed frame- 
shifts, deletion or aberrant splicing mutations. A low level of XPC protein, 
however, was detected in patient XP13PV, who displayed a missense 2069G>C 
transversion, which resulted in the aa change at position 690 from Trp to Ser 
(Chavanne et al., 2000). Trp-690 is conserved in five XPC homologues (human, 
mouse, Drosophila melanogaster, S. cerevisiae and Schizosaccharomyces 
pom be)  and the position of this residue is embedded within an a-helix. 
Therefore, the aa change from Trp to Ser is thought to abolish the a-helical 
conformation, thus inducing a modification to the secondary structure of the XPC 
protein. The presence of the missense 2069G>C transversion, thus resulted in the 
detection of dysfunctional XPC protein. Moreover, from these findings, 
Chavanne et al. (2000) speculated that XPC is dispensable for proliferation and 
cell viability. Additionally, Khan et al. (2006) has suggested that the mutated 
XPC proteins, produced by frame-shifts, deletions or aberrant splicing would 
cause the loss of the COOH-terminus, which possesses domains essential for the 
recruitment of the TFIIH factor to the preincision NER complex (Uchida et al., 
2002).
Like XPC, a multiplicity of protein truncations caused by frame-shifts, deletions 
and abnormal splicing have been described elsewhere in other nonessential DNA 
damage signalling and repair genes, such as ATM  (Rotman & Shiloh, 1998), CSB 
(Colella et al., 1999; Mallery et al., 1998) and XPA  (Cleaver et al., 1999; 
Kuraoka et al., 1996; Sato et al., 1996; states et al., 1998). Another NER factor, 
XPD, is an indispensable constituent of the basal transcription factor, TFIIH. 
Therefore, nonsense mutations in XPD  are incompatible with life, and all gene
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variants characterised in XPD, that result in XP, XP/CS, TTD or COFS are 
missense mutations (Cleaver et al., 1999; Lehmann, 2001; Graham et al., 2001), 
which preserve some XPD protein function for its transcriptional role (Cleaver et 
al., 1999; Lehmann, 2001).
Chavanne et al. (2000) have speculated that missense mutations that cause 
negligible structural modifications to XPC may cause a mild clinical phenotype 
that remains undiagnosed. From the current data, the complete abolition of XPC 
protein and the presence of dysfunctional protein both result in an identical 
clinical phenotype, which display similar levels of photosensitivity and DNA 
repair, as determined by UDS. Chavanne et al. (2000) described 10 of the 12 
diagnosed XP-C cases as presenting clinical features indicative of XP-C. Indeed, 
XP-C individuals are a genotypically diverse group, but the clinical 
manifestations are homogeneous. At the time of biopsy, patient XP8CA 
(described in this study) was 2 months old, and exhibited no clinical symptoms, 
but fibroblasts were defective in DNA repair. At 4 months, however, patient 
XP8CA displayed cutaneous symptoms, such as erythema and a single large (2 to 
5 mm in diameter) pigment patch on the bridge of the nose (Hashem et al., 
1980).
Although a multiplicity of recent studies have identified several key mechanistic 
roles of XPC in the NER pathway (Section 1.6.1), the continued characterisation 
of the molecular defects in XP-C patients will assist in the elucidation of XPC 
function, and the identification of functional domains within the XPC protein. 
Furthermore, recent investigations into the association between phenotype- 
genotype in XP patients, have suggested that variations in NER capacity may 
have significant implications regarding cancer predisposition in heterozygotes 
and the general population. Studies undertaken by Olsen et al. (2001) and Gruber 
et al. (2002) showed an association between increased cancer incidence and 
heterozygotes with mutations in other DNA repair disease genes, such breast 
cancer in ataxia-telangiectasia and colon cancer in Bloom syndrome.
A frequently observed single nucleotide polymorphism (SNP) in the XPC  gene 
(Khan et al., 2000; Khan et al., 2002), has been associated with a reduced DNA
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repair capacity and increased risk of SCC of the head and neck (SCCHN; Shen et 
al., 2001) and of the lung (Marin et al., 2004) in the general population. A 
reduction in XPC  mRNA levels has also been associated with an increase in 
SCCHN (Yang et al., 2005). In addition to X P C , several SNPs have been 
identified in a number of genes involved in NER including ERCC1 (Yu et al., 
1997; Yu et al., 2000b), XPD  (Broughton & Steingrimsdottir, 1996), hHR23B 
(Millikan et al., 2005), XPF  (Millikan et al., 2005; Winsey et al., 2000), XPG  
(Emmert et al., 2001) and XPA (Mellon et al., 2002). The role of these SNPs in 
influencing NER remains poorly delineated. It has been speculated, however, 
that SNPs of NER genes may be utilised as a predictive marker for cancer 
susceptibility in the general population (Gillet & Scharer, 2006). Interestingly, 
NER is known to provide a protective effect against DNA damaging anti-cancer 
treatments. Therefore, it has been speculated that the information on SNPs in 
NER genes could be exploited to predict the efficacy of specific agents, thus 
facilitating the development of tailored anti-cancer therapies.
To date, the data on CKN1 mutations is limited because, although mutations in 
the CKN1 gene account for approximately 20% of CS (Stefanini et al., 1996), 
only 13 have been characterised (Cao et al., 2004; Ren et al., 2003; Bertola et al., 
2006). Here, we report a third novel missense mutation C479T in CKN1, which 
resulted in a change in aa 160 from Ala to Val (A 160V). Interestingly, the Utah 
G e n o m e  C e n t e r  s i n g l e  n u c l e o t i d e  SNP d a t a b a s e  
(http://www.genome.utah.edu/genesnps) and a previous study (Cao et al., 2004) 
indicate that this 479C>T variant is not a SNP. Moreover, the availability of 
genomes from other species has shown that the CSA protein is highly conserved 
(http://www.ensemble.org). In particular, Ala-160 is conserved in all species 
known to possess a CSA homologue (Table 3.1). The two previously reported 
missense mutations, Q106P and A205P (Ren et al., 2003; Cao et al., 2004), lie 
within the WD-40 region. The A160V mutation reported here lies between the 
second and third WD-40 repeats. If undetectably low levels of full-length protein 
are expressed in subject CS3BE, this is likely to be inactive as the sites of all 
three missense mutations (Q106, A205 and A 160) are highly conserved in 
mammalian, chicken and puffer fish CSA protein homologues (Table 3.1).
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Unlike Q106 and A205, A 160 is also retained in Schizosaccharomyces pombe 
and Arabidopsis thaliana (Table 3.1).
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Sequence Name |  < Pos = 128
-W B T  ■  +
i.1■■I:■
^  Consensus 
9 Sequences
FDKTLKVWDTNTLQPfiDVFNFEGTWSHHMSP 1ATKHCL1 RVGTRGPKVQLCDLKSGSCSH 1LQG-------
138 140 150 160 170 180 190
Human
C h ic k e n  CSfl 
Fugu CSfl 
A r a b id o p s is  C 
Mouse CSfl 
Pombe CSfl 
R a t CSfl 
T e tra o a d o n  CS 
Z e b r a f is h  CSfl
f d k t l k v u d t n t l q t a o v f n f e e w s h h m s p v s t k h c l W g t r g p k v q l c o l k s g s c s h il q g -------
FDKTLK1 UDTNTLQPflDVFQFEGTVVSHHMSPVRTKHCL i RVGTKSPKVQLCDLKSGSCSH1 LQG-------
FDKTMKVNDTETLKPREVFEFEGNVYSHHLSP1RKKHTL1W 3 T K N P K 1QLCDLRSGSK1H 1LQG-------
FDHYLKVUDTNTfiQRWDFKMPGKWRTflMSSMRMSHTL ilG TEDVQ VRLCD 1RSGRFSHTLSG-------
FDKTLKVWDTNTLQRRDVFNFEETVYSHHMSPfiflTKHCLVfiVGTRGPKVQLCDLKSGSCSHILQG-------
FDHTLKVWDVSTLQERYTFTMEDM1YSHfiUSP1RS-HCL i RTRYRSSS1RLCOMQSGSYTHSLSG-------
FDKTLKVUDTMTLQRflOVFMFEETVYSHHMSPflRTKHCLYftYGTRGPKVQLCDLKSGSCSH 1 LQG 1FVKY
FDKTMKVWDTETLKPREVFEFEGNVYSHHLSP1RKKHSLSflVGTTNPK1QLCDLRSGSK1H 1LQG-------
FDKTMKVWDRETLKPRDEFQFDGMVYCHHMSP1 RRKHSL#GTKDPKVQLCDLKSGSR 1H 1 LQG-------
Table 3.1. Amino acid sequence alignment of all species known to possess a CKN1 gene homologue, using the MegAlign 
component of the Lasergene software suite. The position of A 160 is highlighted.
The CKN1 gene encodes a 396 aa protein, which is considered a member of the 
WD-repeat family, due to the presence of seven WD-40 repeats. To date, a 
multiplicity of WD-repeat proteins have been characterised and their 
corresponding biological functions elucidated. These include cellular processes 
such as signal transduction, transcription regulation, cell cycle regulation, 
chromatin assembly, vesicular trafficking, cytoskeletal assembly, DNA repair 
and apoptosis (reviewed by Li & Roberts, 2001). WD-repeat proteins, defined by 
virtue of the presence of a minimum of four repeated units, contain a highly 
conserved core o f approximately 40-60 amino acids, that are initiated by a 
glycine-histidine (GH) dipeptide 11 to 24 residues from the N terminus and 
terminate with tryptophan-aspartic acid (WD) dipeptide at the C terminus (Li & 
Roberts, 2001). The 40-60 aa WD-repeat domains in all WD-repeat proteins are 
thought to form a circularised P propeller structure. Molecular modelling studies 
have suggested that the P propeller structure creates a stable platform, thus 
facilitating the formation of protein complexes (Smith et al., 1999). The 
indispensable function of these WD-repeat proteins, in maintaining normal 
cellular functionality and homeostasis, has been exemplified in their involvement 
in at least four inherited human diseases, which exhibit mutations in genes that 
encode W D-repeat proteins, including; CS, lissencephaly, late-onset 
sensorineural deafness and Triple-A syndrome.
Although the WD-repeat motif was first characterised in 1986 (Fong et al., 
1986), the only member of the WD-repeat protein family, whose three- 
dimensional structure has been elucidated, is the p subunit of the G protein (Wall 
et al., 1995). Although WD-repeat proteins exhibit both sequence diversity and 
structural variation in the number of WD-repeats, the common mechanistic 
function of all WD-repeat proteins is orchestrating the sequential assembly of 
multiprotein complexes. This is achieved through coordinating multiple protein- 
protein interactions, by providing a molecular scaffold. Indeed, the mechanistic 
function of many WD-repeat proteins has been elucidated (Smith et al., 1999; 
Neer et al., 1994), yet the precise mechanistic role of CSA in DNA repair and 
possibly basal and/or activated transcription remains poorly understood (Henning 
et al., 1995). Therefore, the existence of this highly conserved WD-repeat region,
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within CSA, provides a possible avenue for elucidating the precise mechanistic 
function of this protein. However, it should be noted that the assignment of WD- 
repeat proteins to specific functional groups has been extensively problematic, as 
the WD-repeat domain is devoid of catalytic activity and does not possess a 
functional domain. Therefore, the elucidation of further structural, functional or 
binding domains is essential in the assignment of some WD-repeat proteins. Ren 
et al. (2003) has speculated that the 42A>C transversion they identified, resulting 
in an amino acid substitution (Q106P), may modify the (3 propeller structure of 
the WD-40 repeat domain in CSA, causing the defect in TCR.
As discussed in Chapter 1, in addition to the indispensable role of CSA in TCR, 
recent studies have elucidated further roles of CS-A. For example, Groisman et 
al. (2003) demonstrated the essential function of CSA in the modulation of NER, 
through the ubiquitin-proteasome pathway. It is thought that, following UV- 
irradiation, CSN rapidly associates with the CSA complex, resulting in the 
suppression of the ubiquitin ligase activity. However, the precise mechanistic 
function of this complex remains poorly understood. More recently, Groisman et 
al. (2006) has shown that the degradation of CSB occurs in a proteasome- and 
CSA-dependent manner, thus for the first time providing evidence for a 
functional relationship between CSA and CSB. Fousteri et al. (2006) has shown 
that functional CSA is dispensable for the recruitment of NER proteins to lesion- 
stalled RNAPIIo, but is essential for the recruitment of HMGN1, XAB2 and 
TFIIS.
Unlike XP, it appears that there are no apparent phenotype-genotype differences 
between characterised CS subjects displaying different mutations in the CKN1 
gene. Recently, Bertola et al. (2006) reported no phenotypical differences 
between eight Brazilian CS-A patients with splicing and frameshift mutations. 
However, as indicated by Bertola et al. (2006), the mutation studies undertaken 
on affected CS-A subjects so far have been performed in the absence of the 
correlation of phenotype to genotype (Bertola et al., 2006; Cao et al., 2004; 
Komatsu et al., 2004; Ren et al., 2003; Ridley et al., 2005). This further 
emphasises the requirement for additional clinical investigation, into the
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phenotype-genotype relationship exhibited by CS-A subjects. This will improve 
our understanding o f the association between genotype and clinical 
symptomology exhibited by CS patients. Furthermore, extensive clinical 
investigation will facilitate the elucidation of the precise mechanistic function of 
CSA in TC-NER and basal and/or activated transcription.
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Chapter 4 
Establishment of hTERT-immortalised 
XP-C (XP8CA) and CS-A (CS3BE) 
Human Dermal Fibroblast Cell Lines
4.1 Introduction
The complete cessation of cellular proliferation due to telomere-dependent 
senescence provides the principle obstacle for the immortalisation of primary 
human cells. Prior to the emergence of telomerase-based immortalisation 
strategies, the generation of cell lines involved the selection of rare clonal 
populations that arose as a consequence of loss of tumour suppressor gene 
function and subsequent genome instability. The availability of established cell 
lines, derived from individuals with syndromes of genomic instability, are 
limited to those created through clonal expansion of tumour derived cells, due to 
the loss of p53 function following spontaneous mutation (Honda et al., 1996), or 
alternatively through the transduction of primary cells with viral oncogenes, such 
as the HPV16 E6/E7 oncoproteins or the SV40 LTAg (Lin & Simmons, 1991). 
Several studies have reported the successful application of the SV40 LTAg in the 
establishment of immortalised cell lines, derived from individuals with defects in 
DNA repair, such as XP, CS, TTD, XP/CS and U V S (Yagi & Takebe, 1983; 
Merk & Speit, 1997; Mayne et al., 1986; Tanaka et al., 1985; Eveno et al., 1995; 
Ellison et al., 1998). Moreover, the SV40 LTAg has been successfully exploited 
to immortalise DNA repair-defective cells, which have subsequently been 
recipients for cDNA library screening for the elucidation of DNA repair genes 
(Tanaka et al., 1990; Itoh & Yamaizumi et al., 2000). Unfortunately, however, 
although these cell lines retain their original DNA repair defect, they exhibit an 
altered karyotype due to the genome instability that occurs during crisis.
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Although many phenotypic characteristics are retained following SV40- 
transformation (reviewed by Bryan & Reddel, 1994), the well-documented 
interaction between the SV40 LTAg and p53 during immortalisation (Lane & 
Crawford, 1979; Linzer & Levine, 1979), suggests that SV40-transformation 
may result in the modification of various p5 3-dependent biological processes 
fundamental to normal cellular functionality (previously discussed in Sections 
1.10.3-5). Although an increase in p53 levels has been reported following SV40 
LTAg/or HPV16 E6 transformation, the apparent stabilisation of p53 levels 
results in the abolition of many p53-dependent functions, such as tumour 
suppression (Moore et al., 1992), site-specific DNA binding (Bargonetti et al., 
1992), transactivation of downstream transcriptional gene targets (Mietz et al., 
1992; Segawa et al., 1993), and regulation of DNA recombination (Mekeel et al., 
1997). In addition to the abrogation of the p53 tumour suppressor pathways 
(Merk & Speit, 1997), the abolition of the pRb/plb1™1^  tumour suppressor 
pathway has also been observed. Furthermore, previous reports suggest that the 
inactivation of p53 function, either through mutation, such as that found in p53- 
deficient cells derived from individuals with Li-Fraumeni syndrome (Ford & 
Hanawalt, 1995; Ford & Hanawalt, 1997), or by oncogenic transformation, 
through the exploitation of the SV40 LTAg or HPV E6/E7 viral oncoproteins, 
abrogates the GGR-NER pathway (Bowman et al., 2000; El-Mahdy et al., 2000; 
Ford et al., 1998; Therrien et al., 1999). Similarly, numerous studies have shown 
that the transcriptional activation of the GGR-specific genes, X PC  and p48  
(DDB2/XP-E), which are essential for the recognition of 6-4PPs and CPDs 
respectively, require functional p53 (Bowman et al., 2000; Amundson et al., 
2002; Porter et al., 2006; Hwang et al., 1999). Several studies have shown that 
the p48  and XPC  gene possess p53 response elements (Itoh et al., 2003; Tan et 
al., 2002; Adimoolam & Ford, 2002), and are thus regulated in a p53-dependent 
manner (Hwang et al., 1999; Adimoolam & Ford, 2002). In agreement with these 
findings, Wei et al. (2005) exploited ChIP coupled with a paired-end ditag 
sequencing strategy to elucidate a whole-genome map of transcription-factor 
binding sites; among the p53 target genes identified were the GGR-specific 
genes XPC  and p48. It has also been suggested that p2 iWAF1/CIP1 plays an 
important role in NER, following the recruitment of PCNA to DNA repair sites 
(Stivala et al., 2001). The precise role of p53/p21WAF1/CIP1 in TCR, however,
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remains controversial. Collectively, these findings reiterate the importance of 
p53/p21WAF1/CIP1 preservation when establishing in vitro culture models of NER.
It has been shown that cell lines established through HPV E6 or E7 
transformation display varying levels of NER. For example, HPV E6 
transformation functionally inhibits p53 and causes a reduction in both GGR and 
TCR. Conversely, HPV E7-mediated transformation inactivates pRb and 
abrogates GGR only, thus suggesting a mechanistic function for pRb in GGR 
(Therrien et al., 1999). As a result, the utilisation of transformed cells lines for 
long-term in vitro analysis of stress signalling pathways and the mechanistic 
functioning of NER has been problematic, particularly with cell lines derived 
from human syndromes already compromised in genome stability. Interestingly, 
a more recent study showed that the abrogation of GGR by the HPV E6 or E6/E7 
oncoproteins occurs in a cell-type-specific manner (Ferguson & Oh, 2005). This 
reiterates the requirement of an alternative immortalisation system, as a critical 
response to DNA damage, namely p53, is missing. Moreover, subtle differences 
in NER may be attributed to a modulation in GGR by oncogenic protein 
transformation rather than the phenotypical characteristics of the cell.
The preservation of the p53/p21WAF1/CIP1 and p R b /p lb ^ ^  tumour suppressor 
pathways is particularly important, as mutations and the subsequent loss of p53 
and p i6 ^ ^  function has been implicated as important targets in the molecular 
pathogenesis of cutaneous malignancy in both the normal population and in XP 
patients (reviewed by Daya-Grosjean & Sarasin, 2005; Melnikova & 
Ananthaswamy, 2005; Pfeifer et al., 2005). Although Ferguson & Oh (2005) 
have recently reported proficient GGR in human keratinocytes defective in p53, a 
growing body of evidence has shown that preservation of p53 and pRb is 
indispensable for the GGR of CPDs and other DNA lesions in non-keratinocyte 
cells (Bowman et al., 2000; El-Mahdy et al., 2000; Ford & Hanawalt, 1995; 
Ferguson & Oh, 2005; Ford & Hanawalt, 1997; Ford et al., 1998; Lloyd & 
Hanawalt, 2000; Therrien et al., 1999; Wani et al., 2002b), although the abolition 
of 6-4PP repair resulting from abolished p53 function has been documented less 
frequently (Ford et al., 1998). Despite the role of p53/p21WAF1/CIP1 being well
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characterised, the precise role of pRb in the repair of UV-induced lesions 
remains controversial.
Indeed, extensively characterised primary human cell cultures, defective in DNA 
repair, derived from several genome instability syndromes such as XP, CS and 
TTD donors, which retain normal p53 functionality, are widely available and 
provide an alternative in vitro culture model to transformed cell lines that 
recapitulate their primary isogenic counterpart. However, the long-term in vitro 
genetic, biochemical and functional analysis of primary cultures is hindered by 
limited proliferative lifespan (and therefore limited cell numbers) and the 
confounding effects of cellular senescence. For example, investigations into 
DNA damage signalling and tumour suppressor function is significantly 
compromised by the alterations in the basal state of p53 activation. Moreover, the 
induction of both the p53/p21WAF1/CIP1 and pR b/plb11^ 4* anti-proliferative 
pathways occur as a result of stress signalling induced by double-stranded DNA 
breaks and the uncapping of telomeres. In stark contrast, Goukassian et al. 
(2000) have shown an association between a reduction in both the basal and 
activated levels of p53 protein with an increase in chronological age of the donor.
The limited expansion of primary cells in culture provides the principle obstacle 
when undertaking genetic manipulations that require subsequent clonal 
expansion. For example, the creation of stable and permanent in vitro gene 
knockout models, through homologous recombination or the exploitation of 
shRNA technologies, requires the extensive propagation of cells during the 
establishment of clones. Furthermore, slowly dividing primary cells derived from 
genome instability syndromes are resistant to transfection.
A multiplicity of conflicting in vitro studies have shown either insignificant or no 
modulation in the repair capacity of various DNA repair pathways in young or 
senescent cells (Painter et al., 1973; Clarkson & Painter, 1974; Merkle et al., 
2004). In congruence, Christiansen et al. (2000) adopted strand-specific DNA 
repair assays to demonstrate that gene-specific NER of CPDs was not 
compromised in senescent human dermal fibroblasts or trabecular osteoblasts. 
More recently, however, Boyle et al. (2005) utilised an anti-CPD monoclonal
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antibody in combination with an in situ immunochemical method, to show that 
senescent cells are compromised in the excision of CPDs following UV- 
irradiation, compared to their young isogenic counterpart. These widely 
conflicting findings have been attributed to differences in culture conditions (Al- 
Baker et al., 2005). It is thought that young cultures grown under high serum 
concentrations (10%) contain cells that are at different phases of the cell cycle. In 
contrast, senescent cultures grown under identical culture conditions contain 
fewer than 4% proliferating cells. This has significant implications for DNA 
repair studies, as damage will occur to young proliferating cells in Gi, S and G2 
phases of the cell cycle, while damage to senescent cultures will predominantly 
occur to cells in Gi. It has been previously shown that cells in Gi are more 
susceptible to DNA damage than cells in S and G2 phases of the cell cycle 
(Watanabe & Horikawa, 1974).
A reduction in NER capacity would be particularly problematic when 
undertaking long-term in vitro NER assays, as a reduction in NER may be 
attributed to the phenotypical characteristics o f the cell, or simply due to the 
onset of replicative senescence.
The initial cloning of the hTERT gene (Nakamura et al., 1997), has provided an 
alternative system for the establishment of permanent cell lines with an unlimited 
proliferative potential (Bodnar et al., 1998; Viziri & Benchimol, 1998), which 
phenotypically resemble their primary isogenic counterpart, without displaying 
the cancer-associated alterations displayed by transformed cell lines (Jiang et al., 
1999; MacKenzie et al., 2000; Morales et al., 1999; Morales et al., 2003), or a 
protracted proliferative capacity exhibited by primary cultures. Initially, it was 
demonstrated that expressing hTERT  restored telomerase activity in normal 
somatic cells (Nakayama et al., 1998; Vaziri & Benchimol, 1998; Weinrich et 
al., 1997). Subsequent to the initial demonstrations that the transient and stable 
transduction of the catalytic subunit o f telomerase (hTERT), resulted in the 
reconstitution of telomerase activity, elongation of telomeres and an extended 
replicative capacity (Bodnar et al., 1998; Steinert et al., 2000; Vaziri & 
Benchimol, 1998; Wang et al., 1998), several reports have exploited telomerase- 
mediated immortalisation to extend the proliferative lifespan, without
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compromising the phenotypic characteristics of the cell or inducing changes 
associated with a malignant phenotype, such as growth in soft agar and tumour 
formation in vivo (Jiang et al., 1999; MacKenzie et al., 2000; Morales et al., 
1999; Morales et al., 2003). Furthermore, it was shown that human skin 
fibroblasts displaying reconstituted telomerase activity retained normal growth 
regulation in response to serum depletion, high confluency, Gi or G2 phase 
inhibitors and spindle inhibitors (Jiang et al., 1999). In addition to an unlimited 
proliferative capacity, hTERT-immortalised cells retain the characteristics 
associated with normal diploid primary fibroblasts cultured in vitro, such as 
contact inhibition, non-tumorigenicity, anchorage dependence, a normal 
karyotype, chromosomal stability and fully functional tumour suppression 
including p53/p21WAF1/CIP1 and pRb /p 16INK4A activity.
Although the ectopic expression of hTERT alone is sufficient to reconstitute 
telomerase activity, elongate telomeres, and extend proliferative lifespan in 
primary human fibroblasts and epithelial cells (Bodnar et al., 1998; Nakayama et 
al., 1998; Vaziri & Benchimol, 1998; Weinrich et al., 1997), conflicting studies 
have shown that several cell types require further manipulation in addition to 
telomerase reactivation.
Interestingly, numerous reports describe the stable and permanent establishment 
of hTERT-immortalised cell lines derived from genetically compromised 
phenotypes, without resulting in alterations associated with oncogenic 
transformation, including the abrogation of the p53/p21WAF1/CIP1 and pRb/pl6 
pathways, which are known to elicit cellular senescence (Bond et al., 1999; 
Hara et al., 1996; Shay et al., 1991). These include cells derived from Werner 
syndrome (WS), AT, Roberts’s syndrome (RBS), XP-E, XP-V, CS-B, Bloom 
syndrome (BLM), Hutchinson-Gilford progeria syndrome (HGPS) and Nijmegen 
breakage syndrome (NBS) (Wyllie et al., 2000; Ouellette et al., 2000; Newman 
et al., 2006; Wood et al., 2001; Ranganathan et a l, 2001).
It has been speculated that hTERT functions in several cellular responses 
independent of telomere length. Recent studies have shown that the interaction 
between hTERT and telomeres increases genome stability and enhances DNA
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repair (Sharma et al., 2003; Shin et al., 2004). Sharma et al. (2003) speculated 
that the increased DNA repair capacity was attributed to the stabilisation of 
telomeres at the nuclear matrix, resulting in the down regulation of senescence- 
associated gene expression and an upregulation of DNA repair-associated genes. 
Conversely, Shin et al. (2004) postulated that hTERT directly mediates the 
recruitment o f DNA repair proteins to the site o f damage. Interestingly, 
Gorbunova et al. (2002) showed that the expression of hTERT in fibroblasts 
confers resistance to UV-induced apoptosis.
In contrast, however, several conflicting studies have shown that hTERT- 
immortalised fibroblasts progressively acquire features closely associated with a 
transformed phenotype. For example, Milyavsky et al. (2003) showed that 
hTERT-immortalised cells remain phenotypically similar to primary cells during 
the first 150 PDs, however, the long-term propagation (s:500 PDs) of hTERT- 
immortalised cells in culture, resulted in the appearance of clones harbouring 
potentially malignant alterations. Although the long-term cultures retained both 
intact p53/p21WAF1/CIP1 and pRb-mediated checkpoints, numerous studies have 
reported conflicting findings for the preservation of p l4 ARF and p i 6 ° ^ ^ . For 
example, Jiang et al. (1999) showed that telomerised BJ foreskin fibroblasts 
display no alterations in a p i6 INK4A response to a cell-cycle checkpoint arrest 
compared to parental non-hTERT expressing cells. Conflicting studies, however, 
have reported fluctuations in p i6 ^ ^  basal protein levels, following continuous 
growth of telomerised cells in culture. Milyavsky et al. (2003) observed a 
significant induction in p i 6 ^ ^  at both the transcriptional and translational 
levels in telomerised WI-38 fibroblasts soon after the cells passed the replicative 
senescence barrier. This resulted in a reduction in colony formation and a 
subsequent senescence-like arrest. A similar induction of p i6 ^ ^  in hTERT- 
immortalised fibroblasts has been reported elsewhere (Wei et al., 2001). 
Milyavsky et al. (2003) also reported a subsequent decline and loss of p i6 INK4A 
expression following prolonged culture of telomerised WI-38 fibroblasts, which 
resulted in loss of contact inhibition. Milyavsky et al. (2003) proposed that the 
stable changes in p i6 ^ ^  expression were due to epigenetic events. The loss of 
p 16INK4A during telomerase-mediated immortalisation has been reported in
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several other fibroblast strains (Kiyono et al., 1998; Tsutsui et al., 2002). 
Consistent with these data, gene expression profiling of normal human 
fibroblasts and endothelial cells immortalised with hTERT revealed a dramatic 
down-regulation in CDKN2A, the gene that encodes p 16INK4A (Kumazaki et al., 
2004). It is of note that the pattern of initial p i6 INK4A induction immediately 
after telom erase-m ediated im m ortalisation followed by the gradual 
disappearance during an accelerated growth phase appears to be a frequently 
reported phenomenon among fibroblast strains (Milyavsky et al., 2003; Noble et 
al., 2004; van Waarde-Verhagen et al., 2006).
Moreover, the long-term propagation of hTERT-immortalised fibroblasts 
resulted in the overexpression of the c-myc and Bmi-1 oncogenes. Similarly, a 
number of studies have reported epigenetic and genetic changes associated with 
alterations in the p53/p21WAF1/CIP1 and pRb/plb™1^  pathways, following 
extensive in vitro subcultivation of hTERT-immortalised cells (Farwell et al., 
2000; Nobel et al., 2004; van Waarde-Verhagen et al., 2006; Wang et al., 2000). 
Interestingly, transcription expression profiling revealed significant differences 
between the profiles o f normal (nontransduced) and isogenic hTERT- 
immortalised fibroblasts (Lindvall et al., 2003). In particular, epiregulin, a 
growth factor of the EGF family was significantly upregulated in hTERT- 
immortalised cells. Epiregulin is thought to play a role in the maintenance of 
continued proliferation (Toyoda et al., 1997). Conversely, it has been speculated 
that excessive telomerase activity induces a senescent-like phenotype 
(Gorbunova et al., 2003), as elevated telomerase activity acts as a 
hyperproliferative signal in a similar manner to that observed following 
overexpression of oncogenic Ras, Raf and E2F1.
Although the ectopic expression of hTERT permits the extension of proliferative 
capacity in primary cells derived from donors of genome instability syndromes, a 
recent study has shown that hTERT does not circumvent stress-induced 
premature senescence (SIPS), irrespective o f extensions on telomere length 
(Naka et al., 2004). In addition to telomere-dependent replicative senescence, 
fibroblasts undergo SIPS in response to DNA damage induced by oxidative 
stress, UV or ionising radiation. Naka et al. (2004) showed that exposure of
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hTERT-immortalised AT fibroblasts to x-rays or H2O2 , resulted in SIPS. This 
suggests that SIPS is not exclusively triggered by telomere shortening, but also 
occurs via a telomere-independent pathway. Therefore, the cessation of cellular 
proliferation may occur subsequent to the ectopic expression of hTERT.
As previously mentioned, the long-term genetic, biochemical and structural in 
vitro analysis of normal NER was restricted to cell lines created by the expansion 
of clones following spontaneous mutation or by oncogenic transformation, as the 
establishment of normal telomerase-immortalised cell lines exhibiting unaltered 
NER remained unreported. However, several investigators have successfully 
established hTERT-immortalised normal fibroblast cultures, which exhibit 
unaltered levels of UV sensitivity and confer normal levels of NER to their 
primary isogenic counterparts (Bates et al., 2005; Ouellette et al., 2000; Porter et 
al., 2006). Moreover, hTERT-immortalisation maintains cell-cycle checkpoint 
controls and permits the continued preservation of genome stability. In 
concordance, Cordeiro et al. (2002) used previously established hTERT- 
immortalised XP-V fibroblasts (Ouellettee et al., 2000), which displayed S phase 
fractions similar to its primary isogenic counterparts, to evaluate checkpoint 
responses. In addition, the utilisation of telomerase-immortalised XP-V cells 
allowed Cordeiro et al. (2002) to substantiate whether the abolition of pol r\ 
activity in XP-V cells increases the risk for accumulating UVC-induced 
chromosomal aberrations.
All previous investigations of CSB function in immortal cells were performed 
using CS-B cell lines established through SV40-transformation (Troelstra et al., 
1992). However, in addition to the known interactions between the SV40 LTAg 
and p53 (Pipas & Levine), studies have shown that p53 directly interacts with 
CSB in vitro and possibly in vivo (Yu et al., 2000a; Wang et al., 1995). 
Therefore, to avoid the confounding functional interactions between SV40 LTAg 
and CSB, Newman et al. (2006) established a permanent CS-B fibroblast cell 
line through telomerase-mediated immortalisation. This provided a control for 
the isogenic SV40-transformed CS-B cell line and allowed Newman et a l  (2006) 
to characterise CSB-dependent transcription expression responses, by expression
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profiling telomerised CS-B fibroblasts that possessed intact tumour suppressor 
pathways.
Therefore, the exploitation of telomerase will provide an invaluable tool in the 
establishment of novel in vitro model systems of ageing, carcinogenesis and 
tumorigenesis, when compared to the conventional exploitation of cell lines 
established by oncogenic transformation. Furthermore, the indefinite expansion 
of human fibroblasts by hTERT reconstitution can provide unlimited access to 
biological material for long-term genetic, biochemical and physiological analysis 
of normal growth and differentiation, without exhausting the proliferative 
capacity of the culture.
Pirzio et al. (2004) reported low frequencies of chromosomal aberrations and the 
maintenance of karyotypic stability in human fibroblasts immortalised through 
the ectopic expression of telomerase, and speculated that reconstituted 
telomerase activity contributed to genome stability via a telomere-independent 
mechanism, suggesting the potential exploitation of hTERT-immortalised human 
fibroblasts in gene targeting studies.
In accordance, Jiang et al. (1999) speculated that the ectopic expression of 
hTERT per se does not elicit oncogenic transformation, as both germ cells and 
stem cells exhibit telomerase activity (Wright et al., 1996), whilst remaining 
functionally normal. Furthermore, a preliminary study undertaken by Morales et 
al. (1999) suggests that in addition to reconstitution of telomerase activity and 
extension of replicative lifespan, the ectopic expression of telomerase facilitates 
the preservation of the p53-mediated cell cycle checkpoint in response to UV. 
Morales et al. (1999) further demonstrated a UV-dependent induction of 
p21WAF1/CIP1 in response to UV, which is indicative of normal p53 functionality. 
Also, they showed that UV-irradiated cells, transformed with HPV E6, are 
devoid of a UV-induced p53-dependent induction of p 2 iWAF1/CIP1 protein levels, 
due to E6-mediated degradation of p53. So, although several caveats have been 
associated with hTERT-immortalisation, the current literature suggests that the 
exploitation of hTERT in the establishment of permanent cell lines provides a 
superior alternative for the long-term in vitro propagation of cell cultures and
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investigations into the DNA damage response and repair mechanisms (Bates et 
al., 2005; Cordeiro et al., 2002; Ouellette et al., 2000; Porter et al., 2006).
The mutator phenotype exhibited by XP cells is exemplified by the high levels of 
UV-specific changes observed in key regulatory genes in XP skin tumours. 
These modifications are also observed in the same genes modified in sporadic 
skin cancer in NER-proficient individuals. This reiterates the relevance of using 
XP as an in vitro model for dissecting the molecular pathogenesis underlying 
cutaneous malignancy (reviewed by Daya-Grosjean & Sarasin, 2005). Since the 
initial association between defective NER and the XP syndrome (Cleaver, 1968; 
Cleaver, 1969), cells derived from XP patients, have been characterised and 
established as permanent cell lines by oncogenic transformation, thereby 
providing in vitro culture models of carcinogenesis.
Currently, established cell lines derived from syndromes of genome instability 
such as XP, CS and TTD, are predominantly limited to those created by SV40 
LTAg, or through HPV 16 E6/E7 oncogenic viral protein transformation. 
Although these cell lines were satisfactory for complementation studies and 
elucidating the mechanistic function of the NER machinery, as they retained their 
DNA repair defect, investigations at the molecular level are problematic due to 
the abrogation of the p53/p21WAF1/CIP1 and pRb/p 16INK4A pathways. This not only 
results in the removal of the DNA damage response, but is also thought to 
severely compromise the NER pathway. Therefore, the application of cell lines 
established through oncogenic transformation for long-term in vitro NER studies, 
involving genetic manipulation or molecular analysis has a multiplicity of 
associated caveats. From the body of evidence, there is a need for immortalised 
cell lines that retain DNA damage response mechanisms and reflect the NER 
capacity displayed by their primary isogenic counterpart, but are devoid of the 
compounding genetic changes frequently observed in cancer-derived cell lines.
To date, alternative XP and CS cell lines, established by telomerase- 
immortalisation, remains limited to XP-E (GM01389), XP-V (GM02359, 
XP115LO) and CS-B (GM00739B, CS1AN) fibroblasts (Ouellette et a l , 2000; 
Newman et al., 2006). The telomerase-mediated immortalisation of primary cells
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derived from the XP and CS complementation groups such as XP-C and CS-A, 
respectively, remains unreported. Furthermore, although Ouellette et al. (2000) 
& Newman et al. (2006) demonstrated the successful establishment of 
telomerase-immortalised XP-E, XP-V and CS-B cells, the p53/p21WAF1/CIP1 and 
pRb/p 16rNK4A pathways were never characterised. Moreover, the applicability of 
currently available telomerase-immortalised cell lines, as in vitro culture models 
of genome instability, has remained poorly delineated. More importantly, the 
ability to recapitulate their in vivo phenotype such as DNA repair capacity 
remains relatively unknown.
4.2 Aims
To address the lack of robust in vitro XP-C and CS-A culture models with 
retained tumour suppressor function and an NER capacity reflecting their 
primary isogenic counterpart, the aim of this investigation was to establish novel 
hTERT-immortalised XP-C (GM02996, XP8CA) and CS-A (GM01856, CS3BE) 
human dermal fibroblasts possessing: (1) reconstituted telomerase (hTERT) 
activity; thereby removing p53 activating senescence signals; (2) an extended 
proliferative lifespan; (3) retained p53/p21WAF1/CIP1 pRb/p 16INK4A tumour 
suppressor function; (4) repair capacity that recapitulates their primary isogenic 
counterparts. A further aim was to evaluate their potential applicability in in vitro 
NER assays.
The successful establishment of these cell lines will permit the preservation of a 
relatively ‘normal’ phenotype that resembles their primary isogenic counterpart, 
thereby providing a biologically pertinent in vitro cell culture model for NER 
studies. The extension of proliferative lifespan will permit clonal expansion for 
subsequent long-term genetic, biochemical and functional in vitro DNA repair 
assays.
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4.3 Materials and methods
Primary human dermal fibroblasts, derived from XP-C and CS-A individuals 
were purchased from the NIGMS Human Genetic Mutant Cell Repository 
(Coriell Institute for Medical Research, Camden, NJ) and the XPC  and CKN1 
gene variants were characterised, respectively, as previously described (Chapter 
3; Ridley et al., 2005).
Retroviral supernatants, containing pBABE-neo-hTERT was previously prepared 
and made available as a general reagent for the laboratory (Section 2.2). The 
catalytic sub-unit of telomerase, hTERT, was transduced into primary XP-C 
(GM02996, XP8CA) and CS-A (GM01856, CS3BE) human dermal fibroblasts, 
using an amphotropic retroviral vector (i^CRIP-pBABE-neo-hTERT), co­
expressing hTERT and the neomycin phosphotransferase selectable (G418) gene 
marker or an empty pBABE-neo vector, as previously described (Section 2.2). 
To confirm telomerase activity approximately 5000 cell equivalents/pl was 
assayed using the TRAP assay (Sections 2.8.1-4).
For the detection of p53, p53(Serl5), p2 iWAF1/CIP1j pRb and p lb 1™*4* protein, 
immunoblotting was performed using a Biorad Mini-Protean II Electrophoresis 
Cell System. Briefly, cells were irradiated or mock-irradiated (Section 2.6) and 
WCEs were prepared as previously described (Sections 2.9.1-2.9.2). Proteins 
were separated on SDS-PAGE gels (Section 2.9.3), transferred to PVDF 
membranes (Section 2.9.3) and exposed to the appropriate primary antibody 
(Section 2.9.4 & Table 2.1). Blots were visualised using an appropriate HRP- 
coupled secondary antibody (Section 2.9.4 & Table 2.1) and an ECL system 
using Hyperfilm (Section 2.9.4). Equal protein loading was confirmed by 
staining the PVDF membrane with India ink (Section 2.9.5).
For the immunocytochemical detection of p21WAF1/CIP1, the VECTRASTAIN® 
ABC system (Vector Laboratories, Peterborough, UK) was used as previously 
described (Section 2.10).
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For colony forming ability assays, initial plating efficiencies were undertaken for 
each cell line (Section 2.5). UV survival curves were constructed by seeding cells 
in 100 mm dishes at varying cloning densities between 5 X 102-2 X 103 
(depending upon cell-type) to produce monoclonal populations. Dishes were 
irradiated with 0-10 J/m2 in increments of 2 J/m2 as previously described 
(Section 2.6). Cells were incubated for the indicated time period (days), fixed 
with methanol: acetic acid (3:1) and stained in Giemsa’s solution. Purple 
colonies with a minimum of 50 cells were scored. Three data points (UV- 
irradiations) were obtained per experiment, which was performed in triplicate. 
Therefore, each data point is representative of nine replicates.
The global repair of CPDs and 6-4PPs was measured using a standard immuno- 
slot-blot assay. Briefly, 1 X 106 cells were seeded into multiple 100 mm Petri 
dishes and subconfluent hTERT-immortalised MRC-5, XP-C (GM02996, 
XP8CA) and CS-A (GM01856, CS3BE) fibroblasts were irradiated with UVC 
(10 J/m2). Dishes were maintained under routine culture conditions for an 
indicated period of time (hours). Genomic DNA was isolated and purified, using 
RNase A treatment and overnight proteinase K digestion, followed by 
phenol/chloroform extraction (Section 2.11.1). For each time point 500 or 1000 
ng of DNA was used for the detection of UV-induced photolesions. DNA was 
denatured and the immuno-slot-blot assay was undertaken by Dr. Shirong Yu, 
using the Bio-Dot SF Microfiltration apparatus (Section 2.7). The detection of 
CPDs or 6-4PPs was performed by incubating the membrane with either the H3 
CPD- or 6-4PP-specific monoclonal mouse antibodies (Mori et al., 1991). The 
membrane was incubated with an alkaline phosphatase-linked anti-mouse 
secondary antibody and detection was performed using the ECF™ Western 
Blotting Analysis System Kit. The fluorescent emission from the samples bound 
to the membrane was detected using a STORM 860 phosphorimager and 
quantification was performed using ImageQuant software. The percentage of 
lesions remaining at each time point was calculated in comparison to the lesions 
present immediately (0 hours) after UV-irradiation. Three biological replicates 
were performed for each indicated time point.
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4.4 Results
4.4.1 Ectopic expression o f the catalytic subunit o f 
telomerase, hTERT, in XP-C and CS-A primary dermal 
fibroblasts resulted in the reconstitution of telomerase 
activity
XP-C and CS-A human fibroblasts were transduced at PDs 17 and 1, 
respectively, with a replication-defective amphotropic pBABE retroviral vector 
co-expressing hTERT cDNA, and the neomycin (G418) resistance gene. In 
parallel, primary XP-C and CS-A fibroblasts were also infected with an empty 
pBABE-neo (control) vector, or mock-infected (nontransduced). XP-C and CS-A 
cells transduced with the amphotropic retroviral vector, expressing hTERT, or 
the empty control vector were assigned as 0 PD post infection. Two days 
posttransduction, XP-C and CS-A dermal fibroblasts, infected with tyCRIP- 
pBABE-neo-hTERT, were serially diluted in non-selective medium and seeded 
at densities appropriate for the generation of polyclonal and monoclonal 
populations. Primary XP-C and CS-A fibroblasts, infected with the empty 
amphotropic (control) vector or mock-infected (nontransduced), were propagated 
as polyclonal populations. Fibroblasts infected with the ^CRIP-pBABE-neo- 
hTERT vector, empty pBABE-neo vector, or mock infected (nontransduced) 
were refed 24 hours post dilution with selective medium, containing G418 at a 
concentration of 400 pg/ml. After serial dilution of transduced cells, 29 XP-C 
and 21 CS-A monoclonal populations, each derived from a single cell, were 
isolated and expanded in culture, and passaged continuously with G418 drug 
selection.
Both the hTERT transduced primary XP-C and CS-A fibroblasts were assayed 
for telomerase activity through the utilisation of the TRAP assay (Kim et al., 
1994). In addition, negative controls were prepared for each lysate (as previously 
described in Section 2.8.2), by incubating an aliquot of each sample at 85°C for 
10 minutes to destroy telomerase activity. In addition, cell extracts, prepared
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from the adenovirus 5-transformed 293 cell line, derived from HEK cells and 
known to express telomerase, were used as a positive control. TRAP reaction 
products appear as a ladder of bands with a periodicity corresponding to the size 
of the 6 bp tandem telomeric repeat sequence, TTAGGG. This confirmed the 
reconstitution of telomerase activity following the ectopic expression of hTERT.
As shown in Fig. 4.1, the retroviral infection of primary XP-C fibroblasts with 
the empty pBABE-neo vector did not confer telomerase activity (Fig. 4.1, lanes 1 
& 2). Conversely, telomerase activity was detected in the non heat-treated extract 
prepared from the polyclonal population of XP-C fibroblasts, infected with 
pBABE-neo-hTERT (Fig. 4.1, lanes 21). As expected, telomerase activity was 
not detected in the heat-treated sample (Fig. 4.1, lane 22). In addition to the 
control extracts, 9 representative monoclonal populations of XP-C cells, infected 
with pBABE-neo-hTERT, were assayed for telomerase activity by the TRAP 
assay (Fig. 4.1, lanes 3-20). The majority of non heat-treated extracts, prepared 
from the monoclonal populations of XP-C fibroblasts, infected with pBABE-neo- 
hTERT, displayed similar levels of telomerase activity. As expected, all heat- 
treated XP-C extracts, prepared from the monoclonal populations, were negative 
for telomerase activity.
Telomerase activity was found to be absent in both the heat-treated and non heat- 
treated cell extract, prepared from the polyclonal population of human CS-A 
fibroblasts, infected with the empty pBABE-neo vector (Figs. 4.2A-C, lanes 3 & 
4). Conversely, telomerase activity was detected in the cell extract prepared from 
the polyclonal population of CS-A fibroblasts, infected with pBABE-neo-hTERT 
(Figs. 4.2A-C, lane 5), while telomerase activity was absent in all heat-treated 
samples. All non heat-treated cell extracts, prepared from 14 representative 
monoclonal populations of CS-A fibroblasts at various PDs, following retroviral 
infection of pBABE-neo-hTERT, displayed telomerase activity (Figs. 4.2A-C). 
Moreover, the level of telomerase activity detected in the monoclonal 
populations of CS-A fibroblasts, infected with hTERT, was comparable to the 
telomerase activity detected in cell extracts prepared from control 293 cells (Figs. 
4.2A-C, lane 1). The data presented here, suggests that the ectopic expression of
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the catalytic unit of telomerase, hTERT, is sufficient to restore telomerase 
activity in vitro in both the primary XP-C and CS-A fibroblasts.
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Figure 4.1. Reconstitution of telomerase activity in primary XP-C 
(GM02996, XP8CA) human dermal fibroblasts following retroviral 
infection with pBABE-neo-hTERT or an empty pBABE-neo vector. 
TRAP assays were performed as previously described (Kim et al., 1994). 
Lanes 1 & 2, NC (negative control); cell extracts derived from polyclonal 
population infected with an empty pBABE-neo vector; lanes 3-20, cell 
extracts prepared from monoclonal populations infected with pBABE- 
neo-hTERT; lanes 21-22, cell extracts obtained from polyclonal 
population (PP) infected with pBABE-neo-hTERT. Each sample was 
assayed with (+) or without (-) prior heat treatment (85°C for 10 minutes).
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Figure 4.2. Determination of telomerase activity by TRAP assay in CS-A primary human fibroblasts 
(GM01856, CS3BE) following retroviral infection with pBABE-neo-hTERT. Each sample was assayed 
with (+) or without (-) prior heat treatment (85°C for 10 minutes). The immortal human epithelial cell 
line, 293, was included as a positve control. The arrows represent the position o f the internal 
telomerase amplification standard (ITAS) as a control for inhibition during the PCR reaction. (A) 
Epithelial cell line 293, CS-A pBABE-neo (negative control) and CS-A pBABE-neo-hTERT 
polyclonal populations, CS-A pBABE-neo-hTERT - clones 1-6. (B) Epithelial cell line 293, CS-A 
pBABE-neo and CS-A pBABE-neo-hTERT polyclonal population, CS-A pBABE-neo-hTERT clones 
7-10. (C) Epithelial cell line 293, CS-A pBABE-neo and CS-A pBABE-neo-hTERT polyclonal 
populations, CS-A pBABE-neo-hTERT clones 11, 12, 15 & 16.
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4.4.2 Ectopic expression of hTERT in primary XP-C and 
CS-A human dermal fibroblasts extends proliferative 
lifespan
Following retroviral infection of primary XP-C and CS-A fibroblasts with 
ipCRIP-pBABE-neo-hTERT, polyclonal populations were propagated under 
routine culture conditions. Monoclonal populations of XP-C and CS-A 
fibroblasts were also obtained by selecting colonies that were resistant to G418 
(400 ng/ml). Primary XP-C and CS-A dermal fibroblasts, infected with an empty 
pBABE-neo (control) vector, were propagated as polyclonal populations and 
passaged continuously following G418 selection until the cultures ceased 
proliferation. Furthermore, mock infected, nontransduced primary XP-C and CS- 
A fibroblasts, were maintained in culture as polyclonal populations with G418 
selection. As expected, both the mock-infected XP-C and CS-A cultures ceased 
proliferation and underwent apoptosis -11 days post G418 drug selection (data 
not shown).
Primary XP-C fibroblasts, transduced with an empty pBABE-neo vector (NC; 
negative control), ceased proliferation at ~31 PDs and 258 days in culture, post 
retroviral infection (Fig. 4.3A). Although the polyclonal population (transduced 
with the empty pBABE-neo vector) was maintained in culture for a further 129 
days (387 days in total), no further extension on proliferative lifespan was 
observed. During the first 41 days in culture, the polyclonal population of XP-C 
fibroblasts (transduced with the empty pBABE-neo vector) accumulated -12 
PDs at a growth rate of -0.36 PDs/day. However, after 64 days in culture and 
-17  PDs, the growth rate slowed down to -0.07 PDs/day between days 65-258 
post retroviral infection. Between days 259 and 387 the polyclonal population of 
XP-C cells (infected with the empty pBABE-neo vector) remained stationary at 
-31 PDs. The culture ceased proliferation and appeared to enter a state of 
permanent growth arrest, which is the principle hallmark indicative of cellular 
senescence. Conversely, the polyclonal population of XP-C fibroblasts, infected 
with pBABE-neo-hTERT, was propagated continuously for -138 PDs and 387
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days in culture (Fig. 4.3A; MP). This culture displayed a logarithmic growth 
pattern during the propagation period in culture, and displayed a growth rate of 
-0.36 PDs/day. At the point at which the culture was terminated (387 days post 
retroviral infection) and stored as a viable culture, the polyclonal population of 
XP-C fibroblasts (infected with pBABE-neo-hTERT) displayed no decline in 
growth rate.
The 29 monoclonal populations of XP-C fibroblast cultures, infected with 
pBABE-neo-hTERT, which exhibited resistance to G418, were maintained in 
culture for a minimum of -23 PDs (Figs. 4.3B-F, 4.4A-F and 4.5A-C). The three 
monoclonal populations of XP-C fibroblasts (clones 16, 19 & 30), which 
exhibited the best growth characteristics, were maintained in culture for an 
additional ^70 PDs (Fig. 4.3B), as immortality was defined at ^100 PDs. This is 
the point at which a normal adult dermal in vitro culture, expressing HPV E6/E7, 
would typically reach a state of M2 ‘crisis’ (Bond et al., 1999). For this reason, 
any fibroblast culture continuing to proliferate ^100 PDs was considered as 
immortal. Like the polyclonal population of XP-C cells, infected with pBABE- 
neo-hTERT, the monoclonal populations of XP-C cells (clones 16, 19 and 30) 
displayed a logarithmic growth pattern whilst in culture. XP-C pBABE-neo- 
hTERT clones 16, 19 and 30 exhibited comparable growth rates during 
propagation. Clones 16 and 30 accumulated -98  and -100 cumulative PDs in 
247 days, respectively, while clone 19 accumulated -106 PDs in 249 days (Fig. 
4.3B).
As shown in Fig. 4.6A (NC), the transduction of primary CS-A fibroblasts, with 
an empty pBABE-neo vector, resulted in no extension of proliferative lifespan, 
and ceased proliferation after -1 .5  cumulative PDs and 21 days following 
retroviral infection. Conversely, the polyclonal population (PP) of isogenic 
primary CS-A fibroblasts, transduced with ^CRIP-pBABE-neo-hTERT (Fig. 
4.6A), were propagated and grown continuously for 38 days under routine 
culture conditions post drug (G418) selection. Moreover, the polyclonal 
population continued to proliferate to the point at which the culture was 
terminated at -16  PDs (Fig. 4.6A). The 21 monoclonal populations of CS-A
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fibroblast cultures, infected with pBABE-neo-hTERT, which exhibited resistance 
to G418, were maintained in culture for a minimum of 19 PDs post retroviral 
infection (Figs. 4.6B-F & 4.7A-E). Following the confirmation of telomerase 
activity by the TRAP assay, three monoclonal cell cultures (clones 2, 3 and 8), 
infected with pBABE-neo-hTERT, which exhibited the best growth 
characteristics, were maintained under routine culture conditions for a further 
-7 0  PDs to confirm the immortalised phenotype (Fig. 4.6B). Both CS-A 
(pBABE-neo-hTERT) clones 2 and 3 continued to display a logarithmic growth 
pattern, accumulating -113 and -116 PD respectively (Fig. 4.6B). Furthermore, 
both CS-A clones 2 and 3 continued to exhibit a logarithmic growth pattern until 
the point at which both cultures where terminated at 302 days post retroviral 
infection (Fig. 4.6B). Interestingly, however, a reduction in growth rate was 
observed in clone 8, which only accumulated -77 cumulative PDs following 303 
days in culture, at which point the culture was terminated and stored as a viable 
stock (Fig. 4.6B). The data presented here, suggests that the ectopic expression of 
hTERT not only resulted in the reconstitution of telomerase activity, but also 
extended the proliferative lifespan of the selected clones.
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Figure 4.3. Extension of proliferative lifespan in monoclonal and polyclonal populations of XP-C (GM02996, XP8CA) human dermal fibroblasts following the ectopic expression of hTERT or 
an empty pBABE-neo vector. Abbreviations: NC, negative control; mixed population.
90
Z
Cu
m
ul
ati
ve
 
po
pu
lat
io
n 
do
ub
lin
gs
 
Cu
m
ul
ati
ve
 
po
pu
lat
io
n 
do
ub
lin
gs
Clone 12
Clone 13
3 0 -
2 0 -
10-
25 1 OO50 75O
4 0 -1
3 0 -
(0O)C
35
3O■o
co3(0
3ao
a
0)>
■5 2 0 -
% 1 0 -
Clone 17 
Clone 18
1 o o
4 0 -
too>c
Z
i  3 0 -  
■D 
C O
Clone 22
Clone 23
*■*ra
3
ao
a .
©>
«
3
E
3o
2 0 -
1 0 -
25 1 OOO 7550
Days post infection Days post infection Days post infection
40 n
Clone 26
Clone 27
1 0 -
2 5
Days post infection
4 0  "1 Clone 31
Clone 32
3  3 0 -
2 0 -
1 0 -
1 oo25 50 75
Days post infection
4 0  “1(0
o>
c
35
C lone 33
Clone 34
3O■o 3 0
co4*
3ao
a
20  _
©>4^«
3
E
3o
25 1 OO7550O
Days post infection
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Figure 4.6. Extension of proliferative lifespan of CS-A (GM01856, CS3BE) human dermal fibroblasts following the ectopic expression of hTERT or an empty pBABE-neo vector. 
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4.4.3 Morphological appearance of XP-C and CS-A human 
dermal fibroblasts following ectopic expression ofhTERT
At various PDs, after the retroviral transduction of tyCRIP-pBABE-neo-hTERT 
or the empty pBABE-neo (control) vector, photomicrographs of the XP-C and 
CS-A fibroblasts where taken.
Primary XP-C fibroblasts, infected with an empty pBABE-neo (control) vector, 
exhibited a relatively normal morphology at PD 24 and 122 days in culture post 
retroviral infection (Fig. 4.8A). However, at PD 31 and 387 days in culture, the 
primary XP-C fibroblasts, infected with the empty pBABE-neo (control) vector, 
displayed an altered morphological appearance, consistent with changes typically 
exhibited by fibroblasts undergoing replicative senescence in vitro. The 
polyclonal population of XP-C cells appeared enlarged and flattened with a 
concomitant increase in the nucleus (Fig. 4.8B). The cells also appeared 
granulated, nonrefractile and exhibited a large number of stress fibres, all of 
which are hallmarks of cellular senescence. Further morphological alterations 
observed in the XP-C fibroblasts, infected with the empty pBABE-neo vector, 
included the appearance of cylindrical cytoplasmic cell surface projections and 
thin peripheral sheet structures frequently associated with cellular senescence, 
such as filopodia, lamellipodia and membrane ruffles (Fig. 4.8B). Conversely, 
the polyclonal population of XP-C fibroblasts transduced with ijiCRIP-pBABE- 
neo-hTERT was morphologically characteristic of young dermal fibroblasts in 
culture at -63 PDs (Fig. 4.8C). Similarly, the three monoclonal XP-C dermal 
fibroblast cultures (transduced with ipCRIP-pBABE-neo-hTERT) including 
clones, 16, 19 and 30, that were isolated and maintained in culture for -98, -106 
and -100 PDs, respectively, displayed a morphology indicative of young dermal 
fibroblasts growing exponentially in vitro (Figs. 4.8D, E & F, respectively). 
Although clones 16, 19 and 30 where photographed at various PDs (-68, -74 
and -75 , respectively), the monoclonal populations were morphologically 
similar, exhibiting minimal differences between clones.
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Immediately following retroviral transduction (~1 PD), primary CS-A 
fibroblasts, infected with an empty pBABE-neo (control) vector, exhibited 
morphologic features, typically observed in senescent fibroblasts in vitro (Fig. 
4.9A). Interestingly, however, the senescent morphological appearance exhibited 
by the CS-A fibroblasts was significantly more pronounced compared to the 
morphology displayed by senescent XP-C cells at later PDs (24 & 31) that were 
transduced with an empty pBABE-neo vector (Figs. 4.8A & B, respectively). 
The CS-A fibroblasts morphologically appeared enlarged, flattened and 
nonrefractile with an increased cytoplasmic to nuclear ratio. A significantly large 
proportion of the CS-A cells within the polyclonal population also displayed a 
fan-like shape. The CS-A fibroblasts exhibited fewer senescence-associated 
appendages, such as filopodia, which was significantly less pronounced, 
compared to XP-C pBABE-neo fibroblasts. However, morphologic features such 
as lamellipodia and membrane ruffles were exhibited by the CS-A pBABE-neo 
fibroblasts. Furthermore, a marked increase in the number of actin filament 
bundles (or ‘stress’ fibers) were observed in the cell body, compared to the XP-C 
fibroblasts, infected with the empty pBABE-neo vector. Conversely, the 
polyclonal population of CS-A dermal fibroblasts infected with tyCRIP-pBABE- 
neo-hTERT, exhibited a morphology indicative of young fibroblasts (Fig. 4.9B), 
compared to its isogenic counterpart infected with an empty pBABE-neo vector. 
Similarly, the isolated and expanded monoclonal CS-A cell populations, 
including clones 2, 3, and 8 (Figs. 4.9C, D & E, respectively), infected with 
pBABE-neo-hTERT, displayed a morphological appearance characteristic of 
young proliferating dermal fibroblasts.
Although clones 2, 3 and 8 exhibited reconstituted telomerase activity (Fig. 4.2A 
& B), an extended proliferative capacity (Fig. 4.6B) and a relatively normal 
morphological appearance (Figs. 4.9C, D & E, respectively), compared to the 
polyclonal population of primary CS-A fibroblasts infected with the empty 
pBABE-neo vector (Fig. 4.9A), a sub-population of cells within the monoclonal 
populations in the hTERT-immortalised cultures, displayed a senescent-like 
morphology. This was particularly evident in clone 8, where a large proportion of 
the cell population appeared to display a marked senescent-like phenotype (Fig.
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4.9E), which was similar to its isogenic primary counterpart, transduced with the 
empty pBABE-neo vector (Fig. 4.9A).
The data presented here, suggests that the telomerised XP-C cells do not (by 
definition) enter growth arrest, nor do they take on the characteristic enlarged 
and vacuolated appearance observed in their primary isogenic senescent 
counterpart, transduced with the empty pBABE-neo vector. In contrast, although 
CS-A cells, infected with tyCRIP-pBABE-neo-hTERT, display a marked 
difference in morphological appearance compared to their isogenic primary 
counterpart infected with the empty pBABE-neo vector, a sub-population of cells 
displayed a senescent-like morphology.
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Figure 4.8. Morphological appearance of primary XP-C (XP8CA) dermal fibroblasts 
following retroviral transduction of \|/CRIP-pBABE-neo-hTERT. Representative 
photomicrographs of polyclonal populations of primary XP-C dermal Fibroblasts infected 
with an empty pBABE-neo control vector at (A) PD 24 & (B) PD 31.25, or (C) \j/CRIP- 
pBABE-neo-hTERT (PD 62.5), or monoclonal populations (D) clone 16 (PD 68), (E) 
clone 19 (PD 73.5), (F) clone 30 (PD 74.5) infected with \|/CRIP-pBABE-neo-hTERT. Bar 
= 100 pm.
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Figure 4.9. Morphological appearance of primary CS-A (CS3BE) dermal fibroblasts following 
retroviral transduction of yCRIP-pBABE-neo-hTERT. Representative photomicrographs of 
polyclonal populations of primary CS-A dermal fibroblasts infected with (A) an empty pBABE- 
neo control vector (PD 0.5), or (B) \jrCRIP-pBABE-neo-hTERT (PD 11), or monoclonal 
populations, (C) clone 2 (PD 49), (D) clone 3 (PD 45.5), (E) clone 8 (PD 38.5) infected with 
yCRIP-pBABE-neo-hTERT. Bar = 100 pm.
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4.4.4 Retained basal and induciblep53/p21WAF1/CIP1 tumour 
suppressor function in hTERT-immortalised XP-C and 
CS-A human dermal fibroblasts
In addition to extended proliferative capacity, a further reason for the 
establishment of telomerase-immortalised XP-C and CS-A cell lines was the 
preservation of functional p53/p21WAF1/CIP1mediated responses to DNA damage. 
Therefore, constitutive levels and the kinetics of UVC-induced, time-dependent 
accumulation of p53 and p2 iWAF1/CIP1 protein was characterised in monoclonal 
populations of telomerase-immortalised XP-C (clone 19) and CS-A (clone 3) 
fibroblasts (transduced with hTERT) by W estern blotting and 
immunocytochemical analysis. p53 expression was detected using an N-terminus 
antibody (DO-1), which binds to an epitope that targets amino acids 21-25. The 
basal level of p53 protein expression was determined over a 24 hour time-course 
at the indicated time points, via time-matched (non-irradiated) controls, 
examined in parallel to the UV-treated samples (at the indicated time points). As 
a control, p53 status was also characterised in telomerase-immortalised normal 
MRC-5 fibroblasts, which were previously established in our laboratory.
Basal levels of p53 protein expression in hTERT-immortalised normal MRC-5 
and DNA repair-detective XP-C and CS-A fibroblasts remained constant 
throughout the time course and displayed minimal fluctuation between the time 
points following mock-irradiation (Figs. 4.10A-C). As expected, the level of p53 
protein in telomerised MRC-5, XP-C and CS-A fibroblasts remained unchanged 
at 0 hours after UV (Figs. 4.10A-C), compared to their time-matched (0 hour) 
non-irradiated control. In contrast, p53 induction was observed at 6 hours in 
hTERT-immortalised MRC-5, XP-C and CS-A fibroblasts following a UVC 
dose of 10 J/m2 (Fig. 4.10A-C). The high level of p53 protein was sustained 
throughout the time course and no further increase in p53 protein was observed 
at -12 and -24 hours in the MRC-5, XP-C or CS-A cells after UV (Figs. 4.10A- 
C).
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Following DNA damage, cells elicit a multiplicity of cellular responses through 
the posttranslational modification and stabilisation of the p53 protein. In 
particular, phosphorylation of p53 at Seri 5, located at the N-terminus, is a well- 
characterised posttranslational target, following UV exposure. To verify the 
preservation of p53 posttranslational modifications in response to UV, following 
the ectopic expression of hTERT, p53(Serl5) phosphorylation was evaluated by 
Western blot analysis, using a phospho-specific antibody.
Similarly to p53 accumulation, phosphorylation of p53 at Seri5 occurred in a 
time-dependent manner after treatment with UV (10 J/m2). As expected, 
phosphorylation of p53 at Ser 15 was not observed in the time-matched, non- 
irradiated hTERT-immortalised MRC-5, or XP-C fibroblasts (Figs. 4.11A & B, 
respectively). However, the phosphorylation of p53 at Seri 5 was observed in the 
time-matched, non-irradiated hTERT-immortalised CS-A fibroblasts (Fig. 
4.11C). The phosphorylation of p53 at Seri 5 reached a peak at -6  hours, which 
subsequently decreased at -12  and -24  hours, following mock-irradiation (Fig. 
4.11C).
As expected, phosphorylation at Seri 5 was not detected in WCE prepared from 
telomerised MRC-5, XP-C and CS-A cells immediately after (0 hours) UV (Figs. 
4.11A-C). Unlike the accumulation of p53 protein, the kinetics of p53 
stabilisation at Ser 15 occurred in a genotype-specific manner. Phosphorylation of 
p53 at Seri5 was observed in hTERT-immortalised MRC-5 fibroblasts at ~6 
hours following UV treatment. The level of phosphorylation at Seri 5 peaked at 
-12 hours after UV-irradiation and was not detected at -24  hours following UV- 
irradiation (Fig. 4.11 A). In contrast, phosphorylation of p53 at Seri 5 paralleled 
p53 accumulation in hTERT-immortalised XP-C fibroblasts in response to UV- 
irradiation (Fig. 4.1 IB). Similarly to p53 accumulation, phosphorylation of p53 
at Seri5 was detected at - 6  hours. The level of phosphorylation at Seri5 
remained elevated at -1 2  hours and reached a peak at -2 4  hours after UV. 
Similarly, phosphorylation of p53 at S eri5 in hTERT-immortalised CS-A 
fibroblasts was observed at -6  hours following UV-irradiation (Fig. 4.11C). Like 
p53 accumulation, phosphorylation at Seri 5 remained elevated at -12 and -24
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hours after UV. However, further increases in phosphorylation at Seri5 were not 
observed. These data indicate that the posttranslational modification at Seri 5, 
which facilitate the stabilisation of p53, has remained intact following the ectopic 
expression of hTERT.
Posttranslational modifications of p53, such as phosphorylation at Seri5, permit 
p53 to function as a transcription factor and regulate the transcriptional activation 
of downstream target genes. For example, p53-dependent cell cycle arrest at Gi 
is partly regulated by the transcriptional activation of the downstream CDK 
inhibitor, p21WAF1/CIP1, thus p 2 iWAF1/CIP1 activity can be used as an indirect 
functional marker of p53. Therefore, the kinetics of p 2 iWAF1/CIP1 accumulation 
was monitored over a 24 hour time course in response to UV, to further confirm 
normal p53 functionality.
Western blot analysis revealed that the level of p 2 iWAF1/CIP1 protein remained at 
basal levels in the time-matched, non-irradiated MRC-5 fibroblasts throughout 
the time course (Fig. 4.12A). Conversely, a fluctuation in p2 iWAF1/CIP1 expression 
was observed in both the time-matched, non-irradiated XP-C and CS-A 
fibroblasts. In XP-C cells, high levels of p2 iWAF1/CIP1 expression were observed 
at 0 and ~6 hours (Fig. 4.12B). Similarly, elevated levels of p 2 iWAF1/CIP1 were 
also detected in CS-A cells at 0 and -6  hours (Fig. 4.12C). Following UV- 
irradiation, similar analysis revealed a gradual increase in p 2 lWAF1/CIP1 
accumulation in hTERT-immortalised MRC-5 fibroblasts. p 2 iWAF1/CIP1 protein 
expression was induced at -6  hours, and further increases were observed at both 
-12 and -24  hours following irradiation (Fig. 4.12A). In contrast, p 2 iWAF1/CIP1 
induction reached a peak at -6  hours in XP-C cells, while further increases in 
p21WAF1/CIP1 protein levels were not observed at -12  and -24  hours. Like XP-C 
cells, induction of p 2 lWAF1/CIP1 was observed at - 6  hours in CS-A cells, 
following UV. Moreover, further increases in p 2 iWAF1/CIP1 expression were 
observed at -12  and -24  hours, where p2 iWAF1/CIP1 levels appeared to peak at 
-24  hours (Fig. 4.12C). The data presented here, show that p 2 lWAF1/CIP1 
accumulation correlated with both p53 accumulation and phosphorylation at 
Seri5 in the hTERT-immortalised XP-C and CS-A fibroblasts following UV.
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Interestingly, although p 2 iWAF1/CIP1 protein levels corresponded to the 
accumulation of p53 in hTERT-immortalised MRC-5 fibroblasts, a concomitant 
increase in p53 phosphorylation at Seri 5 was not observed. Accordingly, these 
data suggest that the transcriptional activation of downstream target genes by 
p53, such as CDKN1A, is preserved following the ectopic expression of hTERT 
in MRC-5, XP-C and CS-A fibroblasts.
In concordance with the Western blot data (Figs. 4.12A-C), the p 2 iWAF1/CIP1 
protein levels, detected by immunocytochemistry, recapitulated the UV-induced 
time-dependent accumulation of p2 iWAF1/CIP1 (Figs. 4.13-15) that was observed 
in hTERT-immortalised MRC-5, XP-C and CS-A fibroblasts. However, due to 
the heterogeneous nature of p2 lWAF1/CIP1 staining, the images presented here 
(Figs. 4.13-15), are not necessarily a precise representation of the percentage 
counts of p2 iWAF1/CIP1 positive cells (obtained following immunocytochemical 
analysis; n=500 cells counted/coverslip).
In hTERT-immortalised MRC-5 cells, p2iWAF1/CIP1 expression remained at basal 
levels in the time-matched, mock-irradiated controls at all time points. The level 
of p2 iWAF1/CIP1 was between 20-24% at 0, ~6, ~12 and -24  hours (Figs. 4.13A, 
C, E & G, respectively). As expected, the level of p 2 iWAF1/CIP1 remained at basal 
levels immediately (0 hours) following UV (Fig. 4.13B). In stark contrast, a 
marked induction in p 2 iWAF1/CIP1 expression was observed at 6 hours post UV, 
with 37% of MRC-5 cells staining positive for p 2 iWAF1/CIP1 (Fig. 4.13D). This 
was indicated by the visualisation of a brown peroxidase reaction product. 
Dramatic increases of 70% and 81% were observed at -1 2  and -2 4  hours, 
respectively, after UV treatment (Figs. 4.13F & H, respectively). 
Immunocytochemical analysis resulted in the detection of p 2 iWAF1/CIP1 protein at 
0 and -6  hours in the hTERT-immortalised XP-C fibroblasts after mock- 
treatment, with 24% and 25% of cells staining positive for p 2 iWAF1/CIP1 (Figs. 
4.14A & C, respectively). This was followed by a reduction in p 2 lWAF1/CIP1 
levels at -12  and -24  hours, with 12% and 6%, respectively, staining positive 
(Figs. 4.14E & G). The higher levels of p2 iWAF1/CIP1 detected at 0 and -6  hours 
in the non-irradiated controls were comparable to the levels observed by Western
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blot analysis (Fig. 4.12B). A small increase in p 2 iWAF1/CIP1 was observed at ~6 
hours after UV, with 27% of cells staining positive for p 2 iWAF1/CIP1 (Fig. 4.14D). 
A marked increase was observed at -12 and ~24 hours after UV treatment with 
40% and 51%, respectively, of XP-C cells staining positive for p2 iWAF1/CIP1 
(Figs. 4.14F & H, respectively).
Interestingly, like XP-C, hTERT-immortalised CS-A fibroblasts exhibited a 
marked level o f p 2 lWAF1/CIP1 staining in the time-matched non-irradiated 
controls. Approximately 21% and 39% of hTERT-immortalised CS-A fibroblasts 
were immunopositive for p2 iWAF1/CIP1 staining at 0 and -6  hours respectively, 
after mock-irradiation (Figs. 4.15A & C). In contrast, 13% and 14% of CS-A 
cells were immunopositive for p 2 iWAF1/CIP1 staining at -1 2  and -2 4  hours, 
respectively, after mock-irradiation (Figs. 4.15E & G). As expected, a marked 
increase in p 2 iWAF1/CIP1 staining was not observed at 0 hours (30%) after UV 
(Fig. 4.15B). No notable increase in p 2 iWAF1/CIP1 protein expression was 
observed at -6  hours after UV with only 34% of CS-A cells staining positive for 
21wafi/cipi (Fig 4 . i 5 D). At -12  hours and -24  hours after UV, p21WAF1/CIP1 
staining dramatically increased with -48%  and -64%  of CS-A cells 
immunopositive for p21WAF1/CIP1 (Figs. 4.15F & H).
In summary, the data presented here suggest that there was a time-dependent 
decrease in p2 iWAF1/CIP1 expression in the hTERT-immortalised XP-C and CS-A 
cells, following mock-irradiation. Moreover, induction of p53, p2 lWAF1/CIP1 and 
phosphorylation of p53 at Seri5 occurred in hTERT-immortalised MRC-5, XP-C 
and CS-A fibroblasts, in a time-dependent manner following 10 J/m2 of UVC. 
Although the accumulation of p53 was comparable between the cell lines, the 
phosphorylation of p53 at Seri 5 occurred in a genotype-specific manner and was 
more apparent in the hTERT-immortalised XP-C and CS-A cells, compared to 
the MRC-5 fibroblasts. Interestingly, Western blot analysis suggested that 
p21WAF1/CIP1 accumulation was higher in the XP-C and CS-A cells, compared to 
the normal MRC-5 fibroblasts. However, immunocytochemical analysis 
suggested that higher p2 iWAF1/CIP1 levels were observed in MRC-5 fibroblasts.
219
A
Tim e point (hr): 0 6 12 24
UVC (10 J/m 2): -
UVC (10 J/m 2): + + + +
Tim e po in t (hr): 0 6 12 24
UVC (10 J/m 2): -
— ------------- —
UVC (10 J/m 2): + + + +
Tim e poin t (hr): 
UVC (10 J/m 2):
UVC (10 J/m 2):
12 24
Figure 4.10. Western blot analysis of UVC-induced time-dependent 
induction of p53 protein, using an anti-p53 (DO-1) mouse monoclonal 
antibody (1:1000). Time course of p53 induction following mock- 
irradiation (-) or exposure to 10 J/m2 (+) UVC in hTERT-immortalised 
(A) MRC-5, (B) XP-C (GM02996, XP8CA) and (C) CS-A (GM01856, 
CS3BE) fibroblasts (20 pg of WCE per lane).
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Figure 4.11. Western blot analysis of UVC-induced time-dependent 
phosphorylation of p53 on Serl5, using an anti-p53 (Serl5) mouse monoclonal 
antibody (1:1000). Time couse of p53 phosphorylation at Ser 15 following 
mock-irradiation (-) or exposure to 10 J/m2 (+) UVC in hTERT-immortalised 
(A) MRC-5, (B) XP-C (GM02996, XP8CA) and (C) CS-A (GM01856, CS3BE) 
fibroblasts (20 pg of WCE per lane). Equal protein loading was confirmed by 
India ink staining (lower panel o f each blot).
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Figure 4.12. Western blot analysis of UVC-induced, time-dependent 
induction of p21WAF1/api protein, using an anti-p21 mouse monoclonal 
antibody (1:250). Time couse of p21WAFl/CIPl induction following mock- 
irradiation (-) or exposure to 10 J/m2 (+) UVC in hTERT-immortalised (A) 
MRC-5, (B) XP-C (GM02996, XP8CA) and (C) CS-A (GM01856, CS3BE) 
fibroblasts (20 pg of WCE per lane).
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Figure 4.13. Time-dependent induction of p21WAF1/CIP1 in hTERT-immortalised 
MRC-5 human lung fibroblasts in response to UVC-irradiation (10 J/m2) or mock- 
irradiated (0 J/m2), measured by ICC analysis, using a p21-specific antibody. Time 
course of p21WAF1/CIP1 induction at (A) 0 hours, 0 J/m2, (B) 0 hours, 10 J/m2, (C) 
6 hours, 0 J/m2, (D) 6 hours, 10 J/m2, (E) 12 hours, 0 J/m2, (F) 12 hours, 10 J/m2, 
(G) 24 hours, 0 J/m2, (H) 24 hours, 10 J/m2. Positivity indicated by a brown 
peroxidase reaction product. Nuclei were counterstained with haematoxylin to aid 
visualisation. B ar= 100 pm.
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Figure 4.14. Time-dependent induction of p21WAFl/CIP1 in hTERT-immortalised 
XP-C (GM02996, XP8CA) human dermal fibroblasts in response to UVC- 
irradiation (10 J/m2) or mock-irradiated (0 J/m2), measured by ICC analysis, using 
a p21-specific antibody. Time course of p21WAF1/CIP1 induction at (A) 0 hours, 0 
J/m2, (B) 0 hours, 10 J/m2, (C) 6 hours, 0 J/m2, (D) 6 hours, 10 J/m2, (E) 12 hours, 
0 J/m2, (F) 12 hours, 10 J/m2, (G) 24 hours, 0 J/m2, (H) 24 hours, 10 J/m2. 
Positivity indicated by a brown peroxidase reaction product. Nuclei were 
counterstained with haematoxylin to aid visualisation. Bar = 100 pm.
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Figure 4.15. Time-dependent induction of p21WAF1/api in hTERT-immortalised 
CS-A (GM01856, CS3BE) human dermal fibroblasts in response to UVC- 
irradiation (10 J/m2) or mock-irradiated (0 J/m2), measured by ICC analysis, using 
a p21 -specific antibody. Time course of p21WAF1/CIP1 induction at (A) 0 hours, 0 
J/m2, (B) 0 hours, 10 J/m2, (C) 6 hours, 0 J/m2, (D) 6 hours, 10 J/m2, (E) 12 hours, 
0 J/m2, (F) 12 hours, 10 J/m2, (G) 24 hours, 0 J/m2, (H) 24 hours, 10 J/m2. 
Positivity indicated by a brown peroxidase reaction product. Nuclei were 
counterstained with haematoxylin to aid visualisation. Bar = 100 pm (except A = 
200 pm).
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4.4.5 Retained pRb/pl6INK4A function in hTERT- 
immortalised XP-C and CS-A human dermal fibroblasts
In addition to extended proliferative capacity, a further reason for the 
establishment of telomerase-immortalised XP-C and CS-A cell lines was the 
preservation of pRb/pl6INK4A tumour suppressor activity. In order to establish 
whether constitutive and induced pRb protein expression was intact, Western 
blot analysis was performed using an anti-Rb-specific antibody that facilitated 
the detection of both the active hypophosphorylated form of Rb (pRb) and the 
inactive hyperphosphorylated form of Rb (ppRb). The preservation of 
constitutive and induced p i6 ^ ^  protein expression was also confirmed by 
Western blot analysis.
Western blot analysis, using the Rb-specific antibody, resulted in the detection of 
Rb that migrated as multiple bands between -110-116 kDa, consistent with 
different Rb phosphorylation states. Both pRb and ppRb forms of Rb protein was 
observed at 0, -6 , -1 2  and -24  hours in the time-matched, non-irradiated 
hTERT-immortalised MRC-5 fibroblasts (Fig. 4.16A). The lower band, 
indicative of pRb, appeared more intense than the upper band. The notable 
increase in pRb compared to ppRb that was observed in telomerised MRC-5 
fibroblasts may have been attributed to cell confluency, resulting in exit from the 
cell cycle. Conversely, the level of ppRb was higher than the level of pRb in the 
time-matched, non-irradiated hTERT-immortalised XP-C fibroblasts (Fig. 
4.16B). Similarly, a marked increase in ppRb was observed in the time-matched, 
non-irradiated hTERT-immortalised CS-A fibroblasts, while the level of pRb 
remained at low levels (Fig. 4. 16C). The increased ppRb/pRb ratio observed in 
telomerised XP-C and CS-A fibroblasts corresponded to a concomitant reduction 
in the cyclin-dependent kinase inhibitor, p21WAF1/CIP1, which occurred at -12 and 
-2 4  hours (Fig. 4.12B & C). The reduced p 2 iWAF1/CIP1 expression and the 
increased level of ppRb observed in this study suggest that both the telomerised 
XP-C and CS-A fibroblasts were progressing through the Gi to S cell cycle 
transition.
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pRb and ppRb remained unchanged in telomerised MRC-5 fibroblasts at 0 hours 
following UV (Fig. 4.16A), compared to the levels observed in the time- 
matched, non-irradiated telomerised MRC-5 cells. A slight reduction in both pRb 
and ppRb was observed at -6  and ~12 hours following UV, compared to the 
levels of pRb and ppRb observed at 0 hours (Fig. 4.16A). However, it is possible 
that this reduction was attributed to a slight reduction in the amount of protein 
present within the sample, as a reduction in band intensity was observed at -6  
hours following India ink staining (Fig. 4.16A, lower panel). Although slight 
differences in protein levels were observed, a reduction in the levels of pRb and 
ppRb at -6  and -12  hours after UV was also observed compared to the time- 
matched, non-irradiated controls. Although the ratio between pRb and ppRb 
remained similar, a concomitant increase was observed in both pRb and ppRb at 
-24  hours post UV, compared to the levels observed at - 6  and -12  hours 
following UV. However, the levels of both pRb and ppRb at -24 hours after UV, 
appeared similar to those observed at -24 hours, following mock-irradiation. The 
reduction in inactive hyperphosphorylated Rb at -6  and -12 hours, suggested 
that the MRC-5 cells entered a state of growth arrest at Gi after UV. However, 
the subsequent accumulation of inactive ppRb at -24 hours indicated that MRC- 
5 cells were committed to cell cycle progression, thereby completing the 
transition from the Gi checkpoint arrest to S-phase.
A marked reduction in both pRb and ppRb was observed in hTERT-immortalised 
XP-C fibroblasts after UV, compared to the time-matched non-irradiated controls 
(Fig. 4.16B). Furthermore, telomerised XP-C fibroblasts exhibited a gradual 
reduction in the level of ppRb following UV (Fig. 4.16B), compared to the level 
of pRb, which remained unchanged. Similarly, the level pRb and ppRb was 
lower in irradiated telomerised CS-A fibroblasts, compared to the levels 
observed in the time-matched non-irradiated controls (Fig. 4.16C). Like XP-C 
fibroblasts, CS-A cells displayed a reduction in the level of ppRb at -6 , -12 and 
-24  hours after UV, compared to the time-matched non-irradiated controls. 
Interestingly, a marked reduction in both pRb and ppRb was observed at -24 
hours in telomerised CS-A cells after UV, compared to that observed at 0, -6  and 
-12 hours following UV, and the time-matched non-irradiated samples (Fig.
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4.16C). The data presented here suggested that, Rb remained in an active 
dephosphorylated state in telomerised XP-C and CS-A fibroblasts following UV, 
thereby resulting in delayed Gi/S cell cycle progression.
p lb^K ^ protejn ieveis remained unchanged throughout the time course in non- 
irradiated hTERT-immortalised MRC-5 fibroblasts (Fig. 4.17A). Although 
p 16INK4A protein levels appeared unchanged in MRC-5 cells at 0 hours following 
UV-irradiation (Fig. 4.17A), a slight increase was observed at -6  and -12 hours. 
Moreover, the level of p i6 ^ ^  appeared to peak at -2 4  hours, as a further 
increase was observed at -2 4  hours post UV. Similarly, the constitutive 
expression of p l6 INK4A remained constant throughout the time course in non- 
irradiated hTERT-immortalised XP-C fibroblasts (Fig. 4.17B). In contrast, a 
progressive reduction in p i6 ^ ^  expression was observed at -12 and -24 hours 
in the time-matched, UV-irradiated hTERT-immortalised XP-C fibroblasts (Fig. 
4.17B). p i6 INK4A levels remained unchanged in mock-irradiated hTERT- 
immortalised CS-A fibroblasts and following UV at all time points (Fig. 4.17C). 
Collectively, the data presented herein, suggested that although constitutive 
p i6 ^ ^  protein expression was observed in all telomerised cell lines following 
the ectopic expression of hTERT, a UV-induced induction of p i6 ^ ^  was 
limited to telomerised MRC-5 fibroblasts.
In summary, these data suggest that the elevated level of pRb, observed in non- 
irradiated MRC-5 fibroblasts was indicative of a Gi/S phase cell cycle arrest. 
UV-irradiation appeared to affect the pRb/ppRb ratio in telomerised XP-C and 
CS-A cells, as a reduction in ppRb was observed in both cell lines following UV. 
This suggested that both XP-C and CS-A cells entered a state of cell cycle arrest 
following UV. The levels of p i6 ° * ^  remained at basal levels in the non- 
irradiated controls. Interestingly, although an increase in the level of p i6 ^ ^  
was observed in telomerised MRC-5 fibroblasts after UV, similar increases were 
not observed in both telomerised XP-C and CS-A fibroblasts. This suggested that 
p l6 INK4A was not UV inducible in both telomerised XP-C (GGR-defective) and 
CS-A (TCR-defective) cell lines.
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Figure 4.16. Western blot analysis of pRb following UV-irradiation, using an anti- 
pRb mouse monoclonal antibody (1:250). Time couse of pRb induction following 
mock-irradiation (-) or exposure to 10 J/m2 (+) UVC in hTERT-immortalised (A) 
MRC-5, (B) XP-C (GM02996, XP8CA) and (C) CS-A (GM01856, CS3BE) 
fibroblasts (20 |ig of WCE per lane). Equal protein loading was confirmed by 
India ink staining (lower panel o f each blot). Abbreviations: pRb, 
hypophosphorylated Rb (lower band); ppRb, hyperphosphorylated (upper band).
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Figure 4.17. Western blot analysis of p l t jP * ^  following UVC-irradiation, 
using an anti-pl6 mouse monoclonal antibody (1:40). Time couse of 
p l^ N K ^  expression following mock-irradiation (-) or exposure to 10 J/m2 
(+) UVC in hTERT-immortalised (A) MRC-5, (B) XP-C (GM02996, 
XP8CA) and (C) CS-A (GM01856, CS3BE) fibroblasts (20 pg of WCE per 
lane).
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4.4.6 Survival curves of SV40-transformed fibroblasts 
following UV- irradiation
To establish whether there was a notable difference between the colony forming 
ability of asynchronous cultures of normal or repair-defective human fibroblasts, 
immortalised by either the SV40 LTAg or through the ectopic expression of 
hTERT, UV survival was determined. Cells were plated at densities that resulted 
in the production of colonies derived from single cells. The dishes were UVC- 
irradiated in increments of 2 J/m2 from 0 to 10 J/m2 and the number of surviving 
cells was determined by scoring colony formation. As a control, preliminary 
survival curves were constructed, using normal isogenic MRC-5 fibroblasts 
transformed with SV40 LTAg or immortalised with hTERT. In addition, colony 
forming ability assays were performed on isogenic SV40-transformed XP-A 
(GM04429, XP12BE) and CS-A (GM16094, CS3BE.s3gl) fibroblasts.
Survival of cell lines was UV dose-dependent. As expected, the SV40 LTAg 
transformed XP-A fibroblasts was the most sensitive cell line with a LD50 of 0.8 
J/m2 (Fig. 4.18). In contrast, the SV40 LTAg transformed CS-A fibroblasts 
displayed an intermediate sensitivity to UV, compared to XP-A and MRC-5 
fibroblasts, with an LD50 of 2 J/m2 (Fig. 4.18). Interestingly, although both the 
isogenic MRC-5 fibroblasts immortalised with SV40 LTAg or hTERT, produced 
survival curves typical of NER proficient cells, a modest but notable difference 
was observed between the two MRC-5 cultures, with an LD50 of 6.3 and 4.9 
J/m , respectively (Fig. 4.18). Attempts were made to construct survival curves 
using a similar approach for the primary XP-C (XP8CA) and CS-A (CS3BE) 
fibroblasts transduced with pBABE-neo-hTERT (clones 19 and 3, respectively). 
Additionally, a monoclonal population of primary isogenic XP-A (XP12BE) 
fibroblasts (clone 13), which were previously transduced with pBABE-neo- 
hTERT in the laboratory and made available, was included as a control. 
Surprisingly, survival data was not obtained for the hTERT-immortalised XP-C, 
CS-A or XP-A dermal fibroblasts. During incubation after UV, the cells 
appeared to migrate across the dish and were unable to form distinct scorable 
colonies.
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Although colony formation is frequently used to assess cell survival, these assays 
also give an indication on the NER capacity of in vitro cell cultures. Therefore, 
due to the absence of colony formation obtained for the hTERT-immortalised 
cell lines, an alternative repair assay was adopted based on an immuno-slot-blot 
methodology, which used CPD- and 6-4PP-specific antibodies (Section 4.4.7).
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Figure 4.18. Survival after exposure to UVC (254 nm) radiation of the hTERT- 
immortalised repair-proficient and SV40-transformed repair-proficient and DNA 
repair-defective cell lines. hTERT-immortalised MRC-5 lung fibroblasts (closed 
square); SV40-transformed MRC-5 lung fibroblasts (closed circle); SV40- 
transformed XP-A (XP12BE) dermal fibroblasts (open circle); SV40-transformed 
CKN1 (CS-A) dermal fibroblasts (closed triangle). Points represent an average of 
three independent biological replicates and triplicate dishes were performed for each 
biological replicate. Bars represent standard error of the mean.
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4.4.7 Global repair of CPDs and 6-4PPs in hTERT- 
immortalised XP-C and CS-A dermal fibroblasts
To investigate whether the removal of UV-induced lesions from the global 
genome was affected by the ectopic expression of hTERT, immunological slot 
blot assays were undertaken. This assay measures the removal of CPDs or 6- 
4PPs from genomic DNA, using specific monoclonal antibodies raised against 
these photolesions (Mori et al., 1991). Cells were irradiated with UV-C (10 J/m2) 
and genomic DNA was isolated immediately after treatment (0 hours) or -6, -12 
and -24 hours post UV. The band intensity measured at 0 hours was defined as 
100% lesions for each cell line, and the lesions removed at each time point (at 
-6 , -12  and -24  hours) was calculated as a percentage of lesions present 
immediately (0 hours) after UV.
Figures 4.19A and B show representative slot blots of the kinetics of the removal 
of 6-4PPs (Fig. 4.19A) and CPDs (Fig. 4.19B) in the global genome in hTERT- 
immortalised MRC-5 (wild-type) and repair-defective XP-C and CS-A 
fibroblasts at the indicated time points after UV (10 J/m2). As expected, only 
-49.8% of CPDs were removed from the overall genome by MRC-5 cells at -6  
hours, and a modest but notable removal of 62.6% and 73.1% was observed at 
-12  and -24  hours after UV (Fig. 4.20). hTERT-immortalised CS-A (CKN) 
fibroblasts, which are defective in TCR, displayed similar levels of CPD removal 
to the MRC-5 cells. The CS-A cells exhibited a slightly higher (55.6%) level of 
CPD removal at -6  hours compared to the MRC-5 cells (Fig. 4.20). However, 
the removal of CPDs at -12  hours (58.5%) and -2 4  hours (74.1%) closely 
resembled the levels observed in MRC-5 cells (Fig. 4.20). In contrast, there was 
a marked reduction in the removal of CPDs in hTERT-immortalised XP-C cells, 
compared to the MRC-5 and CS-A cells. Only 26% and 31.9% of CPDs were 
removed from the overall genome by XP-C cells at - 6  and -12  hours, 
respectively, after UV. Moreover, XP-C cells displayed a protracted half-life of 
-24 hours for the removal of CPDs (Fig. 4.20).
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Immunological slot-blot analysis revealed that both hTERT-immortalised MRC- 
5 and CS-A fibroblasts removed 6-4PPs from the global genome with 
comparable levels of efficiency (Fig. 4.20). At ~6 hours after UV treatment, both 
cell lines had removed almost all 6-4PPs. In contrast, hTERT-immortalised XP-C 
fibroblasts demonstrated a marked (3-4 fold) reduction in the removal of 6-4PPs. 
At 6 hours, only 21.5% of 6-4PPs were removed, while only 33.4% of 6-4PPs 
were removed at ~12 hours and 46% of 6-4PPs were removed at ~24 hours post 
UV (Fig. 4.20).
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Figure 4.19. Kinetics of the removal of 6-4PPs and CPDs from the overall genome in esablished 
hTERT-immortalised cell lines (MRC-5, XP-C (GM02996, XP8CA), CS-A (GM01856, CS3BE) 
and hTERT-immortalised CS-A dermal Fibroblasts infected with a pRETROSUPER retroviral 
vector expressing an XPC-specific shRNA construct) irradiated with UV-C (254 nm; 10 J/m2). 
Representative immuno-slot-blots of the removal of (A) [6-4] photoproducts or (B) CPDs, using 
monoclonal [6-4] photoproduct- and CPD-specific antibodies, respectively. Immuno-slot-blot 
assays were undertaken using 500 ng or 1000 ng of genomic DNA isolated at the indicated time 
points, following exposure of cells to UV.
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Figure 4.20. Time-course of removal of CPDs or 6-4PPs from the overall genome in 
hTERT-immortalised (MRC-5, XP-C (GM02996, XP8CA) and CKN (CS-A; 
GM01856, CS3BE)) cell lines irradiated with UV-C (254 nm; 10 J/m2). Removal of 
CPDs or 6-4PPs was measured at 6 hrs (purple), 12 hrs (yellow) or 24 hrs (blue) 
following UV treatment, using monoclonal CPD- or 6-4PP-specific antibodies, 
respectively. Immuno-slot-blot assays were undertaken using 1000 ng of genomic 
DNA isolated at each time point. Each point represents the mean of three 
independent biological replicates.
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4.5 Discussion
The present investigation demonstrated, for the first time, that the ectopic 
expression of the catalytic subunit of telomerase, hTERT, in primary XP-C 
(GM02996, XP8CA) and CS-A (GM01856, CS3BE) human fibroblasts, resulted 
in reconstituted telomerase activity and a significant extension on proliferative 
lifespan O100 PDs). This was not observed in primary XP-C and CS-A 
fibroblasts infected with an empty pBABE-neo vector. Hence, the ectopic 
expression of telomerase circumvented the onset of telomere-dependent 
replicative senescence in these primary cells. These data corroborated with 
Oullettee et al. (2000), who demonstrated the reconstitution of telomerase 
activity and extended proliferative lifespan in primary fibroblasts derived from 
XP-E and XP-V individuals, following the ectopic expression of hTERT.
Although the ectopic expression of hTERT in primary CS-A (GM01856, 
CS3BE) fibroblasts resulted in the reconstitution of telomerase activity and an 
extension on proliferative lifespan, a slower growth rate was observed in clone 8 
at ~30 PDs. The slow growth rate observed in telomerase-immortalised CS-A 
cells (compared to XP-C cells) reflected the reduced growth rate displayed by 
their primary isogenic counterpart prior to the transduction of hTERT (data not 
shown). Furthermore, the slower growth rate was not simply due to clonal 
variability, as the three telomerase-immortalised CS-A clones exhibited a slower 
growth rate compared to telomerase-immortalised MRC-5 (data not shown) and 
XP-C cell lines. From these data, it can be speculated that cell lines established 
by telomerase-mediated immortalisation reflect the growth kinetics displayed by 
their primary isogenic counterpart, prior to the onset of replicative senescence. 
Interestingly, however, MacKenzie et al. (2000) showed that while telomerase 
reconstitution extended cellular lifespan, telomerase-immortalised cells become 
unstable after prolonged periods of culture and undergo crisis as early as 36 PDs 
after hTERT transduction. They speculated that, although hTERT expression 
extends prolifarative capacity, immortality is not the universal outcome of 
hTERT expression. Interestingly, Gorbunova et al. (2003) reported the isolation 
of telomerase-immortalised fibroblast populations that contained 3-20% of cells
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with a senescent morphology. Further analysis revealed that these subpopulations 
exhibited elevated basal levels of p2 iWAF1/CIP1 and pRb. These authors also 
showed that telomerase activity in these populations was significantly elevated, 
thus suggesting overexpression of hTERT provided a hyperproliferative signal 
that induced a senescent-like phenotype. This is thought to provide a protective 
mechanism that prevents uncontrolled cellular proliferation. However, the 
precise mechanism(s), that signal growth arrest and ultimately crisis following 
telomerase-mediated immortalisation remain unknown.
As previously reported in normal fibroblasts (Bodnar et al., 1998; Vaziri & 
Benchimol, 1998), the ectopic expression of hTERT resulted in primary XP-C 
human dermal fibroblasts displaying a morphology typically observed in young 
fibroblasts growing in vitro. In contrast, a sub-population of cells within the 
polyclonal and monoclonal populations of CS-A cells retained a morphological 
appearance typical of senescent dermal fibroblasts in vitro, following telomerase 
reactivation. This was particularly evident in the CS-A (clone 8) monoclonal 
population, where a large subset of fibroblasts displayed morphological features 
typically associated with a senescent phenotype. Similarly, Davis et al. (2006) 
showed that primary WS cells retain a senescent morphology, following ectopic 
expression of hTERT. Although telomere length was not investigated in the 
present study, it was previously shown by terminal restriction fragment (TRF) 
length analysis, that telomerase-mediated immortalisiation of WS cells resulted 
in an extension on telomere length (Wyllie et al., 2000). This suggests that the 
senescent-like phenotype exhibited by both WS and possibly CS-A cells is 
attributed to a telomere-independent stress-induced pathway.
An essential requisite to the establishment of DNA repair-defective XP-C and 
CS-A dermal fibroblast cell lines was the preservation of both the 
p53/p21WAF1/CIP1 and pRb/plb1^ ^  tumour suppressor pathways. According to 
the data presented here and in agreement with previously published findings 
(Jiang et al., 1999; Milyavsky et al., 2003; Morales et al., 1999), the 
reconstitution of telomerase activity through the ectopic expression of hTERT 
did not affect the constitutive expression of p53 in telomerase-immortalised 
fibroblasts. A high basal level of p53 protein was observed in telomerase-
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immortalised normal MRC-5 and NER-defective XP-C and CS-A fibroblasts 
over a period of 24 hours, thus suggesting the preservation of constitutive p53 
expression. However, unlike in previous studies (Milyavsky et al., 2003; Noble 
et al., 2004; van Waarde-Verhagen et al., 2006), the constitutive p53 status was 
not assessed frequently while in culture. Therefore, the high constitutive level of 
p53 observed in this study may have resulted from an artifactual consequence of 
prolonged culture, resulting from the accumulation of endogenous DNA damage 
(such as ROS) caused by normal cellular metabolism (van Waarde-Verhagen et 
al, 2006), rather than a true reflection of p53 status. Several conflicting studies 
have shown that p53 status during the in vitro proliferative lifespan of 
telomerase-immortalised cells is significantly more complex (Noble et al., 2004; 
Milyavsky et al., 2003; Waarde-Verhagen et al., 2006). Numerous studies have 
shown that the prolonged culture of normal hTERT-immortalised fibroblasts has 
no effect on basal or UV-induced expression of p53 (Jiang et a l, 1999; 
Milyavsky et al., 2003; Morales et al., 1999; Porter et al., 2006), but other 
investigators have reported that prolonged culture (>100 PDs) of telomerase- 
immortalised cells results in an increase in the constitutive expression of p53 
(Kampinga et al., 2004; Noble et al., 2004; van Waarde-Verhagen et al., 2006). 
Overexpression of p53 has been attributed to mutations in the TP 5 3 gene locus, 
rendering the gene inactive, thus resulting in complete loss of wild-type p53 
activity. This is frequently observed in many human cancers (Lane & Benchimol, 
1990; Soussi & Lozano, 2005). In support of these findings, Noble et al. (2004) 
reported the presence of mutations in the TP53 gene in telomerase-immortalised 
human foreskin fibroblasts, which are also frequently reported in numerous 
tumours (Olivier et al., 2002).
Although many studies have confirmed the preservation of constitutive p53 
expression following telomerase-mediated immortalisation, few have reported 
the maintenance of a DNA damage p53-mediated response, such as that observed 
following UV irradiation (Gorbunova et a l, 2002; Morles et al., 2000; Porter et 
al., 2006). In concordance with Porter et al. (2006), a UVC-induced time- 
dependent accumulation of p53 was observed in MRC-5 telomerase- 
immortalised cells. Moreover, the time-dependent accumulation of p53 was of 
similar magnitude to that observed in telomerase-immortalised XP-C and CS-A
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fibroblasts at the indicated time points over a 24 hour period. In agreement with 
Porter et al. (2006), a UV-dependent induction of p53 was observed in 
telomerase-immortalised cells as early as 6 hours after UV treatment. Therefore, 
the data presented here, suggests that a UV-induced p53-dependent DNA 
damage response remained intact in MRC-5, XP-C and CS-A fibroblasts, 
following telomerase-mediated immortalisation. It has been shown that NER- 
defective XP-A cells in Gi phase require a 10-fold lower UV dose to induce p53 
to the same level as wild-type cells in Gi phase (Ljungman & Zhang, 1996). 
Interestingly, Porter et al. (2006) observed a reduction in p53 and a concomitant 
appearance of morphological features indicative of apoptosis at -36  hours after 
UV. This was not seen during the present study, as p53 levels were monitored for 
up to 24 hours post UV. Although p53 status in response to different doses of 
UV was not addressed in this study, it has been shown that the accumulation of 
p53 in telomerase-immortalised fibroblasts can also occur in a UV dose- 
dependent manner (Porter et al., 2006).
As previously mentioned, the stabilisation and activation of p53 occurs in 
response to UV damage, via a series of posttranslational modifications. For 
example, the phosphorylation of Seri5 at the N-terminus has been a well- 
documented target following UV (Bean & Stark, 2001; Prives, 1998; Shieh et al., 
1997; Webley et al., 2000); and is mediated by the phosphoinositide 3-kinase- 
related superfamily member, ATR kinase (Tibbetts et al., 1999). Phosphorylation 
at Seri 5 is thought to induce a conformational change and disrupt mdm2 
binding, thereby inhibiting the degradation of p53 (Shieh et al., 1997). In this 
study, like p53 accumulation, phosphorylation at S eri5 occurred in a time- 
dependent manner in telomerised MRC-5, XP-C and CS-A fibroblasts after 
exposure to 10 J/m2 of UV. Similarly, Porter et al. (2006) reported the time- 
dependent phosphorylation of p53 at Seri 5 in telomerase-immortalised cells 
following UV. Hence, it appears that the UV-induced stabilization of p53 by 
ATR remained intact. Interestingly, the magnitude of Seri 5 phosphorylation was 
significantly higher in telomerase-immortalised XP-C cells, compared to normal 
MRC-5 and DNA repair-defective CS-A cells. Conversely, Ljungman et al. 
(2001) found that the accumulation of Serl5-modified p53 protein occurred in
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CS cells. They suggested that the accumulation of phosphorylated p53 at Seri 5 
occurred due to a UV-induced inhibition of transcription during RNA Pol II 
elongation.
The stabilisation of p53 facilitates the transcriptional activation of the 
downstream CDK inhibitor, p21WAF1/CIP1, a key regulator of Gi cell cycle arrest. 
Moreover, Bean & Stark (2001) showed that following UV, phosphorylation of 
p53 at Seri 5 is required to maintain basal levels of p 2 iWAF1/CIP1. Therefore, the 
analysis of p 2 iWAF1/CIP1 provided an indirect measure of p53 function. In 
concordance with numerous studies (Farwell et al., 2000; Milyavsky et al., 
2003) the data presented here suggests that p 2 iWAF1/CIP1 remained at low basal 
levels in the telomerase-immortalised normal (MRC-5) fibroblasts during the 
first 100 PDs. In disagreement, other studies revealed significant variations in 
constitutive p 2 lWAF1/CIP1 expression between populations of fibroblasts 
immortalised with hTERT following extended (>100 PDs) growth in culture 
(Kampinga et al., 2004; Noble et al., 2004; van Waarde-Verhagen et al., 2006). 
As previously discussed, Gorbunova et al. (2003) found that 3-20% of 
telomerase-immortalised cells displayed a senescent-like phenotype. This 
subpopulation also exhibited elevated p2iWAF1/CIP1 levels. Unlike MRC-5 cells, 
both telomerised XP-C and CS-A fibroblasts displayed heterogeneous basal 
levels of p21WAF1/CIP1. The variable level of p 2 iWAF1/CIP1 expression in XP-C and 
CS-A cells, during the 24 hour time course, may have been attributed to the 
generation of ROS, which may accumulate in culture due to defective GGR and 
TCR, respectively.
Like p53, the preservation of a UV-induced p 2 iWAF1/CIP1 response, following 
telomerase-mediated immortalisation has remained poorly documented 
(Gorbunova et al., 2002; Morales et al., 1999; Porter et al., 2006). In this study, 
an increase in p 2 iWAF1/CIP1 protein expression was observed in both the 
telomerase-immortalised normal MRC-5 and NER-defective XP-C and CS-A 
fibroblasts after UV. Moreover, in agreement with Porter et al. (2006), 
p21WAF1/CIP1 protein levels correlated with the accumulation of p53 after UV. 
Therefore, the UV-induced phosphorylation of p53 at Seri 5, and accumulation of
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p2 jWAFi/cipi 0bserveci jn ^ is  study, provides evidence that p53 activation and 
stabilisation is preserved following telomerase-mediated immortalisation.
Consistent with these data, previous studies reported an induction of p2lWAF1/CIP1 
in human or mouse primary cells after UV (Itoh et al., 2003; Itoh et al., 2004; 
Itoh & Linn, 2005; Li et al., 1996; Poon et al., 1996). This further supports the 
exploitation of telomerase as a vehicle for establishing permanent cell lines. In 
contrast, however, other investigators reported a reduction in p2 iWAF1/CIP1 protein 
levels following UV (Allan & Fried, 1999; Butz et al., 1998; Maki & Howley, 
1997; Rieber & Strasberg, 2000; Schoenfeld et al., 2000; Wang et al., 1999). 
Moreover, Bendjennat et al. (2003) reported the UV-induced ubiquitin- 
dependent degradation of p2 iWAF1/CIP1. More recently, Itoh & Linn (2005) 
suggested that the marked difference in p2 iWAF1/CIP1 expression was attributed to 
experimental variability. In particular, many of the studies that reported 
significant decreases in p2 iWAF1/CIP1 levels used cancer cell lines (Allan & Fried, 
1999; Butz et al., 1998; Maki & Howley, 1997; Rieber & Strasberg, 2000; 
Schoenfeld et al., 2000; Wang et al., 2000). This further reiterates the importance 
of using nontransformed cell lines, as cell cycle regulation and apoptosis in 
response to DNA damaging agents, such as UV, are disrupted in cancer cell 
lines. Furthermore, the precise mechanistic function of p 2 iWAF1/CIP1 in NER 
remains controversial, as conflicting studies have proposed both inhibitory and 
stimulatory roles in NER (Cooper et al., 1999; Sheikh et al., 1997).
pRb phosphorylation is required for progression through S phase (Buchovitch et 
al., 1989; DeCaprio et al., 1989), and is regulated by the cell cycle proteins 
CDK4, cyclin D and p i6 ^ ^  (Weinberg, 1995). To delineate the consequences 
of telomerase-mediated immortalisation on the pRb/pl6INK4A pathway, both pRb 
and p l6 INK4A protein expression was investigated. The data suggest that, although 
both inactive hyperphosphorylated and active hypophosphorylated forms of Rb 
were observed in telomerised non-irradiated MRC-5 fibroblasts, a slight increase 
in pRb was observed. This is consistent with the high proliferative capacity of 
telomerised MRC-5 fibroblasts, which resulted in the culture reaching 
confluency and the possible exit from the cell cycle. In agreement with these 
data, Jiang et al. (1999) and Morales et al. (1999) showed that the pRb response
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to high cell density remained intact in telomerase-expressing cells. In contrast, 
pRb was predominantly in a hyperphosphorylated state in the non-irradiated 
telomerised XP-C and CS-A fibroblasts at all time points. This was attributed to 
the reduced proliferative capacity observed in both telomerised XP-C and CS-A 
cells lines, compared to the MRC-5 cells. Therefore, it can be speculated the XP- 
C and CS-A cells remained in a subconfluent state throughout the time course, 
thus progressing through the Gi/S phase transition. In agreement with these data, 
Jiang et al. (1999) and Morales et al. (1999) showed that Rb remained in a 
hyperphosphorylated state in subconfluent telomerised cells. Unfortunately, pRb 
status or functionality was not investigated in non-telomerised MRC-5, XP-C or 
CS-A fibroblasts in this study. Therefore, the precise effect of telomerase- 
mediated immortalisation on these cell lines remains unknown. However, from 
previous studies (Jiang et al., 1999; Morales et al., 1999) it can be speculated 
that, telomerase-mediated immoralisation had no affect on the state of pRb in 
telomerised MRC-5, XP-C and CS-A cells. Furthermore, it can be speculated that 
the Gi to S phase transition remained intact. However, further assessment of cell 
proliferation and pRb functionality is required to support this.
After UV, a global reduction in Rb protein levels was seen in telomerised MRC- 
5, XP-C and CS-A cells. However, an increased level of pRb and marked 
reduction in ppRb was observed in both telomerised XP-C and CS-A fibroblasts 
following UV. Therefore, it can be speculated that regulation of the Gi to S phase 
transition, following DNA damage, by the pRb/plb1™*^ pathway remained 
intact. Consistent with previous studies (Jiang et al., 1999; Morales et al., 1999), 
it can be speculated that telomerase-mediated immortalisation does not abolish 
the integrity of the pRb checkpoint. However, further investigation into the 
translational and posttranslational modifications of Gi to S phase regulators that 
lie downstream to pRb, such as E2F target genes that are involved in cell cycle 
progression (including cyclin A, cyclin E, cdc2 and cdk2) is required.
The basal level of p i6 ° ^ ^  remained constant in telomerised MRC-5, XP-C and 
CS-A fibroblasts, over a 24 hour period. In agreement, Jiang et al. (1999) 
showed that telomerised BJ foreskin fibroblasts displayed no alterations in a 
p i6 INK4A response to cell-cycle checkpoint arrest compared with parental non-
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telomerised cells. Unlike previous studies (Milyavsky et al., 2003; Noble et al., 
2004; van Waarde-Verhagen et al., 2006), however, the constitutive expression 
of p l6 INK4A was not addressed during the period of continuous growth in culture 
prior to termination (-100 PDs).
Previously, it was shown that p i6 ^ ^  accumulates in keratinocytes that are 
grown in an inadequate culture environment (Ramirez et al., 2001). This has led 
to the assumption that p i6 ^ ^  is a general mediator of the stress response. In 
agreement, a UV-induced time-dependent upregulation of p 16INK4A was observed 
in telomerised MRC-5 fibroblasts following UV in this study. However, in 
agreement with Gorbunova et al. (2002) a UV-induced up-regulation of p i 6INK4A 
was not observed in telomerised XP-C and CS-A fibroblasts. In disagreement 
with these findings, Wang et al. (1996) showed that p l6 INK4A accumulates 
following UV, and correlates with a late S to G2 phase cell cycle arrest. 
Interestingly, Milligan et al. (1998) reported that melanoma cells that are devoid 
of p l6INK4A activity show no delay in G2 after UV, suggesting that inactivation of 
the pi 6™*^ gene, CDKN2A, causes the abolition of a p lb ^^ -d ep en d en t G2 
cell cycle checkpoint arrest. These findings indicate that the preservation of 
p i6 ^ ^  is important following DNA damage. It is possible that alterations in 
p i6 ^ ^  occurred in the telomerised XP-C and CS-A fibroblast cell lines.
As previous studies have reported the establishment of permanent telomerase- 
immortalised cell lines in the absence of changes in p53/p21WAF1/CIP1 and 
pRb/plb1^ ^  status (Jiang et al., 1999; Morales et al., 1999), it has been 
suggested that the manipulation of these pathways is not required in telomerase- 
mediated immortalisation (Noble et al., 2004). As a result, it has been speculated 
that the emergence of clones with altered tumour suppressor responses, following 
prolonged (>100 PDs) growth (van Waarde-Verhagen et al., 2006; Milyavsky et 
al., 2003), is a stochastic process (van Waarde-Verhagen et al., 2006). Clones 
with altered p53/p21WAF1/CIP1 and/or pRb/pl6INK4A responses are selected during 
continuous growth in vitro. Moreover, the abolition of these pathways increase 
the probability that these cells continue to cycle, while their normal counterparts 
undergo a Gi arrest. This permits the accumulation of further genetic changes,
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thereby resulting in the selection of clones possessing a selective growth 
advantage, malignant phenotype and increased growth rate (Noble et al., 2004). 
Clonogenic survival following UV is frequently used to confirm the NER 
capacity of in vitro cell cultures. As expected, the SV40-transformed XP-A 
(XP12BE) fibroblasts displayed the highest level of UV sensitivity and the 
lowest colony forming ability. Correspondingly, Ouellette et al. (2000) observed 
a similar level of survival in an unrelated SV40-transformed XP-A (XP12RO) 
fibroblast cell line. The isogenic SV40-transformed CS-A (CS3BE.s3gl) cell line 
exhibited a UV sensitivity that was intermediate to XP-A and MRC-5. In 
agreement with the data presented here, Henning et al. (1995) previously 
observed an identical pattern of clonogenic survival in the SV40-transformed 
CS-A (CS3BE.s3gl) cell line. The UV survival curves obtained for both the 
isogenic MRC-5 SV40-transformed and hTERT-immortalised fibroblasts were 
indicative of DNA repair-proficient cells. Furthermore, the UV survival observed 
for telomerised normal MRC-5 fibroblasts in this study, were similar to those 
reported elsewhere in the literature for NER-proficient fibroblasts (Bates et al., 
2005; Ouellette et al., 2000; Porter et al., 2006). In the present study, however, 
there was a distinct difference between the SV40-transformed and telomerised 
MRC-5 cell lines. The SV40-transformed MRC-5 fibroblasts displayed a slightly 
increased colony forming ability compared to the telomerase-immortalised 
MRC-5 cells. Previously, it was show that GGR is abrogated in SV40- 
transfomed cells (Bowman et al., 2000), due to the inhibition of normal p53 
function by LTAg. This abolishes the transcriptional activation of several 
downstream transcriptional gene targets that mediate GGR such as DDB2 
(Hwang et al., 1999), XPC (Adimoolam & Ford, 2002) and GADD45a (Smith et 
al., 2000). In accordance, Porter et al. (2006) showed that the inactivation of p53 
expression, through the exploitation of p53-targeted siRNAs, resulted in the 
down regulation of DDB2 protein expression and an increased colony forming 
ability of normal diploid human fibroblasts, following UV radiation. This further 
supported the mounting evidence that suggests p48 activation occurs in a p53- 
dependent manner (Hwang et al., 1999). Although, GGR is compromised in 
SV40-transformed cells, the increased clonogenic survival in the SV40 LTAg 
MRC-5 fibroblasts, observed in this study, was possibly attributed to the
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abolition of p53-dependent Gi cell cycle arrest and apoptosis. In support of these 
findings, Ljungman & Zhang (1996) reported that the induction of apoptosis 
correlated with the induction of p53 and to the abolition of mRNA synthesis.
To determine whether the ectopic expression of hTERT influenced colony 
forming ability, clonogenic survival assays were also undertaken on telomerase- 
immortalised XP-C, CS-A and XP-A cell lines. Surprisingly, data were not 
obtained for these assays due to the absence of colony formation. Conflicting 
studies, reported the construction of clonogenic survival curves and have shown 
that UV dose-dependent survivals obtained for normal primary and telomerase- 
immortalised fibroblasts were indistinguishable, reflecting levels of DNA repair 
typical for proficient cells (Bates e t  al., 2005; Newman et al., 2006; Ouellette e t  
al., 2000; Porter e t  al., 2006). Furthermore, Ouellette et al. (2000) constructed 
survival curves for XP-E and XP-V fibroblasts, and showed that the constitutive 
expression of hTERT had no affect on fibroblast survival.
In the present investigation, the data suggest that telomerase-mediated 
immortalisation had no effect on the repair phenotype for CPDs or 6-4PPs in 
telomerised NER-proflcient MRC-5 or GGR-deficient XP-C or TCR-deflcient 
CS-A fibroblasts following UV. Unlike CPDs, which are repaired at 
heterogeneous rates in different genomic regions, 6-4PPs are rapidly removed 
from the overall genome without any preference towards transcriptionally active 
regions of the genome (reviewed by Balajee & Bohr et al., 2000). Therefore, as 
expected, telomerised MRC-5 fibroblasts removed -98.4% of 6-4PPs within 24 
hours. In stark contrast, telomerised MRC-5 cells removed significantly fewer 
CPDs. In agreement with these findings, Van Hoffen et al. (1995) previously 
showed that the removal of 6-4PPs is at least five-fold faster than that of CPDs. 
Consistent with these findings, numerous studies have adopted strand-specific 
repair assays and ligation-mediated PCR (LMPCR) to show that NER of UV- 
induced photolesions is preserved at the global, strand and nucleotide resolution 
in normal fibroblasts, following telomerase-mediated immortalisation (Bates e t  
al., 2005; Porter e t  al., 2006). In stark contrast, numerous studies have suggested
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that DNA repair is enhanced following telomerase-mediated immortalisation 
(Sharma et al., 2003; Shin et al., 2004).
The removal of CPDs and 6-4PPs from the global genome by telomerised XP-C 
cells was identical. Furthermore, the data herein, showed that the global genomic 
removal of CPDs and 6-4PPs was unaffected in the telomerised GGR-proficient, 
TCR-deficient CS-A cells, as the repair rates were similar to those observed in 
the telomerised normal MRC-5 fibroblasts. This observation may have occurred 
due to several reasons. Firstly, only ~1% of the genome is coding sequence 
(Lander et al., 2001; Venter et al., 2001), which is actively transcribed. However, 
the assay adopted in this study to assess repair, measured global repair (GGR and 
TCR) rather than TCR alone. Therefore, it is possible that the TCR defect was 
not observed, as the CS-A cells were GGR-proficient. Therefore, the exploitation 
of strand-specific DNA repair assays (Bohr et al., 1985) would address this issue. 
Alternatively, it has been shown by numerous investigators that lesions that 
efficiently block transcription may also be efficiently recognised by GGR, as a 
result of local disruption to base paring at the site of the lesion (Hess et al., 
1997), thus the slow GGR apparatus may override TCR and repair photolesions 
present on the transcribed strand (de Boer & Hoeijmakers 2000; Queille et al., 
2001; Van Hoffen et al., 1995). This may explain the efficient removal of both 
CPDs and 6-4PPs from the telomerised TCR-deficient CS-A fibroblasts observed 
in this study. As previously mentioned, the removal of 6-4PPs is five-fold faster 
than the removal CPDs, and it thought to occur within the first few hours 
following UV. In this study, however, the repair of CPDs and 6-4PPs was 
assessed at a limited number of time points (0, ~6, ~12 and ~24 hours) post UV. 
Therefore, it is possible that assessing repair at earlier time points (between 0.5-4 
hours) after UV would have resulted in the detection of slower repair of 6-4PPs 
in the telomerised TCR-deficient CS-A fibroblasts compared to the TCR- 
proficient MRC-5 fibroblasts.
Although this investigation has demonstrated the successful establishment of 
novel hTERT-immortalised XP-C (GM02996, XP8CA) and CS-A (GM01856, 
CS3BE) human dermal fibroblasts, through the ectopic expression of hTERT
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cDNA, significant caution should be applied when undertaking long-term 
genetic, biochemical and functional in vitro assays. Previously, Milyavsky et al. 
(2003) showed that hTERT-immortalised WI-38 fibroblasts exhibit similar 
characteristics as their primary isogenic counterparts, during the first 150 PDs, 
following retroviral infection with hTERT cDNA. However, the long-term (^200 
PDs) in vitro growth of telomerase-immortalised cultures, resulted in a gradual 
reduction in both p i6mK4A and p l4ARF expression. In contrast, an alteration in 
p53 and p 2 lWAF1/CIP1 expression was not observed, following extensive 
subcultivation.
It was initially believed that the ectopic expression of hTERT resulted in the 
establishment of telomerase-immortalised cells, which possessed an infinite 
proliferative capacity and an unaltered phenotype that recapitulated their primary 
isogenic counterpart (Bodnar et al., 1998; Jiang et al., 1999; Morales et al., 1999; 
Nakamura et al., 2002; Vizari & Benchimol, 1998). The exploitation of hTERT, 
however, in the establishment of permanent cell lines remains relatively 
controversial, as more recent studies have shown that telomerase reactivation 
merely extends the proliferative lifespan of primary cells to 100-200 PDs (Di 
Donna et al., 2003; MacKenzie et al., 2000) rather than the creation of 
permanent cell lines with infinite proliferative potential. In stark contrast, 
conflicting reports have observed the emergence of cultures which display 
alterations frequently associated with cell lines established through oncogenic 
transformation, such as loss of the p53/p21WAF1/CIP1 and/or pRb/plb1™1^  
pathways (Milyavsky et al., 2003; Noble et al., 2004; van Waarde-Verhagen et 
al., 2006). Furthermore, the overexpression of oncogenes such as c-myc and Bmi- 
1 has been reported (Milyavsky et al., 2003).
In summary, the data presented in this thesis, for the first time, shows that the 
ectopic expression of hTERT in primary XP-C (GM02996, XP8CA) and CS-A 
(GM01856, CS3BE) human dermal fibroblasts resulted in the reconstitution of 
telomerase activity, extension of proliferative capacity (^100 PD) and the 
preservation of the p53/p21WAF1/CIP1 and pRb/plb™1^  tumour suppressor 
pathways. This suggests that the reconstitution of telomerase activity confers XP-
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C and CS-A dermal fibroblasts with the potential of infinite proliferation. 
Moreover, the telomerase-mediated extension of proliferative lifespan did not 
require additional genetic manipulation, as previously reported by other 
investigators. Collectively, these data suggest that, with the exception of 
extended proliferative capacity, the cellular phenotypes remained unaltered 
following the ectopic expression of hTERT, while the DNA damage responses 
remained intact. The absence of the XP-C and CS-A proteins (Chapter 3) in the 
telomerised XP-C (GM02996, XP8CA) and CS-A (GM01856, CS3BE) 
fibroblasts respectively, indicate that the cells retain the defect that causes the 
syndromes. In agreement with the data presented in this thesis, a growing body 
of evidence suggests that NER remains intact and that no differences are 
observed between telomerase-immortalised normal fibroblasts and their primary 
isogenic (non-telomerised) counterparts. The data presented here, strongly 
supports the use of telomerase-mediated immortalisation as an alternative and 
more robust system to oncogenic-mediated transformation, for studying genetic 
and biochemical events including NER, when the use of primary cells is 
experimentally disadvantageous, due to the caveats associated with cellular 
senescence. Moreover, the stable clonal expansion of telomerised cells provides 
an excellent tool for the dissection of transcriptional responses by transcription 
expression profiling and the selective abrogation of gene expression, using RNAi 
technologies. However, the altered phenotypes observed elsewhere in 
telomerised cells following continuous growth in culture, reiterates the 
importance of continuous monitoring of these cultures for genomic instability 
and changes in the p53/p21WAF1/CIP1 and pRb/p 16INK4A pathways.
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Chapter 5 
Expression Profiling and Validation of 
Transcriptional Responses in hTERT- 
immortalised XP-C and CS-A Human 
Dermal Fibroblasts Following 
UVC-irradiation
5.1 Introduction
The principles of microarray technology are based on Watson-Crick base pairing 
(Watson & Crick, 1953) and the process of hybridisation, which have been 
exploited extensively in established techniques such as Southern and Northern 
blotting (Southern, 1975). The emergence of microarray technologies has 
significantly contributed to our understanding of the intricate networks and 
pathways that regulate fundamental biological processes, thereby facilitating the 
elucidation of gene function and the underlying cause of disease. Furthermore, 
microarrays have permitted the identification of cell-type-specific transcriptional 
portraits and complex expression signatures unique to defined genetic 
backgrounds.
The characterisation of the cellular response to UV has advanced rapidly since 
the advent of microarrays (Schena et al., 1995). Exposure to UV results in 
responses involving several DNA damage-induced signalling cascades such as 
the signalling kinases ATR/Chkl, c-jun N-terminal kinase and the p38 kinase 
pathway, which results in the activation of NER and recovery mechanisms 
through the transcription factors: inhibitor of DNA binding 1 (Idl), Noct-3, Rho 
GTPase activating protein 24 (p73), p53, nuclear factor of kappa light
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polypeptide gene enhancer in B-cells (NF-kB), AP-1, activating transcription 
factor 3 (ATF-3) and cAMP response element binding protein, Mift (reviewed by 
Bender et al., 1997; Yang et al., 2003; Zhou et al., 2000). The activation of these 
factors results in a complex transcriptional response of the cells, resulting in the 
transcriptional activation of downstream target effector molecules that regulate 
DNA damage repair (GADD45a, DDB2 and XPC), cell cycle regulation 
(pl6INK4Aj GADD45a and p21wafi/cipi) and apoptosis (Bax> B cl_2 ^  N0XA;
Gentile et al., 2003). The interactions between these known and as yet-to-be 
identified constituents define the programme of set transcriptional responses in 
the cell. Furthermore, mutations, altered patterns of expression or dysregulation 
of many of these molecules or entire pathways have been implicated in the 
molecular pathogenesis of cutaneous malignancy.
To dissect the temporal and functional relationships of these UV-induced 
transcriptional responses in telomerised XP-C and CS-A cell lines; Affymetrix™ 
GeneChip® technology was used. This system offers extensive coverage of the 
human genome, and is based on oligonucleotides. Light-mediated DNA synthesis 
is exploited to construct high-density arrays using a combination of two 
techniques, namely photolithography and solid-phase DNA synthesis. This 
facilitates the deposition of several hundred thousand 25mer oligos on the 
surface of a prefabricated oligonucleotide GeneChip® array. Approximately 11 
to 20 independent perfect match (PM; perfectly complementary to the mRNA of 
a gene) oligos (probes) are designed to hybridise to different regions of the same 
gene. An additional level of complexity comes from the inclusion of mismatch 
(MM) control probes that are identical to the PM partners, except for a single 
base difference located at the central position (usually at nt 13), where one 
nucleotide has been changed to its complementary nucleotide. The MM probes 
provide controls for specific hybridisation and facilitate direct subtraction of 
background and cross-hybridisation signals (reviewed by Hardiman, 2004). The 
HG-U133A arrays used in this investigation contain 22,283 probe sets, which 
represent 13,387 human genes.
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Numerous investigators have exploited various microarray platforms such as 
cDNA microarrays or Affymetrix™ GeneChip® arrays to delineate the 
transcriptional response to genotoxic stress such as UV. To date, the 
transcriptional responses to genotoxic stress have been characterised in yeast 
(Birrell et al., 2001; Chen et al., 2003; Gasch et al., 2000; Mercier et al., 2001), 
E.coli (Courcelle et al., 2001), mouse dermal fibroblasts (MDF; Garinis et al., 
2001) and rat cardiac myocytes (Boerma et al., 2005). The transcriptional 
response of human epidermis in vivo and various cultured normal human cell 
types of the skin has been extensively investigated, following exposure to 
different UV wavelengths. For example, the global transcriptional response to 
UVA has been investigated in keratinocytes, melanocytes, epithelial cells, 
fibroblasts and an MCF-7 breast cancer cell line (Abe et al., 2003; Andley et al., 
2004; He et al., 2004; Jean et al., 2001; Koch-Paiz et al., 2004). Further 
investigations have been undertaken to dissect the transcriptional response in 
intact human epidermis, keratinocytes, melanocytes and an MCF-7 breast cancer 
cell line after UVB irradiation (Becker et al., 2001; Catani et al., 2001; Dazard et 
al., 2003; Enk et al., 2004; Enk et al., 2006; Li et al., 2001; Lee et al., 2005; 
Murakami et al., 2001; Howell et al., 2004; Koch-Paiz et al., 2004; Pisarchik et 
al., 2004; Sesto et al., 2001; Takao et al., 2002; Valery et al., 2001; Yang et al., 
2006). The UVC-induced transcriptional responses in fibroblasts, lymphoblastoid 
cells, HeLa cells, colon carcinoma EB-1 cells and an MCF-7 breast cancer cell 
line have also been well documented (Gentile et al., 2003; Guo et al., 2002; 
Koch-paiz et al., 2004 McKay et al., 2004; Rieger & Chu, 2004; Wano et al., 
2004; Zhao et al., 2000).
In general, these various cell types display similar patterns of differential 
regulation, which involve genes that regulate DNA-damage-repair, cell cycle 
arrest and apoptosis. Among these studies, a large number of differentially 
regulated genes have also been identified that regulate the expression of 
transcription factors, cytoskeletal proteins, secreted signalling molecules and 
controlling cellular functions such as signal transduction and terminal 
differentiation. However, the regulation of immunomodulatory factors appears 
overlapping but distinct, suggesting that there is a cell-type-specific response of 
skin as an organ to UV (reviewed by Latonen & Laiho, 2005). Interestingly,
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different UV doses eliciting either cell cycle arrest or apoptosis induce highly 
divergent transcriptional responses (Gentile et al., 2003; McKay et al., 2004). 
However, as these studies differ considerably in terms of time kinetics, UV dose, 
light source and microarray technologies applied, it has been difficult to generate 
a comprehensive and coherent model that gives a detailed and definitive global 
picture of the complex transcriptional programme in response to UV.
Several investigators have also reported highly specialised cell-type-specific UV 
responses among various skin cells. For example, Yang et al. (2006) showed that 
epidermal melanocytes execute specific physiological programmes in response to 
UV. These melanocytic responses include increased dendrite formation and 
enhanced melanogenesis/melanisation, all of which are thought to influence the 
ability of melanocytes to survive and attenuate the deleterious consequences of 
UV. Cell-type-specific transcription expression patterns have also been observed 
in keratinocytes. For example, using a novel skin organ culture model, Li et al. 
(2001) showed that epidermal keratinocytes displayed three distinct patterns of 
differential gene expression following exposure to UVB. The first contained 
transcription factors, signal transducers and cytoskeletal proteins that modify the 
cell phenotype from a normal, fast-growing cell to an activated, arrested cell. The 
second contained secretory growth factors, cytokines and chemokines, thus 
alerting the surrounding tissue to UV damage. The third wave of differential 
gene expression included the cell-type-specific response, in which constituents of 
the comified envelope were up-regulated, thus permitting ketatinocytes to 
enhance the epidermal protective covering.
Despite extensive investigation into the UV-induced transcriptional response of 
various normal cell types in response to different wavelengths, a limited number 
of studies have characterised the UV-induced transcriptional response of cells 
derived from individuals defective in NER or cell signalling. To date, studies 
have remained limited to cell lines derived from XP-C, XP/CS, CS-B, TTD or 
AT donors (Chang et al., 2003; Newman et al., 2006; da Costa et al., 2005; 
Heinloth et al., 2003). Therefore, the well-characterised UV-induced 
transcriptional responses in normal cells such as DNA repair, cell cycle arrest 
and apoptosis, remain poorly delineated in cells defective in NER. For example,
254
although CS has been extensively investigated and much is known about the 
genetic defects and cellular functionality of the CSA and CSB genes, which are 
responsible for the syndrome, the precise nature of the molecular defect(s) that 
cause the CS phenotype remains poorly understood. Furthermore, the CSA and 
CSB proteins have been implicated, alone or in various combination with other 
proteins in numerous cellular functions such as TCR of UV-induced lesions 
(Cleaver et al., 1999; Venema et al., 1990), removal of oxidative damage (Tuo et 
al., 2002), transcription initiation by RNA Pol I (Bradsher et al., 2002; Iben et 
al., 2002) and RNA Pol II (Dubaele et al., 2002), elongation by RNA Pol II (Lee 
et al., 2002; Selby & Sancar, 1997a), transcription of induced genes (Kyng et al., 
2003), protein ubiquitylation (Groisman et al., 2003), and recruitment of 
chromatin remodelling and repair factors (Fousteri et al., 2006). Kyang et al. 
(2003) exploited microarray technology to show that the transcriptional response, 
after oxidative stress, was defective in CS-B cells, thus implicating oxidative 
damage as playing a possible role in the pathogenesis of CS. More recently, 
Groisman et al. (2006) has established a functional relationship between CSA 
and CSB through the CSA-dependent degradation of CSB by the ubiquitin- 
proteasome pathway. Furthermore, Proietti-De-Santis et al. (2006) has shown 
that CSB is essential for initiating the transcriptional programme of non p53- 
responsive genes, but is dispensable for the transcription of p53-responsive 
genes. In order to delineate these mechanistic functions further and elucidate 
how defects in CSB cause the molecular defect(s) in CS, Newman et al. (2006) 
used expression microarrays to identify genes regulated by CSB in the absence 
of stress (such as UV), as previous transcription expression studies, although 
comprehensive, failed to provide definitive conclusions (Selzer et al., 2002). 
Furthermore, investigators previously focused on the role of CSB in the 
transcriptional response to oxidative or UV DNA damage (Kyng et al., 2003; da 
Costa et al., 2005), rather than determining the precise function of CSB in cells 
not receiving exogenous DNA damage.
Newman et al. (2006) found that CSB causes significant changes in gene 
expression in the absence of UV. They showed that patterns of gene deregulation 
in CS-B cells resembled those induced by agents that disrupt chromatin structure 
or modifications. Interestingly, however, Newman et al. (2006) showed that CSB
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does not appear to affect the expression of chromatin modifiers, such as HATs or 
methytransferases. From these findings, they concluded that although CSB does 
not regulate chromatin modifying factors, it plays a direct role in facilitating 
chromatin modification, possibly by increasing accessibility of histones to 
modifying enzymes, by transiently moving or displacing nucleosomes, or by 
remodelling histone-histone or histone-DNA interactions. To date, similar 
attempts to dissect and elucidate the global transcriptional responses of genes 
regulated by CSA under normal physiological conditions or after stress (such as 
UV) have remained elusive. More importantly, investigators have failed to 
characterise the differences in UV-induced transcriptional responses between 
genetic backgrounds that display differences in NER capacity, such as those 
observed in XP, CS and TTD, which are defective in GGR and/or TCR. 
Although recent investigations have used expression arrays to characterise the 
UVC-specific transcriptional signatures in cell lines displaying an XP-C, XP/CS 
or TTD phenotype (Chang et al., 2003; da Costa et al., 2005), these cell lines 
were severely compromised. Moreover, several caveats have been identified with 
both the experimental design and statistical approaches adopted in these studies 
(discussed below).
Microarray analysis of the UV-induced transcriptional response in normal human 
cells has been well documented. However, a multiplicity of caveats has been 
identified in the experimental design of many studies due to the limited number 
of samples. This is particularly problematic, as large datasets generated by 
microarray experiments require the inclusion of several replicates to ensure 
statistical validity (Rieger & Chu, 2004). Several studies have used only 
duplicates (Sesto et al., 2002), while other investigators have interrogated data 
from single array experiments (Li et al., 2001). Although many investigators 
have addressed this by the inclusion of additional biological replicates, many 
studies have prepared replicates derived from a single cell line (Becker et al., 
2001; Catani et al., 2001; Chang et al., 2003; da Costa et al., 2005; Gentile et al., 
2003; Guo et al., 2002; He et al., 2004; Kock-Paiz et al., 2004; Li et al., 2001; 
McKay et al., 2004; Murakami et al., 2001; Park et al., 2002; Sesto et al., 2002; 
Wano et al., 2004; Zhao et al., 2000) or donor (Howell et al., 2004; Jean et al., 
2001; Lee et al., 2005), thus failing to account for variation among individuals. A
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limited number of studies have extended transcription expression profiling to 
multiple cell lines or cells derived from multiple donors (Rieger & Chu et al., 
2004; Yang et al., 2006), while others have tried to address the problem of inter 
individual variability by using a polygenic (pooled) cell population (or RNA 
samples) derived from several donors (Enk et al., 2004; Enk et al., 2006; Valery 
et al., 2001). Although the use of polygenic samples addresses the problem of 
inter individual variability, further caveats have been associated with this 
method.
Several studies have characterised the UV-induced transcriptional response in 
primary cell cultures (Andley et al., 2004; Becker et al., 2001; Enk et al., 2006; 
Gentile et al., 2003; Howell et al., 2004; Jean et al., 2001; Li et al., 2001; 
Murakami et al., 2001; Pisarchik et al., 2004; Sesto et al., 2002; Yang et al., 
2006), as they are thought to best recapitulate the responses of their in vivo 
isogenic counterpart. However, the use of primary cells in long-term studies is 
problematic due to the limited proliferative capacity of primary cultures 
(discussed in Chapter 4). Therefore, the establishment of permanent cell lines 
provides an alternative for unlimited clonal expansion of in vitro cultures. 
Despite numerous studies demonstrating the disruption of GGR and/or TCR 
subpathways of NER following oncogenic-mediated transformation (Bowman et 
al., 2000; El-Mahdy et al., 2000; Ford et al., 1998; Therrien et al., 1999), 
investigators have continued to exploit SV40-transformed cell lines in the 
characterisation of transcription responses in NER-defective cells, following 
exposure to UV or oxidative damage (Chang et al., 2003; da Costa et al., 2005; 
Kyng et al., 2003). The use of transformed, NER-defective cell lines in 
transcription expression profiling studies is particularly disadvantageous, as it is 
difficult to substantiate whether the expression profiles displayed by these cell 
lines is attributed to their repair-defective phenotype or loss of p53/p21WAF1/CIP1 
and/or pRb/pl6INK4A function during the establishment of these cell lines. As 
previously discussed (Chapter 4), the ectopic expression of hTERT provides a 
superior alternative for the establishment of permanent cell lines, which not only 
extends prolierative capacity (Bodnar et al., 1998), but also retains NER function 
(Bates et al., 2005; Oullette et al., 2000; Porter et al., 2006). Limited studies 
have realised the potential of telomerase-mediated immortalisation in the
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characterisation of the in vitro UV-induced transcriptional response in cells 
defective in NER. To avoid possible confounding affects of SV40 LgTA on TCR 
function, and to provide a well controlled isogenic pair of cell lines for analysing 
CSi?-dependent gene expression, Newman et al. (2006) established hTERT- 
immortalised isogenic CS-B lines in addition to a CS-B SV40 cell line, derived 
from the same primary CS-B fibroblast culture (GM00739B, CS1AN).
A further caveat in expression studies is the use of artificial systems. For 
example, one of the initial transcription expression profiling studies used a pre­
existing p53 null colon cancer cell line, compared with a derivative that 
expressed p53 in response to zinc (Zhao et al., 2000). This produced a set of p53- 
inducible genes; these were in turn spotted to form a second, custom array that 
was interrogated using RNA derived from cancer cell lines damaged by UV or 
IR. The list of differentially regulated genes identified in this study is 
questionable, as p53 expression in this system was artificially induced. 
Moreover, the cell lines analysed, although wild type for p53, contained pre­
existing mutations.
Many studies have restricted their analysis to a limited number of time points 
following UV, thus preventing the identification of time-dependent 
transcriptional responses. This is exemplified in many studies that have 
characterised the portrait of transcriptional responses to UV after a single time 
point: 4 hours (Catani et al., 2001; Valery et al., 2001), 6 hours (Heinloth et al., 
2003; McKay et al., 2004; Takao et al., 2002; Zhao et al., 2000) or 24 hours 
(Becker et al., 2001; Enk et al., 2004; Rieger & Chu, 2004). Several studies, 
however, have assessed the UV-induced transcriptional response at multiple time 
points up to 24 hours after UV (Andley et al., 2004; da Costa et al., 2005; 
Gentile et al., 2003; Lee et al., 2005; Li et al., 2001; Pisarchik et al., 2004), 
while few have extended the time course up to 72 hours post UV (Enk et al., 
2006; Murakami et al., 2001).
A further obstacle in the experimental design of microarray studies is the 
selection of appropriate and statistically robust methods for the identification of 
differentially regulated genes. Numerous investigators have implemented flawed
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analytical methods to interrogate large datasets generated by microarrays. For 
example, several studies have deemed a gene to be significantly induced or 
repressed if an R-fold change is observed (Becker et al., 2001; da Costa et al., 
2005; Enk et al., 2004; Enk et al., 2006; Gentile et al., 2003; Li et al., 2001; 
McKay et al., 2004; Murakami et al., 2001; Pisarchik et al., 2004; Sesto et al., 
2002; Zhao et al., 2000), where R represents the ratio of differential gene 
expression between two states (i.e. treated Vs non treated). This method does not 
account for the variability in gene expression across the entire sample (array), 
and results in the biased selection of genes with apparent changes in expression 
that are not necessarily statistically significant (Tusher et al., 2001). Several 
investigators have realised the limitations to fold-change and adopted more 
robust statistical approaches to the identification of differentially regulated 
genes, such as principle component analysis (PCA), analysis of variance 
(ANOVA), Student t test, the test statistic and significance analysis of 
microarrays (SAM) (Chang et al., 2003; Guo et al., 2002; He et al., 2004; 
Howell et al., 2004; Newman et al., 2006; Reiger & Chu, 2004).
A major drawback common to almost all transcription expression profiling 
studies discussed here is that they were performed on cultured cells under in vitro 
conditions. This is particularly problematic, as skin tissue cultures differ 
considerably compared to their intact isogenic in vivo counterpart that they are 
supposed to phenotypically resemble. For example, keratinocyte cultures are 
usually supplemented with hormones and growth factors that might affect cell 
cycle regulation, stress response and apoptosis (Gibbs et al., 1998). Furthermore, 
the confluency of an in vitro cell culture can affect the regulation of UV-induced 
apoptosis. Carvalho et al. (2003) showed that confluent GGR-defective XP-C 
and GGR- and TCR-defective TTD primary dermal fibroblasts displayed a 
decreased level of UV-induced apoptosis compared to subconfluent cultures. 
They suggested that in vitro cultures of confluent cells may better reflect how 
cells behave in vivo, as skin fibroblasts in vivo have a quiescent metabolism and 
reduced turnover similar to that observed in confluent in vitro cultures. A further 
caveat associated with in vitro culture models is that the cultures are usually 
derived from a homogeneous population of cells that lack the additional cellular 
components of intact skin, which assist in orchestrating a response to UV
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through the expression of signalling molecules, such as cytokines. Consequently, 
although transcription expression profiling of cultured cells has contributed to 
our understanding of UV-induced stress responses, significant caution should be 
applied when extrapolating from findings based on cultured cells to 
transcriptional responses that occur in vivo. A recent study undertaken by Enk et 
al. (2006) showed for the first time that, the UVB-induced transcriptional 
profiles of human epidermis in vivo significantly differed from that of cultured 
epidermal keratinocytes. They found that the expression profiles between human 
epidermis in vivo and cultured epidermal kerationcytes differed by 1931 genes. 
Moreover, the expression profile of intact epidermis was predominantly 
associated with DNA repair, while cultured epidermal keratinocytes responded 
by activating genes associated with cell cycle arrest and apoptosis. However, 
several experimental caveats have been associated with this study. For example, 
although the profiling of the in vivo intact human epidermis and in vitro 
monolayer of keratinocytes was performed in the same laboratory, they were not 
performed in parallel. Furthermore, different Affymetrix™ GeneChip® arrays 
were used for profiling both the in vivo and in vitro models.
Early attempts at delineating the systematic programme of UV-induced 
transcriptional responses by microarray were limited by the restricted coverage 
of the human genome. However, the recent availability of high-density 
oligonucleotide arrays, more thorough annotation of the human genome and 
more advanced technological platforms for the analysis and interpretation of 
array data has permitted the expression profiling of the entire human genome in 
response to UV. Currently, however, only a limited number of studies have used 
the new high-density oligonucleotide arrays (such as the HG-U133 Set/Plus 2.0 
microarrays) to characterise the UV-induced response (Newman et al., 2006; 
Yang et al., 2006).
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5.2 Aims
Primary XP-C (GM02996, XP8CA) and CS-A (GM01856, CS3BE) human 
dermal fibroblasts were previously characterised (Chapter 3) and immortalised 
by transducing the catalytic sub-unit of telomerase (hTERT) into primary XP-C 
and CS-A fibroblasts (Chapter 4).
To date, information regarding the global transcriptional response to UV remains 
limited in NER-defective cells. Furthermore, most of the genome-wide studies 
that have been undertaken on NER-defective in vitro cell models (with exception 
to Newman et al., 2006) have been compromised by the undesirable legacy of 
immortalisation, namely loss of tumour suppressor function (such as the 
p53/p21WAF1/CIP1 and pRb/plb1^ ^  pathways), due to the utilisation of cell lines 
created through transduction with viral oncogenes (previously discussed in 
Chapter 4). The establishment of hTERT-immortalised XP-C and CS-A cell 
lines, now permit the genome-wide analysis of NER-defective cell lines in 
response to UV, whilst retaining the DNA damage response, which lies upstream 
of DNA repair.
To understand the mechanisms underlying the UV-C transcriptional response in 
the different NER-defective backgrounds, transcription expression profiling was 
undertaken on telomerised XP-C and CS-A human dermal fibroblasts at the 
genome-wide level, using Affymetrix™ GeneChip® HG-U133A probe arrays, 
with the aim to: (1) identify differentially regulated genes (up-regulated or down- 
regulated) and pathways; (2) dissect the global transcriptional response to the 
initiation of DNA repair, in addition to characterising the primary transcriptional 
stress response to DNA damage per se; (3) identify possible UVC-induced, cell- 
type-specific expression signatures between the telomerised XP-C and CS-A 
fibroblasts.
The transcription expression profiles obtained for the telomerised XP-C and CS- 
A cell lines were compared to the wild-type transcriptional response, used as a 
baseline dataset previously characterised in telomerised NER-proficient MRC-5
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fibroblasts. This allowed the identification of genes that fail to be up- or down- 
regulated in the NER-defective backgrounds, thus further facilitating the 
identification of genes that are differentially regulated not as a direct result of 
DNA damage, but as a consequence of the commencement of DNA repair. 
Transcription expression profiling in the different repair-defective backgrounds 
would potentially allow the delineation of repair genes that are activated 
immediately after UV damage and identify what aspect of defective NER repair 
blocks their expression.
To confirm the validity of the UV-induced transcription expression profile data 
generated by the Affymetrix™ GeneChip® HG-U133A arrays, a further aim was 
to validate differentially regulated genes identified in the telomerised XP-C and 
CS-A cell lines, at both the transcriptome and translational levels by RT-PCR 
(using the TaqMan platform) and by Western blot analysis, respectively. The 
rationale behind gene candidate selection for subsequent validation at both the 
mRNA and protein levels were as followed:
• Selection of genes that orchestrate a diverse range of biological 
functions in response to UV, such as transcription, stress signalling, 
cell cycle regulation, DNA repair and apoptosis.
• Demonstrate the establishment of p53/p21WAF1/CIP1, pRb/plb1^ ^  
proficient, hTERT-immortalised NER repair-defective XP-C 
(GM02996, XP8CA) and CS-A (GM01856, CS3BE) fibroblast cell 
lines (Chapter 4).
• Select genes that exhibited genotype-specific signatures between the 
hTERT-immortalised NER repair-defective XP-C and CS-A 
fibroblast cell lines.
• Ascertain whether expression at the translational level recapitulated 
the transcriptome data obtained from the Affymetrix™ microarrays 
and quantitative RT-PCR.
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5.3 Materials & Methods
Telomerised XP-C (GM02996, XP8CA) and CS-A (GM01856, CS3BE) 
fibroblasts were prepared by seeding 5 X 105 cells in three 60 mm dishes/time 
point and allowed to equilibrate overnight (Section 2.13.1). For UV treatment, 
cells (at -80-90% confluency) were UVC irradiated for 10 seconds with a
9  9germicidal lamp (254 nm) at a fluence of 1 J/m /s to a dose of 10 J/m (Sections 
2.6 & 2.13.1).
Cells were harvested at the indicated time points and total RNA was isolated, 
using TRIzol reagent, according to the manufacturer’s recommendations (Section
2.13.2). Total RNA quantity and quality was assessed, using the NanoDrop® 
ND-1000 spectrophotometer and Agilent 2100 Bioanalyser (Section 2.13.2). 10 
pg of total RNA was reverse transcribed and double-stranded cDNA was 
synthesised, using a T7-01io(dT) promoter primer and Superscript II (Section
2.13.3). After second strand synthesis, IVT was performed and single stranded, 
biotin-labelled cRNA was prepared, using the ENZO Bio Array™ High Yield™ 
RNA Transcript Labelling Kit (Section 2.13.4). Unincorporated biotinylated 
nucleotides were removed using a BD Chroma Spin™ Column Kit (Section
2.13.4). Following IVT, the quantity and integrity of the cRNA was assessed as 
above (Section 2.13.4). The adjusted cRNA yield was calculated and 15 pg of 
adjusted cRNA was fragmented (Section 2.13.5). The fragmented cRNA was 
assessed using the Agilent 2100 Bioanalyser as above (Section 2.13.2). 
Microarray hybridisations were performed by our in-house array service 
(Sections 2.13.6), using the Affymetrix™ HG-U133A GeneChip® probe arrays.
cRNA samples prepared from telomerised MRC-5 fibroblasts were used to 
generate the “gold standard” NER proficient transcriptional response, and were 
used as a baseline data set. They were processed by Dr. M. Peake (DNA Repair 
Group, Dept. Pathology, Cardiff Uni.) in an identical manner (as described in 
this thesis). The hybridisations were undertaken by our in-house array service (as 
above).
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The output files generated by the scanned images were analysed using 
Affymetrix™ Microarray Suite 5 (MAS 5.0) software (Section 5.4.2), and global 
scaling to a target intensity of 100 was applied (Section 5.4.4). In addition, probe 
arrays were verified using data obtained for the spiked-in-control probes (BioB, 
BioC, BioD and CreX) and the housekeeping (GAPDH and |3-actin) probe 
controls (Section 5.4.3).
For validation of A TF3, CDKN1A , Ccng2, DDB2, DTR , FDXR, GDF15 , 
PMAIP1, PPM ID  and SAT at the mRNA level, by qRT-PCR, cells were UV- 
irradiated and prepared in an identical manner to the microarray studies (Section
2.13.1). In addition, time-matched mock-irradiated controls were also prepared in 
an identical manner and in parallel with the irradiated samples, except UV 
treatment was omitted (Section 2.14.1). Total RNA was extracted at the indicated 
time points following UV (or mock-irradiation) as previously described (Section
2.13.2) and reverse transcribed using SuperScriptll (Section 2.14.2). RT-PCR 
was performed using gene-specific primers (Table 2.4, Chapter 2) and TaqMan® 
Universal PCR Master Mix No AmpErase® UNG in accordance to the 
manufacturer’s recommendations (Section 2.14.3). The amplification reaction 
was undertaken using an ABI® PRISM® 7000 Sequence Detector (Section
2.14.3). In parallel to the gene-specific assays, GAPDH levels were determined 
for each irradiated and mock-irradiated sample at the indicated time points, by 
performing a GAPDH only RT-PCR assay. The expression value for each gene 
studied was normalised to the relative amounts of GAPDH mRNA present within 
the same sample. In addition to undertaking three independent biological 
replicates (performed on different days), each PCR reaction was performed in 
triplicate. The relative quantification of gene expression was determined using a 
standard curve methodology (Section 2.14.4).
For validation of ATF3, p2 lWAF1/CIP1 (Chapter 4), GADD45a, PMAIP1 and 
FDXR at the protein level, immunoblotting was performed using a Biorad Mini- 
Protean II Electrophoresis Cell System. Briefly, cells were seeded in multiple 
100 mm Petri dishes at a density of 1 X 106 cells/100 mm dish (Section 2.9.1) 
and UV irradiated (Section 2.6). WCEs were prepared and quantified as
264
previously described (Sections 2.9.1-2.9.2). Proteins were separated on SDS- 
PAGE gels (Section 2.9.3), transferred to PVDF membranes (Section 2.9.3) and 
exposed to the appropriate primary antibody (Table 2.1, Section 2.9.4). Immuno 
complexes were detected using an appropriate HRP-coupled secondary antibody, 
and the blots were visualised using an ECL system and Hyperfilm (Section
2.9.4). Equal protein loading was confirmed by staining the PVDF membrane 
with India ink (Section 2.9.5).
5.4 Results
5.4.1 The experimental in vitro NER-defective model 
systems
To investigate the global transcriptional responses in in vitro XP-C and CS-A 
dermal fibroblast cultures following UVC exposure, immortalised XP-C and CS- 
A cell lines were constructed by transducing primary human XP-C and CS-A 
fibroblasts with hTERT (Chapter 4). This ensured the preservation of the DNA 
damage and stress signalling pathways, p53/p21WAF1/CIP1 and pRb/plb1^ 4^  For 
microarray experiments, telomerised XP-C and CS-A cells were grown to near 
confluence (-80-90%) in 10% FCS prior to irradiation. A UV wavelength (UVC; 
254 nm) and dose (10 J/m2) was selected that was in line with other studies 
(Gentile et al., 2003; McKay et al., 2004; Reiger & Chu, 2004). This dose has 
been shown to have significant biological impact and induce apoptosis in <20% 
of UV-irradiated primary human fibroblasts or most other DNA-repair proficient 
human cell lines (Ljungman & Zhang, 1996; McKay & Ljungman, 1999; McKay 
et al., 1998; Queille et al., 2001; McKay et al., 2002; McKay et al., 2000) and 
yields -2 .4  lesions per strand of an average gene (McKay et al., 2004; van 
Hoffen et al., 1995). To analyse the UVC regulated expression patterns, cells 
were harvested at 0, -6  -12 and -24  hours post UVC irradiation. Total RNA was 
extracted from the cells and was further processed and hybridised to 
Affymetrix™ HG-U133A GeneChip® oligonucleotide arrays as described in 
Materials and Methods. Three independent biological replicates were prepared
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for each time point and cell line. Each biological replicate represented 
independent RNA isolations, cRNA synthesises and hybridisations, using the 
same stable telomerised cell line (and clone) at different PDs; each biological 
replicate used for microarray analysis did not exceed 100 cumulative PDs. In 
addition, for each time point and each independent biological replicate, three 
separate RNA isolations were performed (on three separate UVC irradiated 60 
mm dishes) which where eventually pooled following RNA isolation. The 
incorporation of multiple dishes and biological replicates addressed any possible 
variability that occurred within the experimental design such as variation in the 
UV light source (such as fluctuations in fluence), RNA isolation, cRNA 
labelling, array hybridisations or variability in the scanner.
5.4.2 Initial data analysis of transcriptional regulation of 
gene expression in telomerised XP-C and CS-A fibroblasts
The image output data files (.DAT) generated from the scanned images were 
processed and analysed by the probe level software package, Affymetrix™ MAS 
5.0 (Affymetrix™, 2001). This facilitated the conversion of the image data file to 
a CHP file. The CHP file provided the raw signal intensity value for each of the 
22,283 probe sets present on the array, where an absent, present or marginal call 
was assigned to each probe. Subsequent analysis of the data was undertaken 
using the R environment for statistical computing (Gentlemen et al., 2004) along 
with the ‘a ffy \ ‘affyPLM' and ‘simpleajfy’ analysis packages downloaded from 
http://www.bioconductor.org. The .CEL intensity data was analysed to produce a 
single expression value for each probe set using the MAS 5.0 statistical 
algorithm (Affymetrix™, 2002).
5.4.3 Quality control (QC) parameters
The Affymetrix ™ platform has a number of built-in QC metrics, which are 
generated from the MAS 5.0 algorithm, that facilitate the assessment of array 
quality and identification of defective arrays. Therefore, several QC metrics
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(Wilson & Miller, 2005) recommended by Affymetrix™ were assessed. These 
are described in detail in their ‘Expression Analysis Technical Manual’ (http:/ 
www.affymetrix.com/support/technical/mannual/expression_mannual.affx).
To determine whether there was any significant difference in cRNA quality 
between biological replicates used in each array experiment, a series of RNA 
degradation plots were constructed to assess the integrity of the cRNA between 
samples. RNA degradation, or problems during cRNA labelling can cause under 
representation at the 5’ end. Therefore, the ratio between signals from the 5’ and 
3’ probe sets were used to assess RNA quality. RNA degradation plots generated 
using the ’affy’ software package, display expression as a function of 5’-3’ 
position of probes. For each array and within each probe set, probes are arranged 
by their proximity to the 5’ end of the gene. Each line of the RNA degradation 
plots corresponds to an array and the slope of its trend indicates potential RNA 
degradation of the cRNA sample. Additionally, RNA degradation plots assess 
the efficiency of cDNA synthesis and the IVT of biotin labelled cRNA. As 
expected, following the labelling and hybridisation processes, within each probe 
set, the probes matching close to the 5’end of the gene had lower intensity 
measures than that of the probes matching closer to the 3’ (Figs. 5.1 A & B). 
Moreover, the individual lines (representing either an XP-C or CS-A sample) lie 
parallel to each other, which suggests that the degradation patterns between the 
arrays were similar (Figs. 5.1 A & B).
The percentage of genes that call present on a given array is referred to as the 
percent present value and represents the percentage of probe sets called present 
on an array. This is dependent upon multiple factors including cell/tissue type, 
biological or environmental stimuli, and overall quality of the RNA sample and 
the probe array type. The Present/Marginal/Absent cells are calculated from the 
differences between PM and MM values for each probe pair in a probe set 
(described in Section 5.1). Probe sets are deemed marginal or absent when the 
PM values for each Probe set are not significantly above the MM probes. 
Replicate samples, however, should display a similar percent present value, as 
large variations in present calls between similar samples usually suggest that 
varying amounts of cRNA have hybridised to the array. Extremely low percent
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present values are usually indicative of poor sample quality. The percent present 
values for all the arrays performed on the telomerised XP-C and CS-A samples, 
at the indicated time points ranged between 40-50% (Figs. 5.2A & B, 
respectively). Although the absolute % present value is generally not a good QC 
metric, as some cell types naturally express more genes than others, the values 
obtained in this study fall within the expected range for the HG-U133A array.
The average background should be similar across all arrays. Significant 
variations in background has been attributed to several factors such as different 
amounts of cRNA present in the hybridisation cocktail, varying hybridisation 
efficiencies, incorporation of more label or manufacturing variances producing a 
“brighter chip”. Although there are no official guidelines regarding background, 
Affymetrix™ has found that typical average background values range from 20 to 
100 for arrays scanned with the GeneChip® Scanner 3000. As shown by the 
quality control metrics in Figure 5.2, the background values for the 
hybridisations were within the normal range for both the XP-C and CS-A arrays 
(Figs. 5.2A & B, respectively).
By comparing the amount of signal from the 3’ probe set to the 5’ probe set, it is 
possible to assess the quality of the cRNA hybridised to the array, as high ratios 
signify the presence of truncated transcripts. Therefore, as a further internal 
quality control and to assess RNA integrity, GAPDH and |3-actin ratios were 
calculated for each individual array. Both GAPDH 3’:5’ (circles) and p-actin 
3’:5’ (triangles) ratios were plotted for the telomerised XP-C and CS-A samples 
(Figs. 5.2A and B, respectively). GAPDH ratios were ^1 and well below the 
suggested maximum of 1.25 (Wilson & Miller, 2005). As p-actin is a longer 
gene, Affymetrix™ recommend that the 3’:5’ ratios should be below 3. As 
shown in Figures 5.2A and 5.2B the ratios for p-actin were <3 for the XP-C and 
CS-A samples, respectively.
The spike-in hybridisation BioB control was found to be present on all arrays, 
while BioC, BioD and CreX were also present in increasing intensity.
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In summary, the quality control metrics assessed on the probe arrays presented 
here displayed no abnormalities, and were therefore subjected to further 
statistical analysis.
5.4.4 Data normalisation
Although the Affymetrix™ GeneChip® system is a robust platform, differences 
in signal intensity can occur due to experimental variability such as pipetting 
error, hybridisation efficiency, washing and staining efficiency, which are 
independent of relative transcript concentration. Therefore, a method of 
normalisation was required to standardise the target intensity (mean expression 
signal) of each experiment. The target signal was set to TGT= 100. Affymetrix™ 
stipulates that scale factors applied to expression values obtained from their 
GeneChips® should fall within a 3-fold range, as discrepancies in the scale 
factors (2:3 fold) usually indicate variability or cRNA degradation. The quality 
control plots confirm that all XP-C and CS-A arrays were within the 
recommended limits (Figs. 5.2A & B, respectively).
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Figure 5.1. RNA degradation plots for GeneChip data from telomerised (A) XP-C (XP8CA) and (B) CS-A (CS3BE) dermal fibroblasts 
following UVC-irradiation (254 nm) at the indicated time points (h, hour).
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Figure 5.2. SimpleAffy quality control plots for array data from telomerised (a) XP-C (XP8CA) and (B) CS-A (CS3BE) dermal 
fibroblasts
5.4.5 Analysis o f variance (ANOVA)
Statistical analysis was undertaken by Dr. Peter Giles (bioinformaticians), a 
member of our in-house array service.
To identify genes with a statistically significant response to UV that have the 
potential of being biologically meaningful, ANOVA was used to calculate the 
probability of finding the observed differences in means between more than two 
conditions. The ANOVA analysis was designed to identify differentially 
expressed genes in each of the two experimental factors of genotype and time, 
following UV exposure. In addition, an interaction factor was included to 
identify genes changing with both time and between genotypes.
For all statistical tests that calculate a p-value, it was important to consider the 
effect of multiple testing, as each HG-U133A probe array gives an expression 
value for 13,387 human genes, as opposed to a single event. Therefore, the 
resultant p-values from the ANOVA analysis for each factor were subject to 
correction for multiple testing using the Benjamini and Hochberg False 
Discovery Rate (FDR) procedure for multiple testing (Benjamini & Hochberg, 
1995). The FDR procedure simultaneously corrects for multiple testing and false 
discovery rates, yielding a value that describes both (i.e. p=0.05 gives a 95% 
chance of differential gene expression, and a 5% chance of a false hit). Gene lists 
for each factor at the determined p-value/FDR were exported for further analysis 
and visualisation using log transformed mean-centred heatmaps of the 
hierarchical clustering results. Hierarchical clustering subdivided each cluster 
identified into smaller clusters, resulting in the formation of a tree-shaped data 
structure, known as a dendrogram. This was achieved using the Euclidean 
distance method. Once lists of genes that were differentially regulated in 
telomerised MRC-5, XP-C and CS-A fibroblasts were obtained, genes were 
individually assessed for their significance in response to UV.
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5.4.6 Transcription profiles of un-irradiated telomerised 
XP-C and CS-A dermal fibroblasts
In the present study, an important step in the experimental design was the 
selection of appropriate controls, as time-matched, non-irradiated controls for 
comparative analysis with each irradiated sample was beyond the scope of this 
investigation, due to the cost of Affymetrix™ HG-U133A high-density 
oligonucleotide GeneChip® arrays. Therefore, all XP-C and CS-A irradiated 
samples at the indicated time points (~6, ~12 and ~24 hours) were compared to 
irradiated samples extracted immediately after UV (0 hours). However, the 
immediate effects of UV on telomerised XP-C and CS-A fibroblasts were 
unknown. Therefore, three biological replicates were prepared (in an identical 
manner as the irradiated samples except UV was omitted) immediately following 
mock-irradiation for each of the telomerised XP-C and CS-A fibroblast cell lines 
at different PDs. The HG-U133A arrays prepared from mock-irradiated cells 
were compared to the probe arrays prepared immediately after UV. The data 
revealed no significant differences between the mock-irradiated and irradiated 
samples prepared at 0 hours (data not shown). This suggested that UV had no 
immediate effect (at 0 hours) on the transcriptome. Therefore, the irradiated 
samples prepared at 0 hours were used as the control for comparative analysis 
with the corresponding MRC-5, XP-C and CS-A samples prepared at 6, 12 and 
24 hours after UVC treatment.
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5.4.7 Genotype-specific modulation o f the telomerised 
MRC-5, XP-C and CS-A cell transcriptome
Significant changes in transcriptional modulation were observed in hTERT- 
immortalised MRC-5, XP-C and CS-A fibroblasts. ANOVA analysis revealed 
that, of the 22,283 probe sets on the Affymetrix™ HG-U133A GeneChip® array, 
705 probes sets (at an FDR= 0.0000001%), which represented 567 genes, were 
identified as being differentially regulated in a genotype-specific manner (Fig.
5.3). Subsequent hierarchical clustering of the 705 differentially regulated probe 
sets resulted in the formation of a dendogram which revealed five principle 
clusters according to the pattern of differential regulation. The five clusters 
displayed different kinetics of high and low expression levels of probe sets in the 
telomerised MRC-5, XP-C and CS-A fibroblasts at 0, ~6, ~12 and ~24 hours 
following UVC exposure (Fig. 5.4). Table 5.1 summarises the number of 
differentially regulated probe sets identified in this study, which occurred in a 
genotype-specific manner. The probe sets identified in each cluster were 
categorised according to biological function (Appendix 1). Because many of the 
genes present on the HG-U133A array were represented by multiple probe sets, 
several of the 567 genes appear more than once in the gene lists. The five 
clusters displayed differential patterns of expression, which represented a diverse 
range of biological functions, few changes in gene expression appeared UV- 
dependent. For example, the 351 differentially regulated probe sets in cluster 1 
were repressed in telomerised MRC-5 fibroblasts throughout the entire time 
course at 0, ~6, ~12 and ~24 hours following UV. In contrast, although the 
telomerised XP-C and CS-A fibroblasts displayed a differential pattern of 
expression compared to the telomerised MRC-5 cells, both the telomerised XP-C 
and CS-A fibroblasts exhibited a similar programme of transcriptional responses 
for the 351 probe sets (Fig. 5.4, cluster 1). Generally, the 351 probe sets 
identified in cluster 1 were upregulated in both XP-C and CS-A cell lines (this 
was signified by an increase in intensity). Moreover, minimal fluctuations in the 
kinetics of differential regulation occurred between the 351 transcripts 
throughout the time course in MRC-5, XP-C and CS-A cells. Notably, however, 
a small subset of probe sets within cluster 1, displayed a further marked
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induction in the telomerised CS-A cells compared to the XP-C cells (Fig. 5.4, 
cluster 1). The 351 differentially regulated probe sets represented gene 
transcripts from a diverse range of functional categories that regulate a 
multiplicity of pathways that maintain normal cellular homeostasis (Appendix 1). 
In addition to the identification of genotype-specific patterns of differential 
regulation observed in cluster 1, the kinetics of gene expression appeared to be 
similar throughout the time course and displayed minimal changes at 0, -6 , -12 
and -24  hours following UVC irradiation. This suggested that the differential 
regulation of gene expression identified in telomerised MRC-5, XP-C and CS-A 
cell lines, occurred independent of UV-irradiation.
Similar to cluster 1, the patterns of differential gene expression observed among 
the 74 probe sets identified in cluster 2 occurred in a UV-independent manner. 
Unlike cluster 1, however, more than half (45) of the probe sets were deemed 
upregulated in the telomerised MRC-5 cells. In contrast, the 74 probe sets 
appeared to be repressed in telomerised XP-C cells, while the CS-A cell line 
displayed a heterogeneous level of differential gene expression for the same 
probe sets over the time course.
Interestingly, although the expression pattern of the 54 probe sets in cluster 3 
appeared to be genotype-specific, the differential gene expression appeared to 
also occur in a UV-dependent manner (Fig. 5.4, cluster 3). For example, 36 of 
the 54 probe sets were significantly repressed in the CS-A cells at -6  and -12 
hours following UVC-irradiation, compared to the level of expression observed 
at 0 and -24 hours post UV-irradiation. Conversely, 18 probe sets were repressed 
throughout the entire time course, thus further suggesting a genotype-specific 
UV-independent response. In contrast, a large number of the probe sets were up- 
regulated at 0 hours post UV followed by rapid down regulation at 6 hours in 
telomerised MRC-5 cells. The probe sets displayed subsequent induction at -12 
and -24  hours post UV. This suggested that UV caused a repression of these 
probe set in the MRC-5 cell line. However, without time-matched, mock- 
irradiated samples, it can only be speculated that these changes observed in 
cluster 3 for CS-A and MRC-5 occurred as a result of UV-irradiation. The
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telomerised XP-C cells exhibited a heterogeneous level of expression for the 
same 54 probe sets in cluster 3 (Fig. 5.4, cluster 3).
Cluster 4 contained 193 probe sets that presented higher levels in MRC-5 
compared to the XP-C and CS-A cell lines. Notably, the higher levels of 
expression continued throughout the time course at ~6, ~12 and ~24 hours. This 
suggested that the induction of the 193 probe sets identified in cluster 4 in MRC- 
5 cells, occurred in a genotype-specific and UV-independent manner (Fig. 5.4, 
cluster 4). Conversely, the 193 differentially regulated probe sets identified in 
cluster 4, exhibited heterogeneous levels patterns of expression in both 
telomerised XP-C and CS-A cell lines, but displayed no obvious patterns of 
induction or repression. This further suggested that the genotype-specific 
transcriptional responses were UV-independent.
Interestingly, the 33 differentially regulated probe sets in cluster 5 were 
significantly induced throughout the time course at 0, ~6, ~12 and ~24 hours in 
telomerised XP-C cells, irrespective of UV exposure (Fig. 5.4, cluster 5). The 
identical kinetics of induction that were observed at ~6, ~12 and -24  hours 
compared to those observed at 0 hours, indicated that the transcriptional 
responses in XP-C cells were also genotype-specific, rather than UV-dependent. 
In contrast to clusters 1-4, heterogeneous patterns of expression was observed for 
the 33 probe sets in cluster 5 in MRC-5 cells. Similarly, CS-A cells displayed a 
heterogeneous level of expression for the 33 probe sets identified in cluster 5 
(Fig. 5.4, cluster 5).
Although several differentially regulated probe sets identified in the five 
genotype-specific clusters represented biological functions in the cell cycle (such 
as ABL1, CCND1, DUSP6, EREG, G0S2 and PML), regulation of proliferation 
(such as CDKN2A, CREG1, FTH1, HOXCIO , IGF BP 6, IGFBP7, PPAP2A, 
TNFSF9 and TP53111) and apoptosis (such as BAG1 , CASP1, CASP4 and 
PPP2R1B), which are pathways closely associated with the DNA damage 
response, a large number of probe sets represented several other functional 
groups. These common functional groups represented by the 705 differentially
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regulated probe sets identified in clusters 1-5 included: membrane-associated, 
protein binding, nucleus, cytoplasm, metal ion binding, signal transduction and 
transcription factor activity (Table 5.1). Only three probe sets identified in cluster 
1 represented genes that are directly involved in DNA repair (ELN, MGMT and 
PML). Two further probe sets identified in cluster 4 represented DNA repair 
genes (PARP4 and POLE). Notably, however, non of the DNA repair genes 
identified here were associated with the core NER apparatus.
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Figure 5.3. ANOVA of genotype-specific changes in gene expression. Hierarchical 
clustering depicting the genotype-specific transcriptional changes of 705 differentially 
regulated probe sets, whose levels of expression altered in a genotype-specific manner in 
telomerised MRC-5, XP-C (GM02996, XP8CA) and CS-A (GM01856, CS3BE) fibroblast 
cell lines, following UVC (254 nm), at the indicated time points (h, hour). The columns 
correspond to the cell lines and the rows to each gene transcript. The altered expression 
levels are represented in colour and red signifies upregulation, while green, downregulation.
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Figure 5.4. Hierarchical clustering of 
genotype-specific genes following UVC- 
irradiation. The data depicts five distinct 
clusters, which show differentially regulated 
probe sets identified in telomerised MRC-5, 
XP-C (GM02996, XP8CA) and CS-A 
(GM01856, CS3BE) fibroblast cell lines at 
the indicated time points (h, hour), 
following UV-C treatment. The columns 
correspond to the cell lines and the rows to 
each probe set. The change in expression is 
represented in colour and red signifies 
upregulation, while green, downregulation.
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Table 5.1. Functional classes of genotype-specific differentially expressed probe sets.
GO Category
Cluster
1
Cluster
2
Cluster
3
Cluster
4
Cluster
5
Membrane 64 22 4 43 6
Integral to membrane 49 11 3 24 4
Protein binding 46 12 13 30 7
Nucleus 35 8 19 25 8
Cytoplasm 24 5 5 12 3
Metal ion binding 24 9 5 10 3
Signal transduction 21 5 9 23 5
Transcription factor activity 19 3 8 16 4
Regulation of transcription, DNA-dependent 19 4 10 12 4
Zinc ion binding 16 4 5 10 2
Nucleotide binding 15 6 8 13 2
Plasma membrane 14 5 2 9 2
ATP binding 11 3 5 10 2
Skeletal development 9 „ 2 2 2
Cell adhesion 24 8 — 8 4
Receptor activity 21 8 — 16 2
Extracellular matrix (sensu Metazoa) 20 3 _ _ 3 3
Calcium ion binding 16 4 — 11 3
Cell proliferation 8 2 _ _ 2 2
Structural molecule activity 7 2 — 4 3
Cytoskeleton 6 — 5 3
Structural constituent of cytoskeleton 2 — 2 2
Development 18 4 2 10 __
Molecular function unknown 17 2 2 5 _ _
Endoplasmic reticulum 12 2 2 3 —
Membrane fraction 10 5 3 9 __
Cellular component unknown 16 2 5 —
Transferase activity 12 _ _ 6 6 —
Transcription 8 — 6 8 —
Kinase activity 5 _ _ 2 4 —
Regulation of transcription from RNA polymerase II 
promoter 5 2 3
RNA polymerase II transcription factor activity 3 — 2 2 —
Signal transducer activity 3 2 6 —
Ubiquitin cycle 3 — 3 4 —
Protein amino acid phosphorylation 3 — 6 6 —
Transcription from RNA polymerase II promoter 2 — 2 2 —
Regulation of progression through cell cycle 2 2 5 —
Transcription coactivator activity 2 2 3 —
Binding 2 — 2 2
Protein serine/threonine kinase activity 2 3 2 —
Integral to plasma membrane 25 9 — 25 —
Oxidoreductase activity 20 4 — 4 —
Extracellular space 19 6 — 6 —
Extracellular region 18 3 — 10 —
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Table 5.1. Continued
Proteolysis and peptidolysis 15 2 — 8
Biological process unknown 15 2 — 8 —
Cell differentiation 10 4 __ 2 . .
Hydrolase activity 10 3 — 8 . .
Electron transporter activity 9 2 . . 2
Cell-cell signaling 9 6 — 5 —
Neurogenesis 7 4 __ 5 —
Growth factor activity 6 2 — 4 __
Soluble fraction 6 2 __ 4 —
lysosome 5 2 — 2 __
Transport 5 2 — 9 «
Morphogenesis 5 2 — 5 . .
Immune response 5 2 4
carbohydrate metabolism 2 3 — 2
Extracellular matrix structural constituent 19 — — 4 —
G-protein coupled receptor protein signaling pathway 11 — __ 13
Metabolism 10 — __ 4
Negative regulation of cell proliferation 8 __ . . 2
Phosphate transport 8 — — 4 __
Apoptosis 8 — — 2 —
Mitochondrion 7 — 4 __
GTP binding 7 __ __ 2 __
Golgi stack 7 __ — 2 __
Collagen 7 __ __ 4 __
Regulation of cell growth 6 — — 3 —
Cell cycle 6 __ — 3
Magnesium ion binding 6 __ __ 3 __
Protein modification 6 __ __ 2 __
Transmembrane receptor protein tyrosine kinase 
signaling pathway 5 2
Visual perception 5 __ __ 2
Catalytic activity 5 __ — 3
Cytosol 5 „ __ 5 „
Actin binding 5 __ __ 2
Rhodopsin-like receptor activity 5 — 10
Serine-type endopeptidase inhibitor activity 4 — __ 2 __
Blood coagulation 4 __ — 6 __
Circulation 4 — — 2 __
Insulin-like growth factor binding 4 __ __ 3 __
Peptidase activity 4 5 __
Negative regulation of progression through cell cycle 4 __ 2
Cell motility 4 __ __ 3 __
Angiogenesis 4 — __ 2 __
Aminopeptidase activity 4 — __ 2
Positive regulation of cell proliferation 4 __ — 3 __
Intracellular I 3 — — 3 —
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Table 5.1. Continued
Regulation of apoptosis 3 _ — 2 —
DNA repair 3 .. — 2 —
Sensory perception 2 — — 4 —
Lipid metabolism 2 .. — 2 —
Protein complex assembly 2 — — 3 —
Membrane alanyl aminopeptidase activity 2 — — 2 —
Metallopeptidase activity 2 .. — 2 —
Positive regulation of 1-kappaB kinase/NF-kappaB 
cascade 2 _ „ 3 „
Receptor binding 2 — — 2 ..
Extracellular matrix organization and biogenesis 2 — 2 —
Vascular endothelial growth factor receptor activity 2 .. 2
GTPase activity 2 — — 2 —
Induction of apoptosis 2 — — 2 —
Calmodulin binding 2 — — 2 __
Transporter activity 2 __ 6 __
ATPase activity _ 2 — 3
Cation transport — 2 2 ..
RNA binding — — 2 4 —
Protein amino acid dephosphorylation — .. 2 6 „
Ubiquitin thiolesterase activity .. __ 2 2 „
DNA binding 6 __ 5 — __
Intracellular signaling cascade 5 — 3 —
Transcription corepressor activity 3 ~ 2 — —
Chromosome organization and biogenesis (sensu 
Eukaryota) 2 2
Response to stress 2 __ 2 — __
ilon ion binding 6 2 _ „ __
Cell surface receptor linked signal transduction 3 2 __ — __
Hormone activity 3 2 __ __
Cell surface 2 2 __ __ __
Perception of sound 2 3 __ —
Cytokine activity 2 2 — „ __
Growth 2 2 __ __
Axon guidance 2 2 __ __ __
Protein folding 10 __ __
Ion transport 9 — — — __
Electron transport 8 __ __ _
Organogenesis 8 __ __ __ —
Pregnancy 7 __ __ __ _
Muscle development 5 — __ — __
Defense response 5 — __
Heparin binding 5 __ — _ _
Copper ion binding 5 „ __ __ __
Isomerase activity 5 __ __ _
Neuropeptide signaling pathway 5 — — __ __
Nucleic acid binding 5 __ __ __ __
Microsome 4 — — — —
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Table 5.1. Continued
Basement membrane 4 — — —
Unfolded protein binding 4 — — — —
Actin cytoskeleton organization and biogenesis 4 __ — —
Ligase activity 4 _ _ _ _ _ _ —
Sugar binding 4 — _ _ — —
Synaptic transmission 4 — — —
Potassium ion transport 4 — — —
Response to unfolded protein 4 — _ _ __ —
Cytoskeleton organization and biogenesis 4 _ _ . .
Anti-apoptosis 4 — _ _ __ _ _
Epidermis development 3 — — —
Neutral amino acid transporter activity 3 — — __ —
Coated pit 3 — _ _ . . —
Transcription regulator activity 3 — — — _ _
Regulation of transcription 3 — — — —
Collagen binding 3 — — — _ _
Ion channel transport 3 — — _ _ —
Central nervous system development 3 — _ _ __ _ _
Nucleoside metabolism 3 _ _ — _ _ —
Chemotaxis 3 — — — —
Ion channel activity 3 _ _ —
Protein transport 3 — — _ _ —
Voltage-gated ion channel activity 3 — _ _ — _ _
Potassium channel activity 3 — — —
Voltage-gated potassium channel complex 3 — — — —
Potassium ion binding 3 _ _ „ _ _ _ _
Cell cycle arrest 3 — — _ _ —
Cell-cell adhesion 3 _ _ . . __ _ _
Endonuclease activity 3 — _ _ —
Rho protein signal transduction 3 — — — —
Peptidyl-prolyl cis-trans isomerase activity 3 _ _ - - __
GTP biosynthesis 2 _ _ _ _ _ _
Intermediate filament 2 — — - - —
Enzyme inhibitor activity 2 _ _ — _ _ . .
Amino acid metabolism 2 — _ — —
Amino acid transport 2 — — _ _
Amino acid permease activity 2 — _ _ — _ _
Endocytosis 2 _ _ __
Microtubule 2 — — — —
SH3 domain binding 2 — _ _ —
Guanyl-nucleotide exchange factor activity 2 __ _ _ —
Cytochrome-b5 reductase activity 2 _ _ — __ __
Aldehyde dehydrogenase [-D(P)+1 activity 2 — . . __ —
Aldehyde metabolism 2 — — — —
Small GTPase mediated signal transduction 2 — _ _ — —
Collagen type 1 2 — — — —
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Table 5.1. Continued
Structural constituent of bone 2 — — —
Heme bindinq 2 — — —
Nucleosome 2 — — — —
Chromosome 2 — — —
Nucleosome assembly 2 — — — —
ER-Golgi intermediate compartment 2 — — —
Metalloendopeptidase activity 2 — _ _ _ —
inteqrin-mediated signaling pathway 2 — — —
Transferase activity, transferring glycosyl groups 2 — _ — —
Collagen type V 2 — — — —
Microfibril 2 — _ _ — —
Calcium-mediated signaling 2 — _ _ — —
Protein-lysine 6-oxidase activity 2 — — —
Transmembrane receptor activity 2 — _ _ — —
ilntracellular protein transport 2 — — — —
Enzyme activator activity 2 — — — _ _
Peptide hormone processing 2 — _ _ — —
Receptor mediated endocytosis 2 — — — —
Chloride transport 2 — — —
Postsynaptic membrane 2 — — — —
Protein targeting 2 — — —
Protein secretion 2 — _ _ —
Amino acid biosynthesis 2 — — — —
Acyltransferase activity 2 — — — —
Protein homodimerization activity 2 — — —
Cell-matrix adhesion 2 — _ _ — —
Neuropeptide hormone activity 2 — __ —
Sarcoglycan complex 2 — — — —
GTPase activator activity 2 — _ _ — . .
G1/S transition of mitotic cell cycle 2 — — — —
Cell division 2 — _ _ — —
Protein kinase C activation 2 — _ _ —
Protein binding, bridging 2 — — _ _ —
Lipid raft 2 _ _ __ _ _ _ _
Nucleotide metabolism 2 — _ — —
Negative regulation of adenylate cyclase activity 2 — _ _ — —
Ossification 2 — — _ _
Integrin binding 2 — _ _
Dipeptidyl-peptidase IV activity 2 — — —
Prolyl oligopeptidase activity 2 — — _ _ _ _
ILmellipodium 2 — _ _ . . _ _
Motor activity 2 — _ _ __ —
Protein self binding 2 — _ _ — —
Regulation of heart contraction rate 2 — — — —
Positive regulation of cell migration 2 — _ _ . . __
Mesoderm development — 2 — — —
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Table 5.1. Continued
Symporter activity — 2 — . . —
Ubiquitin-dependent protein catabolism — 3 — —
Protein-tyrosine kinase activity — — 2 — —
Protein kinase cascade — — 2 — —
Negative regulation of transcription — — 2 — —
Transcriptional repressor activity — — 2 — -
Negative regulation of transcription, DNA-dependent __ — 2 —
Ribonucleoprotein complex — — 2 — —
JNK cascade — — 2 — —
Cysteine-type endopeptidase activity — . . 2 — —
Inflammatory response — ~ — 4 —
Protein tyrosine phosphatase activity — 4 . .
Collagen type IV — — — 4 —
Response to drug — — _ _ 3 —
Elevation of cytoplasmic calcium ion concentration — — — 3 —
Serine-type endopeptidase activity — — — 3 —
Steroid hormone receptor activity — — _ _ 3 —
Protein serine/threonine phosphatase activity — — — 3 —
Aldehyde dehydrogenase (--D) activity — — — 2 —
Plasminogen activator activity — — — 2 —
Inactivation of MAPK activity - - — _ _ 2 —
Regulation of cell adhesion — — — 2 —
Negative regulation of cell growth — — — 2 —
Protein heterodimerization activity — — _ _ 2 —
MAPKKK cascade — — — 2 —
ATPase activity, coupled to transmembrane movement of 
substances _ 2 „
Sodium ion binding — — — 2 —
RNA processing . . — — 2 —
Caspase activator activity __ — — 2 —
Response to nutrients — — _ _ 2 —
Prostaglandin E receptor activity — — 2 —
G-protein signaling, coupled to cAMP nucleotide second 
messenger _ _ . . 2 . .
Bradykinin receptor activity - - — _ 2 —
Activation of MAPK activity — — — 2 —
Adenylate cyclase activation __ — _ _ 2 —
Transcription factor complex __ — 2 —
Cation channel activity . . _ _ _ _ 2 —
ligand-regulated transcription factor activity _ _ — _ _ 2 —
Cysteine-type peptidase activity — — — 2 —
Caspase activity . . — . . 2 —
Ubiquitin-protein ligase activity __ — _ _ 2 —
Heterogeneous nuclear ribonucleoprotein complex — — — 2 —
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5.4.8 UVC-induced time-dependent modulation of the 
telomerised MRC-5, XP-C and CS-A cell transcriptome
Exposure of telomerised MRC-5, XP-C and CS-A fibroblasts to UV, resulted in 
the time-dependent transcriptional modulation of 763 probe sets (at an FDR of 
0.001%), out of the 22,283 probe sets present on the HG-U133A GeneChip® 
array, (Fig. 5.5). The 763 differentially regulated probe sets, which represented 
612 genes, were further organised by hierarchical clustering into five distinct 
clusters, according to the level and pattern of mRNA expression (Fig. 5.6).
Although many of the differentially regulated probe sets identified in the five 
clusters were common to telomerised MRC-5, XP-C and CS-A cell lines and 
displayed similar levels of induction and/or repression, the differentially 
regulated UV-responsive probe sets displayed marked differences in the kinetics 
of induction and/or repression between the cell lines over the time course.
The kinetics of transcriptional modulation in the 367 probe sets identified in 
cluster 1 was similar for both telomerised MRC-5 and XP-C cells following UV 
exposure (Fig. 5.6). The majority of probe sets within this cluster were highly 
expressed in both MRC-5 and XP-C cells at 0 hours. This was followed by 
kinetics of repression at -6  hours in response to UV. The 367 probe sets were 
induced at both -1 2  and -24  hours post UV. Similarly, the CS-A cell line 
displayed similar kinetics of transcriptional modulation at 0 hours. However, the 
367 probe sets were repressed at -6  and -12  hours following UV. A large 
number of probe sets remained downregulated at -24  hours posts UV, while a 
subset of probe sets were induced at 24 hours (Fig. 5.6, cluster 1).
Similar to cluster 1, the kinetics of the 152 differentially regulated probe sets in 
cluster 2 was similar in both MRC-5 and XP-C cells. Both cell lines displayed 
kinetics of repression at 0 hours post UV. This was followed by an immediate 
upregulation at -6  hours, which was maintained at -12  hours after UV. The 
MRC-5 and XP-C cells displayed heterogeneous levels of transcriptional 
modulation at -24  hours, as the probe sets showed high and low levels of
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expression. These data suggest that, the probe sets differentially induced in the 
MRC-5 and XP-C cell lines reached a peak level of induction at -6  hours after 
UV, and although the kinetics of induction was sustained at -12 hours, no further 
increases in induction was observed. Like MRC-5 and XP-C cells, the 152 probe 
sets were repressed at 0 hours. However, unlike the early kinetics of induction 
observed in the MRC-5 and XP-C cells at ~6 hours, the CS-A cells presented a 
delayed pattern of induction. The pattern of transcription observed at -6  hours 
was similar to that seen at 0 hours post UV. A gradual induction of the 152 probe 
sets was observed at -12 hours. However, unlike the MRC-5 and XP-C cell 
lines, a further upregulation of the probe sets occurred at ~24 hours after UV. 
These data indicate that the UV-induced, time-dependent transcriptional response 
of the 152 probe sets was protracted in the CS-A cell line, compared to the 
MRC-5 and XP-C cell lines.
Cluster 3 (162 probe sets) comprises genes whose expression profiles vary 
significantly between the telomerised MRC-5, XP-C and CS-A cells (Fig. 5.6). 
Unlike clusters 1 and 2, the differentially regulated probe sets observed in cluster 
3 displayed no common pattern of expression between these. In MRC-5, the 162 
probe sets displayed high levels of expression at 0 hours. However, the probe 
sets displayed kinetics of downregulation at ~6 and ~12 post UV, while 
induction was observed at -24 hours. Similarly, the 162 probe sets displayed 
high levels of expression in XP-C cells at 0 hours, followed by a slight 
downregulation at ~6 hours. A further global downregulation was observed at 
-12 hours. However, the transcriptional modulation of the 162 probe sets at -24 
hours post UV exhibited no clear pattern of expression, except for a subset of 
probe sets which displayed a further downregulation in expression. CS-A cells 
presented similar kinetics of transcriptional modulation at 0 and -6  hours post 
UV to MRC-5 and XP-C cells. However, a global repression of the probe sets 
was observed at -12 and -24 hours (Fig. 5.6, cluster 3).
Cluster 4 (81 probe sets) contained probe sets that displayed well-defined and 
similar patterns of transcriptional kinetics between the MRC-5, XP-C and CS-A 
cell lines (Fig. 5.6, cluster 4). The cluster included genes that were
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predominantly induced at 0 and -6  hours after UV. Moreover, the level of 
induction appeared similar between the two time points. Conversely, the 81 
probe sets displayed a generalised pattern of repression at -12 and -24  hours 
after UV. In contrast, the induction of the 81 probe sets in the CS-A cell line was 
sustained at -12, and kinetics of global repression was only observed at -24 
hours post UV.
The differentially regulated probe sets identified in the five time-dependent 
clusters represented biological functions typically associated with a DNA 
damage response such as proliferation, positive and negative regulators of the 
cell cycle and apoptosis. However, differentially regulated probe sets identified 
in clusters 1-4 represented a diverse range of functional groups associated with 
the nucleus, protein binding and regulation of transcription (Appendix 2). In 
contrast to the genotype-specific changes, however, several probe sets associated 
with DNA repair were differentially regulated. For example, CDK7, CSNKID, 
NCOA6, PARP2, PML, POLB, RAD 17 and REV3C were identified in cluster 1. 
Additionally, BTG2, GADD45a, KCTD13, POLG2 and SFPQ were differentially 
regulated in cluster 2 (Appendix 2). Interestingly, D D B2 , an important 
constituent of the GGR subpathway was upregulated in cluster 2.
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Figure 5.5. ANOVA of time-dependent changes in gene expression. Hierarchical 
clustering depicting the time-dependent transcriptional changes o f 763 differentially 
regulated probe sets, whose levels of expression altered in a time-dependent manner in 
telomerised MRC-5, XP-C (GM02996, XP8CA) and CS-A (GM01856, CS3BE) 
fibroblast cell lines, following UVC (254 nm), at the indicated time points (h, hour). The 
columns correspond to the cell lines and the rows to each gene transcript. The altered 
expression levels are represented in colour and red means upregulation, while green, 
downregulation.
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Figure 5.6. Hierarchical clustering of time- 
dependent genes following UVC-irradiation. 
The data depicts five distinct clusters, which 
show d iffe ren tia lly  regulated  genes 
identified in telomerised MRC-5, XP-C 
(GM02296, XP8CA) and CS-A (GM01856, 
CS3BE) fibroblast cell lines at the indicated 
time points (h, hour), following UVC 
treatment. The columns correspond to the 
cell lines and the rows to each gene. The 
change in expression is represented in 
colour and red means upregulation, while 
green, downregulation.
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Table 5.2. Functional classes of time-dependent differentially expressed probe sets.
GO Category
Cluster
1
Cluster
2
Cluster
3
Cluster
4
Nucleus 116 48 30 9
Protein binding 90 26 32 9
Transcription 50 16 9 2
Zinc ion binding 49 15 15 7
Nucleotide binding 48 19 21 8
Metal ion binding 48 14 10 5
ATP binding 38 11 18 6
Transferase activity 35 14 20 8
Membrane 32 18 22 13
Signal transduction 28 8 10 6
Cytoplasm 25 7 12 6
Protein amino acid phosphorylation 24 4 11 4
Protein serine/threonine kinase activity 22 4 7 3
Cellular component unknown 21 8 7 5
Integral to membrane 19 9 13 5
Molecular function unknown 17 5 7 4
Biological process unknown 16 4 7 2
Hydrolase activity 11 4 11 4
Integral to plasma membrane 9 5 5 5
Receptor activity 8 6 2 3
Guanyl-nucleotide exchange factor activity 6 2 2 2
Golgi stack 6 2 4 3
Mitochondrion 5 7 13 2
Kinase activity 4 3 3 3
Magnesium ion binding 4 3 6 2
Oxidoreductase activity 2 2 2 4
Cell surface receptor linked signal transduction 2 3 2 2
Binding 17 — 5 2
Intracellular signaling cascade 9 _ 9 2
Cytoskeleton 7 — 2 3
Calcium ion binding 7 — 13 4
Protein amino acid dephosphorylation 6 — 6 2
Plasma membrane 3 — 5 3
GTPase activator activity 3 _ 5 2
Regulation of progression through cell cycle 6 3 — 3
Cell adhesion 2 2 — 4
Neurogenesis 6 — — 3
Protein transport 6 — — 3
Proteolysis and peptidolysis 4 — — 2
Cell differentiation 2 — — 2
Carbohydrate metabolism 2 — — 2
Protein biosynthesis — 7 — 2
Regulation of transcription, DNA-dependent 60 17 10 _
DNA binding 35 15 7 —
Transcription factor activity 26 9 3 —
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Table 5.2. Continued
Nucleic acid binding 19 3 7 _
Cell cycle 17 6 5
Ubiquitin cycle 15 3 2 . .
Transcription coactivator activity 14 3 3 . .
RNA binding 13 7 5
Development 13 2 2 . .
Signal transducer activity 12 2 3
Intracellular 10 3 2
Transcription from RNA polymerase II promoter 8 3 2 —
Transport 7 2 3 . .
Apoptosis 7 2 2 —
Cytosol 5 2 3 . .
Protein self binding 3 2 2 —
Electron transport 2 2 2 . .
Membrane fraction 2 2 3 —
Cell-cell signaling 2 2 2 —
Regulation of transcription from RNA polymerase II promoter 11 __ 3 —
Intracellular protein transport 10 — 3 —
Cell proliferation 7 — 2 —
Metabolism 6 — 4 —
Ligase activity 6 _ 3 —
Cell division 5 — 2 —
Endocytosis 5 — 4 —
Regulation of transcription 4 — 5 —
Transporter activity 4 — 3 —
Protein complex assembly 4 — 3 —
Acyltransferase activity 4 — 2 —
Protein-tyrosine kinase activity 4 — 4 —
Catalytic activity 4 — 4 —
Transcription regulator activity 4 — 2 —
Transferase activity, transferring glycosyl groups 4 — 2 —
Positive regulation of transcription, DNA-dependent 3 — 2 —
Protein kinase cascade 3 — 2 —
Nucleoplasm 3 — 3 —
Ribonucleoprotein complex 3 — 2 —
G-protein coupled receptor protein signaling pathway 3 — 2 —
Protein serine/threonine phosphatase activity 2 — 2 ~
Protein tyrosine phosphatase activity 2 — 2 ~
Diacylglycerol binding 2 — 3 —
Phosphoprotein phosphatase activity 2 — 2 —
Regulation of GTPase activity 2 — 2 —
Calmodulin binding — 3 2 ~
Lyase activity — 2 2 —
DNA repair 8 5 — —
Transcription corepressor activity 6 3 - -
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Table 5.2. Continued
Nuclear mRNA splicing, via spliceosome 6 3 __ _
Negative regulation of cell proliferation 5 5 __ _
Endoplasmic reticulum 5 4 __ _
Small GTPase mediated signal transduction 5 2 __ _
DNA replication 5 3 __ _
RNA splicing 4 2 „
Immune response 4 4 __
Regative regulation of transcription from RNA polymerase II promoter 4 3 . . _
Positive regulation of cell proliferation 4 2 __ __
Protein folding 3 3 __ „
Response to unfolded protein 3 3 . . „
mRNA processing 3 2 __
Protein dimerization activity 2 3 __ „
Nucleosome 2 3 __
Nucleosome assembly 2 3 —
Transmembrane receptor protein tyrosine kinase signaling pathway 2 2 _ „
DNA-dependent DNA replication 2 2 . . __
Regulation of cyclin dependent protein kinase activity 2 2 — „
Chromosome organization and biogenesis (sensu Eukaryota) 2 3 . . „
Protein kinase activity 2 2 — —
Regulation of apoptosis 2 2 — —
General RNA polymerase II transcription factor activity 2 2 — _
N nucleolus 2 5 — —
Cell cycle arrest 2 3 — —
Positive regulation of 1-kappaB kinase/NF-kappaB cascade 2 3 — —
Translation initiation factor activity 2 3 — —
RNA polymerase II transcription factor activity 12 — — —
Soluble fraction 7 — — —
Ubiquitin-dependent protein catabolism 7 — — —
Regulation of translation 6 — — —
Ubiquitin-protein ligase activity 6 — — —
Microtubule 5 — — —
Peptidase activity 5 — — —
Induction of apoptosis 5 — — —
Negative regulation of progression through cell cycle 5 — — —
Ubiquitin thiolesterase activity 5 — — —
Microtubule associated complex 4 — — —
Chromatin modification 4 — — -
Protein phosphatase type 2A complex 4 — - -
Protein phosphatase type 2A regulator activity 4 — — —
Protein transporter activity 4 — — —
Histone acetyltransferase activity 4 — — —
Specific RNA polymerase II transcription factor activity 4 — — —
Cysteine-type peptidase activity 4 — - -
Response to stress 4 — — —
Positive regulation of transcription from RNA polymerase II promoter 4 - - --
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Table 5.2. Continued
Transcriptional repressor activity 4 __ __ _
Cysteine-type endopeptidase activity 4 __ __ __
Ion transport 3 __ __ __
Structural molecule activity 3 __ __ _
Nuclear pore 3 __ __ _
Protein heterodimerization activity 3 __
Androgen receptor signaling pathway 3 __ __
Androgen receptor binding 3 . . __
JAK-STAT cascade 3 __ __ „
Chromatin 3 __ „
Chromatin binding 3 __ . .
SH3/SH2 adaptor activity 3 __ __ __
JNK cascade 3 __ __ „
Negative regulation of transcription, DNA-dependent 3 — — . .
Transcriptional activator activity 3 — — —
ATP-dependent helicase activity 3 . . — _
Ubiquitin ligase complex 3 __ __ „
Negative regulation of transcription 3 . . __ . .
Transcription initiation from RNA polymerase II promoter 3 — — __
Wnt receptor signaling pathway 3 — — —
Manganese ion binding 3 — — —
Lipid metabolism 2 — — . .
Cell motility 2 — — —
Mitosis 2 — — —
Outer membrane 2 ~ — —
Phosphoinositide binding 2 — — —
Response to hypoxia 2 — — _
Homeostasis 2 — — —
DNA-directed RNA polymerase activity 2 — — —
Inositol or phosphatidylinositol phosphatase activity 2 — — —
Protein phosphatase type 2A activity 2 — — —
Lysosome 2 — — —
Estrogen receptor binding 2 — — —
Response to DNA damage stimulus 2 — — —
Microtubule motor activity 2 — — —
Insulin receptor signaling pathway 2 — — —
mRNA splice site selection 2 — — —
Vesicle-mediated transport 2 — — —
Inactivation of MAPK activity 2 — — -
Regulation of Wnt receptor signaling pathway 2 — — -
Neqative regulation of cell growth 2 — — —
Organogenesis 2 — — —
Electron transporter activity 2 — — —
MAPKKK cascade 2 — — —
Chromatin assembly or disassembly 2 — — -
frizzled signaling pathway 2 - - -
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Table 5.2. Continued
Spliceosome complex 2 _ _ . . _
Transcription cofactor activity 2 _ _ _ . .
Sodium ion binding 2 . .
Ras protein signal transduction 2 _ _
Double-stranded DNA binding 2 _ _ . .
Rho GTPase activator activity 2 — — —
Inflammatory response 2 — —
Heart development 2 _ _ . . . .
Helicase activity 2 — —
Receptor binding 2 — — . .
Endosome 2 — — —
Response to virus 2 — „
DNA damage response, signal transduction by p53 class 
mediator resulting in induction of apoptosis 2 . . . . _
mRNA nucleus export 2 — _ _
Apoptotic program 2 — — —
Caspase activity 2 — — —
G1/S transition of mitotic cell cycle 2 — — —
Establishment and/or maintenance of chromatin architecture 2 — — —
DNA recombination 2 — — —
Thyroid hormone receptor binding 2 — — —
Protein ubiqutylation 2 — — —
PML body 2 — — —
Isomerase activity 2 — — —
Transforming growth factor beta receptor activity 2 — — —
GTP binding — 5 — —
Structural constituent of ribosome — 4 — —
Extracellular space — 4 — —
Unfolded protein binding — 3 — —
Ribosome — 3 — —
Growth factor activity — 3 — —
Chromosome — 3 — —
rRNA processing — 2 — —
Translational initiation — 2 — —
Transcription factor TFIID complex — 2 — —
Cyclin-dependent protein kinase inhibitor activity — 2 — —
Transmembrane receptor activity — 2 — —
GTPase activity — 2 — —
Potassium ion transport — 2 — —
Voltage-qated potassium channel complex — 2 — —
Cytokine activity — 2 — —
Transcription from RNA polymerase I promoter — 2 — —
Motor activity — — 2 —
Actin bindinq — — 2 -
Myosin — — 2 —
ilon ion binding — — 2 —
phospholipase C activation -- - 2 -
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Table 5.2. Continued
Mitochondrial inner membrane — __ 2 __
mRNA 3-UTR binding — — 2 —
Exonuclease activity — 2 —
Positive regulation of apoptosis — 2 . .
Embryonic development __ __ 2
Hindbrain development — __ 2 . .
Regulation of transcriptional preinitiation complex formation — 2 —
Visual perception __ __ 2
Golgi apparatus — __ 2 —
Protein tyrosine/serine/threonine phosphatase activity __ __ 2 —
Centrosome — — 2 —
NF-kappaB binding „ __ 2 „
Coated pit — __ 2
Transcription factor binding — — 2 —
Tight junction — __ 2 —
Ras GTPase binding — — 2 —
Heat shock protein binding __ 2
Axonogenesis — — 2
Actin cytoskeleton - - — 2
Intergrin-mediated signaling pathway — — — 2
Transmembrane receptor protein tyrosine phosphatase activity — — — 2
Ribonucleoside monophosphate biosynthesis — . . . . 2
Muscle development __ — 2
Synaptic transmission — — 2
Perception of sound — . . 2
Protein modification — - — 2
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5.4.9 Combined UVC-induced time-dependent and 
genotype-specific modulation of telomerised MRC-5, XP-C 
and CS-A cell transcriptome
The data presented in Sections 5.4.7 and 5.4.8 describe the effects of the two 
independent variables, namely cell type and time after UV-irradiation. However, 
to determine the combined effect of both genotype and time on the pattern of 
differential gene expression, a two-factor ANOVA was performed. To achieve 
this, an interaction factor was incorporated into ANOVA to facilitate the 
identification of genes that were differentially regulated with both time and 
genotype. The ANOVA revealed that of the 22,283 probe sets present on the 
Affymetrix™ HG-U133A GeneChip® array, 442 probe sets (at an FDR = 
0.01%), which represented 377 genes, were differentially regulated in both a 
genotype- and time-dependent manner and they represented a diverse range of 
functional groups (Table 5.3). Subsequent hierarchical clustering resulted in the 
generation of three distinct clusters that represented different kinetics of 
transcriptional activation and/or repression.
Cluster 1 (270 probe sets) represented kinetics of downregulation at -6  hours in 
both MRC-5 and XP-C cells. In contrast, both induction and repression of the 
270 probe sets was observed in CS-A cells at -6  hours post UV. At -12 and -24 
hours, a marked upregulation was observed in MRC-5 cells. However, the 
kinetics of transcriptional modulation in XP-C cells at -12 and -24  hours was 
more complex (Fig. 5.8, cluster 1). The majority of probe sets remained 
downregulated at -12 hours, while a subset of probe sets were upregulated. 
Conversely, most of the probe sets identified in cluster 1 were upregulated at -24 
hours in XP-C cells. However, a subset of downregulated genes (at -12 hours) 
remained in a repressed state at 24 hours. The downregulated pattern of 
expression observed at -6  hours in CS-A was sustained throughout the time 
course at -12 and -24 hours post UV.
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After UV, the kinetics of transcriptional modulation of the 153 probe sets 
identified in cluster 2 was similar in both the telomerised MRC-5 and XP-C 
cells. At 0 hours, the 153 probe sets were repressed in both MRC-5 and XP-C. 
Rapid induction was observed at ~6 hours in both cell lines. Moreover, the level 
of induction was sustained at ~12 hours post UV in both MRC-5 and XP-C cells. 
A subsequent downregulation of the probe sets occurred at ~24 hours in both cell 
lines. In contrast, the 153 probe sets remained repressed at 0 and ~6 hours post 
UV in telomerised CS-A cells, while both induction and repression of the probe 
sets was observed at ~12 hours post UV. This was followed by a global 
upregulation of the probe sets at ~24 hours. These data suggested that the 
kinetics of UV-induced transcription was delayed in the telomerised CS-A cell 
line when compared to the MRC-5 and XP-C cells (Fig. 5.8).
Cluster 3 (19 probe sets) exhibited no obvious patterns of differential gene 
expression (Fig. 5.8). However, a global downregulation of the probe sets was 
observed throughout the time course in MRC-5 cells after UV. Conversely, the 
XP-C cell line displayed a pattern of moderate induction throughout the time 
course following UV. Although significant levels of induction and repression 
were displayed by CS-A, the heat map revealed no global pattern of expression 
between the 19 differentially regulated probe sets in cluster 3 (Fig. 5.8).
The differentially regulated probe sets identified following two-factor analysis 
resulted in the identification of several functional groups typically associated 
with a DNA-damage response such as proliferation, positive and negative 
regulators of the cell cycle and apoptosis (Appendix 3). However, a large number 
probe sets represented several functional groups that were previously identified 
(Sections 5.4.7 & 5.4.8) and associated with the nucleus, protein binding, 
nucleotide binding, membrane, signal transduction and transcription. Several 
probe sets identified in cluster 1 (MNA T1, PARP4 and XRCC4) and cluster 2 
(BTG2, CSNK1D, GADD45a, HUS1, KCTD13, RBM14 and UBE2B) is closely 
associated with DNA repair.
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Figure 5.7. Hierarchical clustering depicting the transcriptional response to UVC radiation. The 
expression pattern of 442 differentially regulated genes, whose levels of expression altered after 
interaction analysis in telomerised MRC-5, XP-C (GM02996, XP8CA) and CS-A (GM01856, 
CS3BE) dermal fibroblast cell lines, following UVC (254 nm), at the indicated time points (h, 
hour). The columns correspond to the cell lines and the rows to each gene transcript. The altered 
expression levels are represented in colour and red means upregulation, while green, 
downregulation.
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Figure 5.8. H ierarchical clustering of 
damage-responsive genes following UVC- 
irradiation (interaction term). The data 
depicts three distinct clusters, which show 
differentially regulated genes identified in 
telom erised MRC-5, XP-C (GM02996, 
XP8CA) and CS-A (GM01856, CS3BE) 
dermal fibroblast cell lines at the indicated 
time points (h, hour), following UVC 
treatment The columns correspond to the 
cell lines and the rows to each gene. The 
change in expression is represented in 
colour and red means upregulation, while 
green, downregulation.
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Table 5.3. Functional classes of differentially expressed probesets following interaction analysis.
GO Category
Cluster
1
Cluster
2
Cluster
3
Nucleus 71 63 2
Protein binding 56 27 3
Membrane 28 15 2
Signal transduction 27 9 2
Zinc ion binding 27 19 2
Metal ion binding 23 19 2
Cytoplasm 21 8 3
Golgi stack 8 2 2
Biological process unknown 7 5 2
Metabolism 5 2 2
Cytoskeleton 10 __ 2
Integral to plasma membrane 9 — 2
Skeletal development 2 2
Nucleotide binding 40 24 _
ATP binding 26 8 . .
Transferase activity 24 10 —
Regulation of transcription, DNA-dependent 21 25 —
Transcription 19 22 _
Protein amino acid phosphorylation 18 5 —
Binding 16 2 —
Transcription factor activity 14 16 _
RNA binding 14 13 _
ONA binding 14 12 —
Hydrolase activity 14 8 —
Protein serine/threonine kinase activity 13 5 —
Nucleic acid binding 12 9 —
Signal transducer activity 12 5 —
Cell cycle 11 6 —
Integral to membrane 11 7 _
Cellular component unknown 11 7 —
Ubiquitin cycle 10 3 —
Cell proliferation 10 2 —
Protein transport 9 2 —
Cytosol 9 3 —
Intracellular 9 6 —
Ligase activity 8 2 —
Development 8 2 —
Molecular function unknown 8 11 —
Mitochondrion 8 6 —
GTP binding 7 5 —
Transport 7 3 -
Protein amino acid dephosphorylation 7 2 —
Endoplasmic reticulum 7 2 —
Apoptosis 7 7 —
Nuclear mRNA splicing, via spliceosome 5 6 -
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Table 5.3. Continued
Neurogenesis 5 2 . .
Small GTPase mediated signal transduction 5 3 __
Soluble fraction 5 3 __
Negative regulation of progression through cell cycle 5 2 . .
Transcription coactivator activity 5 5 „
Magnesium ion binding 5 4 —
Proteolysis and peptidolysis 5 2 . .
Transcription from RNA polymerase II promoter 4 3 . .
Protein complex assembly 4 2
GTPase activity 4 2 . .
RNA splicing 4 4 —
Response to stress 4 2 . .
Immune response 4 2 . .
Cell differentiation 3 3 —
Double-stranded RNA binding 3 2 _
Regulation of translation 3 2 —
DNA repair 3 7 _
Rbonucleoprotein complex 3 2 —
Protein kinase cascade 3 2 —
Negative regulation of transcription from R - polymerase II promoter 3 4 —
RNA processing 3 2 —
Regulation of progression through cell cycle 3 5 —
Positive regulation of 1-kappaB kinase/NF-kappaB cascade 3 4 —
Negative regulation of cell proliferation 2 7 —
Endonuclease activity 2 2 —
Neqative regulation of cell growth 2 3 —
Regulation of apoptosis 2 2 —
Regulation of transcription 2 3 —
Manganese ion binding 2 2 —
Transcription corepressor activity 2 3 —
Calcium ion binding 10 — —
Intracellular signaling cascade 10 — —
Ubiquitin-dependent protein catabolism 9 — —
Ubiquitin-protein ligase activity 8 — —
Membrane fraction 7 — —
Receptor activity 7 — —
Nuclear pore 6 — —
RNA polymerase II transcription factor activity 6 — —
Intracellular protein transport 6 — —
Regulation of GTPase activity 6 — —
Requlation of transcription from RNA polymerase II promoter 6 — —
GTPase activator activity 6 — —
Cell adhesion 5 — —
Guanyl-nucleotide exchange factor activity 5 — —
Protein-tyrosine kinase activity 5 — —
Protein transporter activity 4 - -
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Table 5.3. Continued
Cysteine-type endopeptidase activity 4 __ _
Ubiquitin thiolesterase activity 4 _ „
G-protein coupled receptor protein signaling pathway 4 _
Transcription factor binding 4 . . _
Protein phosphatase type 2A complex 4 __ __
Protein phosphatase type 2A regulator activity 4 — —
ER to Golgi transport 4 __ __
Plasma membrane 4 — . .
Kinase activity 4 . . . .
Mitosis 3 . . . .
Lipid metabolism 3 — —
Cell growth 3 . . _
Peptidase activity 3 . . . .
Inflammatory response 3 — _
Protein serine/threonine phosphatase activity 3 _ —
Calmodulin binding 3 — _
Protein tyrosine phosphatase activity 3
MAPKKK cascade 3 — —
Protein self binding 3 __ _
ATP-dependent helicase activity 3 — —
Ubiquitin conjugating enzyme activity 3 — —
Nuclear membrane 2 — —
Microtubule 2 — —
Microtubule associated complex 2 — —
Cell motility 2 — —
Cell division 2 — —
Protein-nucleus import, docking 2 — —
Small GTPase regulator activity 2 — —
Ran GTPase binding 2 — —
Protein complex 2 — —
Muscle development 2 — —
Oxidoreductase activity 2 — —
Cell death 2 — —
Epidermis development 2 — —
Transporter activity 2 — —
Vesicle-mediated transport 2 — —
Actin cytoskeleton 2 — —
Structural molecule activity 2 — —
Motor activity 2 — —
Actin bindinq 2 — —
Androqen receptor siqnaling pathway 2 — —
tTansferase activity, transferring glycosyl groups 2 — —
NLS-bearing substrate-nucleus import 2 — —
Nuclear localization sequence binding 2 — —
Autophaqy 2 — —
Protein amino acid ADP-ribosylation 2 - -
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Table 5.3. Continued
Response to drug 2 _ _
Fatty acid catabolism 2 __ __
Iron ion binding 2 _ „
Response to DNA damage stimulus 2 __ _
SH3/SH2 adaptor activity 2 . . . .
Epidermal growth factor receptor signaling pathway 2 — . .
Phospholipase C activation 2 . .
Blood coagulation 2 — —
Diacylglycerol binding 2 — _
Vascular endothelial growth factor receptor activity 2 . . . .
Transmembrane receptor protein tyrosine kinase signaling pathway 2 — —
Chromatin 2 — . .
JNK cascade 2 — —
Double-stranded DNA binding 2 — __
Single-stranded DNA binding 2 — —
Caspase activator activity 2 — —
DNA recombination 2 —
Protein modification 2 — . .
Intracellular transporter activity 2 — —
Negative regulation of signal transduction 2 — —
integrin-mediated signaing pathway 2 — —
MAP kinase phosphatase activity 2 — —
Heterogeneous nuclear ribonucleoprotein complex 2 — —
Wnt receptor signaling pathway 2 — —
Angiogenesis 2 — —
Positive regulation of cell proliferation 2 — —
Calcium ion transport 2 — —
Phosphoinositide binding 2 — —
Centrosome 2 — —
Golgi membrane 2 — —
mRNA processing — 5 —
Induction of apoptosis — 4 —
DNA replication — 4 —
Anti-apoptosis — 3 —
Isomerase activity — 3 —
Translation initiation factor activity — 3 —
mRNA nucleus export — 3 —
mRNA catabolism, nonsense-mediated decay — 2 —
RNA splicing factor activity, transesterification mechanism — 2 —
Mitochondrial outer membrane — 2 —
Protein heterodimerization activity — 2 —
Pseudouridylate synthase activity — 2 —
Nucleoplasm — 2 —
rRNA processing — 2 —
Protein biosynthesis — 2 —
Extracellular space - 2 -
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Table 5.3. Continued
Protein dimerization activity — 2 —
DNA-directed RNA polymerase activity — 2 —
Transcription factor complex — 2
Positive regulation of transcription from RNA polymerase II promoter — 2 —
Transmembrane receptor activity — 2 _
Cell-cell signaling — 2 —
Growth factor activity — 2 —
Cell surface receptor linked signal transduction — 2 —
Extracellular matrix structural constituent — — 2
Extracellular matrix (sensu Metazoa) ~ - 2
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5.4.10 Data annotation and biological relevance
Following the identification of differentially regulated genes in telomerised 
MRC-5, XP-C and CS-A fibroblasts by ANOVA and hierarchical clustering, 
genes were individually assessed for their biological relevance in response to 
UV. This was undertaken using the Microarray Data Review and Annotation 
System (MADRAS; http://madras.uwcm.ac.ukT a web-based software package 
developed in-house by the Microarray Bioinformatics Group at Cardiff 
University. MADRAS provides a single accessible system, which facilitates the 
storage and sharing of gene lists whilst allowing the simultaneous visualisation 
of data and annotation of probes. MADRAS encompasses several web-based 
databases o f descrip tive  annotation  such as L o c u s l i n k  
(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene), H om ologene 
(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=homologene), O M IM  
(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM), P u b M e d 
(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed) and pathway 
packages such as B iocarta  (http://www.biocarta.com/), GenMAPP 
(http://www.genmapp.org/links.html), KEGG (http://www.genome.jp/kegg/) and 
AmiGO (Gene Ontology; http://www.Geneontology.org/; Gene Ontology 
Consortium). The incorporation of these databases by MADRAS facilitates the 
acquisition of knowledge on gene functionality and its interaction with other 
genes and/or pathways. In addition, MADRAS facilitated the visualisation of 
kinetics for each individual probe set by single gene graphing.
To further investigate the precise relationship and biological relevance between 
differentially regulated probe sets identified on the HG-U133A array in 
telomerised MRC-5, XP-C and CS-A fibroblast cells and to obtain a more 
coherent view of the transcriptional changes that occurred in response to UV, 
over-representation analysis was performed using MADRAS. The probe IDs 
from each cluster that presented a change in expression in a time- or genotype- 
dependent manner or a combination of both (interaction term) was interrogated. 
Over-representation was performed using term-enrichment, which relied upon 
membership of a pathway, Gene Ontology terms and word present within the
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functional summary. Although a large number of differentially regulated genes 
were identified in this investigation, none of the functional groups or pathways 
was significantly represented in a time- or genotype-dependent manner (Tables 
5.4 & 5.5, respectively). Furthermore, term-enrichment using MADRAS, failed 
to identify any significantly over-represented terms or pathways following two- 
factor ANOVA analysis (Table 5.6).
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Table 5.4. Over-representation analysis of genotype-specific transcriptional changes using term-enrichment.
Pathway Probe list Global p-value
Cluster 1
BioCarta pathway
Biosynthesis of arginine in bacteria 1/290 3/12986 0.02
BTG family proteins and cell cycle regulation 2 /290 12 / 12986 0.05
GeneMAPP
Extracellular matrix Sensu Metazoa 19/290 227 / 12986 1.00E-05
KEGG
ECM-receptor interaction 13/290 179/ 12986 0.002
Ascorbate and aldarate metabolism 3 /290 19/ 12986 0.026
Words in Official Gene Name
Pregnancy 7 /2 9 0 21 / 12986 4.00E-08
27kda 3 /290 8 / 12986 3.00E-04
Cathepsin 4 /2 9 0 20 /12986 0.005
Collagen 8 /290 81 / 12986 0.009
Homeo 7 /290 65 / 12986 0.01
Neuromedin 2 /2 9 0 6/12986 0.011
Negative 3 /290 3 /290 0.027
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Table 5.4. Continued
Pathway________________________________________________________________________________________________Probe list______ Global__________p-value
Cluster 2
BioCarta pathway
Role of parkin in the ubiquitin-proteasomal pathway 1/63 5/12986 0.002
Msp/Ron receptor signaling pathway 1/63 7/12986 0.006
Adhesion and diapedesis of granulocytes 1/63 10/ 12986 0.014
Adhesion and diapedesis of lymphocytes 1/63 10/12986 0.014
Mechanism of acetaminophen activity and toxicity 1/63 11/12986 0.017
Y branching of actin filaments 1/63 12/12986 0.021
Low-density lipoprotein (LDL) pathway during atherogenesis 1/63 13 / 12986 0.025
Aspirin blocks signaling pathway involved in platelet activation 1/63 16 /12986 0.04
GeneMAPP
Hs 1-tissue-muscle fat and connective 4/63 105 / 12986 0.01
KEGG
Galactose metabolism 2/63 37 / 12986 0.02
Words in official gene name
Activin 2/63 15 / 12986 0.001
A activin 2/63 15/ 12986 0.001
Homeo 3/63 65 / 12986 0.007
Homeo box 3/63 65 /12986 0.007
Table 5.4. Continued
Pathway Probe list______Global__________p-value
Cluster 3
BioCarta pathway
proteolysis and signaling pathway of notch 1/53 6 /  12986 0.003
Generation of amyloid B-peptide by PS1 1/53 9/12986 0.009
G-secretase mediated ErbB4 signaling pathway 1/53 9/12986 0.009
AKAP95 role in mitosis and chromosome dynamics 1/53 10/12986 0.011
Rho-selective guanine exchange factor AKAP13 mediates stress fiber formation 1/53 12 /12986 0.017
Presenilin action in notch and Wnt signaling 1/53 14 /12986 0.024
Protein kinase A at the centrosome 1/53 15 / 12986 0.027
IL 4 signaling pathway 1/53 17 / 12986 0.036
Growth hormone signaling pathway 1/53 18/ 12986 0.041
Multiple antiapoptotic pathways from IGF-1R signaling lead to BAD phosphorylation 1/53 18/ 12986 0.041
KEGG
Notch signaling pathway 3/53 77 / 12986 0.004
Words in official gene name
Ubiquitin 4/53 183/ 12986 0.03
Gene ontology terms
RRNA modification 2/53 16 /12986 2.00E-04
Table 5.4. Continued
Pathway Probe list Global p-value
Cluster 4
BioCarta pathway
Extrinsic prothrombin activation pathway 3 /156 12/ 12986 7.00E-05
Fibrinolysis pathway 2 /156 6 /  12986 2.00E-04
Acute myocardial infarction 2 /1 5 6 10/12986 0.002
Role of PPAR-gamma coactivators in obesity and thermogenesis 1 /156 5/12986 0.023
Basic mechanism of Action of PPARa, PPARb(d) and PPARg and effects on gene expression 1/156 6 /  12986 0.038
Visceral fat deposits and the metabolic syndrome 1 /156 6/12986 0.038
GenMAPP
Hs complement and coagulation cascades KEGG 6 /156 73 / 12986 0.003
KEGG
Complement and coagulation cascades 7 /156 95 / 12986 6.00E-04
Retinol metabolism 1/156 5/12986 0.05
Words in official gene name
Bradykinin 2 /156 2/12986 <2e-16
Pepsinogen 2 /1 5 6 2/12986 <2e-16
Secreted 3 /156 24 /12986 0.02
Tissue 3/156 26/12986 0.02
Table 5.4. Continued
Pathway Probe list Global p-value
Plasminogen 2 /156 12/ 12986 0.03
Coagulation 3 /156 28 / 12986 0.03
Multiple 4 /1 5 6 50/ 12986 0.03
Cluster 5
BioCarta pathway
Biosynthesis of glycine and serine 1/30 3/12986 3.00E-05
Snfl in Yeast glucose repression/derepression 1/30 6/12986 3.00E-04
Regulation of MAP kinase pathways through dual specificity phosphatases 1/30 15 / 12986 0.002
Rho cell motility signaling pathway 1/30 21 / 12986 0.005
Eicosanoid metabolism 1/30 38 / 12986 0.016
KEGG
O-glycan biosynthesis 1/30 32 / 12986 0.03
Dentatorubropallidoluysian atrophy (DRPLA) 1/30 41 / 12986 0.05
Words in official gene name
Homeobox 2/30 67 / 12986 0.005
Table 5.5. Over-representation analysis of time-dependent transcriptional changes by term-enrichment.
Pathway Probe list Global p-value
Cluster 1
BioCarta pathway
Degradation of the RAR and RXR by the proteasome 1/327 1 / 12986 <2e-16
D4-GDI signaling pathway 1/327 3 / 12986 0.05
The information-processing pathway at the IFN-beta enhancer 1/327 3/12986 0.05
Words in official gene name
Meisl 2 /327 2 /  12986 <2e-16
Itam 2/327 4/12986 <2e-16
And itam 2/327 4 /  12986 <2e-16
Vps9 2 /327 4 /  12986 <2e-16
Pumilio 2 /327 5 /  12986 0.005
Ecotropic 3 /327 13 / 12986 0.021
Enhancing 2 /327 7/12986 0.043
Gene ontology
Binding 5 /327 36482 / 12986 NA
Cluster 2
BioCarta pathway
Regulation of EIF2 1/134 6 /  12986 0.04
Eukaryotic protein translation 1/134 7/12986 0.05
Table 5.5. Continued
Pathway Probe list Global p-value
KEGG
Lysine biosynthesis 1/134 6/ 12986 0.02
Words in offficial name
Torsin 3/134 8/12986 6.00E-06
Maturation 2/134 5/12986 1.00E-04
120kda 2/134 5/12986 1.00E-04
1 120kda 2/134 5/12986 1.00E-04
Nucleolar 3/134 38 / 12986 0.05
Cluster 3
BioCarta pathway
Activation of PKC through G protein coupled receptor 1/147 2/ 12986 <2e-16
PKC-catalyzed phosphorylation of inhibitory phosphoprotein of myosin phosphatase 1/147 2/12986 <2e-16
G-protein signaling through tubby proteins 1/147 5/ 12986 0.03
Neuropeptides VIP and PACAP inhibit the apoptosis of activated T cells 1/147 6/ 12986 0.05
Regulation of EIF2 1/147 6/12986 0.05
Words in official gene name
Acids 2/147 12 /12986 0.02
Gene ontology
Binding 2/147 36482 /12986 NA
Table 5.5. Continued
Pathway Probe list Global p-value
Cluster 4
BioCarta pathway
Neuropeptides VIP and PACAP inhibit the apoptosis of activated T cells 1/72 6/12986 0.003
Internal ribosome entry pathway 1/72 9 /  12986 0.007
Role of EGF receptor transactivation by GPCRs in cardiac hypertrophy 1/72 18/ 12986 0.035
Words in official gene name
Branching 2/72 4/12986 <2e-16
Glycogen 2/72 14/12986 0
Cluster 5
GenMAPP
Hs 1-tissue-blood and lymph 1/1 271 /12986 <2e-16
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Table 5.6. Over-representation analysis of genotype- and time-dependent transcriptional changes by term-enrichment.
Pathway Probe list Global p-value
Cluster 1
BioCarta pathway
Degradation of the RAR and RXR by the proteasome 1/327 1 / 12986 <2e-16
D4-GDI signaling pathway 1/327 3/12986 0.05
The information-processing pathway at the IFN-beta enhancer 1/327 3/12986 0.05
Words in official gene name
Meisl 2 /327 2 /  12986 <2e-16
Itam 2/327 4/12986 <2e-16
And Itam 2/327 4/12986 <2e-16
Vps9 2 /327 4/12986 <2e-16
Pumilio 2 /327 5/12986 0.005
Ecotropic 3 /327 13 / 12986 0.021
Enhancing 2 /327 7/12986 0.043
Gene ontology
Binding 5 /327 36482/ 12986 NA
Cluster 2
BioCarta pathway
Regulation of EIF2 1 /135 6/12986 0.04
Eukaryotic protein translation 1/135 7/12986 0.05
Table 5.6. Continued
Pathway Probe list Global p-value
KEGG
Lysine biosynthesis 1 /135 6/12986 0.02
Words in official gene name
Torsin 3 /135 8/12986 6.00E-06
Maturation 2 /135 5/12986 1.00E-04
120kda 2 /135 5/12986 1.00E-04
1 120kda 2 /135 5/12986 1.00E-04
Nucleolar 3 /135 38 / 12986 0.05
Cluster 3
BioCarta pathway
Activation of PKC through G protein coupled receptor 1/217 2/12986 <2e-16
PKC-catalyzed phosphorylation of inhibitory phosphoprotein of myosin phosphatase 1/217 2 /  12986 <2e-16
Neuropeptides VIP and PACAP inhibit the apoptosis of activated T cells 2 /217 6/12986 9.00E-04
Words in official gene name
Branching 2 /217 4/12986 <2e-16
Glycogen 3 /217 14 /12986 0.004
Quinone 2 /217 8/12986 0.016
Gene ontology
Binding 2 /217 36482 / 12986 NA
5.4.11 Validation of Affymetrix™ HG-U133A GeneChip® 
array data by qRT-PCR and Western blotting
To confirm the validity of the transcriptome data, quantitative RT-PCR was 
performed (using the ABI PRISM® 7000 System) on a selection of differentially 
regulated genes detected on the HG-U133A GeneChip® arrays. Genes were 
selected that lie downstream to p53 transactivation such as CDKN1A, the gene 
that encodes the p2 iWAF1/CIP1 tumour suppressor. Genes were selected that 
represented a diverse range of distinct or overlapping biological functions that 
are known to orchestrate several well-characterised DNA-damage responses, 
such as transcription (ATF3), stress signalling (CDKN1A and PPM ID), cell cycle 
regulation (Ccng2 and CDKN1A), growth (DTR), differentiation (GDF15), DNA 
repair (DDB2 and GADD45a), apoptosis (FDXR, PMAIP1 and SAT) and energy 
metabolism (FDXR and SAT). Moreover, many of these genes were selected due 
to their UV-induced genotype-specific signatures displayed by the telomerised 
MRC-5, XP-C and CS-A cell lines.
To increase the statistical validity of the RT-PCR assays, three independent 
biological replicates were prepared by performing additional UV-irradiations, 
RNA isolations and cDNA synthesis, independent of the samples processed for 
microarray analysis. In addition to the UV-irradiated samples, RT-PCR was 
performed on time-matched, non-irradiated controls, which were prepared in 
parallel to the irradiated samples and in an identical manner (except UV- 
irradiation was omitted).
Although Affymetrix™ microarrays and RT-PCR measured the changes in 
response to UV at the mRNA level, it is changes at the protein level that 
ultimately orchestrates cell function. To address this, changes at the protein level 
was investigated for p2 iWAF1/CIP1 (Chapter 4), ATF3, FDXR, GADD45a and 
PMAIP1 (NOXA), by undertaking Western blot analysis.
In Chapter 4, data was presented that confirmed the preservation of the 
p53/p21WAF1/CIP1 and pRb/plb1^ ^  tumour suppressor pathways, following the
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ectopic expression of hTERT. In addition to confirming stabilisation, the 
functional activity of p53 was assessed indirectly by measuring the levels of the 
p53 downstream CDK inhibitor, p21WAF1/CIP1, at the protein level by Western 
blotting and ICC. Global gene expression profiling presented in this Chapter, 
using the Affymetrix™ platform, revealed that CDKN1A was a UV-responsive 
gene that displayed kinetics of induction following UV at the transcriptome level 
in telomerised MRC-5, XP-C and CS-A cell lines (Fig. 5.9). To validate the 
Affymetrix™ data at the transcriptome level and confirm the functional activity 
of p53, CDKN1A was validated at the mRNA level by RT-PCR, using the 
TaqMan® platform.
Figure 5.10 clearly shows that the UV-induced transcriptional response of 
CDKN1A in telomerised XP-C and CS-A, measured by RT-PCR, recapitulated 
the kinetics of CDKN1A measured by Affymetrix™ HG-U133A GeneChip® 
arrays (Fig. 5.9). In agreement with the Affymetrix™ data, RT-PCR showed that 
CDKN1A was rapidly induced in XP-C at ~6 hours after UV (Fig. 5.10A). 
Although this response was sustained throughout the time course at -12 and -24 
hours post UV, a further significant increase in the CDKN1A mRNA transcript 
was not observed in the telomerised XP-C cells (Fig. 5.10A). In addition, the RT- 
PCR data revealed that there was a -2-3 fold induction of CDKN1A in the 
telomerised XP-C cells in response to UV, compared to the time-matched, non­
irradiated controls (Fig. 5.10A). Conversely, and in concordance with the array 
data (Fig. 5.9), RT-PCR revealed that unlike the XP-C cell line, telomerised CS- 
A cells exhibited kinetics of a gradual induction of CDKN1A over the time 
course (Fig. 5.10B). The level of CDKN1A was -1-3 fold higher at -6  and ~12 
hours, compared to the time-matched, non-irradiated controls (Fig. 5.1 OB). The 
level of CDKN1A appeared to peak at -24 hours, displaying a ~7-fold induction, 
compared to the time-matched, non-irradiated control (Fig. 5.1 OB). Notably, a 
slight induction was observed at ~6 hours following mock-irradiation in the 
telomerised CS-A cell line (Fig. 5.10B). This may have been attributed to a 
serum response following feeding with fresh medium after mock-irradiation. 
However, the level of CDKN1A mRNA in the time-matched, non-irradiated 
telomerised XP-C and CS-A cell lines remained relatively constant throughout
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the time course, displaying minimal fluctuations between the time points (Figs. 
5.10A & B, respectively).
The kinetics of p2lWAF1/CIP1 induction in the UV-irradiated telomerised XP-C and 
CS-A cell lines at the protein level, recapitulated the kinetics of CDKN1A 
induction at the mRNA level (Figs. 4.12B & C, respectively). As previously 
discussed (Chapter 4), Western blot analysis and ICC revealed that the level of 
p2 1 wafi/cipi protein in XP-C rapidly accumulated at -6  hours post UV and was 
sustained at high levels throughout the time course at -12 and -24 hours (Figs. 
4.12B & 4.14). Conversely, both Western blotting and ICC showed that 
p21WAF1/CIP1 protein levels gradually accumulated over the time course in the 
telomerised CS-A cell line, with an increase in p2 iWAF1/CIP1 observed at ~6, -12 
and -24 hours post UV (Figs. 4.12C & 4.15). In summary, Western blotting, 
Affymetrix™ and RT-PCR data presented here, clearly showed that 
accumulation of p2 iWAF1/CIP1 protein levels reflected the levels of CDKN1A 
mRNA in telomerised XP-C and CS-A cell lines following UV-irradiation. 
Notably, the levels of CDKN1A mRNA remained relatively constant in XP-C 
and CS-A throughout the time course in the time-matched, non-irradiated 
controls (Figs. 5.10A & B, respectively). In contrast, marked fluctuations were 
observed in p2iWAF1/CIP1 protein levels in both telomerised XP-C and CS-A cell 
lines, with high protein levels detected at 0 and -6  hours, compared to the low 
levels observed at -12 and -24 hours (Figs. 4.12B & C, respectively).
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Figure 5.9. Analysis of the transcriptional response of CDKN1A in response to UV-C radiation, using Affymetrix™ GeneChip® HG-U133A 
arrays. Graphical representation (using MADRAS) of the kinetics of the transcriptional response of CDKN1A over 24 hours in telomerised NER- 
proficient MRC-5, GGR-defective XP-C (GM02996, XP8CA) and TCR-defective CS-A (GM01856, CS3BE) fibroblasts, following exposure to 
10 J/m2 UV-C (254 nm) radiation. The incubation times are indicated. Differential regulation of expression is represented in colour and red 
represents upregulation, while green, downregulation. Abbreviations: hrs, hours.
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Figure 5.10. Verification of CDKN1A mRNA by quantitative RT-PCR. RT-PCR of CDKN1A in 
hTERT-immortalised (A) XP-C (GM02996, XP8CA) and (B) CS-A (GM01856, CS3BE) dermal 
fibroblasts at the indicated time points following UVC-irradiation (10 J/m2) or mock-irradiation 
(0 J/m2). The amplification of GAPDH was performed to normalise expression levels (not 
shown).
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Although RT-PCR confirmed the induction of ATF3 in telomerised XP-C and 
CS-A fibroblasts following UV (Figs. 5.12A & B, respectively), the kinetics of 
induction over the time course differed slightly compared to the ATF3 mRNA 
levels detected by the HG-U133A GeneChip® arrays (Fig. 5.11). The microarray 
data suggested that A TF3 was rapidly induced in XP-C at ~6 hours, while the 
level of ATF3 appeared to decrease at -12 and -24  hours post UV (Fig. 5.11). 
Although RT-PCR revealed the rapid induction of A TF 3  at - 6  hours, a 
corresponding reduction at -12 and -24  hours was less obvious (Fig. 5.12A). 
However, both microarrays and RT-PCR confirmed that a peak induction of 
ATF3 mRNA occurred at -6  hours post UV. Moreover, RT-PCR showed that 
ATF3 remained at constant low basal levels in the time-matched, mock-irradiated 
XP-C controls (Fig. 5.12A). For ATF3 gene expression in telomerised CS-A 
fibroblasts, microarray analysis revealed a pattern of gradual upregulation. This 
was similar to the kinetics observed for CDKN1A expression in CS-A following 
UV treatment (Figs. 5.9 & 5.1 OB). Similar kinetics of ATF3 induction was 
detected by RT-PCR (Fig. 5.12B). However, the gradual induction of ATF3 
mRNA detected by RT-PCR appeared notably reduced at -12  and -24  hours, 
compared to the levels detected by the microarray platform (Fig. 5.11). Similar to 
XP-C, ATF3 mRNA remained at low basal levels in the time-matched, mock- 
irradiated CS-A fibroblasts (Fig. 5.12B).
Interestingly, Western blot analysis revealed a slight delay in the induction of 
ATF3 at the protein level, compared to the rapid induction of ATF3 observed at 
the mRNA level (detected by microarrays) in telomerised GGR- and TCR- 
proficient MRC-5 fibroblasts following UVC-irradiation (Fig. 5.13A). Notably, 
ATF3 was rapidly induced at the mRNA level at -6  hours, and was rapidly 
downregulated at -12  and -24  hours post UV (Fig. 5.11). In stark contrast, a 
delay in ATF3 induction was observed at -12  hours, which reached a peak at 
-24 hours after exposure to UV (Fig. 5.13A). A subsequent decrease in ATF3 
protein was not seen in MRC-5 fibroblasts during the time course in this 
investigation. Conversely, the accumulation of ATF3 protein in telomerised 
GGR- (XP-C) and TCR-deficient (CS-A) fibroblasts appeared to recapitulate the 
kinetics of ATF3 induction at the mRNA level at -6, -12 and -24 hours after UV
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(Figs. 5.13B & C, respectively). For example, a rapid induction of ATF3 protein 
was observed at ~6 hours in XP-C, and was sustained at ~12 and ~24 hours (Fig. 
5.13B). In contrast, a gradual accumulation of ATF3 protein occurred in the 
telomerised CS-A fibroblasts (Fig. 5.13C), and peaked at -24 hours after UV. 
This pattern of kinetics for ATF3 protein induction in CS-A reflected the gradual 
accumulation of ATF3 observed at the mRNA level.
Notably, although the level of ATF3 mRNA remained constant in the time- 
matched, mock-irradiated controls in the telomerised XP-C and CS-A fibroblasts 
(Figs. 5.12A & B, respectively), a slight induction of ATF3 protein was seen in 
telomerised XP-C cells. The level of ATF3 peaked at ~6 hours and was 
subsequently reduced at ~12 and ~24 hours. A similar increase was not observed 
in telomerised MRC-5 and CS-A fibroblasts (Figs. 513A & C, respectively). 
Therefore, the induction of ATF3 at the mRNA and protein levels was UV- 
dependent. Furthermore, the telomerised NER-proficient (MRC-5), GGR- 
deficient (XP-C) and TCR-deficient (CS-A) cells exhibited genotype-specific 
kinetics for the differential regulation of ATF3 at both the transcriptome and 
proteome level. At the mRNA level both MRC-5 and XP-C cells displayed 
kinetics of rapid induction of ATF-3 followed by downregulation, while CS-A 
fibroblasts exhibited a gradual upregulation of ATF3 throughout the time course. 
This suggested a possible delay in the transcriptional expression of ATF3 in CS- 
A cells. Similarly, a gradual delay in the induction of ATF3 protein was observed 
in CS-A, and this further supported these findings.
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Figure 5.11. Analysis of the transcriptional response of ATF3 in response to UVC-irradiation, using Affymetrix™ GeneChip® HG-U133A 
arrays. Graphical representation (using MADRAS) of the kinetics of the transcriptional response of ATF3 over 24 hours in telomerised NER- 
proficient MRC-5 and GGR-defective XP-C (GM02996, XP8CA) and TCR-defective CS-A (GM01856, CS3BE) fibroblasts, following exposure 
to 10 J/m2 UV-C (254 nm) radiation. The incubation times are indicated. Differential regulation of expression is represented in colour and red 
represents upregulation, while green, downregulation. Abbreviations: hrs, hours.
Figure 5.12. Verification of ATF3 mRNA by quantitative RT-PCR. RT-PCR of ATF3 in hTERT- 
immortalised (A) XP-C (GM02996, XP8CA) and (B) CS-A (GM01856, CS3BE) dermal 
fibroblasts at the indicated time points following UVC-irradiation (10 J/m2) or mock-irradiation 
(0 J/m2) . The amplification of GAPDH was performed to normalise ATF3 expression levels (not 
shown).
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Figure 5.13. Induction of ATF3 protein following exposure to UVC-irradiation. 
Varification of microarray results at the protein level by Western blot analysis of 
UVC-induced time-dependent upregulation of ATF3, using an anti-ATF3 mouse 
monoclonal antibody (1:200). Time couse of ATF3 following mock-irradiation 
(-) or exposure to 10 J/m2 (+) UV-C in hTERT-immortalised (A) MRC-5, (B) 
XP-C (GM02996, XP8CA) and (C) CS-A (GM01856, CS3BE) fibroblasts at the 
indicated time points (20 pg of WCE per lane). Equal protein loading was 
confirmed by India ink staining (lower panel of each blot).
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Although the gene expression profiles obtained for Ccng2 in telomerised XP-C 
and CS-A fibroblasts (over the 24 hour time course) were largely discordant 
between the array and RT-PCR data, both methods detected an upregulation in 
Ccng2 mRNA at 24 hours following exposure to 10 J/m2 UV, and which 
appeared to be UV-dependent (Figs. 5.14 & 5.15). The array data showed that 
Ccng2 remained downregulated at 0 and ~6 hours in both XP-C and CS-A 
fibroblasts, while an upregulation of Ccng2 was observed at -12  and -24  hours 
in both cell lines. Conversely, the RT-PCR revealed heterogeneous levels of 
Ccng2 expression at -6  and -12 hours post UV. Furthermore, the level of Ccng2 
in the time-matched non-irradiated controls was similar to that displayed by the 
irradiated samples (Figs. 5.15A & B). Interestingly, the Affymetrix™ data 
showed that induction of Ccng2 in telomerised MRC-5 cells was upregulated at 
-12 hours, while repression of Ccng2 occurred at 24 hours post UV (Fig. 5.14).
The transcriptional kinetics of the GGR-specific gene, D D B2 , detected by 
microarray analysis (Fig. 5.16), recapitulated the levels o f DDB2 mRNA 
obtained by RT-PCR for both XP-C and CS-A cell lines following UV exposure 
(Figs. 5.17A & B, respectively). The Affymetrix™ data revealed that the 
transcriptional response of DDB2 in telomerised CS-A fibroblasts was similar to 
that observed in the telomerised MRC-5 cell line. A small induction was 
observed in both cell lines at -24  hours following UV (Fig. 5.16). In contrast, the 
microarray data showed that DDB2 mRNA gradually accumulated in XP-C cells, 
with a peak induction observed at -2 4  hours after UV. Similarly, RT-PCR 
revealed a marked induction of D D B2  at -1 2  and -2 4  hours in the XP-C 
fibroblasts, compared to the time-matched, mock-irradiated controls (Fig. 
5.17A). Moreover, the level of DDB2 mRNA remained at low basal levels in the 
time-matched, non-irradiated XP-C and CS-A fibroblasts at -6 , -12  and -2 4  
hours (Figs. 5.17A & B, respectively).
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Figure 5.14. Analysis of the transcriptional response of Ccng2 in response to UVC-irradiation, using Affymetrix™ GeneChip® HG-U133A 
arrays. Graphical representation (using MADRAS) of the kinetics of the transcriptional response of Ccng2 over 24 hours in telomerised NER- 
proficient MRC-5 and GGR-defective XP-C (GM02996, XP8CA) and TCR-defective CS-A (GM01856, CS3BE) fibroblasts, following exposure 
to 10 J/m2 UV-C (254 nm) radiation. The incubation times are indicated. Differential regulation of expression is represented in colour and red 
represents upregulation, while green, downregulation. Abbreviations: hrs, hours.
Figure 5.15. Verification of Ccng2 mRNA by quantitative RT-PCR. RT-PCR of Ccng2 in hTERT- 
immortalised (A) XP-C (GM02996, XP8CA) and (B) CS-A (GM01856, CS3BE) dermal 
fibroblasts at the indicated time points following UV-irradiation (10 J/m2) or mock-irradiation (0 
J/m2). The amplification of GAPDH was performed to normalise Ccng2 expression levels (not 
shown).
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Figure 5.16. Analysis of the transcriptional response of DDB2 in response to UVC-irradiation, using Affymetrix™ GeneChip® HG-U133A 
arrays. Graphical representation (using MADRAS) of the kinetics of the transcriptional response of DDB2 over 24 hours in telomerised NER- 
proficient MRC-5 and GGR-defective XP-C (GM02996, XP8CA) and TCR-defective CS-A (GM01856, CS3BE) fibroblasts, following exposure 
to 10 J/m2 UV-C (254 nm) radiation. The incubation times are indicated. Differential regulation of expression is represented in colour and red 
represents upregulation, while green, downregulation. Abbreviations: hrs, hours.
Figure 5.17. Verification of DDB2 mRNA by quantitative RT-PCR. RT-PCR of DDB2 in hTERT- 
immortalised (A) XP-C (GM02996, XP8CA) and (B) CS-A (GM01856, CS3BE) dermal 
fibroblasts at the indicated time points following UV-irradiation (10 J/m2) or mock-irradiation 0 
J/m2). The amplification of GAPDH was performed to normalise DDB2 expression levels (not 
shown).
Figure 5.18 shows the transcriptional profile (obtained by microarray analysis) of 
the DNA repair-associated gene, GADD45 a , at the indicated time points in 
telomerised MRC-5, XP-C and CS-A fibroblasts, following exposure to 10 J/m2 
UV. NER-proficient MRC-5 fibroblasts displayed induction at -6  hours post 
UV, while GADD45a appeared downregulated at 0, ~12 and -24  hours (Fig. 
5.18). Similarly, a rapid upregulation of G AD D 45a  occurred at -6  hours 
following UV in XP-C cells. This was followed by a subsequent downregulation 
at -12 and -24  hours. A rapid induction of GADD45a was also observed at -6  
hours in telomerised CS-A cells following UV. However, the elevated levels of 
GADD45a were sustained at -12  and -24  hours (Fig. 5.18). Moreover, unlike 
MRC-5 and XP-C cells, a downregulation of GADD45a was not observed during 
the time course in CS-A cells.
Western blot analysis was undertaken to examine GADD45a protein levels. 
GADD45a was detected throughout the time course in both the time-matched, 
non-irradiated MRC-5 and XP-C fibroblasts (Figs. 5.19A & B, respectively), 
while GADD45a was undetected by Western blotting in the mock-irradiated CS- 
A cells, as the indicated time points (Fig. 5.19C). Following UV, GADD45a was 
induced at -6  and -12  hours in MRC-5 cells, while the levels of GADD45a 
protein remained at basal levels at 0 and -24  hours (Fig. 5.19A). This shows that, 
following the DNA-damage induction of GADD45a; normal levels were 
maintained within the 24 hour time course. In contrast, a gradual upregulation of 
GADD45a was observed at —6, —12 and —24 hours after UV in telomerised XP- 
C and CS-A fibroblasts, compared to the time-matched, non-irradiated controls 
(Figs. 5.19A & B, respectively). Moreover, GADD45a did not revert to basal 
levels, thus suggesting that the DNA-damage-response was sustained throughout 
the time course in telomerised XP-C and CS-A cells. The data presented here, 
suggests that the accumulation of GADD45a protein recapitulated the induction 
of its mRNA. However, the data also suggested that there was a slight delay in 
kinetics, as peak GADD45a mRNA levels were observed at -6  hours in MRC-5, 
XP-C and CS-A cells, while peak GADD45a protein levels were not observed 
until between 12-24 hours post UV (Figs. 9.19A-C).
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The Affymetrix™ data suggested that the pro-apoptotic gene, PMAIP1 (NOXA), 
was rapidly induced at -6  hours in telomerised MRC-5 fibroblasts following UV 
(Fig. 5.20). A slight induction was also observed in telomerised XP-C cells 
following UV (Fig. 5.20). Like in MRC-5, PMAIP1 was downregulated in XP-C 
cells at -12 and -2 4  hours after UV. In contrast, CS-A displayed kinetics of 
induction that were similar to that observed for CDKN1A and ATF3 (Figs. 5.9 & 
5.11, respectively). A gradual upregulation of PMAIP1 was observed at -6  and 
-12 hours post UV, while PMAIP1 reached a peak at -24  hours. In disagreement 
with these data, RT-PCR suggested that PMAIP1 was rapidly induced at -6  
hours in XP-C cells, which was sustained at -12  and -24  hours (Fig. 5.21A). 
Conversely, RT-PCR revealed a slight induction of PMAIP1 at -6  hours in CS-A 
cells that was followed by a marked upregulation -12  hours (Fig. 5.21B). This 
was followed by a slight downregulation at -2 4  hours (Fig. 5.2IB). PMAIP1 
mRNA levels remained low in the time-matched, non-irradiated telomerised XP- 
C and CS-A controls (Figs. 5.21 A & B, respectively).
Notably, Figure 5.22A shows that PMAIP1 protein levels were elevated in both 
UV- and mock-irradiated MRC-5 cells. Although PMAIP1 was observed at -6  
hours in non-irradiated XP-C cells, PMAIP1 protein levels (Fig. 5.22B), detected 
by Western blotting, appeared to reflect the Affymetrix™ data (Fig. 5.20). A 
slight increase was observed in XP-C cells at —6 hours post UV. This was 
followed by a decrease at —12 and —24 hours. Similarly, the PMAIP1 protein 
levels recapitulated the PMAIP1 mRNA levels in CS-A cells following UV (Fig. 
5.22C). An increase of PMAIP1 was observed at -6  hours, followed by a further 
accumulation at -12 and -24 hours (Fig. 5.22C).
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Figure 5.18. Analysis of the transcriptional response of GADD45a in response to UVC-irradiation, using Affymetrix™ GeneChip® HG-U133A 
arrays. Graphical representation (using MADRAS) of the kinetics of the transcriptional response of GADD45a over 24 hours in telomerised 
NER-proficient MRC-5 and GGR-defective XP-C (GM02996, XP8CA) and TCR-defective CS-A (GM01856, CS3BE) fibroblasts, following 
exposure to 10 J/m2UV-C (254 nm) radiation. The incubation times are indicated. Differential regulation of expression is represented in colour 
and red represents upregulation, while green, downregulation. Abbreviations: hrs, hours.
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Figure 5.19. Induction of GADD45a protein following exposure to UVC- 
irradiation. Varification of microarray results at the protein level by Western blot 
analysis of UVC-induced time-dependent upregulation of GADD45a, using an 
anti-GADD45a mouse monoclonal antibody (1:250). Time couse of GADD45a 
following mock-irradiation (-) or exposure to 10 J/m2 (+) UV-C in hTERT- 
immortalised (A) MRC-5, (B) XP-C (GM02996, XP8CA) and (C) CS-A 
(GM01856, CS3BE) fibroblasts at the indicated time points (20 pg of WCE per 
lane). Equal protein loading was confirmed by India ink staining (lower panel of 
each blot).
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Figure 5.20. Analysis of the transcriptional response of PMA1P1 in response to UVC-irradiation, using Affymetrix™ GeneChip® HG-U133A 
arrays. Graphical representation (using MADRAS) of the kinetics of the transcriptional response of PMAIP1 over 24 hours in telomerised NER- 
proficient MRC-5 and GGR-defective XP-C (GM02996, XP8CA) and TCR-defective CS-A (GM01856, CS3BE) fibroblasts, following exposure 
to 10 J/m2 UV-C (254 nm) radiation. The incubation times are indicated. Differential regulation of expression is represented in colour and red 
represents upregulation, while green, downregulation. Abbreviations: hrs, hours.
7Figure 5.21. Verification of PMAIP1 mRNA by quantitative RT-PCR. RT-PCR of PMAIP1 in 
hTERT-immortalised (A) XP-C (GM02996, XP8CA) and (B) CS-A (GM01856, CS3BE) 
dermal fibroblasts at the indicated time points following UV-irradiation (10 J/m2) or mock- 
irradiation (0 J/m2). The amplification of GAPDH was performed to normalise PMAIP1 
expression levels (not shown).
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Figure 5.22. Induction of PMAIP1 protein following exposure to UVC- 
irradiation. Verification of microarray results at the protein level by Western blot 
analysis of UVC-induced time-dependent upregulation of PMAIP1, using an 
anti-PMAIPl mouse monoclonal antibody (1:400). Time couse of PMAIP1 
following mock-irradiation (-) or exposure to 10 J/m2 (+) UVC in hTERT- 
immortalised (A) MRC-5, (B) XP-C (GM02996, XP8CA) and (C) CS-A 
(GM01856, CS3BE) fibroblasts at the indicated time points (20 |ig of WCE per 
lane).
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The expression profiles of £>77? induction in telomerised XP-C and CS-A cells 
following UV, obtained by microarrays and RT-PCR were concordant (Figs. 
5.23 & 5.24, respectively). Both microarrays and RT-PCR revealed a rapid 
induction of D TR  at ~6 hours in XP-C after UV (Figs. 5.23 & 5.24A, 
respectively). The subsequent repression of DTR observed at -12 and -24 hours 
was further confirmed by both methods. Moreover, the rapid induction of £>77?, 
observed in CS-A cells at -6  hours following UV, which was detected by 
microarrays (Fig. 5.23), was confirmed by RT-PCR (Fig. 5.24B), as were the 
elevated DTR mRNA levels seen at -12  and -24  hours (Figs. 5.23 & 5.24B). 
DTR remained at low basal levels in the time-matched, mock-irradiated XP-C 
and CS-A cells (Figs. 5.24A & B, respectively), thus DTR induction was UV- 
dependent.
In concordance with the Affymetrix™ data (Fig. 5.25), RT-PCR confirmed the 
induction of GDF15 in XP-C cells after UV (Fig. 5.26). Both methods showed a 
slight upregulation of GDF15 at - 6  and -12  hours after UV with a further 
increase in expression at -24  hours (Figs. 5.25 & 5.26).
The transcription expression profiles for the apoptotic- and metabolic-associated 
gene, FDXR, obtained by microarray analysis and RT-PCR were concordant for 
the telomerised XP-C cell line (Figs. 5.27 & 5.28, respectively). Both 
technologies revealed a gradual induction of FDXR at -6  and -12 hours, which 
continued to increase at -2 4  hours, post UV. RT-PCR showed that FDXR  
remained in a repressed state in the time-matched, non-irradiated XP-C controls 
(Fig. 5.28).
Western blot analysis on UV- and mock-irradiated telomerised MRC-5, XP-C 
and CS-A WCEs, revealed marked variations in FDXR expression. For example, 
relatively high levels of FDXR protein were detected in the time-matched, non- 
irradiated MRC-5, XP-C and CS-A controls, thus suggesting that FDXR was 
maintained at high basal levels (Figs. 5.29A-C, respectively). A slight induction 
of FDXR protein occurred at -1 2  and -2 4  hours in MRC-5 following UV 
compared to time-matched, non-irradiated MRC-5 cells (Fig. 5.29A). This
340
recapitulated the transcriptome data obtained by expression profiling (Fig. 5.27). 
However, although gradual FDXR induction was observed at the transcriptome 
level in UV-irradiated XP-C cells (Figs. 5.27 & 5.28), FDXR protein levels 
remained at similar levels to the untreated controls (Fig. 5.29B). In contrast, an 
accumulation of FDXR protein was detected in telomerised CS-A cells at -6 , 
-12 and -24  hours after UV exposure when compared to the untreated XP-C 
cells (Fig. 5.29C). Hence, the induction of FDXR at the protein level 
recapitulated the induction of FDXR at the mRNA level in CS-A fibroblasts 
(Figs. 5.29C and 5.27, respectively).
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Figure 5.23. Analysis of the transcriptional response of DTR in response to UVC-irradiation, using Affymetrix™ GeneChip® HG-U133A arrays. 
Graphical representation (using MADRAS) of the kinetics of the transcriptional response of DTR over 24 hours in telomerised NER-proficient 
MRC-5 and GGR-defective XP-C (GM02996, XP8CA) and TCR-defective CS-A (GM01856, CS3BE) fibroblasts, following exposure to 10 
J/m2 UV-C (254 nm) radiation. The incubation times are indicated. Differential regulation of expression is represented in colour and red 
represents upregulation, while green, downregulation. Abbreviations: hrs, hours.
Figure 5.24. Verification of DTR mRNA by quantitative RT-PCR. RT-PCR of DTR in hTERT- 
immortalised (A) XP-C (GM02996, XP8CA) and (B) CS-A (GM01856, CS3BE) dermal 
fibroblasts at the indicated time points following UV-irradiation (10 J/m2) or mock-irradiation (0 
J/m2). The ampification of GAPDH was performed to normalise DTR expression levels (not 
shown).
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Figure 5.25. Analysis of the transcriptional response of GDF15 in response to UVC-irradiation, using Affymetrix™ GeneChip® HG-U133A 
arrays. Graphical representation (using MADRAS) of the kinetics of the transcriptional response of GDF15 over 24 hours in telomerised NER- 
proficient MRC-5 and GGR-defective XP-C (GM02996, XP8CA) and TCR-defective CS-A (GM01856, CS3BE) fibroblasts, following exposure 
to 10 J/m2 UV-C (254 nm) radiation. The incubation times are indicated. Differential regulation of expression is represented in colour and red 
represents upregulation, while green, downregulation. Abbreviations: hrs, hours.
350
300
250
200
150
Figure 5.26. Verification of GDF15 mRNA by quantitative RT-PCR. RT-PCR of GDF15 in 
hTERT-immortalised XP-C (GM02996, XP8CA) dermal fibroblasts at the indicated time 
points following UV-irradiation (10 J/m2) or mock-irradiation (0 J/m2) . The amplification 
of GAPDH was performed to normalise GDF15 expression levels (data not shown).
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Figure 5.27. Analysis of the transcriptional response of FDXR in response to UVC-irradiation, using Affymetrix™ GeneChip® HG-U133A 
arrays. Graphical representation (using MADRAS) of the kinetics of the transcriptional response of FDXR over 24 hours in telomerised NER- 
proficient MRC-5 and GGR-defective XP-C (GM02996, XP8CA) and TCR-defective CS-A (GM01856, CS3BE) fibroblasts, following exposure 
to 10 J/m2 UV-C (254 nm) radiation. The incubation times are indicated. Differential regulation of expression is represented in colour and red 
represents upregulation, while green, downregulation. Abbreviations: hrs, hours.
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Figure 5.28. Verification of FDXR mRNA by quantitative RT-PCR. RT-PCR of FDXR in 
hTERT-immortalised XP-C (GM02996, XP8CA) dermal fibroblasts at the indicated time 
points following UV-irradiation (10 J/m2) or mock-irradiation (0 J/m2). The amplification of 
GAPDH was performed to normalise FDXR expression levels (data not shown).
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Figure 5.29. Expression of FDXR protein following UVC-irradiation. 
Varification of microarray results by Western blot, using an anti-FDXR mouse 
monoclonal antibody (1:1000). Time couse of FDXR following mock- 
irradiation (-) or exposure to 10 J/m2 (+) UV-C in hTERT-immortalised (A) 
MRC-5, (B) XP-C (GM02996, XP8CA) and (C) CS-A (GM01856, CS3BE) 
fibroblasts at the indicated time points (20 pg of WCE per lane). Equal protein 
loading was confirmed by India ink staining (lower panel o f each blot).
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Both the Affymetrix™ GeneChip arrays and the qRT-PCR assays detected a 
gradual increase in expression for the polyamine catabolic-associated gene, SAT 
(Figs. 5.30 & 5.31A-B, respectively). Both methods detected a temporal pattern 
of gradual induction in both XP-C and CS-A cells at -6  and ~12 hours, which 
peaked at ~24 hours post UV-irradiation (Fig. 5.3IB). Interestingly, the pattern 
of SAT  expression in CS-A was similar to that seen in CDKN1A, ATF3 and 
PMAIP1. Additionally, the levels of SAT remained at basal levels in the time- 
matched, untreated XP-C and CS-A fibroblasts (Figs. 5.31 A & B, respectively).
The transcription profiles obtained for the stress response gene, PPM  ID , 
obtained by expression profiling (Fig. 5.32), recapitulated the PPM1D 
expression profile obtained by RT-PCR for both XP-C and CS-A fibroblasts after 
UV treatment (Figs. 5.33A & B, respectively). Both methods displayed a gradual 
upregulation of PPM ID  at - 6  and -12  hours in XP-C cells. The array data 
suggested that peak induction occurred at -12  hours in XP-C fibroblasts, 
followed by a slight downregulation (Fig. 5.32). In contrast, RT-PCR analysis 
suggested that PPM ID  induction continued at -24 hours post UV. RT-PCR also 
showed that PPM  ID  mRNA remained at low basal levels in untreated XP-C 
cells (Fig. 5.33A).
Both microarray and RT-PCR analysis demonstrated similar kinetics of a 
delayed induction of PPM1D at -24 hours in UV treated CS-A cells (Figs. 5.32 
& 5.33B, respectively). The induction of PPM1D was not observed in CS-A 
fibroblasts at -6  hours post UV. Moreover, RT-PCR showed that the kinetics of 
PPM ID  expression in untreated CS-A fibroblasts at -6  and -12  hours was 
similar to that observed in UV treated CS-A cells (Fig. 5.33B).
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Figure 5.30. Analysis of the transcriptional response of SAT in response to UVC-irradiation, using Affymetrix™ GeneChip® HG-U133A arrays. 
Graphical representation (using MADRAS) of the kinetics of the transcriptional response of &4T7 over 24 hours in telomerised NER-proficient 
MRC-5 and GGR-defective XP-C (GM02996, XP8CA) and TCR-defective CS-A (GM01856, CS3BE) fibroblasts, following exposure to 10 
J/m2 UV-C (254 nm) radiation. The incubation times are indicated. Differential regulation of expression is represented in colour and red 
represents upregulation, while green, downregulation. Abbreviations', hrs, hours.
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Figure 5.31. Verification of SAT mRNA by quantitative RT-PCR. RT-PCR of SAT in hTERT- 
immortalised (A) XP-C (GM02996, XP8CA) and (B) CS-A (GM01856, CS3BE) dermal 
fibroblasts at the indicated time points following UVC-irradiation (10 J/m2) or mock-irradiation (0 
J/m2). The amplification of GAPDH was performed to normalise SAT expressison levels (data not 
shown).
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Figure 5.32. Analysis of the transcriptional response of PPM1D in response to UVC radiation, using Affymetrix™ GeneChip® HG-U133A 
arrays. Graphical representation (using MADRAS) of the kinetics of the transcriptional response of PPM1D over 24 hours in telomerised NER- 
proficient MRC-5 and GGR-defective XP-C (GM02996, XP8CA) and TCR-defective CS-A (GM01856, CS3BE) fibroblasts, following exposure 
to 10 J/m2 UV-C (254 nm) radiation. The incubation times are indicated. Differential regulation of expression is represented in colour and red 
represents upregulation, while green, downregulation. Abbreviations: hrs, hours.
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Figure 5.33. Verification of PPM1D mRNA by quantitative RT-PCR. RT-PCR of PPM1D in hTERT- 
immortalised (A) XP-C (GM02996, XP8CA) and (B) CS-A (GM01856, CS3BE) dermal fibroblasts 
at the indicated time points following UVC-irradiation (10 J/m2) or mock-irradiation (0 J/m2). The 
amplification of GAPDH was performed to normalise PPM ID expression levels (data not shown).
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5.5 Discussion
In this Chapter, microarrays were utilised to characterise the UVC-induced 
transcriptome-wide changes in established telomerised NER-proficient MRC-5, 
GGR-defective XP-C and TCR-defective CS-A fibroblast cell lines.
In contrast to many previous studies, the present investigation has (1) exploited 
the Affymetrix™ HG-U133A GeneChip® arrays (that represent 13,387 genes), 
thus extending the coverage of the human genome, (2) extended analysis to 24 
hours, in order to enrich for downstream effectors following the initial DNA- 
damage response, (3) used hTERT-immortalised cells that retain the 
p53/p21WAF1/CIP1 and pR b/plb1^ ^  stress signalling pathways, and (4) 
undertaken multiple GeneChip® analysis to increase statistical validity. These 
experimental modifications can assist in identifying possible secondary effector 
responses that lie downstream to the early stress responses and which may play a 
role in the pathogenesis of XP and CS.
The different kinetics in gene expression revealed by transcription expression 
profiling, reflect the complexity of the UV-induced responses elicited in the 
repair competent, GGR-defective and TCR-defective genetic backgrounds. In 
agreement, da Costa et al. (2005) demonstrated that XP/CS and TTD patients 
present UVC signatures that appear to be dependent upon the DNA repair status 
of the cell.
Although several of the well-characterised UV-induced transcription factors 
(such as TP53, NF-kB and c-Fos) were not induced, microarray analysis revealed 
that UV significantly affected the regulation of several DNA-damage associated 
transcription factors. For example, members of the AP-1 family of transcription 
factors (such as the Jun, Maf and ATF subfamilies) were differentially regulated. 
Among the transcription factors identified in this study, ATF3, a member of the 
ATF/CREB family of transcription factors, was found differentially regulated at 
both the mRNA and protein levels. Notably, although ATF3 was upregulated in a 
UV-dependent manner in telomerised MRC-5, XP-C and CS-A cells, the kinetics
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of induction differed considerably among the cell lines. A rapid induction of 
ATF3 occurred in MRC-5 cells, while a sustained upregulation was observed in 
XP-C and CS-A cells. In agreement with these data, numerous studies have 
reported the induction of ATF3 in response to UV-A (Abe et al., 2003; Andley et 
al., 2004), UV-B (Yang et al., 2006) and UV-C (da Costa et al., 2005; Gentile et 
al., 2003; Rieger & Chu, 2004). Although the precise function of ATF3 remains 
unclear, several lines of evidence have suggested that ATF3 plays a role in the 
negative regulation of cell cycle progression, wound healing, cell adhesion, 
apoptosis and cell signalling (Fan et al., 2002; Chen et al., 1996; Hai & Hartman, 
2001; Mashima et al., 2001; Wolfgang et al., 2000). Recently, Yan et al. (2005) 
suggested that ATF3 interacts with p53 in response to a broad spectrum of 
genotoxic stresses, and augments the stabilisation of p53 by preventing its 
ubiquitylation and subsequent MDM2-mediated degradation. Recently, Hamdi et 
al. (2005) identified ATF3 as an important sensor of persistent DNA damage in 
the transcribed strand of active genes. They found that ATF3 was selectively 
activated in total NER defective (XP-A and XP-D) cells after irradiation with 3 
or 5 J/m2 of UV-C, while ATF3 was activated in TCR-deficient CS cells 
following doses of 5 to 10 J/m2 of UV-C. Interestingly, the TCR-deficient (CS- 
A) cell line used in this study, namely CS3BE, was also investigated in their 
study, and induction of ATF3 was also observed following 10 J/m2 of UV. They 
also reported that ATF3 induction was only observed in NER-proficient and 
GGR-deficient (XP-C; XP8CA) cells after a high dose of 20 J/m2 of UV-C. In 
contrast, the data presented here showed that ATF3 activation occurred in NER- 
proficient MRC-5 and GGR-defective XP-C (XP8CA) cells after 10 J/m2 of UV- 
C at both the mRNA and protein levels.
Other transcription factors revealed by microarray analysis to be differentially 
regulated in MRC-5, XP-C and CS-A cells included XBP-1, HR Y and TAFII30. 
Several sequence-specific transcription factor families were also identified. The 
ID-family of transcriptional repressors are dominant negative inhibitors of helix- 
loop-helix transcription factors that negatively regulate cell cycle inhibitory 
effects by repressing transcription of p i6 ^ ^  (Idl) and overriding pRb (Id2). 
Both Idl and Id2 were upregulated in XP-C and CS-A cells. Similarly, Id4, a
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regulator of RNA Pol II transcription was found upregulated in XP-C and CS-A 
cells.
In agreement with previous findings (Gentile et al., 2003; Li et al., 2001; Yang et 
al., 2006), the microarray data presented here showed that the actual level of 
TP53 mRNA was not significantly altered in a UV-dependent manner in 
telomerised MRC-5, XP-C or CS-A cells during the course of the experiment, 
and remained at basal levels. These findings can be explained by data obtained 
by other investigators (Bean & Stark, 2001; Prives, 1998; Shieh et al., 1997; 
Webley et al., 2000) and data presented earlier in this thesis (Chapter 4). These 
suggest the UV-dependent modulation of p53 occurs through translational and 
post-translational protein modifications rather than a direct effect on TP5 3 
transcript levels. For example, in this thesis (Chapter 4), it was shown that p53 
stabilisation was mediated via phosphorylation at Seri5, which occurred in an 
UVC- and time-dependent manner. Although an extensive investigation into the 
UVC-mediated translational modification of p53 was beyond the scope of this 
study, the importance of such modifications were clearly evident. A subset of 
UV-induced p53 regulated downstream target genes, which orchestrate the 
immediate DNA-damage signalling cascades and cellular responses (such as cell 
cycle arrest, DNA repair and apoptosis), were identified as differentially 
regulated genes in this study (such as CDKN1A, GADD45a, DDB2, PMAIPl and 
DTR). Accordingly, the array data clearly demonstrated the importance of 
selecting telomerised cell lines as appropriate in vitro models when investigating 
the DNA-damage response at the transcriptome level, as the transcriptional 
activation of these downstream p53 targets is dependent on intact p53 function 
and its posttranslational modification. In agreement, Cleaver et al. (in press) 
suggested that the use of SV40-transformed XP or CS cells may conceal 
important differences associated with these syndromes. Altogether the data 
demonstrated that, although the temporal kinetics of gene expression differed 
significantly between the normal (MRC-5), GGR-defective (XP-C) and TCR- 
defective (CS-A) cell lines, expression of p53-responsive genes (such as 
CDKN1A, GADD45a and PMAIPl) was observed in the TCR- and transcription- 
defective CS-A cell line. In concordance with the CS-A data obtained in this
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thesis, Proietti-De-Santis et al. (2006) showed that CSB was not required for the 
transcription of p53-responsive genes (such as GADD45 and MDM2) following 
genotoxic attack.
CDKN1A, the gene that encodes the CDK inhibitor p21WAF1/CIP1, was upregulated 
at both mRNA and protein levels, with the highest levels observed in CS-A cells 
after UV. It has been shown that following a transient p53-dependent increase 
the degradation of p2 iWAF1/CIP1 is required to facilitate NER (Bendjennat et al., 
2003). However, in conflict with Bendjennat et al. (2003), degradation of 
p21WAF1/CIP1 was not observed at the mRNA or protein levels in this study. In 
concordance with the data here, Cleaver et al. (in press) also showed a marked 
increase in p 2 iWAF1/CIP1 protein levels in CS cells after UV. Cleaver et al. (in 
press) also showed that the half-life of p2 iWAF1/CIP1 following UV was 1.5 hours 
in normal cells compared to 3 hours in CS-B cells, thus indicating a slower rate 
of degradation. From these data, they speculated that the lack of correlation 
between the severity of CS phenotypes and the biochemical and genetic defects 
is attributed to the dysregulation of downstream targets of CS-dependent 
regulation, independent of the TCR defect. They further suggested that the 
accumulation of p 2 iWAF1/CIP1 occurred due to insufficient ubiquitylation by CS- 
dependent E3 ligase activity. The abnormal accumulation of p 2 iWAF1/CIP1 in CS 
cells, resulting from dysregulation in protein processing, may have significant 
consequence for the CS phenotype, as increases in p21WAF/CIP1 may not only 
explain the growth defects displayed by CS patients, but also the absence of 
malignancy, which is a primary hallmark of XP.
GADD45a, a p53- and BRCA1-regulated stress-inducible gene, has been 
characterised as an instrumental player in orchestrating the cellular response to a 
multiplicity of DNA damage agents (reviewed by Zhan, 2005). Here, the data 
showed that, although the induction of GADD45a  was observed in NER- 
proficient MRC-5, GGR-deficient XP-C and TCR-deficient CS-A cell lines, 
there was a marked variation in the kinetics of induction over the time course 
between the cell lines. In disagreement with these data, Chang et al. (2003) 
found that GADD45a was significantly upregulated within 30 minutes after
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UVC-irradiation in SV40-transformed XPC (XP4PA) mutant cells, but was not 
upregulated in NER-proficient HeLa cells. The data presented in this thesis also 
showed that the highest level of induction was observed in the CS-A cell line. In 
conflict with these data, Chang et a l  (2003) showed that GADD45a was induced 
in NER mutant XP-A and XP-D cells; however a similar induction in CS-B 
TCR-deficient cells was not observed. This led Chang et al. (2003) to speculate 
that GADD45a up-regulation is dependent on a GGR defect and may even 
facilitate the restoration of NER, thus providing a compensatory mechanism for 
the defect in GGR.
PPM ID  (or W ipl), the gene that encodes a member of the serine/threonine 
specific protein phosphatase type 2C (PP2C) family, was found upregulated in 
MRC-5, XP-C and CS-A cells. Although PPM1D is a known downstream target 
of p53 (Takekawa et al., 2000), the precise role of PPM1D in response to UV- 
induced damage remains unclear. It has been suggested that PPM ID participates 
in a negative feedback regulatory loop of p38 MAPK-p53 signalling in response 
to UV, by suppressing the ATM/ATR-mediated DNA damage response, via 
dephosphorylation of p53 at Seri5 and Chkl at Ser 345 (Lu et al., 2005; 
Takekawa et al., 2000). From these findings it has been speculated that PPM ID 
functions as a ‘master switch’ for the removal of the DNA-damage response (Lu 
et al., 2005). Additionally, the overexpression of PPM ID  has been implicated in 
tumorigenesis. Notably, PPM ID  mRNA was overexpressed in telomerised XP- 
C cells following UV exposure. PPM ID is also thought to suppress the BER 
enzyme, uracil DNA glycosylase (or UNG2) through dephosphorylation of 
threonine 6. This suggested a homeostatic regulatory mechanism for DNA repair 
and demonstrates a further direct link between p53 signalling and DNA repair 
(Lu et al., 2004). However, a direct link between PPM ID and NER repair 
remains unreported.
As previously discussed (Chapter 1), chromatin remodelling is required to 
facilitate access of DNA repair factors to damaged regions of DNA. Notably, 
microarray analysis revealed the upregulation of histones H IST1H 1C , 
HIST1H2BE, HIST2H2AA, HIST1H2BK and HIST2H2BE  in DNA repair
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defective XP-C and CS-A cells. These histones are involved in chromatin 
assembly and disassembly.
Although several genes directly associated with DNA repair were differentially 
expressed following UVC-irradiation, few genes directly associated with NER 
were found differentially regulated in a UV-dependent manner. These findings 
were consistent with several previous studies (Reiger & Chu, 2004; Gentile et 
al., 2003), which showed that the core components of the NER apparatus (such 
as XPA, XPB , XPD, XPF , XPG, CSA and CSB) are not differentially regulated at 
the mRNA level following UV. It has been speculated that the repair proteins 
directly involved in NER are not regulated transcriptionally, but are present in 
sufficient amounts under ‘normal’ physiological conditions and are functionally 
activated through posttranslational modification or translocation to the site of 
damage. In conflict with the data presented here and elsewhere, da Costa et al. 
(2005) reported the UV-induced upregulation of XPG.
In agreement with previous studies (Hwang et al., 1999; Adimoolam & Ford,
2002), the GGR-speciflc genes, DDB2 and XPC, were identified as UV- 
inducible. Although a multiplicity of microarray studies have been undertaken, 
few have reported DDB2 and XPC  as being UV-inducible (Enk et a l, 2006; 
Gentile et al., 2003; Koch-Paiz et al., 2004; Rieger & Chu, 2004). This may be 
explained by the fact that many investigators have used SV40-transformed cell 
lines that are compromised in the p53/p21WAF1/CIP1 pathway, as both XPC  and 
DDB2 expression is regulated in a UV- and p53-dependent manner (Adimoolam 
& Ford, 2002; Hwang et al., 1999). Data presented elsewhere in this thesis 
(Chapter 3; Ridley et al., 2005), also showed that the basal level of XPC protein 
can vary among cell lines due to its inducible nature (Adimoolam & Ford, 2002). 
Notably, although only a slight induction of DDB2 was observed in normal 
MRC-5 and TCR-defective CS-A cells, a marked upregulation of D D B2  
occurred in GGR-defective XP-C cells. It is possible that in the absence of XPC, 
DDB2 is dramatically upregulated to compensate for the GGR defect in the XP- 
C cell line. Alternatively, it has been speculated that for XPC modification to 
occur, the ubiquitylation and subsequent degradation of DDB2 is required (Ford, 
2005). This suggests a possible negative regulatory role of XPC on DDB2
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expression. The data presented here supports this function, as DDB2 mRNA 
appears to accumulate in the absence of XPC. PCNA , the gene that encodes a 
homotrimeric protein that is involved in repair synthesis following the core NER 
reaction, was found upregulated in MRC-5, XP-C and CS-A cells following UV.
The TCR-speciflc genes, CSA (CKN1) and CSB , were not induced by UV. In 
disagreement with these data, Rieger & Chu (2004) showed that although CSA 
and CSB were not within the top 200 responsive genes, CSA was repressed 1.5- 
fold and CSB was induced 2.3-fold. From these findings, Reiger & Chu (2004) 
speculated that CSB might play a role in processing UV damage after the 
completion of TCR.
The signalling cascades regulating cell proliferation and apoptosis appeared 
complex. Among the UV-responsive genes that regulates cell proliferation, 
included TOB1, a member of the tob/btgl family of anti-proliferative proteins. 
Interestingly, TOB1 was rapidly induced in MRC-5 and XP-C cells, which was 
followed by rapid repression. In contrast, CS-A displayed a temporal pattern of 
delayed expression. Moreover, unlike MRC-5 and XP-C, TOB1 induction 
continued to increase throughout the time course and failed to return to pre­
irradiation mRNA levels. This suggested that the CS-A cells failed to recover 
from the DNA damage induced by UV and where maintained in an anti­
proliferative state. Notably, both anti- and pro-apoptotic genes were highly 
expressed. For example, the anti-apoptotic gene IER3 (immediate early response 
3) gene that functions to protect cells from Fas- or TNFoc-induced apoptosis was 
upregulated in CS-A cells. In contrast, several proapoptotic-associated genes 
were also found upregulated in CS-A cells. For example, the p53 downstream 
target, PM AIPl (NOXA), was found upregulated in MRC-5, XP-C and CS-A 
cells. Interestingly, both higher levels of PMAIPl mRNA and PMAIPl protein 
were observed in CS-A cells. In concordance with other studies (Gentile et al.,
2003), these data indicate that UV-induced DNA damage elicits apoptosis via 
PMAIPl. The p53-regulated pro-apoptotic gene, FD X R , which encodes a 
mitochondrial flavoprotein, was found upregulated in XP-C and CS-A cells in 
response to UV. Similarly, DTR, a heparin-binding growth factor was induced in 
CS-A and XP-C cells in response to UV and is involved in the pro-apoptotic
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response. SAT, a rate-limiting enzyme is involved in the catabolic pathway of 
polyamine metabolism. Polyamines are involved in either inducing or repressing 
apoptosis in a genotype-specific manner. Interestingly, SAT  was found 
upregulated in CS-A cells in a UV-dependent manner. PPP1R15A (protein 
phosphatase 1, regulatory (inhibitor) subunit 15 A) is a member of a group of 
genes whose transcript levels are known to increase following treatment with 
DNA-damaging agents. PPP1R15A was upregulated in CS-A cells following UV 
exposure. As expected, the anti-apoptotic gene, BCL2L1, which regulates outer 
mitochondrial membrane channel opening, release of ROS and cytochrome C 
was repressed in CS-A cells following UV, while an upregulation was observed 
in MRC-5 cells. Additionally, the pro-apoptotic MOAP1 (modulator of apoptosis 
1) was induced in CS-A cells in response to UV. Surprisingly, the pro-apoptotic 
BID (BH3 interaction domain) gene that triggers cytochrome c release via 
caspase 8 (CASP8) was repressed in CS-A cells after UV exposure. Similarly, 
several capsases (such as CASP1, CSAP4, CASP6, CASP8) were also repressed 
in CS-A cells, whereas CASP3 was induced in CS-A cells after UV exposure. 
Interestingly, McKay et al. (2004) showed that the expression of large anti- 
apoptotic genes was suppressed following UV, whereas the expression of small 
pro-apoptotic genes (such as PM AIPl and FDXR) was induced. McKay et al. 
(2004) speculated that gene size is an important determinant of UV-induced gene 
expression, as UV-induced genes enriched for compact genes with fewer and 
small introns, such as those involved in the mitochondrial apoptotic cascade were 
found upregulated. From the data, McKay et al. (2004) have suggested that UV- 
responsive genes, caused by passive effects of UV lesions on transcription act as 
a molecular dosimeter, ensuring the removal of cells sustaining irreparable 
transcription-blocking DNA damage.
Although the experimental design and statistical approaches adopted in this 
investigation were comparatively comprehensive compared to previous studies, it 
is important to note the caveats associated with the present study. As previously 
reported, transcriptional responses can differ considerably in different cell types, 
and in response to different wavelengths (and/or doses) and at different time 
points. The selection of cell type is of particular importance when undertaking 
transcription expression profiling studies, as cells such as keratinocytes are
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habitually exposed to UV radiation, and are therefore more resistant to UV 
compared to fibroblasts due to the development of specialised cell-type-specific 
responses (Otto et al., 1999). In this study, many of these issues were addressed 
by characterising the transcriptional portraits of telomerised XP-C and CS-A 
fibroblasts in three independent biological replicates at several time points over a 
24 hour time course. Although NER-proficient telomerised MRC-5 fibroblasts 
were used as a control for comparative analysis with the telomerised GGR- 
defective XP-C and TCR-defective CS-A cell lines, the control cell line used 
during this investigation was derived from foetal lung. Hierarchical clustering of 
the microarray data highlighted this major caveat of using telomerised MRC-5 
fibroblasts as a control cell line. The pattern of high or low transcript levels 
observed here, suggested that regulation occurred in a UV-independent manner, 
as the level of expression observed at -6, -12 and -24 hours was similar to that 
observed immediately (0 hours) following UV. Moreover, the differential 
expression observed in cluster 1 was also independent of time (Fig. 5.4). 
Therefore, it is possible that the transcriptional responses observed in the wild- 
type MRC-5 fibroblasts compared to the DNA repair defective XP-C and CS-A 
dermal fibroblasts, was attributed to cell-type-specific variability, rather than the 
state of the NER repair pathway. In retrospect, a telomerised wild-type dermal 
fibroblast cell line would have provided a more statistically robust in vitro model 
for comparative analysis with the telomerised XP-C and CS-A dermal fibroblast 
cell lines.
The transcription expression profiles of telomerised XP-C and CS-A cells 
appeared similar in clusters 1 and 4 of the genotype-specific changes compared 
to the MRC-5 cells (Fig 5.4). Notably, genotype-specific signatures were also 
observed between telomerised XP-C and CS-A cell lines. Moreover, the marked 
level of low and high expression observed in the CS-A cells (cluster 2 & 3, 
respectively; Fig. 5.4), compared to XP-C appeared independent o f UV. 
However, it was difficult to substantiate whether these transcriptional signatures 
were attributed to the XP and CS phenotypes, or merely due to variations 
between the dermal fibroblasts, as a single telomerised XP-C and CS-A clone 
was used for analysis. Furthermore, a single XP-C (GM02996, XP8CA) and CS- 
A (GM01856, CS3BE) donor was used. To eliminate this variation from the
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present study, further investigation would require the establishment of several 
telomerised XP-C and CS-A cell lines derived from donors that exhibit an XPC 
or CSA null phenotype, respectively. Alternatively, the establishment of a XPC 
or CSA null phenotype could have been achieved experimentally, by knocking 
out XPC  or CSA in a NER-proficient telomerised cell line that was used as a 
wild-type control. This would facilitate the establishment of NER-proficient and 
deficient cell lines, whose phenotype would be isogenic and any differences 
would be exclusively attributed to the different NER status. However, 
homologous recombination technology was beyond the scope of this 
investigation. Alternatively, to minimise differences in genetic backgrounds, 
investigators have used isogenic cell lines transfected with a mammalian vector 
expressing the wild type gene. For example, Kyang et al. (2003) used CS-B 
SV40-transformed fibroblasts transfected with a plasmid expressing the CSB wt 
gene, thus resulting in the generation of an isogenic TCR-proficient control. 
However, it is possible that the corrected cell line remained compromised, 
irrespective of the restoration of its CSB function, and it is difficult to 
substantiate whether the plasmid is expressing physiologically relevant levels of 
CSB protein. Furthermore, although the exploitation of RNAi technologies has 
resulted in the establishment of XPA*°, X P ( f°  and CSB*0 phenotypes in NER- 
proficient cell lines (Biard et al., 2005; Feng et al., 2006), data presented in this 
thesis (Chapter 6), suggested that phenotypes generated by RNAi are complex 
and can result in a partial biological effect. This results in the generation of a cell 
line that does not fully recapitulate the desired null phenotype.
Transcriptional portraits obtained in this study were obtained for a single cell 
type derived from a single donor for each genetic background following a single 
UV dose. As previously mentioned, the data presented here clearly demonstrated 
cell-type- and genotype-specific signatures between the MRC-5, XP-C and CS-A 
fibroblasts that were both independent and dependent of UV-irradiation. 
Moreover, although many of the differentially regulated genes and patterns of 
expression that were identified in this study were observed in both the NER- 
proficient, GGR-deficient and TCR-deficient cells, the kinetics of differential 
regulation differed between cell types. For example, the response of many of the 
genes identified in the CS-A cell line exhibited delayed kinetics of transcript
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induction. However, the transcriptional responses in the current study were 
limited to a 24 hour time course. Therefore, to further delineate the kinetics of 
differential transcript regulation in the cell lines, further investigation would 
necessitate the inclusion of longer time points.
In addition to inter-individual variability, an unavoidable caveat encountered 
during this investigation was possible clonal variation among isogenic 
monoclonal cell populations, as a single XP-C (clone 19) and CS-A (clone 3) 
clone was used throughout this investigation. Additionally, the selection of an 
appropriate wavelength when undertaking transcriptome analysis in response to 
UV is particularly controversial. Although the vast majority of studies have used 
UV-C, it has been suggested that these studies lack physiological relevance 
(Sesto et al., 2004), as UV-C is absorbed by atmospheric ozone (Kock-Paiz et 
al., 2004). Therefore, many investigators believe that the transcriptional response 
to UV-C does not recapitulate the response following exposure to biologically 
pertinent wavelengths such as UV-A or UV-B. However, my study was 
exclusively interested in the molecular phenotypes exhibited by NER defective 
cells in response to the UV-induced photolesions, CPDs and 6-4PPs. For this 
reason, the use of alternative UV wavelengths was deemed inappropriate, as both 
UV-A and UV-B introduce further variability into the in vitro model. For 
example, both UV wavelengths target cellular constituents other than DNA such 
as proteins and lipids, and a diverse range of lesions are introduced into DNA, 
which elicits the activation of additional DNA repair systems such as BER.
In this thesis, cells were immediately refed with fresh medium after UV 
treatment. It has been reported that fibroblasts present patterns of differential 
gene expression in response to serum (Iyer et al., 1999). Therefore, investigators 
have either used serum-starved cultures, or reused culture medium in order to 
minimise these responses. It is possible that responses observed during this 
investigation were attributed serum. However, RT-PCR and Western blotting 
(which included time-matched non-irradiated controls) showed no evidence of a 
serum response. Furthermore, the most appropriate culture conditions remain 
controversial, as serum starvation can elicit stress signalling pathways.
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Although the issue of statistical validity was addressed in the present study by 
undertaking several independent biological replicates at each time point, the 
issue of inter individual variability was, as previously stated a further caveat in 
this investigation. To eliminate inter clonal variability; the analysis of several 
independently isolated telomerised XP-C and CS-A clones would have been 
required. To address all the experimental caveats identified in this study, further 
investigation would have required a much larger number of HG-U133A arrays, 
which was financially beyond the scope of the current study. Despite this issue, 
the transcriptional portraits obtained for telomerised XP-C and CS-A, for the first 
time, provides detailed information on the molecular signatures of cells defective 
in the GGR and TCR subpathways of NER, without the possibility of 
compromised DNA-damage signalling pathways.
Genes associated with the removal of oxidative damage were upregulated in 
telomerised CS-A fibroblasts. For example, the antioxidant enzymes G PX 1 , 
G PX7  (glutathione peroxidase 1 and 7) and HO-1 (heme oxygenase 1) were 
induced; H O -1  induction is known to occur in most oxidative stressed 
mammalian cells (Keyse & Tyrrel, 1987). da Costa et al. (2005) also reported an 
increase in HO-1 expression, with higher levels observed in TTD cells compared 
to XP/CS. They speculated that the high level of H O -1  in TTD cells is an 
indicator of cellular stress during proliferation. SO D 2 , the gene that encodes 
superoxide dismutase 2, was also induced in telomerised CS-A cells. COLEC12, 
a scavenger receptor, was highly induced in CS-A cells, whereas it was repressed 
in MRC-5 and XP-C cells. COLEC12 plays a role in recognising oxidised 
phospholipids and removes oxidatively damaged or apoptotic cells. FT H 1 , an 
essential mediator of the antioxidant and protective activities of NFkB was also 
upregulated in CS-A cells. The upregulation of ferratin by FTH1 inhibits TNFa- 
induced apoptosis via NFkB, by suppressing ROS. The induction of this subset 
of genes that protect the cell from oxidative damage is particularly interesting, as 
the growth and neurological defects in CS have been attributed to the 
accumulation of oxidative-induced damage generated endogenously by cellular 
metabolism.
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The generation of ROS can occur as a result of high p2 iWAF1/CIP1 levels, which is 
thought to occur through its interaction with mitochondrial apoptosis activating 
factors (Macip e t a l., 2002). As previously mentioned, a high level of 
p21WAF1/CIP1 was observed in telomerised CS-A cells. Cleaver et al. (in press) 
recently showed that under normal in vitro growth conditions (high level of 
oxygenation), a greater level of DNA damage was detected using the double 
strand break marker yH2AX, and was observed in both CS-A and CS-B cells 
compared to XP-A and XP-C cells. They speculated that since XP-C cells are 
defective in GGR and XP-A cells are devoid o f both GGR and TCR, the 
increased level of spontaneous DNA damage in CS cells was attributed to more 
than simply the repair defect. Cleaver et al. (in press) suggested that the increase 
level of p 2 iWAF1/CIP1 in CS-B might be a cause of increased level of ROS 
generation, resulting in further in vivo change such as apoptosis in neuronal cells.
To examine the validity o f the microarray data, quantitative RT-PCR was 
performed. RT-PCR validation of all the UV-responsive genes was beyond the 
scope of this investigation; so several differentially regulated genes that 
represented a diverse range of biologically functional groups (such as 
transcription, cell cycle regulation, growth, DNA repair, apoptosis and 
metabolism) were assayed. The data suggested that the mRNA levels detected by 
microarrays generally reflected those obtained by RT-PCR. Notably, however, 
the inclusion of time-matched, non-irradiated controls in the RT-PCR assays 
reiterated the limitations associated with the interpretation of large datasets 
derived from treated samples in the absence of time-matched, non-irradiated 
controls. For example, the level o f  DDB2  in CS-A cells was similar at 0, ~6 and 
~12 hours in both UV-irradiated and non-irradiated samples. Similarly, the level 
of P P M  ID  mRNA in irradiated CS-A cells was similar to untreated CS-A 
fibroblasts at 0 and ~12 hours, while a marked increase in P P M  ID  was observed 
at ~6 hours in the non-irradiated control, compared to its time-matched irradiated 
counterpart. Notably, although the genes validated in this study represented a 
diverse range of functional groups, all transcripts (except Ccng2) were found in 
cluster 2 of the time-dependent changes.
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Although microarray technologies facilitate the measurement of changes in 
mRNA level across the entire transcriptome, it is modulation of protein 
expression, function or location that ultimately mediates changes in biological 
function. For this reason, validation of microarray data was performed at the 
protein level by Western blotting. The data suggested that, changes at the protein 
level recapitulate the changes observed at the mRNA level. For example, the 
accumulation of p2 iWAF1/CIP1 protein observed in telomerised MRC-5, XP-C and 
CS-A reflected the kinetics of CDKN1A induction following UVC-irradiation. 
Additionally, the upregulation of ATF3 and PMAIPl protein corresponded to the 
induction of A F T 3 and P M A IP l at the transcript level. Although Western blot 
analysis revealed fluctuations in GADD45a protein levels, compared to the 
levels of G A D D 45a  mRNA, a similar pattern of upregulation was observed 
following UV. In contrast, the level of FDXR protein displayed marked 
differences compared to the FD XR  mRNA levels. Although the majority of 
differentially regulated genes that were analysed at the protein level were 
concordant with the mRNA levels, these data suggested that significant caution 
should be applied when extrapolating biological function based on the 
modulation of transcriptional responses.
There has been significant debate over whether the intricate clinical phenotype 
presented by CS patients occurs as a result of the primary defect in DNA repair 
or transcription, as CS cells fail to resume basal transcription following UV- 
irradiation (Balajee et al., 1997; Van den Boom et a l., 2004). This has remained 
controversial, as the CS defect in the TCR of photolesions fails to explain the 
growth and neurological manifestations displayed by CS. In addition to the DNA 
repair and transcription defect, emerging evidence has implicated that defects in 
protein processing contribute to the complex phenotype observed in CS (Cleaver 
et al., in press). The data presented here suggested that the temporal kinetics of 
transcription modulation, in response to genotoxic stress such as UV, could 
contribute significantly to the pathogenesis of syndromes defective in NER such 
as XP and CS. This was particularly evident in CS-A, where the UVC-induced 
signatures differed considerably compared to the MRC-5 and XP-C cell lines. 
The CS-A cell line displayed kinetics of (1) delayed induction or repression over
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the time course, (2) a failure to return to pre-damage mRNA levels within the 
time course, (3) a sustained transcriptional response throughout the time course. 
In concordance with these data, Kyang et al. (2003) showed that the overall 
induction of expression following oxidative stress was impaired in CS-B cells. 
Moreover, da Costa et al. (2005) showed that the transcriptional response to UV 
was delayed in XPB/CS cells. Therefore, the data presented here provides further 
evidence supporting the idea that the phenotype presented by CS is in part 
attributed to a dysregulation of the transcriptional response to genotoxic stress. 
Recently, Newman et al. (2006) provided evidence that CS may be an 
inflammatory disease, as they found that; (1) a large number of inflammatory 
pathways were upregulated such as the TGF|3 and TNFa/JNK pathways, (2) 
transcription factor binding site (TFBS) analysis in the promoters of CSB- 
regulated genes were enriched for NF-xB-related sites, (3) CSB upregulates 
many genes that are also upregulated by anti-inflammatory drugs, (4) the 
hypoxia-response is upregulated in the absence of CSB. Newman et al. (2006) 
concluded that the inflammatory phenotype displayed by CS might explain the 
neurodegenerative and wasting symptoms presented by the syndrome. In 
concordance with Newman et al. (2006), several proinflammatory members of 
the TNFa pathway (such as TNFAIP2 and TNFSF9) were upregulated in CS-A 
cells in my study. The TNFa pathway is also known to initiate the apoptotic 
pathway.
Annotation of the resultant lists of differentially regulated genes was undertaken 
using the frequently adopted approach of trying to manually link single gene 
transcripts to yield some form of biological significance. However, the 
requirement to correct for multiple correction and select a significance level 
during statistical analysis can prove problematic, as other genes in a 
differentially activated functional pathway may fall outside this cut off, and 
hence an interesting line of interpretation and explanation may be missed. To 
overcome these challenges, several methods have been established to enable a 
more comprehensive and less biased functional interpretation of gene lists.
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Hosack et al. (2003) developed the Expression Analysis Systematic Explorer 
(EASE), which can assist in identifying biological themes in a gene list by 
looking for over-representation of a biological theme within the list under test 
when compared with the global background. The hypothesis for an analysis takes 
the form of “are there more genes involved in apoptosis within my list than I 
would expect by chance if I was to randomly sample an equivalent sized gene list 
from my array?” EASE can look for over-represented “terms” against a number 
of annotation resources including Gene Ontology and the public pathway 
databases (GenMapp, KEGG).
Breitling et al. (2004) developed a method termed Iterative Group Analysis 
(iGA). iGA extends the functional annotation analysis beyond just the probe sets 
contained within a significant gene list to the whole dataset. The method 
interrogates the results of statistical testing for changes in transcription levels for 
all the genes identified as belonging to a functional class (e.g. apoptosis), which 
can be derived from many different origins (Gene Ontology, BLAST results, key 
words, literature extracts). As a result, iGA can detect changes in transcription 
level which may be missed by selecting genes at a pre-defined cut-off, so if all or 
many genes within a pathway show moderate changes in transcription this can be 
identified and flagged as significant.
Building on the idea of looking at the full dataset rather than a subset, Gene Set 
Enrichment Analysis (GSEA) (Subramanian et al., 2005) is a knowledge-based 
approach for interpreting genome-wide expression profiles that evaluate 
microarrays at the level of gene sets rather than a single transcript approach. 
GSEA can help identify functional linkage between groups of genes that share 
common biological functions, chromosomal location, or regulation and will 
weight its results according to the predefined significance level (from statistical 
testing) for the members of a functional class. This method has been successfully 
implemented to identify a p53-like, cisplatin-induced transcriptional response in 
mouse embryonic stem cells (Kruse et a l., in press).
Recent advances in bioinformatics methods for the analysis of sequences 
regulating transcription have identified potential factors involved in key
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regulatory networks underlying a transcriptional response (Ho Sui et al., 2005). 
Ho Sui et al. (2005) have developed a novel method, oPOSSUM, which allows 
for the analysis of statistically over-represented TFBSs in the promoters of sets 
of co-expressed genes. oPOSSUM is based on the assumption that some subset 
of the co-expressed genes is co-regulated by one or more common TFs, therefore 
the observed number of binding sites for those TFs should be greater than would 
be expected by chance. Newman et al. (2006) applied oPOSSUM to their dataset 
generated from CS-B cells and found that NF-kB TFBSs were significantly over­
represented in differentially regulated genes identified in CSB null cells. 
Similarly, oPOSSUM may assist in the identification of site over-representation 
in genes differentially expressed in XP-C and CS-A cells, and may assist in 
unravelling potential defects in transcriptional regulation of gene expression that 
may contribute to the pathophysiological manifestations observed in XP and CS 
patients.
Alternatively, systems biology and pathway analysis applications have become 
commercially available, which are designed to assist in the functional annotation 
of microarray data and extend the annotation corpus available by interrogating 
manually curated databases of human protein-protein and protein-DNA 
interactions, transcription factors, signalling or metabolic pathways. Examples of 
such tools include packages such as Metacore (GeneGo, Inc.), Ingenuity Pathway 
Analysis 5.0 (IPA; Ingenuity® systems) or Explain (BioBase).
These packages also claim to provide intuitive tools for data visualisation, 
analysis and exchange along with the functionality to concurrently visualise 
multiple types o f experimental data including gene expression, proteomic, 
metabolic, genetic and screening data. The interpretation of data across multiple 
platforms would be particularly useful for future investigation at the global 
proteome level in the different NER-defective backgrounds investigated in this 
study (Chapter 7).
The application of these annotation analysis methods to the Affymetrix™ data 
generated as part of this study may have assisting in the identification and
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prioritisation of functional classes that are important to the molecular 
pathogenesis of XP and/or CS.
In summary, a transcriptome-wide approach was adopted to dissect the molecular 
pathways involved in the UV-induced DNA-damage-response and to identify 
potential genes that are involved in molecular pathogenesis of XP and CS. The 
UV-induced transcription expression profiles obtained for MRC-5 and XP-C was 
highly diverse, while CS-A cells displayed a UV signature that appeared to be of 
an oxidative-damage-induced, proinflammatory and proapoptotic nature. Many 
of the genes identified in this study represent pathways (such as transcription, 
cell cycle regulation, DNA repair and apoptosis) that have been well 
characterised, as part of the normal UV-induced transcriptional programme. 
However, the role of many UV-responsive genes revealed in this investigation 
remains poorly understood. For example, A T F 3, CDKN1A , G DF15, DDB2 and 
FD XR  have all been implicated in oncogenesis (Yang et al., 2006), yet their 
precise role remains unclear. The temporal regulation of gene expression in XP 
and CS is complex. The comprehensive characterisation of the transcription 
expression portraits in established telomerised XP-C and CS-A in vitro cell 
culture models may assist in unravelling how NER status can influence cell 
metabolism in response to damage. Additionally, these UV signatures may also 
facilitate the elucidation of the molecular mechanisms underlying cutaneous 
tumorigenesis and progeria observed in XP and CS, respectively. This is 
particularly important for CS, as mechanisms that lie downstream to CSA and 
CSB regulation (such as transcription regulation and ubiquitin ligase-mediated 
protein degradation) have been implicated in the molecular pathogenesis of CS. 
Therefore, the generation of expression profiles for CS, such as that presented 
here, could assist in identifying subtle differences at the molecular level that are 
attributed to these causative mechanisms. The data may also assist in our 
understanding of the early UV-radiation responses in both NER syndromes and 
the normal population and might facilitate the elucidation of molecular 
biomarkers to identify radiation susceptible individuals.
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Chapter 6 
Utility of RNAi in the Transient or 
Stable Modulation of the XPC or CSA 
Repair Protein
6.1 Introduction
Many technologies have been previously adopted to experimentally modulate or 
abolish gene expression in in vitro culture or in in vivo  transgenic models, 
including; over expression of cDNA constructs, activation or inactivation by 
homologous recombination, activation by random insertion of strong promoters, 
creation of dominant-negative mutants, antisense oligonucleotides, engineered 
transcription factors and minor groove binders (reviewed by Case, 2003). More 
recently, however, functional genomic research has been revolutionised by the 
advent of RNA interference (RNAi) technologies. RNAi has facilitated the rapid 
and stable manipulation of gene expression in a cell-type- or pathway-specific 
manner with increased efficacy.
RNAi is utilised by eukaryotic organisms to modify gene expression at the pre- 
and post-transcriptional level. In lower eukaryotes (such as nematodes) and 
plants, the RNAi machinery has evolved to facilitate transposon silencing, viral 
processing and maintenance of chromosome integrity, thereby maintaining 
genome stability (Williams, 1997). RNAi is characterised by a series of cellular 
mechanisms that co-ordinate the silencing of specific genes, via the expression of 
small double-stranded RNAs (dsRNAs). RNAi was first described by Fire et al. 
(1998), who showed that injecting dsRNAs could elicit RNAi-mediated gene 
silencing in C. elagans. This resulted in the suppression of genes whose mRNA 
transcripts were complementary to the dsRNAs.
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It was initially believed that analogous RNAi gene silencing mechanisms were 
not utilised by mammalian cells. Moreover, initial attempts to exploit RNAi 
technology as an experimental application in genetic manipulation studies, 
proved problematic due to the caveats associated with using long dsRNA 
molecules (2:50 bp). The delivery of exogenous dsRNA (^50 bp) evokes a series 
of complex cellular responses to the foreign dsRNA molecules, which is part of 
the cell’s antiviral mechanism (Williams et al., 1997). Moreover, long dsRNAs 
cause the abolition of translation, mRNA degradation and interferon secretion 
(Stark et al., 1998; reviewed by Sen, 2001; Bridge et al., 2003; Sledze et a l ,
2003). The initiation of the interferon (IFN) response is particularly problematic 
due to the activation of the interferon-induced dsRNA-dependent protein kinase 
(PKR), which occurs following its interaction with dsRNA and subsequent 
sequence-independent destruction of RNAs. This results in the abolition of 
protein synthesis (Williams, 1997).
It was previously shown that long dsRNA molecules could silence gene 
expression during early mouse development (Svoboda et a l., 2000; Wianny & 
Zemicka-Goetz, 2000). This led to the finding that transfection of short 21mer 
dsRNA duplexes, mediate gene-specific silencing in cultured mammalian cells, 
without inducing the IFN pathway (Elbashir et al., 2001). Since these findings, 
the RNAi mechanism has been identified in several eukaryotic organisms 
(Hannon, 2002).
The delivery of targeted siRNA duplexes in in vitro mammalian cell culture 
models is accomplished via two principal modes. Firstly, transient post- 
transcriptional gene silencing is achieved through the transfection of short (~19- 
mer nucleotide) dsRNA targeted siRNA duplexes with symmetric 2-3 nt 3’ 
overhangs and 5’-phosphate and 3’ hydroxyl groups, which contain one strand 
complementary to the target mRNA. The delivery of siRNA duplexes in 
mammalian cells is achieved using lipid-based transfection reagents. Although 
siRNA-transfected methodologies facilitate immediate and efficient gene 
silencing, the applicability of this technology is limited due to its transient 
nature. Conversely, stable and permanent post-transcriptional gene silencing is
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achieved through the retroviral infection of target cells with siRNA-based 
plasmid-borne virus systems (retrovirus, lentivirus, or adenovirus), encoding a 
short hairpin (sh) RNA stem-loop structure, driven by a polymerase III promoter. 
Two principle types of retroviral vectors have been adopted as vehicles for the 
delivery of shRNA into mammalian cells. These include the oncoretrovirus 
vectors based on the murine stem cell virus (MSCV) or the Moloney murine 
leukaemia virus (MoMuLV; Brummelkamp et al., 2002; Paddison et al., 2002) 
and lentivirus vectors derived from human immunodeficiency virus-1 (HIV-1; 
Stewart et al., 2003; Rubinson et al., 2003; Qin et al., 2003). The shRNA is 
subsequently processed into a 21mer siRNA duplex by the enzymatic activity of 
Dicer. Although shRNA methodologies rely upon de novo siRNA synthesis 
within the cell, the integration of a selectable marker within the retroviral 
construct, such as puromycin drug resistance, facilitates the stable knockdown of 
protein expression. This permits the establishment of permanent genetically 
manipulated mammalian in vitro cell culture models, derived from single-cell 
clones that confer resistance to the selectable drug marker. This facilitates the 
isolation, sub-cloning and screening of cells displaying high levels of 
knockdown, from a polyclonal cell population that displays heterogeneous levels 
of gene expression. Furthermore, the utilisation of retroviral-based vectors, 
expressing shRNAs, permits the expression of siRNA and the efficient 
posttranscriptional gene silencing in slow-growing and post-mitotic cells. 
shRNAs therefore provide an alternative and more advantageous method for the 
delivery of siRNAs in cells resistant to transfection. However, the applicability 
of plasmid-based systems as a vehicle for the delivery of siRNAs is limited in 
cells that can only be maintained in culture for a limited time, such as primary 
cultures that display a protracted proliferative capacity.
The exploitation of RNAi technology, in modulating DNA repair and tumour 
suppressor gene expression, has resulted in the successful elucidation of the 
mechanistic functioning of DNA repair enzymes and the explication of complex 
stress signalling/DNA damage checkpoint pathways (reviewed by Miller & 
Grollman, 2003). Cortez et al. (2001) first reported the modulation of ATR. 
Further reports have demonstrated the successful abrogation of the DNA 
glycosylase, Neil 1 (Rosenquist et al. 2003), in murine embryonic stem cells and
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the knockdown of 53BP1 (Wang et al., 2002). Semizarov et al. (2004) adopted a 
global genome approach to dissect mammalian intracellular signalling pathways, 
by exploiting a combination of siRNA mediated gene silencing and Affymetrix™ 
GeneChip® expression profiling technologies, followed by systematic pathways 
analysis.
The applicability of RNAi in the experimental modulation of the NER pathway 
was first demonstrated by Lee et al. (2002), who showed that the repression of 
the C. elegans CSB homologue hypersensitised C. elegans to UV radiation, 
enhanced cell proliferation arrest and apoptosis, and increased embryonic 
lethality. More recently, however, transient siRNA technology has been utilised 
to dissect the NER pathway in mammalian cells, through the modulation of 
genes involved in NER, such as p53 (Porter et a l., 2006), ATR (Wu et a l., 2006), 
Ubc9 (Wang et a l., 2005c), XPV (Liu & Chen, 2006), XPA (Reynolds et al.,
2004) and hHR23B (Glockzin et al., 2003).
Interestingly, numerous studies have adopted plasmid-based expression systems 
to ablate NER gene function. For example, Biard et al. (2005) successfully 
established stable and permanent XPA™  and X P d ™  phenotypes in HeLa cells, 
using Epstein bar virus- (EBV) based shRNA vectors, targeting the XPA  or XPC  
gene, respectively. Moreover, Biard et al. (2005) reported the isolation of several 
clones, which displayed undetectable levels of XPA or XPC protein, whilst 
maintained in culture for >300 days. More recently, Feng et al. (2006) 
demonstrated the utility of RNAi technologies in the modulation of the NER 
repair protein, CSB, by constructing vectors expressing GStf-specific siRNAs. 
Feng et al. (2006) found that the siRNA-mediated silencing of CSB caused cells 
to proliferate more slowly, increase the sensitivity to genotoxicants, modify UV 
radiation-induced cell cycle changes and potentate radiation-induced apoptosis 
and anti-proliferative effect. In another study, Proietti-De-Santis et al. (2006) 
used CSi?-targeted siRNAs to show that the transcription of p53-responsive 
genes does not require CSB.
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To date, the utilisation of conventional methodologies such as HR to ablate gene 
function, has resulted in the establishment >200 different strains of mice, in 
which the expression of one/more DNA repair and/or DNA damage-signaling 
proteins have been abolished (Friedberg & Meira, 2006). Moreover, 35 of these 
mouse strains carry various combinations of targeted mutations in the NER 
repair pathway (Friedberg & Meira, 2006). This has resulted in the creation of 
transgenic models of rare human hereditary DNA repair syndromes, such as XP, 
CS, TTD and more recently XP/CS (Andressoo et a l., 2006). However, the 
establishment o f transgenic models of disease, through the utility of 
methodologies such as HR, are technically problematic and largely time- 
consuming. Furthermore, the abolition of gene function may not modify the 
phenotype, which is indicative of redundancy within the pathway of interest. 
Although transgenic mouse models have permitted further investigation into 
areas that remain poorly delineated, such as the paradoxical absence of cancer 
development in TTD and CS phenotypes notwithstanding their NER 
deficiencies, transgenic models possess a multitude of caveats, as they may not 
fully recapitulate the clinical manifestations exhibited by the human disease of 
interest. In addition, the abrogation of certain DNA repair genes results in the 
generation of a phenotype that exhibits severe lethality and is not compatible 
with life. Furthermore, the applicability of murine models of NER syndromes 
such as XP, CS and TTD are particularly controversial, as rodent cells display 
reduced GGR due to the absence of a p53 response element that facilitates p53- 
dependent transactivation of the D D B2  gene (Tan & Chu, 2002; Tang et al., 
2000). Many of the phenotypic characteristics observed in XP-A and CS patients 
such as neuopathological features and severe accelerated ageing respectively, are 
absent in Xpa'1' and Csa'1' mice (de Vries et al., 1995; Nakane et al., 1995; van 
der Horst et al., 2002). It has been proposed that the lack of these clinical 
features in murine models is attributed to their protracted lifespan (~2-3 years), 
as these pathological processes may require more time. The absence of clinical 
features suggests that murine models may also differ at the cellular level.
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6.2 Aims
The current availability of permanent human cell lines defective in NER are 
limited to characterised rare human genetic diseases, such as XP, CS and TTD, 
which are defective in a subset of DNA repair genes. Therefore, the aim of this 
chapter was to use RNAi technology for the transient knockdown of XP C  or CSA 
gene expression in NER-proficient, hTERT-immortalised MRC-5 fibroblasts.
A CS-A (GM01856, CS3BE) fibroblast cell line was previously characterised 
(Chapter 3) and immortalised by the ectopic expression of hTERT (Chapter 4). 
The second aim of this chapter was to create a permanent and stable double 
X P C ^ IC S-A double knockdown phenotype, through the retroviral transduction 
of the hTERT-immortalised CS-A fibroblast cell line, with a vector co­
expressing an X P C -specific targeted shRNA and the gene encoding puromycin 
resistance. From the current literature it can be speculated that the DNA damage 
response of a double XP C f^/C S-A  phenotype will recapitulate the DNA damage 
response of an XPA  null phenotype. Interestingly, Koberle et al. (2006) recently 
supported the targeted knockdown of XPC protein, using RNAi technology.
6.3 Materials & Methods
Normal telomerised MRC-5 fibroblast (previously prepared in the laboratory and 
made available as a general reagent) were transfected with three individual 
21mer oligonucleotide siRNA duplexes, targeting the X P C  or CSA DNA repair 
genes. In addition, telomerised MRC-5 fibroblasts were transfected with a non­
targeted scramble, which provided a control for the detection of off-target effects 
(Section 2.3).
The SUPER RNAi™ library, based on the pSUPER RNAi system 
(Brummelkamp et al., 2002) and the human SUPER RNAi™ library (Bems et 
a l ., 2004), provided by CRUK, was used to create a permanent and stable 
hTERT-immortalised double X P C ^/C S-A  knockdown phenotype (Sections
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2.4.0-2.4.3). The pRETROSUPER mammalian expression vector, harbouring the 
59mer shRNA expression cassette, that regulated the expression of a 21mer 
YPC-specific siRNA duplex, was isolated from the DH5a bacterial stock that 
was stored in a 96-well format (Section 2.4.4). The X P C -specific sequence was 
confirmed by sequencing. Two of the possible three X P  C-specific shRNA 
constructs were recovered from the DH5a bacterial stock. The isolated plasmids, 
containing the two ^ PC-specific shRNA expression cassettes, was independently 
expanded and confirmed by sequencing.
For retroviral supernatant production, the isolated plasmid DNA expressing the 
YPC-specific shRNA constructs was transfected into subconfluent FLY A13 
human epithelial cells, using a standard calcium phosphate transfection protocol 
(Section 2.4.8). As controls, retroviral supernatants were generated from plasmid 
DNA expressing an X P A -specific shRNA (previously isolated and validated in 
the laboratory by Rebecca Capper (technician)), or an empty pBABE-puro 
vector. The control transfections were performed in parallel. Retroviral 
supernatants were harvested 24 hours and 48 hours post feeding.
Subconfluent hTERT-immortalised CS-A fibroblasts were transduced with 
retroviral supernatants expressing the X P C  (construct 1 or 2)/XPA  shRNA 
constructs, the empty pBABE-puro vector or mock infected (Section 2.4.9). As 
an infection control, a retroviral supernatant, expressing the empty pBABE-puro 
vector, that was previously prepared and validated in our lab, was transduced 
into hTERT-immortalised CS-A fibroblasts.
The transient or permanent knockdown of XPC, CSA or XPA at the protein level 
was confirmed by immunoblotting. Briefly, WCEs were prepared (Sections
2.9.1-2.9.2), proteins were separated on SDS-PAGE gels (Section 2.9.3), 
transferred to PVDF membranes (Section 2.9.3) and exposed to an anti-XPC 
mouse monoclonal antibody (1:500), an anti-CSA goat polyclonal antibody 
(1:100) or an anti-XPA mouse monoclonal antibody (1:100; Section 2.9.4). Blots 
were visualised using an appropriate HRP-coupled secondary antibody and an
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ECL system using Hyperfilm (Section 2.9.4). Equal protein loading was 
confirmed by staining the PVDF membrane with India ink (Section 2.9.5).
The establishment of a permanent X P C ^°IC S-A or a ATM ^/CS-A double 
knockdown phenotype was further confirmed by the immunocytochemical 
detection of XPC or XPA, using the VECTRASTAIN® ABC system (Vector 
Laboratories, Peterborough, UK) as previously described (Section 2.10). The 
primary anti-XPC and anti-XPA mouse monoclonal antibodies used to verify the 
knockdown phenotypes by immunocytochemical analysis, were identical to those 
used for immunoblotting.
The global repair of CPDs and 6-4PPs was measured using a standard immuno- 
slot-blot assay. Briefly, subconfluent hTERT-immortalised CS-A fibroblasts, 
transduced with the X P C -specific shRNA (sequence 2) were irradiated with 
UVC (10 J/m ). Dishes were maintained under routine culture conditions for an 
indicated period of time (hours). Genomic DNA was isolated and purified, using 
RNase A treatment and overnight proteinase K digestion, followed by 
phenol/chloroform extraction (Section 2.11.1). The immuno-slot-blot assay was 
undertaken using the Bio-Dot SF Microfiltration apparatus. The detection of 
CPDs or 6-4PPs was performed using the H3 CPD- or 6-4PP-specific 
monoclonal mouse antibody.
6.4 Results
6.4.1 Transient knockdown of XPC or CSA utilising XPC- 
and CSA-targeted 21mer siRNA duplexes
hTERT-immortalised MRC-5 fibroblasts were transfected (treatments) separately 
with three individual X P C - or C SA -specific 21mer oligonucleotide siRNA 
duplexes, which targeted the XP C  or CSA genes, respectively. The MRC-5 cells 
received three individual treatments during the course of a nine-day treatment
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cycle (Table 2.1). As a control, MRC-5 fibroblasts were transfected in parallel 
with a non-targeting siRNA scramble control.
Western blot analysis revealed that both XPC and CSA protein levels were 
reduced in MRC-5 cells transfected with XPC- or CSA-specific siRNA duplexes, 
respectively, compared to the scramble control (Figs. 6.1 A & C, 6.2A & C). The 
expected -125 kDa XPC band was visualised in the WCE derived from non­
transfected normal hTERT-immortalised MRC-5 fibroblasts (positive control), 
but was absent from the non-transfected, telomerised XP-C WCE (negative 
control) derived from subject XP8CA (Fig. 6.1 A).
Both X P C  siRNA #1 and #2 produced a reduction in XPC levels, although 
multiple rounds of treatment were required for the maximal effect. Reductions in 
XPC expression were not observed following transfection of the non-targeting 
siRNA control scramble (Fig. 6.1C).
As expected, Western blot analysis, using the anti-CSA goat polyclonal antibody, 
resulted in the detection of a lower non-specific cross-reacting band (as described 
in Chapter 3; Ridley et a l., 2005). However, an upper band (-44 kDa) indicative 
of CSA was detected in the non-transfected MRC-5 WCE (Figs. 6.2A & C). In 
contrast, an upper corresponding band, indicative of CSA was not detected in the 
non-transfected telomerised CS-A WCE derived from subject CS3BE (Figs. 
6.2A & C). Both CSA siRNA #1 and #2 produced a reduction in CSA protein 
levels, although multiple rounds of treatment were required for the maximal 
effect (Fig. 6.2A). In contrast, an upper band indicative of CSA was observed in 
MRC-5 WCEs, transfected with CSA siRNA(#3) following each treatment (Fig. 
6.2C). The level of expression was comparable to the levels of CSA protein 
observed in non-transfected MRC-5 cells (Fig. 6.2C). This suggested that CSA 
expression was not attenuated by the transfection of CSA siRNA(#3). Like XPC 
protein expression, CSA expression was not attenuated in MRC-5 cells by the 
non-targeting siRNA scramble (Fig. 6.2C).
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Significant apoptosis was observed in MRC-5 fibroblasts transfected with either 
XP C - or CSA-specific siRNA duplexes. Because MRC-5 cells transfected with 
the non-targeting siRNA scramble control also exhibited an equally high level of 
cell death, this indicated that the progressive increase in apoptosis was attributed 
to the cytotoxic effect of the oligofectamine transfection reagent, or the 
elicitation of protective mechanisms by the MRC-5 cells, in response to the 
transfection of siRNA molecules per se , irrespective of sequence specificity.
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Figure 6.1. Transient knockdown of XPC in hTERT-immortalised MRC-5 fibroblasts, 
transfected with XPC-specific 21mer siRNA duplexes. (A) XPC protein expression 
detected by Western blot analysis, using an anti-XPC mouse monoclonal antibody 
(1:500), in a normal MRC-5 WCE, XP-C (XP8CA) WCE and in MRC-5 fibroblasts 
following transfection (treatments) with XPC siRNA duplexes (sequences 1 and 2). (B) 
Equal protein loading was confirmed by staining the PVDF membrane with India ink. 
(C) Detection of XPC protein following transfection (treatments) with the non-targeting 
siRNA control scramble. (D) The level of protein loading was determined by India ink 
staining. A band of approximately 125 kDa was indicative of XPC. 20 pg of each WCE 
was loaded into each lane.
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Figure 6.2. Transient knockdown of CSA protein in hTERT-immortalised MRC-5 
fibroblasts transfected with CSA-specific 21mer siRNA duplexes. (A) CSA protein 
expression detected by Western blot analysis, using an anti-CSA goat polyclonal 
antibody (1:100), in a normal MRC-5 WCE, CS-A (CS3BE) WCE and in MRC-5 
fibroblasts following transfection (treatments) with CSA siRNA duplexes (sequences 
1 and 2). (B) Equal protein loading was confirmed by staining the PVDF membrane 
with India ink. (C) Detection of CSA protein following transfection with CSA siRNA 
duplex (sequence 3) and the non-targeting control scramble. (D) The level of protein 
loading was determined by India ink staining. A band of approximately 44 kDa 
{upper band) was indicative of CSA. 20 (ig of each WCE was loaded into each lane.
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6.4.2 Establishment of a permanent and stable telomerase- 
immortalised XPC™/CS-A (GM01856, CS3BE) double 
knockdown phenotype
To investigate the utility of shRNA-based methodologies in silencing repair 
genes involved in NER, hTERT-immortalised CS-A fibroblasts (previously 
established using primary fibroblasts derived from patient CS3BE) were 
retrovirally infected independently with two replication-defective pRS (pMSCV) 
shRNA retroviral vectors, co-expressing an X P C  shRNA construct and the 
puromycin resistance gene (puro), isolated from the CRUK SUPER RNAi™ 
library (Sections 2.4.0-2.4.9). As controls, hTERT-immortalised CS-A (CS3BE) 
fibroblasts were infected with a previously validated XPA  shRNA construct, a 
pBABE-puro only vector or were mock-infected. Two days posttransduction, 
hTERT-immortalised CS-A fibroblasts, infected with the pRS vectors expressing 
the shRNA cassettes, were serially diluted in non-selective medium and seeded 
at densities appropriate for the generation of monoclonal populations. Mock- 
infected hTERT-immortalised fibroblasts were propagated as a polyclonal 
population. Fibroblasts infected with the pRS X P C  (or XPA) shRNA constructs, 
empty pBABE-puro vector, or mock-infected, were refed 24 hours post dilution 
with selective medium, containing puromycin at a concentration of 1 pg/ml. 
After serial dilution of transduced cells, 16 and 7 hTERT-immortalised CS-A 
monoclonal populations of fibroblasts, infected with X P C  shRNA construct 1 or 
2 respectively, were isolated, expanded in culture, and propagated continuously 
with puromycin drug selection. As expected, the mock-infected (nontransduced) 
polyclonal population of hTERT-immortalised CS-A (CS3BE) fibroblasts 
exhibited significant cell death ~2 days after puromycin drug selection.
Western blot analysis revealed that the retroviral infection of hTERT- 
immortalised CS-A fibroblast with the XP C  shRNA (sequence 1 or 2) constructs 
resulted in the heterogeneous silencing of XPC protein in isolated monoclonal 
populations (Figs. 6.3A & C, 6.4A and 6.5A). Although several hTERT- 
immortalised CS-A (CS3BE) monoclonal populations (clones 4, 20 and 21),
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infected with X P C  shRNA sequence 1, displayed a significant reduction in XPC 
protein levels, no clones were isolated that displayed undetectable levels of XPC 
protein by Western blot analysis (Figs. 6.3A, 6.3C and 6.4A). Like the isolation 
of monoclonal populations of CS-A cells infected with X P C  shRNA sequence 1, 
the retroviral infection of hTERT-immortalised CS-A cells with X P C  shRNA 
sequence 2, resulted in the isolation of clones expressing heterogeneous levels of 
XPC protein (Fig. 6.4A & 6.5A). However, transduction of telomerised CS-A 
cells with X P C  shRNA sequence 2 appeared to have a greater affect on XPC 
expression, as several clones (3, 6 & 15) were isolated displaying a significant 
reduction in XPC protein expression (Fig. 6.4A). Moreover, transduction of the 
XPC shRNA sequence 2 construct, resulted in the isolation of clones 10 and 13, 
which no longer showed detectable XPC expression (Figs. 6.4A & 6.5A, 
respectively). This suggested the complete knockdown of XPC at the 
translational level. It is possible, however, that these two hTERT-immortalised 
double X P C ^D/C S-A fibroblast clones expressed residual levels of XPC protein, 
which remain undetected by Western blot analysis. Equal protein loading was 
determined by India ink staining (Figs. 6.3B, 6.3D, 6.4B & 6.5B).
The Western blot and immunocytochemical analysis suggested that the hTERT- 
immortalised CS-A (CS3BE) clones 10 and 13, infected with X P C  shRNA 
sequence 2, were the only isolated clones that failed to express detectable XPC 
protein. From these data, clone 10 was therefore selected for further 
investigation.
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Figure 6.3. Isolation of hTERT-immortalised CS-A fibroblast clones following 
retroviral infection with an XPC-specific shRNA vector (sequence 1). (A) Western 
blot analysis of 6 clones; M, MRC-5 WCE (+ve control); C, CS-A (CS3BE) WCE 
(+ve control); X, XP-C (XP8CA) WCE (-ve control). (B) Equal protein loading was 
confirmed by staining the PVDF membrane with India ink. (C) Western blot analysis 
of 6 clones; M, MRC-5 WCE (+ve control); C, CS-A (CS3BE) WCE (+ve control); 
X, XP-C (XP8CA) WCE (-ve control). (D) The level of protein loading was 
determined by India ink staining. 20 |ig of each WCE was loaded into each lane.
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Figure 6.4. Isolation of hTERT-immortalised CS-A fibroblast clones following 
retroviral infection with an XPC-specific shRNA vector (sequence 1 or 2). (A) 
Western blot analysis of 2 clones (22 & 23) infected with XPC shRNA sequence 1 
and 4 clones (3, 6, 10 & 15) infected with XPC shRNA sequence 2; M, MRC-5 WCE 
(+ve control); C, CS-A (CS3BE) WCE (+ve control); X, XP-C (XP8CA) WCE (-ve 
control). (B) Equal protein loading was confirmed by staining the PVDF membrane 
with India ink. 20 jLig of each WCE was loaded into each lane.
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Figure 6.5. Isolation of hTERT-immortalised CS-A fibroblast clones following 
retroviral infection with an XPC-specific shRNA vector (sequence 2). (A) Western 
blot analysis of 2 clones (13 & 17) infected with XPC shRNA sequence 2; M, MRC-5 
WCE (+ve control); C, CS-A (CS3BE) WCE (+ve control); X, XP-C (XP8CA) WCE 
(-ve control); IC (infection control), polyclonal population of hTERT-immortalised 
CS-A fibroblasts infected with (previously prepared) pBABE-puro retroviral 
supernatant; transfecction controls, monoclonal populations of hTERT-immortalised 
CS-A fibroblasts (clones 4, 5 and 8) infected with a retroviral supernatant expressing 
the empty pBABE-puro vector (pBABE-puro supernatant used for the transfectioin 
controls was prepared in parallel with the XPC and XPA shRNA cDNA plasmid 
transfections and infections). (B) Equal protein loading was confirmed by staining the 
PVDF membrane with India ink. 20 pg of each WCE was loaded into each lane.
Clones transfection controls
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Immunocytochemical analysis further confirmed the heterogeneous levels of 
XPC protein expression in telomerised CS-A fibroblast clones infected with 
either X P C  shRNA constructs 1 or 2 (Figs. 6.6A-H, 6.7A-F & 6.8A-F). As 
expected, both the hTERT-immortalised normal MRC-5 and CS-A (CS3BE) 
fibroblasts were immunopositive for XPC (Figs 6.6A & 6.6C, respectively). In 
contrast, nuclear staining was not detected in the hTERT-immortalised XP-C 
(XP8CA) fibroblasts (Fig. 6.6B). In general, the levels of XPC expression 
detected by immunocytochemical analysis recapitulated the levels of XPC 
protein detected by Western blot analysis in the corresponding clones. For 
example, XPC^/CS-A clones 10 and 13 showed undetectable levels of XPC 
protein by Western blot analysis. Similarly, immunocytochemical analysis of 
clones 10 and 13 failed to detect a brown nuclear peroxidase reaction product 
indicative of XPC protein (Figs. 6.8C & 6.8D, respectively).
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Figure 6.6. Immunocytochemical detection of XPC protein in hTERT-immortalised 
CS-A (CS3BE) fibroblast clones, following the retroviral infection of a 
pRETROSUPER vector expressing the XPC shRNA contruct 1. (A) hTERT- 
immortalised normal MRC-5 fibroblasts (positive control). (B) hTERT- 
immortalised XP-C (XP8CA; negative control) fibroblasts. (C) hTERT- 
immortalised CS-A (CS3BE; positive control) fibroblasts. (D) Polyclonal 
population of hTERT-immortalised CS-A fibroblasts infected with an empty 
pBABE-puro vector (infection control). Stable hTERT-immortalised CS-A (E) 
clone 3, (F) clone 4, (G) clone 5 and (H) clone 6 infected with a pRETROSUPER 
vector expressing the XPC-targeted shRNA construct 1. Positivity indicated by 
brown peroxidase reaction product. Nuclei were counterstained with haematoxylin 
to aid visualisation. Bar = 25 |im.
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Figure 6.7. Stable knockdown of XPC in hTERT-immortalised CS-A (CS3BE) 
humanl fibroblasts. Immunocytochemical detection of XPC protein was performed 
on hTERT-immortalised stable CS-A (A) clone 11, (B) clone 12, (C) clone 14, (D) 
clone 16, (E) clone 17 and (F) clone 23 isolated as monoclonal populations of 
hTERT-immortalised CS-A fibroblasts infected with a pRETROSUPER vector 
expressing the XPC-targeted shRNA construct 1. Positivity indicated by brown 
peroxidase reaction product. Nuclei were counterstained with haematoxylin to aid 
visualisation. Bar = 25 pin.
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Figure 6.8. Immunocytochemical detection of XPC protein in hTERT- 
immortalised CS-A (CS3BE) fibroblasts, following the retroviral infection of a 
pRETROSUPER vector expressing the XPC shRNA construct 2. hTERT- 
immortalised CS-A (A) clone 1, (B) clone 6, (C) clone 10, (D) clone 13, (E) clone 
15 and (F) clone 17 isolated as monoclonal populations of hTERT-immortalised 
CS-A fibroblasts infected with a pRETROSUPER vector expressing the XPC- 
targeted shRNA construct 2. Positivity indicated by brown peroxidase reaction 
product. Nuclei were counterstained with haematoxylin to aid visualisation. Bar = 
25pm.
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6.4.3 Retroviral infection o f an empty pBABE-puro 
(control) vector had no detectable effects on XPC 
expression in hTERT-immortalised CS-A (GM01856, 
CS3BE) fibroblasts
As a transfection control, hTERT-immortalised CS-A (CS3BE) fibroblasts were 
infected with a supernatant that expressed an empty pBABE-puro vector. The 
pBABE-puro retroviral supernatant was prepared from cDNA in parallel with the 
generation of X P C  and X P A  shRNA supernatants, by calcium phosphate 
transfections, using FLY A13 human epithelial cells. Following the preparation 
of the retroviral supernatant, the empty pBABE-puro vector was transduced into 
hTERT-immmortalised CSA fibroblasts. The cells were serially diluted to 
produce monoclonal populations, and 5 clones expressing the empty pBABE- 
puro vector were isolated, expanded and propagated continuously in culture with 
puromycin drug selection.
Western blot analysis clearly demonstrated that retroviral infection of hTERT- 
immortalised CS-A (CS3BE) fibroblasts with the empty pBABE-puro vector had 
no effect on XPC protein expression. Although heterogeneous levels of XPC 
protein were detected, clones 4, 5 and 8 exhibited relatively high levels of XPC 
protein (Fig. 6.5A). Equal protein loading was confirmed by India ink staining 
(Fig. 6.5B). In concordance with these data, immunocytochemical analysis 
resulted in the detection of a brown nuclear peroxidase reaction product 
(indicative of XPC) in the monoclonal populations of hTERT-immortalised CS- 
A (CS3BE) fibroblasts, infected with the empty pBABE-puro vector without 
either of the X P C  shRNA sequences (Figs. 6.9 A-D).
As an infection control, hTERT-immortalised CS-A fibroblasts were transduced 
with retroviral supernatant, expressing the empty pBABE-puro vector that was 
previously prepared and validated in our laboratory from a plasmid containing 
puro  cDNA. Following retroviral infection of the pBABE-puro vector, the CS-A 
fibroblasts were maintained in culture as a polyclonal population with puromycin
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drug selection. Both Western blot and immunocytochemical analysis of the 
polyclonal population of CS-A fibroblasts, infected with the pBABE-puro 
supernatant, displayed high levels of XPC protein (Figs. 6.5A & 6.6D, 
respectively). This suggested that the retroviral infection of an empty pBABE- 
puro vector, expressing the gene for puromycin drug resistance alone, had no 
effect on XPC expression.
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Figure 6.9. Detection of XPC in hTERT-immortalised CS-A (CS3BE) human 
fibroblasts. Immunocytochemical detection of XPC protein in hTERT- 
immortalised CS-A (A) clone 1, (B) clone 5, (C) clone 8 and (D) clone 14 isolated 
as monoclonal populations, following retroviral infection of an empty pBABE- 
puro vector. Positivity indicated by brown peroxidase reaction product. Nuclei 
were counterstained with haematoxylin to aid visualisation. Bar = 25 pm.
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6.4.4 Establishment of a permanent and stable double 
XPA^/CS-A (GM01856, CS3BE) double knockdown 
phenotype
As a transfection control, hTERT-immortalised CS-A (CS3BE) fibroblasts were 
transduced with a previously validated XPA shRNA vector, isolated from the 
CRUK SUPER RNAi™ library. The retroviral infection of the CS-A cells with 
the XPA shRNA vector was performed in parallel with the transduction of the 
XPC shRNA (sequences 1 or 2) vectors. Following retroviral infection, CS-A 
cell infected with the XPA shRNA vector were serially diluted at densities 
appropriate for the production of monoclonal populations. Transduction of 
hTERT-immortalised CS-A fibroblasts with the pRETROSUPER vector, 
expressing the XPA shRNA construct, resulted in the production of fewer clones. 
However, nine monoclonal populations were isolated, expanded in culture and 
propagated continuously with puromycin drug selection.
As expected, Western blot analysis resulted in the detection of a doublet (~46 
kDa) in the WCE derived from non-transduced hTERT-immortalised MRC-5 
fibroblasts (Fig. 6.10). Interestingly, XPA was not detected in the non-transduced 
hTERT-immortalised CS-A fibroblast WCE derived from patient CS3BE (Fig. 
6.10). This was attributed to the degradation of the CS-A WCE, as the expression 
of XPA was clearly evident in hTERT-immortalised CS-A fibroblasts infected 
with an empty pBABE-puro vector, following immunocytochemical detection 
(Fig. 6.11C). As expected, Western blot analysis failed to detect XPA protein in 
the non-transduced hTERT-immortalised XP-A WCE derived from patient 
XP12BE. Interestingly, Western blot analysis revealed that the retroviral 
infection of hTERT-immortalised CS-A fibroblasts with the XPA shRNA vector 
resulted in the isolation of clones expressing heterogeneous levels of XPA 
protein (Fig. 6.10). However, none of the 8 isolated hTERT-immortalised CS-A 
clones, infected with the XPA shRNA vector, exhibited complete cessation of 
XPA protein expression. As expected, immunocytochemical analysis, using the 
same anti-XPA antibody, resulted in the detection of a brown peroxidase reaction
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product in hTERT-immortalised normal MRC-5 fibroblasts, which was 
indicative of XPA expression (Fig. 6.11 A). Conversely, hTERT-immortalised 
XP-A fibroblasts, derived from patient XP12BE were immunonegative for XPA 
(Fig. 6.1 IB). Moreover, in agreement with the W estern blot data, 
immunocytochemical analysis resulted in the detection of heterogeneous levels 
of XPA protein expression among the isolated monoclonal populations of 
hTERT-immortalised CS-A (CS3BE) fibroblasts infected with the XPA shRNA 
vector (Figs. 6.11D-H & 6.12A-B).
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Figure 6.10. Isolation of hTERT-immortalised CS-A fibroblast clones following 
retroviral infection with an XPA-specific shRNA. Western blot analysis of 6 clones, 
using an anti-XPA mouse monoclonal antibody (1:100); M, MRC-5 WCE (+ve 
control); C, CS-A (CS3BE) WCE (+ve control); X, XP-A (XP12BE) WCE (-ve 
control). 20 |Lig of each WCE was loaded into each lane.
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Figure 6.11. Heterogeneous knockdown of XPA protein in hTERT-immortalised 
CS-A (CS3BE) human fibroblasts, following retroviral infection of an XPA 
shRNA vector. Immunocytochemical detection of XPA protein was performed on 
hTERT-immortalised (A) normal MRC-5 (positive control) fibroblasts; (B) XP-A 
(XP12BE; negative control) fibroblasts; (C) hTERT-immortalised CS-A (CS3BE) 
fibroblasts infected with an empty pBABE-puro vector (infection control); 
hTERT-immortalised CS-A (D) clone 1, (E) clone 2, (F) clone 4, (G) clone 5 and 
(H) clone 6 isolated as monoclonal populations, following retroviral infection with 
the pRETROSUPER vector expressing the XPA-targeted shRNA. Positivity 
indicated by brown peroxidase reaction product. Nuclei were counterstained with 
haematoxylin to aid visualisation. Bar = 25 pm.
Figure 6.12. Heterogeneous knockdown of XPA in hTEKT-immortalised CS-A 
(CS3BE) fibroblasts. Immunocytochemical detection of XPA protein was 
performed on (A) clone 7 and (B) clone 8 isolated as monoclonal populations from 
hTERT-immortalised CS-A fibroblasts infected with a pRETROSUPER vector 
expressing the XPA shRNA. Positivity indicated by brown peroxidase reaction 
product. Nuclei were counterstained with haematoxylin to aid visualisation. Bar = 
25 pm.
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6.4.5 Retroviral infection of an empty pBABE-puro control 
vector in hTERT-immortalised CS-A (GM01856, CS3BE) 
dermal fibroblasts had no detectable effects on XPA 
protein expression
As with protein expression, the levels of XPA appeared unaltered in hTERT- 
immortalised CS-A fibroblasts infected with an empty pBABE-puro vector (Fig. 
6.13). Immunocytochemical analysis resulted in the detection of a brown nuclear 
peroxidase reaction product in the monoclonal populations of hTERT- 
immortalised CS-A fibroblasts, infected with the pBABE-puro vector, which was 
indicative of XPA. The evidence presented here, clearly suggests that the 
isolation of clones displaying reduced levels of XPC or XPA protein, following 
transduction of an XPC  or XPA shRNA, respectively, occurred as a result of the 
targeted affect of the shRNA construct rather than the expression of the puro 
gene, which was co-expressed by the pRETRO SUPER shRNA vector.
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Figure 6.13. No detectable effect on XPA expression in hTERT-immortalised CS-A 
(CS3BE) fibroblasts. Immunocytochemical detection of XPA protein was 
performed on hTERT-immortalised CS-A (A) clone 4, (B) clone 5, (C) clone 8, (D) 
clone 14 isolated as monoclonal populations from hTERT-immortalised CS-A 
fibroblasts infected with an empty pBABE-puro vector (transfection control). (E) 
hTERT-immortalised XP-A (XP12BE) fibroblasts (negative control). Positivity 
indicated by brown peroxidase reaction product. Nuclei were counterstained with 
haematoxylin to aid visualisation. Bar = 25 pm.
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6.4.6 Retroviral infection of a pRETROSUPER vector 
expressing an XPA shRNA construct in hTERT- 
immortalised CS-A (GM01856, CS3BE) dermal fibroblasts 
had no off-target effects on XPC protein expression
It has been previously shown that siRNAs can elicit a non-specific effect on the 
protein levels of non-targeted genes (Scacheri et al., 2004). For this reason, 
Western blot and immunocytochemical analysis was undertaken on hTERT- 
immortalised CS-A fibroblasts, following transduction of an X P A -specific 
shRNA, to determine whether XPC expression was affected at the translational 
level. Western blot analysis confirmed the preservation of XPC expression in 6 
monoclonal populations of hTERT-immortalised CS-A cells following retroviral 
transduction of the XPA-specific shRNA vector (Fig. 6.14). The heterogeneous 
levels of XPC expression observed between clones was possibly attributed to 
clonal variation and/or the well-documented inducible nature of XPC. In 
agreement with these data, immunocytochemical analysis confirmed the 
maintenance of XPC at the translational level, as a brown nuclear peroxidase 
reaction product was detected in all clones assayed, albeit at heterogeneous 
levels (Fig. 6.15). The data presented here, suggests that the retroviral 
transduction of hTERT-immortalised CS-A fibroblasts with an ATM-specific 
shRNA had no affect on XPC expression.
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Figure 6.14. Retroviral infection of hTERT-immortalised CS-A Fibroblasts with an 
ATM-specific shRNA vector had no off-target effects on XPC expression. (A) Western 
blot analysis of 6 XPA shRNA infected clones, using an anti-XPC mouse monoclonal 
antibody (1:500). M, MRC-5 WCE (+ve control); C, CS-A (CS3BE) WCE (+ve 
control); X, XP-C (XP8CA) WCE (-ve control). (B) Equal protein loading was 
confirmed by staining the PVDF membrane with India ink. 20 pg of each WCE was 
loaded into each lane.
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Figure 6.15. No off-target effects on XPC protein expression in hTERT- 
immortalised CS-A (CS3BE) Fibroblasts. Immunocytochemical detection of XPC 
protein was performed on hTERT-immortalised stable CS-A (A) clone 2, (B) 
clone 4, (C) clone 5, (D) clone 6, (E) clone 7 and (F) clone 8 isolated as 
monoclonal populations of hTERT-immortalised CS-A fibroblasts infected with an 
XPA-targeted shRNA construct. Positivity indicated by brown peroxidase reaction 
product. Nuclei were counterstained with haematoxylin to aid visualisation. Bar = 
25 pm.
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6.4.7 Measurement of global CPD and 6-4PP repair in 
hTERT-immortalised XPC^/CS-A (GM01856, CS3BE) 
double knockdown
To investigate whether the retroviral transduction of an APC-targeted shRNA in 
CS-A hTERT-immortalised (APCKD/CS-A) fibroblasts affected the removal of 
UV-C radiation-induced lesions from the global genome, an immunological slot- 
blot assay was undertaken by Dr. Shirong Yu on DNA extracts (as previously 
described in Chapter 4). This assay measures the global removal of CPDs and 6- 
4PPs from genomic DNA, using specific monoclonal antibodies raised against 
these photolesions (Mori et al., 1991).
Figure 4.19 (Chapter 4) shows representative slot-blots of the kinetics of the 
removal of 6-4PPs (Fig. 4.19A) and CPDs (Fig. 4.19B) from the global genome 
in hTERT-immortalised CS-A fibroblasts (clone 10), following retroviral 
transduction of the X P C  shRNA (sequence 2) construct. Interestingly, the 
silencing of XPC in the hTERT-immortalised YPC^/CS-A cell line, resulted in 
a marked reduction in the removal of CPDs from the global genome, compared 
to the nontransduced isogenic hTERT-immortalised CS-A cell line (Fig. 6.16). 
A t-6  hours following UV, the hTERT-immortalised X P C ^/C S -A (clone 10) 
cell line removed only 21.1% of CPDs, while nontransduced hTERT- 
immortalised CS-A cells removed 55.6% of CPDs. Similarly, the hTERT- 
immortalised XPCf^/CS-A cell line removed only 28.4% and 46.3% of CPDs 
from the genome at ~12 and -24 hours after UV, respectively. In contrast, the 
nontransduced hTERT-immortalised CS-A cell line displayed repair rates of 
58.5% and 74.1% at -12  and -24  hours, respectively. These observations 
provide further evidence that suggested that the retroviral infection of hTERT- 
immortalised CS-A fibroblasts with an XPC-specific shRNA vector impaired the 
removal of CPDs from the global genome, thus suggesting that the XPC shRNA 
had a biological effect on the hTERT-immortalised CS-A cell line. Moreover, the 
telomerised XPC^/CS-A  cell line displayed similar repair capacity for the 
removal of CPDs as the nontransduced telomerised XP-C (GM02996, XP8CA)
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cell line (Fig. 6.16). This provided further supporting evidence for the biological 
effect of knocking down XPC in the telomerised CS-A cell line.
Surprisingly, however, immuno-slot-blot analysis revealed that the transduction 
of the hTERT-immortalised CS-A (GM01856, CS3BE) cell line, with the XPC 
shRNA (sequence 2) construct, had minimal affect on the global repair of 6-4PPs 
from the genome. The level of 6-4PP repair observed in the XPC^/CS-A cell 
line was similar to that observed in both the hTERT-immortalised normal MRC- 
5 and nontransduced isogenic CS-A (GM01856, CS3BE) cell lines (Fig. 6.16). 
At ~6 hours after UV-irradiation, the hTERT-immortalised XPC^/CS-A cell 
line removed 91.5% of 6-4PPs from the genome, while the hTERT-immortalised 
MRC-5 and CS-A cell lines removed 95.7% and 95.9% of 6-4PPs from the 
genome, respectively. Moreover, the hTERT-immortalised XPCF°/CS-A cell line 
removed 93.6% and 95.7% of 6-4PPs from the genome at ~12 and ~24 hours 
after UV, respectively. As expected, the hTERT-immortalised XP-C (GM02996, 
XP8CA) cell line removed only 46% of 6-4PPs from the genome -24 hours after 
UV-C treatment. Accordingly, although retroviral transduction of the XPC 
shRNA in hTERT-immortalised CS-A fibroblasts had a biological effect on 
global CPD repair, a similar effect on the removal of 6-4PPs from the global 
genome was not observed.
From these data, it can be speculated that the greater repair capacity observed in 
the XPC^/CS-A cell line was attributed to a failure to completely knockdown 
the expression of XPC at the translational level. Therefore, it was possible that 
the hTERT-immortalised XPC^/CS-A cell line expressed residual levels of 
XPC protein, which remained undetected by Western blotting or ICC and were 
sufficient to retain proficient GGR of 6-4PPs, but not CPDs.
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Figure 6.16. Time-course o f the removal of CPDs or 6-4PPs from the overall genome in 
hTERT-immortalised MRC-5, XP-C (GM02996, XP8CA), CS-A (CKN; GM01856, 
CS3BE) cell lines and CS-A infected with a pRETROSUPER retroviral vector expressing 
an XPC-specific shRNA construct (APC^/CS-A; clone 10) cell lines irradiated with UV- 
C (254 nm; 10 J/m2). Removal of CPDs or 6-4PPs was measured at 6 hrs (purple), 12 hrs 
(yellow) and 24 hrs (blue) following UV-C treatment, using monoclonal CPD- or 6-4PP- 
specific antibodies, respectively. Immuno-slot-blot assays were undertaken using 1000 ng 
of genomic DNA isolated at each time point. Each point represents the mean of three 
independent biological replicates.
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6.5 Discussion
The advent of RNAi-mediated gene silencing technologies has facilitated the 
establishment of permanent cell lines with loss-of-function phenotypes that 
recapitulate cells derived from specific genetic backgrounds. The aim of this 
investigation was to extend the utility of RNAi technologies by transiently 
ablating XPC or CSA in normal telomerised MRC-5 fibroblasts. Moreover, a 
further objective was to permanently ablate XPC function in a previously 
established telomerised CS-A cell line (Chapter 4), thereby creating a novel 
double XPCkd/CS-A  mutant phenotype defective in both GGR and TCR.
Although the data presented, clearly demonstrated the utility of RNAi technology 
in the siRNA-mediated knockdown of XPC and CSA in normal MRC-5 
fibroblasts, several caveats were identified with transient siRNA technology. For 
example, multiple rounds of transfection (treatment) were required to completely 
ablate XPC or CSA to undetectable levels at the translational level. Moreover, a 
significant level of apoptosis was observed following multiple treatment cycles. 
This was attributed to the cytotoxicity of the lipid-based transfection reagent, as 
similar levels of apoptosis were observed in telomerised MRC-5 cells, 
transfected with the non-targeting siRNA scramble control. Therefore, the 
CRUK SUPER RNAi™ library based on the pSUPER RNAi system 
(Brummelkamp et al., 2002) and the human SUPER RNAi™ library (Bems, et 
al., 2004) was used to create a permanent and stable double X PC^/CS-A  
knockdown phenotype. This approach, based on an shRNA expression vector 
system, was adopted to circumvent the multiplicity of experimental caveats 
associated with siRNA technology, which have been observed here and 
elsewhere in the literature (reviewed by Dykxhoom et al., 2003).
To date, the manipulation of the NER pathway, using RNAi-mediated 
technologies, have been undertaken in NER-proficient cells (Biard et al., 2005; 
Feng et al., 2006). Evidence presented in this study suggested that the retroviral 
transduction of telomerised CS-A cells with a pRS vector, expressing an XPC  
shRNA construct, resulted in the creation of a double X PC ^/C S-A  mutant
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phenotype. This was confirmed by Western blot analysis and ICC, which 
revealed the isolation of two monoclonal populations (clones 10 and 13) of 
telomerised CS-A cells with undetectable levels of XPC protein. In agreement, 
Biard et al. (2005) showed that HeLa cells, infected with EBV-based vectors 
expressing an XPC  or XPA shRNA, displayed undetectable levels of XPC or 
XPA protein respectively, when maintained in culture for >300 days. However, 
although XPC protein was undetected in clone 10, the resultant XPCf^/CS-A 
double mutant phenotype appeared extremely complex, as the loss of XPC 
protein expression appears to have only partially affected the repair phenotype of 
the double X P C ^/C S-A mutant. Immuno-slot-blot analysis was undertaken on 
the JlPCkd/CS-A double mutant to determine whether the undetectable levels of 
XPC protein observed in the telomerised CS-A cell line, infected with the XPC- 
targeted shRNA, had a biological effect on the removal of CPDs and 6-4PPs. 
Interestingly, the data suggested that the loss of XPC protein expression 
observed in the XPCKD/CS-A knockdown had a biological effect on the removal 
of CPDs from the overall genome, as the repair kinetics of CPDs in the 
APC^/CS-A cell line appeared significantly reduced, compared to that observed 
in the nontransduced isogenic telomerised CS-A cell line. Additionally, the 
repair kinetics displayed by the XPC^/CS-A double knockdown was similar to 
the level of repair observed in the telomerised XP-C cell line. This suggested that 
the retroviral transduction of the APC-targeted shRNA vector caused a reduction 
in the global repair of CPDs. In stark contrast, a similar reduction in the global 
repair of 6-4PPs was not observed, as the level of repair in the overall genome 
observed in the X P C ^/C S-A double knockdown was similar to that observed in 
the nontransduced telomerised isogenic CS-A and NER-proficient MRC-5 cell 
lines. As previously mentioned (Chapter 4), the repair of 6-4PPs can occur at 
least five-fold faster than that of CPDs (Van Hoffen et al., 1995), and is thought 
to occur within the first few hours after UV. However, the rate of repair was 
examined over a limited number of time points (0, 6, 12 and 24 hours) post UV. 
Accordingly, it is possible that assessing the repair kinetics at earlier time points 
(0.5-4 hours) would have allowed the detection of slower 6-4PP repair in the 
telomerised CS-A cell line transduced with an XPC  shRNA (XPCKD/CS-A) 
compared to the nontransduced isogenic telomerised CS-A cell line.
410
Although Western blotting and ICC analysis suggested that the retroviral 
transduction of the XPC-targeted shRNA vector, in a telomerised CS-A cell line, 
resulted in the complete ablation of XPC expression, the repair data suggested 
that the XPC  shRNA had only a partial effect on GGR. The data presented here 
indicate that the pRS shRNA construct utilised in this investigation may be 
unable to target the entire XPC  mRNA transcripts. It is possible that, the 
XPCkd/CS-A cell line created, may have translated a small amount of XPC 
protein from residual XPC  mRNA transcripts that remained untargeted by the 
XPC  shRNA. If this is the case, the residual amount of XPC protein was 
undetectable by Western blotting and ICC. Hence, the residual amount of XPC 
protein translated by the XPC /CS-A double knockdown from the small 
remaining pool of untargeted mRNA transcripts may have been used 
preferentially for the global repair of 6-4PPs. In contrast, it appears that low 
amounts of XPC were insufficient to retain the GGR capacity of CPDs that was 
observed in the nontransduced CS-A cell line, thus explaining the partial effect. 
In agreement, Hey et al. (2002) showed that the XPC-hHR23B complex 
preferentially binds 6-4PPs in high affinity. However, conflicting data published 
by Emmert et al. (2000) showed that XPC selectively repairs CPDs compared to 
6-4PPs. The precise role(s) of XPC in the removal of different UV-induced 
lesions remains unclear.
Koberle et al. (2006) speculated that NER factors such as XPA, RPA, TFIIH, 
XPG and ERCC-1-XPF are present at approximately 100,000-200,000 protein 
molecules per un-irradiated HeLa cell, while XPC is present at about 25,000 
protein molecules per cell (Araujo et al., 2001). For this reason, Koberle et al. 
(2006) suggested that XPC provided the obvious target for abolishing GGR by 
RNAi technology. However, Khan et al. (2002) previously showed that low 
levels of XPC expression (~10 XPC mRNA molecules per cell) were sufficient 
to maintain normal levels of repair activity in normal cells. This supports the 
possibility that in the XPC^/CS-A double knockdown cell line, created in my 
study, low levels of XPC were sufficient to retain some GGR of 6-4PPs. In 
contrast, Biard et al. (2005) suggested that shRNA-mediated knockdown of XPA 
and XPC in NER-proficient cells, facilitated the establishment of cell lines that 
mimic the characteristics of XP cells, namely impaired unscheduled DNA
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synthesis. However, they showed that XPC?1* HeLa cells are more sensitive to 
UV than XPA™ cells.
During this investigation, the XPC^/CS-A (clone 10) cell line was maintained 
in culture with puromycin drug selection. The effect of the withdrawal of 
puromycin on the phenotype of the XPCKD/CS-A cell line was not investigated. 
Interestingly, Biard et al. (2005) showed that the removal of hygromycin B drug 
selection lead to the loss of the EBV shRNA expressing vectors. This resulted in 
the restoration of either XPA or XPC protein. Notably, they observed the 
reversion of the XP phenotype to a wild-type phenotype in HeLa XPA^  cells, 
but not in HeLa XPC?D cells, which remained sensitive to UV. Moreover, they 
showed that hygromycin B withdrawal restored a normal cell cycle arrest in 
XPAkd cells, whereas reverted XPC?D cells accumulated at the Gi-early/S 
transition, thus maintaining the XP phenotype. Biard et al. (2005) concluded that 
a deficiency in XPC triggers irreversible genetic defects. They also speculated 
that XPC is not only important in DNA repair and mutagenesis, but also in 
damage signalling and cell cycle progression.
As previously discussed (Chapter 5), many of the core components of the NER 
machinery (such as XPA, XPB, XPD, XPF, XPG) are not regulated at the 
transcriptional level. However, it has been shown that XPC  is a DNA damage- 
inducible p53-regulated gene that mediates a role in the p5 3-dependent NER 
pathway (Adimoolam & Ford, 2002). In agreement, the transcription expression 
profiling data presented in this thesis (Chapter 5), identified XPC as UV- 
inducible at the mRNA level in the telomerised nontransduced CS-A cell line. 
Therefore, it is possible that XPC mRNA was transcriptionally upregulated in the 
XPCkd/CS-A double knockdown in a p53-dependent manner following UV, thus 
resulting in a higher XPC  mRNA transcript to X PC  shRNA ratio, as the 
expression of the XPC shRNA relies upon de novo synthesis.
It was previously speculated in this thesis (Section 1.14, Chapter 1) that an 
XPC/CSA null would exhibit the repair kinetics of an XPA null cell. However, 
immuno-slot-blot analysis undertaken on a telomerised XP-A (XP12BE) cell line 
established in our laboratory revealed that this is not the case (data not shown),
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as the repair kinetics observed in the XPC™/CS-A cell line does not reflect the 
level of repair observed in XP-A cells. In agreement with the data presented here, 
Verhage et al. (1996) showed that although yeast double mutants o f RAD26 
(CSB) with the GGR determinants RAD 7 {rad7 and rad26) and RAD 16 {rad 16 
and rad26) appeared more UV sensitive that the single rad7 or rad 16 mutant 
strains alone, they were not as sensitive as the completely NER-deficient rad 14 
{XPA) strain. Verhage et al. (1996) speculated that TCR and GGR are partially 
overlapping. Although the relevance of the yeast data is questionable, as 
orthologs of the RAD 7  and RAD 16 have yet-to-be identified in humans, the 
concept that separately removing a TCR gene’s and GGR gene’s function may 
not reflect the phenotype of a cell totally defective in NER, remains a possibility. 
This concept might have been testable via a double knock out, but homozygous 
Csa'^/Xpc*7' double transgenic mice were severely runted and died within a 
month of birth (van der Horst et al., 2002).
Although Biard et al. (2005) recently demonstrated the applicability of RNAi 
technology, through the establishment of stable and permanent XPA™ and 
XPC™ null phenotypes, using NER-proficient HeLa cell lines, investigators 
have shown that NER is severely compromised in transformed cells, due to the 
abolition of p53 function (Bowman et al., 2000; El-Mahdy et al., 2000; Ferguson 
& Oh, 2005; Ford et al., 1998; Therrien et al., 1999). In particular, HeLa cells 
express the viral E6 oncoprotein, which not only abolishes GGR activity, but 
also inhibits p53-dependent apoptosis in the TCR pathway (Ljungman & Zhang, 
1996), thereby potentially reducing the expected death rate observed after UV 
(Biard et al., 2005). This may explain why they observed a higher sensitivity in 
the GGR-defective XPC™ cells compared to the GGR- and TCR-defective 
XPA™ cells.
It is noteworthy that several telomerised CS-A clones were isolated and 
propagated, following transduction of the XPyf-targeted shRNA vector, but none 
of the clones displayed undetectable XPA protein levels. Hence, a double 
XPA™/CS-A double total knockdown may create a lethal phenotype.
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Recently, Feng et al. (2006) demonstrated the potential applicability of RNAi 
technology in ameliorating the efficacy of tailored cancer therapy by targeting 
the TCR pathway. They targeted the CSB gene, using vector-mediated siRNAs, 
and found that the inactivation of the CSB gene caused HeLa cells to proliferate 
more slowly and sensitised cells to genotoxicants such as UV and cisplatin (via 
apoptosis). Additionally, inactivation of CSB resulted in spontaneous apoptosis 
and altered UV-induced cell cycle responses. From these findings, they 
suggested that CSB provides a potential target, which can be exploited in 
combination with radiotherapy or chemotherapy.
In summary, the utility o f RNAi to investigate DNA repair has been 
demonstrated. The data presented suggest that, the transfection of XPC- or CSA- 
specific 21mer siRNA duplexes in telomerised MRC-5 fibroblasts resulted in the 
transient suppression of XPC or CSA at the translational level. Several caveats 
were identified, including the requirement of multiple rounds of treatments to 
reduce XPC or CSA protein to undetectable levels by western blotting. 
Moreover, the cytotoxic effect of the lipid-based transfection reagent resulted in 
extensive apoptosis. This prevented long-term in vitro analysis of siRNA 
generated NER-deflcient phenotypes for several reasons. Firstly, the transient 
nature of the siRNA duplexes suggested that the transfected cells would rapidly 
lose the NER-defective phenotype and revert back to a wild-type background. 
Furthermore, as previously mentioned, any long-term in vitro investigation of the 
NER-defective phenotypes would require multiple treatment cycles. Therefore, it 
would be particularly problematic to determine whether the levels of apoptosis 
observed in the siRNA transfected cells was attributed to the NER defect 
exhibited by the cells as a result of knocking down the gene of interest, thereby 
creating the desired NER defective phenotype, or an artifactual consequence of 
the cytotoxicity of the transfection reagent. Furthermore, although the utilisation 
of shRNA technology resulted in the stable knockdown of XPC in the 
telomerised CS-A dermal fibroblast cell line, the repair data suggested that the 
ablation of XPC protein resulted only in a partial biological effect. Therefore, 
although the applicability o f RNAi technology has been demonstrated as a 
possible tool for unravelling the molecular cause of cancer susceptibility (Biard 
et al., 2005), the data presented here suggests that significant caution should be
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applied when using RNAi as a tool to manipulate gene expression for the 
creation of specific genetic backgrounds. These data also highlight the need for 
rigorous characterisation at both the biochemical and functional level.
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Chapter 7 
General Discussion and 
Future Investigation
In the present study, the characterisation (Ridley et a l , 2005) and establishment 
of hTERT-immortalised XP-C (GM02996, XP8CA) and CS-A (GM01856, 
CS3BE) dermal fibroblast cell lines was described (Chapters 3 & 4, 
respectively). From the data presented here, and in concordance with other 
investigators (Newman et al., 2006; Oullette et al., 2000), it can be concluded 
that telomerase-mediated immortalisation extends the proliferative capacity of 
fibroblast cultures irrespective of defects in NER. However, unlike previous 
investigations (Newman et al., 2006; Oullette et a l , 2000), this thesis has 
extended the investigation to the characterisation of p53/p21WAF1/CIP1 and 
pRb/pl6INK4A function in telomerised NER-defective cell lines (Chapter 4). The 
data suggest that both p53/p21WAF1/CIP1 and pRb/p 16INK4A activity is retained in 
X PC  and CSA null cell lines, following the ectopic expression of hTERT. 
Furthermore, these data confirm the preservation of p53 stabilisation and 
functionality through phosphorylation at Seri 5 and the transcriptional activation 
of the downstream CDK inhibitor, p21WAF1/CIP1. In disagreement with a previous 
study (Naka et a l , 2004), the data presented here also suggests that telomerase- 
mediated immortalisation is sufficient to maintain cells derived from genome 
instability and progeroid syndromes in long-term culture without the induction of 
SIPS.
The characterisation and establishment of hTERT-immortalised XP-C and CS-A 
cell lines described here, has extended the repertoire of currently available 
telomerised GGR- and TCR-defective cells that appear to retain the original NER 
defect displayed by their primary isogenic counterpart. Therefore, the 
establishment of telomerised XP-C and CS-A cell lines provide an alternative 
genomically stable in vitro cell system to investigate the DNA damage responses
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and molecular mechanisms underlying the cellular phenotypes exhibited by XP- 
C and CS-A.
The microarray experiments undertaken during this investigation exclusively 
focused on transcription expression profiling the UVC-induced damage 
responses elicited by telomerised XP-C and CS-A dermal fibroblasts defective in 
the GGR and TCR subpathways o f NER (Chapter 5). However, other 
investigators have shown that in addition to the general DNA damage responses 
(such as cell cycle arrest, DNA repair and apoptosis) cells elicit a series of 
transcriptional responses in a cell-types-specific manner. Therefore, a detailed 
investigation into the cell-type-specific responses mediated by other skin cell 
types such as kerationcytes and melanocytes is required (previous investigators 
have not addressed the differences between cell-type-specific transcription 
profiles observed in normal compared to NER-defective cell lines). This will 
facilitate the identification of any cell-type-specific responses in NER-defective 
cells lines and provide a possible avenue for the elucidation o f molecular 
mechanisms involved in the early initiation, development and progression of 
cutaneous malignancy in XP patients compared to the normal population. 
Extending expression profiling to several different cell-types may facilitate the 
elucidation of the underlying cell-type-specific changes that contribute to the 
progeroid phenotype observed in CS patients.
Although beyond the scope of the current investigation, the establishment of 
telomerised cell lines derived from patients representing all XP, CS and TTD 
complementation groups, would facilitate the generation of comprehensive 
transcription expression profiles for these syndromes. This would permit the 
establishment of a molecular taxonomy for the different syndromes (XP, CS and 
TTD) and complementation groups (XP-A to XP-G, CS-A and CS-B) both in the 
response to the presence and absence of exogenous and/or endogenous stress 
(such as UV and oxidative DNA damage). In support o f this, Newman et al. 
(2006) recently demonstrated the applicability of expression microarrays in 
unravelling the role of CSB in chromatin maintenance and remodelling under 
normal physiological conditions in the absence of external stress. Moreover, 
comprehensive analysis of the entire transcriptome of the different genetic
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backgrounds will facilitate the establishment of transcriptional portraits to give a 
detailed picture of the complex transcriptional programme presented by these 
complex NER syndromes. This will potentially facilitate the establishment of 
sub-classifications of the existing XP and CS complementation groups at the 
molecular level, in addition to the current complementation groups that are based 
on classification according to gene defect. As previously discussed (Chapter 3), 
this is particularly important in CS, as there appears to be no obvious clinical or 
cellular differences between patients assigned to the CS-A and CS-B 
complementation groups. Moreover, there also appears to be no correlation 
between the location or type of mutation and the clinical phenotype. Therefore, 
the lack o f genotype-phenotype relationships in CS, suggests that 
pathophysiological manifestations presented by CS patients are determined by 
unknown mechanisms.
In addition to unravelling the precise phenotype-genotype relationships between 
the NER syndromes (such as XP, CS, TTD, XP-CS, XP-TTD, COFS and UVsS), 
the establishment o f a molecular taxonomy may further facilitate the 
identification of prognostic markers or therapeutic targets for the development of 
tailored therapies. Moreover, a molecular taxonomy of XP and CS may further 
assist in elucidating the precise molecular events that promote cutaneous 
malignancy and progeria in the normal population.
The transcription expression profiling experiments described in Chapter 5, using 
Affymetrix™ HG-U133A GeneChip® arrays, resulted in the identification of 
genes differentially regulated in response to UV exposure. Among these genes, 
were transcription factors, which are requisites to the initiation of many well- 
characterised responses to DNA damage such as cell cycle arrest, DNA repair 
and apoptosis. In concordance with previous studies, the ATF/CREB 
transcription factor, ATF-3, was found significantly upregulated in all cell lines 
transcription expression profiled in this study. Despite many transcription factors 
(such as ATF3) being identified as UV-inducible, the precise molecular 
mechanisms underlying the UV-mediated induction of these genes remains 
unknown.
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Gene expression in eukaryotic organisms is controlled by regulatory elements 
that recruit transcription factors with specific DNA binding properties (Wei et 
al., 2006). Although many of the genes (particularly transcription factors and 
DNA binding proteins) identified in this study and previous investigations are 
known to define the programmed set of responses of the cell cycle, DNA repair 
and apoptotic pathways, the precise relationship and interactions between these 
genes remains poorly delineated. To date, investigators that have characterised 
the cellular transcriptional response to UV have not attempted to elucidate the 
functional elements such as TFBS, or the transcriptional gene targets that lie 
downstream to these transcription factors on a global scale. This in part has been 
attributed to the lack of experimental tools that facilitate the global mapping of 
sites of DNA/protein interaction. Until recently, individual ChIP assays were 
used extensively to characterise DNA/protein interactions and to validate direct 
targets of transcription factors, such as p53-target genes (Mirza et al., 2003). 
More recently, Jiang & Sancar (2006) demonstrated the applicability of ChIP in 
the investigation of DNA repair. They developed a ChIP assay for analysing the 
binding of repair and checkpoint proteins to DNA base lesions in any given 
region of the genome. However, this method is highly inefficient and time 
consuming for identifying transcriptional targets on a global scale. The recent 
development of ChlP-on-CHIP, which encompasses both ChIP technology and 
whole-genome tiling arrays, has permitted the global characterisation of 
DNA/protein interactions and the identification of novel transcriptional targets. 
This method has been successfully used for whole-genome localisation analysis 
in yeast (Ren et al., 2000). Until recently, the exploitation of this technology has 
been limited in humans due to the large size and complexity of the genome. 
However, the recent development of high-resolution tiling arrays, such as the 
Affymetrix™ GeneChip® Human Tiling I.OR or 2.0R Arrays has facilitated the 
accurate mapping of DNA/protein interactions, novel transcript discovery and the 
identification of global epigenomic changes such as methylation and acetylation 
across the entire human genome. Therefore, adopting a ChlP-on-CHIP approach 
will not only facilitate the identification of novel downstream transcriptional 
targets to those transcription factors identified in the present expression profiling 
study (such as ATF3 and p53), but also it will assist in the delineation of the
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sequential and temporal response of genes involved in the UVC-induced 
transcriptional response. For example, inherited polymorphisms in the TP53 gene 
has been reported to dictate melanoma risk. Therefore, the variation in the 
capacity of p53, ATF3 or other transcription factors to induce downstream 
targets may, in part explain these findings and facilitate the identification of the 
underlying molecular defects contributing to the XP or CS phenotype. In 
addition, ChlP-on-CHIP analysis of the telomerised XP-C and CS-A cell lines 
will permit the identification of molecular defects in the regulation of gene 
expression such as dysfunctional transcription factor binding, between cell lines 
defective in GGR, TCR or both. ChlP-on-CHIP analysis over a time course will 
further facilitate the identification of changes in transcription kinetics, thus 
permitting the elucidation of subtle differences in transcription initiation and 
repression between normal and NER-defective phenotypes in response to UV. 
This is particularly important with regards to CS, as defects in TCR are known to 
abolish the resumption of basal transcription following UV-irradiation, which 
may in part explain the delayed and prolonged kinetics of differential gene 
expression observed in this investigation.
ChlP-on-CHIP will further assist in elucidating possible cross talk between 
transcription and DNA repair. For example, the multiprotein TFIIH complex has 
been implicated in orchestrating a multiplicity of functions such as basal 
transcription, activated transcription, NER and TC-NER. Furthermore, CSA and 
CSB have been implicated in regulating the phosphorylation state of the RNA 
Pol II CTD domain, which regulates the initiation of RNA Pol II-dependent 
transcription.
It is important to note that the UV-responsive genes identified in this 
investigation represented changes in mRNA transcript levels. However, these 
changes in expression are not necessarily indicative of rates of transcription, as it 
is possible that the transcript levels revealed by microarrays is attributed to 
changes in the rate o f transcript degradation. For example, exposure to UV 
promotes the stabilisation of c-Fos mRNA and other short lived mRNAs 
(Blattner et a l , 2000). Therefore, future microarray studies should incorporate 
the use of transcription inhibitors (such as actinomycin D), to determine whether
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the differential regulation of transcription is due a change in transcription rates or 
degradation.
As previously discussed (Chapter 5), transcription expression profiling operates 
under the pretense that changes in transcript levels ultimately reflect subsequent 
changes at the protein level. However, this assumption is not necessarily true 
with all genes. Furthermore, gene expression profiling provides no information 
regarding posttranslational modification. Although several genes were 
investigated at the protein level in the present study (Chapters 4 & 5), proteome 
wide analysis was beyond the scope of this investigation. Therefore, the 
utilisation of protein arrays would not only facilitate the global characterisation 
of protein expression in response to UV exposure, but would further assist in the 
characterisation of novel protein-protein interactions and posttranslational 
modifications, such as phosphorylation, ubiquitylation and sumolation. This 
would be particularly advantageous in understanding how these proteins interact 
and assist in the regulation of NER, especially as recent evidence implicates the 
ubiquitin-proteasome pathway in the regulation of NER. A preliminary 
investigation, undertaken by Cleaver et al. (in press) used a protein array 
(composed of 500 monoclonal antibodies) to screen normal and CS-B cells to 
identify possible targets for CSB-dependent over-expression at the proteome 
level.
As previously discussed (Chapters 1 & 3), although the mechanistic function of 
the p53/p21WAF1/CIP1 and pR b/plb1*1^  pathways has been rigorously 
investigated, the precise role(s) o f these pathways in NER remain poorly 
delineated and controversial. Therefore, a combination of ChlP-on-CHIP and 
proteome wide applications should assist in elucidating the precise role(s) of 
p53/p21WAF1/CIP1 and pRb/plb11^ ^  in NER and the DNA damage response 
following UV. In particular, both technologies will help unravel the 
transcriptional regulation of NER factors (such as DDB2 and XPC) by p53. 
Moreover, p53 has been implicated in regulating NER through direct interaction 
with numerous NER factors (such as XPB and XPD), which is independent of 
transcriptional modifications. Therefore, protein arrays will facilitate the precise 
characterisation of these interactions and permit the identification of novel
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protein-protein interactions between proteins, so revealing physical and 
functional links between NER and the DNA damage response. For example, Wu 
et a l  (2006) recently demonstrated that phosphorylation of XPA at Seri96 by 
ATR, positively regulated NER activity. From these data, Wu et a l  (2006) 
speculated that an ATR DNA damage response facilitated cells to recover from 
NER-related DNA damage, thus providing evidence for the existence of links 
between NER and the DNA damage signalling pathways. The implementation of 
ChlP-on-CHIP and protein array technologies will validate these findings on a 
global scale.
Although the kinetics o f CPD repair has been extensively investigated in defined 
genomic regions, using the well-established strand-specific DNA repair assay 
(Bohr et a l ,  1985), which is based on Southern blot technology and the 
functional properties o f T4 endonuclease V, the repair kinetics of CPDs at the 
genome wide level remains unknown. Previous investigations have shown a 
strand bias for the repair of CPDs on the transcribed strand of a limited number 
of active genes, compared to the nontranscribed strand and transcriptionally 
silent regions o f the genome. In addition to preferential TCR repair, the 
heterogeneity o f CPD repair in mammalian genomic sequences has been 
observed at many other levels. For example, in addition to the slower repair of 
CPDs in upstream promoter sequences, a 10-fold faster repair rate has been 
reported at the transcription initiation site in Jun (Tu et a l, 1996). Furthermore, 
the fast repair close to the transcription start site was also observed in the non­
transcribed strand (Tu et a l ,  1996). The complexity of repair kinetics is 
particularly evident in the transcribed strand, as a gradient of DNA repair has 
been reported, with the rate decreasing nearer the 3 ’-end of the gene (Tu et a l, 
1996). Although TCR was discovered more than 19 years ago (Mellon et a l, 
1987), no genome wide survey of differential repair has been undertaken. 
Therefore, it would be of significant interest to extend the utility of the Southem- 
blot based methodology on a global scale. For example, the strand-specific repair 
assays could be exploited to measure the repair kinetics of UV-responsive genes 
identified in this investigation by the transcription expression profiling studies 
(Chapter 5). This will provide a global picture of repair that will complement the 
existing expression data obtained from the transcription expression profile
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studies. This will also provide further information regarding the association 
between the kinetics of the DNA damage response elicited following UV and the 
kinetics of GGR and TCR repair of those genes. It would be particularly 
interesting to compare the DNA damage response kinetics of differential gene 
expression observed between the wild-type (MRC-5), GGR-defective (XP-C) 
and TCR-defective (CS-A) cell lines with their global repair kinetics obtained 
from Southern blot analysis. A working hypothesis is that those genes activated 
as part of the cell’s initial response to stress are likely to be repaired first by 
TCR. Therefore, it is possible that, in addition to the rapid repair of the 
transcribed strand, preferential repair may occur in genes (such as ATF3, p53 and 
p21WAF1/CIP1) that orchestrate the initial DNA damage response.
The microarray data presented here, for the first time, has generated entire 
genome wide transcriptome profiles for telomerised GGR-defective (XP-C) and 
TCR-defective (CS-A) cells following UV. However, further investigation is 
required to delineate the precise cause of the different transcription kinetics 
observed between the cell lines. It is possible that the delayed and prolonged UV- 
induced transcriptional responses displayed by the telomerised CS-A cell line is 
simply attributed to the failure to resume mRNA synthesis following UV 
damage. Alternatively, the responses may have been attributed to a defect at the 
molecular level that remains uncharacterised.
Although the transient and stable utility of RNAi was demonstrated in this 
investigation (Chapter 6), the precise effect o f knocking down XPC in the 
telomerised CS-A cell line on NER remains unclear, as immuno-slot-blot 
analysis revealed only a partial effect on NER. These findings may have been 
simply attributed to the presence of undetectable levels of XPC protein that 
facilitate the preservation of the GGR subpathway, albeit at a reduced activity. 
Alternatively, these data may provide evidence supporting the suggestion that 
there is a complex role for XPC in the recognition and repair of different UV- 
induced photolesions. To further investigate the precise effect of the XPC- 
targeted shRNA vector on the telomerised CS-A cell line, qRT-PCR will 
facilitate the detection of any residual X PC  mRNA molecules that have the 
potential to translate into functional XPC protein. Furthermore, the utilisation of
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strand-specific DNA repair assays (as previously discussed) to measure repair 
along the transcribed and non-transcribed strand should further assist in 
clarifying the repair phenotypes of the cell line.
Extending the present investigation by exploiting ChlP-on-CHIP and proteomic 
technologies will further assist in answering many of the remaining questions. 
However, this will rely on ChIP grade antibodies, specific proteins or tagged 
varieties of them. For example, the precise mechanistic steps involved in lesion 
recognition remains poorly understood. Although the formation of a pre­
assembled repairosome complex has been largely dismissed, the sequential 
assembly and dynamics of protein trafficking of the NER apparatus remains to be 
fully delineated.
A further area of significant controversy includes the cancer-ageing dichotomy in 
XP and CS. Currently, it is believed that cancer predisposition observed in XP is 
attributed to the low levels of UV-induced apoptosis, while the neurological 
dysregulation, progeroid phenotype and lack of cancer susceptibility in CS has 
been attributed to high levels of DNA-damage-induced apoptosis. Further causes 
have also been suggested as possible explanations for the lack of cutaneous 
malignancy in CS such as differences in the immune response, transcriptional 
efficiency and oxidative metabolism. However, the precise underlying molecular 
defect(s) that contribute to the CS phenotype remain uncharacterised.
In conclusion, the characterisation and establishment o f telomerised GGR- 
defective (XP-C) and TCR-defective (CS-A) cell lines extends the number of cell 
lines (to XP-C, CS-A, XP-E, XP-V and CS-B) generated by the ectopic 
expression of hTERT. These cell lines provide investigators with alternative in 
vitro models o f defective NER, to those cell lines traditionally established 
through oncogenic transformation. The GGR and TCR subpathways of NER are 
highly complex, and defects in genes encoding protein products that regulate 
these pathways results in an intricate and a highly pleotrophic set of syndromes. 
Therefore, the generation of transcription expression portraits will assist in 
understanding the molecular defects exhibited by cells derived from NER 
syndromes. Additionally, the transcrip tome data will help unravel the
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heterogeneous nature of the pathophysiological manifestations displayed by XP 
and CS patients. Although the mechanistic function of the NER pathway has 
been well characterised at the level of naked DNA, the intricate network of 
events that is triggered in cells by DNA damage remains poorly understood. The 
data presented here contributes to furthering the understanding of these 
molecular events.
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Appendix 1. Gene Ontology Classification of genotype-specific differentially regulated genes (Cluster 1).
Membrane ALDH3A2, APLP2, ATP6AP2, ATP6V0C, BACE2, BZRP, C16orf30, C20orf35, C20orf59, CLIC3, CMKOR1, COPZ2, COX7A1, CYB561, CYB5R3, CYBA, CYP1B1, DPP4, 
EFEMP2, FAM26B, FAM38A, FAP, GHR, GOLPH2, GPC4, GPM6B, GPNMB, GPR30, HEPH, HERPUD1, ITGBL1, KCNJ8, KCNK1, KCNK2, LRP10, LRP3, LRRC15, LY6E, 
MFAP3L, NOTCH3, NRP1, OLFML2B, PGRMC1, PODXL, PSG1, PSG4, PSG9, PTGER3, RAB40B, RHOD, RNF130, SDC1, SLC1A4, SLC22A17, SLC39A4, SLC7A5, 
SLC7A8, SRPRB, THBD, TMED3, TNFSF9, TSPAN13, UNC5B, VKORC1
Integral to membrane ADAM12, ALDH3A2, APLP2, ATP6AP2, BACE2, BZRP, C16orf30, C20orf35, C20orf59, CMKOR1, COX7A1, DPP4, FAM26B, FAM38A, FAP, FLJ23191, GABRE, GPM6B, 
GPNMB, GPR30, HEPH, HERPUD1, ITGBL1, KCNJ8, KCNK1, KCNK2, LRP10, LRP3, LRRC15, MALL, MFAP3L, NOTCH3, NRP1, PLXNC1, PSG1, PSG4, PSG9, PTGER3, 
RNF130, SGCD, SGCG, SLC22A17, SLC39A4, SLC7A5, SLC7A8, SRPRB, TMED3, UNC5B, VKORC1
Protein binding ACTA2, ADAM12, AKAP12, APLP2, ASS, BAG1, C20orf35, CCND1, CD99, CDKN2A, CHFR, CLIC3, COL18A1, COL6A1, COMP, DNM1, DPT, EFEMP2, EFS, EMX2, FASN, 
FKBP1A, FTH1, GHR, HOXA9, HSPB2, ISLR, LDOC1, LMNA, MALL, NBL1, PARVB, PML, PYCARD, RCN3, RNF130, RNF144, SH3BP5, SH3GL1, SLIT3, SPP1, THBS2, 
THY1, TNC, UNC5B, WISP2
Nucleus AHNAK, APLP2, C20orf11, CCND1, CDKN2A, CHFR, CLIC3, CMPK, EMX2, EN1, FOXL2, GATA2, HIST2H2AA, HIST2H2BE, HOXA10, HOXA11, HOXA9, HOXC10, HOXC11, 
HOXC6, ID1, ID2, ID4, IRX5, LDOC1, LMNA, MAFB, MGMT, MSX1, NET1, PML, PRRX1, RNF144, RUNX3, TFAP2C
Integral to plasma membrane ADRA2A, ANPEP, CCRL1, CD99, CYB561, ENPP2, GABBR2, GABRE, GHR, GOLPH2, GPC4, GPR30, LY6E, NOTCH3, PGRMC1, PODXL, PPAP2A, PTGER3, SDC1, 
SLC1A4, SLC7A8, THBD, THY1, TNFSF9, TSPAN13
Cytoplasm AEBP1, AKAP12, ASS, BAG1, C20orf35, CD99, CKB, CLIC3, CMPK, COL18A1, COL1A1, COL1A2, COL5A1, COL5A3, COL6A1, COL6A2, COL8A2, CRIP1, EFS, ELN, EVL, 
PYCARD, SH3GL1, UPP1
Cell adhesion ADAM12, AEBP1, CD99, COL18A1, COL5A1, COL5A3, COL6A1, COMP, CXCL12, DPT, EFS, FN1, HSPG2, ISLR, ITGBL1, NRP1, PARVB, PLXNC1, PODXL, SPOCK1, 
SPP1, THBS2, TNC, WISP2
Metal ion binding ADAM12, ADAMTS2, ANPEP, ATP6V0C, C9orf3, CHFR, COL18A1, CRIP1, CYB561, CYBA, CYP1B1, FTH1, GATA2, HEPH, HMOX1, IGFBP3, LOX, LOXL1, MT1M, NQ02, 
PML, RASA4, RNF130, RNF144
Receptor activity ADRA2A, ANPEP, ATP6AP2, BZRP, CCRL1, CMKOR1, EPS8L2, FKBP1A, GABBR2, GHR, GPR30, LRP10, LRP3, MRC2, NOTCH3, NRP1, PGRMC1, PLXNC1, PTGER3, 
SRPRB, UNC5B
Signal transduction ADRA2A, AKAP12, BZRP, CCRL1, CLIC3, CMKOR1, CXCL12, GABBR2, GPR30, GRP, IGFBP6, NET1, NMB, NMU, NRP1, PENK, PTGER3, PYCARD, TNFSF9, UNC5B, 
WISP2
Extracellular matrix (Sensu Metazoa) ADAMTS2, BGN, COMP, DCN, DPT, ELN, FBLN2, FBN1, FN1, GPC4, LOX, LTBP2, LUM, MFAP2, MFAP5, SPOCK1, SPP1, THBS2, TIMP3, TNC
Oxidoreductase activity AKR7A2, ALDH1A3, ALDH3A2, CBR3, CD01, COX7A1, CYB5R3, CYBA, FASN, FN1, FTH1, GPX7, HEPH, HMOX1, HSD17B12, IDH2, LOX, LOXL1, NQ02, VKORC1
Extracellular space CXCL12, FBN1, GRP, HSPG2, HTRA1, IGFBP6, LTBP2, MFAP5, PSG1, PSG4, PSG5, PSG6, PSG7, SLIT3, SPOCK1, SPP1, SULF1, TNFAIP2, TNFSF9
Extracellular matrix structural 
constituent
BGN, COL18A1, COL1A1, COL1A2, COL5A1, COL5A3, COL6A1, COL6A2, COL8A2, COMP, EFEMP2, ELN, FBLN2, FBN1, FN1, LUM, MFAP2, MFAP5, WNT2
Transcription factor activity AEBP1, EMX2, EN1, FOXL2, GAS7, GATA2, HOXA10, HOXA11, HOXA9, HOXC10, HOXC11, HOXC6, IRX5, MSX1, PML, PRRX1, PRRX2, RUNX3, TFAP2C
Regulation of transcription, DNA- 
dependent
CDKN2A, EMX2, EN1, FOXL2, GATA2, HOXA10, HOXA11, HOXA9, HOXC10, HOXC11, HOXC6, IRX5, MAFB, MSX1, NOTCH3, PML, PRRX1, PRRX2, RUNX3
Extracellular region CGB, CLEC11A, CLEC3B, COMP, CTSL, CXCL12, FN1, IGFBP3, INHBB, LOXL1, PSG3, PSG9, SERPINE1, SERPINE2, SERPING1, THBS2, WISP2, WNT2
Development BST1, CREG1, EMX2, FBN1, HOXA10, HOXA9, HOXC11, HOXC6, ID1, ID2, MSX1, NGFB, PLXNC1, PRRX1, PRRX2, SPOCK1, UNC5B, WNT2
Molecular function unknown ARMET, AUTS2, BZRP, C10orf116, C21orf2, C9orf16, COL6A1, FN5, GPM6B, HERPUD1, HOXA9, MN1, PSG3, PSG9, RNF130, THY1, TIMP3
Cellular component unknown ARMET, AUTS2, BZRP, C10orf116, C21orf2, C9orf16, CCND1, CHFR, DSCR1L1, EGFL3, FN5, MN1, NET1, PSG3, RNASE4, THY1
Calcium ion bindinq COMP, EFEMP2, EGFL3, FBLN2, FBN1, FKBP9, LTBP2, NOTCH3, PML, RCN3, S100A4, SLIT3, SPARC, SPOCK1, THBD. THBS2
Zinc ion binding ADAM12, ADAMTS2, ANPEP, C9orf3, CHFR, COL18A1, CRIP1, DKFZP686A01247, GATA2, MT1M, NQ02, PML, RASA4, RNF130, RNF144, SLC39A4
Nucleotide bindinq ACTA2, ASS, CMPK, DMPK, DNM1, DSCR1L1, GUK1, MY01D, NME4, RAB40B, RHOD, RP6-213H19.1, SPHK1, SRP46, SRPRB
Proteolysis and peptidolysis ADAM 12, ADAMTS2, AEBP1, ANPEP, C9orf3, CTSB, CTSF, CTSK, CTSL, DPP4, FAP, HTRA1, LGMN, QPCT, RNF130
Appendix 1. Continued (cluster 1)
Biological process unknown ARMET, AUTS2, BGN, BZRP, C10orf116, C21orf2, C9orf16, CMKOR1, COL1A2, EGFL3, FN5, HOXA9, MN1, PTGER3, THY1
Plasma membrane ADAM12, ADRA2A, ARFIP2, CCRL1, CD99, ENPP2, FTH1, PLXNC1, PPAP2A, PTGER3, SGCD, SGCG, SLC7A5, SLC7A8
Transferase activity ABAT, CMPK, DMPK, FASN, GUK1, MGMT, NME4, PRPS1, QPCT, RP6-213H19.1, SAT, SPHK1
Endoplasmic reticulum ALDH3A2, CYB5R3, CYP1B1, FKBP9, HMOX1, PDIA5, PGRMC1, RCN3, SRPRB, SULF1, TXNDC5, VKORC1
ATP binding ACTA2, ASS, CMPK, DMPK, GUK1, MXRA5, MY01D, NME4, RP6-213H19.1, RUNX3, SPHK1
G-protein coupled receptor protein 
signaling pathway
ADRA2A, AKAP12, APLP2, CCRL1, CMKOR1, CXCL12, ENPP2, GABBR2, GPR30, PTGER3, SPHK1
Protein folding BAG1, CKAP1, FKBP11, FKBP1A, FKBP9, HSPB2, HSPB3, HSPB7, PDIA5, SGNE1
Metabolism ALDH1A3, ALDH3A2, ASNS, CBR3, FN1, HSD17B12, IDH2, LHPP, MTHFS, SULF1
Cell differentiation ANPEP, GAS7, GPM6B, INHBB, NOTCH3, NRP1, SERPINE2, SFRP4, SLIT3, TNFAIP2
Membrane fraction BACE2, HMOX1, KCNJ8, KCNK1, NRP1, PPAP2A, PSG9, SLC1A4, SPHK1, TSPAN13
Hydrolase activity ATP6V0C, BST1, DNM1, ENPP2, FAP, LHPP, PPAP2A, PPP1R3C, RNASE4, SULF1
Skeletal development AEBP1, CLEC3B, COL1A1, COL1A2, COMP, EN1, FBN1, GHR, MSX1
Electron transporter activity AKR7A2, CD01, COX7A1, CYBA, CYP1B1, LOXL1, NQ02, PDIA5, TXNDC5
Cell-cell signaling CXCL12, NGFB, NMB, NRP1, PENK, SPP1, TFAP2C, TNFSF9, WISP2
Ion transport ATP6V0C, CLIC3, GABRE, HEPH, KCNJ8, KCNK1, KCNK2, SLC22A17, SLC39A4
Negative regulation of cell 
proliferation
CDKN2A, COL18A1, FTH1, GPNMB, IGFBP6, LDOC1, PPAP2A, TP53I11
cell proliferation CREG1, CRIP1, ELN, FTH1, GPC4, RUNX3, SPOCK1, TNFSF9
Electron transport COX7A1, CYB561, CYB5R3, CYBA, CYP1B1, NQ02, PDIA5, TXNDC5
Organogenesis COL18A1, COL5A3, COMP, DCN, ELN, EVL, MSX1, NRP1
Phosphate transport COL18A1, COL1A1, COL1A2, COL5A1, COL5A3, COL6A1, COL6A2, COL8A2
Transcription CDKN2A, FOXL2, GATA2, MAFB, NOTCH3, PML, RUNX3, TFAP2C
Apoptosis BAG1, CDKN2A, MAGEH1, PML, RNF130, SULF1, TNFSF9, UNC5B
Structural molecule activity COL18A1, COL5A1, EGFL3, HSPG2, LMNA, SLIT3, THBS2
Mitochondrion ABAT, BZRP, COX7A1, CYBA, IDH2, NME4, SH3BP5
GTP binding ARFIP2, DNM1, ELN, RAB40B, RHOD, SGNE1, SRPRB
Golgi stack AKR7A2, C20orf35, COPZ2, GOLPH2, RP6-213H19.1, SULF1, TMED3
Collagen COL18A1, COL1A1, COL1A2, COL5A1, COL5A3, COL6A1, COL6A2
Neurogenesis AHNAK, EVL, GAS7, GPM6B, NRP1, SERPINE2, SPOCK1
Pregnancy PSG1, PSG3, PSG4, PSG5, PSG6, PSG7, PSG9
Cytoskeleton ACTA2, DSP, PARVB, SGCD, SGCG, TNS1
Regulation of cell growth CREG1, HTRA1, IGFBP3, IGFBP6, NET1, WISP2
Cell cycle CCND1, CDKN2A, CHFR, MN1, NBL1, PYCARD
Iron ion binding CD01, CYB561, CYBA, CYP1B1, HEPH, HMOX1
DNA binding APLP2, CDKN2A, HIST2H2AA, HIST2H2BE, MGMT, SPHK1
Magnesium ion binding DMPK, MTHFS, NME4, PRPS1, RP6-213H19.1, SPHK1
Protein modification BACE2, BAG1, HERPUD1, LOX, LOXL1, QPCT
Growth factor activity CLEC11A, CXCL12, GRP, INHBB, NGFB, SPP1
Soluble fraction ASNS, GRP, NMB, PENK, SPHK1, WISP2
Kinase activity CMPK, GUK1, MRC2, NME4, PRPS1
Lysosome CTSB, CTSF, CTSK, CTSL, LGMN
Transmembrane receptor protein COL1A2, FN1, LOX, SPARC, TIMP3
Appendix 1. Continued (cluster 1)
Tyrosine kinase signaling pathway
Visual perception COL18A1, CYP1B1, FBN1, LUM, TIMP3
Transport C20orf59, SGNE1, SLC1A4, SLC7A5, SLC7A8
Regulation of transcription from 
RNA polymerase II promoter
CREG1, HOXC6, ID1, ID4, TFAP2C
Catalytic activity FASN, KCNK2, LHPP, PML, PODXL
Muscle development AEBP1, COL5A3, LMNA, SGCD, SGCG
Intracellular signaling cascade EFS, RASA4, SH3BP5, SPHK1, TNS1
Defence response INHBB, LY6E, PSG3, PSG4, PSG9
Heparin binding COL5A1, FN1, PCOLCE2, SERPINE2, THBS2
Morphogenesis EN1, GPC4, HOXA11, HOXC10, NOTCH3
Cytosol CBR3, HSPB2, MTHFS, SPHK1, THY1
Copper ion binding HEPH, LOX, LOXL1, MT1M, SPARC
Immune response CCRL1, CXCL12, DPP4, FTH1, TNFSF9
Isomerase activity FKBP11, FKBP1A, FKBP9, PDIA5, TXNDC5
Neuropeptide signaling pathway GRP, NMB, NMU, PENK, SGNE1
Actin binding DKFZP686A01247, MY01D, PARVB, PDE4DIP, TNS1
Nucleic acid binding CLEC11A, ENPP2, PML, RNASE4, SRP46
Rhodopsin-like receptor activity ADRA2A, CCRL1, CMKOR1, GPR30, PTGER3
Serine-type endopeptidase inhibitor 
activity
APLP2, SERPINE1, SERPINE2, SERPING1
Blood coagulation EFEMP2, SERPINE1, SERPING1, THBD
Circulation CXCL12, CYB5R3, ELN, SERPING1
Microsome ALDH3A2, CYP1B1, HMOX1, PGRMC1
Insulin-like growth factor binding HTRA1, IGFBP3, IGFBP6, WISP2
Peptidase activity BACE2, HTRA1, QPCT, RNF130
Negative regulation of progression 
through cell cycle
CDKN2A, MN1, NBL1, PYCARD
Basement membrane COL8A2, EFEMP2, HSPG2, SPARC
Unfolded protein binding BAG1, CKAP1, HSPB7, SGNE1
Cell motility ADRA2A, ARFIP2, ENPP2, SPOCK1
Actin cytoskeleton organization and 
biogenesis
ADRA2A, ARFIP2, ARHGAP8, PDE4DIP
Angiogenesis ANPEP, NRP1, THY1, TNFAIP2
Aminopeptidase activity ANPEP, C9orf3, DPP4, FAP
Ligase activity ASNS, ASS, CHFR, MTHFS
Sugar binding CLEC11A, CLEC3B, MRC2, THBD
Synaptic transmission ABAT, DNM1, GABBR2, QPRT
Potassium ion transport EN1, KCNJ8, KCNK1, KCNK2
Response to unfolded protein HERPUD1, HSPB2, HSPB3, HSPB7
Cytoskeleton organization and 
biogenesis
PDE4DIP, SGCD, SGCG, THY1
Positive regulation of cell 
proliferation
ADRA2A, CLEC11A, HOXC10, NRP1
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Anti-apoptosis BAG1, SPHK1, SPP1, TXNDC5
Epidermis development ALDH3A2, COL1A1, DSP
Intracellular CTSB, PDE4DIP, PML
Regulation of apoptosis CTSB, PYCARD, RP6-213H19.1
Neutral amino acid transporter 
activity
SLC1A4, SLC7A5, SLC7A8
RNA polymerase II transcription 
factor activity
CREG1, HOXC10, HOXC11
Transcription corepressor activity CREG1, HOXC6, ID4
Coated pit DNM1, LRP10, LRP3
Transcription regulator activity ID1.ID2, ID4
Regulation of transcription ID1, ID2, ID4
Collagen binding FN1, LUM, SPARC
Iron ion transport CYB5R3, FTH1, HEPH
Central nervous system 
development
ALDH3A2, DSCR1L1, SLIT3
Cell surface receptor linked signal 
Transduction
BAG1, EVL, LY6E
Nucleoside metabolism NME4, PRPS1, UPP1
Signal transducer activity HMOX1, NGFB, WNT2
Chemotaxis CCRL1, CXCL12, ENPP2
Ubiquitin cycle CHFR, FBXL8, RNF144
Ion channel activity GABRE, KCNK1, KCNK2
Protein transport C20orf35, RAB40B, TMED3
Voltage-gated ion channel activity KCNJ8, KCNK1, KCNK2
Potassium channel activity KCNJ8, KCNK1, KCNK2
Voltage-gated potassium channel 
complex
EN1, KCNJ8, KCNK1
Potassium Ion bindinq KCNJ8, KCNK1, KCNK2
DNA repair ELN, MGMT, PML
Hormone activity CGB, INHBB, NMB
Cell cycle arrest CDKN2A, GAS7, PML
Cell-cell adhesion COL6A2, COL8A2, THY1
Endonuclease activity ELN, ENPP2, RNASE4
Protein amino acid phosphorylation DMPK, MXRA5, RP6-213H19.1
Rho protein signal transduction ADRA2A, ARHGEF3, RHOD
Peptidyl-prolyl cis-trans isomerase 
activity
FKBP11, FKBP1A, FKBP9
GTP biosynthesis GUK1, NME4
Structural constituent of cytoskeleton ACTA2, DSP
Intermediate filament DSP, LMNA
Cell surface PGRMC1, SULF1
Enzyme inhibitor activity SGNE1, TIMP3
Sensory perception CXCL12, TIMP3
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Amino acid metabolism SLC7A5, SLC7A8
Amino acid transport SLC7A5, SLC7A8
Amino acid permease activity SLC7A5, SLC7A8
Endocytosis GHR, LRP10
Microtubule CKAP1, DNM1
Sh3 domain binding EVL, SH3BP5
Guanyl-nucleotide exchange factor 
activity
FLJ10357, NET1
Cytochrome-B5 reductase activity CYB561, CYB5R3
Aldehyde dehydrogenase [Nad(P)+] 
activity
ALDH1A3, ALDH3A2
Aldehyde metabolism AKR7A2, ALDH3A2
Lipid metabolism ALDH1A3, ALDH3A2
Small GTPase mediated signal 
transduction
ARFIP2, RAB40B
Carbohydrate metabolism AKR7A2, IDH2
Collagen type 1 COL1A1, COL1A2
Perception of sound COL1A1, COL1A2
Structural constituent of bone COL1A1, COL1A2
Heme binding CYBA, CYP1B1
Nucleosome HIST2H2AA, HIST2H2BE
Chromosome HIST2H2AA, HIST2H2BE
Nucleosome assembly HIST2H2AA, HIST2H2BE
Chromosome organization and 
biogenesis (Sensu Eukaryota)
HIST2H2AA, HIST2H2BE
Protein complex assembly PML, SLC7A8
Membrane alanyl aminopeptidase 
Activity
ANPEP, C9orf3
ER-golgi intermediate compartment ANPEP, FN1
Metallopeptidase activity ANPEP, C9orf3
Metalloendopeptidase activity ADAM12, FAP
Integrin-mediated sianalinq pathway ADAM12, ITGBL1
Transferase activity, transferring 
glycosyl groups
QPRT, UPP1
Collagen type V COL5A1, COL5A3
Microfibril MFAP2, MFAP5
Response to stress PDIA5, TP53I11
Calcium-mediated signaling DSCR1L1, SPHK1
Protein-lysine 6-oxidase activity LOX, LOXL1
Positive regulation of l-kappa B 
kinase/Nf-Kappa B cascade
FKBP1A, HMOX1
Transmembrane receptor activity EFEMP2, THBD
Intracellular protein transport COPZ2, SGNE1
Enzyme activator activity HSPB2, SGNE1
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Peptide hormone processing BACE2, SGNE1
Transcription from RNA polymerase 
II promoter
GATA2, RUNX3
Receptor mediated endocytosis DNM1, LRP3
Chloride transport CLIC3, GABRE
Postsynaptic membrane GABBR2, GABRE
Regulation of progression through 
cell cycle
CCND1, LTBP2
Protein targeting AKAP12, LTBP2
Protein secretion BACE2, LTBP2
Amino acid biosynthesis ASNS, ASS
Acyltransferase activity QPCT, SAT
Cytokine activity INHBB, SPP1
Growth GHR, INHBB
Protein homodimerization activity FAP, INHBB
Cell-matrix adhesion ITGBL1, SPP1
Transcription coactivator activity PML, PRRX1
Receptor binding NMU, PLXNC1
Neuropeptide hormone activity GRP, PENK
Sarcoglycan complex SGCD, SGCG
Binding APLP2, FTH1
GTPase activator activity ARHGAP8, RASA4
G1/S transition of mitotic cell cycle CCND1, PML
Cell division CCND1, CHFR
Protein kinase C activation PPAP2A, SPHK1
Extracellular matrix organization and 
biogenesis
COL6A2, COL8A2
Protein binding, bridging COL6A2, COL8A2
Lipid raft MALL, THY1
Nucleotide metabolism ENPP2, NME4
Vascular endothelial growth factor 
receptor activity
MXRA5, NRP1
Negative regulation of adenylate 
cyclase activity
ADRA2A, GABBR2
Ossification SPARC, SPP1
Integrin bindinq SPP1, THY1
Gtpase activity DNM1, RHOD
Dipeptidyl-peptidase IV activity DPP4, FAP
Prolyl oligopeptidase activity DPP4, FAP
Lamellipodium EVL, FAP
Induction of apoptosis PML, PYCARD
Axon guidance EVL, NRP1
Motor activity DNM1, MY01D
Calmodulin bindinq MY01D, SPHK1
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Protein serine/threonine kinase 
activity
DMPK, RP6-213H19.1
Protein self binding DMPK, RP6-213H19.1
Transporter activity C20orf59, SLC22A17
Regulation of heart contraction rate DMPK, HSPB7
Positive regulation of cell migration ARHGAP8, SPHK1
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Membrane ABCB1, AMFR, ATP9A, CDH13, ChGn, CLGN, CSF1, GPR56, GPRC5B, IL13RA2, ITGB5, LGALS3BP, NT5E, OSTM1, PDGFRL, PTGS1, SLC1A1, SLC6A15, SRPX, 
STOM, TRPV2, TSPAN12
Protein binding AMFR, CDH13, ChGn, COL15A1, GPR56, ICAM2, INHBA, ITGB5, LGALS3BP, SNCA, SPON2, SRPX
Integral to membrane ABCB1, AMFR, ATP9A, ChGn, CLGN, CSF1, GPRC5B, IL13RA2, ITGB5, OSTM1, TSPAN12
Integral to plasma membrane EDNRB, GPR56, ICAM2, MME, SEMA4F, SLC1A1, SLC6A15, STOM, TRPV2
Metal ion binding AMFR, ChGn, LPXN, ME1, MME, NT5E, PIR, PTGS1, SOD2
Cell adhesion CDH13, COL15A1, GPR56, ITGB5, LGALS3BP, LPXN, SPON2, SRPX
Receptor activity AMFR, EDNRB, GPR56, GPRC5B, IL13RA2, ITGB5, PDGFRL, SEMA4F
Nucleus HOXB5, HOXB6, HOXB7, PHLDA1, PIR, PTGS1, SVIL, TCF21
Extracellular space AKR1B1, BMP2, CSF1, IL13RA2, LGALS3BP, SPON2
Nucleotide binding ABCB1, ATP9A, CUGBP2, MY06, NT5E, TUBA3
Cell-cell signaling BMP2, GPR56, INHBA, MME, SEMA4F, STC1
Signal transduction AMFR, GPR56, GPRC5B, LGALS3BP, LPXN
Cytoplasm COL15A1, LPXN, PTGS1, SNCA, SVIL
Plasma membrane EDNRB, ICAM2, MME, SEMA4F, SVIL
Membrane fraction ABCB1, NT5E, SEMA4F, SLC1A1, TSPAN12
Development HOXB6, HOXB7, ITGB5, SPON2
Oxidoreductase activity AKR1B1, ME1, PTGS1, SOD2
Zinc ion binding AMFR, LPXN, MME, NT5E
Calcium ion binding CDH13, CLGN, SVIL, TRPV2
Cell differentiation COL15A1, CSF1, INHBA, SEMA4F
Neurogenesis ChGn, EDNRB, INHBA, SEMA4F
Regulation of transcription, DNA-Dependent HOXB5, HOXB6, HOXB7, TCF21
Extracellular matrix (Sensu Metazoa) COL15A1, LGALS3BP, SPON2
Carbohydrate metabolism AKR1B1, GLB1, ME1
Hydrolase activity ATP9A, BCHE, DUSP3
Perception of sound COCH, EDNRB, MY06
Extracellular region BCHE, INHBA, STC1
Transcription factor activity HOXB5, HOXB6, HOXB7
ATP binding ABCB1, ATP9A, MY06
Electron transporter activity AKR1B1, ME1
Lysosome CTSC, GLB1
Proteolysis and peptidolysis CTSC, MME
Immune response CTSC, SPON2
Endoplasmic reticulum AMFR, CLGN
Structural molecule activity COL15A1, TUBA3
Hormone activity INHBA, STC1
Cell surface receptor Linked signal 
Transduction
INHBA, STC1
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Mesoderm development INHBA, TCF21
Cell surface ABCB1, SRPX
Iron ion binding PIR, PTGS1
Cytokine activity BMP2, INHBA
Growth factor activity BMP2, INHBA
Growth BMP2, INHBA
Morphogenesis ChGn, HOXB5
Soluble fraction ChGn, IL13RA2
Symporter activity SLC1A1, SLC6A15
Biological process unknown MY06, SLC35F2
Molecular function unknown MY06, SLC35F2
Cell proliferation ChGn, CSF1
Transport ABCB1, SLC1A1
Atpase activity ABCB1, ATP9A
Axon guidance SEMA4F, SPON2
Cation transport ATP9A, TRPV2
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Nucleus ABL1, ARID5B, BACH1, CREBBP, CUGBP1, DUSP10, HMGA2, HSA9761, IRS1, MEIS2, MSX2, NCOR1, NUP153, RBPSUH, SMURF2, SYNCRIP, 
TEAD4, TFAP2A, ZFHX1B
Protein binding ABL1, CREBBP, CSNK2A1, IRS1, MARCH7, MSX2, NCOR1, NUP153, PPP2R2A, PSEN1, RBPSUH, SMURF2, TFAP2A
Regulation of transcription, DNA-dependent ABL1, BACH1, CREBBP, HMGA2, MEIS2, MSX2, NCOR1, TEAD4, TFAP2A, ZFHX1B
Signal transduction ARHGEF7, CREBBP, IRS1, PPP2R2A, PPP4R1, PRKAR2A, STAM, STK24, TFAP2A
Nucleotide binding ABL1, CSNK2A1, CUGBP1, MAP4K3, PRKAR2A, STK24, SYNCRIP, TRIB2
Transcription factor activity BACH1, CREBBP, MEIS2, MSX2, RBPSUH, TEAD4, TFAP2A, ZFHX1B
Protein amino acid phosphorylation ABL1, CSNK2A1, MAP4K3, PRKAR2A, STK24, TRIB2
Transferase activity ABL1, CREBBP, CSNK2A1, HSA9761, MAP4K3, STK24
Transcription ARID5B, BACH1, HMGA2, RBPSUH, TEAD4, TFAP2A
DNA binding ABL1, ARID5B, HMGA2, NCOR1, NUP153
Zinc ion binding CREBBP, MARCH7, NUP153, USP3, ZFHX1B
Metal ion binding CREBBP, MARCH7, NUP153, USP3, ZFHX1B
ATP binding ABL1, CSNK2A1, MAP4K3, STK24, TRIB2
Cytoplasm CREBBP, DUSP10, IRS1, PRKAR2A, TRIB2
Membrane ITGB1BP1, NET02, PSEN1, SPTAN1
Integral to membrane NET02, NUP153, PSEN1
Intracellular signaling cascade ABL1, PRKAR2A, PSEN1
Membrane fraction PRKAR2A, PSEN1, SPTAN1
Ubiguitin-dependent protein catabolism SMURF2, USP3, USP47
Ubiguitin cycle SMURF2, USP3, USP47
Protein serine/threonine kinase activity CSNK2A1, MAP4K3, STK24
Transcription coreoressor activity MEIS2, NCOR1
Transcription from RNA polymerase II promoter NCOR1, RBPSUH
RNA binding PUM2, SYNCRIP
Binding PPP4R1, PUM2
Structural constituent of cytoskeleton KRT18, SPTAN1
Regulation of progression through cell cycle ABL1, G0S2
Protein-tyrosine kinase activity ABL1, STK24
Molecular function unknown ABL1, G0S2
Cellular component unknown ABL1, G0S2
Transcription coactivator activity CREBBP, TFAP2A
Signal transducer activity CREBBP, IRS1
Protein amino acid dephosphorylation DUSP10, PPP2R2A
Plasma membrane PRKAR2A, SSFA2
Protein kinase cascade ITGB1BP1, MAP4K3
Endoplasmic reticulum PSEN1, SYNCRIP
Chromosome organization and biogenesis (Sensu 
Eukaryota)
HMGA2, PSEN1
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Negative regulation of transcription SMURF2, ZFHX1B
Transcriptional repressor activity ARID5B, ZFHX1B
Regulation of transcription from RNA polymerase II 
promoter
TEAD4, TFAP2A
Skeletal development MSX2, TEAD4
Development HMGA2, MSX2
Kinase activity PRKAR2A, STK24
Rna polymerase II transcription factor activity RBPSUH, TEAD4
Negative regulation of transcription, DNA-dependent ARID5B, RBPSUH
Ribonucleoprotein complex CUGBP1, SYNCRIP
Response to stress DUSP10, MAP4K3
JNK Cascade DUSP10, MAP4K3
Cysteine-type endopeptidase activity USP3, USP47
Ubiquitin thiolesterase activity USP3, USP47
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Membrane ABCB1, ABCG2, ADFP, ADORA2B, C9orf125, EDG2, EGFL5, EREG, F3, FZD6, GBP1, GPR37, GPRC5A, HRASLS3, HRH1, HSD17B2, LAMA5, MAN1C1, NID2, OGFRL1, 
OPN3, PPP2R1B, PTGER2, PTGER4, PTPRK, RAPGEF2, RTN1, SCN9A, SLC16A6, SLC7A11, SLITRK5, STAMBP, STOM, SV2A, SYNGR3, SYT11, TBC1D8, TEK,
TJP2, TM4SF1, TRHDE, TRPA1, UCP2
Protein binding ACTG2, ADRB2, APBA2, ARTS-1, BID, CASP1, CASP4, COL4A6, DMN, EREG, FOXF1, FST, GNAI1, IKBKAP, LAMA5, MCAM, NE01, PDLIM1, PPARG, PPP2R1B, 
RAPGEF2, RBMX, RBPMS, RELN, RHOBTB3, RPP30, SAV1, STAMBP, TACC1, TJP2
Nucleus AFF1, CDC14B, CREB1, ETS2, FOXF1, FOXF2, GATA3, HHEX, HNRPL, HOXA2, HOXA5, MEIS1, NR2F1, NR2F2, PARP4, PITX1, PLAGL2, POLB, PPARG, PPP2R1B, 
RPP30, STAMBP, TACC1, TBX2, TJP2
Integral to plasma membrane ADORA2B, ADRB2, BDKRB1, BDKRB2, EDG2, EREG, F2R, FZD6, GPR37, GPRC5A, HRH1, MCAM, NE01, OPN3, PTGER2, PTPRK, RAPGEF2, SLC16A6, STOM, 
SYNGR3, TEK, TJP2, TM4SF1, TRHDE, TRPA1
Integral to membrane ABCB1, ABCC4, ABCG2, ARTS-1, C9orf125, EDG2, EGFL5, F3, HRASLS3, HSD17B2, LAMA5, MAN1C1, MCTP2, NE01, OPN3, PTGER4, RTN1, SLC16A6, SLC7A11, 
SLITRK5, SV2A, SYT11, TMEM35, UCP2
Signal transduction ADORA2B, BDKRB1, CASP1, CREB1, EDG2, F2R, GNAI1, GPR37, GPRC5A, HRH1, IGFBP5, NR2F1, NR2F2, NRGN, OPN3, PLAU, PPARG, PTGER2, PTGER4, RTN1, 
SAV1, TEK, TRHDE
Transcription factor activity AFF1, CREB1, ETS2, FOXF1, FOXF2, GATA3, HHEX, HOXA2, HOXA5, MEIS1, NR2F1, NR2F2, PITX1, PLAGL2, PPARG, TBX2
Receptor activity ADORA2B, ADRB2, BDKRB1, BDKRB2, EDG2, F2R, FZD6, GPR37, GPRC5A, HRH1, OGFRL1, OPN3, PTGER2, PTGER4, PTPRK, TEK
Nucleotide binding ABCB1, ABCC4, ABCG2, ACTG2, GBP1, GNAI1, HNRPL, IGF2BP3, MAP3K5, MYLK, RBMX, RBPMS, TEK
G-protein coupled receptor protein 
signaling pathway
ADORA2B, ADRB2, BDKRB1, BDKRB2, EDG2, F2R, FZD6, GNAI1, GPR37, GPRC5A, OPN3, PTGER2, PTGER4
Cytoplasm BID, CASP4, COL4A1, COL4A2, COL4A5, COL4A6, DUSP6, IGF2BP3, JUP, KYNU, POLB, TPP2
Regulation of transcription, DNA- 
dependent
CREB1, ETS2, FOXF2, GATA3, HHEX, HOXA2, HOXA5, MEIS1, NR2F1, PITX1, PLAGL2, TBX2
Calcium ion binding EGFL5, HGF, LTBP1, MAN1C1, MCTP2, MYLK, NID2, NPTX1, RAPGEF2, SCN9A, SYT11
ATP binding ABCB1, ABCC4, ABCG2, ACTG2, FRY, MAP3K5, MYLK, NE01, PALLD, TEK
Extracellular region ADFP, ARTS-1, FST, IGFBP5, IGFBP7, NOV, PLAT, SEMA3A, STC1, TFPI
Zinc ion binding ARTS-1, C14orf130, GATA3, NR2F1, NR2F2, PDLIM1, PLAGL2, PPARG, STAMBP, TRHDE
Metal ion binding ARTS-1, C14orf130, GATA3, NR2F1, NR2F2, PDLIM1, PLAGL2, PPARG, STAMBP, TRHDE
Development FST, FZD6, HHEX, HOXA2, HOXA5, MEIS1, NE01, RELN, SEMA3F, TBX2
Rhodopsin-like receptor activity ADORA2B, ADRB2, BDKRB1, BDKRB2, F2R, GPR37, HRH1, OPN3, PTGER2, PTGER4
Membrane fraction ABCB1, ABCC4, BID, JUP, MCTP2, SCN9A, SLC16A6, TRPA1, UCP2
Transport ABCB1, ABCG2, NPTX1, PARP4, SLC16A6, SLC7A11, SV2A, SYT11, UCP2
Plasma membrane ABCC4, ADRB2, BDKRB1, BDKRB2, EDG2, F2R, F3, MCAM, NE01
Cell adhesion COL4A6, JUP, LAMA5, MCAM, NE01, NID2, RELN, VCL
Hydrolase activity CDC14B, DUSP6, KYNU, MTMR1, NT5C2, PPT1, PTPRK, RPP30
Proteolysis and oeptidolysis CASP1, CASP4, HGF, PGA5, PLAT, PLAU, TPP2, TRHDE
Biological process unknown ABCC4, DOC1, EGFL5, HRASLS3, LTBP1, RBMX, RHOBTB3, TM4SF1
Transcription FOXF1, FOXF2, GATA3, NR2F1, NR2F2, PLAGL2, PPARG, TBX2
Protein amino acid phosphorylation IKBKAP, MAP3K5, MYLK, NE01, PALLD, TEK
Blood coagulation F2R, F3, HGF, PLAT, PLAU, TFPI
Transferase activity GYG2, MAP3K5, MYLK. POLB, SMS, TEK
Signal transducer activity CASP1, GNAI1, IKBKAP, MYLK, RAPGEF2, RTN1
Appendix 1. Continued (cluster 4)
Protein amino acid dephosphorylation CDC14B, DUSP6, MTMR1, PPP2R1B, PTPRK, TNS3
Transporter activity ABCB1, ABCG2, SLC16A6, SV2A, SYT11, UCP2
Extracellular space EREG, PLAU, PTN, RELN, SEMA3F, WFDC1
Neurogenesis APBA2, NRGN, PPT1, PTN, SEMA3A
Cytoskeleton ACTG2, JUP, PDLIM1, STOM, TMOD1
Peptidase activity KYNU, PLAT, PLAU, RELN, TPP2
Regulation of progression through cell 
cycle
DUSP6, EREG, F2R, PPP2R1B, PTN
Cytosol ALDH1A1, ARTS-1, BID, NT5C2, PPP2R1B
Cellular component unknown ABCC4, EGFL5, HGF, HRASLS3, MTMR1
Molecular function unknown DOC1, HRASLS3, RTN1, TM4SF1, WFDC1
Morphogenesis F2R, GATA3, IGF2BP3, MCAM, PITX1
Cell-cell signaling EREG, NE01, STC1, TEK, TRHDE
Structural molecule activity EGFL5, JUP, LAMA5, VCL
Oxidoreductase activity ALDH1A1, ALDH2, HSD17B2, VCL
Sensory perception BDKRB2, OPN3, PPT1, TRPA1
Soluble fraction DUSP6, GYG2, JUP, PPP2R1B
Mitochondrion ALDH2, BID, PPP2R1B, UCP2
Metabolism ALDH1A1, ALDH2, HSD17B2, ISOC1
Inflammatory response BDKRB1, BDKRB2, HRH1, PARP4
Immune response F3, GBP1, IKBKAP, PTGER4
Kinase activity IKBKAP, MYLK, PLAU, TEK
Ubiguitin cycle C14orf130, NEDD4, STAMBP, USP46
Protein tyrosine phosphatase activity CDC14B, DUSP6, MTMR1, PTPRK
RNA binding HNRPL, IGF2BP3, RBMX, RBPMS
Growth factor activity EREG, HGF, NOV, PTN
Extracellular matrix structural constituent COL4A1, COL4A2, COL4A5, COL4A6
Collagen COL4A1, COL4A2, COL4A5, COL4A6
Collagen type IV COL4A1, COL4A2, COL4A5, COL4A6
Phosphate transport COL4A1, COL4A2, COL4A5, COL4A6
Cell cycle HRASLS3, LOH11CR2A, TACC1
Cell motility F2R, NE01, VCL
Regulation of cell growth IGFBP5, IGFBP7, NOV
Insulin-like growth factor binding IGFBP5, IGFBP7, NOV
Catalytic activity DOC1, ISOC1, MEST
Response to druq ABCB1, ABCG2, PARP4
Protein complex assembly IKBKAP, PPP2R1B, SLC7A11
Magnesium ion binding MAP3K5, MYLK, POLB
Extracellular matrix (Sensu Metazoa) LAMA5, LTBP1, RELN
Positive regulation of cell proliferation PTN, STAMBP, TBC1D8
ATPase activity ABCB1, ABCC4, ABCG2
Endoplasmic reticulum ADFP, BDKRB1, RTN1
Positive Regulation Of 1-Kappa B CASP1, EDG2, F2R
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Elevation of cytoplasmic calcium ion 
concentration
BDKRB1, BDKRB2, EDG2
Serine-type endopeptidase activity HGF, PLAU, RELN
Transcription coactivator activity FOXF1, FOXF2, NR2F1
Regulation of transcription from RNA 
polymerase II promoter
FOXF1, NR2F2, PPARG
Steroid hormone receptor activity NR2F1, NR2F2, PPARG
Protein serine/threonine phosphatase 
activity
CDC14B, DUSP6, MTMR1
Intracellular CASP1, CASP4, NEDD4
Vascular endothelial growth factor 
receptor activity
NE01, PALLD
Actin binding TMOD1, VCL
Lysosome ADRB2, PPT1
Protein modification PLAT, PPT1
Visual perception OPN3, PPT1
Negative regulation of cell proliferation EREG, IGFBP7
Skeletal development ETS2, PITX1
Aldehyde dehydrogenase (NAD) activity ALDH1A1, ALDH2
Electron transporter activity ALDH1A1, ALDH2
Carbohydrate metabolism ALDH2, MAN1C1
Plasminogen activator activity PLAT, PLAU
Cell differentiation SEMA3A, SFRP1
DNA repair PARP4, POLB
GTPase activity GBP1, RHOBTB3
GTP binding GBP1, GNAI1
Protein serine/threonine kinase activity MAP3K5, MYLK
Calmodulin binding MYLK, NRGN
Ubiquitin thiolesterase activity STAMBP, USP46
Metallopeptidase activity ARTS-1, STAMBP
Inactivation of MAPK activity DUSP6, PPP2R1B
Binding PPP2R1B, UCP2
Induction of apoptosis CASP4, PPP2R1B
Regulation of cell adhesion LAMA5, PPP2R1B
Negative regulation of cell qrowth PPP2R1B, WFDC1
Protein heterodimerization activity EREG, PPP2R1B
MAPKKK cascade MAP3K5, RAPGEF2
ATPase activity, coupled to 
transmembrane movement of 
substances
ABCB1, ABCC4
Aminopeptidase activity TPP2, TRHDE
Golgi stack AP3M2, MAN1C1
Sodium ion bindinq POLB, SCN9A
RNA processinq IGF2BP3, RBPMS I
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Apoptosis F2R, MAP3K5
Caspase activator activity CASP1, MAP3K5
Receptor binding F2R, LAMA5
RNA polymerase II transcription factor 
activity
FOXF2, MEIS1
Circulation BDKRB2, TBC1D8
Response to nutrients PPARG, STC1
Prostaglandin E receptor activity PTGER2, PTGER4
G-protein signaling, coupled to camp 
nucleotide second messenger
ADRB2, PTGER4
Negative regulation of progression 
through cell cycle
HRASLS3, LOH11CR2A
Angiogenesis ARTS-1, EREG
Cell proliferation EREG, PTN
Bradykinin receptor activity BDKRB1, BDKRB2
Transmembrane receptor protein 
tyrosine kinase signaling pathway
BDKRB2, TEK
Activation of MAPK activity ADORA2B, ADRB2
Adenylate cyclase activation ADORA2B, ADRB2
Transcription factor complex FOXF1, FOXF2
Transcription from RNA polymerase II 
promoter
FOXF2, GATA3
Cation channel activity SCN9A, TRPA1
Cation transport SCN9A, TRPA1
Lipid metabolism NR2F2, PPARG
Ligand-regulated transcription factor 
activity
NR2F1, NR2F2
Cysteine-type peptidase activity CASP1, CASP4
Caspase activity CASP1, CASP4
Regulation of apoptosis CASP1, CASP4
Serine-type endopeptidase inhibitor 
activity
TFPI, WFDC1
Extracellular matrix organisation and 
biogenesis
COL4A2, COL4A6
Ubiquitin-protein liqase activity C14orf130, NEDD4
Heterogeneous nuclear 
ribonucleoprotein complex
HNRPL, RBMX
Membrane alanyl aminopeptidase 
activity
ARTS-1, TRHDE
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Nucleus DIP13B, DUSP2, EHD3, LHX2, NAP1L3, SHOX, TFAP2A, ZIC1
Protein binding ANK1, BAIAP2, COL8A1, DIP13B, DSG2, POSTN, TFAP2A
Membrane DIP13B, DSG2, GALNT14, PEX6, PRSS12, PTGIS
Signal transduction ANK1, CRABP2, DIP13B, IRS2, TFAP2A
Regulation of transcription, DNA-dependent CRABP2, LHX2, SHOX, TFAP2A
Transcription factor activity LHX2, SHOX, TFAP2A, ZIC1
Cell adhesion COL8A1, DSG2, HAPLN1, POSTN
Integral to membrane DSG2, GALNT14, PTGIS, SEZ6L2
Structural molecule activity ANK1, COL8A1, KRT19
Cytoplasm COL8A1, DIP13B, PEX6
Cytoskeleton ANK1, DSG2, GAS2L1
Extracellular matrix (Sensu Metazoa) COL8A1, HAPLN1, POSTN
Metal ion binding LHX2, PTGIS, ZIC1
Calcium ion binding DSG2, EHD3, GALNT14
Structural constituent of cytoskeleton ANK1, KRT19
Nucleotide binding EHD3, PEX6
ATP binding EHD3, PEX6
Cell proliferation DIP13B, PSPHL
Plasma membrane ANK1, OXTR
Zinc ion binding LHX2, ZIC1
Receptor activity OXTR, SEZ6L2
Skeletal development POSTN, SHOX
Appendix 2. Gene Ontology Classification Time-dependent differentially regulated genes (Cluster 1).
Nucleus ABI1, AFF1, AHR, APPBP2, ATF2, C14orf11, CAPN7, CDC73, CDK7, CDYL, CHD1, CITED2, CNOT2, CNOT4, CREBBP, CTBP2, CTCF, 
CTDSP2, CUGBP1, DID01, DUSP10, DYRK1A, EDD1, EIF4ENIF1, ELF4, EP300, EVI1, FOXJ3, FOXK2, GTF2E1, GTF2IRD1, HIVEP2, HMGA2, 
HRB, HSF2, HSPA4L, IFI16, IRF2, LDB1, LPIN2, MAPK14, MAX, MEIS1, MEIS2, MGA, MKL1, MKL2, MYST3, MYST4, N4BP1, NCOA2, NCOA3, 
NCOA6, NCOR1, NFATC3, NIPBL, NPAT, NR2C1, NRIP1, NUP153, OGT, ORC5L, PARP2, PHF20, PHTF1, PML, POLB, POLR3E, PPP2R1B, 
PPP2R5C, PRDM10, RAD17, RAI17, RBMS1, RBPSUH, REV3L, RNPC2, RNUT1, RPP30, RREB1, SAP30, SATB2, SFRS4, SFRS8, SH3BP4, 
SKIV2L2, SLC4A1AP, SMURF2, STAMBP, SYNCRIP, TACC2, TAF4, TCF4, TCF7L2, TEAD4, THRAP2, TLE1, TLE4, TLK1, TOB2, TRIM24, 
TRIM33, TRIP4, TULP3, UPF3A, UTX, WDR50, WHSC2, ZBTB20, ZFPM2, ZFYVE26, ZHX2, ZNF143, ZNF161, ZRANB1, ZZZ3
Protein binding AHR, APAF1, BTBD3, CAB39, CASP7, CDC5L, CITED2, CKAP5, CNOT4, CREBBP, CSNK2A1, CUL1, DID01, DYRK1A, EDD1, EIF4ENIF1, 
ELF4, EPS15, GGA2, GNAI1, GTF2IRD1, HRB, IFI16, ITSN2, JMJD2B, KIAA0182, KLHL22, LRRC8D, MAP2K4, MAPK14, MARCH7, MARK3, 
MAST4, MIDI, MKL1, MPP5, MYST3, MYST4, NCOA3, NCOA6, NCOR1, NMI, NRIP1, NUP153, OGT, PDHX, PEX14, PHF15, PHF20, PHF21A, 
PHF3, PHIP, PIK3R3, PKP4, PML, PPFIA1, PPP2R1B, PPP2R2A, PRKCBP1, PTEN, RAB11FIP5, RAPGEF2, RBPSUH, RGL1, RNF38, RPP30, 
SAP30, SAV1, SEC24B, SKIV2L2, SMURF2, SNX2, SNX4, SOCS5, SOS1, SOS2, SPRED2, STAM2, STAMBP, STARD13, TACC2, TAF4, TCF4, 
TNC, TP53BP2, TRIM33, VPS54, ZBTB20, ZHX2, ZRANB1
Regulation of transcription, DNA-dependent AHR, ATF2, CDC5L, CDK8, CNOT2, CNOT4, CREBBP, DID01, ELF4, EP300, FOXJ3, FOXK2, GTF2E1, GTF2IRD1, HIVEP2, HMGA2, HSF2, 
IFI16, IRF2, JMJD2B, JUN, MAX, MEIS1, MEIS2, MGA, MKL1, MKL2, MYST3, MYST4, NCOA2, NCOA6, NCOR1, NFATC3, NR2C1, PHF15, 
PHF20, PHF21A, PHF3, PHTF1, PML, PRDM10, PRKCBP1, RAI17, RNPC2, RREB1, SAP30, SATB2, SFRS8, TAF4, TCF7L2, TEAD4, THRAP2, 
TLE1, TLE4, TRIM24, TRIM33, TRIP4, TULP3, WHSC2, ZBTB20
Transcription ATF2, CDC73, CDK7, CDK8, CNOT4, CTCF, DID01, ELF4, FOXJ3, FOXK2, GTF2E1, GTF2IRD1, HIVEP2, HMGA2, HSF2, IFI16, IRF2, JUN, 
MKL1, MKL2, MYST3, MYST4, NCOA6, NR2C1, NRIP1, PCM1, PHF20, PHF3, PHTF1, PML, POLR3E, PRDM10, RAI17, RBPSUH, RNPC2, 
RREB1, SAP30, SFRS8, TAF4, TCF7L2, TEAD4, THRAP2, TRIM24, TRIM33, TRIP4, WHSC2, ZBTB20, ZFPM2, ZNF143, ZNF161
Zinc ion binding ATF2, CNOT4, CREBBP, CTCF, DDEF2, DID01, EDD1, EP300, EVI1, FBX011, GTF2E1, HIVEP2, HRB, IBRDC3, JMJD2B, KIAA0182, KIAA0853, 
MARCH7, MIDI, MTMR3, MYST3, MYST4, NR2C1, NUP153, PHF15, PHF20, PHF21A, PHF3, PML, PRDM10, PRKCBP1, PRKD2, RAI17, REV3L, 
RNF38, RREB1, STAMBP, TRIM24, TRIM33, TRIP4, USP3, ZBTB20, ZFPM2, ZFYVE26, ZHX2, ZNF143, ZNF161, ZRANB1, ZZZ3
Nucleotide binding ACVR1B, APAF1, BMPR1A, CDC2L5, CDK7, CDK8, CHD1, CNOT4, CSNK1D, CSNK2A1, CUGBP1, DDX10, DYRK1A, EIF2AK3, EPHB4, GNAI1, 
GRK5, HSPA4L, KIF2, LARP5, MAP2K4, MAP4K3, MAPK14, MARK3, MAST4, MKNK2, ORC5L, PIK3R4, PRKD2, PRKX, RAD 17, RBMS1,
REV3L, RNPC2, RPS6KC1, SART3, SFRS4, SKIV2L2, SLC22A5, STK24, SYNCRIP, TAOK3, TAP1, TBK1, TIAL1, TLK1, TRIO, UPF3A
Metal ion binding ATF2, ATP6V1B2, B4GALT5, CNOT4, CREBBP, CTCF, DDEF2, DID01, EDD1, EP300, EVI1, FBX011, GTF2E1, HIVEP2, HRB, IBRDC3, 
JMJD2B, KIAA0182, KIAA0853, MARCH7, MIDI, MTMR3, MYST3, MYST4, NR2C1, NUP153, PHF15, PHF20, PHF3, PML, PRDM10, PRKCBP1, 
PRKD2, RAI17, REV3L, RNF38, RREB1, STAMBP, TRIM24, TRIM33, TRIP4, USP3, ZBTB20, ZFPM2, ZHX2, ZNF143, ZNF161, ZRANB1
ATP binding ACVR1B, APAF1, ATP6V1B2, BMPR1A, CDC2L5, CDK7, CDK8, CHD1, CSNK1D, CSNK2A1, DDX10, DHX32, DYRK1A, EIF2AK3, EPHB4, 
GRK5, HSPA4L, KIF2, MAP2K4, MAP4K3, MAPK14, MARK3, MAST4, MKNK2, ORC5L, PIK3R4, PRKD2, PRKX, RAD 17, RPS6KC1, SKIV2L2, 
SLC22A5, STK24, TAOK3, TAP1, TBK1, TLK1, TRIO
DNA binding CDC5L, CHD1, EVI1, HIVEP2, HMGA2, HRB, IFI16, MAX, MKL1, MKL2, MYST3, MYST4, NCOR1, NUP153, PARP2, PCM1, PHF20, PRDM10, 
RAD17, RBMS1, REV3L, RREB1, SATB2, SOS1, SOS2, TCF4, TCF7L2, TIAL1, TRIM24, TRIM33, ZBTB20, ZFPM2, ZNF143, ZNF161, ZZZ3
Transferase activity ACVR1B, BMPR1A, CDC2L5, CDK7, CDK8, CREBBP, CSNK1D, CSNK2A1, DYRK1A, EIF2AK3, EP300, EPHB4, GRK5, MAP2K4, MAP4K3, 
MAPK14, MARK3, MAST4, MKNK2, MYST3, MYST4, NCOA3, PIK3R4, POLB, POLR3E, PRKD2, PRKX, REV3L, RPS6KC1, STK24, TAOK3, 
TBK1, TLK1, TMEM23, TRIO
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Membrane ACVR1B, AP1GBP1, APPBP2, B4GALT5, BMPR1A, BTN2A2, CHD9, EGFL5, EIF2AK3, EPHB4, GGA2, GPRC5A, IBRDC3, KIAA0247, LRRC8D, 
MPP5, NUMB, OGFRL1, PAQR3, PEX14, PPP2R1B, RAPGEF2, SEC24B, SLC31A2, SPRED2, STAM2, STAMBP, STOM, STX3A, STX7, TAP1, 
TMEM23
Signal transduction AHR, ARHGEF7, CREBBP, CSNK1D, EP300, GNAI1, GPRC5A, GRK5, IL15, INPP1, MAP2K4, NCOA2, NCOA3, OGT, PAFAH1B1, PBEF1, 
PPFIA1, PPP2R2A, PPP2R5C, PPP2R5E, PPP4R1, RPS6KC1, SAV1, STAM, STK24, TCF7L2, TLE1, TP53BP2
Transcription factor activity AFF1, AHR, CITED2, CREBBP, CTCF, ELF4, EP300, FOXJ3, FOXK2, HSF2, IRF2, JUN, MAX, MEIS1, MEIS2, MGA, NFATC3, NR2C1, PHTF1, 
PML, RBPSUH, SATB2, TAF4, TCF7L2, TEAD4, ZHX2
Cytoplasm APPBP2, ATG5, ATP6V1B2, CASP7, CREBBP, DUSP10, EIF4ENIF1, GRK5, HSPA4L, MAPK14, MTMR3, NCK1, NMI, PCM1, POLB, PPFIA1, 
PPP2R5E, PTEN, RREB1, SCHIP1, SOCS5, TP53BP2, TRIP4, UPF3A, ZRANB1
Protein amino acid phosphorylation ACVR1B, BMPR1A, CDC2L5, CDK7, CDK8, CSNK1D, CSNK2A1, EIF2AK3, EPHB4, GRK5, MAP2K4, MAP4K3, MAPK14, MARK3, MAST4, 
MKNK2, PIK3R4, PRKD2, PRKX, RPS6KC1, STK24, TBK1, TLK1, TRIO
Protein serine/threonine kinase activity ACVR1B, CDC2L5, CDK8, CSNK1D, CSNK2A1, DYRK1A, EIF2AK3, MAP2K4, MAP4K3, MAPK14, MARK3, MAST4, MKNK2, PIK3R4, PRKD2, 
PRKX, RPS6KC1, STK24, TAOK3, TBK1, TLK1, TRIO
Cellular component unknown AMMECR1, CKAP5, CTDSP2, EGFL5, HDHD1A, HECA, KIAA0247, KIAA0553, PHF3, PHIP, PIK3R4, PLEKHA5, RALGDS, RBMS1, RGL1, 
SCHIP1, SLC35D2, SOS2, STXBP3, TIAL1, TLK1
Nucleic acid binding ANKHD1, C10orf56, CTCF, EVI1, GCLC, GPATC2, IFI16, JMJD2B, KIAA0853, OBFC2A, PHF20, PML, PRDM10, RNPC2, RREB1, SART3, 
SKIV2L2, USP6, ZFYVE26
Integral to membrane AKAP1, B4GALT5, BMPR1A, BTN2A2, CHD9, EGFL5, EIF2AK3, EPHB4, IBRDC3, KIAA0247, LRRC8D, NUP153, PAQR3, PPP2R5C, SLC22A5, 
SLC31A2, STX3A, TAP1, TMEM23
Cell cycle AHR, CDC5L, CDC73, CDK7, CDK8, CLASP1, CTCF, CUL1, EP300, NIPBL, PAFAH1B1, PTEN, RAD17, SASH1, SH3BP4, TLK1, TP53BP2
Molecular function unknown AMMECR1, CHMP7, CKAP5, CTDSP2, EVI1, FBX034, HDHD1A, HECA, KIAA0174, KIAA0247, KIAA0553, MRPL39, ORC5L, PHF3, SCHIP1, 
STXBP3, TLE4
Binding APPBP2, ARFGEF1, C15orf29, C1orf73, CAPN7, CKAP5, CLASP1, NIPBL, OGT, OSRF, PKP4, PPP2R1B, PPP4R1, PUM1, PUM2, UTX, ZUBR1
Biological process unknown AMMECR1, CKAP5, CTDSP2, EGFL5, EVI1, HDHD1A, KIAA0247, KIAA0553, MRPL39, PLEKHA5, RAB11FIP5, SCHIP1, SLC35D2, STXBP3, 
TIAL1, TLE4
Ubiquitin cycle CNOT4, CUL1, EDD1, FBX034, FBX042, MIDI, RNF38, SENP6, SMURF2, STAMBP, UBE2G1, USP15, USP3, USP6, ZUBR1
Transcription coactivator activity ATF2, CDK7, CREBBP, EP300, HSF2, MKL2, NCOA2, NCOA3, NFATC3, NRIP1, PML, TAF4, TRIM24, TRIP4
RNA binding AKAP1, CDC5L, CNOT4, DDX10, HRB, PUM1, PUM2, RBMS1, RNPC2, SFRS8, SYNCRIP, TIAL1, UPF3A
Development CDC2L5, EVI1, GTF2IRD1, HECA, HMGA2, LDB1, MEIS1, NUMB, PHF3, RREB1, SPRED2, TLE1, WHSC2
RNA polymerase II transcription factor 
activity
ATF2, CTCF, FOXK2, IRF2, JUN, MEIS1, RBPSUH, TCF4, TCF7L2, TEAD4, TIAL1, ZFPM2
Signal transducer activity CASP8, CREBBP, GNAI1, GRK5, IL15, NCOA2, NCOA3, PPFIA1, PPP1R12A, RAPGEF2, SH3BP4, TBK1
Hydrolase activity ATP6V1B2, CHD1, CTDSP2, DDX10, DUSP10, GNPDA1, INPP1, MTMR3, PTEN, RPP30, SKIV2L2
Regulation of transcription from RNA 
jaolymerase II promoter
CHD1, CITED2, FOXK2, NFATC3, TCF4, TCF7L2, TEAD4, TIAL1, ZFPM2, ZNF143, ZNF161
Intracellular protein transport AP1GBP1, APPBP2, GGA2, SEC24B, SNX2, STAM, STAM2, STX3A, STX7, TLK1
Intracellular APAF1, GGA2, GPATC2, KIAA0182, MIDI, PAXIP1, PML, PRKD2, TRIM24, TRIM33
Integral to plasma membrane ACVR1B, EPHB4, GPRC5A, IL15, NUMB, RAPGEF2, SLC31A2, STOM, STX7
Intracellular signalina cascade ARHGAP29, NCK1, PIK3R3, PRKD2, SNX2, SNX4, SOCS5, SPSB1, TLK1
Transcription from RNA Pol II promoter AHR, HSF2, NCOR1, NMI, RBPSUH, RREB1, TRIM24, TRIP4
Receptor activity ACVR1B, BMPR1A, EPHB4, EPS15, GPRC5A, OGFRL1, PAQR3, THRAP2
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DNA repair CDK7, CSNK1D, NCOA6, PARP2, PML, POLB, RAD17, REV3L
Cytoskeleton ABU, CASP8, CLASP1, KIF2, PAFAH1B1, PKP4, STOM
Soluble fraction ABI1, CTDSP2, EDD1, GRK5, PPP2R1B, PPP4R1, UNC119
Transport HRB, NUP153, PRDM10, RNUT1, SLC22A5, TAP1, UPF3A
Apoptosis AHR, ATG5, DID01, EP300, PML, TIAL1, TP53BP2
Cell proliferation CDK7, EDD1, EPHB4, EPS15, IFI16, IRF2, PTEN
Calcium ion binding AP1GBP1, EGFL5, EPS15, ITSN2, PML, RAPGEF2, SWAP70
Ubiquitin-dependent protein catabolism EDD1, FBX011, LOC220594, SMURF2, USP15, USP3, USP6
Neurogenesis APAF1, CTCF, DYRK1A, EP300, PAFAH1B1, PHF20
Transcription corepressor activity CTCF, MEIS2, NCOR1, NRIP1, SAP30, ZFPM2
Regulation of translation EIF2AK3, MKNK2, PPP2R1B, PUM1, PUM2, RBMS1
Metabolism C12orf5, CDYL, CTBP2, DHRS7, HDHD1A, PDHX
Nuclear mRNA splicing, via spliceosome CDC40, CDC5L, RNPC2, SFRS4, SFRS8, SYNCRIP
Protein amino acid dephosphorylation DNAJC6, DUSP10, MTMR3, PPP2R1B, PPP2R2A, PTEN
Protein transport EIF4ENIF1, PEX14, SNX4, STXBP3, TAP1, VPS54
Guanyl-nucleotide exchange factor activity ARFGEF1, ARHGEF7, BCAR3, RALGDS, SOS2, TRIO
Golgi stack AP1GBP1, B4GALT5, DDEF2, GGA2, SEC24B, TMEM23
Regulation of progression throuqh cell cycle BCAR3, CDK8, HECA, PPP2R1B, TCF7L2, TOB2
Ligase activity CNOT4, EDD1, GCLC, MIDI, SMURF2, UBE2G1
Ubiquitin-protein ligase activity EDD1, FBX011, FBXW11, SMURF2, UBE2G1, ZUBR1
Microtubule APPBP2, CLASP1, KIF2, MIDI, PAFAH1B1
Cell division CDC40, CDK7, CDK8, CLASP1, PAFAH1B1
Negative regulation of cell proliferation ABI1, CTBP2, CUL1, PTEN, TOB2
Mitochondrion AKAP1, CASP8, MRPL39, PDHX, PPP2R1B
Peptidase activity CASP7, CDYL, PPP2R5C, USP15, USP6
Endocytosis AP1GBP1, ITSN2, SH3BP4, SNX2, SNX4
Endoplasmic reticulum ABI1, EIF2AK3, SEC24B, SYNCRIP, TAP1
Induction of apoptosis PML, PPP2R1B, PTEN, TIAL1, TP53BP2
Negative regulation of progression through 
cell cycle
CDC73, CTCF, PTEN, SASH1, TP53BP2
Ubiquitin thiolesterase activity LOC220594, STAMBP, USP15, USP3, USP6
Cytosol ABI1, APAF1, OGT, PPP2R1B, UNC119
Small GTPase mediated siqnal transduction BCAR3, RALGDS, RAPGEF2, RGL1, SOS2
DNA replication NCOA6, ORC5L, RAD 17, RBMS1, REV3L
Microtubule associated complex APPBP2, KIF2, MIDI, PAFAH1B1
Chromatin modification MYST3, MYST4, NCOR1, TLK1
Regulation of transcription MAX, NCOR1, PPP2R1B, ZZZ3
RNA splicinq CDC40, PPP2R1B, SFRS4, SYNCRIP
Protein phosphatase type 2a complex PPP2R1B, PPP2R2A, PPP2R5C, PPP2R5E
Protein phosphatase type 2a regulator PPP2R1B, PPP2R2A, PPP2R5C, PPP2R5E
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Activity__________
Transporter activity NUP153, SEC24B, SLC22A5, TAP1
Protein transporter activity EIF4ENIF1, SNX2, STX3A, STX7
Histone acetyltransferase activity CREBBP, EP300, MYST4, NCOA3
Protein complex assembly CREBBP, GGA2, PML, PPP2R1B
Specific RNA polymerase II transcription 
factor activity_______________________
MEIS2, TRIM24, ZNF143, ZNF161
Immune response IFI16, IL15, IRF2, TAP1
Proteolysis and peptidolysis CAPN7, CASP7, CASP8, SENP6
Cysteine-type peptidase activity CAPN7, CASP7, CASP8, SENP6
Acyltransferase activity MYST3, MYST4, NCOA3, PDHX
Negative regulation of transcription from RNA 
polymerase II promoter___________________
CTCF, IRF2, MEIS2, NRIP1
Response to stress AHR, DUSP10, MAP4K3, MAPK14
Positive regulation of transcription from RNA 
polymerase II promoter__________________
ELF4, MKL2, NCOA6, NRIP1
Kinase activity________
Magnesium ion Binding
PIK3R3, PRKCBP1, STK24, TMEM23
Positive regulation of cell proliferation
ACVR1B, BMPR1A, INPP1, POLB
CDC2L5, IL15, PBEF1, STAMBP
Protein-tyrosine kinase activity EPHB4, MAP2K4, PRKX, STK24
Catalytic activity C10orf6, CDYL, HDHD1A, PML
Transcriptional repressor activity IFI16, LDB1, MYST4, PML
Cysteine-type endopeptidase activity LOC220594, USP15, USP3, USP6
Transcription regulator activity CNOT2, MAX, NCOA2, NCOA3
Transferase activity, transferring glycosyl 
groups____________________________
B4GALT5, OGT, PARP2, PBEF1
Ion transport ATP6V1B2, SLC22A5, SLC31A2
Structural molecule activity EGFL5, PKP4, WDR59
Nuclear pore HRB, NUP153, RNUT1
Protein heterodimerization activity PML, PPP2R1B, TAP1
Plasma membrane SLC22A5, SSFA2, TULP3
Positive regulation of transcription, DNA- 
dependent________________________
CDK7, CTCF, NCOA3
Protein kinase cascade MAP4K3, MAPK14, MKNK2
Androgen receptor signaling pathway CDK7, NCOA3, NRIP1
Androgen receptor binding CDK7, NCOA3, NRIP1
JAK-STAT cascade NMI, SOCS5, STAMBP
Chromatin CDYL, CHD1, HMGA2
Chromatin binding CDYL, CHD1, NCOA6
Sh3/Sh2 adaptor activity ITSN2, STAM, TP53BP2
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JNK cascade
Negative regulation of transcription, DNA-
dependent_____________________________
Transcriptional activator activity
Protein self binding
ATP-dependent helicase activity
Protein folding
Response to unfolded protein
Ubiquitin ligase complex
Negative regulation of transcription
Transcription initiation from RNA polymerase 
II promoter____________________________
nucleoplasm
GTPase activator activity
mRNA processing
Wnt receptor signaling pathway
Ribonucleoprotein complex
G-protein coupled receptor protein signaling 
pathway_____________________________
Manganese ion binding
Lipid metabolism
Cell motility
Mitosis
Cell differentiation
Oxidoreductase activity
Protein dimerization activity
Outer membrane
Cell adhesion
Phosphoinositide binding
Response to hypoxia
Homeostasis
DNA-directed RNA polymerase activity
Electron transport
Inositol or phosphatidylinositol phosphatase 
activity
Protein serine/threonine phosphatase activity
Protein tyrosine phosphatase activity
Membrane fraction
Protein phosphatase type 2a activity
Carbohydrate metabolism
DUSP10, MAP2K4, MAP4K3
LDB1, RBPSUH, ZHX2
ELF4, MYST4, RREB1
CASP8, MKL2, ORC5L
DDX10, DHX32, SKIV2L2
HSF2, HSPA4L, KIAA0674
EIF2AK3, HSF2, HSPA4L
FBXQ11, FBXW11, SMURF2
MYST4, SMURF2, TRIM33
CDK7, GTF2E1, NCOA6
IFI16, PML, RNPC2
ARHGAP12, DDEF2, STARD13
CUGBP1, RNPC2, UPF3A
CSNK1D, CSNK2A1, FBXW11
CUGBP1, MRPL39, SYNCRIP
GNAI1, GPRC5A, TULP3
ACVR1B, B4GALT5, BMPR1A
PAFAH1B1, TMEM23
MAPK14, PAFAH1B1
CLASP1, PAFAH1B1
MKL2, PAFAH1B1
CTBP2, DHRS7
ATF2, JUN
AKAP1, NUP153
PKP4, TNC
SNX2, SNX4
CREBBP, EP300
CREBBP, EP300
PCM1, POLR3E
MRPL39, PCM1
INPP1, MTMR3
MTMR3, PTEN
MTMR3, PTEN
IL15, MTMR3
PPP2R1B, PPP2R2A
B4GALT5, GNPDA1
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Lysosome TIAL1, USP6
Nucleosome MYST3, MYST4
Nucleosome assembly MYST3, MYST4
Cell surface receptor linked signal 
transduction
MAPK14, MKNK2
Estrogen receptor binding NCOA6, NRIP1
Response to DNA damage stimulus EDD1.TLK1
Microtubule motor activity APPBP2, KIF2
Insulin receptor signaling pathway PHIP, PIK3R3
mRNA splice site selection CUGBP1, SFRS8
Vesicle-mediated transport SEC24B, STXBP3
Inactivation of MAPK activity PPP2R1B, SPRED2
Regulation of Wnt receptor signaling pathway PPP2R1B, TCF7L2
Negative regulation of cell growth PML, PPP2R1B
Transmembrane receptor protein tyrosine 
kinase signaling pathway
ABI1, EPHB4
Organogenesis EPHB4, TLE1
Electron transporter activity MRPL39, PDHX
MAPKKK cascade RAPGEF2, TAOK3
Diacylglycerol binding PRKD2, RAPGEF2
Chromatin assembly or disassembly CDYL, CHD1
Frizzled signaling pathway TLE1.TLE4
Spliceosome complex CDC40, CDC5L
Transcription cofactor activity LDB1, NMI
DNA-dependent DNA replication POLB, REV3L
Sodium ion binding POLB, SLC22A5
Ras protein signal transduction RREB1, SOS1
Double-stranded DNA binding IFI16, RBMS1
Rho GTPase activator activity ARHGAP29, SOS1
Inflammatory response NFATC3, NMI
Regulation of cyclin dependent protein 
kinase activity
CDK7, PTEN
Heart development NCOA6, PTEN
Helicase activity CHD1, DHX32
Chromosome organization and biogenesis 
(Sensu Eukaryota)
CHD1, HMGA2
Phosphoprotein phosphatase activity CTDSP2, DNAJC6
Receptor binding NCK1, TRIM24
Protein kinase activity CDK8, MAST4
Regulation of apoptosis APAF1, CASP8
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General RNA Pol II transcription factor 
activity__________________________
Endosome
Cell-cell signaling
Nucleolus
Response to virus
DNA damage response, signal transduction 
by p53 class mediator resulting in induction 
of apoptosis__________________________
Regulation of GTPase activity
mRNA nucleus export
Apoptotic programme
Caspase activity
G1/S transition of mitotic cell cycle
Cell cycle arrest
Establishment and/or maintenance of 
chromatin architecture
DNA recombination
Thyroid hormone receptor binding
Protein ubiguitination
PML body
Isomerase activity
Transforming growth factor beta receptor 
activity____________________________
Positive regulation of l-Kappa B kinase/Nf- 
kappa B cascade____________________
Translation initiation factor activity
GTF2E1, TAF4
IL15, STX7
IL15, PBEF1
IFI16, RBPSUH
IFI16, TBK1
IFI16, PML
DDEF2, HRB
HRB, UPF3A
CASP7, CASP8
CASP7, CASP8
CUL1, PML
CUL1.PML
HMGA2, TCF7L2
NCOA6, RBPSUH
NCOA3, NCOA6
FBXQ11, FBXW11
ELF4, PML
C12orf5, KIAA0674
ACVR1B, BMPR1A
CASP8, TBK1
EIF4ENIF1, WDR44
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Nucleus ATF3, C20orf11, CDKN1A, CEBPZ, DDB2, E2F6, EZH2, GADD45A, HEAB, HEXIM1, HIST1H1C, HIST2H2AA, HIST2H2BE, KCTD13, MAD2L1BP, MAFB, 
MBD4, NET1, NKRF, NOL1, NOL5A, NOLC1, NR4A2, NXF1, PNMA1, PNN, POLE3, POLR1C, PPM1D, RBM13, RBM4, RRS1, RSL1D1, SAS10, SESN1, 
SFPQ, SFRS7, SNIP1, SPEN, TAF7, TAF9, TCF8, TSC22D1, UBQLN2, ZBTB5, ZNF211, ZNF330, ZNF574
Protein binding BYSL, CD3EAP, CDKN1A, EIF5, HEXIM1, ITSN1, KCTD13, KLHL21, MAD2L1BP, MBD4, MYD88, NOL1, NXF1, PLK2, PMAIP1, PNMA1, RNF139, RNF44, 
SFPQ, SFRS7, TAF7, TNFRSF10B, TOB1, TOPORS, ZBTB5, ZNF330
Nucleotide binding ARS2, DYRK3, EIF5, EPHA2, GEM, HEAB, NOLC1, NXF1, PE01, PLK2, RBM4, RFK, RRAD, SFPQ, SFRS7, SPEN, TAF9, TAOK1, TOR1B
Membrane ARL6IP, C5orf15, CD44, EPHA2, FAS, GEM, HBEGF, IFNGR1, KCNJ8, KCTD13, MYD88, RNF139, SDF2, SLC10A3, SLC30A1, SLC35A2, STOM, 
TNFRSF10B
Regulation of transcription, DNA- 
dependent
ATF3, BTG2, CEBPZ, E2F6, EZH2, MAFB, NKRF, NR4A2, PNN, SFPQ, SPEN, TAF7, TAF9, TCF8, TSC22D1, ZBTB5, ZNF211
Transcription ATF3, BTG2, CEBPZ, E2F6, EZH2, MAFB, NKRF, NR4A2, PNN, POLR1C, SFPQ, TAF9, TFAM, TSC22D1, ZBTB5, ZNF211
Zinc ion binding CDKN1A, DNAJA1, NR4A2, RBM4, RFK, RNF139, RNF44, SFRS7, SLC30A1, TCF8, TOPORS, ZBTB5, ZNF211, ZNF330, ZNF574
DNA binding ATF3, CEBPZ, EZH2, HIST1H1C, HIST2H2AA, HIST2H2BE, MBD4, NKRF, PNN, POLG2, POLR1C, SFPQ, SPEN, TAF9, ZBTB5
Metal ion binding CDKN1A, DNAJA1, HCCS, NR4A2, RBM4, RNF139, RNF44, SFRS7, TCF8, TOPORS, ZBTB5, ZNF211, ZNF330, ZNF574
Transferase activity AASDHPPT, DYRK3, EPHA2, ETNK1, HSPB8, NOL1, PLK2, POLE3, POLG2, POLR1C, RFK, SAT, TAF9, TAOK1
ATP binding DYRK3, EPHA2, HEAB, NOLC1, PE01, PLK2, POLG2, RFK, TAF9, TAOK1, TOR1B
Transcription factor activity ATF3, BTG2, E2F6, NR4A2, TAF7, TCF8, TFAM, TSC22D1, ZNF211
Integral to membrane ARL6IP, C5orf15, FAS, KCNJ8, RNF139, SLC10A3, SLC30A1, SLC35A2, TNFRSF10B
Cellular component unknown ARS2, HSPB8, ITSN1, MRPL49, NET1, ODC1, RP5-1104E15.5, TRIAP1
Signal transduction EPHA2, FAS, GDF15, HBEGF, IFNGR1, NET1, NR4A2, TNFRSF10B
RNA binding EIF1AX, NOL5A, NXF1, RBM4, SFPQ, SFRS7, SPEN
Protein biosynthesis ARL6IP, EIF1AX, EIF5, MRPL49, MRPS6, POLG2, RSL1D1
Mitochondrion FDXR, HCCS, MRPL49, MRPS6, PE01, POLG2, TFAM
Cytoplasm BYSL, ETNK1, HEXIM1, MAD2L1BP, NOLC1, PNMA1, RFK
Cell cycle CDKN1A, E2F6, GADD45A, NOLC1, PNN, PPM1D
Receptor activity CD44, EPHA2, HBEGF, IFNGR1, RNF139, TNFRSF10B
Nucleolus NOL1, NOL5A, NOLC1, PNMA1, ZNF330
Integral to plasma membrane CD44, EPHA2, HBEGF, IFNGR1, STOM
DNA repair BTG2, GADD45A, KCTD13, POLG2, SFPQ
Negative regulation of cell 
proliferation
BTG2, CDKN1A, PPM1D, SESN1, TOB1
Molecular function unknown ARS2, MRPL49, RP5-1104E15.5, SAS10, TRIAP1
GtTP binding EIF5, GEM, HEAB, NOLC1, RRAD
Structural constituent of ribosome ARL6IP, MRPL49, MRPS6, RSL1D1
Protein serine/threonine kinase 
activity
DYRK3, HSPB8, PLK2, TAOK1
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Protein amino acid phosphorylation DYRK3, EPHA2, PLK2, TAOK1
Endoplasmic reticulum CES2, EPM2AIP1, RNF139, TOR1B
Extracellular space GDF15, HBEGF, IL11.SDF2
Immune response CD3EAP, FAS, GEM, TCF8
Hydrolase activity CES2, MBD4, PE01, PPM1D
Biological process unknown HSPB8, RP5-1104E15.5, TRIAP1, ZNF330
Calmodulin binding GEM, MARCKSL1, RRAD
Protein folding DNAJA1, HSPB8, TOR1B
Response to unfolded protein DNAJA1, HSPB8, TOR1B
Unfolded protein binding DNAJA1, HSPB8, TOR1B
Nuclear mRNA splicing, via 
spliceosome____________
RBM4, SFPQ, SFRS7
Translation initiation factor activity EIF1AX, EIF5, MRPL49
Transcription coactivator activity TAF7, TAF9, TCF8
Intracellular ARL6IP, GMFB, MRPL49
Ribosome ARL6IP, MRPL49, RSL1D1
Positive regulation of l-kappa B 
kinase/NF-kappa B cascade
MYD88, PLK2, TNFRSF10B
Nucleic acid binding SPEN, ZNF211, ZNF574
Transcription from RNA Pol II 
promoter
CEBPZ, TAF9, TSC22D1
Magnesium ion binding AASDHPPT, PPM1D, RFK
Cell cycle arrest CDKN1A, GADD45A, SESN1
Kinase activity CDKN1A, ETNK1, HSPB8
Growth factor activity GDF15, GMFB, HBEGF
Transcription corepressor activity ATF3, E2F6, TCF8
Protein dimerization activity ATF3, MAFB, POLR1C
Nucleosome HIST1H1C, HIST2H2AA, HIST2H2BE
Chromosome HIST1H1C, HIST2H2AA, HIST2H2BE
Nucleosome assembly HIST1H1C, HIST2H2AA, HIST2H2BE
Chromosome organization and 
biogenesis (Sensu Eukaryota)
HIST1H1C, HIST2H2AA, HIST2H2BE
Negative regulation of transcription 
From RNA Pol II promoter_______
E2F6, HEXIM1, TCF8
Ubiquitin cycle FBXL14, RNF139, RNF44
Regulation of progression through 
cell cycle
E2F6, NOL1, PPM1D
Cell surface receptor linked signal 
transduction
GEM, MYD88, TNFRSF10B
DNA replication KCTD13, PEQ1, POLE3
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Lyase activity HCCS, ODC1
rRNA processing NOL5A, NOLC1
Translational initiation EIF1AX, MRPL49
Transcription factor TFIID complex TAF7, TAF9
General RNA Pol II transcription 
factor activity
TAF7, TAF9
Guanyl-nucleotide exchange factor 
activity
ITSN1, NET1
signal transducer activity MYD88, PLK2
Regulation of cyclin dependent 
protein kinase activity
CDKN1A, GADD45A
Protein kinase activity CDKN1A, DYRK3
Cyclin-dependent protein kinase 
inhibitor activity
CDKN1A, HEXIM1
DNA-dependent DNA replication POLG2, TFAM
Transmembrane receptor protein 
tyrosine kinase signaling pathway
CD3EAP, EPHA2
Development EPHA2, SAS10
Cell adhesion BYSL, CD44
Apoptosis FAS, GADD45A
Electron transport FDXR, HCCS
mRNA processing HEAB, NXF1
Small GTPase mediated signal 
transduction
GEM, RRAD
Transmembrane receptor activity FAS, MYD88
Cytosol EIF5, FAS
Protein self binding FAS, HSPB8
Regulation of apoptosis FAS, TNFRSF10B
GTPase activity EIF5, RRAD
Transport NXF1, SLC10A3
Membrane fraction GOLGA4, KCNJ8
Potassium ion transport KCNJ8, KCTD13
Voltage-gated potassium channel 
complex
KCNJ8, KCTD13
Cytokine activity GDF15, IL11
Cell-cell signaling GDF15, IL11
Positive regulation of cell 
proliferation
IL11, NOL1
Oxidoreductase activity FDXR, UBQLN2
Transcription From RNA Pol 1 POLR1C, RRN3
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Golgi stack GOLGA4, SLC35A2
RNA Splicing SFPQ, SFRS7
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Protein binding AKT3, ANXA11, CBLB, CDH4, CHCHD3, CRSP8, DDEF1, FYN, GRB10, GSK3B, ITSN1, JMJD2C, KCNS3, MNAT1, MPDZ, MYH10, NCK2, NCOR1, 
NEK1, PARD3, PARN, PBX1, PBX3, PDZRN3, PPP2R3A, PRKCA, PRKD1, PTK2, RBPMS, SIPA1L1, SMARCA2, SMARCC1
Nucleus APBB2, ATXN1, CBLB, CDC14B, CRSP8, DIP2C, EGR1, FAF1, JARID2, LDB2, MAD1L1, MLLT3, MNAT1, NCOA1, NCOR1, NEK1, PARN, PBX1, 
PBX3, PFTK1, POLR3B, PPP3CA, RNGTT, SMARCA2, SMARCC1, SSBP2, STK3, TBC1D1, TBL1X, ZNF291
Membrane APBB2, CDC42BPA, CDH4, COVA1, COX10, DDEF1, EDG2, EXT1, FUT8, INPP5A, KCNS3, MPDZ, PARD3, PPAP2B, PTPRK, RHBDL2, 
SLC25A12, SLC25A13, TMCC1, TPST1, UST, ZDHHC14
Nucleotide binding AKT3, ASCC3, CDC42BPA, COVA1, FYN, GNAQ, GSK3B, LARS2, MAP2K5, MYH10, MYO10, NEK1, NME7, PARN, PFTK1, PRKCA, PRKD1, 
PTK2, RBPMS, SMARCA2, STK3
Transferase activity AKT3, CDC42BPA, COX10, FYN, GSK3B, MAP2K5, NCOA1, NEK1, NME7, PFTK1, PIP5K2A, POLR3B, PRKCA, PRKD1, PTK2, RNGTT, STK3, 
TPST1, UST, ZDHHC14
ATP binding AKT3, ASCC3, CDC42BPA, FYN, GSK3B, LARS2, MAP2K5, MYH10, MYO10, NEK1, NME7, PFTK1, PRKCA, PRKD1, PTK2, SMARCA2, STK3, 
TMEM131
Zinc ion binding CBLB, CDC42BPA, DDEF1, EGR1, JMJD2C, MIPEP, MNAT1, PDZRN3, POLR3B, PPP3CA, PRKCA, PRKD1, ZDHHC14, ZFAND3, ZNF291
Mitochondrion AUH, CHCHD3, COX10, ETFA, LARS2, MIPEP, MRPS27, MRPS28, PCCB, SLC25A12, SLC25A13, SQRDL, SUCLG2
Integral to membrane CDH4, COX10, EDG2, EXT1, FUT8, PPAP2B, RHBDL2, SLC25A12, STXBP6, TMCC1, TPST1, UST, ZDHHC14
Calcium ion binding ANXA11, CBARA1, CBLB, CDH4, ITSN1, LTBP1, MIPEP, PPP2R3A, PPP3CA, PRKCA, SLC25A12, SLC25A13, ZZEF1
Cytoplasm ANXA11, ATXN1, DERA, GNAQ, GRB10, NCK2, NEK1, PACSIN2, PARN, PFTK1, PMM2, STK3
Hydrolase activity ASCC3, CDC14B, INPP5A, PARN, PDE6D, PPAP2B, PPP3CA, PRNPIP, PTPRK, RNGTT, SMARCA2
Protein amino acid phosphorylation AKT3, CDC42BPA, FYN, GSK3B, MAP2K5, NEK1, PFTK1, PRKCA, PRKD1, PTK2, STK3
Regulation of transcription, DNA- 
dependent
ASCC3, CRSP8, EGR1, JARID2, JMJD2C, MLLT3, NCOR1, PBX1, PBX3, TBL1X
Metal ion binding CDC42BPA, DDEF1, EGR1, JMJD2C, MNAT1, PDZRN3, POLR3B, PRKD1, ZDHHC14, ZNF291
Signal transduction ADM, AKT3, EDG2, EXT1, GNAQ, MAP2K5, MYO10, NCOA1, STK3, TBL1X
Transcription ASCC3, CRSP8, EGR1, JARID2, MLLT3, MNAT1, POLR3B, SMARCA2, TBL1X
Intracellular signaling cascade APBB2, CDC42BPA, FYN, GRB10, NCK2, PRKCA, PRKD1, RIN3, TNS3
DNA binding JARID2, NCOR1, POLR3B, SMARCA2, SMARCC1, SSBP2, ZFAND3
Biological process unknown FN5, JMJD2C, LTBP1, MAPKAP1, MRPS28, MYH10, SIPA1L1
Molecular function unknown AP2A2, FN5, JMJD2C, MAD1L1, MRPS28, SIPA1L1, ZFAND3
Cellular component unknown FN5, FYN, ITSN1, JMJD2C, MAPKAP1, RIN3, SIPA1L1
Nucleic acid binding ASCC3, COVA1, JMJD2C, MRPS28, R3HDM1, RNGTT, ZNF291
Protein serine/threonine kinase activity AKT3, CDC42BPA, MAP2K5, NEK1, PFTK1, PRKD1, STK3
Protein amino acid dephosphorylation CDC14B, PPP2R3A, PPP3CA, PTPRK, RNGTT, TNS3
Magnesium ion binding CDC42BPA, MIPEP, NEK1, NME7, PARN, STK3
Regulation of transcription APBB2, NCOA1, NCOR1, SMARCC1, SSBP2
Cell cycle EXT1, MAD1L1, MNAT1, NEK1, PARD3
GTPase activator activity DDEF1, RIN3, SIPA1L1, TBC1D1, TBC1D22A
Plasma membrane CDH4, EDG2, GNAQ, GRB10, PRKD1
Appendix 2. Continued (cluster 3)
Integral to plasma membrane EDG2, PRKD1, PTPRK, SLC25A12, SLC25A13
RNA binding ATXN1, AUH, KIAA0427, PARN, RBPMS
binding AP2A2, PTK2, RP3-477H23.1, SLC25A12, SLC25A13
Endocytosis AP2A2, AP4S1, PACSIN2, RIN3
Golgi stack AP2A2, EXT1, FUT8, UST
Metabolism AUH, DIP2C, PMM2, SUCLG2
Protein-tyrosine kinase activity FYN, MAP2K5, NEK1, PTK2
Catalytic activity C20orf19, DIP2C, NCOA1, SUCLG2
Transcription coactivator activity NCOA1, SMARCA2, SMARCC1
Nucleoplasm ANXA11, SMARCA2, SMARCC1
Regulation of transcription from RNA Pol II 
promoter
MNAT1, SMARCA2, SMARCC1
Transporter activity AP4S1, PACSIN2, SLC25A12
Intracellular protein transport AP2A2, AP4S1, PACSIN2
Transcription factor activity EGR1, PBX1, PBX3
Ligase activity LARS2, PCCB, SUCLG2
Signal transducer activity CBLB, GNAQ, NCOA1
Transport AP4S1, SLC25A12, SLC25A13
Protein complex assembly AP2A2, MNAT1, PARD3
Diacylglycerol binding CDC42BPA, PRKCA, PRKD1
Membrane fraction KCNS3, PRKCA, TPST1
Cytosol COVA1, FAF1, PRKD1
Kinase activity MAPKAP1, NME7, PIP5K2A
Transcription from RNA Pol II promoter NCOR1, PBX1
Positive regulation of transcription, DNA- 
dependent
NCOA1, SMARCC1
Electron transport COVA1, ETFA
Motor activity MYH10, MYO10
Actin binding MYH10, MYO10
Cytoskeleton MYO10, PTK2
Myosin MYH10, MYO10
Transferase activity, transferring glycosyl 
groups
EXT1, FUT8
Protein serine/threonine phosphatase 
activity
CDC14B, PPP3CA
Iron ion binding MIPEP, PPP3CA
Calmodulin bindinq MYH10, PPP3CA
G-protein coupled receptor protein 
signaling pathway
EDG2, GNAQ
Phospholipase C activation EDG2, GNAQ
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Cell-cell signaling ADM, GRB10
Protein tyrosine phosphatase activity CDC14B, PTPRK
Receptor activity EDG2, PTPRK
Development JARID2, LDB2
Mitochondrial inner membrane SLC25A12, SLC25A13
Guanyl-nucleotide exchange factor activity ITSN1, PSD3
Cell proliferation MNAT1, PRKD1
Transcription regulator activity NCOA1, SSBP2
Protein self binding CDC42BPA, FYN
mRNA 3'-UTR binding AUH, PARN
Exonuclease activity PARN, PRNPIP
Apoptosis FAF1.STK3
Protein kinase cascade FYN, STK3
Positive regulation of apoptosis FAF1, STK3
Embryonic development PBX1, PBX3
Hindbrain development PBX1, PBX3
Regulation of transcriptional pre-initiation 
complex formation
PBX1, PBX3
Visual perception PDE6D, TBL1X
Golgi apparatus PRKD1, TPST1
Protein tyrosine/serine/threonine 
phosphatase activity
CDC14B, RNGTT
Oxidoreductase activity COVA1, SQRDL
Centrosome CEP63, MAD1L1
Cell division MAD1L1, NEK1
Lyase activity AUH, DERA
Intracellular CBARA1, PRNPIP
Acyltransferase activity NCOA1, ZDHHC14
Cell surface receptor linked signal 
transduction
CBLB, PRKCA
NF-Kappa B binding FAF1, GSK3B
Coated pit AP2A2, AP4S1
Ribonucleoprotein complex MRPS27, MRPS28
Phosphoprotein phosphatase activity PPAP2B, TNS3
Transcription factor binding APBB2, DIP2C
Ubiquitin cycle FBXL7, TBL1X
Tight junction MPDZ, PARD3
Ras GTPase bindinq MAPKAP1, RIN3
Heat shock protein bindinq DNAJC15, FAF1
Regulation of GTPase activity DDEF1, SMAP1
Appendix 2. Continued (cluster 3)
1 Axonogenesis I APBB2, PARD3
Appendix 2. Continued (Cluster 4)
Membrane ANK2, COG5, DIAPH2, DKFZP779L1558, DNAJC1, DOCK1, FARP1, LARGE, PTPRG, PTPRM, R0B01, STX8, VPS13B
Protein binding ADAM12, ANK2, CASK, COG5, CRADD, DOCK1, PRKCA, PTBP1, SMYD3
Nucleus AHNAK, BCAS3, DNAJC1, EGR3, PLCB1, PTBP1, RPS6KA2, SMYD3, SUPT3H
Nucleotide binding CASK, DSCR1L1, DYRK4, FARS2, NUBPL, PRKCA, PTBP1, RPS6KA2
Transferase activity ADK, CASK, DYRK4, PDSS2, PRKCA, PRPS1, RPS6KA2, SMYD3
Zinc ion binding ADAM 12, C9orf3, EGR3, NQ02, PRKCA, PTPRG, SMYD3
Cytoplasm DOCK1, EIF1, EVL, FARP1, GMDS, PLCB1
Signal transduction ANK2, BRE, CRADD, DOCK1, GABBR2, RSU1
ATP binding CASK, DYRK4, FARS2, NUBPL, PRKCA, RPS6KA2
Integral to membrane ADAM12, DNAJC1, LARGE, SGCD, VPS13B
Metal ion binding ADAM12, C9orf3, EGR3, NQ02, SMYD3
Integral to plasma membrane GABBR2, PTPRG, PTPRM, R0B01, STX8
Cellular component unknown DSCR1L1, DYRK4, EIF1, LRBA, PTHB1
Cell adhesion ADAM 12, CASK, FARP1, R0B01
Oxidoreductase activity ANK2, BCKDHB, MSRA, NQ02
Calcium ion binding C14orf143, FBN2, PLCB1, PRKCA
Hydrolase activity ACYP2, PLCB1, PTPRG, PTPRM
Molecular function unknown COG5, LRBA, NUBPL, PTHB1
Protein amino acid phosphorylation CASK, DYRK4, PRKCA, RPS6KA2
Cytoskeleton DOCK1, FARP1, SGCD
Plasma membrane ADAM12, CASK, SGCD
Receptor activity GABBR2, PTPRM, R0B01
Golgi stack COG5, DKFZP779L1558, LARGE
Protein transport COG5, DKFZP779L1558, DNAJC1
Kinase activity ADK, CASK, PRPS1
Regulation of progression through cell cycle PLCB1, PRKCA, SUPT3H
Protein serine/threonine kinase activity CASK, DYRK4, RPS6KA2
Neurogenesis AHNAK, EVL, R0B01
GTPase activator activity DOCK1, TBC1D5
Guanyl-nucleotide exchange factor activity DOCK1, FARP1
Actin cytoskeleton ANK2, CASK
Proteolysis and peptidolysis ADAM 12, C9orf3
Integrin-mediated signaling pathway ADAM12, DOCK1
Carbohydrate metabolism GBE1, GMDS
Transmembrane receptor protein tyrosine phosphatase activity PTPRG,PTPRM
Protein amino acid dephosphorylation PTPRG, PTPRM
Magnesium ion binding ADK, PRPS1
Appendix 2. Continued (cluster 4)
Ribonucleoside monophosphate biosynthesis ADK, PRPS1
Mitochondrion BCKDHB, FARS2
Protein biosynthesis EIF1, FARS2
Cell differentiation DIAPH2, ROBQ1
Transcription EGR3, SUPT3H
Muscle development EGR3, SGCD
Synaptic transmission GABBR2, LARGE
Biological process unknown LRBA, PTHB1
Binding KIAA1797, LRBA
Perception of sound KIAA1199, LARGE
Cell surface receptor linked signal transduction EVL, PRKCA
Intracellular signaling cascade PLCB1, PRKCA
Protein modification MSRA, TTLL5
Appendix 3. Gene Ontology Classification of differentially regulated genes following interaction analysis (Cluster 1).
Nucleus ABI1, APBB2, BMP2K, CDC14B, CDC27, CDC73, CLOCK, CREBBP, CTBP2, CTDSPL, DIP2C, DUSP10, EDD1, ERBB2IP, FOXF1, G3BP, HIP2, HIVEP2, 
HMGA2, HNRPA3, HRB, IP07, KPNA1, MBNL1, MEIS1, MNAT1, N4BP1, NPAT, NR3C1, NUP88, PARP4, PBX3, PDCD11, PHF20, PIK3C2A, PNN, 
PPARD, PPP2R5C, PPP3CA, PRPF4B, PWP1, RAI17, RANBP5, RB1, RBMS1, RBPSUH, RNUT1, SATB2, SFRS3, SH3BP4, SSX2IP, STK17A, STK39, 
STRN3, SYNCRIP, TARDBP, TCF12, TCF4, TCF8, TEX10, THRAP1, TJP2, TLE4, TLK1, TRIP4, UBE3A, USP7, WDR50, XRCC4, ZFPM2, ZMYM4
Protein binding ACTR3, AKT3, ANXA11, APAF1, CAB39, CHCHD3, CREBBP, CSNK2A1, DDEF1, DICER1, DNMBP, EDD1, EPS8, ERBB2IP, EVI5, FGFR1, FOXF1, FYN, 
G3BP, GNA12, HRB, IL4R, JMJD2B, KIAA0182, KPNA1, LAMC1, MAP2K4, MNAT1, NR3C1, PBX3, PEX14, PHF20, PHIP, PIK3C2A, PKP4, PPP2R2A, 
PPP2R3A, PRPF4B, PTK2, RAPGEF2, RB1, RBPSUH, RRAS2, SEC24D, SIPA1L3, SNX13, SOCS5, SSX2IP, STAU1, TARDBP, TCF4, TJP2, UBE2D2, 
UBE2D3, UBE2E1, VPS54
Nucleotide binding ACTR3, AKT3, APAF1, ASCC3, ATP2B1, BMP2K, CSNK2A1, DDX10, DICER1, FGFR1, FYN, G3BP, GNA12, GNAI3, GNAQ, HNRPA3, HNRPDL, 
HNRPH3, MAP2K4, MAP3K5, MAP4K4, MYO10, OPA1, PDGFRA, PRKAR2A, PRPF4B, PTK2, RAB2, RAP1B, RBMS1, ROCK1, RRAS2, SFRS3, STK17A, 
STK24, STK39, SYNCRIP, TARDBP, TLK1, TRIO
Membrane APBB2, ARFGEF2, ATP2B1, C1orf22, CHD9, DDEF1, DKFZP779L1558, EDG2, EMP1, EXT1, FGFR1, GNA12, IL4R, INPP5A, LPGAT1, NRP1, NUMB, 
PDGFRA, PEX14, PPAP2B, PTPRK, RAP1B, RAPGEF2, SLC4A4, TEX10, TJP2, TPST1, VEGFC
Signal transduction AKT3, ARHGEF7, CLOCK, CREBBP, EDG2, EPS8, EXT1, GNA12, GNAI3, GNAQ, IL4R, IP07, MAP2K4, MYO10, NR3C1, NRP1, PAFAH1B1, PDE8A, 
PPP2R2A, PPP2R5C, PPP2R5E, PPP4R1, PRKAR2A, ROCK1, STAM, STK24, VEGFC
Zinc ion binding ARFGAP3, CENTB2, CREBBP, DDEF1, DDEF2, EDD1, HIVEP2, HRB, JMJD2B, KIAA0182, LEREP04, MBNL1, MIPEP, MNAT1, MORC2, NR3C1, PHF20, 
PPARD, PPP3CA, RAM 7, ROCK1, TCF8, TRIM44, TRIP4, USP3, ZFPM2, ZMYM4
ATP binding ACTR3, AKT3, APAF1, ASCC3, ATP2B1, BMP2K, CSNK2A1, DDX10, DICER1, FGFR1, FYN, G3BP, MAP2K4, MAP3K5, MAP4K4, MYO10, PDGFRA, 
PRPF4B, PTK2, ROCK1, STK17A, STK24, STK39, TLK1, TMEM131, TRIO
Transferase activity AKT3, BMP2K, CREBBP, CSNK2A1, FGFR1, FYN, HMBS, LPGAT1, MAP2K4, MAP3K5, MAP4K4, PCMT1, PDGFRA, PIK3C2A, PIP5K2A, PRPF4B, PTK2, 
ROCK1, STK17A, STK24, STK39, TLK1, TPST1, TRIO
Metal ion binding ARFGAP3, CENTB2, CREBBP, DDEF1, DDEF2, EDD1, HIVEP2, HRB, JMJD2B, KIAA0182, MBNL1, MNAT1, MORC2, NR3C1, PHF20, PPARD, RAI17, 
ROCK1, TCF8, TRIM44, TRIP4, USP3, ZFPM2
Regulation of transcription, DNA- 
dependent
ASCC3, CREBBP, HIP2, HIVEP2, HMGA2, JMJD2B, JUN, MEIS1, NR3C1, PBX3, PDCD11, PHF20, PNN, RAI17, RB1, SATB2, TARDBP, TCF8, THRAP1, 
TLE4, TRIP4
Cytoplasm ANXA11, ATG5, CREBBP, DNMBP, DUSP10, DUSP6, ERBB2IP, G3BP, GNAQ, IP07, KPNA1, MBNL1, NR3C1, PCM1, PPP2R5E, PREP, PRKAR2A, 
RANBP5, SOCS5, STK39, TRIP4
Transcription ASCC3, CDC73, FOXF1, HIVEP2, HMGA2, JUN, MNAT1, PCM1, PHF20, PNN, PPARD, PWP1, RAI17, RB1, RBPSUH, TARDBP, THRAP1, TRIP4, ZFPM2
Protein amino acid phosphorylation AKT3, BMP2K, CSNK2A1, FGFR1, FYN, MAP2K4, MAP3K5, MAP4K4, PDGFRA, PRKAR2A, PRPF4B, PTK2, ROCK1, STK17A, STK24, STK39, TLK1, 
TRIO
Binding ARFGEF2, C15orf29, CDC27, CLASP1, IP07, KIAA1012, PKP4, PPP4R1, PSME4, PTK2, PUM1, PUM2, RANBP5, RAP1GDS1, TEX10, TTC17
Transcription factor activity CLOCK, CREBBP, FOXF1, HIP2, JUN, MEIS1, NR3C1, PBX3, PPARD, RB1, RBPSUH, SATB2, TARDBP, TCF8
RNA binding DDX10, G3BP, HNRPA3, HNRPH3, HRB, MRPL3, PDCD11, PUM1, PUM2, RBMS1, SFRS3, SNRPA1, SYNCRIP, TARDBP
DNA binding G3BP, HIVEP2, HMGA2, HRB, PARP4, PCM1, PHF20, PNN, RBMS1, SATB2, TCF12, TCF4, ZFPM2, ZMYM4
Hydrolase activity ARSJ, ASCC3, ATP2B1, CDC14B, DDX10, DICER1, DUSP10, DUSP6, G3BP, INPP5A, PDE8A, PPAP2B, PPP3CA, PTPRK
Protein Ser/Thr kinase activity AKT3, BMP2K, CSNK2A1, FGFR1, MAP2K4, MAP3K5, MAP4K4, PRPF4B, ROCK1, STK17A, STK24, TLK1, TRIO
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Nucleic acid binding ASCC3, G3BP, HNRPDL, JMJD2B, LEREP04, MBNL1, OSBPL3, PHF20, QKI, R3HDM1, SFRS3, TARDBP
Signal transducer activity CASP8, CLOCK, CREBBP, GNA12, GNAI3, GNAQ, PDE8A, PPP1R12A, RAPGEF2, SH3BP4, SNX13, WNT5B
Cell cycle CDC73, CLASP1, ERBB2IP, EXT1, MNAT1, PAFAH1B1, PNN, SASH1, SH3BP4, STRN3, TLK1
Integral to membrane CHD9, EDG2, EMP1, EXT1, LPGAT1, NRP1, PPAP2B, PPP2R5C, SLC4A4, TEX10, TPST1
Cellular component unknown CTDSPL, FYN, KIAA0553, LRRFIP2, MAP4K4, PDE8A, PHIP, RAP1GDS1, RBMS1, SACS, TLK1
Ubiquitin cycle EDD1, HIP2, NEDD4, UBE2D2, UBE2D3, UBE2E1, UBE3A, USP3, USP7, USP9X
Cytoskeleton ABI1, CASP8, CLASP1, DNMBP, MYO10, PAFAH1B1, PKP4, PTK2, RAP1GDS1, ROCK1
Cell proliferation CDC27, EDD1, EMP1, EPS8, EVI5, MNAT1, PDGFRA, PPARD, TCF8, VEGFC
Calcium ion binding ANXA11, ARSJ, ATP2B1, C1orf22, MIPEP, PPP2R3A, PPP3CA, RAPGEF2, TBC1D9, ZZEF1
Intracellular signaling cascade APBB2, ARFGEF2, DNMBP, FYN, PIK3C2A, PRKAR2A, ROCK1, SNX13, SOCS5, TLK1
Protein transport DKFZP779L1558, IP07, NUP88, PEX14, PRPF4B, RAB2, RANBP5, SNX13, VPS54
Cytosol ABI1, APAF1, ARFGAP3, ARFGEF2, ARFIP1, PSMD14, PSMF1, STRN3, TNFSF5IP1
Ubiquitin-dependent protein 
catabolism
EDD1, PSMD14, PSMF1, UBE2E1, UBE3A, USP3, USP34, USP7, USP9X
Intracellular APAF1, DICER1, G3BP, KIAA0182, NEDD4, ROCK1, STAU1, TRIM44, UBE3A
Integral to plasma membrane ATP2B1, EDG2, FGFR1, IL4R, NUMB, PDGFRA, PTPRK, RAPGEF2, TJP2
Ubiquitin-protein liqase activity EDD1, FBXW11, HIP2, NEDD4, UBE2D2, UBE2D3, UBE2E1, UBE3A
Ligase activity EDD1, HIP2, NEDD4, PCCB, UBE2D2, UBE2D3, UBE2E1, UBE3A
Development EMP1, EVI5, HMGA2, MEIS1, NUMB, TCF12, WNT5B, ZMYM4
Golgi stack DDEF2, DKFZP779L1558, DNMBP, EXT1, GOLGA4, KIAA1012, RAB2, SEC24D
Molecular function unknown ARFIP1, CTDSPL, KIAA0553, LPGAT1, RB1, SACS, SEC24D, TLE4
Mitochondrion CASP8, CHCHD3, MIPEP, MRPL3, MRPS35, OPA1, PCCB, SQRDL
GTP binding GNA12, GNAI3, GNAQ, OPA1, RAB2, RAP1B, RRAS2
Transport G3BP, GNAI3, HRB, KIAA1012, PARP4, RNUT1, TEX10
Membrane fraction EMP1, FGFR1, GOLGA4, NRP1, PRKAR2A, STRN3, TPST1
Biological process unknown ARFIP1, CTDSPL, KIAA0553, LPGAT1, LRRFIP2, RAP1GDS1, TLE4
Receptor activity EDG2, FGFR1, IL4R, NRP1, PDGFRA, PTPRK, THRAP1
Protein amino acid 
dephosphorylation
CDC14B, DUSP10, DUSP6, PPP2R2A, PPP2R3A, PPP3CA, PTPRK
Endoplasmic reticulum ABI1, C1orf22, LPGAT1, PCMT1, RAB2, SEC24D, SYNCRIP
Apoptosis ATG5, MAP3K5, PDCD10, PDCD11, PPARD, ROCK1, STK17A
Nuclear pore HRB, IP07, KPNA1, NUP88, RANBP5, RNUT1
RNA Pol II transcription factor 
activity
JUN, MEIS1, RBPSUH, TCF12, TCF4, ZFPM2
Intracellular protein transport ARFGAP3, ARFIP1, KPNA1, SEC24D, STAM, TLK1
Regulation of GTPase activity ARFGAP3, CENTB2, DDEF1, DDEF2, HRB, SMAP1
Regulation of transcription from 
RNA Pol II Promoter
CLOCK, FOXF1, MNAT1, TCF12, TCF4, ZFPM2
GTPase activator activity ARHGAP12, CENTB2, DDEF1, DDEF2, RAP1GDS1, SIPA1L3
mRNA splicing, via spliceosome HNRPH3, PRPF4B, SFRS3, SYNCRIP, TARDBP
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Cell adhesion ERBB2IP, LAMC1, NRP1, PKP4, SSX2IP
Neurogenesis APAF1, MBNL1, NRP1, PAFAH1B1, PHF20
Small GTPase mediated signal 
transduction
BCAR3, RAB2, RAP1B, RAPGEF2, RRAS2
Soluble fraction ABI1, DUSP6, EDD1, IPQ7, PPP4R1
Metabolism ARSJ, ATP2B1, CTBP2, DIP2C, LPGAT1
Negative regulation of progression 
through cell cycle______________
CDC73, EXT1, PNN, RB1, SASH1
Transcription coactivator activity CREBBP, FOXF1, RB1, TCF8, TRIP4
Guanyl-nucleotide exchange factor 
activity_______________________
ARFGEF2, ARHGEF7, BCAR3, DNMBP, TRIO
Protein-tyrosine kinase activity FGFR1, FYN, MAP2K4, PTK2, STK24
Magnesium ion binding ATP2B1, MAP3K5, MIPEP, OPA1, PDE8A
Proteolysis and peptidolysis C1orf22, CASP8, MIPEP, PREP, UBE3A
Transcription from RNA pol II 
promoter_________________
NR3C1, RBPSUH, TARDBP, TRIP4
Protein complex assembly CREBBP, LAMC1, MNAT1, WASPIP
Protein transporter activity ARFGAP3, IP07, KPNA1, RANBP5
Cysteine-type endopeptidase 
activity___________________
USP3, USP34, USP7, USP9X
Ubiquitin thiolesterase activity USP3, USP34, USP7, USP9X
GTPase activity GNA12, GNAI3, GNAQ, OPA1
G-protein coupled receptor protein 
signaling pathway______________
EDG2, GNA12, GNAI3, GNAQ
Transcription factor binding APBB2, DIP2C, JUN, PDCD11
Protein phosphatase type 2a 
complex_________________
PPP2R2A, PPP2R3A, PPP2R5C, PPP2R5E
Protein phosphatase type 2a 
regulator activity__________
PPP2R2A, PPP2R3A, PPP2R5C, PPP2R5E
RNA splicing HNRPH3, PRPF4B, SNRPA1, SYNCRIP
ER to golgi transport ARFGAP3, KIAA1012, RAB2, SEC24D
Plasma membrane EDG2, GNAQ, PRKAR2A, SSFA2
Response to stress DUSP10, MAP3K5, MAP4K4, STK39
Immune response ANXA11, IL4R, TCF12, TCF8
Kinase activity PIP5K2A, PRKAR2A, ROCK1, STK24
Mitosis CLASP1, PAFAH1B1, TARDBP
Lipid Metabolism PAFAH1B1, PPAP2B, PPARD
Cell Differentiation NRP1.PAFAH1B1, VEGFC
Double-stranded RNA binding DICER1, MBNL1, STAU1
Regulation of translation PUM1, PUM2, RBMS1
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Cell growth EMP1, ERBB2IP, FGFR1
Peptidase activity C1orf22, PPP2R5C, USP7
DNA repair MNAT1, PARP4, XRCC4
Inflammatory response NR3C1, PARP4, TPST1
Ribonucleoprotein complex HNRPA3, PARP4, SYNCRIP
Protein serine/threonine 
phosphatase activity
CDC14B, DUSP6, PPP3CA
Calmodulin binding ATP2B1, PPP3CA, STRN3
Protein kinase cascade FYN, MAP4K4, STK17A
Protein tyrosine phosphatase 
activity
CDC14B, DUSP6, PTPRK
MAPKKK cascade FGFR1, MAP3K5, RAPGEF2
Negative regulation of transcription 
From RNA Pol II Promoter
PPARD, RB1, TCF8
RNA processing DICER1, HNRPDL, RBMS1
Protein self binding CASP8, FYN, MAP3K5
Regulation of progression through 
cell cycle
BCAR3, DUSP6, VEGFC
Positive regulation of 1-Kappa B 
kinase/NF-Kappa B cascade
CASP8, EDG2, PDCD11
ATP-dependent helicase activity ASCC3, DDX10, DICER1
Ubiquitin conjugating enzyme 
activity
EDD1, UBE2E1, UBE3A
Nuclear membrane ANXA11, PAFAH1B1
Microtubule CLASP1, PAFAH1B1
Microtubule associated complex PAFAH1B1, STAU1
Cell motility ACTR3, PAFAH1B1
Cell division CLASP1, PAFAH1B1
Protein-nucleus import, docking IP07, RANBP5
Small GTPase regulator activity IP07, MAP4K4
Ran GTPase binding IP07, RANBP5
Protein complex PSMF1, TNFSF5IP1
Muscle development MBNL1, TCF12
Negative regulation of cell 
proliferation
ABU,CTBP2
Oxidoreductase activity CTBP2, SQRDL
Cell death EMP1, PARP4
Epidermis development EMP1, PPARD
Endonuclease activity DICER1, G3BP
Transporter activity G3BP, NUP88
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Vesicle-mediated .transport ARFGAP3, GOLGA4
Actin cytoskeleton PPP1R12A, WASPIP
Structural molecule activity ACTR3, PKP4
Motor activity MYO10, OPA1
Actin binding MYO10, WASPIP
Androgen receptor signaling 
pathway
RB1, THRAP1
Skeletal development EXT 1, FGFR1
Transferase activity, transferring 
glycosyl groups
EXT1, PARP4
Nls-bearing substrate-nucleus KPNA1, RANBP5
import
Nuclear localization sequence 
binding
KPNA1, RANBP5
Autophagy ATG5, PRPF4B
Protein amino acid ADP- GNAQ, PARP4
ribosylation
Response to drug BCAR3, PARP4
Fatty acid catabolism PCCB, PPARD
Iron ion binding MIPEP, PPP3CA
Response to DNA damage stimulus EDD1, TLK1
Sh3/Sh2 adaptor activity EPS8, STAM
Epidermal growth factor receptor 
signaling pathway
EPS8, ERBB2IP
Phospholipase C activation EDG2, GNAQ
Blood coagulation GNA12, GNAQ
Diacylglycerol binding RAPGEF2, ROCK1
Vascular endothelial growth factor 
receptor activity
NRP1, PDGFRA
Transmembrane receptor protein 
tyrosine kinase signaling pathway
ABI1, PDGFRA
Chromatin HMGA2, RB1
Negative regulation of cell growth APBB2, RB1
JNK cascade DUSP10, MAP2K4
Double-stranded DNA binding HNRPDL, RBMS1
Single-stranded DNA binding HNRPDL, RBMS1
Caspase activator activity APAF1, MAP3K5
Regulation of apoptosis APAF1, CASP8
DNA recombination RBPSUH, XRCC4
Protein modification PCMT1, SACS
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Intracellular transporter activity KIAA1012, STAU1
Negative regulation of signal 
transduction
SNX13, SOCS5
Integrin-mediated signaling 
pathway
ERBB2IP, PTK2
Map kinase phosphatase activity DUSP10, DUSP6
Regulation of transcription APBB2, TCF12
Heterogeneous nuclear 
ribonucleoprotein complex
HNRPDL, HNRPH3
Wnt receptor signaling pathway CSNK2A1, FBXW11
Angiogenesis NRP1, VEGFC
Positive regulation of cell 
proliferation
NRP1, VEGFC
Calcium ion transport ATP2B1, FYN
Manganese ion binding MIPEP, PDE8A
Transcription corepressor activity TCF8, ZFPM2
Phosphoinositide binding PIK3C2A, SNX13
Centrosome CDC27, CEP63
Golgi membrane ARFGEF2, ARFIP1
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Nucleus ATF3, BRD1, C20orf11, C4orf9, CTDSP2, DID01, E2F6, EIF4ENIF1, ELF4, GADD45A, GTPBP4, HEAB, HEXIM1, HIST2H2BE, HSPC111, IHPK2, ING1, 
IPPK, KCTD13, MAD2L1BP, MAX, MBD4, MCL1, NFYA, NKRF, NXF1, PER2, PHLDA1, POLR1C, POLR2D, POLS, PPM1D, PPP2R1B, PTDSR, PUS1, 
RAE1, RARA, RBM14, RBM4, RBM4B, RNF4, RNPC2, RNPS1, SAS10, SFRS4, SNAPC4, SNAPC5, SNIP1, SPEN, SRRM1, STK17B, TAF7, TCF8, TOB2, 
TRIM32, UBE2B, UPF3A, ZBTB5, ZNF202, ZNF232, ZNF263, ZNF468, ZNF7
Protein binding BRD1, DID01, EIF4ENIF1, EIF5, ELF4, HEXIM1, ING1, KCTD13, LRRC8D, MAD2L1BP, MBD4, MCL1, MYD88, NFYA, NXF1, PLK2, PMAIP1, PPP2R1B, 
RAB11FIP5, RFP2, RNF4, RNF44, SMNDC1, TAF7, TOB1, TRIM32, ZBTB5
Regulation of transcription, DNA- 
dependent
ATF3, BRD1, BTG2, DID01, E2F6, ELF4, ING1, MAX, NFYA, NKRF, PER2, RARA, RBM14, RNPC2, SNAPC4, SNAPC5, SPEN, TAF7, TCF8, ZBTB5, 
ZNF202, ZNF232, ZNF263, ZNF468, ZNF7
Nucleotide binding ARS2, CSNK1D, DYRK2, EIF5, FLJ12529, GTPBP4, HEAB, IPPK, MKNK2, NXF1, PE01, PLK2, PPRC1, RAB9A, RBM14, RBM4, RBM4B, RIT1, RNPC2, 
RNPS1, SFRS4, SPEN, STK17B, UPF3A
Transcription ATF3, BTG2, DID01, E2F6, ELF4, NFYA, NKRF, PER2, POLR1C, POLR2D, RARA, RBM14, RNF4, RNPC2, RNPS1, SNAPC5, TFAM, ZBTB5, ZNF202, 
ZNF232, ZNF263, ZNF7
Zinc ion binding ADAMTS1, BRD1, DID01, IBRDC3, ING1, RARA, RBM4, RBM4B, RFP2, RNF4, RNF44, TCF8, TRIM32, ZBTB5, ZNF202, ZNF232, ZNF263, ZNF468, ZNF7
Metal ion binding ADAMTS1, BRD1, DID01, IBRDC3, ING1, RARA, RBM4, RBM4B, RFP2, RNF4, RNF44, TCF8, TRIM32, ZBTB5, ZNF202, ZNF232, ZNF263, ZNF468, ZNF7
Transcription factor activity ATF3, BTG2, E2F6, ELF4, MAX, NFYA, RARA, RNF4, SNAPC5, SOLH, TAF7, TCF8, TFAM, ZNF202, ZNF232, ZNF263
Membrane ADFP, CANT 1, FAS, GPRC5A, IBRDC3, KCTD13, LRRC8D, MCL1, MYD88, PPP2R1B, RAB9A, RIT1, SLC25A28, SNN, UBE2B
RNA binding CHERP, DKC1, NXF1, RAE1, RBM14, RBM4, RBM4B, RNASEH1, RNPC2, RNPS1, SPEN, SRRM1, UPF3A
DNA binding ATF3, HIST2H2BE, MAX, MBD4, NKRF, POLR1C, POLS, SNAPC4, SPEN, SRRM1, ZBTB5, ZNF7
Molecular function unknown ARS2, BRD1, CHMP7, CISH, CTDSP2, ING1, KIAA0174, MRPL49, RP5-1104E15.5, SAS10, TRIAP1
Transferase activity CSNK1D, DYRK2, IHPK2, IPPK, MKNK2, PLK2, POLR1C, POLR2D, POLS, STK17B
Nucleic acid binding FLJ12529, PPRC1, RBM14, RNPC2, SPEN, TRIM32, ZNF202, ZNF468, ZNF7
Signal transduction CSNK1D, FAS, GDF15, GPRC5A, INPP1, NTF3, PER2, RARA, RIT1
Cytoplasm CHERP, DYRK2, EIF4ENIF1, HEXIM1, MAD2L1BP, RAE1, SMNDC1, UPF3A
ATP binding CSNK1D, DYRK2, HEAB, IPPK, MKNK2, PE01, PLK2, STK17B
Hydrolase activity CANT1, CTDSP2, INPP1, MBD4, MRPL44, PE01, PPM1D, RNASEH1
Apoptosis CROP, DID01, FAS, GADD45A, PHLDA1, SMNDC1, STK17B
Integral to membrane CANT 1, FAS, IBRDC3, LRRC8D, MCL1, SLC25A28, SNN
Cellular component unknown AMD1, ARS2, CISH, CTDSP2, MRPL49, RP5-1104E15.5, TRIAP1
DNA repair BTG2, CSNK1D, GADD45A, HUS1, KCTD13, RBM14, UBE2B
Negative regulation of cell 
proliferation
ADAMTS1, BTG2, CHERP, ING1, PPM1D, TOB1, TOB2
Nuclear mRNA splicing, via 
spliceosome
RBM4, RBM4B, RNPC2, RNPS1, SFRS4, SRRM1
Mitochondrion MCL1, MRPL44, MRPL49, PE01, PPP2R1B, TFAM
Intracellular CARF, CHERP, MRPL49, RFP2, SOLH, ZNF7
Cell cycle E2F6, GADD45A, ING1, POLS, PPM1D, RFP2
Appendix 3. Continued (cluster 2)
Transcription coactivator activity RARA, RNF4, TAF7, TCF8, TRIM32
mRNA processing HEAB, NXF1, RNPC2, SRRM1, UPF3A
Regulation of progression 
through cell cycle_______
DKC1, E2F6, PPM1D, PPP2R1B, TOB2
Protein serine/threonine kinase 
activity____________________
CSNK1D, DYRK2, MKNK2, PLK2, STK17B
Signal transducer activity CANT1, MYD88, PER2, PLK2, RFP2
Protein amino acid 
phosphorylation
CSNK1D, DYRK2, MKNK2, PLK2, STK17B
GTP binding EIF5, GTPBP4, HEAB, RAB9A, RIT1
Biological process unknown BRD1, CTDSP2, RAB11FIP5, RP5-1104E15.5, TRIAP1
RNA splicing PPP2R1B, RNPS1, SFRS4, SMNDC1
Induction of apoptosis FAS, PPP2R1B, SMNDC1, STK17B
Positive regulation of l-Kappa B 
kinase/NF-Kappa B cascade
CANT1, MYD88, PLK2, RFP2
DNA replication KCTD13, PEQ1, POLS, RBM14
Magnesium ion binding DYRK2, INPP1, PPM1D, RNASEH1
Negative regulation of 
transcription from RNA Pol II 
promoter________________
E2F6, HEXIM1, TCF8, ZNF202
Anti-apoptosis FAS, MCL1, NTF3
Cell differentiation MCL1, PTDSR, TNFAIP2
Isomerase activity C12orf5, DKC1.PUS1
Translation initiation factor 
activity________________
EIF4ENIF1, EIF5, MRPL49
Ubiquitin cycle RNF44, TRIM32, UBE2B
Transcription corepressor activity ATF3, E2F6, TCF8
Soluble fraction CTDSP2, FAS, PPP2R1B
Cytosol EIF5, FAS, PPP2R1B
Negative regulation of cell growth IHPK2, ING1, PPP2R1B
Regulation of transcription KCTD13, MAX, PPP2R1B
Transcription from RNA Pol II 
promoter_________________
NFYA, POLR2D, SNAPC5
mRNA-nucleus export NXF1, RAE1, UPF3A
Transport NXF1, SLC25A28, UPF3A
Small GTPase mediated signal 
transduction
GTPBP4, RAB9A, RIT1
mRNA catabolism, nonsense- 
mediated decay
RNPS1, UPF3A
RNA splicing factor activity, SFRS4, SMNDC1
Appendix 3. Continued (cluster 2)
transesterification mechanism
Mitochondrial outer membrane MCL1, RAB11FIP5
Regulation of apoptosis FAS, MCL1
Protein heterodimerization 
activity
MCL1, PPP2R1B
Pseudouridylate synthase activity DKC1, PUS1
Nucleoplasm DKC1, RNPC2
rRNA processing C4orf9, DKC1
Cell proliferation DKC1.TCF8
Protein biosynthesis EIF5, MRPL49
RNA processing CHERP, MRPL44
Neurogenesis CHERP, NTF3
Ligase activity TRIM32, UBE2B
Extracellular space GDF15, TNFAIP2
Protein dimerization activity ATF3, POLR1C
Binding PPP2R1B, SLC25A28
Regulation of translation MKNK2, PPP2R1B
Protein complex assembly FAS, PPP2R1B
Protein amino acid 
dephosphorylation
PPM1D, PPP2R1B
Manganese ion binding DYRK2, PPM1D
Metabolism C12orf5, SPR
Negative regulation of 
progression through cell cycle
ING1, RFP2
DNA-directed RNA Pol activity POLR1C, POLR2D
Transcription factor complex E2F6, RBM14
ribonucleoprotein complex MRPL44, RBM14
Positive regulation of 
transcription From RNA Pol II 
promoter
ELF4, RBM14
Proteolysis and peptidolysis ADAMTS1, SOLH
Transmembrane receptor activity FAS, MYD88
Immune response FAS, TCF8
Development SAS10, ZNF7
Protein kinase cascade MKNK2, STK17B
Cell-cell signaling GDF15, NTF3
Growth factor activity GDF15, NTF3
GTPase activity EIF5, RAB9A
Endoplasmic reticulum ADFP, CANT1
Cell surface receptor linked MKNK2, MYD88
Appendix 3. Continued (cluster 2)
signal transduction
Response to stress CROP, SNN
Double-stranded RNA binding CARF, MRPL44
Endonuclease activity MRPL44, RNASEH1
Protein transport EIF4ENIF1, RAB9A
Golgi stack CANT1, RAB9A
Appendix 3. Continued (cluster 3)
Cytoplasm COL1A2, GFPT1, RANBP5
Protein binding ANK1, GORASP2, TNC
Biological process unknown COL1A2, TBL2
Skeletal development COL1A2, FBN1
Extracellular matrix structural constituent COL1A2, FBN1
Golgi stack AP3S1, GORASP2
Metabolism GFPT1, MICAL2
Extracellular matrix (Sensu Metazoa) FBN1.TNC
Cytoskeleton ANK1, MICAL2
Signal transduction ANK1, GABBR2
Nucleus PHTF1, RANBP5
Integral to plasma membrane GABBR2, HAS2
Membrane GORASP2, HAS2
Zinc ion binding C9orf3, MICAL2
Metal ion binding C9orf3, MICAL2
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